

## Durham Research Online

---

### Deposited in DRO:

07 August 2018

### Version of attached file:

Published Version

### Peer-review status of attached file:

Peer-reviewed

### Citation for published item:

Abdelhamid, Asmaa S. and Brown, Tracey J. and Brainard, Julii S. and Biswas, Priti and Thorpe, Gabrielle C. and Moore, Helen J. and Deane, Katherine H.O. and AlAbdulghafoor, Fai K. and Summerbell, Carolyn D. and Worthington, Helen V. and Song, Fujian and Hooper, Lee (2018) 'Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.', Cochrane database of systematic reviews., 2018 (7). CD003177.

### Further information on publisher's website:

<https://doi.org/10.1002/14651858.CD003177.pub3>

### Publisher's copyright statement:

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley Sons, Ltd.

## Use policy

---

The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-profit purposes provided that:

- a full bibliographic reference is made to the original source
- a [link](#) is made to the metadata record in DRO
- the full-text is not changed in any way

The full-text must not be sold in any format or medium without the formal permission of the copyright holders.

Please consult the [full DRO policy](#) for further details.



**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

## **Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Review)**

Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KHO, AlAbdulghafoor FK, Summerbell CD, Worthington HV, Song F, Hooper L

Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KHO, AlAbdulghafoor FK, Summerbell CD, Worthington HV, Song F, Hooper L.

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

*Cochrane Database of Systematic Reviews* 2018, Issue 7. Art. No.: CD003177.

DOI: 10.1002/14651858.CD003177.pub3.

[www.cochranelibrary.com](http://www.cochranelibrary.com)

## TABLE OF CONTENTS

HEADER . . . . .	1
ABSTRACT . . . . .	1
PLAIN LANGUAGE SUMMARY . . . . .	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . .	4
BACKGROUND . . . . .	11
OBJECTIVES . . . . .	12
METHODS . . . . .	13
RESULTS . . . . .	18
Figure 1. . . . .	19
Figure 2. . . . .	22
Figure 3. . . . .	24
Figure 4. . . . .	25
Figure 5. . . . .	26
Figure 6. . . . .	28
ADDITIONAL SUMMARY OF FINDINGS . . . . .	37
DISCUSSION . . . . .	50
AUTHORS' CONCLUSIONS . . . . .	53
ACKNOWLEDGEMENTS . . . . .	53
REFERENCES . . . . .	54
CHARACTERISTICS OF STUDIES . . . . .	81
DATA AND ANALYSES . . . . .	246
Analysis 1.1. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 1 All-cause mortality (overall) - LCn3. . . . .	279
Analysis 1.2. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 2 All-cause mortality - LCn3 - sensitivity analysis (SA) fixed-effect. . . . .	281
Analysis 1.3. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 3 All-cause mortality - LCn3 - SA by summary risk of bias. . . . .	283
Analysis 1.4. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 4 All-cause mortality - LCn3 - SA by compliance and study size. . . . .	285
Analysis 1.5. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 5 All-cause mortality - LCn3 - subgroup by dose. . . . .	288
Analysis 1.6. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 6 All-cause mortality - LCn3 - subgroup by replacement. . . . .	291
Analysis 1.7. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 7 All-cause mortality - LCn3 - subgroup by intervention type. . . . .	294
Analysis 1.8. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 8 All-cause mortality - LCn3 - subgroup by duration. . . . .	296
Analysis 1.9. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 9 All-cause mortality - LCn3 - subgroup by primary or secondary prevention. . . . .	299
Analysis 1.10. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 10 All-cause mortality - LCn3 - subgroup by statin use. . . . .	301
Analysis 1.11. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 11 Cardiovascular mortality (overall) - LCn3. . . . .	303
Analysis 1.12. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 12 CVD mortality - LCn3 - SA fixed-effect. . . . .	305
Analysis 1.13. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 13 CVD mortality - LCn3 - SA by summary risk of bias. . . . .	306
Analysis 1.14. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 14 CVD mortality - LCn3 - SA by compliance and study size. . . . .	308
Analysis 1.15. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 15 CVD mortality - LCn3 - subgroup by dose. . . . .	310

Analysis 1.16. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 16 CVD mortality - LCn3 - subgroup by replacement. . . . .	312
Analysis 1.17. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 17 CVD mortality - LCn3 - subgroup by intervention type. . . . .	314
Analysis 1.18. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 18 CVD mortality - LCn3 - subgroup by duration. . . . .	316
Analysis 1.19. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 19 CVD mortality - LCn3 - subgroup by primary or secondary prevention. . . . .	318
Analysis 1.20. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 20 CVD mortality - LCn3 - subgroup by statin uses. . . . .	320
Analysis 1.21. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 21 Cardiovascular events (overall) - LCn3. . . . .	322
Analysis 1.22. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 22 CVD events - LCn3 - SA fixed-effect. . . . .	324
Analysis 1.23. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 23 CVD events - LCn3 - SA by summary risk of bias. . . . .	326
Analysis 1.24. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 24 CVD events - LCn3 - SA by compliance and study size. . . . .	328
Analysis 1.25. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 25 CVD events - LCn3 - subgroup by dose. . . . .	331
Analysis 1.26. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 26 CVD events - LCn3 - subgroup by replacement. . . . .	334
Analysis 1.27. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 27 CVD events - LCn3 - subgroup by intervention type. . . . .	337
Analysis 1.28. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 28 CVD events - LCn3 - subgroup by duration. . . . .	340
Analysis 1.29. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 29 CVD events - LCn3 - subgroup by primary or secondary prevention. . . . .	342
Analysis 1.30. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 30 CVD events - LCn3 - subgroup by statin use. . . . .	345
Analysis 1.31. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 31 Coronary heart disease mortality (overall) - LCn3. . . . .	347
Analysis 1.32. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 32 CHD mortality - LCn3 - SA fixed-effect. . . . .	349
Analysis 1.33. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 33 CHD mortality - LCn3 - SA by summary risk of bias. . . . .	351
Analysis 1.34. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 34 CHD mortality - LCn3 - SA by compliance and study size. . . . .	353
Analysis 1.35. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 35 CHD mortality - LCn3 - SA omitting cardiac death. . . . .	356
Analysis 1.36. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 36 CHD mortality - LCn3 - subgroup by dose. . . . .	358
Analysis 1.37. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 37 CHD mortality - LCn3 - subgroup by replacement. . . . .	361
Analysis 1.38. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 38 CHD mortality - LCn3 - subgroup by intervention type. . . . .	364
Analysis 1.39. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 39 CHD mortality - LCn3 - subgroup by duration. . . . .	366
Analysis 1.40. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 40 CHD mortality - LCn3 - subgroup by primary or secondary prevention. . . . .	368
Analysis 1.41. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 41 CHD mortality - LCn3 - subgroup by statin use. . . . .	370

Analysis 1.42. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 42 CHD mortality - LCn3 - subgroup by CAD history. . . . .	372
Analysis 1.43. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 43 Coronary heart disease events (overall) - LCn3. . . . .	374
Analysis 1.44. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 44 CHD events - LCn3 - SA fixed-effect. . . . .	376
Analysis 1.45. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 45 CHD events - LCn3 - SA by summary risk of bias. . . . .	378
Analysis 1.46. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 46 CHD events - LCn3 - SA by compliance and study size. . . . .	381
Analysis 1.47. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 47 CHD events - LCn3 - subgroup by dose. . . . .	384
Analysis 1.48. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 48 CHD events - LCn3 - subgroup by replacement. . . . .	387
Analysis 1.49. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 49 CHD events - LCn3 - subgroup by intervention type. . . . .	390
Analysis 1.50. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 50 CHD events - LCn3 - subgroup by duration. . . . .	393
Analysis 1.51. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 51 CHD events - LCn3 - subgroup by primary or secondary prevention. . . . .	396
Analysis 1.52. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 52 CHD events - LCn3 - subgroup by statin use. . . . .	399
Analysis 1.53. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 53 CHD events - LCn3 subgroup by CAD history. . . . .	402
Analysis 1.54. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 54 Stroke (overall) - LCn3. . . . .	405
Analysis 1.55. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 55 Stroke - LCn3 - SA fixed-effect. . . . .	407
Analysis 1.56. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 56 Stroke - LCn3 - SA by summary risk of bias. . . . .	408
Analysis 1.57. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 57 Stroke - LCn3 - SA by compliance and study size. . . . .	410
Analysis 1.58. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 58 Stroke - LCn3 - subgroup by stroke type. . . . .	412
Analysis 1.59. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 59 Stroke - LCn3 - subgroup by dose. . . . .	414
Analysis 1.60. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 60 Stroke - LCn3 - subgroup by replacement. . . . .	416
Analysis 1.61. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 61 Stroke - LCn3 - subgroup by intervention type. . . . .	418
Analysis 1.62. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 62 Stroke - LCn3 - subgroup by duration. . . . .	420
Analysis 1.63. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 63 Stroke - LCn3 - subgroup by primary or secondary prevention. . . . .	422
Analysis 1.64. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 64 Stroke - LCn3 - subgroup by statin use. . . . .	424
Analysis 1.65. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 65 Arrhythmia (overall) - LCn3. . . . .	426
Analysis 1.66. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 66 Arrhythmia- LCn3 - SA fixed-effect. . . . .	428
Analysis 1.67. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 67 Arrhythmia- LCn3 - SA by summary risk of bias. . . . .	429
Analysis 1.68. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 68 Arrhythmia- LCn3 - SA by compliance and study size. . . . .	431

Analysis 1.69. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 69 Arrhythmia - LCn3 - subgroup by new or recurrent. . . . .	433
Analysis 1.70. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 70 Arrhythmia - LCn3 - subgroup by fatality. . . . .	435
Analysis 1.71. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 71 Arrhythmia - LCn3 - subgroup by dose. . . . .	437
Analysis 1.72. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 72 Arrhythmia - LCn3 - subgroup by replacement. . . . .	439
Analysis 1.73. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 73 Arrhythmia - LCn3 - subgroup by intervention type. . . . .	442
Analysis 1.74. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 74 Arrhythmia - LCn3 - subgroup by duration. . . . .	444
Analysis 1.75. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 75 Arrhythmia - LCn3 - subgroup by primary or secondary prevention3. . . . .	446
Analysis 1.76. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 76 Arrhythmia - LCn3 - subgroup by statin use. . . . .	448
Analysis 2.1. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 1 MACCEs - LCn3. . . . .	450
Analysis 2.2. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 2 Myocardial infarction (overall) - LCn3. . . . .	451
Analysis 2.3. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 3 Total MI - sensitivity analysis (SA) by summary risk of bias. . . . .	452
Analysis 2.4. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 4 Total MI - LCn3 - SA by compliance and study size. . . . .	454
Analysis 2.5. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 5 Total MI - LCn3 - subgroup by fatality. . . . .	456
Analysis 2.6. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 6 Sudden cardiac death (overall) - LCn3. . . . .	458
Analysis 2.7. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 7 Angina - LCn3. . . . .	459
Analysis 2.8. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 8 Heart failure - LCn3. . . . .	460
Analysis 2.9. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 9 Revascularisation - LCn3. . . . .	461
Analysis 2.10. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 10 Peripheral arterial disease - LCn3. . . . .	463
Analysis 2.11. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 11 PAD - LCn3 - SA by summary risk of bias. . . . .	464
Analysis 2.12. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 12 PAD - LCn3 - SA compliance and study size. . . . .	465
Analysis 2.13. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 13 Acute coronary syndrome - LCn3. . . . .	466
Analysis 2.14. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 14 Body weight, kg - LCn3. . . . .	467
Analysis 2.15. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 15 Weight, kg - LCn3 - SA by summary risk of bias. . . . .	468
Analysis 2.16. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 16 Weight, kg - LCn3 - SA by compliance and study size. . . . .	469
Analysis 2.17. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 17 Weight, kg - LCn3 - subgroup by dose. . . . .	470
Analysis 2.18. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 18 Weight, kg - LCn3 - subgroup by replacement. . . . .	472
Analysis 2.19. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 19 Weight, kg - LCn3 - subgroup by intervention type. . . . .	474
Analysis 2.20. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 20 Weight, kg - LCn3 - subgroup by duration. . . . .	475

Analysis 2.21. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 21 Weight, kg - LCn3 - subgroup by primary or secondary prevention. . . . .	477
Analysis 2.22. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 22 Weight, kg - LCn3 - subgroup by statin use. . . . .	478
Analysis 2.23. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 23 Body mass index, kg/m <sup>2</sup> - LCn3. . . . .	479
Analysis 2.24. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 24 BMI, kg/m <sup>2</sup> - LCn3 - SA by summary risk of bias. . . . .	480
Analysis 2.25. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 25 BMI, kg/m <sup>2</sup> - LCn3 - SA by compliance and study size. . . . .	481
Analysis 2.26. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 26 BMI, kg/m <sup>2</sup> - LCn3 - subgroup by dose. . . . .	482
Analysis 2.27. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 27 BMI, kg/m <sup>2</sup> - LCn3 - subgroup by replacement. . . . .	484
Analysis 2.28. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 28 BMI, kg/m <sup>2</sup> - LCn3 - subgroup by intervention type. . . . .	486
Analysis 2.29. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 29 BMI, kg/m <sup>2</sup> - LCn3 - subgroup by duration. . . . .	487
Analysis 2.30. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 30 BMI, kg/m <sup>2</sup> - LCn3 - subgroup by primary or secondary prevention. . . . .	489
Analysis 2.31. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 31 BMI, kg/m <sup>2</sup> - LCn3 - subgroup by statin use. . . . .	490
Analysis 2.32. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 32 Other measures of adiposity - LCn3. . . . .	491
Analysis 2.33. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 33 Total cholesterol, serum, mmol/L - LCn3. . . . .	492
Analysis 2.34. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 34 TC, mmol/L - LCn3 - SA by summary risk of bias. . . . .	494
Analysis 2.35. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 35 TC, mmol/L - LCn3 - SA by compliance and study size. . . . .	496
Analysis 2.36. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 36 TC, mmol/L - LCn3 - subgroup by dose. . . . .	498
Analysis 2.37. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 37 TC, mmol/L - LCn3 - subgroup by replacement. . . . .	500
Analysis 2.38. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 38 TC, mmol/L - LCn3 - subgroup by intervention type. . . . .	502
Analysis 2.39. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 39 TC, mmol/L - LCn3 - subgroup by duration. . . . .	504
Analysis 2.40. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 40 TC, mmol/L - LCn3 - subgroup by primary or secondary prevention. . . . .	506
Analysis 2.41. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 41 TC, mmol/L - LCn3 - subgroup by statin use. . . . .	508
Analysis 2.42. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 42 Triglycerides, fasting, serum, mmol/L - LCn3. . . . .	510
Analysis 2.43. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 43 TG, fasting, mmol/L - LCn3 - SA by summary risk of bias. . . . .	512
Analysis 2.44. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 44 TG, fasting, mmol/L - LCn3 - SA by compliance and study size. . . . .	514
Analysis 2.45. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 45 TG, fasting, mmol/L - LCn3 - subgroup by dose. . . . .	516
Analysis 2.46. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 46 TG, fasting, mmol/L - LCn3 - subgroup by replacement. . . . .	518

Analysis 2.47. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 47 TG, fasting, mmol/L - LCn3 - subgroup by intervention type. . . . .	520
Analysis 2.48. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 48 TG, fasting, mmol/L - LCn3 - subgroup by duration. . . . .	522
Analysis 2.49. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 49 TG, fasting, mmol/L - LCn3 - subgroup by primary or secondary prevention. . . . .	524
Analysis 2.50. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 50 TG, fasting, mmol/L - LCn3 - subgroup by statin use. . . . .	526
Analysis 2.51. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 51 High-density lipoprotein, serum, mmol/L - LCn3. . . . .	528
Analysis 2.52. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 52 HDL, mmol/L - LCn3 - SA by summary risk of bias. . . . .	530
Analysis 2.53. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 53 HDL, mmol/L - LCn3 - SA by compliance and study size. . . . .	532
Analysis 2.54. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 54 HDL, mmol/L - LCn3 - subgroup by dose. . . . .	534
Analysis 2.55. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 55 HDL, mmol/L - LCn3 - subgroup by replacement. . . . .	536
Analysis 2.56. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 56 HDL, mmol/L - LCn3 - subgroup by intervention type. . . . .	538
Analysis 2.57. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 57 HDL, mmol/L - LCn3 - subgroup by duration. . . . .	540
Analysis 2.58. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 58 HDL, mmol/L - LCn3 - subgroup by primary or secondary prevention. . . . .	542
Analysis 2.59. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 59 HDL, mmol/L - LCn3 - subgroup by statin use. . . . .	544
Analysis 2.60. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 60 Low-density lipoprotein, serum, mmol/L - LCn3. . . . .	546
Analysis 2.61. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 61 LDL, mmol/L - LCn3 - SA by summary risk of bias. . . . .	547
Analysis 2.62. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 62 LDL, mmol/L - LCn3 - SA by compliance and study size. . . . .	549
Analysis 2.63. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 63 LDL, mmol/L - LCn3 - subgroup by dose. . . . .	551
Analysis 2.64. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 64 LDL, mmol/L - LCn3 - subgroup by replacement. . . . .	553
Analysis 2.65. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 65 LDL, mmol/L - LCn3 - subgroup by intervention type. . . . .	555
Analysis 2.66. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 66 LDL, mmol/L - LCn3 - subgroup by duration. . . . .	557
Analysis 2.67. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 67 LDL, mmol/L - LCn3 - subgroup by primary or secondary prevention. . . . .	559
Analysis 2.68. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 68 LDL, mmol/L - LCn3 - subgroup by statin use. . . . .	560
Analysis 3.1. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 1 Blood pressure, mmHg - LCn3. . . . .	562
Analysis 3.2. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 2 Serious adverse events - LCn3. . . . .	564
Analysis 3.3. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 3 Side effects - LCn3. . . . .	566
Analysis 3.4. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 4 Dropouts - LCn3. . . . .	571
Analysis 4.1. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 1 All-cause mortality (overall) - ALA. . . . .	573



Analysis 4.2. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 2 All-cause mortality - ALA - sensitivity analysis (SA) fixed-effect. . . . .	574
Analysis 4.3. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 3 All-cause mortality - ALA - SA by summary risk of bias. . . . .	575
Analysis 4.4. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 4 All-cause mortality - ALA - SA by compliance and study size. . . . .	576
Analysis 4.5. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 5 All-cause mortality - ALA - subgroup by dose. . . . .	577
Analysis 4.6. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 6 All-cause mortality - ALA - subgroup by replacement. . . . .	578
Analysis 4.7. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 7 All cause mortality - ALA - subgroup by intervention type. . . . .	579
Analysis 4.8. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 8 All-cause mortality - ALA - subgroup by duration. . . . .	581
Analysis 4.9. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 9 All-cause mortality - ALA - subgroup by primary or secondary prevention. . . . .	582
Analysis 4.10. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 10 All-cause mortality - ALA - subgroup by statin use. . . . .	583
Analysis 4.11. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 11 Cardiovascular mortality (overall) - ALA. . . . .	584
Analysis 4.12. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 12 CVD mortality - ALA - SA fixed-effect. . . . .	585
Analysis 4.13. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 13 CVD mortality - ALA - SA by summary risk of bias. . . . .	586
Analysis 4.14. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 14 CVD mortality - ALA - SA by compliance and study size. . . . .	587
Analysis 4.15. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 15 CVD mortality - ALA - subgroup by dose. . . . .	588
Analysis 4.16. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 16 CVD mortality - ALA - subgroup by replacement. . . . .	589
Analysis 4.17. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 17 CVD mortality - ALA - subgroup by intervention type. . . . .	590
Analysis 4.18. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 18 CVD mortality - ALA - subgroup by duration. . . . .	591
Analysis 4.19. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 19 CVD mortality - ALA - subgroup by primary or secondary prevention. . . . .	592
Analysis 4.20. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 20 CVD mortality - ALA - subgroup by statin uses. . . . .	593
Analysis 4.21. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 21 Cardiovascular events (overall) - ALA. . . . .	594
Analysis 4.22. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 22 CVD events - ALA - SA fixed-effect. . . . .	595
Analysis 4.23. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 23 CVD events - ALA - SA by summary risk of bias. . . . .	596
Analysis 4.24. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 24 CVD events - ALA - SA by compliance and study size. . . . .	597
Analysis 4.25. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 25 CVD events - ALA - subgroup by dose. . . . .	598
Analysis 4.26. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 26 CVD events - ALA - subgroup by replacement. . . . .	599
Analysis 4.27. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 27 CVD events - ALA - subgroup by intervention type. . . . .	600

Analysis 4.28. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 28 CVD events - ALA - subgroup by duration. . . . .	602
Analysis 4.29. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 29 CVD events - ALA - subgroup by primary or secondary prevention. . . . .	603
Analysis 4.30. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 30 CVD events - ALA - subgroup by statin use. . . . .	604
Analysis 4.31. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 31 Coronary heart disease mortality (overall) - ALA. . . . .	605
Analysis 4.32. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 32 CHD mortality - ALA - SA fixed-effect. . . . .	606
Analysis 4.33. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 33 CHD mortality - ALA - SA by summary risk of bias. . . . .	607
Analysis 4.34. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 34 CHD mortality - ALA - SA by compliance and study size. . . . .	608
Analysis 4.35. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 35 CHD mortality - ALA - subgroup by dose. . . . .	609
Analysis 4.36. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 36 CHD mortality - ALA - subgroup by replacement. . . . .	610
Analysis 4.37. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 37 CHD mortality - ALA - subgroup by intervention type. . . . .	611
Analysis 4.38. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 38 CHD mortality - ALA - subgroup by duration. . . . .	613
Analysis 4.39. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 39 CHD mortality - ALA - subgroup by primary or secondary prevention. . . . .	614
Analysis 4.40. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 40 CHD mortality - ALA - subgroup by statin use. . . . .	615
Analysis 4.41. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 41 CHD mortality - ALA - subgroup by CAD history. . . . .	616
Analysis 4.42. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 42 Coronary heart disease events (overall) - ALA. . . . .	617
Analysis 4.43. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 43 CHD events - ALA - SA fixed-effect. . . . .	618
Analysis 4.44. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 44 CHD events - ALA - SA by summary risk of bias. . . . .	619
Analysis 4.45. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 45 CHD events - ALA - SA by compliance and study size. . . . .	620
Analysis 4.46. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 46 CHD events - ALA - subgroup by dose. . . . .	621
Analysis 4.47. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 47 CHD events - ALA - subgroup by replacement. . . . .	622
Analysis 4.48. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 48 CHD events - ALA - subgroup by intervention type. . . . .	623
Analysis 4.49. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 49 CHD events - ALA - subgroup by duration. . . . .	624
Analysis 4.50. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 50 CHD events - ALA - subgroup by primary or secondary prevention. . . . .	626
Analysis 4.51. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 51 CHD events - ALA - subgroup by statin use. . . . .	627
Analysis 4.52. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 52 CHD events - ALA - subgroup by CAD history. . . . .	628
Analysis 4.53. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 53 Stroke (overall) - ALA. . . . .	629
Analysis 4.54. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 54 Stroke - ALA - SA fixed-effect. . . . .	630

Analysis 4.55. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 55 Stroke - ALA - SA by summary risk of bias. . . . .	631
Analysis 4.56. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 56 Stroke - ALA - SA by compliance and study size. . . . .	632
Analysis 4.57. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 57 Stroke - ALA - subgroup by dose. . . . .	633
Analysis 4.58. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 58 Stroke - ALA - subgroup by replacement. . . . .	634
Analysis 4.59. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 59 Stroke - ALA - subgroup by intervention type. . . . .	635
Analysis 4.60. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 60 Stroke - ALA - subgroup by duration. . . . .	637
Analysis 4.61. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 61 Stroke - ALA - subgroup by primary or secondary prevention. . . . .	638
Analysis 4.62. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 62 Stroke - ALA - subgroup by statin use. . . . .	639
Analysis 4.63. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 63 Stroke - ALA - subgroup by stroke type. . . . .	640
Analysis 4.64. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 64 Arrhythmia (overall) - ALA. . . . .	641
Analysis 4.65. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 65 Arrhythmia - ALA - SA by summary risk of bias. . . . .	642
Analysis 5.1. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 1 MACCEs - ALA. . . . .	643
Analysis 5.2. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 2 Myocardial infarction (overall) - ALA. . . . .	643
Analysis 5.3. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 3 Total MI - ALA - subgroup by fatality. . . . .	644
Analysis 5.4. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 4 Angina - ALA. . . . .	645
Analysis 5.5. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 5 Revascularisation - ALA. . . . .	646
Analysis 5.6. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 6 Peripheral arterial disease - ALA. . . . .	647
Analysis 5.7. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 7 Body weight, kg - ALA. . . . .	647
Analysis 5.8. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 8 Weight, kg - ALA - sensitivity analysis (SA) fixed-effect. . . . .	648
Analysis 5.9. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 9 Weight, kg - ALA - SA by summary risk of bias. . . . .	649
Analysis 5.10. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 10 Weight, kg - ALA - SA by compliance and study size. . . . .	650
Analysis 5.11. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 11 Weight, kg - ALA - subgroup by dose. . . . .	651
Analysis 5.12. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 12 Weight, kg - ALA - subgroup by intervention type. . . . .	652
Analysis 5.13. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 13 Weight, kg - ALA - subgroup by replacement. . . . .	653
Analysis 5.14. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 14 Weight, kg - ALA - subgroup by duration. . . . .	654
Analysis 5.15. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 15 Weight, kg - ALA - subgroup by statin use. . . . .	655
Analysis 5.16. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 16 Weight, kg - ALA - subgroup by primary or secondary prevention. . . . .	656
Analysis 5.17. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 17 Body mass index, kg/m <sup>2</sup> - ALA. . . . .	657

Analysis 5.18. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 18 BMI, kg/m <sup>2</sup> - ALA - SA fixed-effect. . . . .	658
Analysis 5.19. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 19 BMI, kg/m <sup>2</sup> - ALA - SA by summary risk of bias. . . . .	659
Analysis 5.20. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 20 BMI, kg/m <sup>2</sup> - ALA - SA by compliance and study size. . . . .	660
Analysis 5.21. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 21 BMI, kg/m <sup>2</sup> - ALA - subgroup by dose. . . . .	661
Analysis 5.22. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 22 BMI, kg/m <sup>2</sup> - ALA - subgroup by intervention type. . . . .	662
Analysis 5.23. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 23 BMI, kg/m <sup>2</sup> - ALA - subgroup by replacement. . . . .	663
Analysis 5.24. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 24 BMI, kg/m <sup>2</sup> - ALA - subgroup by duration. . . . .	664
Analysis 5.25. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 25 BMI, kg/m <sup>2</sup> - ALA - subgroup by statin use. . . . .	665
Analysis 5.26. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 26 BMI, kg/m <sup>2</sup> - ALA - subgroup by primary or secondary preventionA. . . . .	666
Analysis 5.27. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 27 Other measures of adiposity - ALA. . . . .	667
Analysis 5.28. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 28 Total cholesterol, serum, mmol/L - ALA. . . . .	668
Analysis 5.29. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 29 TC, mmol/L - ALA - SA fixed-effect. . . . .	669
Analysis 5.30. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 30 TC, mmol/L - ALA - SA by summary risk of bias. . . . .	670
Analysis 5.31. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 31 TC, mmol/L - ALA - SA by compliance and study size. . . . .	671
Analysis 5.32. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 32 TC, mmol/L - ALA - subgroup by dose. . . . .	672
Analysis 5.33. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 33 TC, mmol/L - ALA - subgroup by intervention type. . . . .	673
Analysis 5.34. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 34 TC, mmol/L - ALA - subgroup by replacement. . . . .	674
Analysis 5.35. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 35 TC, mmol/L - ALA - subgroup by duration. . . . .	675
Analysis 5.36. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 36 TC, mmol/L - ALA - subgroup by statin use. . . . .	676
Analysis 5.37. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 37 TC, mmol/L - ALA - subgroup by primary or secondary preventionA. . . . .	677
Analysis 5.38. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 38 Triglycerides, fasting, serum, mmol/L - ALA. . . . .	678
Analysis 5.39. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 39 TG, fasting, mmol/L - ALA - SA fixed-effect. . . . .	679
Analysis 5.40. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 40 TG, fasting, mmol/L - ALA - SA by summary risk of bias. . . . .	680
Analysis 5.41. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 41 TG, fasting, mmol/L - ALA - SA by compliance and study size. . . . .	681
Analysis 5.42. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 42 TG, fasting, mmol/L - ALA - subgroup by dose. . . . .	682
Analysis 5.43. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 43 TG, fasting, mmol/L - ALA - subgroup by intervention type. . . . .	683

Analysis 5.44. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 44 TG, fasting, mmol/L-ALA - subgroup by replacementA. . . . .	684
Analysis 5.45. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 45 TG, fasting, mmol/L-ALA - subgroup by duration. . . . .	685
Analysis 5.46. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 46 TG, fasting, mmol/L -ALA - subgroup by statin use. . . . .	686
Analysis 5.47. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 47 TG, fasting, mmol/L-ALA - subgroup by primary or secondary prevention. . . . .	687
Analysis 5.48. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 48 High-density lipoprotein, serum, mmol/L - ALA. . . . .	688
Analysis 5.49. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 49 HDL, mmol/L - ALA - SA fixed-effect. . . . .	689
Analysis 5.50. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 50 HDL, mmol/L - ALA - SA by summary risk of bias. . . . .	690
Analysis 5.51. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 51 HDL, mmol/L - ALA - SA by compliance and study size. . . . .	691
Analysis 5.52. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 52 HDL, mmol/L - ALA - subgroup by dose. . . . .	692
Analysis 5.53. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 53 HDL, mmol/L - ALA - subgroup by intervention type. . . . .	693
Analysis 5.54. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 54 HDL, mmol/L - ALA - subgroup by replacement. . . . .	694
Analysis 5.55. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 55 HDL, mmol/L - ALA - subgroup by duration. . . . .	695
Analysis 5.56. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 56 HDL, mmol/L - ALA - subgroup by statin use. . . . .	696
Analysis 5.57. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 57 HDL, mmol/L - ALA - subgroup by primary or secondary prevention. . . . .	697
Analysis 5.58. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 58 Low-density lipoprotein, serum, mmol/L - ALA. . . . .	698
Analysis 5.59. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 59 LDL, mmol/L - ALA - SA fixed-effect. . . . .	699
Analysis 5.60. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 60 LDL, mmol/L - ALA - SA by summary risk of bias. . . . .	700
Analysis 5.61. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 61 LDL, mmol/L - ALA - SA by compliance and study size. . . . .	701
Analysis 5.62. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 62 LDL, mmol/L - ALA - subgroup by dose. . . . .	702
Analysis 5.63. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 63 LDL, mmol/L - ALA - subgroup by intervention type. . . . .	703
Analysis 5.64. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 64 LDL, mmol/L - ALA - subgroup by replacement. . . . .	704
Analysis 5.65. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 65 LDL, mmol/L - ALA - subgroup by duration. . . . .	705
Analysis 5.66. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 66 LDL, mmol/L - ALA - subgroup by statin use. . . . .	706
Analysis 5.67. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 67 LDL, mmol/L - ALA - subgroup by primary or secondary prevention. . . . .	707
Analysis 6.1. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 1 Blood pressure, mmHg - ALA. . . . .	708
Analysis 6.2. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 2 Serious adverse events - ALA. . . . .	709
Analysis 6.3. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 3 Side effects - ALA. . . . .	710

Analysis 6.4. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 4 Dropouts - ALA. . . .	712
ADDITIONAL TABLES . . . . .	712
APPENDICES . . . . .	721
WHAT'S NEW . . . . .	727
HISTORY . . . . .	727
CONTRIBUTIONS OF AUTHORS . . . . .	728
DECLARATIONS OF INTEREST . . . . .	728
SOURCES OF SUPPORT . . . . .	728
DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . .	729
INDEX TERMS . . . . .	730

# Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Asmaa S Abdelhamid<sup>1</sup>, Tracey J Brown<sup>1</sup>, Julii S Brainard<sup>1</sup>, Priti Biswas<sup>2</sup>, Gabrielle C Thorpe<sup>3</sup>, Helen J Moore<sup>4</sup>, Katherine HO Deane<sup>3</sup>, Fai K AlAbdulghafoor<sup>1</sup>, Carolyn D Summerbell<sup>5</sup>, Helen V Worthington<sup>6</sup>, Fujian Song<sup>1</sup>, Lee Hooper<sup>1</sup>

<sup>1</sup>Norwich Medical School, University of East Anglia, Norwich, UK. <sup>2</sup>MED/HSC, University of East Anglia, Norwich, UK. <sup>3</sup>School of Health Sciences, University of East Anglia, Norwich, UK. <sup>4</sup>Wolfson Research Institute, Durham University, Durham, UK. <sup>5</sup>School of Medicine, Pharmacy and Health, Wolfson Research Institute, Queen's Campus, Durham University, Stockton-on-Tees, UK. <sup>6</sup>Cochrane Oral Health, Division of Dentistry, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK

Contact address: Lee Hooper, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, Norfolk, NR4 7TJ, UK. [l.hooper@uea.ac.uk](mailto:l.hooper@uea.ac.uk).

**Editorial group:** Cochrane Heart Group.

**Publication status and date:** New search for studies and content updated (conclusions changed), published in Issue 7, 2018.

**Citation:** Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KHO, AlAbdulghafoor FK, Summerbell CD, Worthington HV, Song F, Hooper L. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database of Systematic Reviews* 2018, Issue 7. Art. No.: CD003177. DOI: 10.1002/14651858.CD003177.pub3.

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

Researchers have suggested that omega-3 polyunsaturated fatty acids from oily fish (long-chain omega-3 (LCn3), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)), as well as from plants (alpha-linolenic acid (ALA)) benefit cardiovascular health. Guidelines recommend increasing omega-3-rich foods, and sometimes supplementation, but recent trials have not confirmed this.

### Objectives

To assess effects of increased intake of fish- and plant-based omega-3 for all-cause mortality, cardiovascular (CVD) events, adiposity and lipids.

### Search methods

We searched CENTRAL, MEDLINE and Embase to April 2017, plus ClinicalTrials.gov and World Health Organization International Clinical Trials Registry to September 2016, with no language restrictions. We handsearched systematic review references and bibliographies and contacted authors.

### Selection criteria

We included randomised controlled trials (RCTs) that lasted at least 12 months and compared supplementation and/or advice to increase LCn3 or ALA intake versus usual or lower intake.

### Data collection and analysis

Two review authors independently assessed studies for inclusion, extracted data and assessed validity. We performed separate random-effects meta-analysis for ALA and LCn3 interventions, and assessed dose-response relationships through meta-regression.

## Main results

We included 79 RCTs (112,059 participants) in this review update and found that 25 were at low summary risk of bias. Trials were of 12 to 72 months' duration and included adults at varying cardiovascular risk, mainly in high-income countries. Most studies assessed LCn3 supplementation with capsules, but some used LCn3- or ALA-rich or enriched foods or dietary advice compared to placebo or usual diet.

Meta-analysis and sensitivity analyses suggested **little or no effect of increasing LCn3 on all-cause mortality** (RR 0.98, 95% CI 0.90 to 1.03, 92,653 participants; 8189 deaths in 39 trials, high-quality evidence), **cardiovascular mortality** (RR 0.95, 95% CI 0.87 to 1.03, 67,772 participants; 4544 CVD deaths in 25 RCTs), **cardiovascular events** (RR 0.99, 95% CI 0.94 to 1.04, 90,378 participants; 14,737 people experienced events in 38 trials, high-quality evidence), **coronary heart disease (CHD) mortality** (RR 0.93, 95% CI 0.79 to 1.09, 73,491 participants; 1596 CHD deaths in 21 RCTs), **stroke** (RR 1.06, 95% CI 0.96 to 1.16, 89,358 participants; 1822 strokes in 28 trials) or **arrhythmia** (RR 0.97, 95% CI 0.90 to 1.05, 53,796 participants; 3788 people experienced arrhythmia in 28 RCTs). There was a suggestion that LCn3 reduced **CHD events** (RR 0.93, 95% CI 0.88 to 0.97, 84,301 participants; 5469 people experienced CHD events in 28 RCTs); however, this was not maintained in sensitivity analyses - LCn3 probably makes little or no difference to CHD event risk. All evidence was of moderate GRADE quality, except as noted.

**Increasing ALA** intake probably makes **little or no difference to all-cause mortality** (RR 1.01, 95% CI 0.84 to 1.20, 19,327 participants; 459 deaths, 5 RCTs), **cardiovascular mortality** (RR 0.96, 95% CI 0.74 to 1.25, 18,619 participants; 219 cardiovascular deaths, 4 RCTs), and it may make **little or no difference to CHD events** (RR 1.00, 95% CI 0.80 to 1.22, 19,061 participants, 397 CHD events, 4 RCTs, low-quality evidence). However, increased ALA may slightly **reduce risk of cardiovascular events** (from 4.8% to 4.7%, RR 0.95, 95% CI 0.83 to 1.07, 19,327 participants; 884 CVD events, 5 RCTs, low-quality evidence), and probably reduces risk of **CHD mortality** (1.1% to 1.0%, RR 0.95, 95% CI 0.72 to 1.26, 18,353 participants; 193 CHD deaths, 3 RCTs), and **arrhythmia** (3.3% to 2.6%, RR 0.79, 95% CI 0.57 to 1.10, 4,837 participants; 141 events, 1 RCT). Effects on **stroke are unclear**.

Sensitivity analysis retaining only trials at low summary risk of bias moved effect sizes towards the null (RR 1.0) for all LCn3 primary outcomes except arrhythmias, but for most ALA outcomes, effect sizes moved to suggest protection. LCn3 funnel plots suggested that adding in missing studies/results would move effect sizes towards null for most primary outcomes. There were no dose or duration effects in subgrouping or meta-regression.

There was no evidence that increasing LCn3 or ALA altered serious adverse events, adiposity or lipids, although LCn3 slightly reduced triglycerides and increased HDL. ALA probably reduces HDL (high- or moderate-quality evidence).

## Authors' conclusions

This is the most extensive systematic assessment of effects of omega-3 fats on cardiovascular health to date. Moderate- and high-quality evidence suggests that increasing EPA and DHA has little or no effect on mortality or cardiovascular health (evidence mainly from supplement trials). Previous suggestions of benefits from EPA and DHA supplements appear to spring from trials with higher risk of bias. Low-quality evidence suggests ALA may slightly reduce CVD event risk, CHD mortality and arrhythmia.

## PLAIN LANGUAGE SUMMARY

### Omega-3 intake for cardiovascular disease

#### Review question

We reviewed randomised trials (where participants have an equal chance of being assigned to either treatment) examining effects of increasing fish- and plant-based omega-3 fats on heart and circulatory disease (called cardiovascular diseases, CVD, which include heart attacks and stroke), fatness and blood fats (lipids, including cholesterol, triglycerides, high-density lipoprotein (HDL - 'good' cholesterol) and low-density lipoprotein (LDL - 'bad' cholesterol)).

#### Background

Omega-3 fats are essential - to stay healthy we must obtain some from food. The main types of omega-3 fats are alpha-linolenic acid (ALA), a fat found in plant foods, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both found in fish. There is a common belief that eating more fish or taking omega-3 supplements reduces our risk of heart disease, stroke and death.

#### Study characteristics



The evidence is current to April 2017. The review included 79 trials involving over 112,000 people. These studies assessed effects of greater omega-3 intake versus lower or no omega-3 intake for heart and circulatory disease. Twenty-five studies were very trustworthy (well-designed so as not to give biased results). Participants were adults, some with existing illness and some healthy, living in North America, Europe, Australia and Asia. Participants increased omega-3 fats, or maintained their usual fats for at least a year. Most EPA and DHA trials provided capsules, few gave oily fish.

### **Key results**

Increasing EPA and DHA has little or no effect on all-cause deaths and cardiovascular events (high-quality evidence) and probably makes little or no difference to cardiovascular death, coronary deaths or events, stroke, or heart irregularities (moderate-quality evidence, coronary events are illnesses of the arteries which supply the heart). EPA and DHA slightly reduce serum triglycerides and raise HDL (high-quality evidence).

Eating more ALA (for example, by increasing walnuts or enriched margarine) probably makes little or no difference to all-cause or cardiovascular deaths or coronary events but probably slightly reduce cardiovascular events, coronary mortality and heart irregularities (moderate/low-quality evidence). Effects of ALA on stroke are unclear as the evidence was of very low quality.

There is evidence that taking omega-3 capsules does not reduce heart disease, stroke or death. There is little evidence of effects of eating fish. Although EPA and DHA reduce triglycerides, supplementary omega-3 fats are probably not useful for preventing or treating heart and circulatory diseases. However, increasing plant-based ALA may be slightly protective for some heart and circulatory diseases.

## SUMMARY OF FINDINGS FOR THE MAIN COMPARISON *[Explanation]*

### High versus low LCn3 for preventing cardiovascular disease and mortality (primary outcomes)

**Patient or population:** adults with or without existing CVD

**Setting:** participants were living at home for most or all of the duration of their trials. Most studies were carried out in high-income economies ([World Bank 2018](#)), but four trials were carried out in upper-middle income countries (Argentina, Iran, Turkey and China). No studies took place in low- or low-middle income countries.

**Intervention:** higher intake of long-chain omega-3 fats

**Comparison:** lower intake of long-chain omega-3 fats

The intervention was dietary supplementation, a provided diet or advice on diet. Supplementation may have been in oil or capsule form or as foodstuffs provided, to be consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuffs or supplements must have been: oily fish or fish oils as a food, oil, made into a spreading fat or supplementing another food (such as bread or eggs). Refined eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or concentrated fish or algal oils, were also accepted

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Risk with lower LCn3	Risk with higher LCn3				
<b>All-cause mortality</b> - deaths Assessed with: number of participants dying of any cause, whether reported as an outcome or a reason for dropout Duration: range 12 to 72 months	90 per 1,000	88 per 1,000 (83 to 92)	RR 0.98 (0.93 to 1.03)	92,653 (39 RCTs)	⊕⊕⊕⊕ High <sup>a</sup>	Meta-analysis and indications of bias suggest risk reduction of less than 2%. Long-chain omega-3 fat intake makes little or no difference to all-cause mortality
<b>Cardiovascular mortality</b> - cardiovascular deaths Assessed with: deaths from any cardiovascular cause. Where this was not available, cardiac death was used instead where known	69 per 1,000	66 per 1,000 (60 to 71)	RR 0.95 (0.87 to 1.03)	67,772 (25 RCTs)	⊕⊕⊕○ Moderate <sup>b</sup>	Meta-analysis and indications of bias suggest risk reduction of less than 5%. Long-chain omega-3 fat intake probably makes little or no difference to cardiovascular deaths

Duration: range 12 to 72 months						
<b>Cardiovascular events</b> - cardiovascular events Assessed with: number of participants experiencing any cardiovascular event Duration: range 12 to 72 months	165 per 1,000	164 per 1,000 (155 to 172)	RR 0.99 (0.94 to 1.04)	90,378 (38 RCTs)	⊕⊕⊕⊕ High <sup>c</sup>	Meta-analysis and indications of bias suggest risk reduction of less than 1%. Long-chain omega-3 fat intake makes little or no difference to risk of cardiovascular events
<b>Coronary heart disease mortality</b> - CHD deaths Assessed with: coronary deaths, or where these were not reported, IHD death, fatal MI or cardiac death (in that order) Duration: range 12 to 72 months	22 per 1,000	21 per 1,000 (18 to 24)	RR 0.93 (0.79 to 1.09)	73,491 (21 RCTs)	⊕⊕⊕○ Moderate <sup>d</sup>	Meta-analysis and indications of bias suggest risk reduction of less than 7%. Long-chain omega-3 fat intake probably makes little or no difference to coronary heart mortality
<b>Coronary heart disease events</b> - CHD events Assessed with: number of participants experiencing the first outcome in this list reported for each trial: CHD or coronary events; total MI; acute coronary syndrome; or angina (stable and unstable) Duration: range 12 to 72 months	68 per 1,000	63 per 1,000 (59 to 65)	RR 0.93 (0.88 to 0.97)	84,301 (28 RCTs)	⊕⊕⊕○ Moderate <sup>e</sup>	Meta-analysis and indications of bias suggest risk reduction of less than 7%. Long-chain omega-3 fat intake probably makes little or no difference to risk of coronary heart events

<b>Stroke</b> Assessed with: number of participants experiencing at least one fatal or non-fatal, ischaemic or haemorrhagic stroke Duration: range 12 to 72 months	20 per 1,000	21 per 1,000 (19 to 23)	RR 1.06 (0.96 to 1.16)	89,358 (28 RCTs)	⊕⊕⊕○ Moderate <sup>f</sup>	Meta-analysis and indications of bias suggest increased risk of less than 6%. Long-chain omega-3 fat intake probably makes little or no difference to risk of experiencing a stroke
<b>Arrhythmias</b> Assessed with: number of participants experiencing fatal or non-fatal, new or recurrent arrhythmia, including atrial fibrillation, ventricular tachycardia and ventricular fibrillation Duration: range 12 to 72 months	68 per 1,000	66 per 1,000 (62 to 72)	RR 0.97 (0.90 to 1.05)	53,796 (28 RCTs)	⊕⊕⊕○ Moderate <sup>g</sup>	Meta-analysis and indications of bias suggest risk reduction of less than 3%. Long-chain omega-3 fat intake probably makes little or no difference to risk of arrhythmia
<b>Harms: bleeding</b> Assessed with: number of participants experiencing bleeding events Duration: range 12 to 72 months	8 per 1,000	8 per 1,000 (5 to 11)	RR 1.06 (0.73 to 1.52)	45,562 (8 RCTs)	⊕○○○ Very low <sup>h</sup>	The effect of long-chain omega-3 fat intake on bleeding is unclear as the evidence is of very low quality
<b>Harms: pulmonary embolus or DVT</b> Assessed with: number of participants experiencing pulmonary embolus or deep vein thrombosis Duration: range 18 to 36	5 per 1,000	6 per 1,000 (2 to 18)	RR 1.25 (0.41 to 3.78)	3,011 (4 RCTs)	⊕○○○ Very low <sup>i</sup>	The effect of long-chain omega-3 fat intake on pulmonary embolus or DVT is unclear as the evidence is of very low quality

months

\***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CHD:** coronary heart disease; **CI:** confidence interval; **DVT:** deep vein thrombosis; **IHD:** ischaemic heart disease; **MI:** myocardial infarction; **RCT:** randomised controlled trial; **RR:** risk ratio.

#### GRADE Working Group grades of evidence

**High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

**Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

#### <sup>a</sup>All-cause mortality, LCn3

- **Risk of bias:** effect size moved closer to no effect (RR 1.0) when analysis was limited to studies at low summary risk of bias and low risk of compliance bias (adding weight to the suggestion of little or no effect) but did not alter with fixed-effect meta-analysis or results in the analysis limited to larger studies. It was further noted by the WHO NUGAG Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded.

- **Inconsistency:**  $I^2$  was < 60% and  $I^2$  reduced when analysis was limited to studies at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not downgraded.

- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income countries were represented but underrepresented. Not downgraded.

- **Imprecision:** tight confidence intervals, very large numbers of participants have taken part in RCTs in long-term studies with consistent results. Given the lack of a statistically significant effect in this very large set of participants, any effect appears too small to be individually relevant. Not downgraded.

- **Publication bias:** the funnel plot suggested that some small studies with higher numbers of events in the intervention group might be missing. If such missing studies were added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded.

#### <sup>b</sup>Cardiovascular mortality, LCn3

- **Risk of bias:** effect size moved closer to no effect (RR 1.0) when analysis was limited to studies at low summary risk of bias and low risk of compliance bias (adding weight to the suggestion of little or no effect) but did not alter with fixed-effect meta-analysis or results in the analysis limited to larger studies. It was further noted by the WHO NUGAG Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of

effect. This is less of a concern for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded.

- **Inconsistency:**  $I^2$  was < 60% and  $I^2$  reduced when analysis was limited to studies at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not downgraded.

- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. All studies were conducted in high-income countries. Not downgraded.

- **Imprecision:** Although very large numbers of participants have taken part in RCTs in long-term studies, with consistent results, the 95%CI includes the null. Given the lack of a statistically significant effect in this very large set of participants, any effect appears too small to be individually relevant. However, as 95% confidence intervals do not exclude important benefits or harms. Downgraded once.

- **Publication bias:** the funnel plot suggested that some small studies with higher numbers of events in the intervention group might be missing. If such missing studies were added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded.

#### <sup>c</sup>Cardiovascular events, LCn3

- **Risk of bias:** effect size moved closer to no effect (RR 1.0) when analysis was limited to studies at low summary risk of bias and low risk of compliance bias (adding weight to the suggestion of little or no effect) but did not alter with fixed-effect meta-analysis or results in the analysis limited to larger studies. It was further noted by the WHO NUGAG Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded.

- **Inconsistency:**  $I^2$  was < 60% and  $I^2$  reduced when analysis was limited to studies at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not downgraded.

- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income countries were represented but underrepresented. Not downgraded.

- **Imprecision:** very large numbers of participants have taken part in RCTs in long-term studies with consistent results. Given the lack of an important effect in this very large set of participants, any effect appears too small to be individually relevant. However, as 95% confidence intervals do not exclude important benefits or harms, we downgraded once.

- **Publication bias:** the funnel plot suggested that some small studies with higher numbers of events in the intervention group might be missing. If such missing studies were added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded.

#### <sup>d</sup> Coronary heart disease mortality, LCn3

- **Risk of bias:** effect size moved closer to no effect (RR 1.0) when analysis was limited to studies at low summary risk of bias and low risk of compliance bias (adding weight to the suggestion of little or no effect) but did not alter with fixed-effect meta-analysis or results in the analysis limited to larger studies. It was further noted by the WHO NUGAG Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded.

- **Inconsistency:**  $I^2$  was < 60% and  $I^2$  reduced when analysis was limited to studies at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. All studies were conducted in high-income countries. Not downgraded.
- **Imprecision:** very large numbers of participants have taken part in RCTs in long-term studies with consistent results. Given the lack of a statistically significant effect in this very large set of participants, any effect appears too small to be individually relevant. However, as 95% confidence intervals do not exclude important benefits or harms we downgraded once.
- **Publication bias:** the funnel plot suggested that some small studies with higher numbers of events in the intervention group might be missing. If such missing studies were added back in the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded.

#### <sup>e</sup> Coronary heart disease events, LCn3

- **Risk of bias:** effect size moved closer to no effect (RR 1.0) when was analysis limited to studies at low summary risk of bias. This adds weight to the suggestion of little or no effect. However, effect size did not alter with fixed-effect meta-analysis or limiting to studies at low risk of compliance bias or larger trials. It was further noted by the WHO NUGAG Subgroup on Diet and Health that there was a significant effect observed in main analysis but the effect moved closer to a non-significant, null effect when analysis was limited to studies at low summary risk of bias. Downgraded once.
- **Inconsistency:**  $I^2$  was < 60% and  $I^2$  reduced when analysis was limited to studies at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income countries were represented but underrepresented. Not downgraded.
- **Imprecision:** 95%CI did not include the null. Not downgraded.
- **Publication bias:** the funnel plot suggested that some small studies with higher numbers of events in the intervention group might be missing. If such missing studies were added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded.

#### <sup>f</sup> Stroke, LCn3

- **Risk of bias:** effect size moved closer to no effect (RR 1.0) when analysis limited to studies at low summary risk of bias (adding weight to the suggestion of little or no effect), but did not alter with fixed-effect meta-analysis or limiting to larger studies. Limiting to studies at low risk of compliance problems resulted in the suggestion of greater harm. It was further noted by the WHO NUGAG Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded.
- **Inconsistency:**  $I^2$  was < 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income countries were represented but underrepresented. Not downgraded.
- **Imprecision:** very large numbers of participants have taken part in RCTs in long-term studies with consistent results. Given the lack of a statistically significant effect in this very large set of participants any effect appears too small to be individually relevant. However, as 95% confidence intervals do not exclude important benefits or harms, we downgraded once.

- **Publication bias:** the funnel plot did not suggest any small study bias. Not downgraded.

#### <sup>g</sup> Arrhythmias, LCn3

- **Risk of bias:** effect size remained similar in most sensitivity analyses, but moved closer to no effect (RR 1.01) when analysis used fixed-effect meta-analysis (adding weight to the suggestion of little or no effect) and suggested harm when limited to studies at low summary risk of bias. Not downgraded.
- **Inconsistency:**  $I^2$  was < 60% and  $I^2$  reduced when analysis was limited to studies at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income countries were represented but underrepresented. Not downgraded.
- **Imprecision:** As 95% confidence intervals do not exclude important benefits we downgraded once.
- **Publication bias:** funnel plot not interpretable as studies all of a similar size and weight. Not downgraded.

#### <sup>h</sup> Bleeding, LCn3

- **Risk of bias:** effect size changed direction (from harmful to protective) when analysis limited to studies at low summary risk of bias. Downgraded once.
- **Inconsistency:**  $I^2$  was < 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income countries not represented. Not downgraded.
- **Imprecision:** 95% confidence intervals do not exclude large and important benefits or harms. Downgraded twice.
- **Publication bias:** insufficient studies for funnel plot. Not downgraded.

#### <sup>i</sup> Pulmonary embolus or DVD, LCn3

- **Risk of bias:** effect size suggested greater harm when analysis limited to studies at low summary risk of bias. Downgraded once.
- **Inconsistency:**  $I^2$  was < 60%. Not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. Low- and middle-income countries not represented. Not downgraded.
- **Imprecision:** 95% confidence intervals do not exclude large benefits or large harms. Downgraded twice.
- **Publication bias:** insufficient studies for funnel plot. Not downgraded.



## BACKGROUND

### Description of the condition

Cardiovascular diseases (CVDs) are disorders of the heart and blood vessels. They include cerebrovascular disease (including stroke and transient ischaemic attack), coronary heart disease (including heart attack or myocardial infarction and angina), peripheral arterial disease (diseases of the blood vessels to the arms and legs), deep vein thrombosis and pulmonary embolism (blood clots formed in the legs which can move to the heart and lungs), as well as rheumatic and congenital heart disease (WHO 2017); these last two are not discussed in this review. Globally, 31% of all global deaths are due to CVD, more than from any other cause (WHO 2017). Of the 17.7 million people who died from CVDs in 2015, 7.4 million were due to coronary heart disease and 6.7 million due to stroke. Of 17 million premature deaths in 2015 caused by non-communicable diseases, 82% were in low- and middle-income countries, and 37% were caused by CVDs (WHO 2017).

### Description of the intervention

Omega-3 fats (also called  $\Omega 3$  or n-3 fats) from fish sources include eicosapentaenoic acid (EPA, or 20:5), docosahexaenoic acid (DHA, 22:6) and docosapentaenoic acid (DPA, 22:5), the longer chain omega-3 fats (LCn3). Alpha-linolenic acid (ALA or  $\alpha$ -linolenic, 18:3) is the shorter chain omega-3 fat found in plants and grass-fed, which is partially converted to longer chain omega-3 fatty acids within our bodies. There is some debate about the effectiveness of this conversion, which may differ depending on whether it is assessed over the short or long term as well as on other dietary factors (Li 1999; Pawlosky 2001). For this reason the effectiveness of ALA may differ from that of the longer chain omega-3 fats.

Since Bang and colleagues first suggested that the abundance of omega-3 fatty acids in the diet of the Greenland Inuit people was responsible for their low mortality from ischaemic heart disease (Bang 1972; Bang 1976), there has been considerable interest in the protective role and possible mechanism of action of marine unsaturated fats. This interest has spread to encompass plant seeds and oils rich in omega-3 fatty acids, including chia seed, flax (linseed) and rapeseed (canola) oils (Nettleton 1991), their derivatives (e.g. margarines), purslane leaves (Simopoulos 1992), and nuts (especially walnuts).

### How the intervention might work

Proposed mechanisms for the protective role of omega-3 fats against cardiovascular diseases include: lowering the blood pressure; altering the lipid profile, especially reduced serum triglyceride concentration; modulating arterial lipoprotein lipase levels;

reducing thrombotic tendency; producing anti-inflammatory effects and anti-arrhythmic effects; improving vascular endothelial function and insulin sensitivity; and increasing plaque stability and paraoxonase levels (Bharnagar 2003; BNF 1999; Calabresi 2004; Chang 2013; Geelen 2004).

Given that most omega-3 fats are ingested in the form of oily fish or fish oil (often fish liver) capsules, reports of high levels of various toxic compounds such as mercury, dioxins and polychlorinated biphenyls (PCBs) in oily fish and fish oils are concerning (FSA 2000; Liem 1997; MAFF 1998A; USFDA 1995). These are all fat soluble and accumulate over time in the body, so harms may be exhibited only after long-term fish consumption or supplementation with fish oils. Animal intervention studies and human cohorts who have suffered accidental exposure to dioxins and PCBs suggest that pre-natal exposure may cause sub-fertility problems, and adult exposures may lead to an excess of total cancers (JECFA 2001). Human cohorts exposed to high levels of mercury exhibit neurological problems (USFDA 1995). As many people eat oily fish once or twice a week or take fish oil supplements, it is important to explore the potentially harmful effects of fish-associated omega-3 intake. It is also possible that omega-3 fats themselves may exhibit harm, for example through extension of bleeding times or suppression of normal immune responses (USFDA 2000).

Cardiovascular effects of eating more oily fish may differ from those of taking a fish oil supplement because fish (not fish oil) is a rich source of nutrients including selenium, iodine, zinc, calcium and protein. Fish in the diet may also displace a variety of other foods including sources of saturated or trans fats, so it could alter CVD in other ways.

### Why it is important to do this review

There is a great deal of public belief in the cardiovascular benefits of omega-3 fats. Analysis of US National Health and Nutrition Examination Survey data from 2003 to 2008 suggests that in the USA, adults' mean long-chain omega-3 intakes were greater from dietary supplements (0.72 g/d EPA and DHA) than from foods (0.41 g/d, Papanikolaou 2014). But public health advice differs across countries. For example, the National Institute for Health and Clinical Excellence in the UK now encourages fish intake but discourages supplementation: "people with or at high risk of CVD should be advised to consume at least 2 portions of fish per week, including a portion of oily fish". However, it advises that omega-3 fatty acid compounds "should not be offered for primary or secondary prevention of CVD" (NICE 2016). The American Heart Association (AHA) also "recommends eating fish (particularly fatty fish) at least two times (two servings) a week". Although the AHA suggests that omega-3 intake via foods is preferable, the AHA is more positive about omega-3 supplements: "those with coronary artery disease may not get enough omega-3 by diet alone. These people may want to talk to their doctor about supplements.

And for those with high triglycerides, even larger doses could help” (AHA 2016). These recommendations are balanced with a warning about potential excessive bleeding in those taking doses of > 3 g/d omega-3 fatty acids (presumably long-chain omega-3 fats). Such recommendations, and resulting increased fish consumption, have potentially negative long-term consequences for our marine ecosystems (Brunner 2009).

Epidemiological studies have supported the relationship between high omega-3 intake and lower cardiovascular disease (CVD) rates (Ballard-Barbash 1987; Burr 1993; Kris-Etherton 2002). However, these associations could be due to some other characteristic of people who choose to eat fish. In many societies eating fish is associated with better social status and a health-conscientious life view (Cade 2007), so eating fish is highly confounded by dietary quality, socioeconomic status and other markers of healthy lifestyles. As an example, the global attributable burden of eating a diet low in seafood omega-3 fats was estimated as 1.1% of global disability-adjusted life-years (DALYs; 95% CI 0.8 to 1.5), “with 22% of ischaemic heart disease DALYs attributable to low seafood intake” (Engell 2013). The data sources are not described, but when the estimate was derived from RCTs alone, rather than cohort studies and RCTs combined, the estimated global attributable burden was much smaller, 0.5% (95% CI –0.5 to 1.4). Information concerning cause and effect is more reliably supplied by intervention trials in which participants are randomly allocated to receive fish oil or advice to eat more fish.

Systematic reviews of randomised controlled trials (RCTs) have had various findings. An earlier version of this review found no effects for omega-3 fats on all-cause mortality or cardiovascular outcomes in trials of at least six months’ duration (which included > 36,000 participants) (Hooper 2004). Since Hooper 2004 was published, several other systematic reviews have suggested a lack of effect for omega-3 fats on all-cause mortality or a variety of CVDs (Campbell 2013; Chowdhury 2012; Khoueiry 2013; Korwal 2012; Kwak 2012; Mariani 2013; Rizos 2012; Zheng 2014). However, others have highlighted particular outcomes or circumstances in which CVD prevention was evident: after heart surgery (He 2013), for preventing sudden cardiac death (Zhao 2009), for reducing CVD mortality and sudden cardiac death (although with no effect on all-cause mortality) (Trikalinos 2012), for CVD mortality (Sethi 2016), and for reducing the risk of stroke in women (albeit with no effect on stroke overall) (Larsson 2012). Kwak 2012 reported marginal effects on cardiovascular death, though these were lost when a poor-quality trial was removed, and a few others have reported only positive effects in their abstracts (reductions in cardiovascular events, cardiac death and coronary events) (Delgado-Lista 2012). These disparate findings have fuelled both debate and confusion. A recent extensive Agency for Healthcare Research and Quality review meta-analysed risk factors extensively but suggested there was only limited RCT data to assess the effects of omega-3 fats on clinical CVD outcomes (Balk 2016).

This systematic review and meta-analysis aimed to assess the evidence on the effects of omega-3 fats (long-chain and ALA separately) on all-cause mortality and CVDs. It also aimed to assess potentially harmful effects of omega-3 fats or compounds associated with consuming long-chain omega-3 fats such as excessive bleeding. A related review has formally systematically reviewed potential harms such as excessive cancers, rather than simply examining studies included in this review for cancer outcomes (Hanson 2017b). We assessed mechanisms of action such as lipid and body weight changes and antiarrhythmic effects as primary or secondary outcomes in this review, and we have systematically reviewed these outcomes in a formal way by including trials that assessed adiposity, lipids and arrhythmic events even where no CVD events occurred or were reported. Sister systematic reviews have assessed anti-inflammatory effects and effects on inflammatory bowel disease (Thorpe 2017), as well as effects on insulin sensitivity and glucose metabolism (Brown 2017).

The World Health Organization (WHO) is currently updating its guidance on polyunsaturated fatty acid intake in adults and children. The update and expansion of this review was commissioned by WHO in order to inform and contribute to the development of updated WHO recommendations. The results of this review including GRADE assessments were discussed and reviewed by the WHO Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health as part of WHO’s guideline development process.

## OBJECTIVES

To assess the effects of increased intake of fish- and plant-based omega-3 for all-cause mortality, cardiovascular (CVD) events, adiposity and lipids.

The primary review question was, ‘Do long-chain omega-3 (LCn3, fish-based omega-3 fats) or ALA (plant-based omega-3 fats) fats alter risk of all-cause mortality, cardiovascular deaths, cardiovascular events, coronary heart disease deaths, coronary heart disease events, stroke, arrhythmia, adiposity and lipids?’

Secondary questions include the following.

- If omega-3 fatty acids confer protection:
  - does protection occur equally in those at low and at high risk of cardiovascular disease?
  - does protection depend on the dose of omega-3 fats taken per day?
  - do effects differ between dietary and supplemental omega-3 sources?
  - does protection depend on study summary risk of bias?

- Is protection or harm stronger with longer trial duration?

## METHODS

### Criteria for considering studies for this review

#### Types of studies

We included randomised controlled clinical trials that included diet advice or dietary supplementation to promote omega-3 fatty acid intake versus placebo, no supplementation, usual diet or lower dose omega-3. One of our outcomes had to be measured and available (through publications or contact with authors), and trials had to follow participants for at least 12 months (52 weeks or 360 days) for mortality and cardiovascular outcomes. For advice trials, follow-up must have been at least 12 months following advice, and for trials where participants received food or supplementation, provision must have continued for at least 12 months). We accepted randomisation of individuals or of clusters as long as there were at least six clusters randomised.

Careful work by Browning suggests that supplements of EPA and DHA equivalent to one weekly portion of oily fish results in 95% of maximal incorporation by 5 days for EPA in plasma phosphatidylcholine (95% CI 0 to 18 days) to 273 days for DHA into blood mononuclear cells (95% CI 0 to 670 days) (FISH 2012). While this suggests individual variability, on average all compartments except blood mononuclear cells had equilibrated by 117 days (both EPA and DHA into plasma phosphatidylcholine, plasma cholesteryl esters, plasma nonesterified fatty acids, plasma triglycerides, erythrocytes and platelets). The authors stated “EPA and DHA reached a maximum in platelets in 3–4 weeks and 1–2 months, respectively, and in blood mononuclear cells in 6–9 months”. For this reason we chose 12 months as the minimum duration of intervention, as it allows equilibration of most body compartments with EPA and DHA as well as time for this change in body composition to have some effect on cardiovascular risk or mortality.

In previous reviews of dietary effects on cardiovascular outcomes, we limited trials to at least two years’ duration (Hooper 2015), as the proposed mechanism of effects was via LDL cholesterol, atherosclerosis and its sequelae, and this takes time to develop. The 4S trial showed separation of the survival curves at around two years (Scandinavian Simvastatin Survival Study Group 1994). Potential mechanisms for effects of polyunsaturated fatty acids (PUFAs) are broader, including what could be rapid effects on arrhythmias or inflammation, so we decided to include trials of at least 12 months to ensure we did not miss these effects.

#### Types of participants

Studies in adults (18 years or older, men and/or women) at any risk of cardiovascular disease (with or without existing cardiovascular disease) were eligible, including those in participants with increased risk of cancer, those undergoing or who have undergone coronary artery bypass grafting or angioplasty, and those with current or previous cardiovascular disease, nephritis in systemic lupus erythematosus, breast cysts, diabetes mellitus, rheumatoid arthritis, multiple sclerosis, psoriasis, hay fever, asthma or ulcerative colitis. Including these populations allows us to understand both development and progression of cardiovascular disease (primary and secondary prevention). We excluded participants who were pregnant or acutely ill (with acute-stage cancer, undergoing heart or renal transplantation, with HIV or AIDS, on haemodialysis, with IgA glomerulonephritis, or any other renal problem except in diabetes).

#### Types of interventions

The intervention must have been dietary supplementation, a provided diet or advice on diet. The foodstuffs or supplements must have been: oily fish (including mackerel, dogfish, salmon, herring, trout, tuna, sturgeon, stablefish, anchovy, sprat, coho, capelin, sardines, swordfish, sild, pilchard, brisling, menhaden, bloater, whitebait, crab and conger eel); fish oils (made from any of the above or a mixture of fish, or cod liver oil); linseed (flax), canola (rapeseed), perilla, purslane, mustard seed, candlenut, stillingia or walnut as a food, capsule, oil, made into a spreading fat or supplementing another food (such as bread or eggs). For ALA sources the product consumed had to have an omega-3 fat content of at least 10% of the total fat content. Refined eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or alpha-linolenic acids, or concentrated fish or algal oils, were also accepted. Supplementation may have been in oil or capsule form or as foodstuffs provided to be consumed by mouth (excluding enteral and parenteral feeds and enemas).

We excluded studies using multiple risk factor interventions on lifestyle factors (such as weight reduction, smoking or physical activity goals), or differential dietary interventions not involving dietary fats, except where that other intervention was a direct replacement for polyunsaturated fats or the effect of diet or supplementation could be separated out from the other interventions. Studies were eligible if they compared the effect of dietary advice or supplementation to increase omega-3 fats with the usual diet, no advice, no supplementation, placebo or lower dose omega-3.

#### Types of outcome measures

##### Primary outcomes

Primary outcomes included numbers of participants experiencing:

- all-cause mortality (deaths);

- cardiovascular mortality (cardiovascular deaths);
- cardiovascular events (cardiovascular events);
- coronary heart disease mortality (CHD deaths);
- coronary heart disease events (CHD events);
- stroke; and
- arrhythmia (atrial fibrillation).

We analysed coronary heart disease using the first of the following to be reported: number of participants experiencing CHD or coronary events, total myocardial infarction (MI), acute coronary syndrome or angina (stable and unstable). This meant that if trialists reported CHD events, we used these in analysis and ignored the other outcomes; where trials did not report CHD events but did report total MI, we used that (and so on). Combined cardiovascular events included fatal and non-fatal myocardial infarction, angina, stroke, heart failure, peripheral arterial disease, sudden death and non-scheduled cardiovascular interventions - coronary artery bypass surgery or angioplasty. We included all available outcomes where we could be sure that the same participant was not being counted twice.

At the request of WHO NUGAG Subgroup on Diet and Health, we added CHD mortality post hoc as a primary outcome. Data used were the first of the following list reported: coronary death, ischaemic heart disease (IHD) death, fatal MI, cardiac death. We only used cardiac death when no other outcomes in this category were available, and we ran a sensitivity analysis omitting cardiac death. The reason for excluding cardiac death in sensitivity analysis was that it goes slightly outside our area of interest, including other causes of death in addition to CHD, such as cardiomyopathies and congenital and valvular heart diseases. We wanted to include cardiac death in the main analysis as we felt that otherwise we would be missing some important cases of coronary heart mortality, but we decided to exclude it in sensitivity analysis as we were potentially including a few outcomes that CHD mortality did not encompass.

### Secondary outcomes

Secondary outcomes included:

- major adverse cerebrovascular or cardiovascular events (MACCEs) or individual cardiovascular events (total, fatal or non-fatal MI, sudden cardiac death, angina, heart failure, revascularisation, peripheral arterial disease or acute coronary syndrome);
- body weight and other measures of adiposity; and
- lipids (total, LDL or HDL cholesterol and triglycerides).

We defined MACCEs as participants experiencing MI, unstable angina, stroke or death. We did not consider studies that did not provide data on all these health events for this outcome.

The review included studies if any of their participants experienced or were assessed for any primary or secondary outcome. These could have been reported in publications (as outcomes or reasons for dropout or adverse events), supplied by study authors,

or which clearly happened even if exact numbers were not available. However, as almost all trials note if a death or cardiovascular event occurs in a study participant (so ALL trials assess for our primary outcomes) we only included trials where at least one event occurred, or where a continuous outcome was measured.

### Tertiary outcomes

We extracted the following outcomes where available within included studies.

- Blood pressure.
- Serious adverse events (any other reported illnesses).
- Side effects.
- Dropouts.
- Quality of life measures.
- Economic costs.

We originally intended to assess type 2 diabetes diagnoses, measures of glucose metabolism, cancers, breast cancer, neurocognitive outcomes such as dementia, depression and anxiety within included studies. However, as part of the larger set of reviews we formally systematically reviewed effects of omega-3 fats on type 2 diabetes diagnoses and measures of glucose metabolism (Brown 2017), cancers including breast cancer (Hanson 2017b), neurocognitive outcomes such as dementia (Jimoh 2017), irritable bowel disease (IBD) and inflammatory factors (Thorpe 2017), depression and anxiety (Hanson 2017a), and functional outcomes (Abdelhamid 2017), so a partial assessment within this review would be unhelpful and potentially misleading. For this reason we exclude these specific outcomes from our reporting of serious adverse events.

### Key outcomes

When the World Health Organization (WHO) Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health requested this review update they named the following as key outcomes to inform their planned dietary guidance.

- All-cause mortality.
- CVD mortality.
- CVD events.
- CHD mortality.
- CHD events.
- Stroke.
- Arrhythmia (atrial fibrillation).
- Serum lipids including total cholesterol (TC), fasting triglycerides (TG), high-density lipoprotein (HDL) and low-density lipoprotein (LDL).
- Measures of adiposity (body weight and body mass index).

We were not able to make all of these outcomes into primary outcomes. However, because WHO NUGAG Subgroup on Diet and Health will use these outcomes to underpin guidance, we carried out sensitivity analyses, subgroup analyses and GRADE

assessment of quality of evidence for them, even when they were not primary outcomes.

## Search methods for identification of studies

### Electronic searches

We searched the following electronic databases on 27 April 2017 to identify reports of relevant randomised clinical trials.

- Cochrane Central Register of Controlled Trials (CENTRAL; 2017; Issue 3) in the Cochrane Library.
- Epub Ahead of Print, In-Process & Other Non-Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 27 April 2017).
- Embase Classic and Embase (Ovid, 1947 to 2017 week 17).

We applied date limits to the terms from the original strategies so that the search included only new records, but we did not apply any date limits to newly added terms. [Appendix 1](#) shows the MEDLINE search strategy for the original version of this review, and [Appendix 2](#) shows the updated searches. We de-duplicated the results against each other. The RCT filter for MEDLINE was the Cochrane sensitivity and precision-maximising RCT filter, and for Embase, we applied the terms as recommended in the *Cochrane Handbook for Systematic Reviews of Interventions* ([Lefebvre 2011](#)). As we were also running searches for a new systematic review of the effects of polyunsaturated fats on cardiovascular disease ([Abdelhamid 2018](#)), as well as updating and extending a Cochrane Review of the effects of omega-6 polyunsaturated fats on health outcomes ([Hooper 2018](#)), we also ran searches for these reviews using the same RCT filters ([Appendix 3](#)). The results of these searches were de-duplicated against the omega-3 searches, and all the titles and abstracts assessed as a single set for all three reviews. We created a dataset of RCTs that lasted at least six months and compared higher versus lower omega-6, omega-3 or total polyunsaturated fatty acids (PUFA) in adults. We used this dataset as the wider study pool from which we selected included studies for all reviews ([Abdelhamid 2018](#); [Abdelhamid 2017](#); [Hooper 2018](#); [Brown 2017](#); [Hanson 2017a](#); [Hanson 2017b](#); [Jimoh 2017](#); [Thorpe 2017](#); [Hooper 2004](#)).

We searched two trials registers, ClinicalTrials.gov ([clinicaltrials.gov](http://clinicaltrials.gov)) and the WHO International Clinical Trials Registry Platform (ICTRP, [www.who.int/ictRP/en](http://www.who.int/ictRP/en)) on 23 September 2016 for registry entries for relevant completed and ongoing studies.

### Searching other resources

We assessed titles and abstracts retrieved during these electronic searches for relevant RCTs and also relevant systematic reviews. We handsearched the included studies in all relevant systematic reviews for new trials and additional publications of included trials.

We contacted authors of all large included studies (at least 100 participants) and some smaller trials for further study data, methodological details and references to studies not yet identified, including published, unpublished or ongoing studies.

## Data collection and analysis

### Selection of studies

At least two reviewers independently assessed titles and abstracts resulting from the electronic and bibliographic searches. We combined the search results for this review and two others, [Abdelhamid 2018](#) and [Hooper 2018](#), de-duplicating and assessing them at the same time. We rejected titles and abstracts on initial screen only if the reviewer could determine from the title and abstract that the article was not a report of a randomised controlled trial; did not address omega-3 intake (or total polyunsaturated fat or omega-6 fat for the other two reviews); were exclusively in children or young adults (less than 18 years old), pregnant women or the critically ill; were of less than 12 months' duration; or if the intervention was multi-factorial and we could not separate out the effect of dietary fat.

We rejected studies only when it was certain that no primary or secondary outcome events occurred, and none of the secondary outcome risk factors were measured. When we could not reject a title/abstract with certainty, we obtained the full text of the article for further evaluation. We made attempts to obtain full-text translations and/or evaluations of all potentially relevant non-English articles.

We used an in/out form to assess full-text papers and studies for inclusion (or otherwise) into the review. We contacted the authors of all potentially included RCTs for further information on trial methodology and outcomes. Two assessors independently decided on inclusion of full-text RCTs, resolving any differences by discussion and, when necessary, in consultation with the review team.

### Data extraction and management

We designed a data extraction form for this review, which each of the reviewers tested on a common 'training' study ([SCIMO 1999](#)), and we adapted it as appropriate. We extracted data concerning participants, interventions, and outcomes, as described above in the selection criteria section. We extracted dichotomous data from dietary advice studies at the latest point available in the trial (regardless of the amount of reinforcement of the original dietary message), while for supplement studies, we extracted dichotomous data to the point that supplementation or the trial ended, whichever was earlier. We extracted continuous data at the nearest time point to 12 months and also the latest point available in fixed-term trials, but in studies where participants were followed up for varying durations (aside from dropouts), we extracted the



participants' data from the first time point following the mean trial duration. We never used data from periods following the end of a trial in meta-analysis.

We also extracted data on risk of bias, assessed using the Cochrane 'Risk of bias' tool, along with data on potential effect modifiers, including existing cardiovascular disease (primary or secondary prevention), trial duration, intensity of intervention (dietary advice, diet provided, supplemental foods, supplements (capsules) and any combination), long-chain omega-3 fats or ALA and dose, replacement, medications used (including statins, antihypertensive, antiarrhythmic or antithrombotic medication), fatty acid data (from plasma, platelets or adipose tissue) and smoking status.

For primary and secondary dichotomous outcomes, we extracted numbers of participants experiencing an outcome and total numbers of participants randomised (or in whom the outcome was assessed where known) for each study arm. For continuous outcomes, we extracted the number of participants assessed, means and standard deviations of the final readings in each treatment arm; we calculated standard deviations from other variance data where appropriate. Where data were available on both change and final readings, we used data on change.

Two reviewers independently extracted original reports of trial results. We resolved differences between reviewers' results by discussion and, when necessary, in consultation with a third reviewer or the review team.

### Assessment of risk of bias in included studies

Two reviewers independently assessed risk of bias for each included study, using Cochrane criteria (Higgins 2011), including in the domains of sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessors; incomplete outcome data; and selective outcome reporting. Additional review-specific criteria included similarity of type and intensity of intervention in both arms (attention) and evidence of appropriate moderate to high compliance (to establish that the intervention group were receiving a different intake of omega-3 fats than the control group). Table 1 presents specific details of how we interpreted these criteria for this review.

We considered a study to be at low risk of attention bias when participants were given the same amount of time and attention from study staff and health professionals whether they were in the intervention or control arms, and at low risk of compliance bias when adherence was assessed, results of that assessment were clearly reported for both intervention and control arms, and where most participants appeared to have taken at least 75% of the intended PUFA dose.

### Summary risk of bias

Schulz 1995 found that poorly concealed allocation was associated with a 40% greater effect size, so randomisation and allocation concealment are core issues for all trials. Lack of blinding

is associated with bias, though smaller levels of bias than lack of allocation concealment (Savovic 2012), especially in studies with objectively measured outcomes (Wood 2008), such as those we primarily used in our review. Although we originally planned to assess summary risk of bias for all included trials in the same way across this review, the omega-3 review and the total PUFA review (Abdelhamid 2018; Hooper 2018; Hooper 2004), we adopted a different approach after discussing the different nature of supplement trials compared to dietary advice or food provision trials with the WHO NUGAG Subgroup on Diet and Health.

We considered supplement or capsule type trials to be at low summary risk of bias where we judged randomisation, allocation concealment, blinding of participants and personnel, and blinding of outcome assessors to be adequate. We considered all other trials to be at moderate or high risk of bias (a single category).

We considered dietary advice or all-food-provided type trials to be at low summary risk of bias where we judged randomisation, allocation concealment, and blinding of outcome assessors to be adequate. We considered all other trials to be at moderate or high risk of bias (a single category).

### Measures of treatment effect

We pooled dichotomous data using risk ratios (RR) to describe effect sizes and continuous data using mean differences (MD). Where effects were described by different but comparable measures or scales in different studies, we combined them using standardised mean difference (SMD).

### Unit of analysis issues

We considered that we could reduce patient numbers in cluster-randomised trials to an effective sample size, as described by Hauck 1991; however, we identified no such trials. For combined outcomes (e.g. combined cardiovascular events), we made attempts to add numbers of individuals experiencing specific outcomes within studies, but only where we could be certain that we were not counting individual participants more than once within any one of our review outcome categories.

For studies with intervention arms providing different omega-3 doses, we combined data for the intervention groups for binary outcomes and used data on higher dose data versus control for continuous outcomes. We used arms with different doses separately when subgrouping by dose. Where factorial trials ran more than one intervention included in this review (AlphaOmega - ALA 2010; AlphaOmega - EPA+DHA 2010), we did not pool both comparisons in the same meta-analysis.

### Dealing with missing data

We sought trials registry entries and study protocols to help us assess which studies measured each outcome. Where trials appeared to have collected - but did not report - data, we wrote to study

authors to ask for information. We wrote to authors of all studies that randomised at least 100 participants as well as to those of many smaller studies (although not to all due to limited resources), prioritising our efforts on larger studies that would tend to provide more information to the review. For larger studies where we found no trials registry entry or protocol, we wrote to study authors to ask whether they had collected information on any outcomes of interest that we had not yet located. Where it was clear that data existed but could not be located to use within the review, we noted this and assessed the potential effect of this missing data on effect sizes narratively.

### Assessment of heterogeneity

We assessed heterogeneity using the  $I^2$  test and assumed it to be important when  $I^2$  was more than 60% (Higgins 2003).

### Assessment of reporting biases

We used funnel plots to assess for evidence of bias for primary outcomes where at least 10 studies contributed to the meta-analysis (Egger 1997).

### Data synthesis

Primary measures of interest were effects of dietary advice or supplementation of fish-based (long-chain, LCn3) omega-3 fats, and alpha linolenic acid (ALA), on primary outcomes. We separated out effects of LCn3 and ALA in all analyses and thus present two separate sets of results: one for ALA and one for LCn3.

We combined treatment/control differences in the outcomes across studies using relative risks (RR) or mean differences (MD) in random-effects meta-analysis. For combined outcomes (e.g. combined cardiovascular events), we made attempts to add numbers of individuals experiencing specific outcomes within studies, but only where we were certain that we were not counting individual participants more than once within any one of our review outcome categories. However, individuals may have been counted for more than one of the review outcomes (in separate forest plots).

### Subgroup analysis and investigation of heterogeneity

We explored the effects of LCn3 and ALA separately on all primary review outcomes and also on key review outcomes where these were secondary outcomes in our review and included at least six studies by subgrouping. The planned subgroup analyses were:

- type of intervention - dietary advice, supplemental foods (for example margarine fortified with rapeseed, tins of sardines or oils to use in cooking) provided by the study, supplements (capsules or oils) provided to take as medicine or any combination;
- replacement of saturated fatty acids (SFA), mono-unsaturated fatty acids (MUFA), omega-6 fats, fat mixture,

carbohydrates or sugars, non-fat or no placebo, or unclear, with LCn3 or ALA;

- primary prevention versus secondary prevention of CVD;
- LCn3 dose: at least 150 mg/d, 250 mg/d, 400 mg/d from all sources including supplements (above or below each threshold) - low dose 0.4 g/d to 2.4 g/d, medium dose 2.5 g/d to 4.4 g/d, and high dose  $\geq 4.5$  g/d of combined long-chain omega-3 fats,
- ALA dose: higher versus lower levels of intake ( $\geq 5$  g/d versus  $< 5$  g/d);
- trial duration - studies with medium follow-up (12 to 23 months), medium follow-up (24 to 47 months) and long follow-up ( $\geq 48$  months);
- statin use ( $< 50\%$  of control group on statins,  $\geq 50\%$  of control group on statins, use of statins unclear);
- baseline long-chain omega-3 intake, and baseline ALA intake.

There were insufficient data on baseline omega three intake (or intake in control groups which could have been used as a proxy) to subgroup by baseline omega-3 intake.

### Meta-regression

We used meta-regression to further explore effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose (looking for evidence of dose response for each), duration, primary or secondary prevention, food or capsule intervention (food included dietary advice and supplemental foods), and risk of bias (summary risk of bias low or moderate to high) on primary outcomes. We performed random-effects meta-regression using the STATA command `metareg` (Berkley 1995; Sharp 1998):  $\log(e)$  relative risk versus (dose or primary/secondary prevention or type of intervention or risk of bias or duration), weighted by the standard error of the  $\log(e)$  relative risk. Where there were no events in one arm, we added 0.1 to the numbers for both groups (so a trial with 10 people experiencing stroke in one arm but none in the other arm would be entered as 10.1 and 0.1). We analysed all included trials (of at least 12 months' duration) that reported each outcome from this review and its sister reviews (omega-3 trials from this review, omega-6 trials from the update of Hooper 2018, and total PUFA trials from Abdelhamid 2018). We carried out meta-regression of each variable singly, then a multivariate meta-regression of the three variables with lowest P values in single regression for each outcome. Given that we generally included data from around 35 trials and there were some missing data for some trials, we did not run meta-regressions with more than three variables at one time.

### Sensitivity analysis

We carried out sensitivity analyses on all primary outcomes (regardless of the number of included trials) and on key outcomes that were secondary outcomes in this review.

We used sensitivity analyses to assess robustness of results to:

- trial quality (removing trials at moderate or high summary risk of bias);
- study size (retaining only trials that randomised at least 100 participants across all study arms);
- fixed-effect analysis; and
- compliance (retaining only trials where we assessed compliance as conferring low risk of bias).

We tabulated the type and frequency of side effects and adverse effects (with the other extracted data on adverse effects) and compared between different studies and designs.

### 'Summary of findings' tables

Outcome data were interpreted as follows:

1. Is there an effect? (options were 'increased risk', 'decreased risk', or 'little or no effect'). Our main outcome measure was RR so we decided on existence of an effect using RR.  $RR < 0.92$  or  $RR > 1.08$  for the highest quality evidence suggested increased or decreased risk (otherwise little or no effect). The presence or not of an effect was decided on the RR for the main analysis and sensitivity analyses.
2. Quality of evidence was assessed using GRADE assessment (GRADE Working Group 2004) for key outcomes. We used the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence as it related to the studies that contributed data to the meta-analyses for the prespecified outcomes. We used methods and recommendations described in Section 8.5 and Chapter 12 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011), plus GRADEpro GDT software (GRADEpro GDT 2015). We justified all decisions to downgrade the quality of studies using footnotes and made comments to aid reader's understanding of the review.

3. Where there was a suggested effect the size of effect was assessed using the NNT or ARR.

We included three 'Summary of findings' tables: for effects of LCn3 on primary outcomes, effects of ALA on primary outcomes, and for key outcomes that were not included in the review primary outcomes (measures of adiposity and serum lipids).

## RESULTS


### Description of studies

#### Results of the search

The electronic searches for the full set of reviews (populating the dataset of all trials that assessed effects of higher versus lower omega-6, omega-3 or PUFA over at least 6 months) generated 37,810 titles and abstracts, which we de-duplicated to 19,772 hits. We assessed these along with 53 studies previously included from Hooper 2018 and Hooper 2004, to reassess for inclusion; 986 potentially relevant trials registry entries; and 35 new references gained from systematic review reference lists. In total, we assessed 20,846 titles and abstracts in duplicate to decide whether to retrieve full texts. We ultimately assessed 2155 full-text reports, of which 226 were systematic reviews. Two review authors independently assessed the remaining 1929 papers for inclusion and grouped them into studies. Of these, we included 208 RCTs in a wider set of trials that underpinned the full set of reviews (this review and several others including Abdelhamid 2018; Abdelhamid 2017; Hooper 2018; Brown 2017; Hanson 2017a; Hanson 2017b; Jimoh 2017; Thorpe 2017). This wider set of trials included RCTs of omega-3, omega-6 or total polyunsaturated fatty acids (PUFA) interventions with a duration of at least six months (Figure 1) and comprised 730 reports.



**Figure 1. Study flow diagram.**



Of these 208 RCTs:

- 27 RCTs (51 documents) assessed effects of omega-3 fats over at least one year but were ongoing (without published outcome data);
- 102 RCTs (291 documents) did not assess effects of omega-3 fats or had a duration of less than one year, so we excluded them; and
- 79 RCTs (388 documents) were eligible for inclusion in this review.

Of these 79 RCTs, 76 were included in meta-analyses. Three trials clearly collected relevant data but did not report them in a format that could be used in meta-analyses (Gill 2012; Ramirez-Ramirez 2013; Reed 2014; Figure 1).

### Included studies

The 79 included RCTs randomised 112,059 participants, tripling the number of participants in the original version of this review (36,913 participants, some of whom were followed for only six months). The number of participants in included studies ranged from 11 to 18,645. Twelve trials randomised at least 1000 participants (AlphaOmega - ALA 2010; AlphaOmega - EPA+DHA 2010; AREDS2 2014; DART2 2003; DART 1989; GISSI-HF 2008; GISSI-P 1999; JELIS 2007; Norwegian 1968; OMEGA 2009; ORIGIN 2012; Risk & Prevention 2013; SU.FOL.OM3 2010), of which one was a 2 × 2 factorial trial where both interventions were included (AlphaOmega - ALA 2010; AlphaOmega - EPA+DHA 2010). Most of these larger trials assessed effects of longer chain omega-3 fats, but two studies/arms assessed effects of ALA (AlphaOmega - ALA 2010; Norwegian 1968).

Participants had cardiovascular disease at baseline in 33 of the trials (secondary prevention), and the remaining 46 trials were of primary prevention.

Most studies assessed effects of long-chain omega-3 fats.

- Sixty-two studies increased LCn3 intake using supplementary capsules or medicinal oils (ADCS 2010; AFFORD 2013; Ahn 2016; AREDS2 2014; Baldassarre 2006; Bates 1989; Berson 2004; Brox 2001; Caldwell 2011; Derosa 2016; Deslypere 1992; Doi 2014; DO IT 2010; EPE-A 2014 (as two different doses); EPIC-1 2008; EPIC-2 2008; EPOCH 2014; Erdogan 2007; FAAT 2005; FORWARD 2013; Franzen 1993; Gill 2012; GISSI-HF 2008; GISSI-P 1999; HARP 1995; JELIS 2007; Kumar 2012; Kumar 2013; Lorenz-Meyer 1996; MAPT 2017; MARINA 2011; Mita 2007; NAT2 2013; Nodari 2011 AF; Nodari 2011 HF; Norouzi 2014; Nutristroke 2009; Nye 1990; OFAMI 2001; OMEGA 2009; OPAL 2010; ORIGIN 2012; ORL 2013; Özyaydin 2011; Proudman 2015; Puri 2005; Raitt 2005; Ramirez-Ramirez 2013; Reed 2014; Risk & Prevention 2013; Rossing 1996; Sandhu 2016; SCIMO 1999; Shinto 2014; SHOT 1996; Sianni 2013; SOFA 2006; Sofi 2010;

SU.FOL.OM3 2010; Tande 2016; WELCOME 2015; Zhang 2017).

- Two trials used supplemented or supplemental foods, such as enriched margarine or juice to increase LCn3 (AlphaOmega - EPA+DHA 2010; FOSTAR 2016).
- Four increased LCn3 fats using dietary advice (DART2 2003; DART 1989; DISAF 2003; THIS DIET 2008).
- Three provided some combination of these interventions to increase LCn3 (DIPP 2015; SMART 2013; Weinstock-Guttman 2005).

Fewer studies assessed the effects of ALA on health outcomes.

- One trial used supplementary capsules or medicinal oils to increase ALA (Norwegian 1968).
- Six increased ALA using supplemented or supplemental foods, such as enriched margarine, bread, walnuts or other enriched food products (AlphaOmega - ALA 2010; Dodin 2005; FLAX-PAD 2013; HERO 2009; MARGARIN 2002; WAHA 2016).
- One used a combination of these to increase ALA (MENU 2016).

One trial provided an intervention combining LCn3 and ALA as capsules (DIPP 2015). However, trialists did not state the ALA dose, so we treated the study as an LCn3 intervention.

Control groups received olive, corn, sunflower oils, other types of fats (including medium-chain triglycerides and fat replicating the composition of an average European diet), other 'inert' or ill-defined substances (liquid paraffin, aluminium hydroxide, 'placebo' not described), different dietary advice or foods without the omega-3 enrichment, or no treatment/no placebo.

The main study outcome was cardiovascular in 48 studies. Eighteen studies (19 comparisons) aimed to measure death or cardiovascular events (AlphaOmega - ALA 2010; AlphaOmega - EPA+DHA 2010; DART2 2003; DART 1989; Doi 2014; FAAT 2005; FLAX-PAD 2013; GISSI-HF 2008; GISSI-P 1999; JELIS 2007; Norwegian 1968; Nye 1990; OFAMI 2001; OMEGA 2009; ORIGIN 2012; Risk & Prevention 2013; SOFA 2006; SU.FOL.OM3 2010; THIS DIET 2008).

Thirty studies aimed to measure various cardiovascular risk factors or progression of cardiovascular health.

- Atrial fibrillation recurrence or sinus rhythm (AFFORD 2013; DISAF 2003; Erdogan 2007; FAAT 2005; FORWARD 2013; Kumar 2012; Kumar 2013; Nodari 2011 AF; Özyaydin 2011; Raitt 2005; Sianni 2013).
- Atherosclerosis progression/regression (Ahn 2016; DO IT 2010; HARP 1995; SCIMO 1999).
- Left ventricular function (Nodari 2011 HF).
- CABG graft patency (SHOT 1996).

- Lipids and other CVD risk factors (Brox 2001; Deslypere 1992; Franzen 1993; MARGARIN 2002).
- Diabetes, insulin or glucose-based outcomes (Derosa 2016; Rossing 1996).
- Endothelial function or carotid intima-media thickness (IMT) (Baldassarre 2006; Gill 2012; MARINA 2011; Mita 2007).
- Body weight and adiposity (HERO 2009; MENU 2016; SMART 2013).

Thirty-one RCTs assessed effects on other health states.

- Cognitive measures (ADCS 2010; EPOCH 2014; MAPT 2017; OPAL 2010; Shinto 2014; WAHA 2016; Zhang 2017).
- Eye health (AREDS2 2014; Berson 2004; NAT2 2013).
- Multiple sclerosis outcomes (Bates 1989; Weinstock-Guttman 2005).
- Cancer or pre-cancer outcomes (DIPP 2015).
- Bone health (Dodin 2005).
- Liver health (Caldwell 2011; EPE-A 2014; Sofi 2010; WELCOME 2015).
- Gastrointestinal health (Crohn's EPIC-1 2008; EPIC-2 2008; Lorenz-Meyer 1996).
- Arthritis outcomes (FOSTAR 2016; Proudman 2015; Reed 2014).
- Functional status (Nutrirstroke 2009).
- Neurological function after spinal injury or in Huntington's disease (Norouzi 2014; Puri 2005).
- Safety outcomes and adverse events (ORL 2013; Tande 2016).
- Breast health (Sandhu 2016).
- Inflammatory markers (Ramirez-Ramirez 2013).

Most studies took place in high-income economies (World Bank 2018), but four were in upper-middle-income countries: Argentina (FORWARD 2013), Iran (Norouzi 2014), Turkey (Özaydin 2011), and China (Zhang 2017). No studies took place in low- or low-middle income countries.

We identified a further 27 ongoing trials, which we describe in the table of [Characteristics of ongoing studies](#). At the time of writing this review, all of these trials were unpublished, and some were recruiting or delivering interventions or had recently been completed, and trialists were presumably analysing data and writing up results. Others appear overdue for publication, and their status is unclear - they may constitute missing data.

## Excluded studies


We read full texts of over 1000 papers, so the full list of excluded studies is too extensive to add to this review. The main reason for exclusion of full-text papers was duration of less than 12 months (this was often unclear in abstracts, so we collected full-text papers to check).

We initially included several studies into our wider data set (Singh 1992; Singh 1997a; Singh 1997b; Singh 2002), but we later excluded them due to expressions of concern published by the *BMJ* and *The Lancet* (BMJ 2005; Horton 2005; White 2005). These expressions of concern followed extensive examination of the conduct, results and publication of these studies and questioned the veracity of data behind several studies published by RB Singh. Another trial was retracted and so not included (Matsuyama 2005).

## Risk of bias in included studies

We assessed summary risk of bias as low in 25 RCTs (26 comparisons: ADCS 2010; AlphaOmega - ALA 2010; AlphaOmega - EPA+DHA 2010; AREDS2 2014; Berson 2004; Caldwell 2011; Derosa 2016; EPOCH 2014; FLAX-PAD 2013; FORWARD 2013; FOSTAR 2016; Lorenz-Meyer 1996; MAPT 2017; MARGARIN 2002; MARINA 2011; NAT2 2013; OMEGA 2009; OPAL 2010; ORIGIN 2012; Proudman 2015; Puri 2005; Reed 2014; SCIMO 1999; SOFA 2006; SU.FOL.OM3 2010; WELCOME 2015), and we deemed it to be moderate to high in the remainder. Our definition of low summary risk of bias is in the section [Assessment of risk of bias in included studies](#). Figure 2 itemises risk of bias by domain and study.

**Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.**



## Allocation

Of the 79 RCT arms described in the 'Risk of bias' summary (Figure 2), 64 studies described randomisation well enough to merit an assessment of low risk (the remainder were unclear), and 45 study arms described adequate allocation concealment (the remaining 34 were unclear).

## Blinding

We considered blinding of participants and personnel to be at low risk of bias in 37 of the 79 comparisons (Figure 2). Lack of blinding of participants put 22 trials at high risk of bias while the remaining 20 arms were at unclear risk. Blinding of outcome assessors put trials at low risk of detection bias in 53 studies and at high risk in 6 trials; this aspect was unclear in the remainder. We found that 33 studies were at low risk of both performance and detection bias.

## Incomplete outcome data

We found that 53 trials were at low risk of attrition bias, 14 at high risk, and the remaining 12 at unclear risk.

## Selective reporting

We determined that 17 trials had a pre-published trials registry entry or protocol and reported all planned outcomes appropriately so were considered at low risk of selective reporting. Twenty-three trials were at high risk of selective reporting omitting reports on either pre-stated outcomes or time points. We judged the remaining 39 trials to be at unclear risk of reporting bias as we could not find any protocol or prospective trial registry entry (often trials were published prior to trial registration availability).

## Other potential sources of bias

We assessed risk of bias from lack of compliance and attention bias and also noted other sources of bias. We found four studies to be at high risk of compliance bias (FAAT 2005; HERO 2009; Proudman 2015; SMART 2013), while 34 studies provided evidence of good compliance, and the remaining 41 studies were unclear. We noted a high risk of attention bias in three studies where intervention participants potentially had more dedicated time for dietary advice or follow-up (DART2 2003; DART 1989; MARGARIN 2002). Nine trials did not provide enough details to

assess so we considered them to be at unclear risk of attention bias (Ahn 2016; Erdogan 2007; Gill 2012; Kumar 2012; Kumar 2013; Risk & Prevention 2013; Sianni 2013; SMART 2013; WAHA 2016), while we thought the remaining 67 were at low risk of attention bias. We judged three studies to be at high risk of other potential biases: Ahn 2016 because it is unclear whether it was placebo-controlled, and there was concern over reported standard deviations, DISAF 2003 because the study stopped early, and Kumar 2013 due to concerns over design. Three studies were at unclear risk due to insufficient methodological detail being provided (Gill 2012; Sianni 2013; Zhang 2017).

## Effects of interventions

See: [Summary of findings for the main comparison](#) High versus low LCn3 for preventing cardiovascular disease and mortality (primary outcomes); [Summary of findings 2](#) High versus low ALA omega-3 fats for preventing cardiovascular disease (primary outcomes); [Summary of findings 3](#) High versus low omega-3 fats for modification of CVD risk factors (adiposity and lipids): key outcomes

## Primary outcomes

See [Summary of findings for the main comparison](#) for a GRADE summary of our evidence on effects of long-chain omega-3 (LCn3) fats (including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA)) on our primary outcomes.


## Effects of long-chain omega-3 fats on primary health outcomes

### All-cause mortality (LCn3)

High-quality evidence showed little or no effect of LCn3 on all-cause mortality.

There was little or no effect of increasing long-chain omega-3 fats on all-cause mortality, despite 8189 deaths in > 92,000 participants (RR 0.98, 95% CI 0.93 to 1.03,  $I^2 = 12\%$ , [Analysis 1.1](#)). The funnel plot suggested that some small studies with higher numbers of deaths in the intervention group might be missing (Figure 3), indicating small study bias. If such missing studies were added back in the RR would rise (towards the null value of 1.0).

**Figure 3. Funnel plot of comparison: I High vs low LCn3 omega-3 fats (primary outcomes), outcome: I.1 Aall-cause mortality (overall) - LCn3.**



Sensitivity analyses using fixed-effect meta-analysis did not alter the lack of effect on all-cause mortality (RR 0.97, 95% CI 0.93 to 1.01, [Analysis 1.2](#)). Removing RCTs not at low summary risk of bias left us with 15 RCTs involving over 33,000 participants, 3059 of whom died, suggesting no effect of LCn3 on mortality (RR 1.01, 95% CI 0.94 to 1.08,  $I^2 = 0\%$ , [Analysis 1.3](#)). This lack of effect was also evident in sensitivity analyses limited to studies at low risk of compliance bias and to larger studies ([Analysis 1.4](#)). The lack of effect for LCn3 on mortality did not differ by replacement with mono-unsaturated fatty acids (MUFA), omega-3 fats or other types of placebo compounds ([Analysis 1.6](#)). There was no suggestion of any dose effect for long-chain omega-3 fats on mortality ([Analysis 1.5](#)), and subgroups with RRs further away from 1.00 had wider 95% confidence intervals. The lack of effect did not differ by primary versus secondary prevention ([Analysis 1.9](#)) or mode of intervention (dietary advice, supplemental foods, or capsules, [Analysis 1.7](#)). While there was some suggestion of a small risk reduction in total mortality with LCn3 in studies with medium to long duration (2 to < 4 years, RR 0.91, 95% CI 0.86 to 0.96) and this subgroup was clearly different from other durations (test for subgroup differences  $P = 0.007$ ), the effect was not

evident in shorter (1 to < 2 years) or longer studies ( $\geq 4$  years, RR 1.03, 95% CI 0.98 to 1.09). Because of the lack of effect in longer studies, we did not assume any duration effects ([Analysis 1.8](#)).

As there was no suggestion of any effect of LCn3 fats on all-cause mortality, we did not carry out meta-regression.


GRADE assessment suggested that the finding of little or no effect of LCn3 on all-cause mortality was supported by high-quality evidence (not downgraded, [Summary of findings for the main comparison](#)).

#### Cardiovascular mortality (LCn3)

Moderate-quality evidence suggests that long-chain omega-3 fat intake probably makes little or no difference to cardiovascular deaths.

Twenty-five trials in at least 67,000 participants, 4544 of whom died of CVD, reported on cardiovascular mortality (RR 0.95, 95% CI 0.87 to 1.03,  $I^2 = 24\%$ , [Analysis 1.11](#)). The funnel plot suggested that some smaller studies with more cardiovascular deaths in the intervention group were missing (some small study bias, [Figure 4](#)) - if this were the case then adding the missing studies would increase the relative risk towards the null (no effect).

**Figure 4. Funnel plot of comparison: I High vs low LCn3 omega-3 fats (primary outcomes), outcome: I.1 I Cardiovascular mortality (overall) - LCn3.**



Fixed-effect meta-analysis suggested a 6% reduction in CVD mortality risk (RR 0.94, 95% CI 0.89 to 1.00, [Analysis 1.12](#)). However, sensitivity analyses removing RCTs not at low summary risk of bias left nine RCTs in over 29,000 participants, 1539 of whom died, suggesting little or no effect of LCn3 on CVD mortality (RR 0.99, 95% CI 0.90 to 1.09,  $I^2 = 0\%$ , [Analysis 1.13](#)). Removing trials not at low risk of compliance bias had a similar effect ([Analysis 1.14](#)).

There were no statistically significant differences between subgroups and no differential effects by replacement ([Analysis 1.16](#)), mode of intervention ([Analysis 1.17](#)), duration (marginally significant difference between subgroups,  $P = 0.06$ ; effects seen only in medium- to long-term trials and not in shorter or longer studies, [Analysis 1.18](#)), primary or secondary prevention ([Analysis 1.19](#)), statin use ([Analysis 1.20](#)) or omega-3 dose ([Analysis 1.15](#)). There was no suggestion of a dose-response effect.

Meta-regression to assess effects of LCn3 dose (or alpha-linolenic acid (ALA), omega-6 or total poly-unsaturated fatty acid (PUFA) dose), duration, intervention type, primary or secondary prevention and risk of bias (as well as a single multiple regression of the three factors with the smallest  $P$  value) showed no association between these factors and risk of cardiovascular mortality (all  $P$  values were  $> 0.60$ , [Table 2](#)). We saw no suggestion of dose-response

or duration effects.

The suggestion of a protective effect disappeared in studies at low summary risk of bias and at low risk of compliance problems. The funnel plot suggests that the true risk ratio is higher than the main estimate, and there was no suggestion of dose or duration effects; thus we summarised the evidence as showing little or no effect of LCn3 on CVD mortality. GRADE assessment suggested moderate-quality evidence that long-chain omega-3 fat intake probably makes little or no difference to cardiovascular deaths (moderate-quality/certainty evidence, downgraded once for imprecision).

#### Combined cardiovascular events (LCn3)

High-quality evidence suggests that LCn3 intake makes little or no difference to risk of cardiovascular events.

There was little or no effect of increasing LCn3 fats on cardiovascular events (RR 0.99, 95% CI 0.94 to 1.04,  $I^2 = 37\%$ , [Analysis 1.21](#)). Analyses included 14,737 participants with cardiovascular events in more than 90,000 participants in 38 trials. The funnel plot suggested that some smaller studies with more participants experiencing cardiovascular events in the intervention group were missing (some small study bias, not shown) - if this were the case then adding the missing studies would increase the relative risk.

Sensitivity analyses removing trials at moderate to high risk of bias left 14 trials, including more than 31,000 participants, 6695 of whom had CVD events, with no suggestion of any effect of LCn3 fats (RR 1.00, 95% CI 0.96 to 1.05,  $I^2 = 0\%$ , [Analysis 1.23](#)). Sensitivity analyses including studies at low risk of compliance bias, at low risk of small study bias and using fixed-effect meta-analysis did not suggest any effect of LCn3 on CVD events ([Analysis 1.22](#); [Analysis 1.24](#)).

In subgroup analysis, there was no suggestion of a dose-response effect ([Analysis 1.25](#)). Effects did not differ by replacement ([Analysis 1.26](#)), baseline CVD risk ([Analysis 1.29](#)), type of intervention ([Analysis 1.27](#)), statin use ([Analysis 1.30](#)), LCn3 dose ([Analysis 1.25](#)) or study duration ([Analysis 1.28](#)), and there were no important differences between subgroups.

Meta-regression to assess effects of LCn3 dose (or doses of ALA, omega-6 and total PUFA), duration, intervention type, primary or secondary prevention and risk of bias (as well as a single multiple regression of the three factors with the smallest P value) showed no association between these factors and risk of cardiovascular events (all P values were  $\geq 0.24$ , [Table 3](#)). We saw no suggestion of dose or duration effects.

GRADE assessment suggested high-quality evidence that LCn3

intake makes little or no difference to risk of cardiovascular events (high-quality/certainty evidence).


### Coronary heart mortality (LCn3)

Moderate-quality evidence suggests that long-chain omega-3 fat intake probably makes little or no difference to coronary heart mortality.

There was a suggestion that increasing LCn3 fats reduced the risk of coronary heart mortality by 7% (RR 0.93, 95% CI 0.79 to 1.09,  $I^2 = 35\%$ ) in 21 trials reporting 1596 events in more than 73,000 participants ([Analysis 1.31](#)). Sensitivity analyses using a fixed-effect model suggested a 6% reduction in CHD mortality ([Analysis 1.32](#)).

However, retaining only RCTs at low summary risk of bias, meta-analysis of seven trials with more than 16,000 participants and 283 CHD deaths suggested no effect of LCn3 fats on CHD deaths (RR 1.00, 95% CI 0.72 to 1.37,  $I^2 = 18\%$ , [Analysis 1.33](#)). Sensitivity analyses retaining only trials with low risk of compliance bias suggested a 5% increase in risk with LCn3, but retaining only larger trials suggested a 7% reduction ([Analysis 1.34](#)). The funnel plot suggested that some smaller studies with higher RRs were missing ([Figure 5](#)), and if added back these would increase the RR.

**Figure 5. Funnel plot of comparison: I High vs low LCn3 omega-3 fats (primary outcomes), outcome: I.31 Coronary heart disease mortality (overall) - LCn3.**





When we added this outcome we had pre-specified that we would use the first of the following list reported in any trial: coronary death, ischaemic heart disease (IHD) death, fatal MI and cardiac death. We used cardiac death only when no other outcomes in this category were available, and we ran a sensitivity analysis omitting cardiac death as it potentially includes other causes of death in addition to CHD, such as cardiomyopathies and congenital and valvular heart diseases (though numbers are likely to be small). Omitting cardiac death resulted in a 17% reduction in CHD deaths with LCn3 (RR 0.83, 95% CI 0.74 to 0.94,  $I^2 = 0\%$ , 16 trials including 65,325 participants, [Analysis 1.35](#)).

There were no statistically significant differences between subgroups for type of intervention ([Analysis 1.38](#)), dose ([Analysis 1.36](#)), baseline CVD risk ([Analysis 1.40](#)), statin use ([Analysis 1.41](#)) or baseline coronary artery disease status ([Analysis 1.42](#)). There were important differences between subgroups for study duration, with no effect in shorter trials (1 to < 2 years), a significant protective effect of LCn3 fats in medium- to long-term trials (2 to < 4 years) and an almost statistically significant harmful effect in long trials ( $\geq 4$  years, [Analysis 1.39](#)), so we did not assume any differential effect by duration. The differences between subgroups for replacement disappeared when we omitted the 'replacement unclear' category (altering the test for subgroup differences to  $P = 0.46$ , [Analysis 1.37](#)).

Meta-regression to assess effects of LCn3 dose on CHD mortality found no relationship ( $P = 0.94$ , [Table 4](#)). Similarly we saw no relationships between ALA dose, omega-6 dose, total PUFA dose,

duration, intervention type, primary or secondary prevention or risk of bias and CHD deaths (all  $P$  values were  $> 0.40$ , [Table 4](#)). Multiple regression of the three factors with the smallest  $P$  value found no factors associated with risk of CHD deaths. We saw no suggestion of dose or duration effects.


The suggestion of a protective effect disappeared in studies at low summary risk of bias, the funnel plot suggests that the true risk ratio is higher than the main estimate, and there was no suggestion of dose or duration effects, so we summarised the evidence by assuming little or no effect of LCn3 on CHD mortality. GRADE assessment suggested moderate-quality evidence that long-chain omega-3 fat intake probably makes little or no difference to coronary heart mortality (moderate-quality/certainty evidence, downgraded once for imprecision).

### Coronary heart disease events (LCn3)

Moderate-quality evidence suggests that long-chain omega-3 fat intake probably makes little or no difference to risk of coronary heart events.

The main meta-analysis suggested a 7% reduction in people experiencing CHD events with higher intake of LCn3 fats (RR 0.93, 95% CI 0.88 to 0.97,  $I^2 = 0\%$ , 5469 events, > 84,000 participants, [Analysis 1.43](#)). The funnel plot suggested that some smaller studies with more cardiovascular deaths in the intervention group were missing (some small study bias, [Figure 6](#)) - if this were the case then adding the missing studies would increase the relative risk.

**Figure 6. Funnel plot of comparison: I High vs low LCn3 omega-3 fats (primary outcomes), outcome: I.43 Coronary heart disease events (overall) - LCn3.**



Sensitivity analyses using a fixed-effect model did not alter the results (RR 0.92, 95% CI 0.88 to 0.97, [Analysis 1.44](#)). The protective effect was lost in studies at low summary risk of bias ([Analysis 1.45](#)), and the effect was smaller when studies were limited to those with good compliance and to larger studies ([Analysis 1.46](#)). Removing RCTs not at low summary risk of bias left 12 trials with more than 30,000 participants, 2228 of whom developed CHD (RR 0.97, 95% CI 0.90 to 1.05,  $I^2 = 0\%$ , [Analysis 1.45](#)).

There were no statistically significant differences between subgroups ([Analysis 1.47](#); [Analysis 1.48](#); [Analysis 1.49](#); [Analysis 1.50](#); [Analysis 1.51](#); [Analysis 1.52](#); [Analysis 1.53](#)).

Meta-regression to assess effects of LCn3, ALA, omega-6, total PUFA dose and duration, intervention type, primary or secondary prevention, and risk of bias (as well as a single multiple regression of the three factors with the smallest P value) showed no association between these factors and the risk of CHD events (all P values were  $> 0.20$ , [Table 5](#)). We saw no suggestion of dose-response or duration effects.

Because a protective effect was only apparent in studies at higher risk of bias, we were concerned that the reduction in CHD events is residual and arises from methodological weaknesses in some of the studies (there was a marginally significant difference between the group of studies at low risk of bias, and those at moderate to

high risk of bias,  $P = 0.09$ , [Analysis 1.45](#)). GRADE assessment suggested moderate-quality evidence that long-chain omega-3 fat intake probably makes little or no difference to risk of coronary heart events (moderate-quality/certainty evidence, downgraded once for risk of bias).

### Stroke (LCn3)

Moderate-quality evidence suggests that long-chain omega-3 fat intake probably makes little or no difference to risk of experiencing a stroke.

There was a suggestion that increasing intake of LCn3 results in a 6% higher risk of stroke (RR 1.06, 95% CI 0.96 to 1.16,  $I^2 = 0\%$ , 1822 reported strokes, [Analysis 1.54](#)), and the funnel plot did not suggest any small study bias (not shown).

Sensitivity analyses removing trials not at low summary risk of bias left 12 trials with 888 participants experiencing strokes, suggesting little or no effect of LCn3 fats on stroke (RR 0.98, 95% CI 0.86 to 1.12,  $I^2 = 0\%$ , [Analysis 1.56](#)). Using fixed-effect meta-analysis also suggested a 6% increase in risk ([Analysis 1.55](#)), while sensitivity analysis removing trials with risk from poor compliance and smaller trials suggested there may be harm from increased LCn3 ([Analysis 1.57](#)).

When studies reported stroke type separately, the risk of both haemorrhagic (RR 1.20, 95% CI 0.85 to 1.69,  $I^2 = 0\%$ , 130 participants with events) and ischaemic stroke were increased (RR 1.09, 95% CI 0.89 to 1.33,  $I^2 = 13\%$ , 556 people with events, in 8 trials each, [Analysis 1.58](#)). Five trials reported only 40 participants experiencing transient ischaemic attack (TIA), suggesting a 26% reduction in risk but with very wide confidence intervals (TIAs were not included in any other stroke categories, [Analysis 1.58](#)). Subgrouping did not suggest important differences by intervention type, replacement, statin use, trial duration or dose ([Analysis 1.59](#); [Analysis 1.60](#); [Analysis 1.61](#); [Analysis 1.62](#); [Analysis 1.64](#)). There was a suggestion of increased stroke risk in people with CVD at baseline (RR 1.21, 95% CI 1.05 to 1.40,  $I^2 = 0\%$ , with differences in effect size between subgroups by primary or secondary prevention,  $P = 0.02$ , [Analysis 1.63](#)).

Meta-regression to assess effects of LCn3 dose did not find any clear dose response on risk of stroke ( $P = 0.42$ , [Table 6](#)). Univariate meta-regression suggested that trials of shorter duration showed a greater effect on reducing stroke ( $P = 0.012$ ) and that LCn3 fats may be more protective against stroke in secondary prevention than primary ( $P = 0.04$ , [Table 6](#)). There were no clear relationships between dose of any PUFA type, risk of bias, or use of food or capsules, and no significant relationships in multivariate meta-regression.

Given that studies at low summary risk of bias suggested little or no effect of LCn3 on stroke risk, and there were no dose-response or duration relationships, we assumed little or no true effect. GRADE assessment suggests moderate-quality evidence that long-chain omega-3 fat intake probably makes little or no difference to risk of experiencing a stroke (moderate-quality/certainty evidence, downgraded once for imprecision).

### Arrhythmia (LCn3)

Moderate-quality evidence suggests that long-chain omega-3 fat intake probably makes little or no difference to risk of arrhythmia. There was no effect of LCn3 fats on incidence of new or recurrent (fatal and non-fatal) arrhythmias (RR 0.97, 95% CI 0.90 to 1.05,  $I^2 = 43\%$ , 3788 events in > 53,000 participants, [Analysis 1.65](#)). The funnel plot was not interpretable as studies were clustered (not shown).

Sensitivity analyses removing trials not at low summary risk of bias left 10 trials with 1146 events (> 25,000 participants), suggesting a 10% increase in risk of arrhythmia with increased LCn3 (RR 1.10, 95% CI 0.98 to 1.23,  $I^2 = 0\%$ , [Analysis 1.67](#)). Restricting the analysis to studies at low summary risk of bias removed heterogeneity, and there was a statistically significant difference in effect size between subgroups at low versus moderate to high risk of bias ( $P = 0.03$ , [Analysis 1.67](#)). Using fixed-effect methodology did not alter the apparent lack of effect of LCn3 on arrhythmia ([Analysis 1.66](#)), and sensitivity analysis by compliance and study size also suggested little or no effect of LCn3 on arrhythmia ([Analysis 1.68](#)).

Subgrouping by new or recurrent arrhythmias suggested differences between subgroups, with LCn3 increasing the risk of new arrhythmias and reducing the risk of recurrent arrhythmia ([Analysis 1.69](#)). There were also statistically significant differences between subgroups by fatality, with a suggestion that LCn3 increased the risk of fatal arrhythmias but reduced the risk of non-fatal arrhythmias ([Analysis 1.70](#)). Subgroup analyses by type of intervention, replacement, baseline CVD risk, statin use, dose and study duration did not suggest any statistically significant differences between subgroups ([Analysis 1.71](#); [Analysis 1.72](#); [Analysis 1.73](#); [Analysis 1.74](#); [Analysis 1.75](#); [Analysis 1.76](#)).

Meta-regression suggested a marginally significant negative dose-response relationship with LCn3 fats, such that lower dose was associated with lower risk of arrhythmia ( $P = 0.06$ , [Table 7](#)). The effect remained marginally significant when we controlled for primary or secondary prevention and study duration ( $P = 0.09$ ). Because of the negative direction of this apparent dose-response relationship, we assumed it was likely to be a chance occurrence resulting from running a large number of statistical tests. There was also a marginally significant relationship for arrhythmia with primary versus secondary prevention, suggesting greater reduction in arrhythmia risk in primary prevention ( $P = 0.07$ , [Table 7](#)). There were no other suggested relationships.

GRADE assessment suggested moderate-quality evidence that long-chain omega-3 fat intake probably makes little or no difference to risk of arrhythmia (moderate-quality/certainty evidence, downgraded once for imprecision).

### Effects of ALA on primary health outcomes

See [Summary of findings 2](#) for a summary of our evidence on effects of ALA on our primary outcomes.

As there were fewer than 10 studies for all ALA analyses we did not use funnel plots, though we did run sensitivity analyses and subgroups. We assessed ALA dose-response and duration effects in meta-regression of all included LCn3, ALA, omega-6 and total PUFA trials (but not of ALA trials alone as there were too few studies to carry out meta-regression with any reliability).

### All-cause mortality (ALA)

Moderate-quality evidence suggests that ALA intake probably makes little or no difference to all-cause mortality.

There was little or no effect of increasing ALA omega-3 fats on all-cause mortality, with 458 deaths in more than 18,000 participants involved in four studies (RR 1.01, 95% CI 0.84 to 1.20,  $I^2 = 0\%$ , [Analysis 4.1](#)).

Sensitivity analyses removing RCTs not at low summary risk of bias left three trials with 375 deaths, again suggesting little or no effect (RR 1.02, 95% CI 0.72 to 1.45,  $I^2 = 3\%$ , [Analysis 4.3](#)). Using fixed-effect meta-analysis suggested a 6% increase in risk of all-cause mortality with increased ALA (RR 1.06, 95% CI 0.84

to 1.34, [Analysis 4.2](#)), while limiting the analysis to studies at low risk of compliance problems showed a 5% increase, and including only larger trials showed little or no effect ([Analysis 4.4](#)).

Subgrouping by ALA dose, trial duration, statin use, replacement, primary or secondary prevention, or intervention type did not result in any significant differences between subgroups ([Analysis 4.5](#); [Analysis 4.6](#); [Analysis 4.7](#); [Analysis 4.8](#); [Analysis 4.9](#); [Analysis 4.10](#)). As there was no suggestion of effect in any subgroup, we did not carry out meta-regression.

GRADE assessment suggested that ALA intake probably makes little or no difference to all-cause mortality (moderate-quality/certainty evidence, downgraded once for imprecision).

### Cardiovascular mortality (ALA)

Moderate-quality evidence suggests that increasing ALA intake probably has little or no effect on cardiovascular mortality.

Four studies contributed data to this outcome. There was little or no effect of increasing ALA omega-3 fats on cardiovascular mortality (RR 0.96, 95% CI 0.74 to 1.25,  $I^2 = 0\%$ , [Analysis 4.11](#)), but confidence intervals were very wide. Analyses included 219 CVD deaths in > 18,000 participants.

Sensitivity analyses using fixed-effect meta-analysis did alter the lack of effect (RR 0.96, 95% CI 0.74 to 1.25, [Analysis 4.12](#)). Removing studies not at low risk of bias left three trials with 165 cardiovascular deaths, suggesting a 5% reduction of cardiovascular death risk with higher ALA (RR 0.95, 95% CI 0.70 to 1.28, [Analysis 4.13](#)). Sensitivity analysis by compliance or study size again suggested 6% and 4% reductions, respectively, in CVD mortality risk ([Analysis 4.14](#)).

Subgrouping by ALA dose, study duration, replacement, intervention type, statin use or primary/secondary prevention did not suggest important differences between subgroups ([Analysis 4.15](#); [Analysis 4.16](#); [Analysis 4.17](#); [Analysis 4.18](#); [Analysis 4.19](#); [Analysis 4.20](#)). Meta-regression to assess for effects of ALA dose on cardiovascular mortality did not suggest dose effects ( $P = 0.91$ , [Table 2](#)). GRADE assessment suggested that increasing ALA intake probably has little or no effect on cardiovascular mortality (moderate-quality/certainty evidence, downgraded once for imprecision).

### Cardiovascular events (ALA)

GRADE assessment suggested that increasing ALA intake may reduce the risk of cardiovascular events by a small amount.

There was a 5% reduction in risk of cardiovascular events in five trials with increased ALA intake (RR 0.95, 95% CI 0.83 to 1.07,  $I^2 = 0\%$ , 884 out of > 19,000 participants experienced at least one cardiovascular event, [Analysis 4.21](#)).

Sensitivity analyses removing studies at moderate to high risk of bias left three trials in which 691 of > 5,000 enrolled participants experienced at least one cardiovascular event, suggesting a 9% reduction in risk of CVD events with higher ALA (RR 0.91, 95%

CI 0.79 to 1.04,  $I^2 = 0\%$ , [Analysis 4.23](#)). Fixed-effect analysis suggested a 5% reduction in risk ([Analysis 4.22](#)), while studies at low risk of compliance bias suggested a 10% reduction in risk, and larger studies a 5% reduction ([Analysis 4.24](#)).

Subgrouping by ALA dose, study duration, replacement, intervention type, statin use or primary/secondary prevention did not suggest significant differences between subgroups ([Analysis 4.25](#); [Analysis 4.26](#); [Analysis 4.27](#); [Analysis 4.28](#); [Analysis 4.29](#); [Analysis 4.30](#)). Meta-regression to assess for effects of ALA dose on cardiovascular events did not suggest any dose effects ( $P = 0.70$ , [Table 3](#)).

GRADE assessment suggested that increasing ALA intake may reduce the risk of cardiovascular events by a small amount (low-quality/certainty evidence, downgraded once for risk of bias and once for imprecision).

### Coronary heart disease mortality (ALA)

GRADE assessment suggested that increasing ALA intake probably reduces the risk of CHD mortality a little.

Three studies reported 193 CHD deaths in > 18,000 participants, suggesting a 5% reduction in CHD mortality with increased ALA (RR 0.95, 95% CI 0.72 to 1.26,  $I^2 = 0\%$ , [Analysis 4.31](#)).

Sensitivity analyses using fixed-effect meta-analysis did not alter the effect (RR 0.95, 95% CI 0.72 to 1.26, [Analysis 4.32](#)). Studies at low summary risk of bias suggested a 7% reduction in risk of CHD mortality (including 2 trials with 4947 participants, RR 0.93, 95% CI 0.67 to 1.30,  $I^2 = 0\%$ , [Analysis 4.33](#)), with similar effects in studies at low risk of compliance bias, or low risk of small study bias ([Analysis 4.34](#)).

Subgrouping by ALA dose, study duration, replacement, intervention type, statin use, primary/secondary prevention or previous history of coronary artery disease did not suggest important differences between subgroups ([Analysis 4.35](#); [Analysis 4.36](#); [Analysis 4.37](#); [Analysis 4.38](#); [Analysis 4.39](#); [Analysis 4.40](#); [Analysis 4.41](#)). Meta-regression to assess for effects of ALA dose on CHD deaths did not suggest any dose effects ( $P = 0.93$ , [Table 4](#)).

GRADE assessment suggested that increasing ALA intake probably reduces the risk of CHD mortality a little (moderate-quality/certainty evidence, downgraded once for imprecision).

### Coronary heart disease events (ALA)

Low-quality evidence suggests that ALA intake may make little or no difference to CHD events.

Three studies contributed data to this outcome, with 396 out of over 18,000 participants experiencing at least one CHD event. There was little or no effect on CHD risk with increased ALA (RR 1.00, 95% CI 0.82 to 1.22,  $I^2 = 2\%$ , [Analysis 4.42](#)).

Sensitivity analyses using fixed-effect meta-analysis did not alter the lack of effect (RR 1.00, 95% CI 0.82 to 1.21, [Analysis 4.43](#)). Removing studies not at low summary risk of bias left two studies with almost 5000 participants, suggesting a 9% reduction in

risk of a CHD event (RR 0.91, 95% CI 0.71 to 1.15, [Analysis 4.44](#)), similar to sensitivity analysis omitting studies with potential compliance problems ([Analysis 4.45](#)), though no effects were seen when restricting analysis to larger trials ([Analysis 4.45](#)).

Subgrouping by ALA dose, study duration, replacement, intervention type, statin use, primary/secondary prevention or previous history of coronary artery disease did not suggest important differences between subgroups ([Analysis 4.46](#); [Analysis 4.47](#); [Analysis 4.48](#); [Analysis 4.49](#); [Analysis 4.50](#); [Analysis 4.51](#); [Analysis 4.52](#)). Meta-regression did not suggest that there was a direct relationship between ALA dose and CHD events ([Table 5](#)).

Given the differences in sensitivity analyses, GRADE assessment suggested that ALA intake may make little or no difference to CHD events (low-quality/certainty evidence, downgraded once for risk of bias and once for imprecision).

### Stroke (ALA)

The effect of ALA intake on stroke is unclear, as the evidence is of very low quality.

Five RCTs involved 51 people out of more than 18,000 participants experiencing a stroke, suggesting a 15% increase in stroke risk with increased ALA (RR 1.15, 95% CI 0.66 to 2.01,  $I^2 = 0\%$ , [Analysis 4.53](#)). Sensitivity analyses removing studies not at low summary risk of bias left three studies with 27 stroke events and no suggestion of effect ([Analysis 4.55](#)). Using a fixed-effect model suggested a 23% increased risk of stroke ([Analysis 4.54](#)), while removing studies at high risk of bias due to compliance suggested a 15% reduction in stroke risk, while larger studies suggested a 15% greater stroke risk ([Analysis 4.56](#)).

Subgrouping by ALA dose, study duration, replacement, intervention type, statin use or primary/secondary prevention did not result in significant differences between subgroups ([Analysis 4.57](#); [Analysis 4.58](#); [Analysis 4.59](#); [Analysis 4.60](#); [Analysis 4.61](#); [Analysis 4.62](#)). When examining data reported by type of stroke, only three studies reported on 28 ischaemic strokes, with no clear effects, and no studies reported on haemorrhagic stroke ([Analysis 4.63](#)). Meta-regression did not suggest any relationship between ALA dose and risk of stroke ([Table 6](#)).

The effect of ALA on stroke is unclear as the evidence is of very low quality (downgraded twice for risk of bias and once for imprecision).

### Arrhythmia (ALA)

Moderate-quality evidence suggested that ALA intake probably reduces the risk of arrhythmias.

Only one study reported effects of ALA on arrhythmia, with 141 new arrhythmias in 4837 participants, suggesting a 21% reduction in arrhythmia but with wide confidence intervals (RR 0.79, 95% CI 0.57 to 1.10, [Analysis 4.64](#)). The results were identical when sensitivity analysis retained only studies at low summary risk of

bias (as we judged the single included study to be at low risk of bias, [Analysis 4.65](#)). As there was only one trial, we did not carry out further sensitivity analyses or subgrouping. There was no suggestion of a dose-response relationship between ALA and arrhythmia risk in meta-regression ( $P = 0.67$ , [Table 7](#)).

GRADE assessment suggested that ALA intake probably reduces the risk of arrhythmias (moderate-quality/certainty evidence, downgraded once for imprecision).

## Secondary outcomes

See [Summary of findings 3](#) for a summary of our evidence on effects of long-chain omega-3 fats and ALA on serum lipids and measures of adiposity.

### Effects of long-chain omega-3 fats (EPA, DHA and DPA) on secondary health outcomes

We did not carry out sensitivity analyses or subgrouping on secondary outcomes, except for adiposity and lipids (which were key outcomes). We did carry out some post hoc sensitivity analyses to further assess effects of LCn3 on MI, to ascertain whether the suggested protection was stable to sensitivity analyses.

### Major adverse cerebrovascular or cardiovascular events (LCn3)

Five trials reported on major adverse cerebrovascular or cardiovascular events (MACCEs) in more than 34,000 participants, 4232 of whom suffered from a MACCE, suggesting little or no effect of LCn3 fats (RR 1.03, 95% CI 0.97 to 1.09,  $I^2 = 0\%$ , [Analysis 2.1](#)).

### Myocardial infarction (LCn3)

Twenty-three studies (> 72,000 participants) reported on total (fatal and non-fatal) myocardial infarction (MI). Meta-analyses suggested that increasing LCn3 fats resulted in a small reduction in total MI (RR 0.95, 95% CI 0.88 to 1.03,  $I^2 = 0\%$ , 2200 MI events, [Analysis 2.2](#)). This was confirmed in sensitivity analyses limited to studies without compliance problems and to studies that randomised at least 100 participants ([Analysis 2.4](#)), but analyses limited to studies at low summary risk of bias suggest little or no effect of LCn3 on MI (RR 1.03, 95% CI 0.92 to 1.15,  $I^2 = 0\%$ , > 30,000 participants in 11 trials, and reporting on 1154 people experiencing at least one MI, [Analysis 2.3](#)). This suggests little or no true effect of LCn3 on MI.

We ran subgroup analyses by fatality at the request of the WHO NUGAG Subgroup on Diet and Health, finding no significant difference between fatal and non-fatal MI subgroups ( $P = 0.23$ , [Analysis 2.5](#)).



### Sudden cardiac death (LCn3)

There was little or no effect of LCn3 fats on sudden cardiac death (RR 0.97, 95% CI 0.80 to 1.18,  $I^2 = 38\%$ , 1274 deaths, 14 studies in > 65,000 people, [Analysis 2.6](#)).

### Angina (LCn3)

Meta-analysis of 11 studies involving more than 39,000 participants, 2418 of whom reported new or worsening angina, suggested little or no effect of increasing LCn3 fats (RR 0.99, 95% CI 0.92 to 1.07,  $I^2 = 0\%$ , [Analysis 2.7](#)).

### Heart failure (LCn3)

Meta-analysis suggested a small effect for LCn3 fatty acids on heart failure diagnosis in 15 trials with 4098 people experiencing events (RR 0.93, 95% CI 0.85 to 1.03,  $I^2 = 31\%$ , [Analysis 2.8](#)). Because of this suggested effectiveness, we ran a sensitivity analysis limited to the six studies at low summary risk of bias, which suggested little effect (RR 0.97, 95% CI 0.89 to 1.06,  $I^2 = 0\%$ , 1809 participants experiencing heart failure). For this reason we concluded that there was little or no effect of LCn3 on risk of heart failure.

### Revascularisation (LCn3)

Meta-analysis suggested little or no effect of LCn3 fats on revascularisation (all types combined, RR 0.98, 95% CI 0.94 to 1.03, 6558 participants experiencing revascularisation,  $I^2 = 0\%$ , [Analysis 2.9](#)). Data on angioplasty alone were similar (RR 0.96, 95% CI 0.74 to 1.24, 215 events), and there were insufficient reported CABGs to give meaningful results (9 events, [Analysis 2.9](#)).

### Peripheral arterial disease (LCn3)

Meta-analysis suggested that LCn3 reduced the risk of peripheral arterial disease (PAD) by 7% (RR 0.93, 95% CI 0.74 to 1.18,  $I^2 = 0\%$ , 282 events in > 49,000 participants, 7 trials, [Analysis 2.10](#)). All relevant studies had randomised at least 100 participants, so this sensitivity analysis did not alter the effect, but limiting the analysis to studies at low risk of compliance bias suggested little or no effect of LCn3 on PAD, and limiting analyses to studies at low summary risk of bias suggested an increase in PAD with increased LCn3 ([Analysis 2.11](#); [Analysis 2.12](#)). The effect of LCn3 on peripheral arterial disease is unclear - there may be increased, decreased or no effect.

### Acute coronary syndrome (LCn3)

There were limited data on effects of increasing LCn3 fats on acute coronary syndrome (RR 1.19, 95% CI 0.71 to 2.00,  $I^2 = 0\%$ , 55 events in > 2000 participants, 2 trials, [Analysis 2.13](#)).

### Body weight, body mass index (BMI) and other measures of adiposity (LCn3)

#### Body weight

High-quality evidence shows that LCn3 intake makes little or no difference to body weight.

Twelve studies, 11 of which were included in meta-analysis, reported on the effect of increasing LCn3 on body weight, suggesting little or no effect in > 15,000 participants (mean difference (MD) -0.01 kg, 95% CI -0.84 to 0.82,  $I^2 = 49\%$ , [Analysis 2.14](#)). Sensitivity analysis limited to studies at low summary risk of bias, low risk from compliance, larger trials or fixed-effect analysis (not shown) did not alter this lack of effect ([Analysis 2.15](#); [Analysis 2.16](#)).

Subgroup analysis by intervention type, primary or secondary prevention, statin use and trial duration did not suggest important differences between subgroups ([Analysis 2.19](#); [Analysis 2.20](#); [Analysis 2.21](#); [Analysis 2.22](#)). There was a marginally significant difference between dose subgroups ( $P = 0.06$ , [Analysis 2.17](#)) and increased body weight when participants received very high LCn3 doses (> 4.4 g/d LCn3, MD 1.51 kg, 95% CI 0.28 to 2.75,  $I^2 = 0\%$ , 2 trials including 261 participants, [Analysis 2.17](#)). Subgrouping by replacement suggested differences between subgroups ( $P < 0.001$ , [Analysis 2.18](#), with reduced body weight when LCn3 replaced saturated fatty acids (SFA) or carbohydrates but increased weight when LCn3 replaced nil or low LCn3 ([Analysis 2.18](#)).

Several studies clearly measured body weight but did not report it in a useable way ([Baldassarre 2006](#); [Caldwell 2011](#); [Deslypere 1992](#); [EPE-A 2014](#); [MARINA 2011](#); [Nutrirstroke 2009](#)). Body weight is commonly measured in healthcare settings, so there may be considerably more missing data than these.

GRADE evidence suggests high-quality evidence that LCn3 intake makes little or no difference to body weight (high-quality/certainty evidence).

#### BMI

High-quality evidence shows that LCn3 intake makes little or no difference to BMI.

Fourteen trials, 12 of which were included in meta-analysis, reported on BMI, suggesting little or no effect of LCn3 on BMI (MD 0.04 kg/m<sup>2</sup>, 95% CI -0.16 to 0.24,  $I^2 = 40\%$ , > 15,000 participants, [Analysis 2.23](#)). This lack of effect was also apparent in sensitivity analyses limited to studies at low summary risk of bias ([Analysis 2.24](#)), with good compliance or with large study size ([Analysis 2.25](#)), as well as fixed-effect analysis (not shown). Subgroup analyses by primary or secondary prevention, LCn3 dose, intervention type, statin use and trial duration did not suggest important differences between subgroups ([Analysis 2.26](#); [Analysis](#)

2.28; Analysis 2.29; Analysis 2.30; Analysis 2.31). There were significant differences between subgroups when subgrouped by replacement, suggesting lower BMI when LCn3 was replaced by SFA and carbohydrate, but increased BMI with LCn3 in other replacements ( $P = 0.04$ , Analysis 2.27).

Several studies clearly measured BMI but did not report it in a useable way (Caldwell 2011; EPE-A 2014; Nutristroke 2009; Ramirez-Ramirez 2013; Sofi 2010), suggesting that missing data may be an issue with this outcome.

GRADE evidence suggests high-quality evidence that LCn3 intake makes little or no difference to BMI (high-quality/certainty evidence).

### **Other measures of adiposity**

Few studies reported on other measures of adiposity (percentage body fat, percentage visceral fat, waist circumference, waist/hip ratio, abdominal circumference and hip circumference) with some suggesting higher adiposity and some lower adiposity in groups with more LCn3 (Analysis 2.32).

### **Serum lipids (LCn3)**

Several studies clearly measured lipids but did not report them in a way that we could include in our meta-analyses. These generally included Baldassarre 2006, Gill 2012, Ramirez-Ramirez 2013 and Reed 2014, plus Ahn 2016, Caldwell 2011, Franzen 1993 and Rossing 1996, which assessed but did not report triglycerides, and Franzen 1993, which measured but did not provide useable data for HDL and LDL cholesterol. For this reason missing data may potentially bias these outcomes.

### **Serum total cholesterol**

Moderate-quality evidence shows that LCn3 intake probably makes little or no difference to serum total cholesterol.

Twenty-eight trials provided data on long-term effects of LCn3 fats on serum total cholesterol, suggesting little or no effect in more than 37,000 participants (MD  $-0.01$  mmol/L, 95% CI  $-0.5$  to  $0.04$ ,  $I^2 = 19\%$ , Analysis 2.33). Sensitivity analyses limited to trials at low summary risk of bias, low risk of compliance issues, and larger trials also suggested little or no effect of LCn3 on serum total cholesterol (Analysis 2.34; Analysis 2.35), but fixed-effect meta-analysis suggested that LCn3 reduced serum total cholesterol (MD  $-0.04$  mmol/L, 95% CI  $-0.06$  to  $-0.02$ ,  $I^2 = 19\%$ , not shown). Subgrouping by duration did not suggest any differential effects of LCn3 (Analysis 2.39). There were significant differences between subgroups by dose but no logical sequence suggesting a true dose-response effect ( $P = 0.03$ , Analysis 2.36). There were also subgroup differences for replacement and intervention type (Analysis 2.37; Analysis 2.38), with reductions in serum total cholesterol

when supplemental capsules were used and when LCn3 replaced carbohydrates (Analysis 2.36; Analysis 2.37; Analysis 2.38).

GRADE assessment suggests moderate-quality evidence that LCn3 intake probably makes little or no difference to serum total cholesterol (moderate-quality/certainty evidence, downgraded once for imprecision).

### **Serum triglycerides**

High-quality evidence suggests that LCn3 intake reduces serum triglycerides in a dose-dependent manner.

LCn3 fats significantly reduced serum triglycerides in > 35,000 participants in 23 trials (MD  $-0.24$  mmol/L, 95% CI  $-0.31$  to  $-0.16$ ,  $I^2 = 48\%$ , Analysis 2.42). This effect was not lost in sensitivity analysis excluding studies at moderate to high risk of bias, those without clear compliance or small studies (Analysis 2.43; Analysis 2.44), or using fixed-effect analysis (not shown). Subgrouping suggested that the reduction of serum triglycerides did not differ between subgroups by primary or secondary prevention, statin use, replacement, intervention type or trial duration (Analysis 2.46; Analysis 2.47; Analysis 2.48; Analysis 2.49; Analysis 2.50). There was a suggestion of a dose-response relationship with greater reductions in triglycerides at higher LCn3 doses, with significant differences between subgroups ( $P = 0.04$ , Analysis 2.45).

GRADE evidence suggests high-quality evidence that LCn3 intake reduces serum triglycerides in a dose-dependent manner (not downgraded).

### **HDL cholesterol**

High-quality evidence suggests that LCn3 intake increases HDL cholesterol a small amount.

Twenty-seven trials including more than 37,000 participants suggested an increase in serum HDL cholesterol with increased LCn3 (MD  $0.02$  mmol/L, 95% CI  $0.00$  to  $0.04$ ,  $P = 0.03$ ,  $I^2 = 48\%$ , Analysis 2.51). There was still a suggestion of a small HDL increase when we limited analysis to the eight studies at low summary risk of bias (MD  $0.03$  mmol/L, 95% CI  $-0.01$  to  $0.07$ ,  $I^2 = 66\%$ , > 14,000 participants, Analysis 2.52) where heterogeneity was very high. Limiting analyses by compliance and study size (Analysis 2.53) and in fixed-effect analysis (not shown), results suggested increases in HDL with LCn3. There were no significant differences between subgroups in any analysis except by duration, where shorter trials suggested HDL increases, with no effect in longer trials ( $P = 0.05$ , Analysis 2.57). There were no important differences between other subgroups and no suggestion of a dose-response relationship (Analysis 2.54; Analysis 2.55; Analysis 2.56; Analysis 2.58; Analysis 2.59).

GRADE assessment suggests high-quality evidence that LCn3 intake increases HDL cholesterol a little (not downgraded).

## LDL cholesterol

GRADE assessment suggests moderate-quality evidence that LCN3 intake probably makes little or no difference to LDL cholesterol.

There was little or no effect of increasing LCN3 on serum LDL cholesterol in over 35,000 participants from 23 trials (MD 0.01 mmol/L, 95% CI -0.01 to 0.03,  $I^2 = 0\%$ , [Analysis 2.60](#)). This lack of effect did not alter in sensitivity analyses limited to trials at low summary risk of bias, to trials with good evidence of compliance ([Analysis 2.61](#)), larger studies ([Analysis 2.62](#)) or in fixed-effect meta-analysis (not shown). We saw no statistically significant differences between subgroups except for with regard to statin use, where there was an increase in LDL cholesterol in nine trials where statin use was low ([Analysis 2.63](#); [Analysis 2.64](#); [Analysis 2.65](#); [Analysis 2.66](#); [Analysis 2.67](#); [Analysis 2.68](#)).

GRADE assessment suggests moderate-quality evidence that LCN3 intake probably makes little or no difference to LDL cholesterol (moderate-quality/certainty evidence, downgraded once for imprecision).

## Effects of ALA on secondary health outcomes

We did not plan any sensitivity or subgroup analyses on secondary outcomes, except for adiposity and lipids (key outcomes). As fewer than 10 ALA trials were available for these outcomes, we carried out only sensitivity analyses.

## Major adverse cerebrovascular or cardiovascular events (ALA)

One trial reported on MACCEs in 110 participants, 9 of whom experienced an event. There were insufficient data to suggest any effect of ALA on MACCEs (RR 1.12, 95% CI 0.32 to 3.95, [Analysis 5.1](#)).

## Myocardial infarction (ALA)

Three studies reported that 333 out of more than 18,000 participants experienced a fatal or non-fatal MI, suggesting little or no effect of ALA on MI (RR 1.00, 95% CI 0.76 to 1.32,  $I^2 = 26\%$ , [Analysis 5.2](#)).

We carried out subgroup analyses by fatality at the request of the WHO NUGAG Subgroup on Diet and Health, and these suggested no significant differences between fatal and non-fatal MI subgroups ( $P = 0.36$ , [Analysis 5.3](#)).

## Sudden cardiac death (ALA)

No studies assessed effects of ALA on sudden cardiac death.

## Angina (ALA)

Two trials assessed the effects of increasing ALA on diagnosis of new or worsening angina (39 of > 13,000 participants experienced this). There were insufficient data to suggest any effect of ALA on angina (RR 1.41, 95% CI 0.75 to 2.64,  $I^2 = 0\%$ , [Analysis 5.4](#)).

## Heart failure (ALA)

No studies assessed effects of ALA on heart failure.

## Revascularisation (ALA)

Only one trial (3 events in 266 participants) reported on the effects of increased ALA on revascularisation (RR 0.72, 95% CI 0.07 to 7.84, 3 events, [Analysis 5.5](#)) or CABG specifically (RR 0.29, 95% CI 0.01 to 5.93, 2 events, [Analysis 5.5](#)). There were insufficient data to suggest any effect of ALA on revascularisation.

## Peripheral arterial disease (ALA)

Meta-analysis suggested no clear effect of ALA on PAD in a single study (RR 0.25, 95% CI 0.05 to 1.17, 10 of the > 13,000 participants experienced PAD, [Analysis 5.6](#)). There were insufficient data to suggest any effect of ALA on the outcome.

## Acute coronary syndrome (ALA)

There were no trials assessing effects of ALA on acute coronary syndrome.

## Body weight, BMI and other measures of adiposity (ALA)

Low-quality evidence suggests that ALA intake may make little or no difference to BMI, but the effect of LCN3 intake on body weight is unclear as the evidence is of very low quality.

Four studies reported on the effect of ALA on body weight in 664 participants, suggesting some weight reduction in those taking more ALA but with extremely high heterogeneity (MD -1.49 kg, 95% CI -4.17 to 1.18,  $I^2 = 73\%$ , [Analysis 5.7](#)). Sensitivity analysis using fixed-effect meta-analysis suggested a slight increase in body weight with ALA ([Analysis 5.8](#)), while no studies were at low summary risk of bias ([Analysis 5.9](#)). Retaining only trials at low risk for compliance bias or only larger trials suggested weight reduction with ALA ([Analysis 5.10](#)). There were no significant differences between subgroups by intervention type, dose, duration, replacement, statin use, or primary or secondary prevention of CVD ([Analysis 5.11](#); [Analysis 5.12](#); [Analysis 5.13](#); [Analysis 5.14](#); [Analysis 5.15](#); [Analysis 5.16](#)). GRADE assessment suggests that the effect of ALA intake on body weight is unclear, as the evidence is of very low quality (downgraded once each for risk of bias, inconsistency and imprecision).

Three trials reported on BMI, suggesting a reduction in BMI with increased ALA (MD -0.42 kg/m<sup>2</sup>, 95% CI -1.53 to 0.69,  $I^2$



= 65%, 1581 participants, [Analysis 5.17](#)), again with high heterogeneity. Sensitivity analyses using fixed-effect analysis or only retaining studies at low summary risk of bias suggested a small increase in BMI with ALA ([Analysis 5.18](#); [Analysis 5.19](#)), while limiting to studies at low risk of compliance bias or eliminating smaller studies suggested a small reduction in BMI with increased ALA ([Analysis 5.20](#)). There were no statistically significant differences between subgroups differentiated by replacement or statin use ([Analysis 5.23](#); [Analysis 5.25](#)), but there were differences by dose - subgrouping by dose suggested greater reduction of BMI in studies giving more ALA ( $P = 0.03$ , [Analysis 5.21](#)). All included studies gave supplemental foods ([Analysis 5.22](#)). There were greater reductions in BMI in shorter studies ( $P = 0.02$ , [Analysis 5.24](#)) and in primary prevention studies ( $P = 0.03$ , [Analysis 5.26](#)), but the inclusion of [Dodin 2005](#) in any subgroup tended to differentiate that group from the others. GRADE assessment suggests low-quality evidence that ALA intake may make little or no difference to BMI (low-quality/certainty evidence, downgraded once each for imprecision and inconsistency).

One study reported on visceral adipose tissue, suggesting no clear effect, but three trials reported on waist circumference. Meta-analysis of two of these suggested that increasing ALA resulted in reduced weight circumference (MD  $-1.59$  cm, 95% CI  $-3.10$  to  $-0.07$ ,  $I^2 = 0\%$ , [Analysis 5.27](#)). However, the single trial that we could not include in the meta-analysis due to lack of information on variance suggested effects in the opposite direction. Sensitivity analyses (only retaining studies at low summary risk of bias, not shown) removed all trials.

## Serum lipids (ALA)

### Serum total cholesterol

Low-quality evidence suggests that ALA intake may make little or no difference to serum total cholesterol.

Six trials provided data on the long-term effects of ALA on serum total cholesterol, suggesting that increased ALA intake leads to a small reduction in total cholesterol, but with high heterogeneity (MD  $-0.09$  mmol/L, 95% CI  $-0.23$  to  $0.05$ ,  $I^2 = 63\%$ , in  $> 2000$  participants, [Analysis 5.28](#)). Restricting analyses to studies at low summary risk of bias suggested no effect of ALA ([Analysis 5.30](#)), but fixed-effect analysis suggested that the intervention led to a reduction ([Analysis 5.29](#)), as did sensitivity analyses limited to studies at low risk of compliance bias or larger studies ([Analysis 5.31](#)). All studies provided food supplements ([Analysis 5.33](#)), but subgroup analyses suggested greater reductions in total cholesterol in shorter duration studies ( $P = 0.02$ , [Analysis 5.35](#)). Other differences between subgroups resulted from effects groups where ALA replacement or statin use was 'unclear' ([Analysis 5.34](#); [Analysis 5.36](#)), or there were no differences ([Analysis 5.32](#); [Analysis 5.37](#)).

GRADE assessment suggests low-quality evidence that ALA intake may make little or no difference to serum total cholesterol (downgraded once each for imprecision and inconsistency).

### Serum triglycerides

Moderate-quality evidence suggests that ALA intake probably makes little or no difference to serum triglycerides.

There was little or no effect of ALA on serum triglycerides in 1776 participants in six trials (MD  $-0.03$  mmol/L, 95% CI  $-0.11$  to  $0.05$ ,  $I^2 = 0\%$ , [Analysis 5.38](#)). There was little or no effect of ALA in sensitivity analysis removing trials of moderate to high risk of bias ([Analysis 5.40](#)), in fixed-effect meta-analysis ([Analysis 5.39](#)), or limiting by compliance bias or study size ([Analysis 5.41](#)). Subgrouping suggested no important differential effects by dose, duration, replacement, intervention type, statin use, or primary or secondary prevention ([Analysis 5.42](#); [Analysis 5.43](#); [Analysis 5.44](#); [Analysis 5.45](#); [Analysis 5.46](#); [Analysis 5.47](#)). GRADE assessment suggests moderate-quality evidence that ALA intake probably makes little or no difference to serum triglycerides (downgraded once for imprecision).

### HDL cholesterol

Moderate-quality evidence suggests that ALA probably reduces HDL cholesterol.

There was little or no effect of ALA on HDL cholesterol in 1776 participants of 6 trials (MD  $-0.02$  mmol/L, 95% CI  $-0.08$  to  $0.03$ ,  $I^2 = 53\%$ , [Analysis 5.48](#)), although there were reductions of HDL in both analyses by risk of bias and using fixed-effect meta-analysis ([Analysis 5.49](#); [Analysis 5.50](#)) with similar effects in studies with good compliance and in larger trials ([Analysis 5.51](#)). A further trial, [WAHA 2016](#), also measured HDL but did not provide data in a useable format for meta-analysis. There was a suggestion of greater HDL reduction with greater ALA dose ( $P = 0.09$ , [Analysis 5.52](#)), but no other subgrouping effects were evident ([Analysis 5.53](#); [Analysis 5.54](#); [Analysis 5.55](#); [Analysis 5.56](#); [Analysis 5.57](#)). GRADE assessment suggests moderate-quality evidence that ALA probably reduces HDL cholesterol (downgraded for imprecision).

### LDL cholesterol

Low-quality evidence suggests that ALA intake may make little or no difference to LDL cholesterol.

There was a small reduction of LDL cholesterol with ALA in 2201 participants of 7 trials (MD  $-0.05$  mmol/L, 95% CI  $-0.15$  to  $0.04$ ,  $I^2 = 46\%$ , [Analysis 5.58](#)), with similar effects in studies with good compliance and in larger trials ([Analysis 5.61](#)). While fixed-effect analysis suggested marginal statistical significance of this

reduction ( $P = 0.06$ , [Analysis 5.59](#)), there were no effects when we limited analyses to studies at low summary risk of bias (MD 0.02 mmol/L, 95% CI  $-0.05$  to  $0.10$ ,  $I^2 = 0\%$ , [Analysis 5.60](#)). Subgrouping suggested no differences in effect by ALA dose or primary or secondary prevention ([Analysis 5.62](#); [Analysis 5.67](#)), but shorter studies, those with unclear replacement and unclear statin use suggested reductions in LDL with ALA ([Analysis 5.64](#); [Analysis 5.65](#); [Analysis 5.66](#)). All studies provided supplemental foods ([Analysis 5.63](#)). GRADE assessment suggests low-quality evidence that ALA intake may make little or no difference to LDL cholesterol (downgraded once each for risk of bias and imprecision).

## Tertiary outcomes

### Effects of long-chain omega-3 fats (EPA, DHA and DPA) on tertiary health outcomes

We extracted these outcomes from studies that we included for other outcomes, so we did not assess them completely or systematically. We did not carry out sensitivity analyses or subgrouping for these outcomes. We are aware of missing data for some of these outcomes, including blood pressure in [Ramirez-Ramirez 2013](#).

### Blood pressure (LCn3)

Fifteen included trials ( $> 34,000$  participants) contributed data on effects of LCn3 fats on blood pressure. Meta-analysis suggested little or no effect of LCn3 on systolic (MD 0.02 mmHg, 95% CI  $-0.32$  to  $0.35$ ,  $I^2 = 0\%$ , [Analysis 3.1](#)) or diastolic (MD  $-0.02$  mmHg, 95% CI  $-0.22$  to  $0.17$ ,  $I^2 = 0\%$ , [Analysis 3.1](#)) blood pressure in trials of at least one year.

### Serious adverse effects (LCn3)

As part of the larger set of reviews we formally systematically reviewed effects of omega-3 fats on type 2 diabetes diagnoses, measures of glucose metabolism ([Brown 2017](#)), cancers including breast cancer ([Hanson 2017b](#)), neurocognitive outcomes such as dementia ([Jimoh 2017](#)), irritable bowel disease (IBD) and inflammatory factors ([Thorpe 2017](#)), depression and anxiety ([Hanson 2017a](#)), and functional outcomes ([Abdelhamid 2017](#)), so we do not present these outcomes here.

We did collect data on the following potentially important health outcomes ([Analysis 3.2](#)).

- Any serious adverse event (RR 1.05, 95% CI 0.78 to 1.41,  $I^2$  NA, 126 events in  $> 400$  participants in 1 trial).
- Bleeding (RR 1.06, 95% CI 0.73 to 1.52,  $I^2 = 49\%$ , 374 events in  $> 45,000$  participants in 8 trials).
- Gastrointestinal hospitalisation (RR 1.75, 95% CI 0.53 to 5.79,  $I^2$  NA, 11 events in 200 participants in 1 trial).

- Pulmonary embolus or DVT (RR 1.25, 95% CI 0.41 to 3.78,  $I^2 = 11\%$ , 18 events in  $> 3000$  participants in 4 trials).
- Progression to advanced age-related macular degeneration (RR 0.96, 95% CI 0.90 to 1.02,  $I^2$  NA, 2049 events in  $> 4000$  participants in 1 trial).
- Thrombophlebitis: no data identified.
- Urolithiasis: no data identified.

### Side effects (non-serious, LCn3)

To assess side effects we collected data on the following potential side effects ([Analysis 3.3](#)).

- Withdrawal: the data suggest more participants taking LCn3 fats dropped out because of side effects (RR 1.16, 95% CI 0.99 to 1.36,  $I^2 = 1\%$ , 620 dropouts in  $> 16,000$  participants, 23 trials).
- Increased abdominal pain or discomfort: data suggest an association with higher LCn3 (RR 1.10, 95% CI 0.84 to 1.45,  $I^2 = 24\%$ , 303 events in  $> 14,000$  participants, 7 trials).
- Diarrhoea: the data suggested an increased risk with increased LCn3 (RR 1.15, 95% CI 0.92 to 1.43,  $I^2 = 0\%$ , 284 events in  $> 2000$  participants, 10 trials).
- Nausea: risk increased with LCn3 (RR 1.76, 95% CI 1.25 to 2.48,  $I^2 = 0\%$ , 140 events in  $> 1000$  participants, 6 trials).
- Any gastrointestinal side effect: risk also appeared to increase with LCn3, albeit with very high heterogeneity (RR 1.12, 95% CI 0.94 to 1.34,  $I^2 = 74\%$ , 2545 events in  $> 65,000$  participants, 29 trials).
- Skin problems, including itching or rashes: these were not affected by LCn3 in a meta-analysis with high heterogeneity (RR 1.04, 95% CI 0.47 to 2.30,  $I^2 = 72\%$ , 290 events in  $> 36,000$  participants, 8 trials).
- Headache or worsening migraine: there were limited data on this outcome (RR 0.81, 95% CI 0.48 to 1.36,  $I^2 = 0\%$ , 55 events in 996 participants, 3 trials).
- Reflux: there were limited data (RR 1.42, 95% CI 0.71 to 2.81,  $I^2$  NA, 29 events in 202 participants, 1 trial).
- Joint lumbar and muscle pain: one study provided data suggesting that LCn3 reduced the risk of such pain (RR 0.80, 95% CI 0.64 to 0.99, 324 out of  $> 18,000$  participants experiencing pain).

- All adverse effects: there was no suggestion that LCn3 increased or decreased all side effects combined in a meta-analysis with very high heterogeneity (RR 1.01, 95% CI 0.95 to 1.08,  $I^2 = 81\%$ , 9534 people with at least one side effect in  $> 38,000$  participants, 13 trials).

### Dropouts (LCn3)

Included studies reported 5515 dropouts over  $> 31,000$  participants in 30 trials, suggesting no difference in dropout rates between intervention and control arms (RR 1.02, 95% CI 0.95 to 1.09,  $I^2 = 11\%$ , [Analysis 3.4](#)).

### Quality of life, economic costs (LCn3)

We found no data on quality of life outcomes or economic costs.

### Effects of ALA on tertiary health outcomes

We extracted these outcomes from studies that we included for other outcomes, so we did not assess them completely or systematically. We did not carry out sensitivity analyses or subgrouping for these outcomes.

### Blood pressure (ALA)

Four included trials (1671 participants) contributed data on effects of ALA on blood pressure. Meta-analysis suggested little or no effect of ALA on systolic (MD  $-0.87$  mmHg, 95% CI  $-4.48$  to  $2.75$ ,  $I^2 = 58\%$ , [Analysis 6.1](#)) or diastolic (MD  $-1.42$  mmHg, 95% CI  $-4.40$  to  $1.57$ ,  $I^2 = 74\%$ , [Analysis 6.1](#)) blood pressure in trials of at least one year. The heterogeneity in these results reflect a single trial, [FLAX-PAD 2013](#), that showed large diastolic and systolic blood pressure effects. The other (larger) trials did not suggest such effects.

### Serious adverse effects (ALA)

As part of the larger set of reviews we formally systematically reviewed effects of omega-3 fats on type 2 diabetes diagnoses and measures of glucose metabolism ([Brown 2017](#)), cancers including breast cancer ([Hanson 2017b](#)), neurocognitive outcomes such as dementia ([Jimoh 2017](#)), irritable bowel disease (IBD) and inflammatory factors ([Thorpe 2017](#)), depression and anxiety ([Hanson 2017a](#)), and functional outcomes ([Abdelhamid 2017](#)), so we do not present these outcomes here.

We did collect data on the following potentially important health outcomes ([Analysis 6.2](#)).

- Any serious adverse event: no data identified.
- Bleeding: no data identified.
- Gastrointestinal hospitalisation: no data identified.
- Pulmonary embolus or DVT: only one event was identified in a single study, so there were insufficient data to assess effects
  - Progression to advanced age-related macular degeneration: no data identified.

- Thrombophlebitis: there were insufficient data to assess effects (RR 1.59, 95% CI 0.72 to 3.51,  $I^2$  NA, 26 events, > 13,000 participants, 1 trial).

- Urolithiasis: there were insufficient data to assess effects (RR 0.80, 95% CI 0.47 to 1.36,  $I^2$  NA, 54 events, > 13,000 participants, 1 trial).

### Side effects (non-serious, ALA)

To assess potential side effects, we collected data on the following ([Analysis 6.3](#)).

- Dropouts due to side effects: data suggested that ALA increased the risk of withdrawal, although there was high heterogeneity (RR 2.10, 95% CI 0.66 to 6.71,  $I^2 = 62\%$ , 68 events, > 3000 participants, 5 trials).

- Abdominal pain or discomfort: no data identified.
- Diarrhoea: a single study identified 10 participants with diarrhoea, suggesting a higher risk of diarrhoea with greater ALA intake (RR 3.82, 95% CI 0.82 to 17.88).

- Nausea: there were insufficient data to assess effects of ALA (RR 6.29, 95% CI 0.33 to 118.93,  $I^2$  NA, 3 events, 110 participants, 1 trial).

- Any gastrointestinal side effect: there were insufficient data to assess effects of ALA (RR 1.79, 95% CI 0.48 to 6.69,  $I^2 = 69\%$ , 46 events, > 3000 participants, 3 trials). The very high heterogeneity suggests that gastrointestinal side effects may be collected in different ways in different trials.

- Skin problems, including itching or rashes: no data identified.

- Headache or worsening migraine: no data identified.

- Reflux: no data identified.

- All side effects combined: no data identified.

### Dropouts (ALA)

Included studies reported 558 dropouts over > 3000 participants in 6 trials, suggesting slightly higher dropout rates in participants taking higher ALA (RR 1.08, 95% CI 0.92 to 1.25,  $I^2 = 0\%$ , [Analysis 6.4](#)).

### Quality of life, economic costs (ALA)

We found no data on quality of life outcomes or economic costs.

## ADDITIONAL SUMMARY OF FINDINGS *[Explanation]*

High versus low ALA omega-3 fats for preventing cardiovascular disease (primary outcomes)						
<p><b>Patient or population:</b> adults with or without existing CVD</p> <p><b>Setting:</b> participants were living at home for most or all of the duration of their trials. Most studies were carried out in high-income economies (<a href="#">World Bank 2018</a>), but four trials were carried out in upper-middle income countries (Argentina, Iran, Turkey and China). No studies took place in low- or low-middle income countries.</p> <p><b>Intervention:</b> higher intake of ALA</p> <p><b>Comparison:</b> lower intake of ALA</p> <p>The intervention was dietary supplementation, a provided diet or advice on diet. Supplementation may have been in oil or capsule form or as foodstuffs provided, to be consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuffs or supplements must have been: refined ALA, linseed (flax), canola (rapeseed), perilla, purslane, mustard seed, candlenut, stillingia or walnut as a food, oil, made into a spreading fat or supplementing another food (such as bread or eggs). For ALA sources the product consumed had to have an omega-3 fat content of at least 10% of the total fat content</p>						
Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Risk with lower ALA	Risk with higher ALA				
<p><b>All-cause mortality</b> - deaths</p> <p>Assessed with: number of participants dying of any cause, whether reported as an outcome or a reason for dropout</p> <p>Duration: range 12 to 40 months</p>	25 per 1000	25 per 1000 (21 to 29)	RR 1.01 (0.84 to 1.20)	19327 (5 RCTs)	⊕⊕⊕○ Moderate <sup>a</sup>	Meta-analysis and sensitivity analyses suggest risk increase of less than 1%. ALA intake probably makes little or no difference to all-cause mortality
<p><b>Cardiovascular mortality</b> - cardiovascular deaths</p> <p>Assessed with: deaths from any cardiovascular cause. Where this was not available cardiac death was used instead where known</p>	12 per 1000	12 per 1000 (9 to 15)	RR 0.96 (0.74 to 1.25)	18619 (4 RCTs)	⊕⊕⊕○ Moderate <sup>b</sup>	Meta-analysis and sensitivity analyses suggest risk reduction of less than 5%. ALA intake probably makes little or no difference to cardiovascular mortality

Duration: range 12 to 40 months						
<b>Cardiovascular events</b> - cardiovascular events Assessed with: number of participants experiencing any cardiovascular event Duration: range 12 to 40 months	48 per 1000	47 per 1000 (39 to 57)	RR 0.95 (0.83 to 1.07)	19327 (5 RCTs)	⊕⊕○○ Low <sup>c</sup>	Meta-analysis and sensitivity analyses suggest risk reduction of 5% to 10%. ALA intake may reduce the risk of cardiovascular events but by a very small amount (from 4.8 to 4.7%). One thousand people would need to consume more ALA to prevent a single person experiencing a CVD event (NNT=1000)
<b>Coronary heart mortality</b> - CHD deaths Assessed with: Coronary deaths, or where these were not reported, IHD death, fatal MI or cardiac death (in that order) Duration: range 12 to 40 months	11 per 1000	10 per 1000 (8 to 14)	RR 0.95 (0.72 to 1.26)	18353 (3 RCTs)	⊕⊕⊕○ Moderate <sup>d</sup>	Meta-analysis and sensitivity analyses suggest risk reduction of 5% to 8%. ALA intake probably reduces risk of CHD mortality but by a very small amount (from 1.1 to 1.0%). One thousand people would need to consume more ALA to prevent a single person experiencing a CHD death (NNT=1000)
<b>Coronary Heart Disease</b> - CHD events Assessed with: number of participants experiencing the first outcome in this list	22 per 1000	22 per 1000 (17 to 28)	RR 1.00 (0.82 to 1.22)	19061 (4 RCTs)	⊕⊕○○ Low <sup>e</sup>	Meta-analysis and sensitivity analyses suggest risk reduction of 0% to 9%. ALA intake may make little or no dif-

reported for each trial: CHD or coronary events; total MI; acute coronary syndrome; or angina (stable and unstable) Duration: range 12 to 40 months						ference to CHD events
<b>Stroke</b> Assessed with: number of participants experiencing at least one fatal or non-fatal, ischaemic or haemorrhagic stroke Duration: range 12 to 40 months	2 per 1000	3 per 1000 (2 to 5)	RR 1.15 (0.66 to 2.01)	19327 (5 RCTs)	⊕○○○ Very low <sup>f</sup>	Meta-analysis and sensitivity analyses suggest risk increase of –15% to 23%. The effect of ALA intake on stroke is unclear as the evidence is of very low quality
<b>Arrhythmias</b> - AF, VT, VF Assessed with: number of participants experiencing fatal or non-fatal, new or recurrent arrhythmia, including atrial fibrillation, ventricular tachycardia and ventricular fibrillation Duration: 1 trial of 40 months	33 per 1000	26 per 1000 (19 to 36)	RR 0.79 (0.57 to 1.10)	4837 (1 RCT)	⊕⊕⊕○ Moderate <sup>g</sup>	Meta-analysis and sensitivity analyses suggest risk reduction of 21%. ALA intake probably reduces the risk of arrhythmias a small amount (from 3.3 to 2.6%). 143 people would need to consume more ALA to prevent a single person experiencing an arrhythmic event (NNT= 143)
<b>Harms: bleeding</b> Assessed with: number of participants experiencing bleeding events	The effect of ALA intake on bleeding is unclear as no studies reported this outcome					

<b>Harms: pulmonary embolus or DVT</b> Assessed with: number of participants experiencing pulmonary embolus or deep vein thrombosis Duration: range 24 months	3 per 1000	<b>1 per 1000</b> (0 to 23)	<b>RR 0.32</b> (0.01 to 7.80)	708 (1 study)	⊕○○○ Very low <sup>h</sup>	The effect of ALA intake on pulmonary embolus or DVT is unclear as the evidence is of very low quality
---	------------	--------------------------------	----------------------------------	------------------	-------------------------------	--

\* **The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**ALA:** alpha-linolenic acid; **CHD:** coronary heart disease; **CI:** confidence interval; **DVT:** deep vein thrombosis; **IHD:** ischaemic heart disease; **MI:** myocardial infarction; **RCT:** randomised controlled trial; **RR:** risk ratio.

#### GRADE Working Group grades of evidence

**High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

**Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

#### <sup>a</sup> All-cause mortality, ALA

- **Risk of bias:** there was little or no effect in the main meta-analysis or when data were limited to RCTs at low summary risk of bias, low risk of compliance problems or larger trials, though a suggestion of increased risk of death with fixed-effect meta-analyses. Not downgraded.

- **Inconsistency:**  $I^2$  was < 60%; not downgraded.

- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. All studies were conducted in high-income countries. Not downgraded.

- **Imprecision:** large numbers of participants have taken part in RCTs in long-term studies with consistent results.

However, as 95% confidence intervals do not exclude important benefits or harms we downgraded once.

- **Publication bias:** funnel plot not useful as fewer than 10 trials included. Not downgraded.

#### <sup>b</sup> Cardiovascular mortality, ALA

- **Risk of bias:** there was little or no effect in the main analysis, or when data were limited to RCTs at low summary risk of bias, larger trials or fixed-effect meta-analysis, though a small benefit was suggested when studies were limited to trials with low risk of compliance bias. Not downgraded.

- **Inconsistency:**  $I^2$  was < 60%; not downgraded.

- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. All studies were conducted in high-income countries. Not downgraded.

- **Imprecision:** large numbers of participants have taken part in RCTs in long-term studies with consistent results.

However, as 95% confidence intervals do not exclude important benefits or harms we downgraded once.

- **Publication bias:** funnel plot not useful as fewer than 10 trials included. Not downgraded.

#### <sup>c</sup> **Cardiovascular events, ALA**

- **Risk of bias:** there was a small effect in the main analysis, with larger trials and in fixed-effect analysis, and a larger effect when data were limited to RCTs at low summary risk of bias or at low risk from compliance problems. Downgraded once.

- **Inconsistency:**  $I^2$  was <60%; not downgraded.

- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. All studies were conducted in high-income countries. Not downgraded.

- **Imprecision:** large numbers of participants have taken part in RCTs in long-term studies with consistent results.

However, as 95% confidence intervals do not exclude important benefits or harms we downgraded once.

- **Publication bias:** funnel plot not useful as fewer than 10 trials included. Not downgraded.

#### <sup>d</sup> **Coronary heart disease mortality, ALA**

- **Risk of bias:** while ALA reduced CHD mortality by 5% in the main analysis, fixed-effect analysis and in larger trials, limiting data to RCTs at low summary risk of bias and low risk of compliance problems resulted in 7%-8% reductions. Not downgraded.

- **Inconsistency:**  $I^2$  was < 60%; not downgraded.

- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. All studies were conducted in high-income countries. Not downgraded.

- **Imprecision:** large numbers of participants have taken part in RCTs in long-term studies with consistent results.

However, as 95% confidence intervals do not exclude important benefits or harms we downgraded. Downgraded once.

- **Publication bias:** funnel plot not useful as fewer than 10 trials included. Not downgraded.

#### <sup>e</sup> **Coronary heart disease events, ALA**

- **Risk of bias:** there was little or no effect in the main analyses, in fixed-effect meta-analysis, or in larger studies, but some risk reduction (8 to 9%) when data were limited to RCTs at low summary risk of bias or low risk of compliance bias. Downgraded once.

- **Inconsistency:**  $I^2$  was < 60%; not downgraded.

- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. All studies were conducted in high-income countries. Not downgraded.

- **Imprecision:** large numbers of participants have taken part in RCTs in long-term studies with consistent results.

However, as 95% confidence intervals do not exclude important benefits or harms we downgraded. Downgraded once.

- **Publication bias:** funnel plot not useful as fewer than 10 trials included. Not downgraded.

#### <sup>f</sup> **Stroke, ALA**



- **Risk of bias:** the main analysis, fixed-effect analysis, and larger trials suggest increased risk of stroke with more ALA, but there was little or no effect when data were limited to RCTs at low summary risk of bias, and a suggestion of benefit when limited to trials with low risk of compliance problems. Downgraded twice.

- **Inconsistency:**  $I^2$  was < 60%; not downgraded.

- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non-CVD health problems. All studies were conducted in high-income countries. Not downgraded.

- **Imprecision:** large numbers of participants have taken part in RCTs in long-term studies, but only 49 participants experienced strokes. 95% confidence intervals do not exclude important benefits or harms, downgraded once.

- **Publication bias:** funnel plot not useful as fewer than 10 trials included. Not downgraded.

#### <sup>g</sup> Arrhythmias, ALA

- **Risk of bias:** there was a 21% reduction in risk of arrhythmia in the main analysis, when data were limited to RCTs at low summary risk of bias, in larger trials and when data were limited to trials at low risk from compliance. Not downgraded.

- **Inconsistency:** only one trial, no inconsistency. Not downgraded.

- **Indirectness:** a single trial, which included adults with previous MI in a high-income country and only assessed new arrhythmia. Not downgraded.

- **Imprecision:** large numbers of participants have taken part in this long term study. However, as 95% confidence intervals do not exclude important benefits or harms we downgraded once.

- **Publication bias:** funnel plot not useful as fewer than 10 trials included. Not downgraded.

#### <sup>h</sup> Pulmonary embolus or DVT, ALA

- **Risk of bias:** the single trial was not at low summary risk of bias. Downgraded once.

- **Inconsistency:** with one trial no inconsistency. Not downgraded.

- **Indirectness:** healthy men and women, no participants with CVD risk factors or previous CVD; low- and middle-income countries not represented. Not downgraded.

- **Imprecision:** only one event included in a single trial. Downgraded twice.

- **Publication bias:** insufficient studies for funnel plot. Not downgraded.

High versus low omega-3 fats for modification of CVD risk factors (adiposity and lipids)					
<p><b>Patient or population:</b> adults with or without existing CVD</p> <p><b>Setting:</b> participants were living at home for most or all of the duration of their trials. Most studies were carried out in high-income economies (<a href="#">World Bank 2018</a>), but four trials were carried out in upper-middle income countries. No studies took place in low- or low-middle income countries</p> <p><b>Intervention:</b> higher omega-3 intake (LCn3 or ALA)</p> <p><b>Comparison:</b> lower omega-3 intake (LCn3 or ALA)</p> <p>The intervention was dietary supplementation, a provided diet or advice on diet. Supplementation may have been in oil or capsule form or as foodstuffs provided, to be consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuffs or supplements must have been: oily fish; fish oils; linseed (flax), canola (rapeseed), perilla, purslane, mustard seed, candlenut, stillingia or walnut as a food, oil, made into a spreading fat or supplementing another food (such as bread or eggs). For ALA sources the product consumed had to have an omega-3 fat content of at least 10% of the total fat content. Refined eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or alpha-linolenic acids, or concentrated fish or algal oils, were also accepted</p>					
Outcomes All in trials of 12 to 72 months' duration	Anticipated absolute effects* (95% CI)		No. of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Risk with low omega-3	Risk with high omega-3			
Measures of adiposity - LCn3 - Weight, kg	Mean body weight was 81.2 kg	MD 0.01 kg lower (0.84 lower to 0.82 higher)	15812 (12 RCTs)	⊕⊕⊕⊕ High <sup>a</sup>	LCn3 intake makes little or no difference to body weight.
Measures of adiposity - LCn3 - BMI, kg/m <sup>2</sup>	Mean BMI was 27.3 kg/m <sup>2</sup>	MD 0.04 higher (0.16 lower to 0.24 higher)	15234 (14 RCTs)	⊕⊕⊕⊕ High <sup>b</sup>	LCn3 intake makes little or no difference to BMI.
Serum total cholesterol - LCn3 - TC, mmol/L	Mean TC was 5.61 mmol/L	MD 0.01 lower (0.05 lower to 0.04 higher)	37281 (28 RCTs)	⊕⊕⊕○ Moderate <sup>c</sup>	LCn3 intake probably makes little or no difference to serum total cholesterol
Serum triglyceride, fasting - LCn3 - TG, mmol/L	Mean TG was 1.59 mmol/L	MD 0.24 lower (0.32 lower to 0.17 lower)	35534 (24 RCTs)	⊕⊕⊕⊕ High <sup>d</sup>	Increasing LCn3 intake reduces serum triglyceride.
Serum high density lipoprotein - LCn3 - HDL, mmol/L	Mean HDL was 1.32 mmol/L	MD 0.02 higher (0 to 0.04 higher)	37237 (27 RCTs)	⊕⊕⊕⊕ High <sup>e</sup>	Increasing LCn3 intake increases serum HDL.

Serum low density lipoprotein - LCn3 - LDL, mmol/L	Mean LDL was 3.27 mmol/L	MD 0.01 higher (0.01 lower to 0.03 higher)	35035 (23 RCTs)	⊕⊕⊕○ Moderate <sup>f</sup>	LCn3 intake probably makes little or no difference to serum LDL
Measures of adiposity - ALA - Weight, kg	Mean weight was 80.9 kg	MD 0.17 higher (0.61 lower to 0.96 higher)	664 (4 RCTs)	⊕○○○ Very low <sup>g</sup>	The effect of ALA intake on body weight is unclear as the evidence is of very low quality
Measures of adiposity - ALA - BMI, kg/m <sup>2</sup>	Mean BMI was 27.4 kg/m <sup>2</sup>	MD 0.12 higher (0.06 lower to 0.3 higher)	1581 (3 RCTs)	⊕⊕○○ Low <sup>h</sup>	ALA intake may make little or no difference to BMI.
Serum total cholesterol - ALA - TC, mmol/L	Mean TC was 5.02 mmol/L	MD 0.09 lower (0.23 lower to 0.05 higher)	2164 (6 RCTs)	⊕⊕○○ Low <sup>i</sup>	ALA intake may make little or no difference to serum total cholesterol (low-quality/certainty evidence)
Serum Triglyceride, fasting - ALA - TG, mmol/L	Mean TG was 1.48 mmol/L	MD 0.03 lower (0.11 lower to 0.05 higher)	1776 (6 RCTs)	⊕⊕⊕○ Moderate <sup>j</sup>	ALA intake probably makes little or no difference to serum triglycerides (moderate-quality/certainty evidence)
Serum high density lipoprotein - ALA - HDL, mmol/L	Mean HDL was 1.49 mmol/L	MD 0.02 lower (0.08 lower to 0.03 higher)	1776 (6 RCTs)	⊕⊕⊕○ Moderate <sup>k</sup>	ALA intake probably reduces serum HDL.
Serum low density lipoprotein - ALA - LDL, mmol/L	Mean LDL was 2.88 mmol/L	MD 0.05 lower (0.15 lower to 0.04 higher)	2201 (7 RCTs)	⊕⊕○○ Low <sup>l</sup>	ALA intake may make little or no difference to serum LDL.

**\*The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**BMI:** body mass index; **CI:** confidence interval; **HDL:** high-density lipoprotein; **LCn3:** long-chain omega-3 fatty acids; **LDL:** low-density lipoprotein; **MD:** mean difference; **RCT:** randomised controlled trial; **TC:** total cholesterol; **TG:** triglycerides.

## GRADE Working Group grades of evidence

**High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate certainty:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low certainty:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

**Very low certainty:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

### <sup>a</sup> Measures of adiposity, weight, LCn3

- **Risk of bias:** there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.
- **Inconsistency:**  $I^2$  was < 60%; not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were underrepresented. Not downgraded.
- **Imprecision:** large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% confidence intervals exclude important benefits or harms. Not downgraded.
- **Publication bias:** funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.

### <sup>b</sup> Measures of adiposity, BMI, LCn3

- **Risk of bias:** there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.
- **Inconsistency:**  $I^2$  was < 60%; not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were underrepresented. Not downgraded.
- **Imprecision:** large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% confidence intervals exclude important benefits or harms. Not downgraded.
- **Publication bias:** funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included. Not downgraded.

### <sup>c</sup> Lipids, serum total cholesterol, LCn3

- **Risk of bias:** there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.
- **Inconsistency:**  $I^2$  was < 60%; not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** when we ran fixed-effect analysis, a statistically significant effect was suggested. The 95% CI included null but excluded important benefits or harms. Downgraded once..
- **Publication bias:** funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.

### <sup>d</sup> Lipids, serum triglycerides, LCn3

- **Risk of bias:** there was a statistically significant effect overall and in all sensitivity analyses, including when data were limited to RCTs at low summary risk of bias. Not downgraded.
- **Inconsistency:**  $I^2$  was < 60%; not downgraded.

- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% confidence intervals exclude harms. Not downgraded.
- **Publication bias:** funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.

#### <sup>e</sup> Lipids, HDL, LCn3

- **Risk of bias:** the suggested increase in HDL with increased LCn3 was apparent in all sensitivity analyses. Not downgraded.
- **Inconsistency:**  $I^2$  was < 60%; not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% confidence intervals exclude harms. Not downgraded.
- **Publication bias:** funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.

#### <sup>f</sup> Lipids, LDL, LCn3

- **Risk of bias:** there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.
- **Inconsistency:**  $I^2$  was < 60%; not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% confidence intervals included the null but excluded important benefits or harms. Downgraded once.
- **Publication bias:** funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.

#### <sup>g</sup> Measures of adiposity, weight, ALA

- **Risk of bias:** no included trials were at low summary risk of bias. Downgraded once.
- **Inconsistency:**  $I^2$  was > 60%, downgraded once.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% confidence intervals include some benefits or harms. Downgraded once.
- **Publication bias:** funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.

#### <sup>h</sup> Measures of adiposity, BMI, ALA

- **Risk of bias:** there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.
- **Inconsistency:**  $I^2$  was > 60%, downgraded once.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.

- **Imprecision:** large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% confidence intervals include some benefits and harms. Downgraded once.
- **Publication bias:** funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.

<sup>i</sup> **Lipids, serum total cholesterol, ALA**

- **Risk of bias:** there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.
- **Inconsistency:**  $I^2$  was > 60%. Downgraded once.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** when we ran fixed-effect analysis a statistically significant effect was suggested, but main analysis includes some benefits and harms. Downgraded once.
- **Publication bias:** funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.

<sup>j</sup> **Lipids, serum triglycerides, ALA**

- **Risk of bias:** there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded.
- **Inconsistency:**  $I^2$  was < 60%; not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% include benefits and harms. Downgraded once.
- **Publication bias:** funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.

<sup>k</sup> **Lipids, HDL, ALA**

- **Risk of bias:** there was a statistically significant effect with fixed effects analysis and when data were limited to RCTs at low summary risk of bias, but the main analysis and other sensitivity analyses also suggested reductions in HDL. Not downgraded.
- **Inconsistency:**  $I^2$  was < 60%; not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.
- **Imprecision:** large numbers of participants have taken part in RCTs in long-term studies with consistent results. 95% CI includes benefits and harms. Downgraded once.
- **Publication bias:** funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.

<sup>l</sup> **Lipids, LDL, ALA**

- **Risk of bias:** apparent effect altered from slight benefit to slight harm when data were limited to RCTs at low summary risk of bias. Downgraded once.
- **Inconsistency:**  $I^2$  was < 60%; not downgraded.
- **Indirectness:** representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low- and middle-income countries were not represented. Not downgraded.

- **Imprecision:** when we ran fixed-effect analysis a statistically significant effect was suggested. For main analysis 95% CI included benefits and harms. Downgraded once.
- **Publication bias:** funnel plot was not interpretable, no clear small study bias. However, we are aware of several studies whose data could not be included; not downgraded.

## DISCUSSION

### Summary of main results

We included 79 randomised controlled trials (112,059 participants), of which 25 were at low summary risk of bias (randomisation, allocation concealment, selection and detection bias all at low risk for supplementation trials; randomisation, allocation concealment and detection bias all at low risk for dietary advice trials). Trials of 12 to 72 months' duration included adults at varying levels of cardiovascular risk, mainly in high-income countries. Most studies assessed LCn3 supplementation with capsules, but some used LCn3- or ALA-rich or enriched foods or dietary advice compared to placebo or usual diet.

Pooled trial results suggested there is probably little or no effect of increasing long-chain omega-3 fats on risk of our primary outcomes: all-cause mortality, cardiovascular deaths, cardiovascular events, coronary heart disease deaths, coronary heart disease events, stroke or arrhythmias (moderate and high-quality evidence). For all of these outcomes except arrhythmia, limiting LCn3 analyses to trials at low summary risk of bias moved the effect size towards 1.0 (the null value) whether initial analyses suggested a protective effect (for example, for CHD mortality, whose effect size moved from RR 0.93 to RR 1.00) or a harmful effect (for example, stroke, whose effect size moved from RR 1.06 to RR 0.98). We found no suggestion of dose response (in subgrouping or meta-regression), or important effects regardless of sensitivity analysis, subgrouping or meta-regression. These results apply to supplemental LCn3 intake. We did not see important differences in LCn3 trials between those providing oily fish (dietary source) or EPA/DHA capsules (supplemental source), but as few trials provided whole fish health effects may differ.

On the other hand we found moderate-quality evidence that increasing ALA probably reduces risk of CHD mortality a very small amount (from 1.1% to 1.0%) and arrhythmia (from 3.3% to 2.6%), and low-quality evidence that increasing ALA may reduce risk of CVD events a little (from 4.8% to 4.7%). However, there is probably little or no effect on all-cause or cardiovascular mortality or coronary heart disease events (low and moderate-quality evidence), and effects on stroke are unclear. For ALA, limiting analyses to studies at low summary risk of bias tended to reduce the RR, or increase the suggested protection. Data were more limited than for LCn3, and there were too few studies for informative funnel plots or subgroup analyses. These suggested benefits of ALA need to be considered with caution, as effects were small, and few trials (though often at low summary risk of bias) addressed the outcomes.

Meta-analyses suggested little or no effect of long-chain omega-3 fats or ALA intake on secondary outcomes: major adverse cerebrovascular or cardiovascular events, fatal and/or non-fatal myocardial infarction, sudden cardiac death, new or worsening angina, heart failure, revascularisation, peripheral arterial disease or acute coronary syndrome.

There was no evidence for effects of LCn3 or ALA on measures of adiposity, but LCn3 did reduce serum triglycerides and increase HDL cholesterol a little. We did not see these effects in trials of ALA, and no omega-3 fats altered total or LDL cholesterol in these long-term trials. Within the included studies we assessed effects on blood pressure, serious adverse effects, side effects and dropouts. There was no suggestion that blood pressure or risk of adverse events such as bleeding differed by LCn3 or ALA intake. Thus, proposed mechanisms for omega-3 activity, including lowering of blood pressure, reduced thrombotic tendency and anti-arrhythmic effects are not apparent in adult humans, but LCn3 does lower serum triglyceride levels.

The review has provided some answers for its secondary questions.

- If omega-3 fatty acids confer protection:

- does protection occur equally in those at low and at high risk of cardiovascular disease? There is no evidence of differential effects on mortality or cardiovascular health by primary or secondary CVD prevention.

- does protection depend on the dose of omega-3 fats taken per day? We ran subgroup analyses for primary and key outcomes and meta-regression for primary outcomes but found no evidence of differential effects by LCn3 or ALA dose on any outcomes except LCn3 on serum triglycerides, where there was a statistically significant difference between different dose subgroups and greater effects with higher dose.

- do effects differ between dietary and supplemental omega-3 sources? We assessed this question by looking for statistically significant differences between subgroups but found no evidence of differential effects by dietary or supplemental LCn3 or ALA sources. However, few of the LCn3 trials advised or gave fish, most gave supplemental fish oils, so our ability to assess effects of eating more oily whole fish are limited.

- does protection depend on study summary risk of bias? Some analyses suggested a protective effect of LCn3 fats, but these effects disappeared when analyses were limited to studies at low summary risk of bias. The stronger studies with higher internal validity suggested few or no effects of LCn3 on mortality or CVD outcomes. On the other hand, for most primary cardiovascular outcomes, ALA trials at low summary risk of bias suggested greater protection with higher ALA than in the main analysis (including trials of all levels of summary risk of bias).

- Is protection or harm stronger with longer trial duration? In subgroup analyses for primary and key outcomes and in meta-regression for primary outcomes, there was no evidence that longer trials increased the effect of LCn3 or ALA.

### Overall completeness and applicability of evidence

We searched very carefully to find all studies relevant to this review and located 79 trials randomising 112,059 participants to higher and lower omega-3 fats (LCn3 or ALA) for at least 12 months.



To reduce selection bias, we contacted authors of trials that appeared to have randomised appropriate participants to appropriate intervention and comparator but may not have published relevant outcomes. If trialists had assessed any of our outcomes, we requested data and included the study. This enabled us to include several additional trials. We also contacted authors of all included trials that randomised at least 100 participants (and most smaller trials) to request data on any further outcomes (as well as on methodological issues) that may have been recorded but not reported. We tried to contact 72 of the 79 included studies (all except [Baldassarre 2006](#); [HERO 2009](#); [Mita 2007](#); [Nutrirstroke 2009](#); [Özaydin 2011](#); [Shinto 2014](#); [Sofi 2010](#)). This allowed us to collect useful additional data on outcomes such as deaths and cardiovascular events that we would not have had access to otherwise.

We identified 27 trials that appeared to be unpublished at the time of writing ([Characteristics of ongoing studies](#)). We have labelled these trials as ongoing, although some appear overdue for publication, and their status is unclear - they may constitute missing data. We tried to contact authors of all 'overdue' ongoing studies, and some stated that publications are forthcoming; others did not reply. We suspect that if trialists have not published outcomes, it is likely that any protective health effects did not reach statistical significance. Given that existing studies suggest no effects of omega-3 fats on cardiovascular health outcomes, any missing data may not affect outcomes greatly; however, for completeness we would prefer to include all available data.

Post hoc, we followed advice to assess differences in effects between EPA and DHA within the review. However, most LCn3 trials provided or advised changes resulting in increased intakes of both EPA and DHA (as in natural fish oil), though in different ratios. Only three trials provided data on DHA only ([ADCS 2010](#); [Berson 2004](#); [Zhang 2017](#)), and five provided data on EPA only ([Doi 2014](#); [JELIS 2007](#); [Mita 2007](#); [Nye 1990](#); [Puri 2005](#)). Unfortunately for any single outcome only two or three of these trials were represented, so our ability to assess differential effects of the DHA-only and EPA-only interventions was very limited, and we have not presented these analyses or attempted to draw any information from them.

## Quality of the evidence

[Figure 2](#) displays risk of bias of included studies. Of the 79 RCTs, 25 were at low summary risk of bias (at low risk of selection bias, performance bias and detection bias, plus low risk of performance bias in supplemental trials). We assessed the validity of evidence in meta-analyses by running sensitivity analyses that removed trials not at low summary risk of bias. When sensitivity analyses removed LCn3 trials at moderate to high summary risk of bias, effect sizes moved closer to no effect (RR 1.0) for all primary outcomes except arrhythmias, where the RR rose to 1.10. Funnel plots for LCn3 trials suggested that there may be missing studies for all primary

outcomes except stroke and arrhythmia, and in all cases adding such studies back in would move effect sizes closer to no effect (RR 1.0). This lack of effect in the studies at lowest risk of bias (with suggestions of effect in studies at moderate to high risk of bias) was an important finding from this review and supported our interpretation of lack of effect of long-chain omega-3 fats on our primary outcomes.

As there were fewer ALA trials, funnel plots were not useful, but sensitivity analyses retaining only trials at low summary risk of bias were more variable, often suggesting lower risk of a cardiovascular outcome.

## Potential biases in the review process

Potential adverse effects include cancers and neurological problems associated with polychlorinated biphenyls (PCBs) or mercury in fish oils, and bleeds associated with reductions in clotting (see [How the intervention might work](#)). Any data on bleeds, including haemorrhagic stroke, have been collated in this review, though we did not ask authors specifically for additional data on these outcomes. Unfortunately there were insufficient data on serious harms (bleeding and pulmonary embolism or deep vein thrombosis) to assess these potential harms. We have not collated data on cancers and neurological problems within this review but have formally systematically reviewed them elsewhere ([Hanson 2017b](#); [Jimoh 2017](#)). This approach is preferable to including data on these outcomes from within included studies, which would be incomplete and potentially underpowered to show important effects.

One problem with CVD outcomes is that they are collected together in a variety of ways, depending on the study. For example, in assessing CHD mortality, we pre-specified that we would include the first of the following list reported in any trial: coronary death, ischaemic heart disease death, fatal myocardial infarction, cardiac death. Each included trial includes outcome data in its own way, so we had to adapt to this in our analysis. One way to get around this problem would be to use individual patient data, as in one recent meta-analysis that included fewer trials than this review but was able to formulate their outcome data to match precisely between trials ([Aung 2018](#)). The next section discusses similarities and differences between this review and [Aung 2018](#), but their findings were highly similar. For CHD mortality, our meta-analytic estimate of effect of LCn3 was RR 0.93, (95% CI 0.79 to 1.09,  $I^2 = 35\%$ ) in 21 trials reporting 1596 CHD deaths, while theirs was RR 0.93 (95% CI 0.83 to 1.03) in 10 trials reporting 2695 CHD deaths.

While we tried hard to locate all available trials and collect additional outcome data where possible, there was evidence from funnel plots of some small study bias. Some smaller studies showing increased risk of CVD outcomes with omega-3 fats may be missing from some of the meta-analyses. If these studies were replaced they would tend to increase risk ratios. This suggests that there is some underlying small study bias within the review.

Given that the many LCn3 studies at moderate to high risk of bias appear to be inflating any protective effects, and that small study bias is also inflating any protective effects, it is justified to view with skepticism the occasional suggestion of a protective effect. Given the very large number of subgroup analyses we carried out, it is also important to treat the occasional subgroup analysis that throws up a statistically significant difference between subgroups very cautiously.

A secondary question asked by this review was about differential effects of dietary and supplemental LCn3 fats. LCn3 interventions included dietary advice (advice to eat more oily fish), supplemental foods (LCn3 fats incorporated into other foods such as margarine) and supplements or capsules (by far the greatest proportion of studies). Dietary fish is likely to have different health effects, as it may take the place of less healthy foods in the diet (leading to reduced saturated fat intake, for example) and provides many nutrients in addition to omega-3 fats (such as protein, selenium, iodine, calcium, magnesium, etc.). There were only four LCn3 dietary advice trials with event data (DART 1989; DART2 2003; DISAF 2003; THIS DIET 2008), and two of these also provided fish oil capsules when participants did not want to eat more fish (DART 1989; DART2 2003). We found no statistically significant differences between dietary advice subgroups and supplemental foods or capsule subgroups for primary outcomes. This may mean that health effects between the two types of intervention are not different, but it is likely that our analysis was underpowered to see any such differences if they exist.

Population LCn3 status varies widely across the world, from over 8% of fatty acids in Japan, Scandinavia and other areas with non-Westernised dietary patterns to less than 4% in North, South and Central America; Europe; the Middle East; Southeast Asia; and Africa (Stark 2016). We hypothesised that additional LCn3 might have greater health effects in people whose usual LCn3 intake was relatively low, but unfortunately we were not able to ascertain baseline LCn3 intake or status for most of our included trials. However, most of the included studies were carried out in areas of the world with lower LCn3 status, so we would expect to see effects of increasing LCn3 in most included trials if such effects exist - the fact that we did not see them suggests that any such effects may not be important in the populations included in this review.

## Agreements and disagreements with other studies or reviews

One potential difference between the findings of this review and some other trials and reviews is our running sensitivity analyses assessing effects exclusively in studies at low summary risk of bias. This clarified the lack of effect of LCn3 fats on CHD mortality, CHD events and heart failure, which otherwise appeared slightly protective, and on stroke, which otherwise appeared slightly harmful. On the other hand, these sensitivity analyses suggested some

protective effects for ALA (on CVD events, CHD mortality, CHD events and arrhythmia), though these were small and evidence limited.

The effect of LCn3 on arrhythmias was unclear. There was a suggestion that LCn3 was harmful regarding development of new arrhythmia (where trials were not set up with arrhythmia as a primary outcome), but protective of recurrent arrhythmia. However, trials at low summary risk of bias suggested harm, and other trials (at moderate to high risk of bias) suggested benefit. Eight of the 10 included studies at low summary risk of bias were trials assessing new arrhythmia. It is possible that the apparent difference between effects on new and recurrent arrhythmia are related to summary risk of bias.

There was no suggestion that blood pressure or risk of adverse events such as bleeding differed by LCn3 or ALA intake. This suggests that possible mechanisms for omega-3 activity, including lowering of blood pressure, reduced thrombotic tendency and anti-arrhythmic effects are not important in most adult humans, though LCn3 does appear to lower serum triglyceride levels. We did not systematically review blood pressure data so may have missed a few long-term studies (though not many) - missing data from included studies is likely to be a bigger issue. Of the 15 included trials that reported blood pressure outcomes, nine reported numbers of hypertensive participants at baseline, ranging from 5% in MARINA 2011 to 79% of participants in ORIGIN 2012. Effects did not differ by proportions of hypertensive participants ( $I^2$  was 0% for both systolic and diastolic blood pressure, Analysis 3.1).

Nearly 20 years ago, the GISSI-P 1999 trial suggested that LCn3 had its primary effects in reducing sudden cardiac death. However, the forest plot clearly shows that subsequent trials have not seen this effect individually or in aggregate (Analysis 2.6).

The scope of this review is similar to that of the extensive Agency for Healthcare Research and Quality review (Balk 2016), so we have compared our results with theirs. Given that our review included 79 RCTs randomising more than 112,000 participants, who experienced over 8000 deaths and upwards of 4000 CVD deaths, we were surprised to read that Balk and colleagues characterised the body of evidence as having "limited data ... from RCTs on the effect of n-3 FA on clinical CVD outcomes" (Balk 2016). This appears to be because the Balk review excluded RCTs of people with non-CVD and non-diabetes related diseases at baseline, while we included them. While Balk 2016 excluded some studies we included, it did not include any studies providing all-cause mortality data that we excluded. This meant that in analysing effects on all-cause mortality, Balk 2016 included 18 RCTs randomising 81,027 participants experiencing 8480 deaths, while we included 112,059 participants randomised to high or low LCn3 or ALA experiencing 8648 deaths. Balk 2016 excluded studies that we included, such as AREDS2 2014, a high-quality trial with 368 deaths in more than 4000 participants with age-related macular degeneration. This sort of population appeared ideal to us for as-

assessment of omega-3 fats on primary prevention of CVD, as these people tend to be elderly but there is no clear reason why omega-3 fats would affect CVD differently in this population than in other older adults at usual CVD risk.

Despite these slight differences in approach, we obtained very similar effect estimates to [Balk 2016](#). We meta-analysed effects of LCn3 and ALA trials, finding an RR for all-cause mortality of 0.98 (95% CI 0.93 to 1.03,  $I^2 = 6\%$ ), compared to a pooled RR for all-cause mortality of 0.97 (95% CI 0.92 to 1.03) in [Balk 2016](#). While that review seldom pooled their results, we can compare our results with theirs where they did. Despite our slightly different inclusion criteria, our results are very comparable ([Table 8](#)).

A recent individual meta-analysis of 10 large trials in almost 78,000 people at high risk of CVD found no associations of LCn3 with CHD mortality (RR 0.93, 99% CI 0.83 to 1.03), nonfatal MI (RR 0.97, 99% CI 0.87 to 1.08), CHD events (RR 0.96, 95% CI 0.90 to 1.01) or major vascular events (RR 0.97, 95% CI 0.93 to 1.01, [Aung 2018](#)). [Aung 2018](#) included individual patient data from the participants of large, long trials (randomising at least 500 participants and following them for at least one year) ([AlphaOmega - EPA+DHA 2010](#); [AREDS2 2014](#); [DO IT 2010](#); [GISSI-HF 2008](#); [GISSI-P 1999](#); [JELIS 2007](#); [OMEGA 2009](#); [ORIGIN 2012](#); [Risk & Prevention 2013](#); [SU.FOL.OM3 2010](#)), and this review includes all their trials. Their review had the advantage of being able to ensure that they had complete and equivalent data for all of their key outcomes from all the trials, reducing the risk of publication bias, but the disadvantage of missing all the data from many large LCn3 trials such as [DART2 2003](#) [DART 1989](#) [FORWARD 2013](#), [MAPT 2017](#) [SHOT 1996](#) and [SOFA 2006](#) (all LCn3 trials randomising at least 500 participants). It also missed large trials of LCn3 in lower risk participants such as [OPAL 2010](#), and large trials of ALA such as [MARGARIN 2002](#), [Norwegian 1968](#) and [WAHA 2016](#), as well as all the smaller trials. However, though taking different approaches, the results of this review and [Aung 2018](#) are also very similar ([Table 8](#)). LCn3 has little or no effect on major cardiovascular outcomes. This review, [Balk 2016](#) and [Aung 2018](#) addressed the analysis of the data in slightly different ways, creating sensitivity analyses for each other. The fact that they came to the same conclusions reassures us that our conclusions are solidly based.

Our results, suggesting high-quality evidence of no clinically useful cardiovascular health effects of either LCn3 or ALA, are consistent with many further high-quality recent systematic reviews ([Campbell 2013](#); [Chowdhury 2012](#); [Enns 2014](#); [He 2013](#); [Khoueiry 2013](#); [Kotwal 2012](#); [Kwak 2012](#); [Mariani 2013](#); [Rizos 2012](#); [Zheng 2014](#)), and they confirm and expand on the findings of earlier versions of this review ([Hooper 2004](#); [Hooper 2006](#)).

## AUTHORS' CONCLUSIONS

## Implications for practice

We found high-quality evidence that long-chain omega-3 fats do not have important positive or negative effects on mortality or CVD events and moderate-quality evidence that they have little or no effect on other measures of cardiovascular health in primary or secondary prevention. Most evidence on long-chain omega-3 fats came from trials of capsules of fish oil or EPA/DHA mixtures. While we did not see important differences between trials of supplemental capsules and trials of oily fish, there were few trials of oily fish.

We found moderate-quality evidence that increasing ALA probably slightly reduces risk of CHD mortality and arrhythmia, and may slightly reduce risk of CVD events. However, there is probably little or no effect on all-cause or cardiovascular mortality or coronary heart disease events (low and moderate-quality evidence). Effects of ALA were very small - 143 people would need to increase their ALA intake to prevent one person developing arrhythmia, and 1000 would need to take more ALA to prevent one person experiencing a CVD event or dying from CHD. Trials of ALA gave ALA-rich or enriched foods such as walnuts or enriched margarine.

Supplemental long-chain omega-3 fats are probably not useful for preventing or treating cardiovascular disease, although long-chain omega-3 fats can help to reduce serum triglycerides and raise HDL a little. Fish and seafood are nutrient-dense and rich in a variety of other nutrients (such as vitamin D, calcium, iodine, selenium) so are useful foods even without cardiovascular benefits. In light of the evidence in this review it would be appropriate to review official recommendations supporting supplemental LCn3 fatty acid intake.

ALA is an essential fatty acid, an important part of a mixed diet, and increasing intakes may be very slightly beneficial for prevention or treatment of cardiovascular disease.

## Implications for research

There are several large ongoing trials of supplemental long-chain omega-3 fats (see [Characteristics of ongoing studies](#)). We suggest that given the lack of convincing effects suggested for omega-3 fats in the large number of trials to date, no further trials should be initiated until the ongoing trials have reported. Further large and high-quality trials of ALA carried out in lower and higher income countries and that assess baseline ALA intake and use biomarkers to assess compliance would be helpful to clarify the cardiovascular effects of ALA. Similarly trials of dietary fish would be helpful.

## ACKNOWLEDGEMENTS

The wider set of reviews, including this one, were carried out by the Polyunsaturated Fats and Health (PUFAH) group. PU-

FAH includes Asmaa Abdelhamid, Zoya Ahmed, Sarah MA Ajabnoor, Fai K AlAbdulghafoor, Lena Al-Khudairy, Priti Biswas, Julii Suzanne Brainard, Charlene Bridges, Tracey J Brown, Katherine HO Deane, Daisy H Donaldson, Sarah Hanson, Lee Hooper, Oluseyi F Jimoh, Nicole Martin, Katie Maas, Helen J Moore, Alex T O'Brien, Karen Rees, Ruksana Sivakaran, Fujian Song, Carolyn D Summerbell, Gabrielle C Thorpe, Xia Wang, Ailsa Welch, Lauren Winstanley, and Helen V Worthington.

The review authors thank all of the authors of primary studies who kindly provided us with the best set of data available, including: D Kromhout, Wageningen University ([AlphaOmega - ALA 2010](#); [AlphaOmega - EPA+DHA 2010](#)); Emily Chew, NIH ([AREDS2 2014](#)); J Brox, University Hospital of North Norway ([Brox 2001](#)); C Argo, University of Virginia ([Caldwell 2011](#)); ML Burr, University of Wales and A Ness, University of Bristol ([DART 1989](#); [DART2 2003](#)); G Derosa and P Maffioli, University of Pavia ([Derosa 2016](#)); PNM Demacker, University Hospital Nijmegen ([Deslypere 1992](#)); S Tokudome, National Institute of Health and Nutrition, Japan ([DIPP 2015](#)); R Harrison, University of Manchester, UK ([DISAF 2003](#)); G Einvik, Akershus University Hospital and H Arnesen, Oslo University Hospital ([DO IT 2010](#)); S Dodin, Université Laval ([Dodin 2005](#)); D Schoenfeld, Harvard Medical School ([FAAT 2005](#)); A Macchia, Fundació GESICA ([FORWARD 2013](#)); C Hill, the Queen Elizabeth Hospital ([FOSTAR 2016](#)); D Franzen, Universität zu Köln ([Franzen 1993](#)); P Bauer, Medical University of Vienna ([Lorenz-Meyer 1996](#)); WJ Bemelmans, National Institute for Public Health and the Environment, Bilthoven ([MARGARIN 2002](#)); T Sanders, King's College, London ([MARINA 2011](#)); E Souied, Hôpital intercommunal de Créteil, France ([NAT2 2013](#)); D Nilsen, University of Bergen, Norway ([OFAMI 2001](#)); S Schneider, Institut für Herzinfarktforschung, Germany ([OMEGA 2009](#)); A Dangour, London School of Hygiene & Tropical Medicine ([OPAL 2010](#)); M James, Royal Adelaide Hospital, Australia ([Proudman 2015](#)); R Zurier, University of Massachusetts Medical School ([Reed 2014](#)); C Roncaglioni and I Marzona, IRCCS-Istituto di Ricerche Far-

macologiche Mario Negri, Italy ([Risk & Prevention 2013](#)); A Manni, Penn State College of Medicine, USA ([Sandhu 2016](#)); C von Schacky, Ludwig Maximilians University, Munich, Germany ([SCIMO 1999](#)); L Tapsell, M Batterham and E Neale, University of Wollongong, Australia ([SMART 2013](#)); P Galan, Université Paris ([SU.FOL.OM3 2010](#)); K Tande, Calanus AS, Norway ([Tande 2016](#)); K Tuttle, Sacred Heart Medical Center, Spokane ([THIS DIET 2008](#)); J Sabaté, Loma Linda University, California ([WAHA 2016](#)); E Scorletti, University of Southampton, UK ([WELCOME 2015](#)).

Thanks also to the authors who replied but were not able to provide further details or confirmed no relevant outcomes, including: S Jebb, University of Oxford ([FISH 2012](#)); R Holman, University of Oxford ([AFORRD 2010](#)); J Quinn, Oregon Health & Science University ([ADCS 2010](#)); D Bates, Royal Victoria Infirmary, Newcastle on Tyne and R Dworkin, University of Rochester, UK ([Bates 1989](#)); E Berson, Harvard Medical School, USA ([Berson 2004](#)); A Sanyal, Virginia Commonwealth University, USA ([EPE-A 2014](#)); G Pierce, St. Boniface Hospital Research Centre, Canada ([FLAX-PAD 2013](#)); H Gerstein, McMaster University, Canada ([ORIGIN 2012](#)); B Puri, Imperial College London ([Puri 2005](#)); M Raitt, Oregon Health & Science University, USA ([Raitt 2005](#)); J Eritsland, Oslo University Hospital, Norway ([SHOT 1996](#)); and I Brouwer, Vrije Universiteit Amsterdam, the Netherlands ([SOFA 2006](#)).

Warm thanks and appreciation to the authors of the first review who did not continue as authors in the review update, including Roger A Harrison, Andrew Ness, Nigel E Capps, George Davey Smith, Shah BJ Ebrahim and Rudolph A Riemersma. Acknowledgements for the earlier version of this systematic review, which we have built on to create the current review: our thanks to Julian Higgins, who was involved in the design of the review, along with Theresa Moore and Margaret Burke from the Cochrane Heart Group. Also to Charlotte C Hammer for help with German translation for [Franzen 1993](#).

## REFERENCES

### References to studies included in this review

#### ADCS 2010 {published data only}

Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *JAMA* 2010;**304**(17):1903–11.

#### AFFORD 2013 {published data only}

\* Nigam A, Talajic M, Roy D, Nattel S, Lambert J, Nozza A, et al. Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress. *Journal of the American College of Cardiology* 2014;**64**(14):1441–8.  
Nigam A, Talajic M, Roy D, Nattel S, Lambert J, Nozza

A, et al. Multicentre trial of fish oil for the reduction of atrial fibrillation recurrence, inflammation and oxidative stress: the atrial fibrillation fish oil research study. *Canadian Journal of Cardiology* 2013;**1**:S383.

#### Ahn 2016 {published data only}

Ahn J, Park SK, Park TS, Kim JH, Yun E, Kim SP, et al. Effect of n-3 polyunsaturated fatty acids on regression of coronary atherosclerosis in statin treated patients undergoing percutaneous coronary intervention. *Korean Circulation Journal* 2016;**46**(4):481–9. PUBMED: 27482256]

#### AlphaOmega - ALA 2010 {published and unpublished data}

Brouwer IA, Geleijnse JM, Klaassen VM, Smit LA, Giltay

EJ, de Goede J, et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the alpha omega trial. *PLOS ONE* 2013;**8**(12): e81519.

Eussen SR, Geleijnse JM, Giltay EJ, Rompelberg CJ, Klungel OH, Kromhout D. Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. *European Heart Journal* 2012;**33**(13):1582–8.

Geleijnse J, Giltay E, Kromhout D. Effects of n-3 fatty acids on cognitive decline: a randomized double-blind, placebo-controlled trial in stable myocardial infarction patients. *Alzheimer's & Dementia* 2011;**1**:S512.

Geleijnse JM, Giltay EJ, Kromhout D. Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients. *Alzheimer's & Dementia* 2012;**8**(4):278–87.

Geleijnse JM, Giltay EJ, Schouten EG, de Goede J, Oude Griep LM, Teitsma-Jansen AM, et al. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. *American Heart Journal* 2010;**159**(4):539–46. DOI: 10/1016/j.ahj.2009.12.033

Giltay EJ, Geleijnse JM, Heijboer AC, de Goede J, Oude Griep LM, Blankenstein MA, et al. No effects of n-3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. *International Journal of Andrology* 2012;**35**(5):680–7.

Giltay EJ, Geleijnse JM, Kromhout D. Effects of n-3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. *American Journal of Clinical Nutrition* 2011;**94**(6):1442–50.

Hoogeveen E, Gemen E, Geleijnse M, Kusters R, Kromhout D, Giltay E. Effects of N-3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. *Nephrology Dialysis Transplantation* 2012;**27**:ii64.

Hoogeveen EK, Geleijnse JM, Kromhout D, Giltay EJ. No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: the Alpha Omega Trial. *European Journal of Preventive Cardiology* 2014;**21**(11): 1429–36.

Hoogeveen EK, Geleijnse JM, Kromhout D, Stijnen T, Gemen EF, Kusters R, et al. Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. *Clinical Journal of The American Society of Nephrology: CJASN* 2014;**9**(10):1676–83.

Kromhout D, Geleijnse JM, de Goede J, Oude Griep LM, Mulder BJ, de Boer MJ, et al. N-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. *Diabetes Care* 2011;**34**(12):2515–20.

\* Kromhout D, Giltay EJ, Geleijnse JM, Alpha Omega Trial Group. N-3 fatty acids and cardiovascular events after myocardial infarction. *New England Journal of Medicine* 2010;**363**(18):2015–26.

#### AlphaOmega - EPA+DHA 2010 {published and unpublished data}

Brouwer IA, Geleijnse JM, Klaasen VM, Smit LA, Giltay EJ, de Goede J, et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the alpha omega trial. *PLOS ONE* 2013;**8**(12): e81519.

Eussen SR, Geleijnse JM, Giltay EJ, Rompelberg CJ, Klungel OH, Kromhout D. Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. *European Heart Journal* 2012;**33**(13):1582–8.

Geleijnse J, Giltay E, Kromhout D. Effects of n-3 fatty acids on cognitive decline: A randomized double-blind, placebo-controlled trial in stable myocardial infarction patients. *Alzheimer's & Dementia* 2011;**1**:S512.

Geleijnse JM, Giltay EJ, Kromhout D. Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients. *Alzheimer's & Dementia* 2012;**8**(4):278–87.

Geleijnse JM, Giltay EJ, Schouten EG, de Goede J, Oude Griep LM, Teitsma-Jansen AM, et al. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. *American Heart Journal* 2010;**159**(4):539–46. DOI: 10/1016/j.ahj.2009.12.033

Giltay EJ, Geleijnse JM, Heijboer AC, de Goede J, Oude Griep LM, Blankenstein MA, et al. No effects of n-3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. *International Journal of Andrology* 2012;**35**(5):680–7.

Giltay EJ, Geleijnse JM, Kromhout D. Effects of n-3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. *American Journal of Clinical Nutrition* 2011;**94**(6):1442–50.

Hoogeveen E, Gemen E, Geleijnse M, Kusters R, Kromhout D, Giltay E. Effects of N-3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. *Nephrology Dialysis Transplantation* 2012;**27**:ii64.

Hoogeveen EK, Geleijnse JM, Kromhout D, Giltay EJ. No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: the Alpha Omega Trial. *European Journal of Preventive Cardiology* 2014;**21**(11): 1429–36.

Hoogeveen EK, Geleijnse JM, Kromhout D, Stijnen T, Gemen EF, Kusters R, et al. Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. *Clinical Journal of The American Society of Nephrology: CJASN* 2014;**9**(10):1676–83.

Kromhout D, Geleijnse JM, de Goede J, Oude Griep LM, Mulder BJ, de Boer MJ, et al. N-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. *Diabetes Care* 2011;**34**(12):2515–20.

\* Kromhout D, Giltay EJ, Geleijnse JM, Alpha Omega Trial Group. N-3 fatty acids and cardiovascular events after myocardial infarction. *New England Journal of Medicine*



2010;**363**(18):2015–26.

**AREDS2 2014 {published and unpublished data}**

Age-Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. *JAMA* 2013;**309**(19):2005–15. PUBMED: 23644932]

Age-Related Eye Disease Study, Chew EY, Clemons TE, SanGiovanni JP, Danis RP, Ferris FL 3rd, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. *JAMA Ophthalmology* 2014;**132**(2):142–9.

Age-Related Eye Disease Study, Chew EY, SanGiovanni JP, Ferris FL, Wong WT, Agron E, et al. Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. *JAMA Ophthalmology* 2013;**131**(7):843–50.

Age-Related Eye Disease Study, Huynh N, Nicholson BP, Agron E, Clemons TE, Bressler SB, et al. Visual acuity after cataract surgery in patients with age-related macular degeneration: age-related eye disease study 2 report number 5. *Ophthalmology* 2014;**121**(6):1229–36.

\* Bonds DE, Harrington M, Worrall BB, Bertoni AG, Eaton CB, et al. Writing Group for the AREDS Research Group. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. *JAMA Internal Medicine* 2014;**174**(5):763–71.

Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally A, et al. Group Areds Research. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). *Ophthalmology* 2012;**119**(11):2282–9.

Chew EY, Clemons TE. In reply: Making sense of the evidence from the age-related eye disease study 2 randomized clinical trial. *JAMA Ophthalmology* 2014;**132**(8):1031–2.

Chew EY, Clemons TE, Agron E, Launer LJ, Grodstein F, Bernstein PS, et al. Effect of omega-3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. *JAMA* 2015;**314**(8):791–801.

**Baldassarre 2006 {published data only}**

Baldassarre D, Amato M, Eligini S, Barbieri SS, Mussoni L, Frigerio B, et al. Effect of n-3 fatty acids on carotid atherosclerosis and haemostasis in patients with combined hyperlipoproteinemia: a double-blind pilot study in primary prevention. *Annals of Medicine* 2006;**38**(5):367–75. DOI: 10.1080/07853890600852880

**Bates 1989 {published data only}**

Bates D, Cartledge NE, French JM, Jackson MJ, Nightingale S, Shaw DA, et al. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. *Journal of Neurology, Neurosurgery & Psychiatry* 1989;**52**(1):18–22.

**Berson 2004 {published data only}**

\* Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. *Archives of Ophthalmology* 2004;**122**(9):1297–305.

Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. *Archives of Ophthalmology* 2004;**122**(9):1306–14.

**Brox 2001 {published and unpublished data}**

Brox J, Olaussen K, Osterud B, Elvevoll EO, Bjornstad E, Brattebog G, et al. A long-term seal- and cod-liver-oil supplementation in hypercholesterolemic subjects. *Lipids* 2001;**36**(1):7–13.

**Caldwell 2011 {published data only}**

Argo CK, Patrie JT, Lackner C, Henry TD, de Lange EE, Weltman AL, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. *Journal of Hepatology* 2015;**62**(1):190–7. PUBMED: 25195547]

\* Caldwell SH, Argo CK, Henry TD, Lackner C, Pramoonjago P, Weltman AL, et al. Dissociated histological and metabolic effects of omega-3 (3000 mg/d) versus placebo with both exercise and diet in a double-blind randomized controlled trial of NASH. *Journal of Hepatology* 2011; Vol. 54, issue Supplement 1:S8.

**DART 1989 {published and unpublished data}**

Burr ML, Fehily AM. Fatty fish and heart disease: a randomized controlled trial. *World Review of Nutrition and Dietetics* 1991;**66**:306–12.

Burr ML, Fehily AM. Fish and the heart. *Lancet* 1989;**ii**:1451–2.

\* Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). *Lancet* 1989;**2**(8666):757–61. Burr ML, Fehily AM, Rogers S, Welsby E, King S, Sandham S. Diet and reinfarction trial (DART): design, recruitment, and compliance. *European Heart Journal* 1989;**10**(6):558–67.

Burr ML, Holliday RM, Fehily AM, Whitehead PJ. Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART). *European Heart Journal* 1992;**13**(2):166–70. Burr ML, Sweetnam PM, Fehily AM. Diet and reinfarction. *European Heart Journal* 1994;**15**(8):1152–3.

Fehily AM, Vaughan-Williams E, Shiels K, Williams AH, Horner M, Bingham G, et al. Factors influencing compliance with dietary advice: the Diet and Reinfarction Trial (DART). *Journal of Human Nutrition and Dietetics* 1991;**4**:33–42.

Fehily AM, Vaughan-Williams E, Shiels K, Williams AH, Horner M, Bingham G, et al. The effect of dietary advice on nutrient intakes: evidence from the diet and reinfarction

- trial (DART). *Journal of Human Nutrition & Dietetics* 1989; **2**:4235.
- Ness AR, Hughes J, Elwood PC, Whitley E, Smith GD, Burr ML. The long-term effect of dietary advice in men with coronary disease: follow-up of the Diet and Reinfarction Trial (DART). *European Journal of Clinical Nutrition* 2002; **56**(6):512–8.
- Ness AR, Whitley E, Burr ML, Elwood PC, Smith GD, Ebrahim S. The long-term effect of advice to eat more fish on blood pressure in men with coronary disease: results from the diet and reinfarction trial. *Journal of Human Hypertension* 1999; **13**(11):729–33.
- DART2 2003 {published and unpublished data}**
- Burr ML. Secondary prevention of CHD in UK men: the diet and reinfarction trial and its sequel. *Proceedings of the Nutrition Society* 2007; **66**(1):9–15. PUBMED: 17343767]
- \* Burr ML, Ashfield-Watt PA, Dunstan FD, Fehily AM, Breay P, Ashton T, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. *European Journal of Clinical Nutrition* 2003; **57**(2):193–200.
- Burr ML, Dunstan FD, George CH. Is fish oil good or bad for heart disease? Two trials with apparently conflicting results. *Journal of Membrane Biology* 2005; **206**(2):155–63. PUBMED: 16456725]
- Ness AR, Ashfield-Watt PAL, Whiting JM, Smith GD, Hughes J, Burr ML. The long-term effect of dietary advice on the diet of men with angina: the diet and angina randomized trial. *Journal of Human Nutrition and Dietetics* 2004; **17**:1–3.
- Ness AR, Gallacher JE, Bennett PD, Gunnell DJ, Rogers PJ, Kessler D, et al. Advice to eat fish and mood: a randomised controlled trial in men with angina. *Nutritional Neuroscience* 2003; **6**(1):63–5.
- Derosa 2016 {published and unpublished data}**
- Derosa G, Cicero AF, D'Angelo A, Borghi C, Maffioli P. Effects of n-3 PUFAs on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. *BioFactors (Oxford, England)* 2016; **42**(3):316–22. PUBMED: 27040503]
- Deslypere 1992 {published and unpublished data}**
- Blok WL, Deslypere JP, Demacker PN, van der Ven-Jongekrijg J, Hectors MP, van der Meer JW, et al. Pro- and anti-inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year. *European Journal of Clinical Investigation* 1997; **27**(12):1003–8. PUBMED: 9466128]
- \* Deslypere JP. Influence of supplementation with n-3 fatty acids on different coronary risk factors in men: a placebo controlled study. *Verhandelingen - Koninklijke Academie voor Geneeskunde van België* 1992; **54**(3):189–216. PUBMED: 1413984]
- Katan MB, Deslypere JP, van Birgelen AP, Penders M, Zegwaard M. Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. *Journal of Lipid Research* 1997; **38**(10):2012–22. PUBMED: 9374124]
- DIPP 2015 {published and unpublished data}**
- \* Tokudome S, Kuriki K, Yokoyama Y, Sasaki M, Joh T, Kamiya T, et al. Dietary n-3/long-chain n-3 polyunsaturated fatty acids for prevention of sporadic colorectal tumors: a randomized controlled trial in polypectomized participants. *Prostaglandins Leukotrienes and Essential Fatty Acids* 2015; **94**:1–11. PUBMED: 25451556]
- Tokudome S, Yokoyama Y, Kamiya T, Seno K, Okuyama H, Kuriki K, et al. Rationale and study design of dietary intervention in patients polypectomized for tumors of the colorectum. *Japanese Journal of Clinical Oncology* 2002; **32**(12):550–3. PUBMED: 12578906]
- DISAF 2003 {published and unpublished data}**
- Harrison RA. *Dietary Intervention for Maintaining Sinus Rhythm Following Cardioversion for Atrial Fibrillation: a Randomised Controlled Trial [PhD thesis]*. Manchester (UK): Faculty of Medicine, Dentistry, Nursing and Pharmacy, 2005.
- Harrison RA, Elton P. From pies to pilchards: dietary assistants increase consumption of oil rich fish. *Journal of Epidemiology and Community Health* 2000; **Suppl**:6.
- Harrison RA, Elton PJ. Can an oil-rich fish diet improve treatment outcomes following cardioversion for atrial fibrillation? A randomised controlled trial. Study design and compliance. International Society for the Study of Fatty Acids and Lipids (ISSFAL); 2002 May; Montreal, Canada. 2002.
- Harrison RA, Elton PJ. Is there a role for long-chain omega3 or oil-rich fish in the treatment of atrial fibrillation?. *Medical Hypotheses* 2005; **64**(1):59–63. PUBMED: 15533612]
- Harrison RA, Purnell P, Elton PJ. Using community-based dietary assistants to increase the intake of oil-rich fish among older people. *European Journal of Public Health* 2003; **13**(Suppl 1):105.
- Harrison RA, Suresh V, Purnell B, Roberts C, Houghton P, Miller J, et al. Can oil-rich fish sustain normal sinus rhythm after cardioversion for atrial fibrillation? An RCT (DISAF). Author supplied data 29 September 2010.
- Dodin 2005 {published data only}**
- Dodin S, Cunnane SC, Masse B, Lemay A, Jacques H, Asselin G, et al. Flaxseed on cardiovascular disease markers in healthy menopausal women: a randomized, double-blind, placebo-controlled trial. *Nutrition (Burbank, CA)* 2008; **24**(1):23–30. PUBMED: 17981439]
- \* Dodin S, Lemay A, Jacques H, Legare F, Forest JC, Masse B. The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. *Journal of Clinical Endocrinology and Metabolism* 2005; **90**(3):1390–7. PUBMED: 15613422]
- Doi 2014 {published data only}**
- Doi M, Nosaka K, Miyoshi T, Iwamoto M, Kajiya M, Okawa K, et al. Clinical outcomes of early initiation of pure eicosapentaenoic acid supplement after percutaneous coronary intervention in patients with acute coronary

syndrome. *European Heart Journal* 2014;**35**(Abstract Suppl):1156.

\* Doi M, Nosaka K, Miyoshi T, Iwamoto M, Kajiya M, Okawa K, et al. Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. *International Journal of Cardiology* 2014;**176**(3):577–82. PUBMED: 25305703]

Nosaka K, Miyoshi T, Iwamoto M, Kajiya M, Okawa K, Tsukuda S, et al. Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study. *International Journal of Cardiology* 2017;**228**:173–9. DOI: 10.1016/j.ijcard.2016.11.105

Nosaka K, Miyoshi T, Okawa K, Tsukuda S, Sogo M, Nishibe T, et al. Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study. *Journal of the American College of Cardiology*. 2016; Vol. 67:573.

#### DO IT 2010 *{published and unpublished data}*

Berstad P, Seljeflot I, Veierod MB, Hjerkin EM, Arnesen H, Pedersen JI. Supplementation with fish oil affects the association between very long-chain n-3 polyunsaturated fatty acids in serum non-esterified fatty acids and soluble vascular cell adhesion molecule-1. *Clinical Science* 2003;**105**(1):13–20.

Eid HM, Arnesen H, Hjerkin EM, Lyberg T, Ellingsen I, Seljeflot I. Effect of diet and omega-3 fatty acid intervention on asymmetric dimethylarginine. *Nutrition & Metabolism* 2006;**3**:4.

Eid HMA, Arnesen H, Hjerkin EM, Lyberg T, Ellingsen I, Seljeflot I. Effect of diet and omega-3 fatty acid intervention on asymmetric dimethylarginine. *Nutrition and Metabolism* 2006;**3**:1–10.

Einvik G, Ekeberg O, Klemsdal TO, Sandvik L, Hjerkin EM. Physical distress is associated with cardiovascular events in a high risk population of elderly men. *BMC Cardiovascular Disorders* 2009;**9**:14. PUBMED: 19331677]

Einvik G, Ekeberg O, Lavik JG, Ellingsen I, Klemsdal TO, Hjerkin EM. The influence of long-term awareness of hyperlipidemia and of 3 years of dietary counselling on depression, anxiety, and quality of life. *Journal of Psychosomatic Research* 2010;**68**(6):567–72.

\* Einvik G, Klemsdal TO, Sandvik L, Hjerkin EM. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. *European Journal of Cardiovascular Prevention & Rehabilitation* 2010;**17**(5):588–92.

Ellingsen I, Hjerkin EM, Arnesen H, Seljeflot I, Hjermann I, Tonstad S. Follow-up of diet and cardiovascular risk factors 20 years after cessation of intervention in the Oslo Diet and Antismoking study. *European Journal of Clinical*

*Nutrition* 2006;**60**(3):378–85.

Furenes EB, Seljeflot I, Solheim S, Hjerkin EM, Arnesen H, Furenes EB. Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and pregnancy-associated plasma protein-A in men at high risk of coronary heart disease. *Scandinavian Journal of Clinical and Laboratory Investigation* 2008;**68**(3):177–84.

Hjerkin EM, Abdelnoor M, Breivik L, Bergengen L, Ellingsen I, Seljeflot I, et al. Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. *European Journal of Cardiovascular Prevention & Rehabilitation* 2006;**13**(3):325–33.

Hjerkin EM, Seljeflot I, Ellingsen I, Berstad P, Hjermann I, Sandvik L, et al. Influence of long-term intervention with dietary counselling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia. *American Journal of Clinical Nutrition* 2005;**81**(3):583–9.

Lindman AS, Pedersen JI, Hjerkin EM, Arnesen H, Veierod MB, Ellingsen I, et al. The effects of long-term diet and omega-3 fatty acid supplementation on coagulation factor VII and serum phospholipids with special emphasis on the R353Q polymorphism of the FVII gene. *Thrombosis & Haemostasis* 2004;**91**(6):1097–104.

Troset M, Arnesen H, Hjerkin EM, Seljeflot I. Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men. *Metabolism: Clinical & Experimental* 2009;**58**(11):1543–9.

Troset M, Seljeflot I, Weiss TW, Klemsdal TO, Hjerkin EM, Arnesen H. Arterial stiffness is independently associated with interleukin-18 and components of the metabolic syndrome. *Atherosclerosis* 2010;**209**(2):337–9.

#### EPE-A 2014 *{published and unpublished data}*

Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of ethyl-eicosapentaenoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. *Gastroenterology* 2014;**147**(2):377–84.e1. PUBMED: 24818764]

#### EPIC-1 2008 *{published and unpublished data}*

Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. *JAMA* 2008;**299**(14):1690–7.

#### EPIC-2 2008 *{published and unpublished data}*

Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. *JAMA* 2008;**299**(14):1690–7.

#### EPOCH 2014 *{published and unpublished data}*

Danthiir V, Burns NR, Nettelbeck T, Wilson C, Wittert G. The older people, omega-3, and cognitive health (EPOCH) trial design and methodology: a randomised, double-blind, controlled trial investigating the effect of long-chain omega-3 fatty acids on cognitive ageing and wellbeing in



- cognitively healthy older adults. *Nutrition Journal* 2011;**10**:117. PUBMED: 22011460]
- \* Danthiir V, Hosking D, Burns NR, Wilson C, Nettelbeck T, Calvaresi E, et al. Cognitive performance in older adults is inversely associated with fish consumption but not erythrocyte membrane n-3 fatty acids. *Journal of Nutrition* 2014;**144**(3):311–20. PUBMED: 24353345]
- Erdogan 2007** *{published data only}*
- \* Erdogan A, Bayer M, Kollath D, Greiss H, Voss R, Neumann T, et al. Omega AF study: polyunsaturated fatty acids (PUFA) for prevention of atrial fibrillation relapse after successful external cardioversion. *Heart Rhythm* 2007; **4**(5):S185–6.
- Heidt MC, Vician M, Stracke SKH, Stadlbauer T, Grebe MT, Boening A, et al. Beneficial effects of intravenously administered n-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. *Thoracic and Cardiovascular Surgeon* 2009;**57**:276–80. DOI: 10.1055/s-0029-1185301
- Mariani J, Doval HC, Nul D, Varini S, Grancelli H, Ferrante D, et al. N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials. *Journal of the American Heart Association* 2013;**2**(1):e005033.
- FAAT 2005** *{published and unpublished data}*
- Leaf A, Albert CM, Josephson M, Steinhaus D, Kluger J, Kang JX, et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. *Circulation* 2005; **112**(18):2762–8.
- FLAX-PAD 2013** *{published data only (unpublished sought but not used)}*
- Caligiuri SP, Aukema HM, Ravandi A, Guzman R, Dibrov E, Pierce GN. Flaxseed consumption reduces blood pressure in patients with hypertension by altering circulating oxylipins via an alpha-linolenic acid-induced inhibition of soluble epoxide hydrolase. *Hypertension* 2014;**64**(1):53–9. PUBMED: 24777981]
- Caligiuri SP, Rodriguez-Leyva D, Aukema HM, Ravandi A, Weighell W, Guzman R, et al. Dietary flaxseed reduces central aortic blood pressure without cardiac involvement but through changes in plasma oxylipins. *Hypertension* 2016;**68**(4):1031–8. PUBMED: 27528063]
- Edel A, Rodriguez-Leyva D, Weighell W, La Vallee R, Aliani M, Guzman R, et al. Flaxseed lignan metabolites elicit antihypertensive effects in pad patients in the flax-pad trial. *Annals of Nutrition and Metabolism* 2013;**63**:1339.
- \* Edel AL, Rodriguez-Leyva D, Maddaford TG, Caligiuri SP, Austria JA, Weighell W, et al. Dietary flaxseed independently lowers circulating cholesterol and lowers it beyond the effects of cholesterol-lowering medications alone in patients with peripheral artery disease. *Journal of Nutrition* 2015;**145**(4):749–57. PUBMED: 25694068]
- Leyva DR, Zahradka P, Ramjiawan B, Guzman R, Aliani M, Pierce GN. The effect of dietary flaxseed on improving symptoms of cardiovascular disease in patients with peripheral artery disease: rationale and design of the FLAX-PAD randomized controlled trial. *Contemporary Clinical Trials* 2011;**32**(5):724–30. PUBMED: 21616170]
- Pierce GN, Edel AL, LaVallee R, Caligiuri S, Aukema H, Ravandi A, et al. The use of dietary flaxseed to promote cardiovascular health. *Acta Physiologica* 2014;**211**:15.
- Pierce GN, Rodriguez-Leyva D, Edel A, Guzman R, Aliani M. The clinical use of flaxseed as a powerful nutritional intervention to treat cardiovascular disease. *Cardiology (Switzerland)* 2013;**126**:201.
- Rodriguez-Leyva D, Weighell W, Edel AL, LaVallee R, Dibrov E, Pinneker R, et al. Potent antihypertensive action of dietary flaxseed in hypertensive patients. *Hypertension* 2013;**62**(6):1081–9. PUBMED: 24126178]
- FORWARD 2013** *{published and unpublished data}*
- Macchia A, Grancelli H, Varini S, Nul D, Ferrante D, Mariani J, et al. Late-breaking clinical trials: treatments for prevention of cardiovascular events: a population perspective. *Circulation*. 2012; Vol. 126:2780–1.
- \* Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, et al. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (randomized trial to assess efficacy of PUFA for the maintenance of sinus rhythm in persistent atrial fibrillation) trial. *Journal of the American College of Cardiology* 2013;**61**(4):463–8. PUBMED: 23265344]
- Macchia A, Varini S, Grancelli H, Nul D, Laffaye N, Ferrante D, et al. The rationale and design of the FORomegaARD trial: a randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. *American Heart Journal* 2009;**157**(3):423–7. PUBMED: 19249410]
- FOSTAR 2016** *{published and unpublished data}*
- Chen JS, Hill CL, Lester S, Ruediger CD, Battersby R, Jones G, et al. Supplementation with omega-3 fish oil has no effect on bone mineral density in adults with knee osteoarthritis: a 2-year randomized controlled trial. *Osteoporosis International* 2016;**27**(5):1897–905. PUBMED: 26694596]
- Hill C, Lester SE, Jones G. Response to 'Low-dose versus high-dose fish oil for pain reduction and function improvement in patients with knee osteoarthritis' by Chen et al. *Annals of the Rheumatic Diseases* 2016; Vol. 75, issue 1:e8. PUBMED: 26662278]
- \* Hill CL, March LM, Aitken D, Lester SE, Battersby R, Hynes K, et al. Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose. *Annals of the Rheumatic Diseases* 2016;**75**(1):23–9. PUBMED: 26353789]
- Franzen 1993** *{published and unpublished data}*
- Franzen D. A prospective, randomized, and double-blind trial on the effect of fish oil on the incidence of restenosis following ptca. *Catheterization and Cardiovascular Diagnosis* 1993;**28**(4):301–10.
- \* Franzen D, Geisel J, Hopp HW, Oette K, Hilger HH. Long-term effects of low dosage fish oil on serum lipids and lipoproteins [Langzeiteffekte von niedrigdosiertem Fischöl

auf Serumlipide und Lipoproteine]. *Medizinische Klinik* 1993;**88**(3):134–8.

**Gill 2012** {published data only}

Gill EA, Chen MA, Paramsothy P, Fish B, Isquith D, Thirumalai A, et al. Omega-3 fatty acids effects on carotid IMT in metabolic syndrome. *Circulation* 2014;**130**:A1269. Abstract no. 12697.

Gill EA, Chen MA, Thirumalai A, Fish B, Paramsothy P. Omega-3 fatty acids improve dyslipidemia but not inflammatory markers in metabolic syndrome. *Journal of Clinical Lipidology* 2012;**6**:278–9.

**GISSI-HF 2008** {published data only}

Aleksova A, Masson S, Maggioni AP, Lucci D, Fabbri G, Beretta L, et al. N-3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI-HF trial. *European Journal of Heart Failure* 2013;**15**(11):1289–95.

Canepa M, Temporelli PL, Rossi A, Gonzini L, Nicolosi GL, Staszewsky L, et al. Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure. Data from the GISSI-Heart Failure trial. *European Journal of Heart Failure* 2016;**18**:442–3.

Cowie MR, Cure S, Bianic F, McGuire A, Goodall G, Tavazzi L. Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. *European Journal of Heart Failure* 2011;**13**(6):681–9. DOI: 10.1093/eurjhf/hfr023

Finzi A, Barlera S, Serra DM, Rossi MG, Ruggeri A, Mezzani A, et al. Antiarrhythmic effects of n-3 PUFA in patients with heart failure and an implantable cardioverter defibrillator in the GISSI-HF trial. *European Heart Journal* 2009;**30**:279.

Finzi AA, Latini R, Barlera S, Rossi MG, Ruggeri A, Mezzani A, et al. Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial. *American Heart Journal* 2011;**161**(2):338–43. DOI: 10.1016/j.ahj.2010.10.032

Ghio S, Scelsi L, Latini R, Masson S, Eleuteri E, Palvarini M, et al. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. *European Journal of Heart Failure* 2010;**12**(12):1345–53.

\* GISSI-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;**372**(9645):1223–30. DOI: 10.1016/S01406736(08)61239-8

La Rovere MT, Barlera S, Staszewsky L, Mezzani A, Midi P, Marchioli R, et al. Effect of n-3PUFA on heart rate variability. Data from the GISSI-HF holter substudy. *Circulation* 2011;**124**(21 Suppl 1):A14829.

La Rovere MT, Pinna GD, Maestri R, Barlera S,

Bernardinangeli M, Veniani M, et al. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial. *European Journal of Heart Failure* 2012;**14**(12):1410–9.

La Rovere MT, Staszewsky L, Barlera S, Maestri R, Mezzani A, Midi P, et al. n-3PUFA and Holter-derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) Holter substudy. *Heart Rhythm* 2013;**10**(2):226–32.

Latini R, Masson S, Tacconi M, Bernasconi R, Dragani L, Milani V, et al. Circulating levels of n-3 polyunsaturated fatty acids in patients with chronic heart failure. Data from the GISSI-HF trial. *European Heart Journal* 2011;**32**:919.

Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. *European Heart Journal* 2009;**30**(19):232736.

Marchioli R, Aldegheri MP, Borghese L, Franzosi MG, Latini R, Marfisi RM, et al. Time course analysis of the effect of n-3 PUFA on fatal and non fatal arrhythmias in heart failure: secondary results of the GISSI-HF trial. *European Heart Journal* 2009;**30**:165.

Marchioli R, Cucchi G, Gualco A, Franzosi MG, Levantesi G, Maggioni AP, et al. Time course analysis of the effect of n-3 PUFA on fatal and non fatal heart failure: secondary results of the GISSI-HF trial. *European Heart Journal* 2009;**30**:432.

Marchioli R, Franzosi MG, Latini R, Maggioni AP, Marfisi RM, Minneci C, et al. Prognostic ability of a Mediterranean dietary score in heart failure: preliminary analysis of the GISSI-Heart failure Trial. *European Heart Journal* 2009;**30**:1026.

Marchioli R, Franzosi MG, Latini R, Maggioni AP, Marfisi RM, Nicolosi GL, et al. Effect of n-3 PUFA in heart failure patients with different dietary habits: preliminary results of the GISSI-heart failure trial. *European Heart Journal* 2009;**30**:426.

Marchioli R, Franzosi MG, Levantesi G, Marfisi RM, Maggioni AP, Nicolosi GL, et al. Effect of n-3 PUFA according to fish intake: preliminary results of GISSI-Heart Failure. *European Heart Journal* 2009;**30**:707.

Marchioli R, Levantesi G, Silletta MG, Barlera S, Bernardinangeli M, Carbonieri E, et al. Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. *Expert Reviews Cardiovascular Therapy* 2009;**7**(7):735–48.

Masson S, Latini R, Milani V, Moretti L, Rossi MG, Carbonieri E, et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial. *Circulation: Heart Failure* 2010;**3**(1):65–72.

Masson S, Marchioli R, Mozaffarian D, Bernasconi R, Milani V, Dragani L, et al. Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: relation with fish intake, circulating biomarkers, and

- mortality. *American Heart Journal* 2013;**165**(2):208–15.
- Røysland R, Masson S, Omland T, Milani V, Bjerre M, Flyvbjerg A, et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI-HF trial. *American Heart Journal* 2010;**160**(2):286–93. DOI: 10.1016/j.ahj.2010.05.015
- Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. *European Journal of Heart Failure* 2004;**6**(5):635–41. DOI: 10.1016/j.ejheart.2004.03.001
- GISSI-P 1999 {published data only}**
- Franzosi MG, Brunetti M, Marchioli R, Marfisi RM, Tognoni G, Valagussa F, GISSI-Prevenzione I. Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. *Pharmacoeconomics* 2001;**19**(4): 411–20.
- \* GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. *Lancet* 1999;**354**:447–55.
- Marchioli R. Treatment with n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSI-Prevenzione Trial. *European Heart Journal Supplements* 2001;**3**(Suppl D):D85–D97.
- Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio DDMR, Franzosi MG, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. *Circulation* 2002;**105**:1897–903.
- Marchioli R, Di Pasquale A. The biochemical, pharmacological and epidemiological reference picture of the GISSI-Prevenzione. The Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. *Giornale Italiano di Cardiologia* 1993;**23**(9):933–64.
- Marchioli R, Valagussa F. The results of the GISSI-Prevenzione trial in the general framework of secondary prevention. *European Heart Journal* 2000;**21**(12):949–52.
- HARP 1995 {published and unpublished data}**
- Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and “normal” cholesterol levels. A randomized, placebo-controlled trial. *Annals of Internal Medicine* 1996;**125**(7): 529–40. PUBMED: 8815751]
- Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. *Lancet* 1994;**344**(8931):1182–6. PUBMED: 7934538]
- \* Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC. Controlled trial of fish oil for regression of human coronary atherosclerosis. *Journal of the American College of Cardiology* 1995;**25**(7):1492–8.
- HERO 2009 {published and unpublished data}**
- Tan SY. *Dietary Manipulation and Weight Management [PhD thesis]*. Wollongong, Australia: University of Wollongong, 2010.
- \* Tapsell LC, Batterham MJ, Teuss G, Tan SY, Dalton S, Quick CJ, et al. Long-term effects of increased dietary polyunsaturated fat from walnuts on metabolic parameters in type II diabetes. *European Journal of Clinical Nutrition* 2009;**63**(8):1008–15. PUBMED: 19352378]
- JELIS 2007 {published data only}**
- Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. *European Journal of Heart Failure* 2006;**8**(1):105–10. DOI: 10.1016/j.ejheart.2005.12.003
- Ishikawa Y, Yokoyama M, Saito Y, Matsuzaki M, Origasa H, Oikawa S, et al. Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. *Circulation Journal* 2010;**74**(7):1451–7. DOI: 10.1253/circj.CJ-09-0520
- Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, et al. Relationships between plasma fatty acid composition and coronary artery disease. *Journal of Atherosclerosis and Thrombosis* 2011;**18**(2):99–107. PUBMED: 21099130]
- Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, et al. The change in low-density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid. *Journal of Atherosclerosis and Thrombosis* 2012;**19**(7):673–9. PUBMED: 22653220]
- Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Secondary prevention analysis from JELIS. *Circulation Journal* 2009;**73**(7):1283–90.
- Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). *Atherosclerosis* 2009;**206**(2):535–9. DOI: 10.1016/j.atherosclerosis.2009.03.029
- Origasa H, Yokoyama M, Matsuzaki M, Saito Y, Matsuzawa Y, JELIS Investigators. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia. *Circulation Journal* 2010;**74**(3): 510–7. DOI: 10.1253/circj.CJ-09-0746
- Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). *Atherosclerosis* 2008;**200**(1):135–40. DOI: 10.1016/

- j.atherosclerosis.2008.06.003
- Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. *Stroke* 2008;**39**(8):2052–8. DOI: 10.1161/STROKEAHA.107.509455
- Yamanouchi D, Komori K. Eicosapentaenoic acid as the gold standard for patients with peripheral artery disease? Subanalysis of the JELIS trial. *Circulation Journal* 2010;**74**(7):1298–9. DOI: 10.1253/circj.CJ-10-0449
- \* Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *Lancet* 2007;**369**(9567):1090–8.
- Yokoyama M, Origasa H, for the JELIS Investigators. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolaemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). *American Heart Journal* 2003; **146**:613–20.
- Kumar 2012** {published data only (unpublished sought but not used)}
- Kumar S, Sutherland F, Morton JB, Lee G, Morgan J, Wong J, et al. Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion. *Heart Rhythm* 2012;**9**(4):483–91. DOI: 10.1016/j.hrthm.2011.11.034
- Kumar 2013** {published data only (unpublished sought but not used)}
- Kumar S, Sutherland F, Stevenson I, Lee JM, Garg ML, Sparks PB. Effects of long-term omega-3 polyunsaturated fatty acid supplementation on paroxysmal atrial tachyarrhythmia burden in patients with implanted pacemakers: results from a prospective randomised study. *International Journal of Cardiology* 2013;**168**(4):3812–7. PUBMED: 23890856]
- Lorenz-Meyer 1996** {published and unpublished data}
- Lorenz-Meyer H, Bauer P, Nicolay C, Schulz B, Purrmann J, Fleig WE, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. *Scandinavian Journal of Gastroenterology* 1996;**31**(8):778–85.
- MAPT 2017** {published data only}
- \* Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. *Lancet Neurology* 2017;**16**:377–89. DOI: 10.1016/S1474-4422(17)30040-6
- Carrie I, van Kan GA, Gillette-Guyonnet S, Andrieu S, Dartigues JF, Touchon J, et al. Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). *Journal of Nutrition, Health & Aging* 2012;**16**(4):355–9.
- Delrieu J, Andrieu S, Pahor M, Cantet C, Cesari M, Ousset PJ, et al. Neuropsychological profile of “cognitive frailty” subjects in MAPT study. *Journal of Prevention of Alzheimer's Disease* 2016;**3**(3):151–9. DOI: 10.14283/jpad.2016.94
- Delrieu J, Payoux P, Hitzel A, Peiffer S, Abellan Van Kan G, Gillette S, et al. Multidomain alzheimer's disease preventive trial: florbetapir ancillary study. *Alzheimer's and Dementia* 2011;**1**:S419.
- Fougere B, Barreto PD, Goisser S, Soriano G, Guyonnet S, Andrieu S, et al. Red blood cell membrane omega-3 fatty acid levels and physical performance: cross-sectional data from the MAPT study. *Clinical Nutrition* 2017 Apr 12 [Epub ahead of print]:1–4. DOI: 10.1016/j.clnu.2017.04.005
- Gillette S. The multidomain Alzheimer preventive trial (MAPT): a new approach for the prevention of Alzheimer's disease. *Alzheimer's & Dementia* 2009;**S4-02-05**:145.
- Gillette-Guyonnet S, Andrieu S, Dantoine T, Dartigues JF, Touchon J, Vellas B, et al. Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease. *Alzheimer's & Dementia* 2009;**5**(2):114–21.
- Gillette-Guyonnet S, Vellas B, Sandrine A, Charlotte D, Isabelle C. MAPT study: a 3-year randomized trial of omega 3 and/or multidomain intervention for the prevention of cognitive decline in frail elderly subjects-rationale, design and baseline data. *Alzheimer's & Dementia* 2011;**1**:S97–8.
- Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues JF, et al. MAPT Study: a multidomain approach for preventing Alzheimer's disease: design and baseline data. *Journal of Prevention of Alzheimers Disease* 2014;**1**(1):13–22.
- Vellas B, Carrie I, Guyonnet S, Touchon J, Dantoine T, Dartigues JF, et al. MAPT (multi-domain Alzheimer's prevention trial): Results at 36 months. *Alzheimer's & Dementia* 2015;**1**:331.
- Vellas B, Touchon J, Weiner M. MAPT (multidomain Alzheimer preventive trial) imaging (MRI, FDG-PET, amyloid-PET) data. *Journal of Nutrition, Health and Aging* 2012;**16**(9):812–5.
- MARGARIN 2002** {published data only (unpublished sought but not used)}
- \* Bemelmans WJ, Broer J, Feskens EJ, Smit AJ, Muskiet AJ, Lefrandt JD, et al. Effect of an increased intake of alpha-linolenic acid and group nutritional education on cardiovascular risk factors: the Mediterranean alpha-linolenic enriched Groningen dietary intervention (MARGARIN) study. *American Journal of Clinical Nutrition* 2002;**75**:221–7.
- Bemelmans WJ, Broer J, de Vries JH, Hulshof KE, May JF, Meyboom-De Jong B. Impact of Mediterranean diet education versus posted leaflet on dietary habits and serum cholesterol in a high risk population for cardiovascular disease. *Public Health Nutrition* 2000;**3**(3):273–83.
- Bemelmans WJ, Lefrandt JD, Feskens EJ, Broer J, Tervaert JW, May JF, et al. Change in saturated fat intake is associated with progression of carotid and femoral intima-media thickness, and with levels of soluble intercellular

- adhesion molecule-1. *Atherosclerosis* 2002;**163**(1):113–20.
- Bemelmans WJ, Lefrandt JD, Feskens EJ, van Haelst PL, Broer J, Meyboom-de Jong B, et al. Increased alpha-linolenic acid intake lowers C-reactive protein, but has no effect on markers of atherosclerosis. *European Journal of Clinical Nutrition* 2004;**58**(7):1083–9.
- Bemelmans WJ, Muskiet FA, Feskens EJ, de Vries JH, Broer J, May JF, et al. Associations of alpha-linolenic acid and linoleic acid with risk factors for coronary heart disease. *European Journal of Clinical Nutrition* 2000;**54**(12):865–71.
- Siero FW, Broer J, Bemelmans WJ, Meyboom-de Jong BM. Impact of group nutrition education and surplus value of Prochaska based stage-matched information on health-related cognitions and on Mediterranean nutrition behaviour. *Health Education Research* 2000;**15**(5):635–47.
- MARINA 2011 {published and unpublished data}**
- Al-Hilal M, Alsaleh A, Maniou Z, Lewis FJ, Hall WL, Sanders TA, et al. Genetic variation at the FADS1-FADS2 gene locus influences delta-5 desaturase activity and LC-PUFA proportions after fish oil supplement. *Journal of Lipid Research* 2013;**54**(2):542–51. PUBMED: 23160180]
- AlSaleh A, Maniou Z, Lewis FJ, Hall WL, Sanders TA, O'Dell SD. Interaction between a CSK gene variant and fish oil intake influences blood pressure in healthy adults. *Journal of Nutrition* 2014;**144**(3):267–72. PUBMED: 24401815]
- Alsaleh A, Crepostnaia D, Maniou Z, Lewis FJ, Hall WL, Sanders TA, et al. Adiponectin gene variant interacts with fish oil supplementation to influence serum adiponectin in older individuals. *Journal of Nutrition* 2013;**143**(7):1021–7. PUBMED: 23658423]
- Hall WL, Hay G, Maniou Z, Seed PT, Chowienzyk PJ, Sanders TA. Effect of low doses of long chain n-3 polyunsaturated fatty acids on sleep-time heart rate variability: a randomized, controlled trial. *International Journal of Cardiology* 2013;**168**:4439–42.
- Pinto AM, Hall WL, Sanders TAB. Effect of low doses of long chain n-3 PUFA intake on daytime heart rate variability: results from the MARINA study. *European Journal of Preventive Cardiology* 2015;**1**:S146.
- \* Sanders TA, Hall WL, Maniou Z, Lewis F, Seed PT, Chowienzyk PJ. Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial. *American Journal of Clinical Nutrition* 2011;**94**(4):973–80. PUBMED: 21865334]
- Sanders TAB, Chowienzyk PJ, Hall W, Lewis F, Seed P, Maniou Z, et al. The influences of increasing intakes of EPA and DHA on vascular function and risk factors for cardiovascular disease. Food Standards Agency Project N02041. Final Report 2011.
- MENU 2016 {published data only (unpublished sought but not used)}**
- Le T, Flatt SW, Natarajan L, Pakiz B, Quintana EL, Heath DD, et al. Effects of diet composition and insulin resistance status on plasma lipid levels in a weight loss intervention in women. *Journal of the American Heart Association* 2016;**5**(1):e002771. DOI: 10.1161/JAHA.115.002771
- \* Rock CL, Flatt SW, Pakiz B, Quintana EL, Heath DD, Rana BK, et al. Effects of diet composition on weight loss, metabolic factors and biomarkers in a 1-year weight loss intervention in obese women examined by baseline insulin resistance status. *Metabolism* 2016;**65**(11):1605–13. DOI: 10.1016/j.metabol.2016.07.008
- Mita 2007 {published data only}**
- Mita T, Watada H, Ogihara T, Nomiyama T, Ogawa O, Kinoshita J, et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. *Atherosclerosis* 2007;**191**(1):162–7.
- NAT2 2013 {published data only}**
- Merle BM, Benlian P, Puche N, Bassols A, Delcourt C, Souied EH. Circulating omega-3 fatty acids and neovascular age-related macular degeneration. *Investigative Ophthalmology & Visual Science* 2014;**55**(3):2010–9. PUBMED: 24557349]
- Merle BM, Richard F, Benlian P, Puche N, Delcourt C, Souied EH. CFH Y402H and ARMS2 A69S polymorphisms and oral supplementation with docosahexaenoic acid in neovascular age-related macular degeneration patients: the NAT2 study. *PLOS ONE* 2015;**10**(7):e0130816. PUBMED: 26132079]
- Querques G, Merle BM, Pumariega NM, Benlian P, Delcourt C, Zourdani A, et al. Dynamic drusen remodelling in participants of the nutritional AMD treatment-2 (NAT-2) randomized trial. *PLOS ONE* 2016;**11**(2):e0149219. PUBMED: 26901353]
- \* Souied EH, Delcourt C, Querques G, Bassols A, Merle B, Zourdani A, et al. Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: the nutritional AMD treatment 2 study. *Ophthalmology* 2013;**120**(8):1619–31. PUBMED: 23395546]
- Nodari 2011 AF {published data only}**
- Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, et al. N-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. *Circulation* 2011;**124**(10):1100–6. PUBMED: 21844082]
- Nodari 2011 HF {published and unpublished data}**
- NCT01223703. PUFAs and left ventricular function in heart failure (CS-PUFA-02) [Effects of n-3 Polyunsaturated Fatty Acids (PUFAs) on Left Ventricular Function and Functional Capacity in Patients With Dilated Cardiomyopathy]. <https://clinicaltrials.gov/ct2/show/NCT01223703> (first received 19 October 2010).
- Nodari S, Triggiani M, Berlinghieri N, Milesi G, Foresti A, Gheorghide M, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in heart failure patients. *European Heart Journal* 2010;**31**:850.
- \* Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. *Journal of the American College of Cardiology* 2011;**57**(7):870–9.
- Nodari S, Triggiani M, Campia U, Zhao L, Manerba A, Milesi G, et al. Plasma levels of n-3 polyunsaturated fatty acids and risk of hospitalization in patients with

non-ischemic cardiomyopathy. *Circulation. Conference: American Heart Association* 2012;**126**(21 Suppl 1):A17431.

**Norouzi 2014** {published data only}

\* Norouzi Javidan A, Sabour H, Latifi S, Abrishamkar M, Soltani Z, Shidfar F, et al. Does consumption of polyunsaturated fatty acids influence on neurorehabilitation in traumatic spinal cord-injured individuals? A double-blinded clinical trial. *Spinal Cord* 2014;**52**(5):378–82. PUBMED: 24637568]  
Sabour H, Norouzi Javidan A, Latifi S, Shidfar F, Heshmat R, Emami Razavi SH, et al. Omega-3 fatty acids' effect on leptin and adiponectin concentrations in patients with spinal cord injury: a double-blinded randomized clinical trial. *Journal of Spinal Cord Medicine* 2015;**38**(5):599–606. PUBMED: 25096818]

**Norwegian 1968** {published data only}

Natvig H. The effect of unsaturated fatty acids on the incidence of coronary infarction, etc [Effekten av umettede fettsyrer hyppigheten av hjerteinfarkt M.M.]. *Tidsskrift for Den Norske Laegeforening* 1967;**87**(11):1033–41.  
\* Natvig H, Borchgrevink CF, Dedichen J, Owren PA, Schiotz EH, Westlund K. A controlled trial of the effect of linolenic acid on incidence of coronary heart disease. The Norwegian vegetable oil experiment of 1965-66. *Scandinavian Journal of Clinical & Laboratory Investigation* 1968;**105**(Suppl):1–20.

**Nutristroke 2009** {published data only}

Garbagnati F, Cairella G, De Martino A, Multari M, Scognamiglio U, Venturiero V, et al. Is antioxidant and n-3 supplementation able to improve functional status in post-stroke patients? Results from the Nutristroke Trial. *Cerebrovascular Diseases* 2009;**27**(4):375–83. DOI: 10.1159/000207441

**Nye 1990** {published data only}

Ilsey CDJ, Nye ER, Sutherland W, Ram J, Ablett MB. Randomised placebo controlled trial of MAXEPA and aspirin/persantin after successful coronary angioplasty. *Australian & New Zealand Journal of Medicine* 1987;**17**:559.  
\* Nye ER, Ablett MB, Robertson MC, Ilsey CD, Sutherland WH. Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty. *Australian and New Zealand Journal of Medicine* 1990;**20**(4):549–52.

**OFAMI 2001** {published and unpublished data}

Aarsetoy H, Brugger-Andersen T, Hetland O, Grundt H, Nilsen DW. Long term influence of regular intake of high dose n-3 fatty acids on CD40-ligand, pregnancy-associated plasma protein A and matrix metalloproteinase-9 following acute myocardial infarction. *Thrombosis & Haemostasis* 2006;**95**(2):329–36.  
Grundt H, Hetland O, Nilsen DW. Changes in tissue factor and activated factor XII following an acute myocardial infarction were uninfluenced by high doses of n-3

polyunsaturated fatty acids. *Thrombosis & Haemostasis* 2003;**89**(4):752–9.

Grundt H, Nilsen DW, Hetland O, Mansoor MA. Clinical outcome and atherothrombotic risk profile after prolonged wash-out following long-term treatment with high doses of n-3 PUFAs in patients with an acute myocardial infarction. *Clinical Nutrition* 2004;**23**(4): 491–500.

Grundt H, Nilsen DW, Mansoor MA, Hetland O, Nordoy A. Reduction in homocysteine by n-3 polyunsaturated fatty acids after 1 year in a randomised double-blind study following an acute myocardial infarction: no effect on endothelial adhesion properties. *Pathophysiology of Haemostasis & Thrombosis* 2003;**33**(2):88–95.

Grundt H, Nilsen DW, Mansoor MA, Nordoy A. Increased lipid peroxidation during long-term intervention with high doses of n-3 fatty acids (PUFAs) following an acute myocardial infarction. *European Journal of Clinical Nutrition* 2003;**57**(6):793–800.

Naesgaard PA, Grundt H, Brede C, Nilsen DW. The effect on vitamin D levels of long-term high-dose treatment with a concentrated omega-3 compound (Omacor/Lovaza) in patients hospitalized with a myocardial infarction. *Circulation* 2014;**130**(Suppl 2):A17245.

\* Nilsen DW, Albrektsen G, Landmark K, Moen S, Aarsland T, Woie L. Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. *American Journal of Clinical Nutrition* 2001;**74**(1):50–6.  
Poenitz V, Grundt H, Bottazzi B, Cuccovillo I, Mantovani A, Nilsen DW. Pentraxin 3 is uninfluenced by high doses of concentrated omega-3 fatty acids administered for 12 months following an acute myocardial infarction. *Circulation. Conference: American Heart Association* 2012; **126**(21 Suppl 1):A13464.

**OMEGA 2009** {published and unpublished data}

Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. *Circulation* 2010;**122**(21):2152–9. DOI: 10.1161/CIRCULATIONAHA.110.948562  
Rauch B, Schiele R, Schneider S, Gohlke H, Diller F, Gottwik M, et al. Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction—aims and methods of the OMEGA-study. *Cardiovascular Drugs Therapy* 2006;**20**(5):365–75. DOI: 10.1007/s10557-006-0495-6  
Zimmer R, Riemer T, Rauch B, Schneider S, Schiele R, Gohlke H, et al. Effects of 1-year treatment with highly purified omega-3 fatty acids on depression after myocardial infarction: results from the OMEGA trial. *Journal of Clinical Psychiatry* 2013;**74**(11):e1037–45. PUBMED: 24330904]

**OPAL 2010** {published and unpublished data}

\* Dangour AD, Allen E, Elbourne D, Fasey N, Fletcher AE, Hardy P, et al. Effect of 2-y n-3 long-chain polyunsaturated

fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. *American Journal of Clinical Nutrition* 2010;**91**(6):1725–32.

Dangour AD, Allen E, Elbourne D, Fletcher A, Richards M, Uauy R. Fish consumption and cognitive function among older people in the UK: baseline data from the OPAL study. *Journal of Nutrition, Health & Aging* 2009;**13**(3):198–202.

Dangour AD, Allen E, Elbourne D, Fletcher AE, Neveu MM, Uauy R, Holder G. N-3 fatty acids and retinal function. *Ophthalmology* 2013;**120**(3):643. DOI: dx.doi.org/10.1016/j.ophtha.2012.09.043

Dangour AD, Clemens F, Elbourne D, Fasey N, Fletcher AE, Hardy P, et al. A randomised controlled trial investigating the effect of n-3 long-chain polyunsaturated fatty acid supplementation on cognitive and retinal function in cognitively healthy older people: the Older People And n-3 Long-chain polyunsaturated fatty acids (OPAL) study protocol [ISRCTN72331636]. *Nutrition Journal* 2006;**5**: 20.

ISRCTN72331636. The OPAL Study: Older People And n-3 Long-chain polyunsaturated fatty acids. <http://www.isrctn.com/ISRCTN72331636> (first received 27 April 2004). ISRCTN72331636]

#### ORIGIN 2012 {published data only}

Bordeleau L, Yakubovich N, Dagenais G, Rosenstock J, Ryden LE, Spinass G, et al. Cancer outcomes in patients with dysglycemia on basal insulin: results of the Origin trial. *Diabetes* 2013;**62**:A72.

Bordeleau L, Yakubovich N, Dagenais GR, Rosenstock J, Probstfeld J, Chang Yu P, et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. *Diabetes Care* 2014;**37**(5): 1360–6.

Lonn EM, Bosch J, Diaz R, Lopez-Jaramillo P, Ramachandran A, Hancu N, et al. Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). *Diabetes Care* 2013;**36**(9): 2466–74.

Maggioni AP, Fabbri G, Bosch J, Dyal L, Ryden LE, Gerstein HC, et al. Effects of n-3 fatty acids on long-term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. *European Heart Journal* 2013;**34**:352.

\* Origin Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, et al. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. *New England Journal of Medicine* 2012;**367**(4):309–18.

Origin Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). *American Heart Journal* 2008;**155** (1):26–32, 32.

Origin Trial Investigators, Gerstein HC, Bosch J, Dagenais

GR, Diaz R, Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. *New England Journal of Medicine* 2012;**367**(4):319–28.

Punthakee Z, Gerstein HC, Bosch J, Tyrwhitt J, Jung H, Lee SF, et al. Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE). *Diabetes Care* 2016;**39**(5):709–16.

#### ORL 2013 {published data only}

\* Tatsuno I, Saito Y, Kudou K, Ootake J. Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study. *Journal of Clinical Lipidology* 2013;**7**(6):615–25. PUBMED: 24314359]

Tatsuno IT, Saito YS, Kudou KK, Otake JO, Minamide YM. Effects of long-term treatment with omega-3 polyunsaturated fatty acids (Lotriga) on atherogenic lipoproteins in hypertriglyceridemia: results from a phase 3 randomized, open-label, 1-year study. *European Heart Journal* 2013;**34**:768.

#### Özaydin 2011 {published data only}

Özaydin M, Erdoğan D, Tayyar S, Uysal BA, Doğ an A, Içli A, et al. N-3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation after electrical cardioversion: a prospective randomized study. *Anadolu Kardiyoloji Dergisi* 2011;**11**(4):305–9. DOI: 10.5152/akd.2011.080

#### Proudman 2015 {published and unpublished data}

Proudman S, Spargo L, Hall C, McWilliams L, Lee A, Maureen R, et al. Fish oil in rheumatoid arthritis: a randomised, double blind trial comparing high dose with low dose. *Internal Medicine Journal* 2012;**42**(Suppl 1):2–3.

Proudman SM, Cleland LG, Metcalf RG, Sullivan TR, Spargo LD, James MJ. Plasma n-3 fatty acids and clinical outcomes in recent-onset rheumatoid arthritis. *British Journal of Nutrition* 2015;**114**(6):885–90. PUBMED: 26283657]

Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M, et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. *Annals of the Rheumatic Diseases* 2015;**74**(1):89–95. PUBMED: 24081439]

#### Puri 2005 {published data only}

Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. *Neurology* 2005;**65**(2):286–92.

#### Raitt 2005 {published data only}

Raitt MH, Connor WE, Morris C, Kron J, Halperin B, Chugh SS, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. *JAMA* 2005;**293**(23):2884–91.

**Ramirez-Ramirez 2013 {published data only}**

\* Ramirez-Ramirez V, Macias-Islas MA, Ortiz GG, Pacheco-Moises F, Torres-Sanchez ED, Sorto-Gomez TE, et al. Efficacy of fish oil on serum of TNF  $\alpha$ , IL-1  $\beta$ , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b. *Oxidative Medicine and Cellular Longevity* 2013;**2013**:709493. DOI: 10.1155/2013/709493

Sorto-Gomez TE, Ortiz GG, Pacheco-Moises FP, Torres-Sanchez ED, Ramirez-Ramirez V, Macias-Islas MA, et al. Effect of fish oil on glutathione redox system in multiple sclerosis. *American Journal of Neurodegenerative Disease* 2016;**5**(2):145–51.

**Reed 2014 {published and unpublished data}**

Olendzki BC, Leung K, Van Buskirk S, Reed G, Zurier RB. Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum lipids. *Evidence-Based Complementary & Alternative Medicine: eCAM* 2011;**2011**:827286.

\* Reed GW, Leung K, Rossetti RG, Vanbuskirk S, Sharp JT, Zurier RB. Treatment of rheumatoid arthritis with marine and botanical oils: an 18-month, randomized, and double-blind trial. *Evidence-Based Complementary & Alternative Medicine: eCAM* 2014;**2014**:857456.

**Risk & Prevention 2013 {published and unpublished data}**

Rischio and Prevenzione Investigators. Efficacy of n-3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice. *Trials* 2010;**11**(1):68.

\* Risk and Prevention Study Collaborative Group, Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, Caimi V, et al. N-3 fatty acids in patients with multiple cardiovascular risk factors. *New England Journal of Medicine* 2013;**368**(19):1800–8.

Visentin G, Risk & Prevention Study Grp. Towards evidence-based practice via practice-based evidence: the Italian experience. *Family Practice* 2008;**25**(Suppl 1):i71–4.

**Rossing 1996 {published and unpublished data}**

Myrup B, Rossing P, Jensen T, Parving H-H, Holmer G, Gram J, et al. Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathy. *Scandinavian Journal of Clinical & Laboratory Investigation* 2001;**61**(5):349–56.

\* Rossing P, Hansen BV, Nielsen FS, Myrup B, Holmer G, Parving HH. Fish oil in diabetic nephropathy. *Diabetes Care* 1996;**19**(11):1214–9.

**Sandhu 2016 {published data only}**

\* Sandhu N, Schetter SE, Liao J, Hartman TJ, Richie JP, McGinley J, et al. Influence of obesity on breast density reduction by omega-3 fatty acids: evidence from a randomized clinical trial. *Cancer Prevention Research* 2016;**9**(4):275–82. PUBMED: 26714774]

Signori C, DuBrock C, Richie JP, Prokopczyk B, Demers LM, Hamilton C, et al. Administration of omega-3 fatty

acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial. *European Journal of Clinical Nutrition* 2012;**66**(8):878–84. PUBMED: 22669332]

**SCIMO 1999 {published and unpublished data}**

Angerer P, Kothny W, Stork S, von Schacky C. Effect of dietary supplementation with omega-3 fatty acids on progression of atherosclerosis in carotid arteries. *Cardiovascular Research* 2002;**54**(1):183–90.

\* von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. *Annals of Internal Medicine* 1999;**130**(7):554–62.

von Schacky C, Baumann K, Angerer P. The effect of n-3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications. *Lipids* 2001;**36**(Suppl):S99–102.

**Shinto 2014 {published data only}**

NCT00090402. Fish oil and alpha lipoic acid in treating Alzheimer's Disease [Fish Oil and Alpha Lipoic Acid in Mild Alzheimer's Disease]. <https://clinicaltrials.gov/ct2/show/NCT00090402> (first received 24 August 2004). CENTRAL: NCT00090402]

\* Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S, et al. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. *Journal of Alzheimer's Disease: JAD* 2014;**38**(1):111–20. PUBMED: 24077434]

**SHOT 1996 {published and unpublished data}**

Eritsland J, Arnesen H, Berg K, Seljeflot I, Abdelnoor M. Serum Lp(a) lipoprotein levels in patients with coronary artery disease and the influence of long-term n-3 fatty acid supplementation. *Scandinavian Journal of Clinical and Laboratory Investigation* 1995;**55**(4):295–300.

\* Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. *American Journal of Cardiology* 1996;**77**(1):31–6.

Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M. Effect of supplementation with n-3 fatty acids on graft patency in patients undergoing coronary artery bypass operation. Results from SHOT study. *European Heart Journal* 1994;**15**:29.

Eritsland J, Arnesen H, Seljeflot I, Hostmark AT. Long-term metabolic effects of n-3 polyunsaturated fatty acids in patients with coronary artery disease. *American Journal of Clinical Nutrition* 1995;**61**(4):831–6.

Eritsland J, Arnesen H, Seljeflot I, Kierulf P. Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease. *Blood Coagulation & Fibrinolysis* 1995;**6**(1):17–22.

Eritsland J, Seljeflot I, Abdelnoor M, Arnesen H. Long-term influence of omega-3 fatty acids on fibrinolysis, fibrinogen, and serum lipids. *Fibrinolysis* 1994;**8**(2):120–5.

Eritsland J, Seljeflot I, Abdelnoor M, Arnesen H, Torjesen



- PA. Long-term effects of n-3 fatty acids on serum lipids and glycaemic control. *Scandinavian Journal of Clinical and Laboratory Investigation* 1994;**54**(4):273–80.
- Eritsland J, Seljeflot I, Arnesen H, Abdelnoor M. Long-term effects of fish oil supplementation in patients with coronary artery disease: influence on lipoproteins, coagulation and fibrinolysis. *Thrombosis Research* 1992;**65**:75.
- Eritsland J, Seljeflot I, Arnesen H, Abdelnoor M. Long-term influence of omega-3 fatty acids on fibrinolysis, fibrinogen, and serum lipids. *Thrombosis and Haemostasis* 1993;**69**:1065.
- Eritsland J, Seljeflot I, Arnesen H, Westvik AB, Kierulf P. Effect of long-term, moderate-dose supplementation with omega-3 fatty acids on monocyte procoagulant activity and release of interleukin-6 in patients with coronary artery disease. *Thrombosis Research* 1995;**77**(4):337–46.
- Sianni 2013 {published data only}**
- Sianni A, Matsoukis I, Ganotopoulou A, Paraskevas P, Asimis A, Tsvilis N, et al. Effect of omega 3 fatty acids in patients with hypertension and atrial fibrillation. *Clinical Nutrition* 2013;**32**:S70–1.
- SMART 2013 {published and unpublished data}**
- Anil S, Charlton KE, Tapsell LC, Probst Y, Ndanuko R, Batterham MJ. Identification of dietary patterns associated with blood pressure in a sample of overweight Australians. *Journal of Human Hypertension* 2016;**30**(11):672–8. DOI: 10.1038/jhh.2016.10
- Tapsell LC, Batterham MJ, Charlton KE. Effect of dietary restriction and n-3 PUFA supplementation on insulin resistance in obese adults. *FASEB Journal* 2010;**24**:733.9.
- \* Tapsell LC, Batterham MJ, Charlton KE, Neale EP, Probst YC, O'Shea JE, et al. Foods, nutrients or whole diets: effects of targeting fish and LCn3PUFA consumption in a 12mo weight loss trial. *BMC Public Health* 2013;**13**:1231. PUBMED: 24369765]
- Zhang Q, O'Shea JE, Thorne RL, Tapsell LC, Batterham M, Charlton KE. Baseline characteristics of volunteers in the smart clinical trial: associations between habitual physical activity and lifestyle disease risk factors.. *Nutrition and Dietetics* 2010;**67**(Suppl 1):67–8.
- SOFA 2006 {published and unpublished data}**
- Brouwer IA, Katan MB, Schouten EG, Camm AJ, Hauer RNW, Wever EFD, et al. Rationale and design of a clinical trial on n-3 fatty acids and cardiac arrhythmia (SOFA). *Annals of Nutrition & Metabolism* 2001;**45**(Suppl 1):79.
- Brouwer IA, Raitt MH, Dullemeijer C, Kraemer DF, Zock PL, Morris C, et al. Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. *European Heart Journal* 2009;**30**(7):820–6.
- \* Brouwer IA, Zock PL, Camm AJ, Böcker D, Hauer RN, Wever EF, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the study on omega-3 fatty acids and ventricular arrhythmia (SOFA) randomized trial. *JAMA* 2006;**295**(22):2613–9.
- Brouwer IA, Zock PL, Wever EFD, Hauer RNW, Camm AJ, Böcker D, et al. Rationale and design of a randomised controlled clinical trial on supplemental intake of n-3 fatty acids and incidence of cardiac arrhythmia: SOFA. *European Journal of Clinical Nutrition* 2003;**57**:1323–30.
- Sofi 2010 {published data only}**
- Sofi F, Giangrandi I, Cesari F, Corsani I, Abbate R, Gensini GF, et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. *International Journal of Food Sciences and Nutrition* 2010;**61**(8):792–802. PUBMED: 20465434]
- SU.FOL.OM3 2010 {published and unpublished data}**
- Ahluwalia N, Blacher J, Szabo De Edelenyi F, Faure P, Julia C, Hercberg S, et al. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. *Atherosclerosis* 2013;**228**(2):478–84.
- Andreeva VA, Galan P, Torres M, Julia C, Hercberg S, Kesse-Guyot E. Supplementation with B vitamins or n-3 fatty acids and depressive symptoms in cardiovascular disease survivors: ancillary findings from the SUpplementation with FOLate, vitamins B-6 and B-12 and/or OMega-3 fatty acids (SU.FOL.OM3) randomized trial. *American Journal of Clinical Nutrition* 2012;**96**(1):208–14.
- Andreeva VA, Kesse-Guyot E, Barberger-Gateau P, Fezeu L, Hercberg S, Galan P. Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. *American Journal of Clinical Nutrition* 2011;**94**(1):278–86.
- Andreeva VA, Latache C, Hercberg S, Briancon S, Galan P, Kesse-Guyot E. B vitamin and/or n-3 fatty acid supplementation and health-related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial. *PLOS ONE* 2014;**9**(1):e84844.
- Andreeva VA, Touvier M, Kesse-Guyot E, Julia C, Galan P, Hercberg S. B vitamin and/or omega-3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega-3 fatty acids (SU.FOL.OM3) randomized trial. *Archives of Internal Medicine* 2012;**172**(7):540–7.
- Blacher J, Czernichow S, Paillard F, Ducimetiere P, Hercberg S, Galan P, et al. Cardiovascular effects of B-vitamins and/or n-3 fatty acids: the SU.FOL.OM3 trial. *International Journal of Cardiology* 2013;**167**(2):508–13.
- Blacher J, Safar ME, Ly C, Szabo De Edelenyi F, Hercberg S, Galan P. Blood pressure variability: cardiovascular risk integrator or independent risk factor. *Journal of Human Hypertension* 2015;**29**(2):122–6.
- Fezeu LK, Laporte F, Kesse-Guyot E, Andreeva VA, Blacher J, Hercberg S, et al. Baseline plasma fatty acids profile and incident cardiovascular events in the SU.FOL.OM3 trial: the evidence revisited. *PLOS ONE* 2014;**9**(4):e92548.
- Galan P, Briancon S, Blacher J, Czernichow S, Hercberg S. The SU.FOL.OM3 Study: a secondary prevention trial testing the impact of supplementation with folate and B-vitamins and/or Omega-3 PUFA on fatal and

non fatal cardiovascular events, design, methods and participants characteristics. *Trials* 2008;**9**:35. DOI: 10.1186/1745-6215-9-35

Galan P, Briançon S, Blacher J, Czernichow S, Hercberg S. The SU.FOL.OM3 Study: a secondary prevention trial testing the impact of supplementation with folate and B-vitamins and/or Omega-3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics. *Trials* 2008;**9**:35.

Galan P, Briançon S, Blacher J, Czernichow S, Hercberg S. The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events. *Sang Thrombose Vaisseaux* 2009; **21**(4):207–13.

Galan P, Briançon S, Blacher J, Czernichow S, Hercberg S. The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events [Bases scientifiques de l'étude SUFOLOM3: essai de prévention secondaire visant à tester l'impact d'une supplémentation en folates, vitamines B6 et B12 et/ ou acides gras oméga-3 dans la prévention de la récurrence de pathologies ischémiques]. *Sang Thrombose Vaisseaux* 2009;**21**(4):207–13.

Galan P, Kesse-Guyot E, Czernichow S, Briançon S, Blacher J, Hercberg S, SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. *BMJ* 2010; **341**:c6273. DOI: 10.1136/bmj.c6273

Galan P, de Bree A, Mennen L, Potier de Courcy G, Preziosi P, Bertrais S, Castetbon K, Hercberg S. Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. *Journal of Nutrition, Health and Aging* 2003;**7**(6):428–35.

Kesse-Guyot E, Peneau S, Hercberg S, Galan P, Vogt L, Escande M, et al. Thirteen-year prospective study between fish consumption, long-chain N-3 fatty acids intakes and cognitive function. *Journal of Nutrition, Health and Aging* 2011;**15**(2):115–20.

Szabo De Edelenyi F, Vergnaud AC, Ahluwalia N, Julia C, Hercberg S, Blacher J, et al. Effect of B-vitamins and n-3 PUFA supplementation for 5 years on blood pressure in patients with CVD. *British Journal of Nutrition* 2012;**107**(6):921–7.

Vesin C, Galan P, Gautier B, Czernichow S, Hercberg S, Blacher J. Control of baseline cardiovascular risk factors in the SU-FOL-OM3 study cohort: does the localization of the arterial event matter?. *European Journal of Cardiovascular Prevention & Rehabilitation* 2010;**17**(5):541–8.

de Bree A, Mennen LI, Hercberg S, Galan P. Evidence for a protective (synergistic?) effect of B-vitamins and omega-3 fatty acids on cardiovascular diseases. *European Journal of*

*Clinical Nutrition* 2004;**58**(5):732–44.

#### **Tande 2016 {published and unpublished data}**

Tande KS, Vo TD, Lynch BS. Clinical safety evaluation of marine oil derived from *Calanus finmarchicus*. *Regulatory Toxicology and Pharmacology: RTP* 2016;**80**:25–31. PUBMED: 27233921]

#### **THIS DIET 2008 {published and unpublished data}**

Packard DP, Milton JE, Shuler LA, Short RA, Tuttle KR. Implications of chronic kidney disease for dietary treatment of cardiovascular disease. *Journal of Renal Nutrition* 2006; **16**(3):259–68.

\* Tuttle KR, Shuler LA, Packard DP, Milton JE, Daratha KB, Bibus DM, et al. Comparison of low-fat versus Mediterranean-style dietary intervention after first myocardial infarction (from The Heart Institute of Spokane Diet Intervention and Evaluation Trial). *American Journal of Cardiology* 2008;**101**(11):1523–30. PUBMED: 18489927]

#### **WAHA 2016 {published and unpublished data}**

Bitok E, Jaceldo-Siegl K, Rajaram S, Serra-Mir M, Roth I, Feitas-Simoes T, et al. Favourable nutrient intake and displacement with long-term walnut supplementation among elderly: results of a randomised trial. *British Journal of Nutrition* 2017;**118**(3):201–9. DOI: 10.1017/S0007114517001957

Bitok E, Rajaram S, Ros E. Does a daily walnut supplement given for a year result in body weight gain?. *FASEB Journal* 2016; Vol. 30:1157.5.

Huey L, Bitok E, Kazzi N. Dietary compliance of walnut or no walnut intake in a 1-year randomized intervention trial among free-living elderly in the Walnuts and Healthy Aging Study (WAHA). *FASEB Journal* 2016; Vol. 30:1157.10.

Rajaram S, Valls-Pedret C, Cofan M, Sabate J, Serra-Mir M, Perez-Heras AM, et al. The Walnuts and Healthy Aging Study (WAHA): protocol for a nutritional intervention trial with walnuts on brain aging. *Frontiers in Aging Neuroscience* 2016;**8**:333. PUBMED: 28119602]

\* Ros, Emilio, Rajaram, Sujatha, Sala-Vila, Aleix, et al. Effect of a 1-year walnut supplementation on blood lipids among older individuals: findings from the Walnuts and Healthy Aging (WAHA) study. *FASEB Journal* 2016; Vol. 30, issue 1 Suppl:293.4.

#### **Weinstock-Guttman 2005 {published data only}**

Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher E, et al. Low fat dietary intervention with n-3 fatty acid supplementation in multiple sclerosis patients. *Prostaglandins, Leukotrienes and Essential Fatty Acids* 2005; **73**:397–404. DOI: 10.1016/j.plefa.2005.05.024

#### **WELCOME 2015 {published and unpublished data}**

Bhatia L, Scorletti E, Curzen N, Clough GF, Calder PC, Byrne CD. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. *Atherosclerosis* 2016;**246**: 13–20. PUBMED: 26748347]

Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. *Arteriosclerosis, Thrombosis, and*

*Vascular Biology* 2014;**34**(6):1155–61. PUBMED: 24743428]

Byrne CD, Targher G. Time to replace assessment of liver histology with MR-based imaging tests to assess efficacy of interventions for nonalcoholic fatty liver disease. *Gastroenterology* 2016; Vol. 150, issue 1:7–10. PUBMED: 26602219]

Clough GF, McCormick KG, Scorletti E, Bhatia L, Calder PC, Griffin MJ, et al. Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex evaluation of fatty liver and cardiovascular markers in NAFLD with omacor therapy trial (WELCOME) trial. *Diabetologia* 2016;**59**(7):1422–9. PUBMED: 27106721]

Hodson L, Bhatia L, Scorletti E, Smith DE, Jackson NC, Shojaae-Moradie F, et al. Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study. *European Journal of Clinical Nutrition* 2017;**71**(8):973–9. PUBMED: 28294174]

McCormick KG, Scorletti E, Bhatia L, Calder PC, Griffin MJ, Clough GF, et al. Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial. *Diabetologia* 2015;**58**(8):1916–25. PUBMED: 26021488]

McCormick KG, Scorletti ES, Bhatia L, Calder PC, Griffin MJ, Clough GF, et al. Peripheral sensory nerve function is independently associated with microvascular function, but neither are improved by n-3 fatty acids. *Diabetic Medicine* 2015;**32**(S1):99.

Scorletti E, Bhatia B, McCormick KG, Clough GF, Nash K, Hodson L, et al. Potential benefits of purified long chain omega-3 fatty acid treatment in non-alcoholic fatty liver disease (NAFLD): a potential treatment for early NAFLD in metabolic syndrome and type 2 diabetes? Results from the WELCOME study. *Diabetic Medicine* 2014;**31**:1.

Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC, et al. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]. *Contemporary Clinical Trials* 2014;**37**(2):301–11. PUBMED: 24556343]

Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC, et al. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease. *Contemporary Clinical Trials* 2014;**38**(1):156.

Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome\* study. *Hepatology (Baltimore, MD)* 2014;**60**(4):1211–21. PUBMED: 25043514]

Scorletti E, West AL, Bhatia L, Hoile SP, McCormick KG,

Burdge GC, et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. *Journal of Hepatology* 2015;**63**(6):1476–83. PUBMED: 26272871]

Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. *Journal of Clinical Endocrinology and Metabolism* 2013;**98**(2):483–95. PUBMED: 23293330]

#### Zhang 2017 {published data only (unpublished sought but not used)}

Zhang Y-P, Rujuan M, Qing L, Wu T, Ma F. Effects of DHA supplementation on hippocampal volume and cognitive function in older adults with mild cognitive impairment: a 12-month randomized, double-blind, placebo-controlled trial. *Journal of Alzheimer's Disease* 2016;**55**(2):497–507.

### References to studies excluded from this review

#### Alekseeva 2000 {published data only}

Alekseeva RI, Sharafetdinov K, Plotnikova OA, Meshcheriakova VA, Mal'tsev GI, Kulakova SN. Effects of a diet including linseed oil on clinical and metabolic parameters in patients with type 2 diabetes mellitus. *Voprosy Pitaniia* 2000;**69**(6):32–5.

#### Baleztena 2015 {published data only}

\* Baleztena Gurrea J, Ruiz-Canela M, Pardo M, Castellanos MC, Gozalo MJ, Añorbe T, et al. Utility of heavy food supplement in omega-3 fatty acids in the prevention of dementia, in relation to the basal nutritional level, in people of advanced age: randomized multicenter study. *Revista Española de Geriatria y Gerontología* 2015;**50**:1–49.

Bes-Rastrollo M, Baleztena J, Aguirre I, Ruiz-Canela M. Utility of a rich food supplement Omega-3 fatty acids in the prevention of dementia, in relation to baseline nutritional level, in people with advanced age: multicentre randomised study [Complemento alimenticio rico en ácidos grasos omega-3 en la prevención de la demencia: estudio aleatorizado multicéntrico]. *Nutrición Clínica en Medicina* 2015;**9**(1):38.

#### Belch 1988 {published data only}

Belch JJ, Ansell D, Madhok R, O'Dowd A, Sturrock RD. Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: a double blind placebo controlled study. *Annals of the Rheumatic Diseases* 1988;**47**(2):96–104.

#### Belluzzi 1996 {published and unpublished data}

Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. *New England Journal of Medicine* 13–6–1996;**334**(24):1557–60.

#### Berthouex 1992 {published data only}

Berthouex FC, Guerin C, Burgard G, Berthouex P, Alamartine E. One-year randomized controlled trial with omega-3 fatty acid-fish oil in clinical renal transplantation. *Transplantation Proceedings* 1992;**24**(6):2578–82.

**Borchgrevink 1966 {published and unpublished data}**

Borchgrevink CF, Berg KJ, Skaga E, Skjaeggstad O, Stormorken H. Effect of linseed oil on platelet adhesiveness and bleeding time in patients with coronary heart disease. *Lancet* 1965;ii:980–2.

\* Borchgrevink CF, Skaga E, Berg KJ, Skjaeggstad O. Absence of prophylactic effect of linolenic acid in patients with coronary heart disease. *Lancet* 1966;2(456):187–9.

**Busnach 1998 {published data only}**

Busnach G, Stragliotto E, Minetti E, Perego A, Brando B, Broggi ML, et al. Effect of N-3 polyunsaturated fatty acids on cyclosporine pharmacokinetics in kidney graft recipients: a randomized placebo-controlled study. *Journal of Nephrology* 1998;11(2):87–93.

**CANN 2015 {unpublished data only}**

NCT02525198. The cognitive ageing nutrition and neurogenesis trial (CANN) [A randomised controlled trial in 'at risk' humans investigating the cognitive benefits of a combined flavonoid/fatty acid intervention and underlying mechanisms of action: the Cognitive Aging Nutrition and Neurogenesis 8CANN trial]. [clinicaltrials.gov/ct2/show/NCT02525198](http://clinicaltrials.gov/ct2/show/NCT02525198) (first received 17 August 2015).

**Cappelli 1997 {published data only}**

Cappelli P, Di LL, Stuard S, Ballone E, Albertazzi A. N-3 polyunsaturated fatty acid supplementation in chronic progressive renal disease. *Journal of Nephrology* 1997;10(3):157–62.

**CARES 2015 {published data only}**

ISRCTN10431469. Changes in brain function among individuals with a mild memory impairment (CARES). [www.isrctn.com/ISRCTN10431469](http://www.isrctn.com/ISRCTN10431469) (first received 21 December 2015). ISRCTN10431469]

**Cheng 1990a {published data only}**

Cheng A, Bustami M, Norell MS, Mitchell AG, Ilsey CDJ. The effect of omega-3 fatty acids on restenosis after coronary angioplasty. *European Heart Journal* 1990;11:368.

**Cheng 1990b {published data only}**

Cheng IKP, Chan PCK, Chan MK. The effect of fish oil dietary supplement on the progression of mesangial IgA glomerulonephritis. *Nephrology, Dialysis, Transplantation* 1990;5:241–16.

**Clark 1993 {published data only}**

Clark WF, Parbtani A, Naylor CD, Levinton CM, Muirhead N, Spanner E, et al. Fish oil in lupus nephritis: clinical findings and methodological implications. *Kidney International* 1993;44(1):75–86.

**Clark 1994 {published data only}**

Clark WF, Parbtani A. Omega-3 fatty acid supplementation in clinical and experimental lupus nephritis. *American Journal of Kidney Diseases* 1994;23(5):644–7.

**Clark 2001 {published data only}**

Clark WF, Kortas C, Heidenheim AP, Garland J, Spanner E, Parbtani A. Flaxseed in lupus nephritis: a two-year nonplacebo-controlled crossover study. *Journal of the American College of Nutrition* 2001;20(2 Suppl):143–8. PUBMED: 11349937]

**Clausen 1989 {published data only}**

Clausen J, Nielsen SA, Kristensen M. Biochemical and clinical effects of an antioxidative supplementation of geriatric patients. A double blind study. *Biological Trace Element Research* 1989;20(1-2):135–51.

**Diskin 1990 {published data only}**

Diskin CJ, Thomas CE, Zellner CP, Lock S, Tanja J. Fish oil to prevent intimal hyperplasia and access thrombosis. *Nephron* 1990;55(4):445–7.

**Donadio 1994 {published data only}**

Donadio JJ, Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. *New England Journal of Medicine* 1994;331:1194–9.

**Doyle 2001 {published data only}**

Doyle W, Srivastava A, Crawford MA, Bhatti R, Brooke Z, Costeloe KL. Inter-pregnancy folate and iron status of women in an inner-city population. *British Journal of Nutrition* 2001;86(1):81–7.

**Dry 1991 {published and unpublished data}**

Dry J, Vincent D. Effect of a fish oil diet on asthma: results of a 1-year double-blind study. *International Archives of Allergy and Applied Immunology* 1991;95(2-3):156–7.

**Ezaki 1999 {published data only}**

Ezaki O, Takahashi M, Shigematsu T, Shimamura K, Kimura J, Ezaki H, et al. Long-term effects of dietary alpha-linolenic acid from perilla oil on serum fatty acids composition and on the risk factors of coronary heart disease in Japanese elderly subjects. *Journal of Nutritional Science & Vitaminology* 1999;45(6):759–72.

**Fehér 2005 {published data only}**

Fehér J, Kovacs B, Kovacs I, Schveoller M, Papale A, Balacco Gabrieli C. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. *Ophthalmologica* 2005;219(3):154–66. PUBMED: 15947501]

**FISH 2012 {published data only (unpublished sought but not used)}**

\* Browning LM, Walker CG, Mander AP, West AL, Madden J, Gambell JM, et al. Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. *American Journal of Clinical Nutrition* 2012;96(4):748–58. PUBMED: 22932281]

Walker CG, Browning LM, Mander AP, Madden J, West AL, Calder PC, et al. Age and sex differences in the incorporation of EPA and DHA into plasma fractions, cells and adipose tissue in humans. *British Journal of Nutrition* 2014;111(4):679–89. PUBMED: 24063767]

Walker CG, Browning LM, Stecher L, West AL, Madden J, Jebb SA, et al. Fatty acid profile of plasma NEFA does not reflect adipose tissue fatty acid profile. *British Journal of Nutrition* 2015;114(5):756–62. PUBMED: 26205910]

Walker CG, West AL, Browning LM, Madden J, Gambell JM, Jebb SA, et al. The pattern of fatty acids displaced by EPA and DHA following 12 months supplementation

- varies between blood cell and plasma fractions. *Nutrients* 2015;**7**(8):6281–93. PUBMED: 26247960]
- Fonolla 2009** *[published data only]*  
Fonolla J, Lopez-Huertas E, Machado FJ, Molina D, Alvarez I, Marmol E, et al. Milk enriched with “healthy fatty acids” improves cardiovascular risk markers and nutritional status in human volunteers. *Nutrition* 2009;**25**(4):408–14. PUBMED: 19084376]
- Fonolla-Joya 2016** *[published data only]*  
Fonolla J, Diaz-Ropero M, Geerlings A, Marti J, Lopez-Huertas E. Daily intake of a dairy drink enriched with omega-3 (EPA+DHA) and oleic acid improves cardiovascular markers in healthy postmenopausal women. *Atherosclerosis Supplements* 2010;**11**(2):58.  
Fonolla J, Diaz-Ropero P, Marti JL, Rodriguez-Martinez C, Lopez-Huertas E. Daily intake of a low lactose dairy drink enriched with omega-3 (EPA+DHA), oleic acid and calcium improves nutritional and bone status in healthy postmenopausal women. *Clinical Nutrition* 2011;**6**(1):86.  
\* Fonolla-Joya J, Reyes-García R, García-Martín A, López-Huertas E, Muñoz-Torres M. Daily intake of milk enriched with n-3 fatty acids, oleic acid, and calcium improves metabolic and bone biomarkers in postmenopausal women. *Journal of the American College of Nutrition* 2016;**35**(6): 529–36. DOI: 10.1080/07315724.2014
- Franzen 1989** *[published data only]*  
Franzen D, Hopp HW, Schanwell M, Hilger HH. Long-term effect of fish oil and olive oil on plasma lipids in patients with CHD. *Zeitschrift für Kardiologie* 1989;**78** (Suppl 4):28.
- Galarraga 2008** *[published data only]*  
Galarraga B, Ho M, Youssef HM, Hill A, McMahon H, Hall C, et al. Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. *Rheumatology* 2008;**47**(5):665–9. DOI: 10.1093/rheumatology/ken024
- Gapparova 2000** *[published data only]*  
Gapparova KM, Pogozheva AV, Kulakova SN, Tutel’ian VA. Effects of omega-3 polyunsaturated fatty acids of vegetable and animal origin on clinical and metabolic indicators and the intensity of lipid peroxidation in patients with ischemic heart disease and impaired carbohydrate tolerance. *Voprosy Pitaniia* 2000;**69**(1-2):46–9.
- Gazso 1992** *[published data only]*  
Gazso A, Horrobin D, Sinzinger H. Influence of omega-3 fatty acids on the prostaglandin-metabolism in healthy volunteers and patients suffering from PVD. *Agents and Actions. Supplements* 1992;**37**:151–6.
- Geusens 1994** *[published data only]*  
Geusens P, Wouters C, Nijs J, Jiang Y, Dequeker J. Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study. *Arthritis and Rheumatism* 1994;**37**(6):824–9.
- Gogos 1998** *[published data only]*  
Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos NC, Kalfarentzos F. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. *Cancer* 1998;**82**(2):395–402.
- Greatrex 2000** *[published data only]*  
Greatrex JC, Drasdo N, Dresser K. Scotopic sensitivity in dyslexia and requirements for DHA supplementation. *Lancet* 2000;**355**(9213):1429–30.
- Griffin 1999** *[published data only]*  
Griffin BA, Minihane AM, Furlonger N, Chapman C, Murphy M, Williams D, et al. Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects. *Clinical Science* 1999;**97**(3):269–76.
- Hamazaki 1984** *[published data only]*  
Hamazaki T, Tateno S, Shishido H. Eicosapentaenoic acid and IgA nephropathy. *Lancet* 1984;**1**(8384):1017–8.
- Hansen 1996** *[published data only]*  
Hansen GV, Nielsen L, Kluger E, Thysen M, Emmertsen H, Stengaard PK, et al. Nutritional status of Danish rheumatoid arthritis patients and effects of a diet adjusted in energy intake, fish-meal, and antioxidants. *Scandinavian Journal of Rheumatology* 1996;**25**(5):325–30.
- Harris 1991** *[published data only]*  
Harris WS, Windsor SL, Dujovne CA. Effects of four doses of n-3 fatty acids given to hyperlipidemic patients for six months. *Journal of the American College of Nutrition* 1991;**10**(3):220–7.
- Hashimoto 2012** *[published data only]*  
Hashimoto M, Yamashita K, Kato S, Tamai T, Matsumoto I, Tanabe Y, et al. Beneficial effects of dietary docosahexaenoic acid intervention on cognitive function in elderly people with very mild dementia in Japan. *Alzheimer's and Dementia* 2011;**1**:S610–1.  
\* Hashimoto M, Yamashita K, Kato S, Tamai T, Tanabe Y, Mitarai M, et al. Beneficial effects of daily dietary omega-3 polyunsaturated fatty acid supplementation on age related cognitive decline in elderly Japanese with very mild dementia: a 2-year randomized, double-blind, placebo-controlled trial. *Journal of Aging Research & Clinical Practice* 2012;**1**(3):193–201.
- Hashimoto 2016** *[published data only]*  
Hashimoto M, Kato S, Tanabe Y, Katakura M, Mamun AA, Ohno M, et al. Beneficial effects of dietary docosahexaenoic acid intervention on cognitive function and mental health of the oldest elderly in Japanese care facilities and nursing homes. *Geriatrics & Gerontology International* 2017;**17**(2): 330–7. PUBMED: 26822516]
- Hawthorne 1992** *[published and unpublished data]*  
Hawthorne AB, Daneshmend TK, Hawkey CJ, Belluzzi A, Everitt SJ, Holmes GK, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. *Gut* 1992;**33**(7):922–8.
- HEARTS 2015** *[published data only]*  
Lakshminarayan DK, Elajami TK, Soliman M, Alfaddagh A, Wely FK. Omega-3 fatty acids supplementation

- attenuates the progression of microalbuminuria in diabetics with coronary artery disease. *Circulation* 2015;**132**:A15530.
- Hogg 1995** *{published data only}*  
Hogg RJ. A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with immunoglobulin A nephropathy. *American Journal of Kidney Diseases* 1995;**26**(5):792–6.
- HOPE epilepsy 2012** *{published data only}*  
NCT01744275. High dose omega 3 fatty acids supplementation in patients with epilepsy: the HOPE-Epilepsy trial. [clinicaltrials.gov/ct2/show/NCT01744275](http://clinicaltrials.gov/ct2/show/NCT01744275) (first received 6 December 2012).
- Huang 1996** *{published data only}*  
Huang YC, Jessup JM, Forse RA, Flickner S, Pleskow D, Anastopoulos HT, et al. N-3 fatty acids decrease colonic epithelial cell proliferation in high-risk bowel mucosa. *Lipids* 1996;**31**:S313–7.
- Huang 2008** *{published and unpublished data}*  
Huang LL, Coleman HR, Kim J, de Monasterio F, Wong WT, Schleicher RL, et al. Oral supplementation of lutein/zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years or older, with or without AMD. *Investigative Ophthalmology & Visual Science* 2008;**49**(9):3864–9.
- ISRCTN38354847** *{published data only}*  
ISRCTN38354847. A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate [EPA]) as adjunct therapy in patients who remain depressed following treatment with standard antidepressant therapy. [www.isrctn.com/](http://www.isrctn.com/) ISRCTN38354847 (first received 3 February 2003).
- Junker 1990** *{published data only}*  
Junker L, Engel S, Berger I, Barleben H. Serum enzymes in grade I hypertensive patients before and following a change in nutrition in relation to polyene acid and electrolyte content. *Zeitschrift für die Gesamte Innere Medizin und Ihre Grenzgebiete* 1990;**45**(11):323–4.
- Kachorovskii 1977** *{published data only}*  
Kachorovskii BV, Zhoglo FA, Zaverbnyi MI. Total lipid content in the blood after using fish oil in natural and emulsified forms. *Farmatsiia* 1977;**26**(5):86.
- Kanorskii 2007** *{published data only}*  
Kanorskii SG, Bodrikova VV, Kanorskaia Iu S. Influence of perindopril, rosuvastatin, or omega-3 polyunsaturated fatty acids on efficacy of antirecurrence therapy with sotalol in patients with persistent atrial fibrillation. *Kardiologiia* 2007;**47**(12):39–44.
- Karlsson 1998** *{published data only}*  
Karlsson J, Hesselius G, Nygard B, Ronneberg R. Plasma omega-3 fatty acids before and after nutritional therapy. *Journal of Nutritional & Environmental Medicine* 1998;**8**(1):25–34.
- Kaul 1992** *{published and unpublished data}*  
Kaul U, Sanghvi S, Bahl VK, Dev V, Wasir HS. Fish oil supplements for prevention of restenosis after coronary angioplasty. *International Journal of Cardiology* 1992;**35**(1):87–93.
- Khan 2003** *{published and unpublished data}*  
Khan F, Elherik K, Bolton-Smith C, Barr R, Hill A, Murrie I, Belch JJJ. The effects of dietary fatty acid supplementation on endothelial function and vascular tone in healthy subjects. *Cardiovascular Research* 2003;**59**(4):955–62.
- Konya 2000** *{published data only}*  
Konya E, Tsuji H, Umekawa T, Kurita T, Iguchi M. Effect of ethyl icosapentate on urinary calcium and oxalate excretion. *International Journal of Urology* 2000;**7**(10):361–5.
- Kremer 1995** *{published data only}*  
Kremer JM, Lawrence DA, Petrillo GF, Litts LL, Mullaly PM, Rynes RI, et al. Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Clinical and immune correlates. *Arthritis and Rheumatism* 1995;**38**(8):1107–14.
- Kruger 1998** *{published data only}*  
Kruger MC, Coetzer H, de Winter R, Gericke G, van Papendorp DH. Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. *Aging (Milano)* 1998;**10**(5):385–94.
- Kurabayashi 2000** *{published data only}*  
Kurabayashi T, Okada M, Tanaka K. Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women. The Niigata Epadel Study Group. *Obstetrics & Gynecology* 2000;**96**(4):521–8.
- Lau 1993** *{published and unpublished data}*  
Lau CS, McMahon H, Morley KD, Belch JJJ. Effects of Maxepa on non-steroidal anti-inflammatory drug usage in patients with mild rheumatoid arthritis. *British Journal of Rheumatology* 1991;**30**:137.  
\* Lau CS, Morley KD, Belch JJ. Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis: a double-blind placebo controlled study. *British Journal of Rheumatology* 1993;**32**(11):982–9.
- Leaf 1995** *{published data only}*  
Leaf DA, Connor WE, Barstad L, Sexton G. Incorporation of dietary n-3 fatty acids into the fatty acids of human adipose tissue and plasma lipid classes. *American Journal of Clinical Nutrition* 1995;**62**(1):68–73.
- Lee 2010** *{published and unpublished data}*  
Lee TKM, Clandinin MT, Hébert M, MacDonald IM. Effect of docosahexaenoic acid supplementation on the macular function of patients with Best vitelliform macular dystrophy: randomized clinical trial. *Canadian Journal of Ophthalmology* 2010;**45**(5):514–9.
- Leng 1998** *{published data only}*  
\* Leng GC, Lee AJ, Fowkes FG, Jepson RG, Lowe GD, Skinner ER, et al. Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease. *Clinical Nutrition* 1998;**17**(6):265–71.  
Leng GC, Lee AJ, Fowkes FGR, Jepson RG, Horrobin D, Lowe GDO, et al. Randomised controlled trial of y-

linolenic and eicosapentaenoic acid in peripheral vascular disease. *Prostaglandins, Leukotrienes and Essential Fatty Acids* 1997;**57**(2):218.

**LipiDiDiet 2016 {published data only}**

Freund-Levi Y, Visser PJ, Kivipelto M, Wieggers RL, Hartmann T, Soininen H. The Lipididiet study: rationale and study design. *Alzheimer's & Dementia* 2012;**1**:602.  
\* Soininen H, Visser PJ, Kivipelto M, Van Hees A, Rouws C, Hartmann T. A clinical trial investigating the effects of Souvenaid in prodromal Alzheimer's disease: progress and baseline characteristics of the Lipididiet study. *Neurobiology of Aging* 2014;**35**:S20.  
Visser PJ, Soininen H, Kivipelto M, Freund-Levi Y, Kamphuis P, Wieggers RL, et al. A randomized controlled trial investigating the effects of Souvenaid in prodromal Alzheimer's disease: baseline characteristics of the LipiDiDiet study. *Alzheimer's & Dementia* 2013;**9**(4 Suppl): 669–70. DOI: dx.doi.org/10.1016/j.jalz.2013.05.1381

**Loeschke 1996 {published and unpublished data}**

Loeschke K, Ueberschaer B, Pietsch A, Gruber E, Ewe K, Wiebecke B, et al. N-3 fatty acids only delay early relapse of ulcerative colitis in remission. *Digestive Diseases and Sciences* 1996;**41**(10):2087–94.

**LUTEGA 2013 {published data only}**

Arnold C, Winter L, Frohlich K, Jentsch S, Dawczynski J, Jahreis G, et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. *JAMA Ophthalmology* 2013;**131**(5):564–72. PUBMED: 23519529]  
\* Dawczynski J, Jentsch S, Schweitzer D, Hammer M, Lang GE, Strobel J. Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. *Graefes Archive for Clinical and Experimental Ophthalmology* 2013;**251**(12):2711–23. PUBMED: 23695657]

**Lyon Diet Heart 1994 {published data only}**

\* De Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. [Erratum appears in Lancet 1995 Mar 18;345(8951): 738]. *Lancet* 1994;**343**(8911):1454–9. DOI: 10.1016/S0140-6736(94)92580-1  
De Lorgeril M, Salen P, Caillaud-Vallet E, Hanauer MT, Barthelemy JC, Mamelle N. Control of bias in dietary trial to prevent coronary recurrences: the Lyon Diet Heart Study. *European Journal of Clinical Nutrition* 1997;**51**(2):116–22.  
De Lorgeril M, Salen P, Martin JL, Mamelle N, Monjaud I, Touboul P, et al. Effect of a Mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutrients. *Journal of the American College of Cardiology* 1996;**28**(5):1103–8.  
De Lorgeril M, Salen P, Martin JL, Monjaud I, Boucher P, Mamelle N. Mediterranean dietary pattern in a randomized

trial: prolonged survival and possible reduced cancer rate. *Archives of Internal Medicine* 1998;**158**(11):1181–7.  
De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation* 1999;**99**(6):779–85.  
De Lorgeril M, Salen P, Spodick DH. Does a Mediterranean dietary pattern prolong survival?. *Cardiology Review* 1999; **16**(12):30–4.  
Renaud S, de Lorgeril M, Delaye J, Guidollet J, Jacquard F, Mamelle N, et al. Cretan Mediterranean diet for prevention of coronary heart disease. *American Journal of Clinical Nutrition* 1995;**61**(6 Suppl):1360S–7S.

**Maachi 1995 {published data only}**

Maachi K, Berthoux P, Burgard G, Alamartine E, Berthoux F. Results of a 1-year randomized controlled trial with omega-3 fatty acid fish oil in renal transplantation under triple immunosuppressive therapy. *Transplantation Proceedings* 1995;**27**(1):846–9.

**Macasai 2008 {published data only}**

Macasai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). *Transactions of the American Ophthalmological Society* 2008;**106**:336–56. PUBMED: 19277245]

**Mansel 1990 {published data only}**

Mansel RE, Harrison BJ, Melhuish J, Sheridan W, Pye JK, Pritchard G, et al. A randomized trial of dietary intervention with essential fatty acids in patients with categorized cysts. *Annals of the New York Academy of Sciences* 1990;**586**:288–94.

**Mantzaris 1996 {published data only}**

Mantzaris GJ, Archavlis E, Zografos C, Petraki K, Spiliades C, Triantafyllou G. A prospective, randomized, placebo-controlled study of fish oil in ulcerative colitis. *Hellenic Journal of Gastroenterology* 1996;**9**(2):138–41.

**Mate-Jimenez 1991 {published and unpublished data}**

Mate J, Castanos R, Garcia-Semaniego J, Pajares JM. Does dietary fish oil maintain the remission of Crohn's disease: a study case control. *Gastroenterology* 1991;**100**:A228.

**Matsuyama 2005 {published and unpublished data}**

Matsuyama W, Mitsuyama H, Watanabe M, Oonakahara K, Higashimoto I, Osame M, et al. Effects of omega-3 polyunsaturated fatty acids on inflammatory markers in COPD. *Chest* 2005;**128**(6):3817–27.

**Middleton 2002 {published data only}**

Middleton SJ, Naylor S, Woolner J, Hunter JO. A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. *Alimentary Pharmacology & Therapeutics* 2002;**16**(6):1131–5. PUBMED: 12030955]

**MoodFOOD 2016 {published data only}**

Roca M, Kohls E, Gili M, Watkins E, Owens M, Hegerl U, et al. Prevention of depression through nutritional strategies in high-risk persons: rationale and design of the

- MooDFOOD prevention trial. *BMC Psychiatry* 2016;**16**(1):192.
- NAYAB 2017** *{published data only}*  
Qurashi I, Chaudhry IB, Khoso AB, Farooque S, Lane S, Husain MO, et al. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol. *Trials* 2017;**18**(1):524.
- NCT01235533** *{unpublished data only}*  
NCT01235533. Fish oil supplementation in late-life depression. [clinicaltrials.gov/ct2/show/NCT01235533](http://clinicaltrials.gov/ct2/show/NCT01235533) (first received 5 November 2010).
- NU-AGE 2014** *{published data only}*  
Berendsen A, Santoro A, Pini E, Cevenini E, Ostan R, Pietruszka B, et al. Reprint of: a parallel randomized trial on the effect of a healthful diet on inflammation and its consequences in European elderly people: design of the NU-AGE dietary intervention study. *Mechanisms of Ageing and Development* 2014;**136**:14–21.  
\* Santoro A, Pini E, Scurti M, Palmas G, Berendsen A, Brzozowska A, et al. Combating inflammaging through a Mediterranean whole diet approach: the NU-AGE project's conceptual framework and design. *Mechanisms of Ageing and Development* 2014;**136-137**:3–13.
- NutriMEMO 2014** *{published data only}*  
Laake K, Myhre P, Nordby LM, Seljefflot I, Abdelnoor M, Smith P, et al. Effects of omega3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study. *BMC Geriatrics* 2014;**14**:74.
- OFAMS 2012** *{published data only}*  
Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, et al. Omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. *Archives of Neurology* 2012;**69**(8):1044–51. PUBMED: 22507886]
- Okuda 1996** *{published data only}*  
Okuda Y, Mizutani M, Ogawa M, Sone H, Asano M, Asakura Y, et al. Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus. *Journal of Diabetes and its Complications* 1996;**10**(5):280–7.
- OLIVE 1998** *{published data only}*  
Colquhoun DM, Hicks BJ, Somerset S. Rationale and design of the “OLIVE” study (comparison of an olive oil enriched to a low fat diet intervention study using vascular endpoints). *Atherosclerosis* 1997;**134**(1-2):326–27.  
\* Colquhoun DM, Somerset S, Glasziou PP, Richards D, Weyers J. Comparison of an olive oil enriched diet to a low fat diet intervention study using vascular endpoints: assessed by repeat quantitative angiography (OLIVE study). *Australian Journal of Nutrition and Dietetics* 1998;**55**(Suppl 4):S24–9.
- Oslo DIET HEART 1970** *{published data only}*  
\* Leren P. The Oslo diet-heart study. Eleven year report. *Circulation* 1970;**42**:935–42.  
Leren P. The effect of a cholesterol lowering diet in male survivors of myocardial infarction. (A controlled clinical trial). *Nordisk Medicin* 1967;**77**(21):658–61.  
Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. A controlled clinical trial. *Acta Medica Scandinavica* 1966;**466**(Suppl):1–92.  
Leren P. The effect of plasma-cholesterol-lowering diet in male survivors of myocardial infarction. A controlled clinical trial. *Bulletin of the New York Academy of Medicine* 1968;**44**:1012–20.
- Pogozheva 1997** *{published data only}*  
Pogozheva AV, Rozanova IA, Sorokovoi KV, Karagodina ZV, Levachev MM. Lipid peroxidation in patients with ischemic heart disease, hyperlipidemia and/or hypertension while polyunsaturated omega-3 fatty acids of plant and animal origin were in their diet. *Voprosy Pitaniia* 1997;**4**:32–5.
- Pogozheva 2000** *{published data only}*  
Pogozheva AV, Tutel'ian VA, Gapparova KM, Trushina EN, Miagkova MA. The effect of an antiatherosclerotic diet including omega-3 polyunsaturated fatty acids of marine and plant origins on the indices of cellular and humoral immunity in patients with ischemic heart disease and a disordered carbohydrate tolerance. *Voprosy Pitaniia* 2000;**69**(4):33–5.
- Puri 2008** *{published and unpublished data}*  
Moher D, Weeks L, Ocampo M, Seely D, Sampson M, Altman DG, et al. Describing reporting guidelines for health research: a systematic review. *Journal of Clinical Epidemiology* 2011;**64**(7):718–42. DOI: 10.1016/j.jclinepi.2010.09.013  
\* Puri BK, Bydder GM, Manku MS, Clarke A, Waldman AD, Beckmann CF. Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington's disease. *Journal of International Medical Research* 2008;**36**:896–905.
- Quazi 1994** *{published data only}*  
Quazi S, Mohiduzzaman M, Mostafizur RM, Keramat AS. Effect of hilsa (*Tenualosa ilisha*) fish in hypercholesterolemic subjects. *Bangladesh Medical Research Council Bulletin* 1994;**20**(1):1–7.
- Sacks 1994** *{published data only}*  
He J, Klag MJ, Appel LJ, Charleston J, Whelton PK. Seven-year incidence of hypertension in a cohort of middle-aged African Americans and whites. *Hypertension* 1998;**31**(5):1130–5.  
Meilahn EN, Kuller LH, Kiss JE, Sacks FM. Coagulation parameters among healthy adults taking fish oil versus placebo. *Arteriosclerosis* 1990;**10**:916A.  
\* Sacks FM, Hebert P, Appel LJ, Borhani NO, Applegate WB, Cohen JD, et al. Short report: the effect of fish oil on blood pressure and high-density lipoprotein-cholesterol



- levels in phase I of the Trials of Hypertension Prevention. *Journal of Hypertension* 1994;**12**(2):209–13.
- Sacks FM, Hebert P, Appel LJ, Borhani NO, Applegate WB, Cohen JD, et al. The effect of fish oil on blood pressure and high-density lipoprotein-cholesterol levels in phase I of the trials of hypertension prevention. *Journal of Hypertension. Supplement* 1994;**12**(7):S23–31.
- Satterfield S, Borhani NO, Whelton P, Goodwin L, Brinkmann C, Charleston J, et al. Recruitment for phase I of the Trials of Hypertension Prevention. *American Journal of Preventive Medicine* 1993;**9**(4):237–43.
- Trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, phase I. *JAMA* 1992;**267**(9):1213–20.
- Whelton PK, Kumanyika SK, Cook NR, Cutler JA, Borhani NO, Hennekens CH, et al. Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: results from phase I of the Trials of Hypertension Prevention. *American Journal of Clinical Nutrition* 1997;**65** (2 Suppl):652S–60S.
- Saynor 1988 {published data only}**  
Saynor R, Gillott T. Fish oil and plasma fibrinogen. *BMJ* 1988;**297**:1196.
- Saynor 1992 {published data only}**  
Saynor R, Gillott T. Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years. *Lipids* 1992;**27**(7):533–8.
- Selvais 1995 {published and unpublished data}**  
Selvais PL, Ketelslegers JM, Buysschaert M, Hermans MP. Plasma endothelin-1 immunoreactivity is increased following long-term dietary supplementation with omega-3 fatty acids in microalbuminuric IDDM patients. *Diabetologia* 1995;**38**:253.
- Shimizu 1995 {published and unpublished data}**  
Shimizu H, Ohtani K, Tanaka Y, Sato N, Mori M, Shimomura Y. Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients. *Diabetes Research and Clinical Practice* 1995;**28**(1):35–40.
- Singh 1992 {published data only}**  
Singh RB, Fedacko J, Vargova V, Pella D, Niaz MA, Ghosh S. Effect of low W-6/W-3 fatty acid ratio Paleolithic style diet in patients with acute coronary syndromes: a randomized, single blind, controlled trial. *World Heart Journal* 2012;**4**(1):71–84.  
\* Singh RB, Rastogi SS, Verma R, Laxmi B, Singh R, Ghosh S, et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. *BMJ* 1992;**304**:1015–9.
- Singh 1997a {published and unpublished data}**  
Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival 4. *Cardiovascular Drugs and Therapy* 1997;**11**(3):485–91.
- Singh 1997b {published and unpublished data}**  
Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival 4. *Cardiovascular Drugs and Therapy* 1997;**11**(3):485–91.
- Singh 2002 {published data only}**  
Pella D, Dubnov G, Singh RB, Sharma R, Berry EM, Manor O. Effects of an Indo-Mediterranean diet on the omega-6/omega-3 ratio in patients at high risk of coronary artery disease: the Indian paradox. *World Review of Nutrition and Dietetics* 2003;**92**:74–80.  
\* Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS, et al. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. *Lancet* 2002;**360**(9344):1455–61.
- Tariq 1989 {published data only}**  
Tariq T, Close C, Dodds R, Viberti GC, Lee T, Vergani D. The effect of fish-oil on the remission of type 1 (insulin-dependent) diabetes in newly diagnosed patients. *Diabetologia* 1989;**32**(10):765.
- Terano 1999 {published and unpublished data}**  
Terano T, Fujishiro S, Ban T, Yamamoto K, Tanaka T, Noguchi Y, et al. Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases. *Lipids* 1999;**34**:S345–6.
- Tomer 2001 {published data only}**  
Tomer A, Kasey S, Connor WE, Clark S, Harker LA, Eckman JR. Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids. *Thrombosis & Haemostasis* 2001;**85**(6):966–74.
- Torjesen 1997 {published data only}**  
Torjesen PA, Birkeland KI, Anderssen SA, Hjermann I, Holme I, Urdal P. Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study: a randomized trial. *Diabetes Care* 1997;**20** (1):26–31.
- VSDR 2015 {published data only}**  
Roig-Revert MJ, Lleo-Perez A, Zanon-Moreno V, Vivar-Llopis B, Marin-Montiel J, Dolz-Marco R, et al. Enhanced oxidative stress and other potential biomarkers for retinopathy in type 2 diabetes: beneficial effects of the nutraceutical supplements. *BioMed Research International* 2015;**2015**:408180. PUBMED: 26618168]
- Wheaton 2010 {published and unpublished data}**  
Wheaton DH, Hoffman DR, Locke KG, Watkins RB, Birch DG. Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa. *Archives of Ophthalmology* 2010;**121**(9):1269–78.

**Yasui 2001** *{published data only}*

Yasui T, Tanaka H, Fujita K, Iguchi M, Kohri K. Effects of eicosapentaenoic acid on urinary calcium excretion in calcium stone formers. *European Urology* 2001;**39**(5): 580–5.

**Zinger 1987** *{published data only}*

Zinger P, Berger I, Liuk K, Taube K, Naumann E. Changes in arterial pressure, serum lipids and thromboxane B2 after using a diet with various levels of eicosapentaenoic acid in patients with hypertension. *Klinicheskaia Meditsina* 1987; **65**(1):62–4.

**References to ongoing studies**

**AC Omega3 2014** *{published data only}*

ACTRN12614000732684. The Aboriginal cardiovascular omega-3 randomised controlled trial [The effect of omega-3 supplementation on adverse cardiovascular (CV) events among Indigenous Australians with stable coronary artery disease: A randomized controlled trial Query!]. [www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366337](http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366337) (first received 10 July 2014).

**AFORRD 2010** *{published and unpublished data}*

Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA, et al. Atorvastatin in factorial with omega-3 EE90 risk reduction in diabetes (AFORRD): a randomised controlled trial. *Diabetologia* 2009;**52**(1):50–9.

\* Neil HA, Ceglarek U, Thierry J, Paul S, Farmer A, Holman RR. Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial. *Atherosclerosis* 2010;**213**(2):512–7.

**ASCEND 2012** *{published data only}*

Bowman L, Aung T, Haynes R, Armitage J. ASCEND: design and baseline characteristics of a large randomised trial in diabetes. *Diabetes* 2012;**61**:A556–7.  
NCT00135226. ASCEND: A Study of Cardiovascular Events iN Diabetes [A Study of Cardiovascular Events iN Diabetes – A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes]. <https://clinicaltrials.gov/ct2/show/NCT00135226> (first received 25 August 2005).

**Bartold 2010** *{published data only}*

ACTRN12610000594022. Fish oil as adjunct therapy for periodontitis [Clinical efficacy of fish oil as adjunct therapy for patients with chronic periodontitis]. [www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335470](http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335470) (first received 23 July 2010).

**Beyond Aging Project 2015** *{published data only}*

ACTRN12610000032055. The Beyond Ageing Project: A selective prevention trial using novel pharmacotherapies in an older age cohort at risk for depression Query! [In older adults (60+ years) at risk for depression, can sertraline and/or omega-3 fatty acids compared with a placebo, reduce or prevent depressive symptoms, incidence of new

cases of depression and/or cognitive decline]. <https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=308413> (first received 22 October 2009).

Cockayne NL, Duffy SL, Bonomally R, English A, Amminger PG, Mackinnon A, et al. The Beyond Ageing Project Phase 2: a double-blind, selective prevention, randomised, placebo-controlled trial of omega-3 fatty acids and sertraline in an older age cohort at risk for depression: study protocol for a randomized controlled trial. *Trials* 2015;**16**:247.

**Chandrakala 2010** *{published data only (unpublished sought but not used)}*

\* Chandrakala G, Arpana G, Rao PV. Long-term effects of a reduced fat diet intervention in pre-diabetes. 70th Scientific Sessions of the American Diabetes Association; 25–29 June 2010; Orlando (FL). 2010; Vol. [professional.diabetes.org/meeting/scientific-sessions/70th-scientific-sessions-2010](http://professional.diabetes.org/meeting/scientific-sessions/70th-scientific-sessions-2010): 195–PO.

Chandrakala G, Arpana G, Sreenivas T, Rao PV. Low-fat (< 20%) diets prevent type 2 diabetes mellitus. *Diabetes* 2012; **61**:A190.

**ChiCTR-TRC-12002014** *{published data only}*

ChiCTR-TRC-12002014. Influence of different source of n-3 fatty acid on plasma lipid in moderately hypercholesterolemia subject and the valid dosage. [www.chictr.org.cn/hvshowproject.aspx?id=2374](http://www.chictr.org.cn/hvshowproject.aspx?id=2374) (first received 3 May 2015).

**DO HEALTH** *{published data only}*

Do-Health. DO-HEALTH trial web site. [do-health.eu/wordpress](http://do-health.eu/wordpress) (accessed prior to 10 May 2018).

\* NCT01745263. DO-HEALTH / Vitamin D3 - Omega3 - Home Exercise - Healthy Ageing and Longevity Trial (DO-HEALTH). <https://clinicaltrials.gov/ct2/show/NCT01745263> (first received 10 December 2012).

**DREAM 2014** *{published data only}*

NCT02128763. Dry eye assessment and management study (DREAM). [clinicaltrials.gov/ct2/show/NCT02128763](http://clinicaltrials.gov/ct2/show/NCT02128763) (first received 1 May 2014).

**ENRGISE 2016** *{published data only}*

NCT02676466. The ENRGISE pilot study (ENRGISE) [The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study]. [clinicaltrials.gov/ct2/show/NCT02676466](http://clinicaltrials.gov/ct2/show/NCT02676466) (first received 8 February 2016).

**InTrePad 2013** *{published data only}*

ACTRN12613000034730. Intervention of testosterone & fish oil as a possible strategy for the prevention of Alzheimer's disease. [www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363372](http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363372) (first received 14 January 2013).

**MAPT PLUS** *{published data only}*

NCT01513252. Long-term effects of interventional strategies to prevent cognitive decline in elderly (MAPT-PLUS). [clinicaltrials.gov/ct2/show/NCT01513252](http://clinicaltrials.gov/ct2/show/NCT01513252) (first received 20 January 2012).

**NCT00010868 {published data only}**

NCT00010868. Omega-3 fatty acids in bipolar disorder [Omega-3 Fatty Acids in Bipolar Disorder Prophylaxis]. [clinicaltrials.gov/ct2/show/NCT00010868](https://clinicaltrials.gov/ct2/show/NCT00010868) (first received 5 February 2001).

**NCT00309439 {published data only}**

NCT00309439. ALA and prostate cancer [Studies of Serum PSA to Help Resolve the Current Implication of Alpha-linolenic Acid (ALA) and Prostate Cancer]. [clinicaltrials.gov/ct2/show/NCT00309439](https://clinicaltrials.gov/ct2/show/NCT00309439) (first received 31 March 2006).

**NCT00410020 {published data only}**

NCT00410020. Arrhythmia prevention with an alpha-linolenic enriched diet [Secondary Prevention of Atrial Fibrillation With an Alpha-Linolenic Enriched Diet : a Randomized Study]. [clinicaltrials.gov/ct2/show/NCT00410020](https://clinicaltrials.gov/ct2/show/NCT00410020) (first received 12 December 2006).

**NCT01784042 {published data only}**

NCT01784042. Dietary energy restriction and omega-3 fatty acids on mammary tissue [Effect of Dietary Energy Restriction and Omega-3 Fatty Acids on Mammary Tissue and Systemic Biomarkers of Breast Cancer Risk]. [clinicaltrials.gov/ct2/show/NCT01784042](https://clinicaltrials.gov/ct2/show/NCT01784042) (first received 5 February 2013).

**NCT02211560 {published data only}**

NCT02211560. Investigating a phosphatidylserine based dietary approach for the management of mild cognitive impairment [A, Multi-center, Double-blind, Randomized, Placebo-controlled Study for the Efficacy of Phosphatidylserine in Mild Cognitive Impairment (MCI)]. [clinicaltrials.gov/ct2/show/NCT02211560](https://clinicaltrials.gov/ct2/show/NCT02211560) (first received 7 August 2014).

**NCT02295059 {published data only}**

NCT02295059. Omega 3 fatty acids and ERPR(-)HER2 (+/-) breast cancer prevention [Omega-3 Fatty Acids and ERPR(-) and HER-2/Neu(+/-) Breast Cancer Prevention]. [clinicaltrials.gov/ct2/show/NCT02295059](https://clinicaltrials.gov/ct2/show/NCT02295059) (first received 20 November 2014).

**NCT02719327 {published data only}**

NCT02719327. Brain amyloid and vascular effects of eicosapentaenoic acid (BRAVE-EPA) [Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults]. [clinicaltrials.gov/ct2/show/NCT02719327](https://clinicaltrials.gov/ct2/show/NCT02719327) (first received 25 March 2016).

**OMEMI 2014 {published data only}**

\* Laake K, Myhre P, Nordby LM, Seljeflot I, Abdelnoor M, Smith P, et al. Effects of omega 3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study. *BMC Geriatrics* 2014;**14**:74.  
Laake K, Seljeflot I, Schmidt EB, Myhre P, Tveit A, Arnesen H, et al. Serum fatty acids, traditional risk factors, and comorbidity as related to myocardial injury in an elderly population with acute myocardial infarction. *Journal of*

*Lipids* 2016;**2016**:4945720. [dx.doi.org/10.1155/2016/4945720](https://doi.org/10.1155/2016/4945720)

NCT01841944. Omega-3 Fatty Acids in Elderly Patients With Acute Myocardial Infarction (OMEMI) [Giving Omega-3 Fatty Acids to Elderly Patients Diagnosed With Acute Myocardial Infarction to Investigate the Effect on Cardiovascular Morbidity and Mortality]. <https://clinicaltrials.gov/ct2/show/NCT01841944> (first received 29 April 2013).

**REDUCE-IT 2011 {published data only}**

NCT01492361. A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE-IT). [clinicaltrials.gov/ct2/show/NCT01492361](https://clinicaltrials.gov/ct2/show/NCT01492361) (first received 15 December 2011).

**seAFOOD 2013 {published data only}**

Hull MA, Sandell AC, Montgomery AA, Logan RE, Clifford GM, Rees CJ, et al. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial. *Trials* 2013;**14**:237.

**Shinto 2015 {published data only}**

NCT01953705. n-3 PUFA for Vascular Cognitive Aging [Omega 3 PUFA for the Vascular Component of Age-related Cognitive Decline]. <https://clinicaltrials.gov/ct2/show/NCT01953705> (first received 1 October 2013).  
Shinto L, Silbert LC, Dodge HH, Quinn JF, Howieson D, Kaye J, et al. Omega 3 fatty acids for the prevention of vascular cognitive aging: methods and rationale for a phase II trial. *Alzheimer's & Dementia* 2015;**11**(7):610.

**STRENGTH 2015 {published data only}**

EudraCT 2014-001069-28. A long-term outcomes study to assess statin residual risk reduction with EpaNova in high cardiovascular risk patients with hypertriglyceridemia (STRENGTH). [www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001069-28](http://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001069-28) (first received 10 February 2015).

**SUPERIORSVG 2010 {published data only}**

NCT01047449. Improving the results of heart bypass surgery using new approaches to surgery and medication (SUPERIORSVG) [Surgical and Pharmacological Novel Interventions to Improve Overall Results of Saphenous Vein Graft Patency in Coronary Artery Bypass Grafting Surgery: An International Multi-Center Randomized Controlled Clinical Trial]. [clinicaltrials.gov/ct2/show/NCT01047449](https://clinicaltrials.gov/ct2/show/NCT01047449) (first received 13 January 2010).

**UMIN000012825 {published data only}**

UMIN000012825. Effect of polyunsaturated fatty acids on vascular healing process in hyper-cholesterolemic patients with acute coronary syndrome. [upload.umin.ac.jp/cgi-open-bin/ctr\\_e/ctr\\_view.cgi?recptno=R000014981](http://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014981) (first received 1 February 2015).

## VITAL 2018 {published data only}

Bassuk SS, Manson JE, Lee IM, Cook NR, Christen WG, Bubes VY, et al. Baseline characteristics of participants in the VITamin D and Omega-3 Trial (VITAL). *Contemporary Clinical Trials* 2016;**47**:235–43.

Gold DR, Litonjua AA, Carey VJ, Manson JE, Buring JE, Lee IM, et al. Lung VITAL: rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega-3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. *Contemporary Clinical Trials* 2016;**47**:185–95.

Gold DR, Luttmann-Gibson H, Litonjua AA, FriedenberG, Gordon D, Lee IM, et al. Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega-3 trial. *American Journal of Respiratory and Critical Care Medicine* 2014;**189**:D44 COPD.

Kang JH, Grodstein F, Manson JAE. Cognitive substudy of the vitamin d and omega-3 trial (vital-cog): design of a large randomized trial of omega-3 and vitamin d supplements in relation to cognitive change. *Alzheimer's & Dementia* 2015;**1**:608.

LeBoff MS, Yue AY, Copeland T, Cook NR, Buring JE, Manson JE. VITAL-Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega-3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and Omega-3 Trial (VITAL). *Contemporary Clinical Trials* 2015;**41**: 259–68.

Manson JAE. Vitamin D and cancer and cardiovascular disease: ready for prime time?. *Menopause* 2010;**17**(6): 1215.

Manson JE. Vitamin D and the heart: why we need large-scale clinical trials. *Cleveland Clinic Journal of Medicine* 2010;**77**(12):903–10.

Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, et al. The VITamin D and Omega-3 Trial (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. *Contemporary Clinical Trials* 2012;**33**(1):159–71.

\* NCT01169259. Vitamin D and Omega-3 Trial (VITAL) (VITAL). <https://clinicaltrials.gov/ct2/show/record/NCT01169259> (first received 26 July 2010).

Pradhan AD, Manson JE. Update on the Vitamin D and Omega-3 trial (VITAL). *Journal of Steroid Biochemistry & Molecular Biology* 2016;**155**(Pt B):252–6.

## Additional references

### Abdelhamid 2017

Abdelhamid A, Hooper L, Welch A. Polyunsaturated fatty acids for musculoskeletal health and functional status in older adults. *PROSPERO* 2017;[www.crd.york.ac.uk/prospERO/displayRecord.php?RecordID=79211](http://www.crd.york.ac.uk/prospERO/displayRecord.php?RecordID=79211): CRD42017079211.

### Abdelhamid 2018

Abdelhamid AS, Martin N, Bridges C, Brainard JS, Wang X, Brown TJ, et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database of Systematic Reviews* 2018, Issue 6. DOI: 10.1002/14651858.CD012345.pub2

### AHA 2016

American Heart Association. Fish and Omega-3 Fatty Acids. [www.heart.org/HEARTORG/HealthyLiving/HealthyEating/HealthyDietGoals/Fish-and-Omega-3-Fatty-Acids\\_UCM\\_303248\\_Article.jsp#.WhfuRzenzIU](http://www.heart.org/HEARTORG/HealthyLiving/HealthyEating/HealthyDietGoals/Fish-and-Omega-3-Fatty-Acids_UCM_303248_Article.jsp#.WhfuRzenzIU) (accessed 24 November 2017).

### Aung 2018

Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. *JAMA Cardiology* 2018;**3**(3):225–34. DOI: 10.1001/jamacardio.2017.5205

### Balk 2016

Balk EM, Adam GP, Langberg V, Halladay C, Chung M, Lin L, et al. Omega-3 fatty acids and cardiovascular disease: an updated systematic review. Rockville (MD): Agency for Healthcare Research and Quality; 2016. Evidence report/technology assessment no. 223. AHRQ Publication No. 16-E002-EF. [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm). DOI: 10.23970/AHRQEPERTA223

### Ballard-Barbash 1987

Ballard-Barbash R, Callaway CW. Marine fish oils: role in prevention of coronary artery disease. *Mayo Clinic Proceedings* 1987;**62**:113–8.

### Bang 1972

Bang HO, Dyerberg J. Plasma lipids and lipoproteins in Greenlandic west coast eskimos. *Acta Medica Scandinavica* 1972;**192**:85–94.

### Bang 1976

Bang HO, Dyerberg J, Hjorne N. The composition of food consumed by Greenland Eskimos. *Acta Medica Scandinavica* 1976;**200**:69–73.

### Berkley 1995

Berkley CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-analysis. *Statistics in Medicine* 1995;**14**:395–411.

### Bhatnagar 2003

Bhatnagar D, Durrington PN. Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications. *International Journal of Clinical Practice* 2003;**57**(4):305–14.

### BMJ 2005

BMJ editors. Expression of concern. *BMJ* 2005;**331**:266. DOI: 10.1136/bmj.331.7511.266

### BNF 1999

British Nutrition Foundation. N-3 fatty acids and health. London: British Nutrition Foundation; 1999. Briefing paper.

**Brown 2017**

Brown T, Song F, Wang X, Brainard J, Hooper L. Dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus. *PROSPERO* 2017;[www.crd.york.ac.uk/prospero/display?record.php?RecordID=641110](http://www.crd.york.ac.uk/prospero/display?record.php?RecordID=641110): CRD42017064110.

**Brunner 2009**

Brunner EJ, Jones PJ, Friel S, Bartley M. Fish, human health and marine ecosystem health: policies in collision. *International Journal of Epidemiology* 2009;**38**(1):93–100. DOI: 10.1093/ije/dyn157

**Burr 1993**

Burr ML. Fish and ischaemic heart disease. *World Review of Nutrition and Dietetics* 1993;**72**:49–60.

**Cade 2007**

Cade JE, Burley VJ, Greenwood DC, UK Women's Cohort Study Steering Group. The UK Women's Cohort Study: comparison of vegetarians, fish-eaters and meat-eaters. *Public Health Nutrition* 2007;**7**(7):871–8. DOI: 10.1079/PHN2004620

**Calabresi 2004**

Calabresi L, Villa B, Canavesi M, Sirtori CR, James RW, Bernini F, et al. An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. *Metabolism* 2004;**53**(2):153–8.

**Campbell 2013**

Campbell A, Price J, Hiatt WR. Omega-3 fatty acids for intermittent claudication. *Cochrane Database of Systematic Reviews* 2013, Issue 7. DOI: 10.1002/14651858.CD003833.pub4

**Chang 2013**

Chang CL, Deckelbaum RJ. Omega-3 fatty acids: mechanisms underlying “protective effects” in atherosclerosis. *Current Opinion in Lipidology* 2013;**24**(4):345–50. DOI: 10.1097/MOL.0b013e3283616364

**Chowdhury 2012**

Chowdhury R, Stevens S, Gorman D, Pan A, Warnakula S, Chowdhury S, et al. Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. *BMJ* 2012;**345**(7881):e6698.

**Delgado-Lista 2012**

Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. *British Journal of Nutrition* 2012;**107**(Suppl 2):S201–13.

**Egger 1997**

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. *BMJ* 1997;**315**:629–34.

**Engell 2013**

Engell RE, Sanman E, Lim SS, Mozaffarian D. Seafood omega-3 intake and risk of coronary heart disease death: an updated meta-analysis with implications for attributable

burden. *Lancet* 2013;**381**(Special Issue):S45. DOI: 10.1016/S0140-6736(13)61299-4

**Enns 2014**

Enns JE, Yeganeh A, Zarychanski R, Abou-Setta AM, Friesen C, Zahradka P, et al. The impact of omega-3 polyunsaturated fatty acid supplementation on the incidence of cardiovascular events and complications in peripheral arterial disease: a systematic review and meta-analysis. *BMC Cardiovascular Disorders* 2014;**14**:70.

**FSA 2000**

Food Standards Agency UK. Dioxins and PCBs in the UK diet: 1997 Total diet study samples. Food Surveillance Information Sheet. Number 4/00; 2000. [FSIS 4/00]

**Geelen 2004**

Geelen A, Brouwer IA, Zock PL, Katan MB. Antiarrhythmic effects of n-3 fatty acids: evidence from human studies. *Current Opinion in Lipidology* 2004;**15**:25–30.

**GRADE Working Group 2004**

GRADE Working Group. Grading quality of evidence and strength of recommendations. *British Medical Journal* 2004;**328**(7454):1490.

**GRADEpro GDT 2015 [Computer program]**

McMaster University (developed by Evidence Prime, Inc). GRADEpro GDT. Version accessed 30 Sept 2017. Hamilton (ON): McMaster University (developed by Evidence Prime, Inc), 2015.

**Hanson 2017a**

Hanson S, Biswas P, Jimoh OF, O'Brien A, Hooper L, Abdelhamid A, et al. Dietary polyunsaturated fat for prevention and treatment of depression and anxiety. *PROSPERO* 2017;[www.crd.york.ac.uk/prospero/display?record.php?RecordID=56092](http://www.crd.york.ac.uk/prospero/display?record.php?RecordID=56092): CRD42017056092.

**Hanson 2017b**

Hanson S, Thorpe G, Winstanley L, Abdelhamid A, Hooper L. Effects of supplementary dietary polyunsaturated fat on cancer incidence. *PROSPERO* 2017;[www.crd.york.ac.uk/prospero/display?record.php?RecordID=56109](http://www.crd.york.ac.uk/prospero/display?record.php?RecordID=56109): CRD42017056109.

**Hauck 1991**

Hauck WW, Gilliss CL, Donner A, Gortner S. Randomisation by cluster. *Nursing Research* 1991;**40**(6):356–8.

**He 2013**

He Z, Yang L, Tian J, Yang K, Wu J, Yao Y. Efficacy and safety of omega-3 fatty acids for the prevention of atrial fibrillation: a meta-analysis. *Canadian Journal of Cardiology* 2013;**29**(2):196–203.

**Higgins 2003**

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557–60.

**Higgins 2011**

Higgins JP, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP,

- Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [handbook.cochrane.org](http://handbook.cochrane.org).
- Hooper 2015**  
Hooper L, Martin N, Abdelhamid A, Davey Smith G. Reduction in saturated fat intake for cardiovascular disease. *Cochrane Database of Systematic Reviews* 2015, Issue 6. DOI: 10.1002/14651858.CD011737
- Hooper 2018**  
Hooper L, Al-Khudairy L, Abdelhamid AS, Rees K, Brainard JS, Brown TJ, et al. Omega-6 fats for the prevention and treatment of cardiovascular disease. *Cochrane Database of Systematic Reviews* 2018, Issue 6. DOI: 10.1002/14651858.CD011094.pub3
- Horton 2005**  
Horton R. Expression of concern: Indo-Mediterranean Diet Heart Study. *Lancet* 2005;**366**(9483):354–6. DOI: 10.1016/S0140-6736(05)67006-7
- JECFA 2001**  
Joint FAO/WHO Expert Committee on Food Additives. Summary of the fifty-seventh meeting of JECFA, 2001. [http://apps.who.int/iris/bitstream/handle/10665/42578/WHO\\_TRS\\_909.pdf?sequence=1](http://apps.who.int/iris/bitstream/handle/10665/42578/WHO_TRS_909.pdf?sequence=1).
- Jimoh 2017**  
Jimoh OF, Brainard J, Deane KA, Biswas P, Donaldson D, Hooper L. Dietary polyunsaturated fat for prevention and treatment of neurocognitive disorders. *PROSPERO* 2017;[www.crd.york.ac.uk/prospere/display-record.php?RecordID=19049](http://www.crd.york.ac.uk/prospere/display-record.php?RecordID=19049):CRD42017019049.
- Khoueiry 2013**  
Khoueiry G, Abi Rafeh N, Sullivan E, Saiful F, Jaffery Z, Kenigsberg DN, et al. Do omega-3 polyunsaturated fatty acids reduce risk of sudden cardiac death and ventricular arrhythmias? A meta-analysis of randomized trials. *Heart & Lung* 2013;**42**(4):251–6.
- Kotwal 2012**  
Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B. Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis. *Circulation. Cardiovascular Quality & Outcomes* 2012;**5**(6):808–18.
- Kris-Etherton 2002**  
Kris-Etherton PM, Harris WS, Appel LJ for the Nutrition Committee of the American Heart Association. Fish consumption, fish oil, omega 3 fatty acids, and cardiovascular disease. *Circulation* 2002;**106**:2747–57.
- Kwak 2012**  
Kwak SM, Myung SK, Lee YJ, Seo HG. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. *Archives of Internal Medicine* 2012;**172**(9):686–94.
- Larsson 2012**  
Larsson SC, Orsini N, Wolk A. Long-chain omega-3 polyunsaturated fatty acids and risk of stroke: a meta-analysis. *European Journal of Epidemiology* 2012;**27**(12):895–901.
- Lefebvre 2011**  
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [handbook.cochrane.org](http://handbook.cochrane.org).
- Li 1999**  
Li D, Sinclair A, Wilson A, Nakkote S, Kelly F, Abedin L, et al. Effect of dietary alpha-linolenic acid on thrombotic risk factors in vegetarian men. *American Journal of Clinical Nutrition* 1999;**69**:872–82.
- Liem 1997**  
Liem AKD, Theelen RMC. *Dioxins: Chemical Analysis, Exposure and Risk Assessment*. Utrecht: Universiteit Utrecht, 1997. [ISBN 90 393 2012 8]
- MAFF 1998A**  
MAFF UK. Concentrations of metals and other elements in marine fish and shellfish. Food Surveillance Information Sheet no.151; 1998. [FSIS 151]
- Mariani 2013**  
Mariani J, Doval HC, Nul D, Varini S, Grancelli H, Ferrante D, et al. N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials. *Journal of the American Heart Association* 2013;**2**(1):e005033.
- Nettleton 1991**  
Nettleton JA. Omega-3 fatty acids: comparison of plant and seafood sources in human nutrition. *Journal of the American Dietetic Association* 1991;**91**:331–7.
- NICE 2016**  
NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification Clinical guideline [CG181]. [www.nice.org.uk/guidance/cg181](http://www.nice.org.uk/guidance/cg181) July 2014, last updated September 2016.
- Papanikolaou 2014**  
Papanikolaou Y, Brooks J, Reider C, Fulgoni VL. U.S. adults are not meeting recommended levels for fish and omega-3 fatty acid intake: results of an analysis using observational data from NHANES 2003–2008. *Nutrition Journal* 2014;**13**:31. DOI: 10.1186/1475-2891-13-31
- Pawlosky 2001**  
Pawlosky RJ, Hibbeln JR, Novotny JA, Salem N Jr. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. *Journal of Lipid Research* 2001;**42**:1257–65.
- Rizos 2012**  
Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. *JAMA* 2012;**308**(10):1024–33.
- Savovic 2012**  
Savovic J, Jones H, Altman D, Harris R, Jüni P, Pildal J, et al. Influence of reported study design characteristics on

- intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. *Health Technology Assessment* 2012;**16**:1–82.
- Scandinavian Simvastatin Survival Study Group 1994**  
Scandinavian Simvastatin Survival Study Group.  
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994;**344**(8934):1383–9.
- Schulz 1995**  
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;**273**:408–12.
- Sethi 2016**  
Sethi A, Bajaj A, Khosla S, Arora RR. Statin use mitigate the benefit of omega-3 fatty acids supplementation: a meta-regression of randomized trials. *American Journal of Therapeutics* 2016;**23**(3):e737–48.
- Sharp 1998**  
Sharp S. Meta-analysis regression. *Stata Technical Bulletin* 1998;**42**:16–22.
- Simopoulos 1992**  
Simopoulos AP, Norman HA, Gillaspie JE, Duke JA. Common purslane: a source of omega-3 fatty acids and antioxidants. *Journal of the American College of Nutrition* 1992;**11**(4):374–82.
- Stark 2016**  
Stark KD, Van Elswyk ME, Higgins R, Weatherford CA, Salem N Jr. Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults. *Progress in Lipid Research* 2016;**63**:132–52. DOI: 10.1016/j.plipres.2016.05.001
- Thorpe 2017**  
Thorpe G, Ajabnoor S, Ahmed Z, Abdelhamid A, Hooper L. Dietary polyunsaturated fat for prevention and treatment of inflammatory bowel disease. *PROSPERO* 2017;[www.crd.york.ac.uk/prospere/display-record.php?RecordID=68704](http://www.crd.york.ac.uk/prospere/display-record.php?RecordID=68704):CRD42017068704.
- Trikalinos 2012**  
Trikalinos TA, Moorthy D, Chung M, Yu WW, Lee J, Lichtenstein AH, et al. Concordance of randomized and nonrandomized studies was unrelated to translational patterns of two nutrient-disease associations. *Journal of Clinical Epidemiology* 2012;**65**(1):16–29.
- USFDA 1995**  
US Food, Drug Administration. What You Need to Know About Mercury in Fish and Shellfish. [www.fda.gov/food/foodborneillnesscontaminants/metals/ucm351781.htm](http://www.fda.gov/food/foodborneillnesscontaminants/metals/ucm351781.htm) (accessed May 2018).
- USFDA 2000**  
U. S. Food, Drug Administration. Center for Food Safety and Applied Nutrition, Office of Nutritional Products. Labeling, and Dietary Supplements: Letter Regarding Dietary Supplement Health Claim for Omega-3 Fatty Acids and Coronary Heart Disease (Docket No. 91N-0103). [www.fda.gov/Food/LabelingNutrition/ucm073992.htm#cardio](http://www.fda.gov/Food/LabelingNutrition/ucm073992.htm#cardio) 2004.
- White 2005**  
White C. Suspected research fraud: difficulties of getting at the truth. *BMJ* 2005;**331**(7511):281–8. DOI: 10.1136/bmj.331.7511.281
- WHO 2017**  
World Health Organization. Cardiovascular Diseases (CVDs).. Fact sheets; May 2017. [www.who.int/mediacentre/factsheets/fs317/en](http://www.who.int/mediacentre/factsheets/fs317/en) (accessed 24 November 2017).
- Wood 2008**  
Wood L, Egger M, Gluud LL, Schulz K, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ* 2008;**336**:601–5.
- World Bank 2018**  
World Bank. World Bank Country and Lending Groups - country classification. [datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups](http://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups) (accessed 3 April 2018).
- Zhao 2009**  
Zhao YT, Chen Q, Sun YX, Li XB, Zhang P, Xu Y, et al. Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials. *Annals of Medicine* 2009;**41**(4):301–10.
- Zheng 2014**  
Zheng T, Zhao J, Wang Y, Liu W, Wang Z, Shang Y, et al. The limited effect of omega-3 polyunsaturated fatty acids on cardiovascular risk in patients with impaired glucose metabolism: a meta-analysis. *Clinical Biochemistry* 2014;**47**(6):369–77.

## References to other published versions of this review

- Hooper 2004**  
Hooper L, Harrison RA, Summerbell CD, Moore H, Worthington HV, Ness A, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. *Cochrane Database of Systematic Reviews* 2004, Issue 4. DOI: 10.1002/14651858.CD003177.pub2
- Hooper 2006**  
Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. *BMJ* 2006;**332**:752. DOI: 10.1136/bmj.38755.366331.2F

\* Indicates the major publication for the study

## CHARACTERISTICS OF STUDIES

### Characteristics of included studies *[ordered by study ID]*

#### ADCS 2010

Methods	Alzheimer's Disease Cooperative Study (ADCS) RCT, parallel, (n-3 DHA vs n-6 LA), 18 months Summary risk of bias: low
Participants	Individuals with mild to moderate Alzheimer's disease N: 238 intervention, 164 control Level of risk for CVD: low Men: 52.9% intervention, 40.2% control Mean age in years (SD): 76 (9.3) intervention, 76 (7.8) control Age range: unclear Smokers: 24.4% intervention, 21.9% control Hypertension: not reported Medications taken by at least 50% of those in the control group: cholinesterase inhibitor, memantine Medications taken by 20%-49% of those in the control group: none Medications taken by some, but less than 20% of the control group: none Location: USA Ethnicity: not reported
Interventions	Type: supplement (capsule) Comparison: DHA vs omega 6 Intervention: 2 × 1 g algal-derived DHA capsules (Neuromins) per day for a total daily dose of 2 g, each capsule contain 45% to 55% of DHA and does not contain EPA (950 mg soft-gel capsules which contain approximately 510 mg DHA). Dose: +DHA 1.02 g/d Control: 2 × 1 g placebo capsules per day (made up of corn or soy oil) Compliance: measured by pill counts at every visit Length of intervention: 18 months
Outcomes	Main study outcome: change in the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) and change in the Clinical Dementia Rating (CDR) Dropouts: 67 intervention, 40 control (discontinued treatment but included in main analyses) Available outcomes: mortality, measures of cognition, baseline & change in plasma DHA, adverse events Response to contact: no data provided
Notes	Study funding; quote: "grant U01-AG10483 from the National Institute on Aging. The National Institute on Aging was not otherwise involved in the design and conduct of the study, or in the analysis of data or preparation of the manuscript". "The placebo and DHA study drugs were provided by Martek Biosciences. Martek also provided plasma and cerebrospinal fluid measurements of fatty acids, as well as partial financial support for the magnetic resonance imaging sub study. (Martek Biosciences produces nutritional supplements from cultivated fungi and microalgae). Martek employees participated in



	design of the study and in revision of the manuscript, but were not involved in data management or data analysis.” (Quinn 2010, p. 1910)	
<i>Risk of bias</i>		
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was achieved with a centralised interactive voice response system, using a block design with a block size of 5 (3 in the DHA group and 2 in the placebo group)
Allocation concealment (selection bias)	Low risk	Randomisation was achieved with a centralised interactive voice response system, using a block design with a block size of 5 (3 in the DHA group and 2 in the placebo group)
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo capsules (made up of corn or soy oil) were identical in appearance. The adequacy of blinding was assessed by questionnaires completed by caregivers, study coordinators, and site physicians
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The adequacy of blinding was assessed by questionnaires completed by caregivers, study coordinators, and site physicians with results showing no difference between groups and the majority did not know
Incomplete outcome data (attrition bias) All outcomes	Low risk	Intention-to-treat analysis. At 12 months data were available for > 80% (ITT analysis)
Selective reporting (reporting bias)	Low risk	Prospectively registered February 2007, study started February 2007, completed May 2009. Primary outcomes were rate of change in ADAS-Cog11 and CDR-SOB, which are both reported in main report. NPI and ADL were secondary outcomes also reported
Attention	Low risk	Both study arms had the same follow-up and care.
Compliance	Unclear risk	Measured by pill count at every visit. 28% intervention and 24% control discontinued supplement with a minority discontin-

## ADCS 2010 (Continued)

		uing due to adverse events. A further 8% were excluded for < 80% compliance in both intervention and control arms
Other bias	Low risk	None noted

## AFFORD 2013

Methods	Multi-center study to evaluate the effect of n-3 fatty acids on arrhythmia recurrence in atrial fibrillation (AFFORD) RCT, parallel, (n-3 EPA + DHA vs n-6), 12 months Summary risk of bias: moderate or high
Participants	People with symptomatic paroxysmal or persistent AF N: 165 intervention, 172 control. (analysed, intervention: 153 control: 163) Level of risk for CVD: high Men: 69% intervention, 65% control Mean age in years (SD): 60 (12) intervention, 62 (13) control Age range: not reported Smokers: not reported Hypertension: 45% intervention, 42% control Medications taken by at least 50% of those in the control group: oral anticoagulant Medications taken by 20%-49%: beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers Medications taken by some, but < 20%: none Location: Canada Ethnicity: not reported
Interventions	Type: supplement (fish oil) Comparison: EPA + DHA vs omega 6 safflower oil Intervention: 4 × 1 g enteric-coated fish oil capsules/d (1.6 g/d EPA + 0.8 g/d DHA, Genuine Health, Toronto, Ontario, Canada). Dose: +2.4 g/d EPA + DHA, Control: 4 × 1 g matching placebo capsules, 4 g/d safflower oil Compliance: omega-3 index increased in intervention group, but not control, over the study Duration of intervention: 6 to 16 months
Outcomes	Main study outcome: AF recurrence Dropouts: 21 intervention, 19 control Available outcomes: all-cause mortality, stroke, AF recurrence, TIA, CV events, CRP (not usable) Response to contact: no
Notes	Authors contacted about QoL, resource use and dietary habits Study funding: Canadian Institutes for Health Research and the Heart and Stroke Foundation of Quebec
<i>Risk of bias</i>	

**AFFORD 2013** (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"[R]andomised"
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Described as double-blind, but blinding not described or tested
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	An independent events committee adjudicated AF recurrences, bleeding, strokes, transient ischemic attacks, and deaths, but unclear if blinded to allocation
Incomplete outcome data (attrition bias) All outcomes	Low risk	Participant flow well described. ITT analysis
Selective reporting (reporting bias)	High risk	NCT01235130 registered July 2010, recruitment March 2009-March 2012, follow-up finished December 2012. Results published 2014, but no data on quality of life, resource utilisation, or dietary habits (stated in registry) found
Attention	Low risk	No problem with attention bias
Compliance	Low risk	Omega-3 index measured
Other bias	Low risk	None noted

**Ahn 2016**

Methods	RCT, parallel, (EPA + DHA + statins vs statins), 12 months Summary risk of bias: moderate to high
Participants	Statin treated CAD patients undergoing PCI N: 38 intervention, 36 control Level of risk for CVD: high Men: 63.2% intervention, 72.2% control Mean age in years (SD): 59.6 (9.1) intervention, 60.7 (0.8) [sic] control Age range: unclear Smokers: 36.8% intervention, 58.3% control Hypertension: 50% in both groups Medications taken by at least 50% of those in the control group: aspirin, clopidogrel, ACE inhibitors/ARB, beta-blockers, atorvastatin Medications taken by 20%-49% of those in the control group: cilostazol

	Medications taken by some, but less than 20% of the control group: rosuvastatin, nitrates, calcium antagonists Location: South Korea Ethnicity: not reported
Interventions	Type: supplement (capsule) Comparison: EPA + DHA vs unclear (nil) Intervention: 3 g of $\omega$ -3 PUFA containing 1395 mg of EPA and 1125 mg of DHA per day. No further details. Dose: +2.52 g/d EPA + DHA Control: unclear whether control group were given placebo or only statins Compliance: unclear how it was measured but reported good compliance with no numbers Length of intervention: 12 months
Outcomes	Main study outcome: change in atherosclerotic burden Dropouts: none Available outcomes: lipids (TG reported as median, IQR so not used), atheroma volume, neointimal volume index Response to contact: no
Notes	Study funding: the study was supported by clinical research grant from Pusan National University Hospital

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Simple randomisation was carried out using random number tables to assign each participant to the intervention or control group
Allocation concealment (selection bias)	Low risk	Participants were assigned randomisation numbers sequentially on recruitment to the study, and the randomisation codes were retained by the clinical research coordinator
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The personnel responsible for randomisation as well as those performing laboratory measurements were blinded to the randomisation assignments
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts reported

Selective reporting (reporting bias)	Unclear risk	No protocol or trial register entry found
Attention	Unclear risk	No details
Compliance	Unclear risk	No details on how it was measured and no fatty acid levels reported
Other bias	High risk	It's unclear whether the study was placebo controlled or the control group had no intervention. Also, some of the SDs appear to be incorrectly reported

## AlphaOmega - ALA 2010

Methods	RCT, (n-3 ALA vs MUFA), 40 months Summary risk of bias: low
Participants	60-80 year-olds with previous MI N: 1197 ALA intervention, 1236 control (1212 ALA + EPA/DHA intervention group) Level of risk for CVD: high Men: 77.9% intervention, 78.7% control Mean age in years (SD): 69.0 (5.6) intervention, 68.9 (5.6) control Age range: 60-80 years Smokers: 17.4% intervention, 18% control Hypertension: unclear Medications taken by at least 50% of those in the control group: lipid lowering medication, antihypertensives, antithrombotics Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: antiarrhythmic drugs, antidiabetic drugs Location: the Netherlands Ethnicity: not reported
Interventions	Type: supplementary margarine Comparison: ALA vs MUFA Intervention 20 g of enriched margarine per day incorporating: 2 g ALA. 8 × 250 g margarine tubs delivered every 12 weeks. Dose: average achieved +1.9 g/d ALA Control: 20 g of margarine per day. No additional n-3 PUFAs. Identical margarine (oleic acid) placebo Compliance: unused margarine tubs were returned- daily intakes of margarine and n-3 fatty acids were calculated on the basis of the amount unused. Adherence was measured by levels of fatty acids in plasma cholesteryl esters, margarine and questionnaires. 90.5% of patients adhered to the protocol and consumed 20.6 (SD 2.8) g of margarine/d Length of intervention: 40 months
Outcomes	Main study outcome: cardiovascular disease events Dropouts: 91 died, 98 discontinued intervention, 93 died, 93 discontinued control Available outcomes: deaths, MI, cardiovascular events, ventricular arrhythmia, Incident

	cardiovascular disease Response to contact: yes (data provided)	
Notes	The study has 3 intervention arms (ALA margarine, EPA/DHA margarine, mixture of the two interventions). This table represents the ALA only intervention. Outcome data is used for the ALA group where reported separately or for the combined (ALA arm, ALA + EPA/DHA arm) Study funding: Netherlands Heart Foundation, National Institutes of Health and Unilever R&D (latter provided unrestricted grant for distribution of trial margarines)	
<i><b>Risk of bias</b></i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	On the computer by a random number generator before the start of the trial
Allocation concealment (selection bias)	Low risk	Author confirmed allocation was concealed from clinicians/ researchers
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The 4 types of margarine were “similar in taste, texture and colour”. A trained test panel did not perceive a fishy taste or odour. Randomisation tables were stored safely under supervision
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Randomisation tables were stored safely under supervision. There was an independent statistician for data analysis. Quote: “Events were coded by three members of the end-point adjudication committee who were unaware of the identity of the patient, the identity of the treating physician and the patients assigned study group”
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients were followed up for events computerised linkage with municipal registries. 2531 patients were only followed up for baseline anthropometric and medical measurements
Selective reporting (reporting bias)	High risk	Sudden cardiac death endpoint omitted. Registered in August 2005, recruitment was from 2002 to 2006. Outcomes papers published in 2010
Attention	Low risk	All participants appear to have had similar frequency and quantity of attention and follow-up

## AlphaOmega - ALA 2010 (Continued)

Compliance	Low risk	Unused margarine tubs were returned; daily intakes of margarine and n-3 fatty acids were calculated on the basis of the amount unused. Adherence was measured by levels of fatty acids in plasma cholesteryl esters, margarine and questionnaires. 90.5% of patients adhered to the protocol and consumed 20.6 (SD 2.8) g of margarine/d
Other bias	Low risk	None noted

## AlphaOmega - EPA+DHA 2010

Methods	RCT, (EPA + DHA vs MUFA), 40 months Summary risk of bias: low
Participants	60-80 year-olds with previous MI N: 1192 EPA/DHA intervention, 1236 control (1212 ALA + EPA/DHA intervention group) Level of risk for CVD: high Men: 78.1% intervention, 78.7% control Mean age in years (SD): 69.1 (5.6) intervention, 68.9 (5.6) control Age range: 60-80 years Smokers: 16.8%, intervention, 18% control Hypertension: unclear Medications taken by at least 50% of those in the control group: lipid-lowering medication, antihypertensives, antithrombotics Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: antiarrhythmic drugs, antidiabetic drugs Location: the Netherlands Ethnicity: not reported
Interventions	Type: supplementary margarine Comparison 1: EPA + DHA vs MUFA Intervention: 20 g of enriched margarine per day incorporating 400 mg EPA-DHA (240 mg EPA and 160 mg DHA). Dose: average achieved 376 mg/d EPA + DHA Control: 20 g of margarine per day. No additional n-3 PUFAs. Identical margarine (oleic acid) placebo Compliance: unused margarine tubs were returned; daily intakes of margarine and n-3 fatty acids were calculated on the basis of the amount unused. Adherence was measured by levels of fatty acids in plasma cholesteryl esters, margarine and questionnaires. 90.5% of patients adhered to the protocol Length of intervention: 40 months
Outcomes	Main study outcome: cardiovascular disease events Dropouts: 95 died, 119 discontinued intervention, 93 died, 93 discontinued control Available outcomes: deaths, MI, cardiovascular events, ventricular arrhythmia, incident

	cardiovascular disease Response to contact: yes (data provided)	
Notes	The study has three intervention arms (ALA margarine, EPA/DHA margarine, mixture of the two interventions). This table represents the EPA/DHA only intervention. Outcome data is used for the EPA/DHA group where available or for the combined (EPA/DHA arm, EPA/DHA + ALA arm) Study funding: Netherlands Heart Foundation, National Institutes of Health and Unilever R&D (latter provided unrestricted grant for distribution of trial margarines)	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	On the computer by a random number generator before the start of the trial
Allocation concealment (selection bias)	Low risk	Author confirmed allocation was concealed from clinicians/ researchers
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The 4 types of margarine were “similar in taste, texture and colour”. A trained test panel did not perceive a fishy taste or odour. Randomisation tables were stored safely under supervision
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Randomisation tables were stored safely under supervision. There was an independent statistician for data analysis. Quote: “Events were coded by three members of the end-point adjudication committee who were unaware of the identity of the patient, the identity of the treating physician and the patients assigned study group”
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients were followed up for events computerised linkage with municipal registries. 2531 patients were only followed up for baseline anthropometric and medical measurements
Selective reporting (reporting bias)	High risk	Sudden cardiac death endpoint omitted. Registered from August 2005, recruitment was from 2002 to 2006. Outcomes papers published in 2010
Attention	Low risk	All participants appear to have had similar frequency and quantity of attention and follow-up



Compliance	Low risk	Unused margarine tubs were returned; daily intakes of margarine and n-3 fatty acids were calculated on the basis of the amount unused. Adherence was measured by levels of fatty acids in plasma cholesteryl esters, margarine and questionnaires. 90.5% of patients adhered to the protocol and consumed 20.6 (SD 2.8) g of margarine/d
Other bias	Low risk	None noted

## AREDS2 2014

Methods	Age-Related Eye Disease Study 2 (AREDS2) RCT, parallel, 2 × 2 factorial (n-3 EPA + DHA vs nil) also randomised to lutein and zeaxanthin vs nil), 5 years Summary risk of bias: low
Participants	People aged 50-85 years at high risk of progression to advanced age-related macular degeneration (AMD) N: 2147 intervention (1068 DHA/EPA, 1079 DHA/EPA + lutein/zeaxanthin), 2056 control (1012 placebo, 1044 lutein/zeaxanthin) Level of risk for CVD: low (however ~20% had previous CV event) Men: intervention 42.1%, control 44.4% Age in years: intervention median 74.6 (IQR 11.1), control median 74 (IQR 11.1) Age range: 68-79 years Smokers: intervention 6.3%, control 7.2% Hypertension: unclear Medications taken by at least 50% of those in the control group: multivitamins Medications taken by 20%-49% of those in the control group: cholesterol lowering drugs, aspirin Medications taken by some, but less than 20% of the control group: NSAID, paracetamol Location: USA Ethnicity: white 96.5% intervention, 96.6% control; Hispanic: 2.6 intervention, 1.3 control
Interventions	Type: supplement (capsule) Comparison: EPA + DHA vs nil Intervention 350 mg/d DHA plus 650 mg/d EPA added to the standard AREDS supplement of Vitamin C (500 mg/d), Vitamin E (440 IU/d), beta-carotene (15 mg/d), zinc oxide (80 mg/d) and cupric oxide (2 mg/d). Dose: +1 g/d EPA + DHA Control: standard AREDS supplement of Vitamin C (500 mg/d), Vitamin E (400IU/d), beta-carotene (15 mg/d), zinc oxide (80 mg/d) and cupric oxide (2 mg/d). Compliance: assessed by pill count - 84% of participants in each group took at least 75% of study medications Length of intervention: 60 months

Outcomes	Main study outcome: development of advanced AMD Dropouts: intervention 200 died, 165 discontinued, 80 were lost to follow-up; control 168 died, 140 discontinued, 61 were lost to follow-up Available outcomes: deaths, cardiovascular death, MI, stroke, angina, heart failure, revascularisation, cognition, eye health, (authors provided data on diabetes diagnosis, depression diagnosis, breast cancer) Response to contact: yes (data provided)	
Notes	Study funding: National Eye Institute/National Institutes of Health, Department of Health and Human Services	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: “random block design was implemented using the AREDS2 Advantage Electronic Data Capture system by the AREDS2 Coordinating Center”
Allocation concealment (selection bias)	Low risk	Each treatment was assigned 5 bottle numbers. Bottle numbers were issued via an electronic randomisation system for each participant once study eligibility was verified. The assigned bottle number was used to distribute the study treatment(s) . AREDS2 Coordinating centre personnel involved in creating the randomisation system had access to the bottle number/treatment assignments
Blinding of participants and personnel (performance bias) All outcomes	Low risk	“Participants, investigators, study coordinators, and all other study personnel are masked to treatment assignment”. However, no information was given regarding the taste, smell, or appearance of the active or placebo capsules
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The coordinating centre randomly assigned the event to a study adjudicator, who made the final determination of these study endpoints through review of the medical records and applying the endpoint criterion defined a priori. All adjudicators were masked to study assignment
Incomplete outcome data (attrition bias) All outcomes	Low risk	< 20% attrition over 5 years, balanced reasons for dropouts

**AREDS2 2014** (Continued)

Selective reporting (reporting bias)	Low risk	Outcomes in trials registry entry appear to all be reported (NCT00345176). Entry received June 2006, recruitment September 2006 - October 2012
Attention	Low risk	Participants, investigators, study coordinators, and all other study personnel are masked to treatment assignment, so attention bias not feasible
Compliance	Unclear risk	Assessed by pill count - 84% of participants in each group took at least 75% of study medications
Other bias	Low risk	None noted

**Baldassarre 2006**

Methods	RCT, (n-3 EPA + DHA vs MUFA), 24 months Summary risk of bias: moderate or high
Participants	45-70 year olds with combined hyperlipoproteinaemia N: 32 intervention, 32 control Level of risk for CVD: moderate Men: 29% intervention, 29% control Mean age in years (SD): 53.7 (7.2) intervention, 53.7 (6.9) control Age range: 45-70 years (inclusion) Smokers: 28.1% intervention, 28.1% control Hypertension: none (exclusion criteria) Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported (patients on HRT, anti-hypertensive drugs, lipid lowering drugs, or who smoked > 10 cigarettes were excluded) Location: Italy Ethnicity: not reported
Interventions	Type: capsules Comparison: LCn3 vs MUFA Intervention: 1 g × 6 soft gelatin capsules/d of fatty acid mixture (19% EPA), 13% DHA, 19% palmitic acid, 18% oleic acid, 2% LA and 29% other minor components) providing 1.08 g/d EPA, 0.72 g/d DHA, 0.01 g/d tocopherol acetate, divided to three doses. Dose: 1.8 g/d EPA + DHA Control: 1 g × 6 opaque identical soft gelatin capsules/d of olive oil divided in 3 doses Compliance: assessed by counting returned capsules at each visit and by measuring EPA and DHA levels at month 24 Length of intervention: 24 months

Outcomes	Main study outcome: carotid atherosclerosis measures Dropouts: 2 intervention, 5 control Available outcomes: deaths (nil), MI (lipids, weight, BP and heart rate reported but not in a usable format; lipid data were presented at various times without clear numerical data, suggesting falls in TGs in the intervention but not control arms, and rises in LDL and HDL cholesterol in intervention but not control arms. For the other outcomes the text states “a rise in body weight (+ 3%, P < 0.01) was observed at the end of the study in both groups. Blood pressure and heart rate were unchanged”. Effects on IMT and platelets also reported but not used) Response to contact: not yet attempted	
Notes	Study funding: supported by Institut De Recherche Pierre Fabre, Departement Recherche Clinique	
<i><b>Risk of bias</b></i>		
<b>Bias</b>	<b>Authors’ judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	An appropriate software was used to obtain 2 groups balanced for sex, age and smoking
Allocation concealment (selection bias)	Unclear risk	No further details
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double-blind and placebo capsules were opaque and identical looking to intervention. However no information provided on capsules taste or smell
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details
Incomplete outcome data (attrition bias) All outcomes	Low risk	All dropouts are accounted for. “One patient left the study after 3 months because he moved to another city and was therefore excluded from statistical analyses. Two patients were excluded because of major deviation from the protocol during the follow-up (anti-hypertensive assumption) and four because of non-compliance on the basis of returning capsules (compliance < 70%). The final analysed group included 57 patients (30 on active treatment).”
Selective reporting (reporting bias)	Unclear risk	No protocol or trial register record
Attention	Low risk	Both groups had the same contact and number of visits.

Compliance	Low risk	Pill count, we know they excluded 4/64 who returned > 70% of capsules. So 60/64 had > 70% compliance with significant increase in serum EPA and DHA in the intervention group
Other bias	Low risk	None noted

**Bates 1989**

Methods	RCT, parallel, (n-3 EPA + DHA vs MUFA), 24 months Summary risk of bias: moderate or high
Participants	People with multiple sclerosis N: 155 intervention, 157 control. (analysed, intervention: 145 control: 147) Level of risk for CVD: low Men: 34.2% intervention, 30.6% control Mean age in years (SD): 34.0 (6.6) intervention, 33.7 (6.3) control Age range: not reported but 16-45 years inclusion criteria Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49%: not reported Medications taken by some, but < 20%: not reported Location: UK Ethnicity: not reported
Interventions	Type: supplement (fish oil capsule) Comparison: EPA + DHA vs MUFA Intervention: 20 × 0.5 g/d capsules MaxEPA fish body oil (10 g/d fish oil providing 1.71 g/d EPA +1.14 g/d DHA +10 IU/d vitamin E), plus all advised to reduce animal fat and ensure plentiful omega-6 fats. Dose: +2.85 g/d EPA + DHA Control: 20 × 0.5 g/d capsules olive oil (10 g/d olive oil), plus all advised to reduce animal fat and ensure plentiful omega-6 fats. All capsules contained 0.5 IU vit E and 100 ppm dodecyl gallate to minimise peroxide formation Compliance: serum EPA and DHA rose in intervention group but fell in controls Duration of intervention: 24 months (5 years mentioned but outcomes not reported)
Outcomes	Main study outcome: multiple sclerosis progress Dropouts: 10 intervention, 10 control Available outcomes: all-cause mortality, progress of MS, rate of MS relapse Response to contact: yes (no data provided)
Notes	Study funding: Multiple Sclerosis Society of Great Britain and Northern Ireland, but Marfleet Refining provided fish oil and placebo capsules

***Risk of bias***

**Bates 1989** (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomised"
Allocation concealment (selection bias)	Unclear risk	No further details
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Paper states research was "double blind" and control capsules "had the same appearance and flavour as the fish oil capsules and were packed and dispensed in identical fashion"
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low risk at reported time points
Selective reporting (reporting bias)	High risk	No protocol or trials registration entries found. Study was intended to run for 5 years, but outcomes only appear to be reported for the first 2 years
Attention	Low risk	Unlikely as each had capsules
Compliance	Low risk	Serum EPA and DHA rose in intervention group but fell in controls
Other bias	Low risk	Not noted

**Berson 2004**

Methods	RCT, parallel, (n-3 DHA vs n-6 LA), 48 months Summary risk of bias: low
Participants	People with retinitis pigmentosa aged 18-55 years N: 221 randomised overall, analysed 105 intervention, 103 control Level of risk for CVD: low Men: 48% intervention, 54% control Mean age in years (SD): 37.8 (6.5) intervention, 36.0 (7.2) control Age range: unclear (18-55 inclusion criterion) Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: vitamin A Medications taken by 20%-49% of those in the control group: multivitamins Medications taken by some, but less than 20% of the control group: not reported

	Location: USA Ethnicity: unclear (6% of the study population were minorities)	
Interventions	Type: supplement (DHA capsules) Comparison: DHA vs omega 6 Intervention: 6 × 500 mg capsules/d of DHA (1.2 g/d DHA plus 1.8 g vegetable oil) plus < 0.0006 mg/d tocopherols plus 15,000 IU retinyl palmitate (vitamin A). Dose: +1.2 g/d DHA Control: 6 × 500 mg capsules/d of soy and corn oils (half each) with 120 mg/d ALA, plus < 0.0006 mg/d tocopherols plus 15000 IU retinyl palmitate (vitamin A) Compliance: 92% of capsules taken by both intervention and control groups (assessed by monthly calendars), Plasma DHA much higher in intervention than control Length of intervention: 48 months	
Outcomes	Main study outcome: retinal degeneration Dropouts: 5 or 6 intervention, 7 or 8 control Available outcomes: mortality, cancer diagnoses, lipids, eyesight Response to contact: yes (no data provided)	
Notes	Study funding: National Eye Institute and Foundation Fighting Blindness	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated random numbers
Allocation concealment (selection bias)	Low risk	Random numbers available only to programmer who provided assignments to data manager, all staff in contact with patients were masked to group assignment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	States that all staff in contact with participants were masked to group assignment, as were participants. However no information was provided regarding the taste, smell and appearance of the active and placebo capsules
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All assessments were performed blind to study allocation. Each ocular examination was performed without review of previous records. All serum samples were analysed without knowledge of treatment group assignment

**Berson 2004** (Continued)

Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Numbers of dropouts and reasons for dropouts not stated. 221 participants randomised, data presented on 208 participants
Selective reporting (reporting bias)	Unclear risk	No trials registry entry or protocol found.
Attention	Low risk	Staff in contact with patients were masked, so unable to bias time, etc
Compliance	Low risk	92% of capsules taken by both intervention and control groups (assessed by monthly calendars), Plasma DHA much higher in intervention than control
Other bias	Low risk	None noted

**Brox 2001**

Methods	RCT, parallel, 3 arms (n-3 EPA + DHA from cod liver vs n-3 EPA + DHA from seal oil vs nil), 14 months Summary risk of bias: moderate or high
Participants	Subjects with moderate hypercholesterolaemia N: 40 seal oil (SO), 40 cod liver oil (CLO), 40 control (numbers analysed vary by outcome) Level of risk for CVD: moderate (dyslipidaemia) Men: 53% seal oil, 50% cod liver oil, 48% control Mean age in years: 53.2 seal oil, 55.0 cod liver oil, 55.8 control Age range: 43-66 years Smokers: unclear Hypertension: unclear Medications taken by at least 50% of those in the control group: none allowed Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: Norway Ethnicity: not reported
Interventions	Type: supplement (oil) Comparison: EPA + DHA vs nil Intervention: Intervention: seal oil - 15 mL/d (2.6 g, 1.1 g/d EPA + 1.5/d DHA) (total n-3 3.9 g/d, total PUFA 4.2 g/d): SO dose: EPA + DHA 2.6 g/d Cod liver oil - 15 mL/d (3.3 g, 1.5 g /d EPA + 1.8 g/d DHA) (total n-3 4.1 g/d, total PUFA 4.35 g/d): CLO dose: EPA + DHA 3.3 g/d Control: nil, no supplement Compliance: serum omega-3 fatty acids, rose from around 1 mmol/L to 2.4 (seal oil), 2.1 (cod liver oil) and 1.2 mmol/L (control) Length of intervention: 14 months



Outcomes	Main study outcome: serum lipids Dropouts: 8 seal oil, 2 cod liver oil, 1 control Available outcomes: total and cardiovascular deaths, MI, combined CV events, lipids, adverse events Response to contact: yes (author provided methodological details)	
Notes	Data of two intervention groups combined for dichotomous outcomes and CLO vs control data used for continuous outcomes Study funding: the study was supported by the programme Medical Research in Finnmark County, University of Tromsø	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	J Brox stated (personal communication, January 2017): "The randomization of the 120 participants was done by first generating 3 groups (seal oil, cod liver oil, control) , then giving each participant a number (1-120), "putting all the numbers into the same har' and blindly drawing one number at the time from the hat. The first 40 numbers (1-40) were allocated to the seal oil group, the next 40 numbers (41-80) to the cod liver oil group and the rest (81-120) were allocated to the control group."
Allocation concealment (selection bias)	Low risk	J Brox stated (personal communication, January 2017): "The researcher/clinician who invited the participants had no knowledge of to which group the participants would be allocated."
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "controls were aware - not given a supplement"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	J Brox stated (personal communication, 2003): "All the persons involved in the drawing & analysing of blood were unaware of treatment. The technicians analysing the blood did not have any personal contact with the participants except K. Olaussen who did the FA analysis ... she only had access to the sample numbers not names and code. The participants did not know their number (says elsewhere

**Brox 2001** (Continued)

		that K Olaussen did not know allocations). The only outcome assessor was J Brox who did not have personal contact with participants, randomising, collecting results or analysing process." "The only assessor was J Brox who did not have any personal contact with the participants, had nothing to do with the randomising or analysing process, or the collecting of results."
Incomplete outcome data (attrition bias) All outcomes	High risk	Control group 3 dropouts, seal oil group 10 dropouts, cod liver oil 3 dropouts. So substantial differences in rates of dropouts between the groups
Selective reporting (reporting bias)	Unclear risk	No study protocol or trials register entry was found
Attention	Low risk	No suggestion of differential attention
Compliance	Low risk	Serum omega-3 fatty acids, rose from around 1 mmol/L to 2.4 (seal oil), 2.1 (cod liver oil) and 1.2 mmol/L (control)
Other bias	Low risk	No further bias noted

**Caldwell 2011**

Methods	RCT, parallel, (n-3 EPA + DHA vs n-6 LA), 12 months Summary risk of bias: low
Participants	Participants with non-cirrhotic NASH (non-alcoholic steatohepatitis) N: 20 intervention, 21 control (analysed 17 intervention, 17 control) Level of risk for CVD: moderate Men: 35.3% intervention, 41.2% control Mean age in years (SD): 46.4 (12.1) intervention, 47.2 (12) control Age range: 25-72 years Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: USA Ethnicity: intervention, 100% white, control 94.% white, 5.9% other
Interventions	Type: supplement (capsule) Comparison: EPA + DHA vs omega 6 Intervention: 3 × 1 g fish oil capsules/d (Nordic Natural) for a total 2.1 g/d n-3, each capsule contained 70% of n-3 (1050 mg EPA, 750 mg DHA + 300 mg other n-3). Dose:

	<p>1.8 g/d EPA + DHA</p> <p>Control: 3 × 1 g identical placebo (soybean) capsules per day containing 8% fish oils</p> <p>Both groups had dietary counselling on caloric intake and physical activity</p> <p>Compliance: unclear (measured n-6-n-3 ratio due to its link to hepatic lipid composition)</p> <p>Length of intervention: 12 months</p>
Outcomes	<p>Main study outcome: NASH activity score</p> <p>Dropouts: 3 intervention, 3 control</p> <p>Available outcomes: lipids (TG too unbalanced at baseline to use), measures of adiposity (weight, BMI, visceral fat - all unbalanced at baseline so not used), fasting glucose, insulin, HOMA-IR, QUICKI (also NASH progression, hepatic fat, ALT, VO<sub>2</sub> max, activity level, markers of cell injury, adiponectin not used)</p> <p>Response to contact: yes, change data supplied for BMI and body weight, confirmed no deaths, cardiovascular events, diabetes, depression, breast cancer or IBD diagnoses</p>
Notes	<p>Data on; BMI, weight, visceral fat, TG and glucose were not used as they were different between groups at baseline</p> <p>Study funding: study was supported by NIH NCCAM Grant 5R21AT2901-2 and 5 M01 RR00847. Study medication and identical appearing placebo was provided at no charge by Nordic Natural. RBC phospholipid profile was performed by Metamatrix (<a href="http://www.metamatrix.com">www.metamatrix.com</a>). M30, M65, adiponectin, and IGFBP-1 electro chemiluminescence assays were performed by Wellstat Diagnostics (<a href="http://www.wellstatdiagnostics.com">www.wellstatdiagnostics.com</a>).</p>

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomised to n-3 or placebo using a stratified block 1:1 randomisation scheme. An independent biostatistician generated the randomisation list which was confidentially forwarded to the Investigational pharmacy
Allocation concealment (selection bias)	Low risk	As above
Blinding of participants and personnel (performance bias) All outcomes	Low risk	All staff and subjects were blinded to therapy assignment throughout the study period. Both capsules were identical. However no information provided on capsules taste or smell
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinded for main outcome
Incomplete outcome data (attrition bias) All outcomes	Low risk	15% dropouts explained and equal in both groups

Selective reporting (reporting bias)	Low risk	The trial was prospectively registered
Attention	Low risk	Both groups had the same attention
Compliance	Unclear risk	No details on compliance measurement
Other bias	Low risk	None noted

**DART 1989**

Methods	Diet And Reinfarction Trial (DART) - oily fish advice (or capsule) arm RCT - parallel, 2 × 2 × 2 factorial (n-3 EPA + DHA vs nil or fat advice vs not, oily fish advice (or capsule) vs not, dietary fibre advice vs not), 2 years Summary risk of bias: moderate or high
Participants	Men recovering from myocardial infarction N: 1015 intervention, 1018 Level of risk for CVD: high (post-MI) Men: 100% Mean age, SD: 56.7 intervention, 56.4 control (SDs not stated) Age range: unclear Smokers: 61.7% intervention, 62.2% control Hypertension: 22.7% intervention, 24.6% control Medications taken by at least 50% of those in the control group: none reported Medications taken by 20%-49%: beta-blockers, other antihypertensives, antianginals Medications taken by some, but < 20%: anticoagulant, aspirin/antiplatelet, digoxin/antiarrhythmic Location: UK Ethnicity: not stated
Interventions	Type: dietary advice (to eat more oily fish) Comparison: EPA + DHA vs SFA + MUFA (by dietary achievement below) Intervention: advised to eat at least 2 weekly portions of 200-400 g fatty fish (mackerel, herring, kipper, pilchard, sardine, salmon, trout). If this was not possible, given MaxEPA capsules, 3/d (0.5 g EPA/d). 191/883 participants were taking MaxEPA at 2 years. Advice was reinforced 3-monthly. Dose: aimed for 0.5 g/d EPA Control: No such dietary advice or capsules Compliance: 7 day weighed food diary of a random sub-sample indicated intake of 2.5 g/week EPA intervention, 0.8 g/week EPA control <b>Dietary achievements</b> Total fat intake, %E (through study): control 35 (SD 6), intervention 31 (SD 7) (MD -4.00, 95% CI -4.57 to -3.43); significant reduction Saturated fat intake, %E (through study): control 15 (SD 3), intervention 11 (SD 3), (MD -4.00, 95% CI -4.26 to -3.74); significant reduction PUFA intake (through study), %E: control 7 (SD unclear), intervention 9 (SD unclear), (MD 2.00, 95% CI 1.57 to 2.43 assuming SDs of 5) significant increase PUFA n-3 intake: EPA, control 0.6 (SD 0.7) g/week, intervention 2.4 (SD 1.4) g/week PUFA n-6 intake: not reported

	<p>MUFA intake (through study), %E: control 13 (SD unclear), intervention 11 (SD unclear) (MD -2.00, 95% CI -2.43 to -1.57 assuming SDs of 5); significant reduction</p> <p>CHO intake (through study), %E: control 44 (SD 6), intervention 46 (SD 7) (MD 2.00, 95% CI 1.43 to 2.57); significant increase</p> <p>Protein intake (through study), %E: control 17 (SD 4), intervention 18 (SD 4) (MD 1.00, 95% CI 0.65 to 1.35); significant increase</p> <p>Trans fat intake: not reported</p> <p>Length of intervention: 24 months</p>
Outcomes	<p>Main study outcome: total mortality, reinfarction, CHD death</p> <p>Dropouts: none for mortality</p> <p>Available outcomes: total and CV deaths, MI, CHD events, lipids, blood pressure, cancer deaths</p> <p>Response to contact: yes (data provided)</p>
Notes	<p>Some of each group were also advised on low fat and high PUFA and/or high fibre diets, all participants who smoked were advised to stop and all with a BMI &gt; 30 kg/m<sup>2</sup> were given weight reduction advice, regardless of randomisation arm. The low fat high PUFA comparison was included in the omega-6 review</p> <p>Study funding: by the Welsh Scheme for the Development of Health and Social Research, the Welsh Heart Foundation and the Health Promotion, Research Trust. Seven Seas Health Care and Duncan Flockhart provided Maxepa capsules</p>

### *Risk of bias*

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "randomised" confirmed by author
Allocation concealment (selection bias)	Unclear risk	Pre-prepared sequentially numbered envelopes opened by dietitian (unclear if envelopes were opaque)
Blinding of participants and personnel (performance bias) All outcomes	High risk	Blinding of dietary advice (or lack of it) is not possible
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome assessors were not aware of study allocation (Prof Burr stated he did not know assignments)
Incomplete outcome data (attrition bias) All outcomes	Low risk	Hospital notes and death registers were flagged to catch all outcome data
Selective reporting (reporting bias)	Unclear risk	No study protocol or trials register entry was found

## DART 1989 (Continued)

Attention	High risk	More attention was paid to those given dietary advice
Compliance	Unclear risk	7 day weighed food diary of a random subsample indicated intake of 2.5 g/week EPA intervention, 0.8 g/week EPA control
Other bias	Low risk	None noted

## DART2 2003

Methods	Diet and Angina Randomised Trial (DART2) RCT, 2 × 2, (oily fish or capsules n-3 EPA + DHA vs nil, also no specific advice, also fruit, vegetables and oats vs no specific advice), 3-9 years Summary risk of bias: moderate or high
Participants	Men treated for angina N: 1571 intervention, 1543 control (all analysed for events) Control level of risk for CVD: high Men: 100% Mean age in years (SD): 61.1 (NR) intervention, 61.1 (NR) control Age range: unclear Smokers: 25% intervention, 23% control Hypertension: 49% intervention, 47% control Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49%: lipid lowering, beta-blockers Medications taken by some, but less than 20% of the control group: not reported Location: UK Ethnicity: not reported
Interventions	Type: dietary advice (to eat more oily fish or take fish oil capsules) Comparison: EPA + DHA vs unclear (not total fat, SFA or alcohol, presumably CHO and/or protein but not clear) Intervention: most (1109) advised to eat at least 2 weekly portions of fatty fish OR take MaxEPA capsules, 3/d (0.5 g EPA/d). But 462 participants were sub-randomised to receive only fish oil capsules, not dietary fish advice. Dose: aimed for 0.5 g/d EPA Control: none specific sensible eating advice that did not include either of the interventions Compliance: postal dietary questionnaire suggested dietary EPA intake increased by 2.4 g /week intervention, 0.2 g /week control <b>Dietary achievements</b> Total fat intake, (change from baseline to 6 months): control -8.6 g/d (SD 20.9), intervention -5.2 (g/d SD 21.4) (MD 3.4 g/d) Saturated fat intake, (change from baseline to 6 months): control -3.5 g/d (SD 9.3), intervention -2.8 g/d (SD 9.4), (MD 0.7 g/d) PUFA intake (change from baseline to 6 months): control -1.6 g/d (SD 5.4), intervention -0.1 g/d (SD 5.8) (MD 1.5 g/d) PUFA n-3 intake (change from baseline to 6 months): EPA, control 0.12 g/week (SD 0.

	73), intervention 2.65 g/week (SD 1.35) (MD 2.53 g/week) PUFA n-6 intake: not reported MUFA intake: not reported CHO intake: not reported Protein intake: not reported Trans fat intake: not reported Duration of intervention: 36 to 108 months	
Outcomes	Main study outcome: total mortality Dropouts: none for mortality Available outcomes: total and CV deaths, sudden death, stroke, heart failure, cancer deaths Response to contact: yes (data provided)	
Notes	Some of each group were also advised on high fruit, vegetables and oat diets, and those who received neither fish nor fruit advice received 'non-specific' dietary advice. All those whose BMI > 30 kg/m <sup>2</sup> in both groups received weight reduction advice. Study funding: probably British Heart Foundation, Seven Seas Ltd, Novex Pharma Ltd and the Fish Foundation (these were acknowledged)	
<i><b>Risk of bias</b></i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly allocated"
Allocation concealment (selection bias)	Unclear risk	Pre-prepared sequentially numbered envelopes opened by dietitian (unclear if envelopes were opaque)
Blinding of participants and personnel (performance bias) All outcomes	High risk	Dietary advice, so not possible for participants to be blinded to intervention
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome assessors were not aware of study allocation (Prof Burr stated he did not know assignments)
Incomplete outcome data (attrition bias) All outcomes	Low risk	Hospital notes and death registers were flagged to catch all outcome data
Selective reporting (reporting bias)	Unclear risk	No study protocol was found, or trials registry entry
Attention	High risk	More attention was paid to those given dietary advice

**DART2 2003** (Continued)

Compliance	Unclear risk	Postal dietary questionnaire suggested dietary EPA intake increased by 2.4 g/week intervention, 0.2 g/week control
Other bias	Low risk	None noted

**Derosa 2016**

Methods	RCT, parallel, (n-3 PUFA capsules vs placebo), 18 months Summary risk of bias: low
Participants	White overweight/obese patients with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) N: 138 intervention, 143 control (analysed 128 intervention, 130 control) Level of risk for CVD: low Men: 50.72% intervention, 48.95% control Mean age in years (SD): 53.4 (11.2) intervention, 54.8 (12.1) control Age range: unclear Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: Italy Ethnicity: white
Interventions	Type: capsule (n-3 PUFA) Comparison: EPA + DHA vs CHO + SFA Intervention: 3 × 1 g capsule/ day n-3 PUFAs (ethyl esters, each 1-g capsule of n-3 PUFAs contains highly concentrated ethyl esters of omega-3 fatty acids, primarily EPA, and DHA in the proportion of 0.9-1.5). Dose: unclear (approx 2-3 g/d) Control: placebo (a capsule containing sucrose, mannitol and mineral salts, magnesium stearate (a saturated fat) and silicon dioxide, used as anti-caking agents) Both groups were given diet advice to follow a controlled-energy diet based on AHA recommendations (50% of calories from carbohydrates, 30% from fat (6% saturated), and 20% from proteins, with a maximum cholesterol content of 300 mg/day and 35 g/day of fibre). Individuals were also encouraged to increase their physical activity by walking briskly for 20 to 30 min, 3 to 5 times per week, or by cycling Compliance: measured by counting the number of pills returned at the time of specified clinic visits Length of intervention: 18 months
Outcomes	Main study outcome: insulin resistance Dropouts: 23 across arms (no details on groups but stated that there were no difference between groups) Available outcomes: mortality, CV mortality, CHD event, stroke, combined CVD events, MI, AF, weight, BMI, lipids, diabetes mellitus Response to contact: yes (data provided)



Notes	Study funding: “The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties”	
<i>Risk of bias</i>		
<b>Bias</b>	<b>Authors’ judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Randomisation was done using a drawing of envelopes containing randomisation codes prepared by a statistician
Allocation concealment (selection bias)	Low risk	Author stated that allocation was concealed from clinicians and researchers, but no methodology provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Both n-3 PUFAs and placebo were supplied as identical, opaque, white capsules in coded bottles to ensure the blind status of the study. However no information provided on capsules taste or smell
Blinding of outcome assessment (detection bias) All outcomes	Low risk	A copy of the code was provided only to the person performing the statistical analysis
Incomplete outcome data (attrition bias) All outcomes	Low risk	An intention-to-treat analysis was conducted for patients who received 1 dose of study medication
Selective reporting (reporting bias)	Unclear risk	No trial registry or protocol found
Attention	Low risk	No difference reported
Compliance	Unclear risk	Measured by counting the number of pills returned at the time of specified clinic visits
Other bias	Low risk	None noted

## Deslypere 1992

Methods	RCT 4 arms, ( n-3 EPA + DHA (3 different doses) vs MUFA), 12 months Summary risk of bias: moderate or high	
Participants	Healthy monks N: 14 high, 15 medium, 15 low dose intervention, 14 control Level of risk for CVD: low Men: 100% Mean age in years (SD): 56.2 (16.5) (not reported by arm) Age range: 21-87 Smokers: none Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported (no medications influencing lipid metabolism or non-steroidal anti-inflammatory drugs were allowed) Location: the Netherlands Ethnicity: not reported	
Interventions	Type: capsules Comparsion: LCn3 vs MUFA Intervention 9 capsules (9 g vol.) per day, of which 3, 6 or 9 were fish oil (Labaz, Brussels, Belgium) and any remainder were placebo (providing respectively 1.12; 2.24 or 3.37 g n-3 FA/day). Dose: 1.12 g/d; 2.24 g/d or 3.37 g/d EPA + DHA) Control: 9 placebo capsules made up of olive oil (Puget Marseille, France) and Palmoil (Loders-Kroklaan Wormerveen, the Netherlands) with the same SFA, cholesterol and vitamin E as the fish oil capsules Compliance: assessed by counting remaining capsules every 2 months and by measuring EPA concentration. Excellent compliance reported and shown by the EPA concentration results Length of intervention: 12 months	
Outcomes	Main study outcome: effect on coronary risk factors Dropouts: none Available outcomes: deaths (nil), CVD events (nil), lipids, BP, HbA1c, weight (measured but only text suggests “no significant changes in the anthropometric parameters (weight, length, waist, hip and thigh circumferences) during the study”), IL-6, TNF-alpha and several IL-1s (IL-6 reported as below detection range, for the others there was “no significant difference between the two treatment groups at any point in time”) Response to contact: yes	
Notes	Study funding: capsules supplied by Labaz (Brussels Belgium). The placebo capsules contained olive oil (Puget) and palm oil (Loders-Kroklaan, Wormerveer). Financial support by Sanofi-Labaz Data entered for high fish oil versus placebo groups	
Risk of bias		
Bias	Authors’ judgement	Support for judgement

**Deslypere 1992** (Continued)

Random sequence generation (selection bias)	Low risk	Quote (author correspondence): "The manufacturer provided envelopes containing numbers corresponding with boxes of capsules. For each enrolled subject, random envelope was opened."
Allocation concealment (selection bias)	Low risk	Allocation concealed from all this way
Blinding of participants and personnel (performance bias) All outcomes	High risk	Although double blind, the fishy taste of the active treatment was not matched (author states that the fishy taste was clear in the intervention capsules)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Authors confirmed outcome assessors were unaware until afterwards
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts
Selective reporting (reporting bias)	Unclear risk	No protocol or trial registry record
Attention	Low risk	No difference between groups
Compliance	Low risk	Significant difference in EPA concentration
Other bias	Low risk	None noted

**DIPP 2015**

Methods	Dietary Intervention for Patients Polypectomized for tumours of the colorectum (DIPP) RCT, parallel, 2 arms (n-3 EPA + DHA + n-3 ALA vs nil), 24 months Summary risk of bias: moderate or high
Participants	Patients previously polypectomised for colorectal tumours N: 104 intervention, 101 control Level of risk for CVD: low Men: 73.1% intervention, 74.3% control Mean age in years (SD): 58.3 (9.5) intervention, 59.7 (8.9) control Age range: 35-75 Smokers: 65.4% intervention, 61.4% control Hypertension: not reported Medications taken by at least 50% of those in the control group: supplements Medications taken by 20%-49% of those in the control group: none Medications taken by some, but less than 20% of the control group: oral contraceptive pills Location: Japan

	Ethnicity: not reported	
Interventions	Type: advice + supplement (fish oil capsules) Comparison: EPA + DHA + ALA vs omega-6 Intervention: advice to reduce total fat intake, decrease consumption of n-6 PUFAs, increase intake of n-3 PUFAs from fish/marine foods, increase intake of n-3 PUFAs from perilla oil rich in ALA, take 8 capsules of fish oil/day (equivalent to 96 mg/day of EPA and 360 mg/day of DHA). Dose: 456mg/d EPA + DHA and unknown dose of ALA Control: advice to decrease intake of fats/oils as a whole Compliance: measured via semi-quantitative food frequency questionnaire, plasma fatty acid concentrations, fatty acid compositions in the membranes of red blood cells and the sigmoid colon. Reported satisfactorily high compliance with protocol in both groups but no figures provided Length of intervention: 24 months	
Outcomes	Main study outcome: number and size of colorectal tumours Dropouts: 3 intervention, 5 control Available outcomes: all cause mortality, dietary intake, plasma fatty acids, lipids, side effects, glucose Response to contact: yes (methodological details provided)	
Notes	Study funding: all were either government or charity grants	
<i>Risk of bias</i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Randomly allocated using random digit number for allocation of participants
Allocation concealment (selection bias)	Low risk	Author confirmed "Allocation information was blinded to clinicians and researchers"
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	From the 2015 paper, "The attending physicians as well as the participants were blinded to the assignment information". However in the discussion section they say "complete participant blinding could not have been achieved because free living participants might have exchanged information on their dietary intervention, say in the hospital waiting room". Author confirmed blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "physicians, including colonoscopists, a scientist who conducted blood and specimen analyses, and pathologists were blinded"

## DIPP 2015 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	All those randomised were accounted for
Selective reporting (reporting bias)	High risk	The researchers chose not to report data on the number, size and pathological type of the colorectal tumours as they said they would in the trials register. They reported more outcomes in the paper than initially stated UMIN000000461 Registered 3 August 2006, recruitment completed 1 March 2007
Attention	Low risk	Participants were given equal follow-up
Compliance	Unclear risk	Reported satisfactorily high compliance with protocol was noted in both groups but no figures
Other bias	Low risk	None noted

## DISAF 2003

Methods	Dietary Intervention Study for AF (DISAF) RCT, parallel, 2 arms (n-3 EPA + DHA vs nil), 12 months Summary risk of bias: moderate or high
Participants	People presenting for first treatment of acute/persistent atrial fibrillation or flutter, confirmed by ECG N: intervention 201, control 206 Level of risk for CVD: high (patients with atrial fibrillation) Men: intervention 64.7%, control 63.6% Mean age in years (SD): intervention 67.7 (9.4), control 68.7 (9.5) Age range: unclear Smokers: intervention 10.9%, control 12.1% Hypertension: intervention 48.2%, control 40.8% Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: antiarrhythmics, antithrombotics Medications taken by some, but less than 20% of the control group: not reported Location: UK Ethnicity: white British
Interventions	Type: dietary advice Comparison: EPA + DHA vs unclear Intervention: dietary assistants gave advice and support to eat 2 to 3 portions of oily fish per week (providing up to 10 g LCn3/ week), plus 2 to 3 portions of fruit and vegetables per day. Dose: 1.4 g/d EPA + DHA

	Control: dietary assistants gave advice and support to eat 2 to 3 portions of fruit and vegetables per day. No other health/lifestyle given as part of the trial Compliance: assessed red blood cell fatty acids and found some increases in EPA and DHA in intervention compared to control (no further intake data) Length of intervention: 12 months	
Outcomes	Main study outcome: sinus rhythm after 12 months Dropouts: unclear Available outcomes: deaths, AF recurrence Response to contact: yes (data provided)	
Notes	Study funding: not reported	
<i>Risk of bias</i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Randomisation was by phone to an independent randomisation office, which used pre-printed random number tables
Allocation concealment (selection bias)	Low risk	Randomisation was by phone to an independent randomisation office, which used pre-printed random number tables
Blinding of participants and personnel (performance bias) All outcomes	High risk	Dietary advice was clear, so allocation known by participants
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear
Incomplete outcome data (attrition bias) All outcomes	High risk	Some discrepancies between papers, reasons unclear
Selective reporting (reporting bias)	High risk	ISRCTN16448451 registered 23 January 2004, recruitment from 1 July 1998 to 1 July 2002; some secondary outcomes were not reported
Attention	Low risk	Intervention (advice to eat more oil-rich fish, fruit and vegetables) and control (advice to eat more fruit and vegetables) groups appeared to be given equivalent time and attention

**DISAF 2003** (Continued)

Compliance	Low risk	Assessed red blood cell fatty acids and found some increases in EPA and DHA in intervention compared to control
Other bias	High risk	The trial was stopped early

**DO IT 2010**

Methods	Diet and Omega 3 Intervention Trial on Atherosclerosis (DO IT) Randomisation: RCT, parallel, 2 × 2 factorial, (n-3 DHA + EPA vs n-6 LA also dietary advice intervention), 36 months Summary risk of bias: moderate or high
Participants	Elderly men with longstanding dyslipidaemia or hypertension (a subset of Oslo Diet heart study) N: intervention 282 (140 n-3 capsules + 142 n-3 capsules and dietary advice), control 281 (142 placebo capsules + 139 placebo capsules and dietary advice) Level of risk for CVD: moderate Men: intervention 100%, control 100% Mean age in years (SD): intervention 70.4 (2.9), control 69.7 (3.0) years Age range: 64-76 years Smokers: intervention 35%, control 33% Hypertension: intervention 29%, control 27% Medications taken by at least 50% of those in the control group: none Medications taken by 20%-49% of those in the control group: statins and acetylsalicylic acid Medications taken by some, but less than 20% of the control group: $\beta$ -blockers, ACE inhibitors and nitrates Location: Norway Ethnicity: not reported
Interventions	Type: supplement/ capsule (also dietary advice as the factorial intervention) Comparison: EPA + DHA vs omega-6 Intervention: 2 × 2 capsules/d incl 2.4 g/d of omega-3 PUFA (Pikasol, 0.84 g/d EPA plus 0.48 g/d DHA plus 8.4 mg/d tocopherols). Dose: 1.32 g/d EPA + DHA Control: 2 × 2 capsules/d incl 4 g/d corn oil (2.24 g/d linoleic, 1.28 g/d oleic acid, 16 mg/d tocopherols) Compliance: pharmacy records suggested that > 90% of supplements were taken, and plasma EPA and DHA were raised in intervention compared to control participants Duration of intervention: 36 months
Outcomes	Main study outcome: atherosclerosis progression. Dropouts: intervention 14 died, 20 others discontinued, control 24 died, 18 others discontinued Available outcomes: mortality, cardiovascular deaths, CHD events, CV events, MI, stroke, diabetes, glucose, lipids, cancer diagnosis, cancer deaths, sudden death, BMI (waist circumference reported as median, IQR) Response to contact: yes (data provided)

Notes	The other 2 × 2 intervention was dietary counselling to increase both omega-3 and omega-6 fats as well as fruit and vegetables Study funding: Norwegian Cardiovascular Council, Norwegian retail company RIMI, vegetable oil and margarine supplied by the Norwegian food company Mills DA and placebo capsules by LUBE	
<i><b>Risk of bias</b></i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Permuted block randomisation, no clear mechanism provided
Allocation concealment (selection bias)	Unclear risk	No details provided
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Capsules of fish oil or placebo taken, but unclear whether blinded and if so, how well or successfully
Blinding of outcome assessment (detection bias) All outcomes	Low risk	“Mortality data were supplied from the Norwegian Cause of Death Registry, and all clinical events were confirmed by hospital records and verified by an independent cardiologist”
Incomplete outcome data (attrition bias) All outcomes	Low risk	No attrition as deaths and events collected from centralised register
Selective reporting (reporting bias)	Unclear risk	Trials registry entry submitted after the outcomes papers were published
Attention	Low risk	No suggestion of attention bias between verum and placebo supplement arms
Compliance	Low risk	Pharmacy records suggested that > 90% of supplements were taken, and plasma EPA and DHA were raised in intervention compared to control participants
Other bias	Low risk	None noted



Methods	RCT, parallel, (n-3 ALA vs n-6 LA), 12 months Summary risk of bias: moderate or high
Participants	Healthy menopausal women N: 101 intervention, 98 control. (analysed, intervention: 85 control: 94) Level of risk for CVD: low Men: 0% intervention, 0% control Mean age in years (SD): 54.0 (4.0) intervention, 55.4 (4.5) control Age range: 49-65 Smokers: 8% intervention, 6% control Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: Canada Ethnicity: French Canadian
Interventions	Type: food supplement (flaxseed) Comparison: ALA vs unclear (probably includes lipids, CHO and protein, but not clear) Intervention: 40 g/d flaxseed incorporated into diets (providing 21,071 g total lignans, 180 calories, 16 g lipids (57% ALA), and 11 g total dietary fibre). Dose: 9.1 g/d ALA Control: 40 g/d wheat germ incorporated into diets (providing 196 g total lignans, 144 calories, 4 g lipids (6.9% ALA), and 6 g total dietary fibre Compliance: first morning urine collection was performed at randomisation and at month 12 to measure urinary lignin levels. In addition, study participants recorded their daily intake of seeds on diary cards and were asked to return unused bread and packages of seeds at each visit. Good compliance reported Duration of intervention: 12 months
Outcomes	Main study outcome: bone mineral density Dropouts: 26 intervention, 17 control (but 13/17 had an endpoint evaluation) Available outcomes: weight, BMI, QoL, blood pressure, lipids, glucose, adverse events, dietary intake, plasma fatty acids Response to contact: yes
Notes	Auhors replied to tell us that there were no deaths or CV events during the study Study funding: not reported

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The randomisation schedule was prepared by the clinical unit of the research centre using computer generated randomisation in blocks of 4-8
Allocation concealment (selection bias)	Unclear risk	No details

Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants, investigators, staff, and statisticians were blinded to dietary assignments for the duration of the study Quote: "a local baker prepared loaves of bread. Each week, the loaves of bread were delivered in sealed, opaque unmarked wrappers to the Department of Food and Nutrition Sciences at Laval University. The seeds were ground up and vacuum-packed in the same laboratory. The Department of Food and Nutrition Sciences was responsible for labelling the bags of bread and packages of seeds with the subject's randomization number. Bread and packages of seeds were provided on a 3-month basis. The foods that both groups received was similar in appearance and packaging and was kept frozen until consumption to avoid essential fatty acid
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants, investigators, staff, and statisticians were blinded to dietary assignments for the duration of the study
Incomplete outcome data (attrition bias) All outcomes	Low risk	Intention-to-treat analysis. Loss to follow-up 10%, reasons given
Selective reporting (reporting bias)	Unclear risk	No protocol or clinical trial registry entry found
Attention	Low risk	All participants had same number of visits
Compliance	Low risk	First morning urine collection was performed at randomisation and at month 12 to measure urinary lignin levels. In addition, study participants recorded their daily intake of seeds on diary cards and were asked to return unused bread and packages of seeds at each visit. Good compliance reported
Other bias	Low risk	None noted

Methods	RCT, parallel, (n-3 EPA vs nil), 12 months Summary risk of bias: moderate or high
Participants	Patients having PCI after acute MI N: 119 intervention, 119 control analysed Level of risk for CVD: high Men: 77% intervention, 76% control Mean age in years (SD): 70 (11) intervention, 71 (12) control Age range: unclear Smokers: 28% intervention, 32% control Hypertension: 71% intervention, 69% control Medications taken by at least 50% of those in the control group: aspirin, ticlopidine, beta-blockers, statins (as part of treatment) Medications taken by 20%-49% of those in the control group: ARB/ACE inhibitors Medications taken by some, but less than 20% of the control group: none Location: Japan Ethnicity: not reported
Interventions	Type: supplement (EPA) Comparison: EPA vs nil Intervention: purified EPA ethyl esters (> 98%) 1800 mg EPA/day within 24 hours after PCI plus statins. Dose: 1.8 g/d EPA Control: statins with no EPA Compliance: not reported Length of intervention: 12 months
Outcomes	Main study outcome: cardiovascular events Dropouts: 1 intervention, 2 control Available outcomes: mortality, stroke, MI, sudden death, CV death, revascularisation Response to contact: no
Notes	Study funding: trial registry state "self-funded". The authors received honoraria from Mochida Pharmaceutical Co

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	A computer-generated, randomisation plan, which included stratification by age and sex
Allocation concealment (selection bias)	Unclear risk	Carried out by research technician but unclear
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open label but blind endpoint

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Data on outcomes were collected from clinical charts. Unclear if blinded. Diagnoses were confirmed by investigator blind to treatment allocation
Incomplete outcome data (attrition bias) All outcomes	Low risk	Only 3 dropouts, similar rates between the groups and reasons given
Selective reporting (reporting bias)	High risk	Data collection completed before trial registry entry. Only 1% dropouts
Attention	Low risk	Timing of follow-up similar
Compliance	Unclear risk	Not reported
Other bias	Low risk	None observed

**EPE-A 2014**

Methods	EPE-A RCT, parallel, 3 arms (n-3 EPA, low dose vs high dose vs unclear placebo), 12 months Summary risk of bias: moderate or high
Participants	People with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) N: 86 intervention-high, 82 int low, 75 control (analysed 64, 55, 55 respectively, ITT analysis for primary outcomes) Level of risk for CVD: low (although 35% had type II diabetes) Men: 33.7% intervention-high, 41.5% intervention-low, 42.7% control Mean age in years (SD): 47.8 (11.1) intervention-high, 47.8 (12.5) intervention-low, 50.5 (12.5) control Age range: not reported Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: USA Ethnicity: white intervention-low: 94%, intervention-high: 87%, control: 90.7% African American intervention-low: 3.7%, intervention-high: 2.3%, control: 4.0% Others intervention-low: 2.4%, intervention-high: 10.5%, control: 5.3%
Interventions	Type: supplement (omega 3 capsule) Comparison 1: high EPA vs low EPA (unclear what replaced EPA) Comparison 2: EPA vs unclear (placebo contents not reported) Intervention-high: EPA-E 2.7 g/d, 3 × EPA-E 300 mg capsules. Dose: 2.7 g/d EPA + DHA Intervention-low: EPA-E 1.8 g/d, 2 × EPA-E 300 mg capsules + 1 placebo capsule

	Dose: 1.8 g/d EPA + DHA Control: 3 × placebo capsules. The pills were identical with respect to size, colour and smell Compliance: estimated by pill count and measuring the ratio of serum EPA to arachidonic acid. compliance rates for the 3 groups (placebo vs EPA-E 1800 mg/d vs EPA-E 2700 mg/d) were 89.5% (6.8%), 90.3% (5.7%) and 89.5% (5.3%), respectively Length of intervention: 12 months	
Outcomes	Main study outcome: histological response in standardised scoring of liver biopsies and change in ALT level Dropouts: 22 intervention-high, 27 intervention-low, 20 control Available outcomes: cardiac events, deaths (none), angina, adverse events (weight, BMI, lipids, glucose, HbA1c, HOMA, hsCRP all reported as medians so not useable in meta-analyses) Response to contact: yes (provided methodological details)	
Notes	Data combined for the 2 intervention groups for binary outcomes and higher dose data vs control used for continuous outcomes Study funding: supported entirely by Mochida Pharmaceuticals	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Block randomisation using an interactive voice-response system to assign subjects in a 1:1:1 ratio between the 2 arms for each site separately. Participants were stratified by the presence of type 2 diabetes. The total fraction of such individuals was capped at 40% of the study cohort
Allocation concealment (selection bias)	Low risk	As above (remote computer-generated randomisation)
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind stated, but no further details. Author confirmed researchers and outcome assessors were blinded to treatment allocation and pills were identical with respect to size, colour and smell
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details
Incomplete outcome data (attrition bias) All outcomes	High risk	Number and characteristics of participants lost to follow-up similar across arms, however < 80% provided outcome data relevant to this systematic review

Selective reporting (reporting bias)	Low risk	Registered June 2010, study started June 2010, completed October 2012. All outcomes in trials registry entry were also reported in the trials registry. Secondary outcomes reported were not planned (compared with first version of clinicaltrials.gov entry)
Attention	Low risk	All participants had same follow-up visits.
Compliance	Low risk	Compliance was estimated by pill count and measuring the ratio of serum EPA to arachidonic acid. Compliance rates for the 3 groups (placebo vs EPA-E 1800 mg/d vs EPA-E 2700 mg/d) were 89.5% (6.8%), 90.3% (5.7%) and 89.5% (5.3%) respectively
Other bias	Low risk	None noted

## EPIC-1 2008

Methods	EPANOVA in Crohn's disease, study 1 (EPIC-1) RCT, parallel, 2-arm (omega 3 vs MCT), 52 weeks Summary risk of bias: moderate or high
Participants	Adults with quiescent Crohn's disease (CDAI) score < 150 N: 188 intervention, 186 control Level of risk for CVD: low Men: 48.1% intervention, 41.1% control Mean age in years (SD): 40.5 (15.2) intervention, 38.2 (13.1) control Age range: 18-70 years Smokers: 30.6% intervention, 34.4% control Hypertension: unclear Medications taken by at least 50% of those in the control group: oral 5-ASA therapy, Systemic corticosteroids - prednisolone, budesonide Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: antibiotic therapy, topical rectal therapy, immune-modifying agents, immune modifiers/biologics Location: Canada, Europe, Israel, USA Ethnicity: not reported
Interventions	Type: supplement (capsule) Comparison: EPA + DHA vs SFA (medium chain triglycerides of short SFAs) Intervention: 2 x 2 1 g gelatin capsules omega-3 free fatty acids (Epanova- 2.2 g EPA, 0.8 g DHA). Dose: 3 g/d EPA + DHA Control: 4 x1 g capsules medium chain triglycerides Compliance: pill counts, 79.2% adhered intervention, 75.6% adhered control

	Length of intervention: mean 52 weeks	
Outcomes	Main study outcome: Crohns relapse-free time Dropouts: 80 intervention, 91 control Available outcomes: total deaths, non-fatal arrhythmias, cancer diagnoses, cancer deaths, adverse events Response to contact: yes (data provided)	
Notes	Study funding: Tillotts Pharma, authors had extensive financial disclosures	
<i><b>Risk of bias</b></i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Randomisation by number generator. Used a centralised randomisation procedure via interactive voice recognition system
Allocation concealment (selection bias)	Low risk	Centralised randomisation (see above)
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double blinding stated, identical capsule (slow-release capsules). Neither investigator nor participant knew the allocation
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Study states double-blind but does not state that outcome assessors were blinded or provide a mechanism for this
Incomplete outcome data (attrition bias) All outcomes	Low risk	Number of dropouts and reasons provided. 171 of 187 in intervention group and 174 of 184 in control group provided data for primary outcome, (7% dropout), though 80 in the intervention group and 91 in the control group terminated early
Selective reporting (reporting bias)	High risk	Trials registration (NCT00613197) first received in 2008, but study started in 2003 and was published in 2008
Attention	Low risk	As investigators were blinded attention bias was not possible
Compliance	Unclear risk	Pill counts, 79.2% adhered intervention, 75.6% adhered control
Other bias	Low risk	No further bias noted

Methods	EPANOVA in Crohn's Disease, Study 2 (EPIC-2) RCT, parallel, 2 arms (omega 3 vs MCT), 58 weeks Summary risk of bias: moderate or high	
Participants	Adults with a confirmed diagnosis of Crohn's Disease and a Crohn's Disease Activity Index (CDAI) score < 150 who are responding to steroid induction therapy N: intervention, 189, control 190 (187 intervention, 188 control analysed) Level of risk for CVD: low (people with quiescent Crohn's disease) Men: 48.1% intervention, 41.1% control Mean age in years (SD): 38.5 (13.8) intervention, 40.0 (13.6) years control Age range: > 16 years Smokers: 25.1% intervention, 37.2% control Hypertension: unclear Medications taken by at least 50% of those in the control group: systemic corticosteroids - prednisolone, budesonide (but tapered and discontinued during the study) Medications taken by 20%-49% of those in the control group: only reported for prior 12 months Medications taken by some, but less than 20% of the control group: only reported for prior 12 months Location: Canada, Europe, Israel, USA Ethnicity: not reported	
Interventions	Type: supplement (capsule) Comparison: EPA + DHA vs SFA (medium chain triglycerides of short SFAs) Intervention: 2 × 2 1 g gelatin capsules omega-3 free fatty acids (Epanova) providing total dose ~2.2 g/d EPA, 0.8 g/d DHA. Dose: ~3.0 g/d EPA + DHA Control: 2 × 2 1 g capsules medium chain triglyceride oil Compliance: measured by patient interviews and pill counts, 75.4% adhered intervention, 81.4% adhered control Length of intervention: mean 58 weeks	
Outcomes	Main study outcome: maintain Crohns symptomatic remission Dropouts: 114 intervention, 112 control Available outcomes: mortality, CV events (nil), cancer diagnoses, adverse events Response to contact: yes (data provided)	
Notes	Study funding: Tillotts Pharma, authors had extensive financial disclosures	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation by number generator. Used a centralised randomisation procedure via interactive voice recognition system
Allocation concealment (selection bias)	Low risk	Centralised randomisation (see above)



**EPIC-2 2008** (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blinding stated, identical capsule (slow-release capsules). Neither investigator nor participant knew the allocation. However no information provided on capsules taste or smell
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Study states double-blind but does not state that outcome assessors were blinded or provide a mechanism for this
Incomplete outcome data (attrition bias) All outcomes	High risk	Number of dropouts and reasons provided, however 114 of 189 in intervention group and 112 of 190 in control group terminated early
Selective reporting (reporting bias)	High risk	NCT00074542. First received 2003, study start 2002. Published 2008. Some outcomes, such as quality of life, stated in trials registry but not in published papers
Attention	Low risk	As investigators were blinded, attention bias was not possible
Compliance	Unclear risk	Measured by patient interviews and pill counts, 75.4% adhered intervention, 81.4% adhered control
Other bias	Low risk	No further bias noted

**EPOCH 2014**

Methods	Older People, Omega-3 and Cognitive Health (EPOCH) RCT, parallel (n-3 EPA + DHA vs MUFA), 18 months Summary risk of bias: low
Participants	Healthy older adults with no cognitive impairment N: 195 intervention, 196 control (reported by author) Level of risk for CVD: low Men: not reported Mean age in years (SD): not reported Age range: not reported, but 65-90 recruited Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: Australia Ethnicity: not reported

Interventions	<p>Type: supplement (fish oil capsules)</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 4 capsules/d (1.72 g/d DHA and 0.60 g/d EPA). Dose: 2.32 g/d EPA + DHA</p> <p>Control: 4 capsules/d (3.960 g/d olive oil and 40 mg/d fish oil)</p> <p>Compliance: count of all unused supplements returned at three-monthly intervals, plus self-report calendars, mailed back on a monthly basis. If compliance fell below 85% (re calendars), they were contacted by a researcher who noted the reasons. Compliance also assessed by erythrocyte membrane n-3 LC PUFA status</p> <p>Length of intervention: 18 months</p>
Outcomes	<p>Main study outcome: change in cognitive performance</p> <p>Dropouts: not reported</p> <p>Available outcomes: mortality (nil), MI, stroke, revascularisation, arrhythmias, CV events</p> <p>Response to contact: yes (data provided)</p>
Notes	<p>Authors reported some events, but don't appear to be published</p> <p>Study funding: EPAX donated the Omega-3 concentrate and Blackmores Pty Ltd donated the placebo and packaging of the Omega-3 concentrate. The trial was supported by the Brailsford Robertson Award 2007-2008 (University of Adelaide and CSIRO Food and Nutritional Sciences), and is funded by a National Health and Medical Research Project Grant (#578800)</p>

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Age-stratified, permuted-block randomisation, with mixed block-sizes (2-8, size unknown to study investigators), 1:1 allocation. Computer-generated randomisation schedule
Allocation concealment (selection bias)	Low risk	An independent researcher prepared allocation to treatment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The researchers, project staff, and participants remained blinded to treatment allocation until the trial was completed and the database locked. However, no information provided on capsules appearance, taste or smell
Blinding of outcome assessment (detection bias) All outcomes	Low risk	As above
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No data for each group presented, and no attrition data presented

Selective reporting (reporting bias)	High risk	Only cognitive functions reported for whole population (not by arm). No secondary outcomes reported (MMSE; perceived health status, depressive symptoms, positive and negative affect, life satisfaction, self-reported cognitive functioning, and functional capacity; blood pressure; biomarkers of glucose, glycated haemoglobin, triglycerides, total cholesterol, HDL, LDL, homocysteine, CRP, MDA, and telomere length)
Attention	Low risk	All had the same contact and attention
Compliance	Unclear risk	Count of all unused supplements returned at 3-monthly intervals, plus self-report calendars, mailed back on a monthly basis. If compliance fell below 85% (re calendars), they were contacted by a researcher who noted the reasons. Compliance also assessed by erythrocyte membrane n-3 LC PUFA status but results not reported
Other bias	Low risk	None noted

**Erdogan 2007**

Methods	RCT, parallel (n-3 EPA + DHA vs unclear), 12 months Summary risk of bias: moderate to high
Participants	People with successful external cardioversion N: unclear intervention, unclear control (54 analysed intervention, 54 control) Level of risk for CVD: high Men: 70% intervention, 74% control Mean age in years (SD): 65.0 (mean for whole group, SD not reported) Age range: not reported Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: Germany Ethnicity: not reported
Interventions	Type: supplement (probably, not described) Comparison: high EPA + DHA vs unclear placebo Intervention: described only as "PUFA" but included in systematic review (Mariani 2013) by Erdogan et al on effects of n-3 PUFA. Dose: unclear

	Control: described only as “placebo” Compliance: not reported Length of intervention: 12 months	
Outcomes	Main study outcome: atrial fibrillation relapse Dropouts: not reported Available outcomes: recurrent AF (reported in Mariani 2013), mortality (none) Response to contact: no reply to date	
Notes	Funding source: not reported	
<i>Risk of bias</i>		
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: “randomly assigned”
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Described as triple blind, but no further details provided (only an abstract with some details in a related trial publication and some in a systematic review by the same author)
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described, but analysis appears to have been carried out blind to intervention/control status
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Number randomised not described
Selective reporting (reporting bias)	Unclear risk	Unclear, no trial registry entry or protocol found
Attention	Unclear risk	Not described
Compliance	Unclear risk	Not described
Other bias	Low risk	None noted

## FAAT 2005

Methods	Fatty Acid Antiarrhythmia Trial - FAAT Randomisation: RCT, parallel, 2 arms, (n-3 EPA + DHA vs MUFA), 12 months Summary risk of bias: moderate or high
Participants	People with implanted cardioverter defibrillators (ICDs) N: intervention 200, control 202 Level of risk for CVD: high (patients with ICDs). Men: intervention 84.5%, control 81.7% Mean age in years (SD): intervention 65.7 (11.6), control 65.3 (11.7) Age range: unclear Smokers: intervention 15%, control 11.4% Hypertension: unclear Medications taken by at least 50% of those in the control group: ACE inhibitors, beta-blockers Medications taken by 20% - 49%: diuretics Medications taken by some, but < 20%: calcium channel blockers, amiodarone, sotalol, type 1 antiarrhythmics Location: USA Ethnicity: intervention 95.5% white, control 96.5% white
Interventions	Type: supplement/capsule Comparison: EPA + DHA vs MUFA Intervention: 4 ×1 g/d fish oil gelatin capsules, 2.6 g/d EPA + DHA (Pronova Biocare, quantities of EPA + DHA unclear). Dose: 2.6 g/d EPA + DHA Control: 4 ×1 g/d olive oil capsules, 4 g/d (in identical gelatin capsules, < 0.06 g/d EPA and < 0.06 g/d DHA) All were advised to use olive oil rather than the common plant seed oils for cooking, dressings, and sauces Compliance: pill counts and platelet phospholipid data suggested greater omega 3 intake in intervention participants. 35% were non-compliers (36.5% intervention, 34.2% control) Duration of intervention: 12 months
Outcomes	Main study outcome: fatal ventricular arrhythmias Dropouts: intervention 13 deaths, unclear no. of dropouts, control 12 deaths, dropouts unclear Available outcomes: deaths, cardiovascular deaths, CVD events, deaths from heart failure, fatal arrhythmias, MI, angina Response to contact: yes (data provided)
Notes	Study funding: the study was supported in part by a grant from the NHLBI, NIH (HL62154)

### *Risk of bias*

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated randomisation tables for each collaborating site, stratified by site

**FAAT 2005** (Continued)

Allocation concealment (selection bias)	Low risk	Author confirmed allocation was concealed from investigators
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Study referred to as “double blind” and gelatin capsules (verum and placebo) were stated as being of identical appearance but no discussion of taste or smell. Author confirmed that investigators and patients were blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	VT and VF events were assessed blinded to allocation
Incomplete outcome data (attrition bias) All outcomes	High risk	Large numbers dropped out so some deaths, etc. may have been missed, 35% discontinued early due to non-compliance but were assessed at study end, data censored for some participants
Selective reporting (reporting bias)	High risk	Trials registry data received September 2005, paper published November 2005
Attention	Low risk	Time and attention appeared similar between the 2 arms
Compliance	High risk	Pill counts and platelet phospholipid data suggested greater omega 3 intake in intervention participants. 35% were non-compliers (36.5% intervention, 34.2% control)
Other bias	Low risk	None noted

**FLAX-PAD 2013**

Methods	Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease (FLAX PAD) RCT, parallel, (n-3 ALA vs mixed fat), 12 months Summary risk of bias: low
Participants	Patients with peripheral artery disease, over 40 years old N: 58 intervention, 52 control Level of risk for CVD: high (all had peripheral artery disease, 80% had hyperlipidaemia) Men: 74.1% intervention, 73.1% control Mean age in years (SD): 67.4 (8.06) intervention, 65.3 (9.4) control Age range: unclear Smokers: 19.2% intervention, 34.6% control Hypertension: 81% intervention, 69.2% control

	<p>Medications taken by at least 50% of those in the control group: lipid lowering medication, antihypertensives, antithrombotics</p> <p>Medications taken by 20%-49% of those in the control group: not reported</p> <p>Medications taken by some, but less than 20% of the control group: insulin or blood sugar-lowering drugs</p> <p>Location: Canada</p> <p>Ethnicity: unclear</p>
Interventions	<p>Type: food supplement (milled flaxseed)</p> <p>Comparison: ALA vs unclear (mix of wheat, wheat germ and mixed dietary oils)</p> <p>Intervention: food products (i.e. bagels, muffins, bars, pasta, buns, and milled seeds) containing 30 g of milled flaxseed daily. Dose: ~6.8 g/d ALA (calculated based on 30 g milled flaxseed/d)</p> <p>Control: placebo food products (i.e. bagels, muffins, bars, pasta, buns, and milled seeds) containing a mixture of wheat, wheat bran, and mixed dietary oils to replace the flaxseed daily</p> <p>Compliance: plasma levels of enterolignans and the n-3 fatty acid ALA were used as markers of dietary compliancy</p> <p>Length of intervention: 12 months</p>
Outcomes	<p>Main study outcome: all-cause mortality, cardiovascular mortality, stroke, and myocardial infarctions</p> <p>Dropouts: 15 intervention, 11 control</p> <p>Available outcomes: blood pressure, lipids, adverse events, plasma ALA</p> <p>Response to contact: yes (but no data provided)</p>
Notes	<p>Different intervention dropout figures reported in two publications (13 or 15)</p> <p>Study funding: funded by government organisations but foods created and provided by a company</p>

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomly selected by a computer programme
Allocation concealment (selection bias)	Low risk	Allocation was concealed. The person who determined if a participant was eligible for inclusion in the trial was unaware, when this decision was made, of which group the subject would be allocated
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Product colour and texture were similar to disguise the composition of the product. Participants, personnel administering the intervention and those assessing the outcomes were blinded to group assignment

## FLAX-PAD 2013 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	All personnel that collected or analysed data were blinded to the intervention
Incomplete outcome data (attrition bias) All outcomes	Low risk	All randomised accounted for in main outcomes
Selective reporting (reporting bias)	High risk	Prospectively registered October 2008, study start October 2008, primary outcome data completed March 2011, end date December 2017. Cardiovascular mortality and measures of adiposity not reported in a useable way
Attention	Low risk	Both groups had the same care
Compliance	Unclear risk	12 in intervention group and 8 in placebo group unwilling to comply with diet
Other bias	Low risk	None noted

## FORWARD 2013

Methods	Randomized trial to assess efficacy of PUFA for the maintenance of sinus rhythm in persistent atrial fibrillation (FORWARD) RCT, parallel, (n-3 EPA + DHA vs MUFA), 12 months Summary risk of bias: low
Participants	Patients with paroxysmal atrial fibrillation N: 289 intervention, 297 control Level of risk for CVD: high Men: 57.8% intervention, 51.9% control Mean age in years (SD): 66.3 (12) intervention, 65.9 (10.5) control Age range: > 21 Smokers: 9% intervention, 6.2% control Hypertension: 92.2% intervention, 90.8% control Medications taken by at least 50% of those in the control group: aspirin, amiodarone, 'any antithrombotic treatment', beta-blockers Medications taken by 20%-49% of those in the control group: anticoagulants Medications taken by some, but less than 20% of the control group: none reported Location: Argentina Ethnicity: not reported
Interventions	Type: supplement (capsule) Comparison: EPA + DHA vs MUFA Intervention: one capsule/ day containing 1 g of n-3 PUFA (Società Prodotti Antibiotici and SigmaTau, Italy) (provided 850 mg to 882 mg EPA/DHA). Dose: 0.85 g/d EPA + DHA



	Control: identical placebo capsule containing olive oil Compliance: not reported. Length of intervention: 12 months	
Outcomes	Main study outcome: survival free of atrial fibrillation Dropouts: 20 intervention, 25 control Available outcomes: mortality, MI, AF, heart failure, stroke, hospitalisation, side effects. Authors supplied further info on CVD events and methodology Response to contact: yes	
Notes	Study funding: through unrestricted grants provided by companies that supplied study drugs, however “these companies did not have representatives on the Steering Committee” who terminated the trial after 1 year	
<i>Risk of bias</i>		
<b>Bias</b>	<b>Authors’ judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote: “Participants were centrally assigned to receive either 1 g of n-3 PUFA or placebo in a ratio of 1:1” - computer generated in blocks of 4 and 6 stratified by study location
Allocation concealment (selection bias)	Low risk	As above, centrally allocated. Communication from authors was ambiguous, stated that the person recruiting <i>was</i> aware of which arm the individual would be allocated to, but that the “study was double-blind, placebo-controlled.”
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: “Each study site will be supplied with study drug and placebo in identically appearing packaging”. “Both placebo and active treatment have the same odour and produce a comparable degree of fishy after-taste”
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: “Patients, investigator staff, persons performing the assessments, and data analysts will remain blind to the identity of the treatment from the time of randomisation until database lock” “The adjudication committee members are unaware of participant allocation and assess all available data and documentation with reference to pre-established criteria”

## FORWARD 2013 (Continued)

Incomplete outcome data (attrition bias) All outcomes	High risk	Quote: “the study was cut short by the trial steering committee due to ‘a slower-than-expected recruitment rate and lower event rates’. This ‘resulted in an underpowered clinical trial unable to verify its hypothesis’. Therefore the outcome data were not as complete as they were initially meant to be”
Selective reporting (reporting bias)	Low risk	Prospectively registered January 2008, study start January 2008, completion August 2011. All outcomes in trials registry appear to have been reported
Attention	Low risk	Both intervention and control given the same exposure to research personnel. 2013 paper: “Clinical outcomes, adherence, and adverse events were assessed 2, 4, 8, and 12 months after randomization”
Compliance	Unclear risk	Not reported
Other bias	Low risk	None noted

## FOSTAR 2016

Methods	Fish Oil in knee OSTeoARthritis (FOSTAR) RCT, parallel, (n-3 EPA + DHA vs low n-3), 24 months Summary risk of bias: low
Participants	Adults aged 40+ years with knee osteoarthritis N: 101 intervention, 101 control Level of risk for CVD: low Men: 41% intervention, 60% control Mean age in years (SD): 60.8 (10) intervention, 61.1 (10) control Age range: > 40 Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: none reported Medications taken by 20%-49% of those in the control group: not reported at baseline, but ‘during’ includes Vit. D ~ 32% Medications taken by some, but less than 20% of the control group: not reported at baseline, but ‘during’ includes Glucocorticoid, HRT/anti-resorptive, both ~ 10% Location: Australia Ethnicity: not reported
Interventions	Type: supplementary food (enriched orange juice) Comparison: high EPA + DHA vs low EPA + DHA plus ALA (replacement unclear, but

	<p>low omega 3)</p> <p>Intervention: 1-3 × a day drink of fruit juice mixed with day total = 15 mL of fish oil supplement (18% EPA, 12% DHA, 4.5 g/day total omega 3). Dose: 4.5 g/d EPA + DHA</p> <p>Control: liquid oral oil 15 mL sunola oil/day (which contains fish oil 2 mL plus 13 mL canola oil) (total omega-3 fat: ≥ 0.45 g EPA + DHA from 15 mL)</p> <p>Compliance: assessed by measuring the oil volume in returned bottles, compliance was &gt; 80% in both groups. Both groups had increases from baseline in plasma EPA and DHA with the high-dose group having substantially larger increases, consistent with compliance with study oil</p> <p>Length of intervention: 24 months</p>	
Outcomes	<p>Main study outcome: change in pain scale of WOMAC index</p> <p>Dropouts: 18 intervention, 16 control</p> <p>Available outcomes: mortality, CVD events, adverse events, analgesic use, bone marrow density, weight gain and serum fatty acids</p> <p>Response to contact: yes</p>	
Notes	<p>Data on quality of life and pain score are presented in a figure and not in a usable format</p> <p>Study funding: government funding</p>	
<i><b>Risk of bias</b></i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Computer-generated random allocation sequence
Allocation concealment (selection bias)	Low risk	A security-protected central automated allocation procedure was used to allocate participants to one of the 2 treatment arms. This was performed centrally at one pharmacy and then used to allocate and administer the oil at each site
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Citrus flavouring was added to both oils to achieve comparable taste and optimise masking. Both were provided in identical dark 500-mL bottles with <i>similar</i> labelling. At the end of the study, 52% of participants were unsure which group to which they had been allocated (50% high dose, 50% low dose). Of the remaining who thought they knew which group they were allocated, only 57% answered correctly, suggesting that blinding had been well maintained

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants and staff involved in patient care and assessment of BMD remained blinded throughout the study
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Oil intolerance in 1 <sup>st</sup> year differed, others appear similar, but numbers confused
Selective reporting (reporting bias)	High risk	Prospectively registered August 2007, recruitment started July 2007, outcomes published 2016. Variety of outcomes such as quality of life stated in trials registry but not published
Attention	Low risk	Same contact and instruction schedule for all participants.
Compliance	Low risk	Assessed by measuring the oil volume in returned bottles, compliance was > 80% in both groups. Both groups had increases from baseline in plasma EPA and DHA with the high-dose group having substantially larger increases, consistent with compliance with study oil
Other bias	Low risk	None noted

## Franzen 1993

Methods	RCT, parallel (n-3 EPA + DHA vs MUFA), 12 months Summary risk of bias: moderate to high
Participants	Adults with documented coronary heart disease N: 15 intervention, 15 control Level of risk for CVD: high Men: unclear Mean age in years (SD): 52 (9) intervention, 54 (7) control Age range: not reported Smokers: 87% intervention, 100% control Hypertension: not reported Medications taken by at least 50% of those in the control group: aspirin, beta-blockers Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Lipid lowering medications were not allowed Location: Germany Ethnicity: not reported

Interventions	Type: fish oil capsules Comparison: EPA + DHA vs MUFA Intervention: 9 × 1 g capsules/day of fish oils (20% EPA, 15% DHA, 3.15 g/day total omega 3). Dose: 3.15 g/d EPA + DHA Control: 9 × 1 g capsules/day olive oil (which contains 6.3 g/day MUFA, 1.35 g/day SFA, 1.35 g/d total omega 6 fat) Compliance: assessed by pill counts and FA in body tissue analysis Length of intervention: 12 months	
Outcomes	Main study outcome: blood lipids and FA in body tissues Dropouts: 0 intervention, 0 control Available outcomes: mortality (nil death), CVD events (nil), lipids (only TC used as the others were different at baseline), adverse events, serum fatty acids Response to contact: yes	
Notes	Study funding: unclear	
<i><b>Risk of bias</b></i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Computer-generated list
Allocation concealment (selection bias)	Unclear risk	No details. They received their initial allocation in a sealed box in person; subsequent doses arrived in the post
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No further details beyond stating “double blind”
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details
Incomplete outcome data (attrition bias) All outcomes	Low risk	No attrition
Selective reporting (reporting bias)	Unclear risk	No trial register or protocol found
Attention	Low risk	No difference between groups
Compliance	Unclear risk	Measured but no results
Other bias	Low risk	None noted

Methods	RCT, parallel, (EPA + DHA vs unclear), 24 months Summary risk of bias: moderate or high	
Participants	Adults with Metabolic syndrome N: unclear, total randomised 101 Level of risk for CVD: low Men: 47% total, no details by group Mean age in years (SD): 55 (10) total Age range: 18-75 years Smokers: 0% intervention, 0% control Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: USA Ethnicity: unclear	
Interventions	Type: supplement (fish oil capsules) Comparison: EPA + DHA vs placebo (unclear what) Intervention: fO3FA capsules 1.8 g of EPA + DHA daily. Dose: 1.8 g/d EPA + DHA Control: matching placebo supplement Compliance: not reported Length of intervention: 12 months	
Outcomes	Main study outcome: change in carotid IMT Dropouts: unclear Available outcomes: lipids, insulin and glucose are stated as secondary outcomes but no usable data published Response to contact: no	
Notes	Results cannot be used as numbers are not reported by study arm Study funding: unclear, but mentions that Pfizer, NIH and “Northwest Lipids Clinic” are partners	
<i>Risk of bias</i>		
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details
Allocation concealment (selection bias)	Unclear risk	No details
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No data

**Gill 2012** (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No data
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No data
Selective reporting (reporting bias)	High risk	Inadequate detail in reporting as no full text publication found; Gill 2014 does give detail on carotid IMT, but not on other primary or secondary outcomes. The trial was prospectively registered (registered July 2006, unclear when recruitment started, final data collection 2011, first data published 2012)
Attention	Unclear risk	No data
Compliance	Unclear risk	No data
Other bias	Unclear risk	No data

**GISSI-HF 2008**

Methods	Gruppo Italiano per la Sperimentazione della Streptochinasi nell'Infarto Miocardico - Heart Failure (GISSI-HF) RCT, parallel, 2 arms (n-3 EPA + DHA vs MUFA), 3.9 years Summary risk of bias: moderate or high
Participants	Patients with chronic heart failure N: 3494 intervention, 3481 control Level of risk for CVD: high Men: 77.8% intervention, 78.8% control Mean age: 67 (11) intervention, 67 (11) control Age range: 18+ years Smokers: 14.4% intervention, 13.9% control Hypertension: 54.0% intervention, 55.2% control Medications taken by at least 50% of those in the control group: ACE inhibitors, beta-blockers, diuretics Medications taken by 20%-49% of those in the control group: spironolactone, digitalis, oral anticoagulants, aspirin, nitrates, statin Medications taken by some, but less than 20% of the control group: ARBs, other antiplatelets, calcium channel blockers, amiodarone Location: Italy Ethnicity: unclear
Interventions	Type: supplement (capsule) Comparison: EPA + DHA vs MUFA

	Intervention:1 capsule per day of 1 g n-3 mainly EPA and DHA as ethyl esters in the average ratio of 1:1.2. Dose: ~0.866 g/d EPA + DHA Control: 1 g/d matching olive oil placebo capsule Compliance: unclear Length of intervention: median 3.9 years	
Outcomes	Main study outcome: time to death or admission to hospital for cardiovascular reasons Dropouts: 34 intervention, 46 control (1004 intervention and 1029 control stopped study treatment) Available outcomes: mortality, CV mortality, MI, stroke, new heart failure, incident AF, resumed arrhythmia gatalitis Response to contact: yes (no data provided)	
Notes	Study funding: funders included Pfizer, AstraZeneca and others	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomly assigned (with stratification by site) to treatment groups
Allocation concealment (selection bias)	Low risk	Randomly assigned (with stratification by site) to treatment groups by a concealed computerised telephone randomisation system
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blinding stated, but taste not reported as masked and blinding of participants not checked
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All events “adjudicated blindly by an ad-hoc committee on the basis of pre-agreed definitions and procedures”
Incomplete outcome data (attrition bias) All outcomes	Low risk	Reasons for attrition and exclusion were stated and addressed. Numbers in each intervention compared to numbers were similar
Selective reporting (reporting bias)	Unclear risk	Published rationale and design (Tavazzi 2004) suggested primary outcomes were deaths and death or CV hospitalisation (published). Secondary outcomes not stated and no trials registry entry found
Attention	Low risk	Scheduled clinic visits at 1, 3, 6 months then 6 monthly until the end of the trial



## GISSI-HF 2008 (Continued)

		(for both arms)
Compliance	Unclear risk	No details
Other bias	Low risk	No further bias noted

## GISSI-P 1999

Methods	Gruppo Italiano per la Sperimentazione della Streptochinasi nell'Infarto Miocardico - Prevention (GISSI-P) RCT, 2 × 2 (n-3 EPA + DHA vs nil), 42 months Summary risk of bias: moderate or high
Participants	People with recent ( $\leq 3$ months) myocardial infarction N: 5666 intervention, 5658 control (99.9% follow-up at study end) Level of risk for CVD: high Men: 85.7% intervention, 84.9% control Mean age in years (SD): 59.3 (10.6) intervention, 59.5 (10.5) years control Age range: < 50 to > 80 Smokers: 42.6% intervention, 42.3% control Hypertension: 36.2% intervention, 34.9% control Medications taken by at least 50% of those in the control group: anti-platelet Medications taken by 20%-49% of those in the control group: ACE inhibitors, beta-blockers Medications taken by some, but less than 20% of the control group: lipid lowering Location: Italy Ethnicity: not reported
Interventions	Type: supplement (capsule) Comparison: EPA + DHA vs nil Intervention: gelatin capsules of omega-3-acid ethyl esters 90 (Omacor), 1/d (850-882 mg/d EPA + DHA daily, ratio 1:2) Dose: ~0.866 g/d EPA + DHA Control: nil (no placebo) Compliance: capsule counts, 11.6% had stopped taking Omacor by 12 months, 28.5% by the end of the study Duration of intervention: median follow-up 40 months
Outcomes	Main study outcome: all cause mortality, CV mortality, stroke, MI Dropouts: unclear (however, all randomised were included in analyses) Available outcomes: total, sudden and CV deaths, MI, stroke, angioplasty or CABG, angina, CHD, cancer diagnosis, cancer death, combined CV events, side effects Response to contact: no
Notes	Numbers are slightly different in different publications (Lancet 1999 paper used as main source). Half of both groups were on vitamin E supplements (300 mg/d synthetic $\alpha$ -tocopherol) as this was the other 2 × 2 intervention Study funding: Bristol Meyers Squibb, Pharmacia Upjohn, Societa Prodotti Antibiotici,

GISSI-P 1999 (Continued)

	Pfizer	
<i>Risk of bias</i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Telephone/computer network, stratified by hospital, based on a biased coin algorithm
Allocation concealment (selection bias)	Low risk	Randomisation by telephone with the co-ordinating centre
Blinding of participants and personnel (performance bias) All outcomes	High risk	No placebo intervention (capsule vs nil) so participants not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	“validation of clinical events ... was assured by an ad-hoc committee of expert cardiologists and neurologists blinded to patients treatment assignment”
Incomplete outcome data (attrition bias) All outcomes	Low risk	Clearly described, good follow-up (< 28% dropped out over 3.5 years)
Selective reporting (reporting bias)	Unclear risk	No study protocol or trials registry entry was found
Attention	Low risk	Slight as no placebo, otherwise similar
Compliance	Unclear risk	Capsule counts, 11.6% had stopped taking Omacor by 12 months, 28.5% by the end of the study
Other bias	Low risk	No further bias noted

HARP 1995

Methods	Harvard Atherosclerosis Reversibility Project (HARP) RCT, (n-3 EPA + DHA vs MUFA), 24 months Summary risk of bias: moderate or high
Participants	Patients with coronary heart disease N: 41 intervention, 39 control (99.9% follow-up at study end) Level of risk for CVD: high Men: 93.5% intervention, 92.9 % control Mean age in years (SD): 62 (7) intervention, 62 (7) years control Age range: 30-75 Smokers: 0% (exclusion criteria)

	<p>Hypertension: 48% intervention, 36% control</p> <p>Medications taken by at least 50% of those in the control group: beta blockers, antiplatelet agents</p> <p>Medications taken by 20%-49% of those in the control group: calcium channel blockers, nitrates</p> <p>Medications taken by some, but less than 20% of the control group: ACE inhibitors, oral hypoglycaemic drugs</p> <p>Location: USA</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: LCn3 vs MUFA</p> <p>Intervention: 12 fish oil capsules/day (Promega, Parke-Davis) in divided doses, preferably after meals. Each fish oil capsule contained 500 mg of n-3 polyunsaturated fatty acids composed of EPA (240 mg), DHA (160 mg) and other (100 mg) (mainly DPA) providing total daily dose of 6 g of n-3 fatty acids. Dose: 6 g/d LCn3</p> <p>Control: olive oil capsules identical in appearance to the fish oil capsules.</p> <p>Compliance: capsule counts and serum level measurements. Adherence averaged 80% intervention, and 90% control with significant levels of adipose n-3 fatty acids in the fish oil group.</p> <p>Duration of intervention: average 28 months</p>
Outcomes	<p>Main study outcome: regression of coronary artery lesions</p> <p>Dropouts: 10 intervention, 11 control</p> <p>Available outcomes: all-cause and CV deaths, fatal and non-fatal MI, stroke, angioplasty or CABG, unstable angina, CHD, cancer diagnosis, combined CV events, side effects</p> <p>Response to contact: yes</p>
Notes	<p>Study funding: National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, Bethesda, Maryland, Warner Lambert-Parke Davis, East Hanover, New Jersey; and by an Established Investigator Award to Dr Sacks from the American Heart Association, Dallas, Texas</p>

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "randomization" stratified by clinical management regime and total/HDL cholesterol ratio
Allocation concealment (selection bias)	Unclear risk	No further details
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "patients and personnel responsible for lab measurements, cardiac catheterization, and analysis of angiography films were blinded to the treatment assignment". Although capsules were identical in appearance, no information on their taste and

## HARP 1995 (Continued)

		smell
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "patients and personnel responsible for lab measurements, cardiac catheterization, and analysis of angiography films were blinded to the treatment assignment"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low attrition rate over 28 months and all reasons are well documented
Selective reporting (reporting bias)	High risk	Trial registered retrospectively after publication
Attention	Low risk	Nothing in description implies the arms were treated differently
Compliance	Low risk	Very clear ( $P < 0.001$ ) differences between arms for the 3 main n-3 components in the fish oil
Other bias	Low risk	None noted

## HERO 2009

Methods	Healthy Eating to Reduce Overweight in people with type 2 diabetes (HERO) RCT, parallel, (n-3 ALA vs low n-3), 12 months Summary risk of bias: moderate or high
Participants	Overweight adults with non-insulin treated diabetes N: 26 intervention, 24 control (analysed, intervention: 18 control: 17) Level of risk for CVD: moderate Male %: not reported Mean age in years (SD): 54 (8.7), not reported by arm Age range: 33-70 years Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: lipid lowering drugs, oral hypoglycemics Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: Australia Ethnicity: not reported
Interventions	Type: food supplement (walnuts) Comparison: ALA vs nil Intervention: 30 g/d snack portions of walnuts (provided 10% MUFA, 10% E PUFA, and a P/S ratio of 1.0) and advised not to take fish oil supplements. ALA dose not reported. Dose: ~3 g/d ALA based on 30 g/d intake of walnuts Control: no supplements

	Both groups were given low-fat isocaloric dietary advice (30% E fat (10% E SFA, 15% E MUFA; 5% E PUFA, P/S ratio of 0.5), 20% E protein and 50% E CHO) plus advice to brisk walk 30 min × 3 times/week Compliance: measured by erythrocyte membrane fatty acid levels which were similar in both groups Duration of intervention: 12 months	
Outcomes	Main study outcome: change in body weight and % body fat Dropouts: 8 intervention, 5 control Available outcomes: all cause mortality (nil deaths), weight, visceral adipose tissue, lipids, glucose, insulin, HbA1c (body fat % and subcutaneous adipose tissue measured but too different at baseline to use) Response to contact: not yet attempted	
Notes	Body fat % was too different between groups at baseline hence data not used Study funding: California Walnuts Commission	
<i><b>Risk of bias</b></i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Randomisation was conducted using a computerised random number generator by a researcher independent of the subject interface
Allocation concealment (selection bias)	Unclear risk	No further details
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: “Subjects, but not dietitians, were blinded to the type of overall diet (a prepackaged 30 g snack portion of walnuts was given to the walnut group unbeknown to the controls)”. However, there was no placebo supplement, so blinding easily broken
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Paper states “code was concealed from the researchers collecting data, as well as from subjects.” However as participants could not be blinded outcome assessors may not have been (problem for measures of adiposity, not for biochemical measures)
Incomplete outcome data (attrition bias) All outcomes	High risk	High dropout rate 35 of 50 analysed (30% attrition rate)
Selective reporting (reporting bias)	Unclear risk	Trial was registered postanalysis

## HERO 2009 (Continued)

Attention	Low risk	Both groups appear to have had same level of attention
Compliance	High risk	ALA levels almost exactly the same in intervention and control
Other bias	Low risk	None noted

## JELIS 2007

Methods	Japan Eicosapentaenoic acid Lipid Intervention Study (JELIS) RCT, parallel, 2-arm (EPA capsule vs nil), 5 years Summary risk of bias: moderate or high
Participants	People with hypercholesterolaemia N: intervention, 9326, control 9319 (analysed intervention 9326, control 9319) Level of risk for CVD: moderate (Patients with hypercholesterolaemia) Men: 32% intervention, 31% control Mean age in years (SD): 61 (8) intervention 61 (9) control Age range: 40-75 years Smokers: 20% intervention, 18% control Hypertension: 36% intervention, 35% control Medications taken by at least 50% of those in the control group: statins Medications taken by 20%-49% of those in the control group: calcium channel blockers, other antihypertensives Medications taken by some, but less than 20% of the control group: beta-blockers, antiplatelet, hypoglycemics, nitrates Location: Japan Ethnicity: Japanese
Interventions	Type: supplement (EPA capsule) Comparison 1: EPA vs nil Intervention: 3 × 2 × 300 mg capsules/d EPA ethyl ester (total dose of 1.8 g/d EPA), after meals. Dose: 1.8 g/d EPA Control: nothing (though all in both groups received “appropriate” dietary advice). All patients in both groups were on statins Compliance: monitored by local physicians and measuring plasma fatty acids concentrations. Study drug regimens, 71% adhered EPA intervention, 73% adhered EPA control, 74% adhered statin Duration of intervention: maximum 5 years, mean 4.7 (1.1) years
Outcomes	Main study outcome: major coronary events Dropouts: 1766 intervention, 1582 control (but all had endpoint evaluation) Available outcomes: major coronary events: sudden cardiac death, fatal or non-fatal MI, unstable angina, angioplasty or CABG. Also all-cause mortality, stroke, peripheral artery disease, cancer, lipids, rise in blood sugar, fasting glucose, HbA1c Response to contact: no

Notes	Study funding: Mochida Pharmaceutical Company	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Statistical co-ordination centre: "permitted block randomisation with a block size of 4"
Allocation concealment (selection bias)	Low risk	Centralised. Statistical coordinating centre (see above)
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not blinded as there was no placebo. Quote: "[o]pen label blinded end point"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"Clinical endpoints ... reported by local physicians were checked by members of a regional organizing committee in a blinded fashion. Then an endpoints adjudication committee ... confirmed them once a year without knowledge of the treatment allocation"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Well documented, dropout numbers low
Selective reporting (reporting bias)	Unclear risk	NCT00231738 registered October 2005, recruitment November 1996 to November 1999, main results published 2007. Rationale and design paper published in 2003 (reported baseline characteristics, so before completed follow-up, but after data collection began). All reported outcomes appear to have been published
Attention	Low risk	Slight, as no placebo provided to control group, but only capsules to intervention group. Otherwise 2 groups appeared to be treated equally
Compliance	Unclear risk	Monitored by local physicians and measuring plasma fatty acids concentrations. Study drug regimens, 71% adhered EPA intervention, 73% adhered EPA control, 74% adhered statin
Other bias	Low risk	No further bias noted

Methods	RCT, parallel, (fish oil vs nil), 12 months Summary risk of bias: moderate or high	
Participants	Patients with persistent atrial fibrillation (AF) on warfarin N: 92 intervention, 90 control (91 and 87 analysed ITT) Level of risk for CVD: high Male %: 82.4 intervention, 72.4 control Mean age in years (SD): 63 (10) intervention, 61(13) control Age range: 18-85 years (inclusion criteria) Smokers: 22.2% intervention, 11.5% control Hypertension: 45.6% intervention, 58.6% control Medications taken by at least 50% of those in the control group: anti-arrhythmic drugs, renin-angiotensin system inhibitors Medications taken by 20%-49% of those in the control group: statins Medications taken by some, but less than 20% of the control group: not reported Location: Australia Ethnicity: not reported	
Interventions	Type: fish oil capsule Comparison: EPA + DHA vs nil Intervention: 6 capsules/day of a fish oil preparation containing a total dose of 1.02 g of EPA and 0.72 g DHA. Participants in the omega-3 group were asked to continue fish oils till a maximum of 1 year or till return of persistent AF. Dose: 1.7 g/d EPA + DHA Control: no supplements. Patients were advised not to take any fish oil supplements All patients underwent cardioversion following randomisation Compliance: was monitored on a weekly basis via telephone and during follow-up by using a pill count plus serum EPA and DHA levels which were significantly increased Duration of intervention: 1 year (or AF recurrence)	
Outcomes	Main study outcome: atrial fibrillation recurrence Dropouts: 4 intervention, 0 control Available outcomes: all-cause mortality (nil death), AF recurrence, time to AF recurrence, adverse events Response to contact: contact not yet established	
Notes	Study funding: the study was funded in part by the National Heart Foundation of Australia and the Pfizer Cardiovascular Lipid Research Grant	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Patients were randomised to a control or an omega-3 group in a 1:1 fashion (no details of method)
Allocation concealment (selection bias)	Unclear risk	No further details



**Kumar 2012** (Continued)

Blinding of participants and personnel (performance bias) All outcomes	High risk	Open label with no placebo control
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open label
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis was conducted
Selective reporting (reporting bias)	Unclear risk	Trial registered 2005 but data collection started 2003
Attention	Unclear risk	Intervention group had capsules, while control group did not. Potential for greater contact and checking with intervention group on this basis, although otherwise both groups seem to have had the same care
Compliance	Low risk	EPA and DHA levels were significantly higher in intervention group
Other bias	Low risk	None noted

**Kumar 2013**

Methods	RCT, parallel, (fish oil vs nil), 12 months Summary risk of bias: moderate or high
Participants	Patients > 60 years with sinoatrial node disease and dual chamber pacemakers N: 39 intervention, 39 control randomised (18 intervention vs 39 control at 12 months) Level of risk for CVD: moderate/high Male %: 46% intervention, 56% control Mean age in years (SD): 78 (7) intervention, 77(8) control Age range: not reported Smokers: not reported Hypertension: 72% Medications taken by at least 50% of those in the control group: statin, renin-angiotensin system inhibitors Medications taken by 20%-49% of those in the control group: anti-arrhythmic drugs Medications taken by some, but less than 20% of the control group: not reported Location: Australia Ethnicity: not reported
Interventions	Type: omega 3 capsule Comparison: EPA + DHA vs nil Intervention: a triglyceride preparation containing a total of 6 g/day of omega-3 polyun-

	saturated fatty acids of which 1.8 g/day were n-3 (1.02 g EPA and 0.72 g DHA). Dose: 1.8 g/d EPA + DHA Control: no supplements Compliance: measured by weekly dietary history and pill count. Fatty acid status measured at randomisation and between 1-3 months post randomisation (blood samples) Duration of intervention: median 378 days	
Outcomes	Main study outcome: atrial fibrillation burden Dropouts: 1 intervention, 0 control Available outcomes: all cause mortality, CV mortality, AF (frequency and duration but not recurrence so not used), adverse events Response to contact: written but no contact yet	
Notes	Study funding: unclear	
<i><b>Risk of bias</b></i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Randomisation was performed using sequentially numbered, opaque, sealed envelopes
Allocation concealment (selection bias)	Low risk	As above
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open label design
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "At each visit, stored AT/AF diagnostic data were retrieved in an un-blinded fashion"
Incomplete outcome data (attrition bias) All outcomes	High risk	Only 1 lost, and reason explained. 21 of the 39 randomised to the intervention were crossed over to control at 6 months so 12-month outcomes are reported for 17/18 intervention while baseline characteristics are reported for the 39 patients
Selective reporting (reporting bias)	Low risk	Trial prospectively registered and outcomes stated were reported
Attention	Unclear risk	As only the intervention group had supplements there was potential for attention differences. Other contact appears the same

Compliance	Low risk	EPA was 3-fold higher and DHA 1.8 fold higher compared with controls. EPA and DHA did not change significantly in controls upon repeat testing
Other bias	High risk	Odd design - 21 of the 39 randomised to the intervention were crossed over to control at 6 months

## Lorenz-Meyer 1996

Methods	RCT- parallel, 2 arms (omega 3 vs corn oil), 12 months Summary risk of bias: low
Participants	People with Crohn's disease in remission (but with a recent relapse) N: 70 intervention, 63 control Level of risk for CVD: low Men: 35.7% intervention, 27.0% control Mean age in years (SD): 29.5 (9.6) intervention, 31.8 (10.9) control Age range: 17-62 years intervention, 17-65 years control Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: methylprednisolone (all for 1st 8 weeks) Medications taken by 20%-49%: not reported Medications taken by some, but < 20%: not reported Location: Germany Ethnicity: not reported
Interventions	Type: supplement (fish oil) Comparison: EPA + DHA vs omega 6 Intervention: 2 × 3 1 g gelatin capsules/d of ethylester fish oil concentrate (3.3 g/d EPA + 1.8 g/d DHA). Dose: 5.1 g/d EPA + DHA Control: 2 × 3 1 g gelatin capsules/d of corn oil Compliance: pill count, 5 non-compliant patients, among compliant patients, 18 were censored (for not using the medication for 3 continuous weeks) Duration of intervention: 12 months
Outcomes	Main study outcome: Crohn's disease duration of remission Dropouts: unclear Available outcomes: mortality (nil), Crohn's disease activity and relapses, serum triglycerides Response to contact: yes (methodological details provided)
Notes	There was a third arm of dietary advice (for low CHO diet) Study funding: not reported

*Risk of bias*

**Lorenz-Meyer 1996** (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised within the centres in blocks of six (block size blinded to the centres)
Allocation concealment (selection bias)	Low risk	Author reported allocation was concealed
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "Double blind conditions were intended for the verum-placebo comparisons". Author stated that capsules were identical in appearance (taste not mentioned)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Primary outcome was relapses "classified in a blind fashion by a primary end-point committee"
Incomplete outcome data (attrition bias) All outcomes	High risk	Participants were accounted for based on the main outcome of the study (relapses), however 20% omitted from analyses and numbers confusing
Selective reporting (reporting bias)	Unclear risk	No trials registry entry or protocol found
Attention	Low risk	All patients were seen by their physician in the respective centre after regular time intervals (1, 2, 3, 6, 9 and 12 months)
Compliance	Unclear risk	Pill count, 5 non-compliant patients, among compliant patients, 18 were censored (for not using the medication for three continuous weeks). 23 of 133 non-compliant
Other bias	Low risk	None noted

**MAPT 2017**

Methods	Multidomain Alzheimer Preventive Trial (MAPT) 4 arms RCT, parallel, (n-3 ± multidomain intervention vs placebo ± multidomain intervention), 36 months Summary risk of bias: low
Participants	Population: people aged at least 70 years without dementia but with memory complaint, IADL limitation or slow gait speed N: 840 intervention (arms 1 and 3), 840 control (arms 2 and 4) randomised. Numbers analysed differ by outcome Level of risk for CVD: low

	<p>Men: 37.2% intervention, 34.5% control. (combined groups)</p> <p>Mean age in years (SD): 75.6 (4.7) and 74.4 (4.4) intervention, 75.1 (4.3) and 75 (4.1) control</p> <p>Age range: not reported</p> <p>Smokers: not reported</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: not reported</p> <p>Medications taken by 20%–49% of those in the control group: not reported</p> <p>Medications taken by some, but less than 20% of the control group: not reported</p> <p>Location: France and Monaco</p> <p>Ethnicity: not reported</p>	
Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: EPA + DHA vs paraffin oil (non-fat)</p> <p>Intervention</p> <p>Arm 1: omega-3 (V0137 CA 800 mg/d DHA; 225 mg/d EPA in soft caps). Dose for arms 1 and 3: 1.025 g/d EPA + DHA</p> <p>Arm 3: omega 3 (V0137 CA 800 mg/d DHA; 225 mg/d EPA in soft caps) plus multi-domain intervention (nutrition, physical exercise, cognitive stimulation, social activities)</p> <p>Control:</p> <p>Arm 2: placebo capsules containing flavoured paraffin oil. All capsules were supplied by Pierre Fabre Médicament (Castres, France)</p> <p>Arm 4: placebo capsules plus multi-domain intervention (nutrition, physical exercise, cognitive stimulation, social activities)</p> <p>Compliance: adherence to study interventions was assessed every 6 months. For supplementation, adherence was assessed by counting the number of capsules returned by participants (or based on treatment dates if the number of capsules was missing). Furthermore, biological samples were obtained at baseline and after 12 months to assess concentrations of DHA and EPA in red blood cell membranes</p> <p>Duration of intervention: 36 months</p>	
Outcomes	<p>Main study outcome: change in cognitive function )</p> <p>Dropouts: 200 intervention, 194 control</p> <p>Available outcomes: mortality, CVD events, haemorrhagic stroke, adverse events, functional capacity, other cognitive functions, safety and tolerability</p> <p>Response to contact: no</p>	
Notes	<p>Study funding: G�rontop�le of Toulouse, the French Ministry of Health (PHRC 2008, 2009), the Pierre Fabre Research Institute (manufacturer of the polyunsaturated fatty acid supplement), Exhonit Therapeutics, and Avid Radiopharmaceuticals</p>	
<i>Risk of bias</i>		
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomly assigned (1:1:1:1) to the combined intervention (i.e. the multidomain intervention plus polyunsaturated fatty acids), the multidomain inter-

		vention plus placebo, polyunsaturated fatty acids only, or placebo only. A computer-generated randomisation procedure (done by ClinInfo, a subcontractor) was used with block sizes of 8 and stratification by centre
Allocation concealment (selection bias)	Low risk	A clinical research assistant, who was not involved in the assessment of participants, used a centralised interactive voice response system to identify which group to allocate the participant to, and which lot number to administer
Blinding of participants and personnel (performance bias) All outcomes	Low risk	All participants and study staff were blinded to polyunsaturated fatty acid or placebo assignment - both sets of capsules looked and tasted identical. In view of the nature of the multidomain intervention, the study was unblinded for this component, but the independent neuropsychologists who were trained to assess cognitive outcomes were blinded to group assignment
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All participants and study staff were blinded to polyunsaturated fatty acid or placebo assignment-both sets of capsules looked and tasted identical. In view of the nature of the multidomain intervention, the study was unblinded for this component, but the independent neuropsychologists who were trained to assess cognitive outcomes were blinded to group assignment. Data analysts were not blinded to group assignment, but two data managers, one statistician (CC) and two physicians (SA and BV) did a blinded data review
Incomplete outcome data (attrition bias) All outcomes	Low risk	1680 participants were enrolled and randomly allocated, the modified intention-to-treat population (N = 1525), i.e. 155 excluded (9% over 3 years)
Selective reporting (reporting bias)	Low risk	Protocol registered ClinicalTrials.gov (NCT00672685) - outcomes match report. Because of advances in the field since our trial was designed in 2007, we decided to modify the primary outcome from one cognitive test to a composite cog-

# MAPT 2017 (Continued)

		<p>nitive score, which is now thought to be a better endpoint</p> <p>This protocol amendment was submitted to the local ethical committee on 2 February 2015 and was subsequently approved</p>
Attention	Low risk	Both groups assessed at baseline, 6, 12, 24, 36 months. Groups 1 and 2 only differed by content of capsules
Compliance	Unclear risk	Adherence to study interventions was assessed every 6 months, by counting the number of capsules returned (or based on treatment dates if the number of capsules was missing). Biological samples were obtained at baseline and after 12 months to assess concentrations of DHA and EPA in red blood cell membranes, but outcomes not reported
Other bias	Low risk	None noted

# MARGARIN 2002

Methods	<p>Mediterranean alpha-linolenic enriched Groningen dietary intervention study (MARGARIN)</p> <p>RCT, factorial 2 × 2 (ALA rich margarine vs LA rich margarine, also nutrition education vs no education but this is not included), 2 years</p> <p>Summary risk of bias: low</p>
Participants	<p>Hypercholesterolemic adults with 2 or more CVD risk factors</p> <p>N: total 282 randomised; 114 intervention (51 with nutrition education, 58 without NE) 157 control (52 with NE, 105 without NE)</p> <p>Level of risk for CVD: moderate (multiple cardiovascular risk factors, 10-year IHD risk ~20%)</p> <p>Men: 41.9% intervention, 45.7% control</p> <p>Mean age in years (SD): 54.4 (9.5) intervention, 53.9 (9.8) control</p> <p>Age range: 30-70</p> <p>Smokers: 49.1% intervention, 49.3% control</p> <p>Hypertension: 52.9% intervention, 45.3% control (on anti-hypertensives)</p> <p>Medications taken by at least 50% of those in the control group: antihypertensives</p> <p>Medications taken by 20%-49%: not reported</p> <p>Medications taken by some, but &lt; 20%: not reported</p> <p>Location: the Netherlands</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplementary food (ALA enriched margarine)</p> <p>Intervention: provided with ALA rich margarine (80% fat of which 15% was ALA and 46% LA) to be eaten ad libitum. Dose: average intake 6.3 g/d ALA (was also 1 g/d ALA</p>

	<p>in the control group)</p> <p>Control: provided with linoleic rich margarine (80% fat of which 0.3% was ALA and 58% LA), identical in taste and packaging. Both margarines contained 0.66 mg vit E/g, 9 micro-g vit A/g and 0.023 micro-g vit D/g</p> <p>Comparison: ALA vs omega 6</p> <p>Compliance: serum fatty acids used to assess, ALA rose by 0.47 mol % (SD 0.04) and 0.36 mol% (SD 0.04) intervention arms (with and without NE) and fell by 0.06 mol % (SD 0.04) and 0.11 mol % (SD 0.03) control arms (with and without NE), significantly different.</p> <p>Duration of intervention: 24 months</p>
Outcomes	<p>Main study outcome: cardiovascular risk factors and IHD risk</p> <p>Dropouts: unclear</p> <p>Available outcomes: total and CV deaths, non-fatal MI, stroke, CABG and angioplasty, BMI, lipids, BP</p> <p>Response to contact: yes</p>
Notes	<p>Study funding: Prevent fund and Unilever Research</p> <p>Other intervention (2 × 2) was educational, teaching a multifactorial dietary intervention. It was excluded as multifactorial</p>

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated random allocation, allocated by an independent trial coordination centre that organised masked distribution of margarines
Allocation concealment (selection bias)	Low risk	Allocated by an independent trial coordination centre which organised masked distribution of margarines
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind; the 2 margarines are described as identical as to taste and packaging (though not reported as checked)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	2 independent physicians, a cardiologist and a general practitioner validated and classified results in a blinded fashion
Incomplete outcome data (attrition bias) All outcomes	Low risk	The number randomised to each arm was unclear, but one publication clarifies (55 randomised to each arm, 51 intervention and 52 control analysed)
Selective reporting (reporting bias)	Unclear risk	No study protocol or trials registry entry was found.



## MARGARIN 2002 (Continued)

Attention	High risk	There was no difference in attention between margarine types, but the dietary advice group spent more time with study staff than the control group, and some (not quite randomly allocated) were sent individual motivational letters (Siero 2000)
Compliance	Low risk	Serum fatty acids used to assess, ALA rose by 0.47 mol% (SD 0.04) and 0.36 mol % (SD 0.04) intervention arms (with and without NE) and fell by 0.06 mol % (SD 0.04) and 0.11 mol % (SD 0.03) control arms (with and without NE), Significantly different
Other bias	Low risk	No further bias noted

## MARINA 2011

Methods	Modulation of Atherosclerosis Risk by Increasing dose of n-3 fatty Acids (MARINA) RCT, parallel, 4 arms (n-3 PUFA 3 different doses or olive oil placebo), 12 months Summary risk of bias: low
Participants	Non-smoking men and women aged 45-70 years N: intervention. 279 in 3 groups (G1 0.45 g/d n = 94, G2 0.9 g/d n = 93, G3 1.8 g/d n = 92); control: 88 (analysed G1 0.45 g/d n = 81, G2 0.9 g/d n = 80, G3 1.8 g/d n = 80, control 71) Level of risk for CVD: low Men: 38.7% intervention, 38.6% control Mean age in years (CI): G1: 55 (53, 56), G2: 55 (54, 56), G3: 55 (54, 57) intervention 55 (54,57) control Age range: 45-70 Smokers: 0% intervention, 0% control Hypertension: 5.4% intervention, 5% control Medications taken by at least 50% of those in the control group: none Medications taken by 20%-49% of those in the control group: none Medications taken by some, but less than 20% of the control group: statins, antihypertensives, HRT, thyroxine Location: UK Ethnicity: G1: white 80.9%, black 4.3%, Asian 6.4%, East Asian 4.3%, other 4.3% G2: white 78.5%, black 6.5%, Asian 10.8%, East Asian 0%, other 4.3% G3: white 85.9%, black 1.1%, Asian 2.2%, East Asian 4.3%, other 6.5% Control: white 77.3%, black 10.2%, Asian 6.8%, East Asian 2.3%, other 3.4%
Interventions	Type: supplement (fish oil capsules) Comparison 1: EPA + DHA vs MUFA Comparison 2: high EPA + DHA vs low EPA + DHA Intervention: 3 × 1 g oil gelatin capsule/day consisting of blend of EPA concentrate,

	<p>DHA concentrate, refined olive oil and 0.1% peppermint oil. Providing a daily dose of: 0.45 g, 0.9 g, or 1.8 g per day (all with EPA/DHA ratio of 1.51). Dose: 1.8 g/d EPA + DHA (G3 used for outcomes)</p> <p>Control: 3 gelatin capsules/ day containing refined olive oil + 0.1% peppermint oil</p> <p>Compliance: measured by capsule counting and erythrocyte lipids for proportion of EPA/DHA @ baseline, 6 months, 12 months. 88.5% of participants consumed &gt; 90% of capsules provided. EPA and DHA in erythrocyte lipids increased in dose-dependent manner compared with placebo, indicating long-term compliance with intervention</p> <p>Length of intervention: 12 months</p>	
Outcomes	<p>Main study outcome: endothelial function, arterial stiffness</p> <p>Dropouts: 38 intervention (13,13,12), 17 control</p> <p>Available outcomes: lipids, dietary intake, CRP, BP (supine and ambulatory - numeric data not provided, but study states that there were no significant differences between arms). Weight data not used as baseline is different between groups (FMD, arterials stiffness, carotid intima media thickness, heart rate variability, heart rate, endothelial progenitor cells reported but not used)</p> <p>Contact with authors: yes (many outcomes above provided in end of study report from authors)</p>	
Notes	<p>Outcome data used G3 (highest dose) vs placebo for continuous outcomes and combined the 3 intervention groups vs placebo for dichotomous outcomes</p> <p>Study funding: Food Standards Agency</p>	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote: “the random allocation sequence was generated with a computer program by using the process of minimisation to balance age, sex and ethnicity between treatment groups.”
Allocation concealment (selection bias)	Low risk	Quote: “We enrolled eligible participants and the study database program allocated a serious of capsules to the participant. The treatments associated with the capsule codes were concealed from all investigators and associated clinical staff until the data analysis was complete. The code breaker was an employee of MedSciNet who constructed the trial database.”
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: “We enrolled eligible participants and the study database program allocated a serious of capsules to the participant. The treatments associated with the capsule codes were concealed from all investigators

## MARINA 2011 (Continued)

		and associated clinical staff until the data analysis was complete. The code breaker was an employee of MedSciNet who constructed the trial database.” “blends of the test fat with 0.1% peppermint oil to disguise the fish taste of the EPA and DHA” (peppermint oil in both intervention and control capsules)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: “We enrolled eligible participants and the study database program allocated a series of capsules to the participant. The treatments associated with the capsule codes were concealed from all investigators and associated clinical staff until the data analysis was complete. The code breaker was an employee of MedSciNet who constructed the trial database.”
Incomplete outcome data (attrition bias) All outcomes	Low risk	15% withdrawal, reasons for attrition reported
Selective reporting (reporting bias)	Low risk	Outcomes published match trials register. Registered September 2008, trial started June 2008, ended December 2010, main publication 2011
Attention	Low risk	No difference between groups
Compliance	Low risk	Statistically significant difference in erythrocyte omega 3 fats at 12 months between different arms
Other bias	Low risk	None noted

## MENU 2016

Methods	Metabolism, Exercise and Nutrition at UCSD (MENU) RCT, parallel, (walnut rich moderate fat diet vs moderate fat diet), 12 months Summary risk of bias: moderate or high
Participants	Overweight and obese women, of whom half were insulin resistant N: 82 intervention, 81 control (analysed, intervention: 65 control: 61) Level of risk for CVD: low Men: 0% intervention, 0% control Mean age (SD) years: 51 (NR) intervention, 50 (NR) control Age range: 22-67 years intervention, 25-72 years control Smokers: not reported Hypertension: not reported

	<p>Medications taken by at least 50% of those in the control group: not reported</p> <p>Medications taken by 20%-49% of those in the control group: not reported</p> <p>Medications taken by some, but less than 20% of the control group: 10% were on cholesterol medications</p> <p>Location: USA</p> <p>Ethnicity: Hispanic 18% intervention, 14% control; black 9% intervention, 3% control; Asian American 1% intervention, 4% control; white non-Hispanic 71% intervention, 78% control</p>	
Interventions	<p>Type: food and advice</p> <p>Comparison: walnut rich moderate fat diet (ALA) vs moderate fat diet (MUFA)</p> <p>Intervention: advice to follow walnut-rich higher fat diet (35%E fat with limited SFA, MUFA encouraged, including 42 g/d walnuts (provided by study), 45%E CHO, 20%E protein). Participants given print materials on diet and exercise, attended group sessions weekly for 1st 4 months, biweekly for next 2 months, then monthly to 1 year), provided web-based tracking for dietary constituents, scale, pedometer, measuring cups and exercise videos. Regular dietetic and group leader support. Clinic visits were at 0, 6 and 12 months. Dose: ~4.2 g/d ALA (calculated based on 42 g/d intake of walnuts)</p> <p>Control: exactly as intervention for goals, materials and support except higher fat diet did not include walnuts (35% E fat with limited SFA, MUFA encouraged, 45%E CHO, 20%E protein)</p> <p>Compliance: walnut consumption reported on form and nuts provided. Red blood cell ALA significantly higher in intervention at 12 months than control</p> <p>Duration of intervention: 12 months</p>	
Outcomes	<p>Main study outcome: body weight</p> <p>Dropouts: 13 of 82 intervention, 12 of 81 control</p> <p>Available outcomes: weight, waist circumference, HDL and LDL cholesterol, triglycerides, insulin, glucose, HOMA-IR, HOMA-beta, CRP and IL-6 (estradiol, SHBG, nutrient gene interactions, physical activity and heart rate also presented)</p> <p>Response to contact: no reply received to date</p>	
Notes	<p>Study funding: National Cancer Institute and California Walnut Commission</p>	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation stratified by age and insulin resistance
Allocation concealment (selection bias)	Unclear risk	No details
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open study, participants were advised on their diets extensively
Blinding of outcome assessment (detection bias)	Unclear risk	Blinding not mentioned, so unclear for their primary outcome, weight

**MENU 2016** (Continued)

All outcomes		
Incomplete outcome data (attrition bias) All outcomes	Low risk	Paper states ITT analysis but 25 dropouts (15%) not included in 1 year data, but dropout reasons clear
Selective reporting (reporting bias)	Low risk	Pre-registered, all mentioned outcomes reported at 12 months
Attention	Low risk	Appear very equal
Compliance	Low risk	Statistically significant difference between intervention and control arms for ALA in blood cell membranes at 12 months
Other bias	Low risk	None noted

**Mita 2007**

Methods	RCT, parallel, (EPA capsules vs nil), 2 years Summary risk of bias: moderate to high
Participants	Japanese type 2 diabetics N: intervention. 40, control: 41 (analysed 30, 30) Level of risk for CVD: moderate Men: 53% intervention, 67% control Mean age in years (SD): 59 (11.2) intervention 61.2 (8.4) control Age range: not reported Smokers: 40% intervention, 43% control Hypertension: not reported Medications taken by at least 50% of those in the control group: oral hypoglycemics Medications taken by 20%-49% of those in the control group: insulin, lipid lowering drugs, antihypertensives Medications taken by some, but less than 20% of the control group: antithrombotics Location: Japan Ethnicity: 100% Japanese
Interventions	Type: supplement (EPA oil capsules) Comparison: EPA vs nil Intervention: 1800 mg/d EPA EPADEL capsules (Mochida Pharmaceutical Co Ltd Japan)- 98% pure ethyl-ester EPA (unclear how many caps). Dose: ~1.8 g/d EPA Control: no intervention Compliance: checked during 3 month reviews throughout trial and 5 participants were excluded for poor compliance but no details on method or results Length of intervention: mean 2.1 (0.2) years
Outcomes	Main study outcome: progression of diabetic macroangiopathy measured by carotid intima-media thickness and brachial-ankle pulse wave velocity Dropouts: 10 intervention, 11 control

**Mita 2007** (Continued)

	Available outcomes: BMI, lipids, BP, HbA1c, cancer diagnosis Response to contact: not yet attempted	
Notes	Blood pressure data not used as groups are different at baseline Study funding: not stated	
<i><b>Risk of bias</b></i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Patients randomly divided into 2 groups matched for age and gender
Allocation concealment (selection bias)	Unclear risk	No details
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open label
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessors of main study outcomes were blinded to the treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Dropout rate (26%) over 2 years. All dropouts explained, however, 5 were excluded for poor compliance but no clear predefined protocol for exclusion
Selective reporting (reporting bias)	Unclear risk	No protocol
Attention	Low risk	All participants had the same contact
Compliance	Unclear risk	Compliance measured but no clear methods or reported results
Other bias	Low risk	None noted

**NAT2 2013**

Methods	Nutritional AMD Treatment-2 (NAT2) RCT, parallel, (EPA + DHA vs MUFA), 36 months Summary risk of bias: low
Participants	Patients with early age related macular degeneration N: 150 intervention, 150 control Level of risk for CVD: high (92.5% intervention and 79.8 controls had past CVD) Men: 31.3% intervention, 39.5% control Mean age in years (SD): 73.9 (6.6) intervention, 73.2 (6.8) control

	<p>Age range: 55-85</p> <p>Smokers: 6.7% intervention, 8.5% control</p> <p>Hypertension: 58% total (not reported by study arm)</p> <p>Medications taken by at least 50% of those in the control group: lipid-lowering medication</p> <p>Medications taken by 20%-49% of those in the control group: agents acting on renin-angiotensin system, anti-inflammatory and anti-rheumatic products</p> <p>Medications taken by some, but less than 20% of the control group: insulin or blood sugar lowering drugs</p> <p>Location: France</p> <p>Ethnicity: unclear</p>	
Interventions	<p>Type: supplement (fish oil capsule)</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 3 daily fish oil capsules containing 1110 total n-3 FAs (EPA: 270 mg/day DHA: 840 mg/day) and vit E: 6 mg/day. Dose: 1.1 g/d EPA + DHA</p> <p>Control: 3 × 602 mg olive oil capsules a day containing 0.2 g total PUFA and vit E: 0.09 g/d</p> <p>Compliance: assessed during visits from unused capsules and serum PUFA levels. Overall compliance over the 3 years; 69.4% intervention, 70.5% control</p> <p>Length of intervention: 36 months</p>	
Outcomes	<p>Main study outcome: time to occurrence of choroidal new vessels (CNV) in the study eye from prospective assessment of fluorescein angiography</p> <p>Dropouts: 29 intervention, 34 control</p> <p>Available outcomes: all cause mortality, plasma lipids, adverse events, serum FAs</p> <p>Response to contact: yes (no added data)</p>	
Notes	<p>TG data not used as presented as median (5th-95th percentile)</p> <p>Study funding: Laboratoire Chauvin, Bausch &amp; Lomb Inc</p>	
<i>Risk of bias</i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	QL Rancin software was used to generate the randomisation list before enrolment. The patients and the study personnel both were blinded to the treatment assignment
Allocation concealment (selection bias)	Low risk	As above
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The capsules had the same appearance, the same size, and the same weight (602 mg) in both DHA and placebo groups. No masking flavour was added to the capsules, which were otherwise odourless

**NAT2 2013** (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Author confirmed blinding of outcome assessors
Incomplete outcome data (attrition bias) All outcomes	Low risk	Any temporary discontinuation of the treatment was considered to be a deviation from the study protocol. Discontinuation for more than 5 months was considered to be a major deviation from the study protocol. Participants who dropped out were taken in account in the survival analysis and occurrence of CNV and were counted at last angiography performed
Selective reporting (reporting bias)	Unclear risk	ISRCTN98246501. Retrospectively registered May 2007, recruitment started December 2003, completed November 2008, key publication 2013
Attention	Low risk	Same amount of time spend with both study arms
Compliance	Low risk	Assessed during visits from unused capsules and serum PUFA levels. Overall compliance over the 3 years; 69.4% intervention, 70.5% control
Other bias	Low risk	None noted

**Nodari 2011 AF**

Methods	RCT, parallel, (DHA + EPA vs MUFA), 12 months Summary risk of bias: moderate or high
Participants	Patients with persistent atrial fibrillation with at least 1 relapse after cardioversion N: 102 intervention, 103 control. (analysed, intervention: 94 control: 94) Level of risk for CVD: high Men: 70% intervention, 63% control Mean age in years (SD): 70 (6) intervention, 69 (9) control Age range: not reported (18-80 inclusion criteria) Smokers: 10% intervention, 9.1% control Hypertension: 47% intervention, 40% control Medications taken by at least 50% of those in the control group: beta-blockers, ACE inhibitors, anticoagulant therapy, amiodarone Medications taken by 20%-49% of those in the control group: diuretics, antiplatelet, statins Medications taken by some, but less than 20% of the control group: calcium channel blockers



	Location: Italy Ethnicity: not reported
Interventions	Type: supplement (omega-3-acid ethyl esters 90: Omacor) Comparison: EPA + DHA vs MUFA Intervention: 2 × 1 g/d Omacor (total 1.7 g/d EPA + DHA at a ratio of 0.9 to 1.5). Dose: 1.7 g/d EPA + DHA Control: 2 × 1 g/d olive oil (gelatin capsules identical in appearance to Omacor) Compliance: no details Duration of intervention: 12 months
Outcomes	Main study outcome: probability of maintenance of sinus rhythm Dropouts: 6 intervention, 5 control Available outcomes: adverse events, AF recurrence (nil death) Response to contact: no
Notes	Study funding: 'Centro per lo Studio ed il Trattamento dello Scompenso Cardiaco' of the University of Brescia, Brescia, Italy. The work of Dr Campia was supported by National Institutes of Health grant K12 HL083790-01a1

### ***Risk of bias***

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Random assignment followed a computer-generated randomisation list obtained using blocks of size 4
Allocation concealment (selection bias)	Low risk	The randomisation schedule was kept in the research pharmacy area and was available only to unblinded pharmacy personnel until after the database was locked. At that time, the unblinded patient treatment information was made available to the investigators
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Placebo gelatin capsules identical in appearance to Omacor. However no information provided as to their smell and taste
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details
Incomplete outcome data (attrition bias) All outcomes	Low risk	All randomised were accounted for. ITT analysis for main outcomes

**Nodari 2011 AF** (Continued)

Selective reporting (reporting bias)	Unclear risk	NCT01198275. Registered retrospectively in September 2010, study started January 2006, completed May 2008, main publication 2011
Attention	Low risk	No difference between groups
Compliance	Unclear risk	No details
Other bias	Low risk	None noted

**Nodari 2011 HF**

Methods	RCT, parallel, (DHA + EPA vs MUFA), 12 months Summary risk of bias: moderate or high
Participants	People with heart failure (non-ischaemic dilated cardiomyopathy) N: 67 intervention, 66 control. (analysed, intervention: 67 control: 66) Level of risk for CVD: high Men: 95.5% intervention, 84.9% control Mean age in years (SD): 61 (11) intervention, 64 (9) control Age range: not reported (18-75 inclusion criteria) Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: beta-blockers, ACE inhibitors, furosemide, amiodarone, aldosterone blockers Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: statins, ARB Location: Italy Ethnicity: not reported
Interventions	Type: supplement (Omacor) Comparison: EPA + DHA vs MUFA Intervention: 2 × 1 g/d Omacor (1.7 g/d EPA + DHA at a ratio of 0.9 to 1.5) Control: 2 × 1 g/d olive oil (gelatin capsules identical in appearance to Omacor) Compliance: pill counts - participants were withdrawn if < 80% capsules taken (none were withdrawn). Fatty acid EPA + DHA 0.83% in intervention group, 0.41% in control group Duration of intervention: 12 months
Outcomes	Main study outcome: left ventricular function and functional capacity Dropouts: 0 intervention, 0 control Available outcomes: mortality (nil death), combined CVD events, AF, BMI, hospitalisation for cardiovascular reasons, hospitalisation for worsening heart failure, lipids, blood glucose (but too different at baseline to use), serum cytokine Response to contact: yes

Notes	Study funding: Centro per lo Studio ed il Trattamento dello Scompenso Cardiaco, one author was a consultant for 8 pharmaceutical companies	
<i>Risk of bias</i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Quote: “randomised”
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Paper states that placebo and verum were identical and that the study was double blind, but blinding of participants not checked. Author confirmed investigators not blinded
Blinding of outcome assessment (detection bias) All outcomes	High risk	Author confirmed assessors not blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear whether all participants were assessed for all outcomes (e.g. hospitalisation) , but some outcomes report no attrition
Selective reporting (reporting bias)	Unclear risk	NCT01223703 - study registration October 2010, recruitment November 2007 to June 2009. Retrospective
Attention	Low risk	No suggestion of this, and investigators appeared blinded (so could not differ in attention provided by allocation)
Compliance	Low risk	See characteristics table
Other bias	Low risk	None noted

#### Norouzi 2014

Methods	RCT, parallel, (MorDHA capsules vs unclear placebo), 14 months Summary risk of bias: moderate or high
Participants	Patients with chronic traumatic spinal cord injury N: 55 intervention, 55 control. (analysed, intervention: 54 control: 50) Level of risk for CVD: low Men: 81.5% intervention, 82% control Mean age in years (SD): 51.15 (13.43) intervention, 54.12 (11.76) control

	Age range: 15-74 years intervention, 30-74 years control Smokers: 0% (exclusion criteria) Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: Iran Ethnicity: not reported	
Interventions	Type: supplement (n-3 capsules) Comparison: EPA + DHA vs placebo (unclear what) Intervention: 2 MorDHA capsules (providing 870 mg DHA and 130 mg EPA) per day. Dose: 1 g/d DHA + EPA Control: 2 placebo capsules per day. Both capsules were similar in colour, shape, and taste. Both groups received one calcium capsules per day consisting of 1000 mg calcium and 400 IU vitamin D Compliance: pill counts - compliance averaged 80% in both groups Duration of intervention: 14 months	
Outcomes	Main study outcome: professionals evaluation of neurological function Dropouts: 1 intervention, 5 control Available outcomes: functional measures (total and sub-scales), BMI, leptin and adiponectin concentration Response to contact: no	
Notes	Study funding: PhD university funding. Omega 3 capsules were provided by Minami Nutrition Co (Aartselaar, Belgium) and placebo capsules were supplied by Zahravi Pharmaceutical Co. (Tabriz, Iran). Calcium capsules were provided by Darou Paksh Pharm Co. (Tehran, Iran) Data were collected at the beginning of the study and after 14 months	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised using permuted balanced block randomisation method
Allocation concealment (selection bias)	Unclear risk	No further detail on allocation
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Stated as double blind but content of placebo not stated and no report of attempt to mask n-3 FA taste
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Unclear, few details

**Norouzi 2014** (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition was 1 in intervention group, 5 in control group, so minor. "the two most common reasons for dropouts were experiencing GI side effects or difficulty to maintain scheduled clinic visits"
Selective reporting (reporting bias)	High risk	Some of the outcomes stated in the trial register are not reported. Registered March 2011, study start November 2010, completion April 2012
Attention	Low risk	No difference between groups
Compliance	Unclear risk	Pill counts - compliance averaged 80% in both groups
Other bias	Low risk	None noted

**Norwegian 1968**

Methods	Norwegian Vegetable Oil Experiment of 1965-6 RCT, parallel, 2 arms (ALA linseed oil vs omega 6 sunflower oil), 1 year Risk of bias: moderate or high
Participants	Men working in Norwegian companies aged 50-59 years N: 6716 intervention, 6690 control Level of risk for CVD: low (working men, though a few had had a previous MI or angina) Men: 100% Mean age in years (SD): unclear Age range: 50-59 years Smokers: unclear (~48% non-smokers) Hypertension: unclear Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: Norway Ethnicity: unclear
Interventions	Type: supplementary food (oil) Comparison: ALA vs omega 6 Intervention: linseed oil, 10 mL/d (55% ALA), 5.5 g/d ALA, 1.5 g/d linoleic. Dose: 5.5 g/d ALA Control: sunflower oil, 10 mL/d (1.4% ALA), 0.1 g/d ALA, 6.3 g/d linoleic. Vitamin E was added to both oils Compliance: 73% were still taking the linseed oil at 1 year, 72% were still taking their sunflower oil at 1 year (unclear how this was ascertained) Duration of intervention: 12 months

Outcomes	Main study outcome: morbidity and mortality Dropouts: survival status was traced for all but 4 included men, health status was missing for about 80 men in total or 0.6% Available outcomes: total and CV deaths, MI, angina, stroke, peripheral vascular disease, combined CV events, total cholesterol (subgroup) Response to contact: no	
Notes	Study funding: not stated	
<i><b>Risk of bias</b></i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Paper states “simple randomisation” without clarification
Allocation concealment (selection bias)	Unclear risk	Few details provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Paper states that the workplace doctors who administered the trial locally were sent bottles for each participant marked only with their trial number, and that “appearance and taste of the products were so similar that most participants were unable to identify the type”
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Company physicians recorded health status, and were also blinded to intervention (as above)
Incomplete outcome data (attrition bias) All outcomes	Low risk	Detailed description, and those who left employment during the study were followed up for survival and morbidity via the main health system
Selective reporting (reporting bias)	Unclear risk	No protocol or trials registration found
Attention	Low risk	As company physicians administered oils and assessed outcomes but were blind to treatment arm there could not be attention bias
Compliance	Unclear risk	73% were still taking the linseed oil at 1 year, 72% were still taking their sunflower oil at 1 year (unclear how this was ascertained)
Other bias	Low risk	No further bias noted

## Nutristroke 2009

Methods	Nutristroke RCT, parallel, (diet rich in vitamins and omega 3 plus omega 3 supplement vs diet rich in vitamins and omega 3), 12 months Summary risk of bias: moderate or high	
Participants	People in a rehabilitation unit who had survived a stroke N: 38 intervention, 34 control. (analysed, intervention: 32 control: 20) Level of risk for CVD: high Men: 74% intervention, 56% control Mean age in years (SD): 61.3 (13.6) n-3, 66.3 (11.4) n-3 + antioxidant intervention, 68.4 (12.6) placebo, 65.1 (12.8) antioxidant - control Age range: not reported Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: Italy Ethnicity: not reported	
Interventions	Type: supplement (capsule) Comparison: fish oil vs unclear placebo Intervention: fish oil gelatin capsules including 250 mg DHA + 250 mg EPA. Dose: 0.5 g/d EPA + DHA Control: “identical to supplement but contained no antioxidants or polyunsaturated fatty acids” Compliance: appears to have been assessed at meetings or on the phone monthly, but results unclear Duration of intervention: 12 months	
Outcomes	Main study outcome: functional status in stroke survivors Dropouts: 6 intervention, 14 control Available outcomes: mortality and cardiovascular mortality, lipids (6 months), albumin and lymphocyte counts (6 months), Barthel Index (functional status), neurological impairment (not reported by intervention group), mobility, adiposity (no numerical data presented; quote: “there were no statistically significant differences in body weight, BMI, arm circumference and triceps skin fold at the different time points”) Response to contact: not yet attempted	
Notes	2 × 2 study that also had an antioxidant supplementary focus (supplementary vitamins C and E, beta carotene and polyphenols) Study funding: Italian Ministry of Health, Sigma-Tau Health Science provided omega 3 capsules	
Risk of bias		
Bias	Authors’ judgement	Support for judgement

Random sequence generation (selection bias)	Unclear risk	Quote: “randomized by means of a specific list”
Allocation concealment (selection bias)	Unclear risk	Randomisation methodology not mentioned
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: “the placebo was identical to the supplement but contained no antioxidants or polyunsaturated fatty acids; no patient, research assistant, investigator or any other medical or nursing staff could distinguish the placebo from the supplements during the study”. However, only one placebo discussed and unclear whether it was a placebo capsule (for omega 3) or pill (for antioxidants)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: “assays were quality control checked by internal standard and calibration curve in a random and double blind way”
Incomplete outcome data (attrition bias) All outcomes	High risk	High rates of dropouts
Selective reporting (reporting bias)	Unclear risk	No protocol or trials registry entry found
Attention	Low risk	All assessments and treatments appear equal across the intervention groups
Compliance	Unclear risk	Appears to have been assessed at meetings or on the phone monthly, but results unclear
Other bias	Low risk	None noted

## Nye 1990

Methods	Randomisation: parallel, 3 groups (omega 3 vs olive oil vs aspirin and dipyridamole), 1 year Risk of bias: moderate or high
Participants	People undergoing PTCA N: 36 intervention, 37 control (also 35 allocated to arm 3, aspirin and dipyridamole) Level of risk for CVD: high (people undergoing angioplasty) Men: 78% intervention, 76% control Mean age in years (SD): 54 (8) intervention, 55 (8) control years Age range: unclear



	<p>Smokers: unclear</p> <p>Hypertension: unclear</p> <p>Medications taken by at least 50% of those in the control group: not reported</p> <p>Medications taken by 20%-49% of those in the control group: not reported</p> <p>Medications taken by some, but less than 20% of the control group: not reported</p> <p>Location: New Zealand</p> <p>Ethnicity: unclear</p>
Interventions	<p>Type: supplement (capsules)</p> <p>Comparison: EPA vs MUFA</p> <p>Intervention: MaxEPA capsules 12/d (2.2 g EPA). Dose: 2.2 g/d EPA</p> <p>Control: olive oil capsules, 12/d, identical to MaxEPA. Both capsules included vitamin E</p> <p>Compliance: no data</p> <p>Length of intervention: 12 months</p>
Outcomes	<p>Main study outcome: angina, restenosis</p> <p>Dropouts: none</p> <p>Available outcomes: angina, interventions, lipids (Nil death)</p> <p>Response to contact: no</p>
Notes	<p>Study funding: Medical Research Council of New Zealand and Scherer Ltd (who supplied MaxEPA and the olive oil capsules)</p>

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly divided without exclusions into 3 groups"
Allocation concealment (selection bias)	Unclear risk	Unclear, no further info
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	States that placebo capsules were identical to the MaxEPA, and "neither the patient nor the attending cardiologist knew which capsules were being used" (but no masking of taste was reported, and participant guesses as to allocation were not reported)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "neither the patient, nor the attending cardiologist knew which capsules were being used" ... "Angioplasty was repeated electively at one year or before where symptoms recurred, and assessed without knowledge of the patient's treatment group."
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Some participants were lost to follow-up and reasons for this were unclear

**Nye 1990** (Continued)

Selective reporting (reporting bias)	Unclear risk	No protocol or trials registration found
Attention	Low risk	No suggestion of attention bias, symptomatic patients were reviewed between scheduled visits, otherwise all on the same schedule
Compliance	Unclear risk	No data
Other bias	Low risk	No further bias noted

**OFAMI 2001**

Methods	Omacor Following Acute Myocardial Infarction (OFAMI) RCT, parallel, 2 arms (omega 3 vs corn oil), 2 years Summary risk of bias: moderate or high
Participants	Patients recruited 4-8 days after confirmed MI N: 150 intervention, 150 control Level of risk for CVD: high Men: 77% intervention, 82% control Mean age in years (SD): 64.4 intervention, 63.6 control (no SD) Age range: 28-86 years intervention, 29-87 years control Smokers: 39% intervention, 38% control Hypertension: 29% intervention, 23% control Medications taken by at least 50% of those in the control group: b-blockers, aspirin Medications taken by 20%-49% of those in the control group: statins, ACE inhibitors Medications taken by some, but less than 20% of the control group: diuretics, warfarin Location: Norway Ethnicity: unclear
Interventions	Type: supplement (capsules) Comparison: EPA + DHA vs omega 6 Intervention: 4 gelatin capsules of omega-3-acid ethyl esters 90 (Omacor, Pronova A/S, Oslo, Norway), each is 1 g containing 850-882 mg EPA and DHA as concentrated ethylesters Dose ~3.4- 3.5 g/d EPA + DHA Control: corn oil capsules, 4/d, each contains 1 g of corn oil Compliance: assessed by questionnaire and capsule count, 82% intervention group had complete compliance after 6 weeks, 86% of controls Length of intervention: 24 months
Outcomes	Main study outcome: CV events Dropouts: unclear Available outcomes: total and CV deaths, MI, unstable angina, interventions, combined CV events, BMI, lipids, BP (authors provided additional data on glucose, AF, stroke) Response to contact: yes
Notes	Study funding: Pharmacia-Upjohn and Pronova

<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly assigned" - Pharmacia was responsible for randomisation. Author response: participants were randomised in blocks of 4
Allocation concealment (selection bias)	Low risk	Author confirmed allocation was concealed
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical capsules containing either Omacor or corn oil. Double blinding stated, but taste not reported as masked and blinding of participants not checked
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Author stated: all later analyses performed without the knowledge of outcome
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Number of dropouts was unclear
Selective reporting (reporting bias)	Unclear risk	Trials registry NCT01422317. Outcomes reported in trials registry appear to have been published, but registration was retrospective
Attention	Low risk	All participants appear to have been reviewed at the same intervals
Compliance	Unclear risk	Assessed by questionnaire and capsule count, 82% intervention group had complete compliance after 6 weeks, 86% of controls
Other bias	Low risk	No further bias noted

## OMEGA 2009

Methods	Effect of Omega 3 fatty acids on reduction of sudden cardiac death after MI (OMEGA) 2 arm, parallel RCT (omega 3 vs olive oil), 12 months Summary risk of bias: low
Participants	People who have had an acute myocardial infarction N: 1940 intervention, 1911 control (analysed for primary endpoints 1919 intervention, 1885 control)

	Level of risk for CVD: high Men: 75.1% intervention, 73.7% control Age (median): 64.0 years, intervention, 64.0 years control Age range: unclear (upper and lower quartiles 54-72) Smokers: 35.9% intervention, 37.5% control Hypertension: 66.9% intervention, 66.1% control Medications taken by at least 50% of those in the control group: statins, ACE inhibitors, beta-blockers, clopidogrel, aspirin Medications taken by 20%-49%: diuretics Medications taken by some, but < 20%: AT1 receptor blockers, vit K antagonist, calcium channel blockers, digitalis, amiodarone, oral antidiabetics, insulin Location: Germany Ethnicity: not reported	
Interventions	Type: supplement (capsules) Comparison: EPA + DHA vs MUFA Intervention: 1 × 1 g/d Pronova BiCare soft gelatin capsule 'zodin' omega-3 acid ethyl esters (460 mg/d EPA and 386 mg/d DHA). Dose: 0.85 g/d EPA + DHA Control: 1 × 1 g/d olive oil capsule identical to intervention Compliance: 93.1% of intervention group and 93.2% of control participants took > 70% of capsules Duration of intervention: 12 months	
Outcomes	Main study outcome: sudden cardiac death, cardiac arrest Dropouts: Control: 26 (8-lost to follow-up, 2-withdrew before allocation, 16-excluded.) intervention: 21 Available outcomes: deaths, CV mortality, MACCE, MI, arrhythmias, heart failure, stroke, revascularisation, lipids, authors supplied information on angina, depression, cancers, AF Response to contact: yes	
Notes	Study funding: Tromsdorff Arzneimittel commissioned the research	
<i>Risk of bias</i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Randomisation code generated by alpha med PHARBIL, done in blocks of 8. Randomisation was stratified by centre
Allocation concealment (selection bias)	Low risk	Appearance of the drugs or the drug containers did not allow patients and physicians to deduce the study arm. 4-digit number on a concealed container
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Capsules for placebo and intervention looked the same, randomisation code unknown to investigator (taste and smell not

**OMEGA 2009** (Continued)

		mentioned)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Classification of adverse events blinded to allocation, and there was a blinded end-point committee for all pre-specified outcomes
Incomplete outcome data (attrition bias) All outcomes	Low risk	All events were documented by the investigators and reported to the assigned clinical research organisation and the sponsor. The data safety monitoring board judged any imbalances between the study arms
Selective reporting (reporting bias)	Low risk	NCT00251134 registered in 2005. Study start date: 2003, Completed: 2008, study design: 2006, Published paper: 2010. All trials registry primary and secondary outcomes reported
Attention	Low risk	Capsules for both arms
Compliance	Low risk	93.1% of intervention group and 93.2% of control participants took > 70% of capsules. EAIC 0.65 intervention, and control
Other bias	Low risk	None noted

**OPAL 2010**

Methods	Older People And n-3 Long-chain polyunsaturated fatty acid (OPAL) 2 arm, parallel, RCT, 12 months Summary risk of bias: low
Participants	Healthy cognitively normal adults aged 70-79 years N: 434 intervention, 433 control (analysed 376 intervention, 372 control) Level of risk for CVD: low Men: 53.4% intervention, 56.6% control Mean age in years (SD): 74.7 (2.5) intervention, 74.6 (2.7) control Age range: 70-79 years Smokers: not reported Hypertension: 54.9% intervention, 56.9% control Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49%: not reported Medications taken by some, but < 20%: not reported Location: England and Wales Ethnicity: not reported

Interventions	<p>Type: supplement (capsules)</p> <p>Comparison: EPA + DHA vs MUFA</p> <p>Intervention: 2 × 650 mg capsule/d Ocean Nutrition vanilla flavoured soft gelatin capsule (total daily dose of 200 mg EPA and 500 mg DHA). Dose: 0.7 g/d EPA + DHA</p> <p>Control: 2 × 650 mg olive oil capsule identical to intervention</p> <p>Compliance: count returned capsules.</p> <p>Capsules not returned:</p> <ul style="list-style-type: none"> <li>• Intervention - median: 0.95; IQR: 0.82, 1.00</li> <li>• Control - median: 0.95; IQR: 0.81, 1.00</li> </ul> <p>Fasting serum fatty acids, mg/L, mean (SD)</p> <ul style="list-style-type: none"> <li>• EPA: intervention 49.9, (2.7); control 39.1 (3.1)</li> <li>• DHA: intervention 95.6 (3.1); control, 70.7 (2.9)</li> <li>• <math>\alpha</math>-linoleic: intervention 21.5 (0.8); control 22.0 (0.9)</li> </ul> <p>Length of intervention: 24 months</p>
Outcomes	<p>Main study outcome: delayed onset of cognitive decline</p> <p>Dropouts: control: 78 (8 died, 53 withdrew, 17 discontinued intervention but provided data);</p> <p>intervention: 67 (9 died, 49 withdrew, 9 discontinued intervention but provided data)</p> <p>Available outcomes: deaths, MI, arrhythmias, stroke, diabetes, lipids</p> <p>Response to contact: yes</p>
Notes	Study funding: UK Food Standards Agency, NHS R&D provided support costs

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were "selected in random blocks". "Research nurses telephoned a central computerized randomization service to obtain treatment allocation codes"
Allocation concealment (selection bias)	Low risk	Central allocation via telephone
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical capsules (vanilla-flavoured, dark-brown coloured). Supplements packaged into identical pots, each containing 180 capsules, labelled by staff not involved in the study. All project staff were unaware of group assignments until after data analysis
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All project staff were unaware of group assignments until after data analysis
Incomplete outcome data (attrition bias) All outcomes	Low risk	Participants who discontinued the supplements invited to an interview at 24 months.

		Dropouts explained and similar in both arms (intervention 49 withdrew, control 53 withdrew)
Selective reporting (reporting bias)	High risk	ISRCTN72331636. Trial registered 2004, before study began. Protocol published 2006. Publication of first results 2010. Many outcomes, such as depression and BP were stated in trials registry entry but not reported
Attention	Low risk	All participants had the same review schedule, and staff were unaware of assignments
Compliance	Low risk	Count returned capsules. Capsules not returned (intervention - median: 0.95; IQR: 0.82, 1.00; control - median: 0.95; IQR: 0.81, 1.00). Fasting serum fatty acids, mg/L, mean (SD): EPA, intervention 49.9 (2.7); control 39.1 (3.1). DHA, intervention 95.6 (3.1); control 70.7 (2.9). $\alpha$ -linoleic: intervention 21.5 (0.8); control 22.0 (0.9)
Other bias	Low risk	No further bias noted

## ORIGIN 2012

Methods	Outcome Reduction With Initial Glargine Intervention (ORIGIN) RCT, 2 × 2 factorial, (capsule of n-3 fatty acids or placebo), 72 months Summary risk of bias: low
Participants	People at high risk of CV events with impaired fasting glucose, impaired glucose tolerance or diabetes N: 6319 intervention, 6292 control. (analysed, intervention: 6281 control: 6255) Level of risk for CVD: moderate Men: 65.4% intervention, 64.7% control Mean age in years (SD): 63.5 (7.8) intervention, 63.6 (7.9) control Age range: unclear, eligible if aged ≥ 50 years Smokers: current smokers 12.1% intervention, 12.6% control Hypertension: 78.7% intervention, 80.3% control Medications taken by at least 50% of those in the control group: ACE inhibitor or ARB, aspirin or other antiplatelet, beta-blocker, statin, glucose-lowering drug Medications taken by 20%-49%: calcium-channel blocker Medications taken by some, but less than 20%: thiazide diuretics, anticoagulant Location: 40 study locations in Europe and the Americas Ethnicity: unclear

Interventions	Type: supplement capsule (Omacor) Comparison: EPA + DHA vs MUFA Intervention: 1 gelatin capsule/d Omacor containing at least 900 mg ethyl esters of n-3 fats (465 mg EPA + 375 mg DHA). Dose: 0.84 g/d EPA + DHA Control: 1 × 1 g gelatin capsule/d olive oil Compliance: methods of assessment unclear, but reported that “rates of adherence to the study-drug regimen were similar in the two groups with 96% of patients continuing to receive the study drug at 1 year ... and 88% at the end of the study” Length of intervention: 74 months mean follow-up (median 6.2 years)	
Outcomes	Main study outcome: composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke Dropouts: 38 intervention, 37 control (some of the remainder did not have final outcome status, were lost or withdrew consent, but were included in analysis) Available outcomes: mortality, CV mortality, fatal arrhythmia, MI, stroke, heart failure, angina, revascularisation, breast cancer, cancer diagnoses and cancer deaths, BP, lipids (HbA1c given as medians only) Response to contact: yes but no data provided	
Notes	The other 2 × 2 assignment was to insulin glargine versus standard care, and is not discussed here. Results are reported here for the trial duration and not the follow-up post trial (the ORIGIN and Legacy Effects, ORIGINALE) Study funding: Sanofi Aventis, Omacor provided by Pronova Biocare	
<i>Risk of bias</i>		
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: “randomized by an automated telephone randomization system (using randomly varying block sizes)”
Allocation concealment (selection bias)	Low risk	As above
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Study described as “double blind” and placebo described as identical. Blinding of patients, investigators, local and central trials personnel described. However, no information provided as to the capsule’s smell and taste
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: “all primary and secondary outcomes were adjudicated with the use of pre-specified definitions by a committee whose members were unaware of study-group assignments”



## ORIGIN 2012 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Almost all participants were included in outcomes
Selective reporting (reporting bias)	Low risk	NCT00069784 - registered October 2003, study started August 2003, final data collection December 2011. Most outcomes appear to have been reported in various publications (cardiovascular events only reported by glargine randomisation)
Attention	Low risk	No suggestion of differences between groups
Compliance	Unclear risk	Methods of assessment unclear, but reported that "rates of adherence to the study-drug regimen were similar in the two groups with 96% of patients continuing to receive the study drug at 1 year ... and 88% at the end of the study"
Other bias	Low risk	None noted

## ORL 2013

Methods	Omega-3 fatty acids randomised long-term (ORL) RCT- parallel, 3 arms (TAK-085 2 g, TAK-085 4 g, and EPA-E 1.8 g), 12 months Summary risk of bias: moderate or high
Participants	Population: Japanese adults with hypertriglyceridaemia N: 171 intervention (4 g TAK), 165 control (2 g TAK) Level of risk for CVD: moderate Men: 70.8% intervention, 71.5% control Mean age in years (SD): 55.9 (10.12) intervention, 56 (10.95) control Age range: 20-74 Smokers (current): 27.5% intervention, 31.5% control Hypertension: 66.7% intervention, 67.3% control Medications taken by at least 50% of those in the control group: HMG-CoA reductase inhibitor Medications taken by 20%-49%: statin Medications taken by some, but less than 20%: not reported Location: Japan Ethnicity: unclear
Interventions	Type: supplement (TAK-085 capsules) Comparison: EPA + DHA higher vs lower dose Intervention: 1 × 2/d capsule each containing 2 g of TAK-085 (1 g of fatty acid in TAK-085 capsules contains approximately 465 mg of EPA-E plus 375 mg of DHA-E). Total dose of 1.86 g/d EPA + 1.5 g/d DHA. Dose: ~3.4 g/d EPA + DHA (difference of +1.7

	g/d from control arm) Control: 1 capsule/d containing 2 g of TAK-085 (1 g of fatty acid in TAK-085 capsules contains approximately 465 mg of EPA-E plus 375 mg of DHA-E). Total dose of 0.93 g/d EPA + 0.75 g/d DHA. Dose: 1.7 g/d EPA + DHA Compliance: monitored every 4 weeks, mean rate of compliance reported as > 96% in each group Length of intervention: 12 months	
Outcomes	Main study outcome: safety outcomes and adverse events Dropouts: group 1: 8, group 2: 14, group 3 (not analysed): 21 Available outcomes: adverse events (including CVD events, cancers), CRP, waist circumference, weight, blood pressure (nil death), lipids provided as % change from baseline, but no baseline data available, so not used in meta-analyses Response to contact: no	
Notes	A third arm of EPA-E 1.8 g supplementation is not used here. Outcome data used TAK-4 vs TAK-2 Study funding: Takeda Pharmaceutical Company	
<i><b>Risk of bias</b></i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Randomisation was stratified according to statin use and performed by an independent registration centre
Allocation concealment (selection bias)	Low risk	As above
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open label
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open label
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were accounted for and analysed for main outcomes
Selective reporting (reporting bias)	Low risk	Trials registry entry May 2011, study start date November 2009, completion November 2011, so partially retrospective. However, entry appears to reflect reported outcomes
Attention	Low risk	Capsules, appears similar

Compliance	Low risk	Monitored every 4 weeks, mean rate of compliance reported as > 96% in each group
Other bias	Low risk	None noted

## Proudman 2015

Methods	RCT, parallel, (EPA + DHA fish oil vs omega 6 sunola oil), 12 months Summary risk of bias: low
Participants	Patients with rheumatoid arthritis < 12 months' duration, DMARD-naïve N: 87 intervention, 53 control. (analysed, intervention: 75 control: 47) Level of risk for CVD: low Men: 29% intervention, 25% control Mean age in years (SD): 56.1 (15.9) intervention, 55.5 (14.1) control Age range: unclear Smokers: 65.1% intervention, 54.7% control (includes current and previous smokers) Hypertension: not reported Medications taken by at least 50% of those in the control group: triple DMARD therapy (SSZ 0.5 g/d, HCQ 200 mg twice/day and MTX 10 mg once per week) Medications taken by 20%-49% of those in the control group: NSAIDS Medications taken by some, but less than 20% of the control group: oral or parenteral steroids Location: Australia Ethnicity: not reported
Interventions	Type: supplement (fish oil) Comparison: high EPA + DHA vs omega 6 (low EPA + DHA with sunola oil) Intervention: 10 mL/d fish oil concentrate (BLT Incromega TG3525) providing 5.5 g/day (3.2 EPA + 2.3 DHA). Dose: 5.5 g/d EPA + DHA Control: 10 mL/d sunola oil:capelin oil (2:1) providing 0.21 g EPA + 0.19 g DHA/d as TAG (0.40 g/day EPA + DHA) Compliance: consumption checked at each visit. 100% compliance would be consumption of 3650 mL oil at 12 months. The fish oil group was less compliant than the control group with median intakes of 2482 mL and 3248 mL, respectively (P = 0.015, Mann-Whitney U test). This provided an average daily intake of EPA + DHA of 3.7 g and 0.36 g in the fish oil and control groups, respectively Duration of intervention: 12 months
Outcomes	Main study outcome: disease-modifying anti-rheumatic drugs (DMARD) failure and remission Dropouts: 11 intervention, 6 control Available outcomes: mortality (nil death), adverse events including CVD, DAS score, diabetes, authors supplied methodology data plus BMI change Response to contact: yes

Notes	DAS scores are reported as median and IQR in Proudman 2012 abstract Study funding: National Health Medical Research Council of Australia and Royal Adelaide Hospital Research Committee. Melrose Health provided support for ongoing studies. The oil was made by the Royal Adelaide Hospital Pharmacy	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote: "The randomisation schedule was prepared using an online random number generator and involved randomly permuted blocks of size six."
Allocation concealment (selection bias)	Low risk	Quote: "Randomisation was performed by the RAH pharmacy, which also prepared and provided the study oils in 500 mL identical dark brown bottles labelled with consecutive study numbers"
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "Both participants and investigators/assessors were blinded to the group allocation. Although the control oil was paler in colour than the fish oil, this was not evident in the brown bottles. The 'fishy' odour of each oil was similar."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Both participants and investigators/assessors were blinded to the group allocation. Quote: "Investigators and subjects remained blinded for all withdrawals."
Incomplete outcome data (attrition bias) All outcomes	Low risk	The flow of all study participants shown in FIGURE 2
Selective reporting (reporting bias)	Unclear risk	Outcomes reported in trial register matched with the outcomes reported in publications. However, the study was retrospectively registered - registered in 2013, recruitment began in 2001
Attention	Low risk	No difference between groups
Compliance	High risk	Consumption checked at each visit. 100% compliance would be consumption of 3650 mL oil at 12 months. The fish oil group was less compliant than the control group with median intakes of 2482 mL (68%) and 3248 mL (89%), respectively

**Proudman 2015** (Continued)

		(P = 0.015, Mann-Whitney U test). This provided an average daily intake of EPA + DHA of 3.7 g and 0.36 g in the fish oil and control groups, respectively
Other bias	Low risk	None noted

**Puri 2005**

Methods	RCT, parallel (ethyl-EPA vs paraffin), 2 arm, 12 months Summary risk of bias: low	
Participants	People with Huntington's Disease N: 67 intervention, 68 control (analysed, intervention: 39 control: 44) Level of risk for CVD: low Men: 57% intervention, 44% control Mean age in years (SD): 50 (9.3) intervention, 49 (9.0) control Age range: not reported Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: antidepressants Medications taken by some, but < 20%: neuroleptics Location: UK, USA, Canada, Australia Ethnicity: intervention: 94% white, 4% black, 1% Asian; control: 97%, 3%, 0%, respectively	
Interventions	Type: supplement (ethyl-EPA) Comparison: EPA vs paraffin (non-fat) Intervention: 2 × 2 × 500 mg capsules/d, total dose of 2 g/day ethyl-EPA (code name LAX-101, purity 95%). Dose: 1.9 g/d EPA Control: 2 × 2 × 500 mg capsules/d liquid paraffin Compliance: 38 were excluded for protocol violations, 4 intervention and 16 control were non-compliant with capsules Duration of intervention: 12 months	
Outcomes	Main study outcome: functional status in Huntington's Disease Dropouts: 7 intervention, 7 control Available outcomes: measures of functional capacity, CV events, cancers (nil deaths) Response to contact: yes (no additional data provided)	
Notes	Study funding: Amarin Neuroscience Ltd. (formerly known as Laxdale Ltd.), provided organisation, funding and salaries	
Risk of bias		
Bias	Authors' judgement	Support for judgement

**Puri 2005** (Continued)

Random sequence generation (selection bias)	Low risk	Quote: "After screening and acceptance... patients were assigned to treatment by receiving a numbered pack supplied by a clinical trials packaging organization ... independent of all other aspects of the trial. Randomization was stratified in a block size of four, with the appropriate number of blocks allocated to each center. PCI Clinical Services held the randomization code until the database had been closed and all patients had been assigned"
Allocation concealment (selection bias)	Low risk	As above
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "[p]lacebo and ethyl-EPA capsules were of identical appearance" (though taste and smell not reported)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Randomisation described as "double-blind", "neither the patients nor the participating medical staff had access to this code during the course of the study"
Incomplete outcome data (attrition bias) All outcomes	High risk	Clearly reported and complete, however > 20% attrition
Selective reporting (reporting bias)	Unclear risk	No protocol or trials registry entry identified
Attention	Low risk	Unlikely
Compliance	Unclear risk	38 were excluded for protocol violations, 4 intervention and 16 control were non-compliant with capsules
Other bias	Low risk	None noted

**Raitt 2005**

Methods	RCT, parallel, (fish oil or olive oil), 24 months Summary risk of bias: moderate or high
Participants	People with implantable cardioverter defibrillators and recent sustained ventricular tachycardia or ventricular fibrillation (VT/VF) N: 100 intervention, 100 control Level of risk for CVD: high Men: 86% intervention, 86% control Mean age in years (SD): 63 (13) intervention, 62 (13) control

	Age range: not reported but 18-75 inclusion criteria Smokers: not reported Hypertension: 46% intervention, 55% control Medications taken by at least 50% of those in the control group: diuretic, beta blockers, ACE inhibitors Medications taken by 20%-49% of those in the control group: digoxin, statins Medications taken by some, but less than 20% of the control group: calcium channel blocker Location: USA Ethnicity: 94% white in intervention group, 97% in control group	
Interventions	Type: supplement (fish oil capsules vs olive oil capsules) Comparison: EPA + DHA vs MUFA Intervention: 1.8 g/d fish oil capsules (Hoffman LaRoche, including ethyl esters of EPA and DHA, 0.76 g/d EPA, 0.54 g/d DHA). Dose: 1.3 g/d EPA + DHA Control: 1.8 g/d olive oil capsules (Hoffman LaRoche, 73% oleic acid) Compliance: while control group plasma and platelet DHA and EPA did not change, there were increases of 2%-8.3% in the intervention group Duration of intervention: 24 months (median 718 days)	
Outcomes	Main study outcome: time to first episode of VT/VF Dropouts: 17 intervention, 26 control Available outcomes: deaths, CV death, MI, angina, revascularisation, arrhythmias, sudden cardiac death, cancer Response to contact: yes but no data provided	
Notes	Study funding: NIH and Hoffman LaRoche	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "computer generated block randomisation scheme"
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Participant blinding unclear
Blinding of outcome assessment (detection bias) All outcomes	Low risk	ICD traces were viewed by researchers blinded to allocation, "double blind placebo-controlled"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Almost all participants were included in outcome assessment, well described

**Raitt 2005** (Continued)

Selective reporting (reporting bias)	High risk	NCT registered in February 2000, study carried out from February 1999 to January 2004. Most outcomes stated in registry entry reported, but quality of life missing
Attention	Low risk	Capsules were the only different interventions between arms, little opportunity for attention bias
Compliance	Low risk	While control group plasma and platelet DHA and EPA did not change, there were increases of 2%-8.3% in the intervention group
Other bias	Low risk	None noted

**Ramirez-Ramirez 2013**

Methods	RCT, parallel, (fish oil vs sunflower oil), 12 months Summary risk of bias: moderate or high
Participants	People with relapsing remitting multiple sclerosis N: 25 intervention, 25 control. (analysed, intervention: 20 control: 19) Level of risk for CVD: low Men: 83% intervention, 82% control (but these appear unlikely) Mean age (SD) years: 35.1 (7.6) intervention, 34.9 (7.8) control Age range: not reported but 18-55 years were inclusion criteria Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: 100% treated with interferon beta1b for at least 1 year before the trial began Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: Mexico Ethnicity: not reported
Interventions	Type: supplement Comparison: DHA + EPA vs sunflower oil Intervention: 4 g/d omega Rx capsules (Dr Sears zone diet, with excipient of glycerin, water, tocopherol, sunflower oil, titanium dioxide, includes 0.8 g/d EPA plus 1.6 g/d DHA). Dose: 2.4 g/d EPA + DHA Control: excipient only (Perfect Source Natural Products, glycerin, water, tocopherol, sunflower oil, titanium dioxide) Compliance: consumption diary plus pills returned at each visit, adherence calculated (correct formula?? pills consumed $\times$ 100/pills returned), optimal adherence was considered to be > 80%, 1 intervention and 3 control were excluded due to compliance < 80%. Blood DHA and EPA were significantly different at 12 months Duration of intervention: 12 months



Outcomes	Main study outcome: TNF-alpha Dropouts: 5 of 25 intervention, 6 of 25 control Available outcomes: TNF-alpha, IL-6, IL-1 beta, nitric oxide catabolites, MS relapse, disability EDSS, liver and renal function tests, haemoglobin, leucocytes, platelets, oxidative outcomes (glucose and lipids data collected but not reported, for BMI and BP paper reports “no difference through study”) Response to contact: not yet attempted	
Notes	Study funding: not reported	
<i><b>Risk of bias</b></i>		
<b>Bias</b>	<b>Authors’ judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Computer-generated randomisation sequence (blocks of 4)
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: “capsules were identical in appearance, packaging and labelling”, “physicians and patients were blind to the intervention”, and there was a rosemary flavour to mask
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: “an independent physician evaluated the EDSS score and collected samples at each clinic visit”
Incomplete outcome data (attrition bias) All outcomes	High risk	Loss of 11/50 over 1 year, 22% loss
Selective reporting (reporting bias)	High risk	Paper reports analysis of glucose and lipids but these are not reported
Attention	Low risk	Appeared similar, reviewed every 3 months
Compliance	Low risk	Blood DHA and EPA were significantly different at 12 months
Other bias	Low risk	None noted

Methods	RCT, parallel, 3 arms (fish oil or borage oil), 18 months Summary risk of bias: low	
Participants	Adults with rheumatoid arthritis N: 53 intervention, 52 control (28 intervention, 24 control analysed) Level of risk for CVD: low Men: 13.2% intervention, 23.1% control Mean age in years (SD): 57.3 (12.3) intervention, 60.3 (9.2) control Age range: not reported but 18-85 inclusion criteria Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: methotrexate, DMARDs, and TNF blockers Medications taken by 20%-49% of those in the control group: corticosteroids and TNF blockers Medications taken by some, but less than 20% of the control group: not reported Location: USA Ethnicity: black/African-American: intervention (fish oil): 7.8% control (borage oil): 7.8%	
Interventions	Type: supplement (fish oil vs borage oil) Comparison: EPA + DHA vs Omega 6 Intervention: 7 fish oil (2.1 gm EPA:1.4 gm DHA) capsules and 6 sunflower seed oil capsules daily = 13 capsules divided doses. Dose: 3.5 g/d EPA + DHA Control: 6 borage seed oil (1.8 g GLA) capsules plus 7 sunflower seed oil capsules daily Compliance: assessed by capsule counts and patient report. Patient report, indicates that 45% of patients reported ever missing a dose (borage: 42%, fish 48%). Median total capsules missed (excluding those with 0) were 182 (borage: 164, fish 169) Duration of intervention: 18 months	
Outcomes	Main study outcome: RA modified disease activity score Dropouts: 25 intervention, 28 control Available outcomes: mortality (nil death), CVD events (nil), DAS score, CDAI score. Authors suggested that LDL and total cholesterol were reduced in the intervention group at 18 months, and HDL was increased in both intervention and control at 18 months, while diastolic BP was reduced in the intervention group at 18 months, but no numbers provided. CRP and ESR data were provided combined for the intervention and control arms in the author response, so not useable Response to contact: yes, authors supplied details of methodology but no usable outcome data	
Notes	A third arm (45 participants) were given a combination of both oils but not discussed here Study funding: National Institutes of Health Grant RO1-AT000309 from the National Center for Complementary and Alternative Medicine	
Risk of bias		
Bias	Authors' judgement	Support for judgement

Random sequence generation (selection bias)	Low risk	Author stated “stratified random block, stratified by site using random blocks of 3 & 6”
Allocation concealment (selection bias)	Low risk	No methodology provided in the paper, but the author suggested concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, all capsules were identical in appearance and colour, they were shipped in opaque plastic bottles to the University of Massachusetts University Hospital pharmacy, from where they were distributed to participating centres. However no information provided as to their smell and taste
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Author confirmed outcome assessors were blinded.
Incomplete outcome data (attrition bias) All outcomes	High risk	Authors mention intention-to-treat analysis but shows completers analysis. Numbers of participants are not provided for all outcomes measured. Provide results for the overall group (69 participants table 3a) while the flow diagram states there are 74 completers. 51% dropped out
Selective reporting (reporting bias)	Low risk	Study prospectively registered in 2003, estimated study completion November 2008, published in 2014. Both outcomes reported in registry are reported in the publication
Attention	Low risk	All patients were evaluated at 3-month intervals, by the same examiner
Compliance	Unclear risk	Assessed by capsule counts and patient report. Patient report, indicates that 45% of patients reported ever missing a dose (borage: 42%, fish 48%). Median total capsules missed (excluding those with 0) were 182 (borage: 164, fish 169)
Other bias	Low risk	None noted

Methods	RCT, parallel, (n-3 vs olive oil), 60 months Summary risk of bias: moderate or high	
Participants	Patients with multiple cardiovascular risk factors N: 6244 intervention, 6269 control (analysed, intervention: 6239 control: 6266) Level of risk for CVD: high Men: 62.3% intervention, 60.6% control Mean age in years (SD): 63.9 (9.3) intervention, 64.0 (9.6) control Age range: not reported Smokers: 22.1% intervention, 21.4% control. Hypertension: 84.6% intervention, 84.5% control Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: ACE inhibitor; ARB; diuretic agent; calcium-channel blocker; beta-blocker; oral hypoglycaemic drug; statin; antiplatelet agent Medications taken by some, but less than 20% of the control group: insulin Location: Italy Ethnicity: not reported	
Interventions	Type: supplement (n-3 capsules) Comparison: EPA + DHA vs MUFA Intervention: 1 g/d n-3 capsules polyunsaturated fatty acid ethyl esters (EPA and DHA content 850-882 mg with an average ratio of 1.0 to 1.2). Dose: ~0.87 g/d EPA + DHA Control: 1 g/d olive oil capsules Compliance: measured by self-report during follow-up visits but no results reported Duration of intervention: 60 months	
Outcomes	Main study outcome: composite of time to death from cardiovascular causes or hospital admission for cardiovascular causes Dropouts: intervention: 5 withdrew consent before baseline, 43 lost to follow-up, 1115 stopped treatment. 6239 analysed Control: 3 (withdrew consent before baseline), 39 lost to follow-up, 1218 stopped treatment. 6266 analysed Available outcomes: mortality, CV mortality, CV events, coronary related events and mortality, MI, AF, heart failure, side effects, stroke, cancer diagnosis, cancer death. Authors provided data on diabetes diagnosis, glucose and HbA1c Response to contact: yes	
Notes	All continuous outcomes change data are reported as least squares mean hence not used Study funding, quote: “The steering committee had the full and sole responsibility for planning and coordinating the study, analyzing and interpreting the data, and preparing the manuscript and submitting it for publication. Società Prodotti Antibiotici, Pfizer, and Sigma Tau funded the trial but had no role in the study design, planning, conduct, or analysis or in the interpretation or reporting of the results”	
Risk of bias		
Bias	Authors’ judgement	Support for judgement

Random sequence generation (selection bias)	Low risk	Quote: "Treatment was centrally assigned by means of telephone on the basis of a concealed, computer-generated randomization list, stratified according to general practitioner."
Allocation concealment (selection bias)	Low risk	As above
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "Patients, general practitioners, coordination and statistical staff, and outcome assessors were unaware of the study assignments until the final analyses were completed." However, there was no mention of placebo appearance or other methods of blinding, so unclear
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "Patients, general practitioners, coordination and statistical staff, and outcome assessors were unaware of the study assignments until the final analyses were completed." Quote: "All events included in the primary efficacy end point were documented with the use of a narrative summary and supporting documentation and were adjudicated on the basis of prespecified criteria by an ad hoc committee consisting of a cardiologist, an internist, and a neurologist who were unaware of the study assignments"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "Analyses were performed in the intention-to-treat population, except for a prespecified per protocol analysis of the primary end point in patients with no major protocol violations who did not permanently stop treatment." Figures differ in Visentin 2008: (p. i73) "At the end of March 2006, 12 521 patients have been Randomized"; "After 1-year of follow-up, 2.5% of the patients withdrawn from the trial and 5% of the patients discontinued treatment. The reasons for drug discontinuation were 1.7% for side effects (mainly gastrointestinal) and 3.3% others (clinical or patient's refusal)... After 1-year of follow-up, 1.0% had CV death and 3.4% hospitalisation for CV events (primary end point)"

Selective reporting (reporting bias)	High risk	Primary endpoint was amended part way through study. Differences in groupings of cardiovascular events in tables 2; S4 and S5. For hospital admissions notes each patient could have more than one cardiovascular cause
Attention	Unclear risk	Does not state attention differs or is the same between groups- regularly see GP for follow-up and blinding not clear
Compliance	Unclear risk	No results
Other bias	Low risk	None noted

## Rossing 1996

Methods	RCT, parallel, (fish oil vs olive oil), 12 months Summary risk of bias: moderate or high
Participants	Adults with insulin-dependant diabetes mellitus, diabetic nephropathy and normal BP N: 18 intervention, 18 control (analysed, 17 intervention, 15 control) Level of risk for CVD: moderate Men: 64% intervention, 67% control Mean age (SD) years: 32 (7) intervention, 34 (10) control Age range: 18-55 years Smokers: 50% intervention, 47% control Hypertension: not reported Medications taken by at least 50% of those in the control group: insulin Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: Denmark Ethnicity: not reported
Interventions	Type: supplement Comparison: EPA + DHA vs MUFA Intervention: cod-liver oil emulsion (Pharma-Vinci A/S Denmark). EPA 2 g, DHA 2.6 g, total PUFA 4.6 g/day. Dose: 4.6 g/d EPA + DHA Control: olive oil emulsion (Pharma-Vinci A/S Denmark) Compliance: assessed through omega 3 incorporation in platelets, and the paper reports significantly higher omega 3 levels in platelets at 12 months Duration of intervention: 12 months
Outcomes	Main study outcome: diabetic nephropathy Dropouts: 1 intervention, 3 control (though 3 further intervention participants are not included in all data) Available outcomes: mortality (nil), breast cancer, total and LDL cholesterol, sBP (TGs reported as medians so not used, albuminuria, fractional albumin clearance, transcap-

	illary escape rate of albumin, prothrombin fragment reported as geometric means or medians, HbA1c, HDL and diastolic BP too different at baseline to include, GFR, PAI1, TPA, fibrinogen, etc. not relevant) Response to contact: yes	
Notes	Study funding: the Danish Heart Association. Eskisol Fish oil and placebo oil emulsions were provided by Pharma-Vinci A/S, Frederiksvaerk, Denmark	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Patients were randomised using concealed randomisation to receive either fish oil or olive oil in blocks of 4 according to their glomerular filtration rate.”
Allocation concealment (selection bias)	Unclear risk	No further details
Blinding of participants and personnel (performance bias) All outcomes	Low risk	“Active and placebo (olive oil) were given as emulsions with orange flavour. At the end patients were allowed to guess about treatment and ~50% were right”
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details
Incomplete outcome data (attrition bias) All outcomes	Low risk	Dropouts similar between groups although relatively high for small sample size. 3 dropouts from fish oil and 1 from control due to side effects. Intention-to-treat analysis appears to have been given for albuminuria only
Selective reporting (reporting bias)	Unclear risk	No trials registry entry or protocol found
Attention	Low risk	Time and attention appear to be the same. All patients were given dietary advice
Compliance	Low risk	Reports significantly higher omega 3 levels in platelets at 12 months for the intervention group
Other bias	Low risk	None noted

Methods	RCT, parallel 5 arms (combined groups 4 and 5 omega-3-acid ethyl esters (Lovaza) n-3 ± raloxifene vs control groups 1 and 3 ± raloxifene), 24 months Summary risk of bias: moderate or high	
Participants	Healthy postmenopausal women (50% normal weight, 30% overweight, 20% obese) with high breast density detected on their routine screening mammograms N: 54 + 53 intervention, 53 + 53 control Level of risk for CVD: low Men: 0% intervention, 0% control Mean age in years (SD): 56.56 (6.9) + 57.85 (5.1) intervention, 57.11 (5.9) + 57.68 (5.1) control Age range: not reported Smokers: 0% intervention, 0% control Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: USA Ethnicity: not reported	
Interventions	Type: supplement (n-3 capsules) Comparison: EPA + DHA vs nil Intervention: group 4, Lovaza 4 g per day. Lovaza is the FDA-approved n-3 FA formulation containing 465 mg of EPA + 375 mg of DHA per gram, total dose; 1860 mg/d EPA, 1500 mg/d DHA. Group 5 as group 4 plus 30 mg raloxifene/d. Dose: 3.36 g/d EPA + DHA Control: group 1, no treatment; group 3, 30 mg raloxifene/d Compliance: measured by pill count, recorded at follow-up visits and further verified by serum fatty acids monitoring. Compliance was 94% (SE 2%) at 6 months and 97% (SE 2%) at 12 months. Only 2 participants had a compliance < 85% (84% and 81%) Duration of intervention: 24 months	
Outcomes	Main study outcome: change in breast density Dropouts: 5 intervention, 6 control Available outcomes: cardiovascular events, breast cancer, lipids, dietary intake, plasma FAs, adverse events (including one incidence of hyperglycaemia) Response to contact: yes	
Notes	The study had 5 arms: group 1, no treatment, control; group 2, raloxifene 60 mg orally daily; group 3, raloxifene 30 mg orally daily; group 4, Lovaza 4 g orally daily; and group 5, Lovaza 4 g/d plus raloxifene 30 mg orally daily. Data here is combined for groups 4 and 5 vs 1 and 3 for binary outcomes and group 1 vs 4 used for continuous outcomes Study funding: GlaxoSmith Kline and Eli Lilly provided Lovaza and raloxifene, respectively. Funded by Susan G Komen for the Cure, KG081632 (A Manni) and pilot funds from the Penn State Hershey Cancer Institute (K El-Bayoumy)	
Risk of bias		
Bias	Authors' judgement	Support for judgement



Random sequence generation (selection bias)	Low risk	Sandhu 2016 pg 276: "each study participant was randomly assigned with equal probability to one of the following five groups. A block randomization scheme was used to ensure balance treatment allocation during the course of enrolment."
Allocation concealment (selection bias)	Unclear risk	No description of concealment of allocation
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open label
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open label
Incomplete outcome data (attrition bias) All outcomes	Low risk	< 20% lost over 2 years, detailed reasons provided, no suggestion these are unbalanced
Selective reporting (reporting bias)	High risk	Biomarkers of oxidative stress (Urinary 8-(isoprostane) F-2 $\alpha$ and 8OHdG, Lymphocyte 8-OHdG, DNA etheno adducts), Urinary 2-OHE1, 4-OHE1, and 16 $\alpha$ -OHE1, Serum level of C-reactive protein and IL-6, Serum level of IGF-I and IGFBP-3, complete blood count mentioned in trial registry but not reported in Sandhu 2016. (More outcomes reported than in registry - diet, physical activity levels, adverse events)
Attention	Low risk	Participants assessed at baseline, 1-year and 2-year follow-up
Compliance	Unclear risk	Measured by pill count, recorded at follow-up visits and further verified by serum fatty acids monitoring. Compliance was 94% (SE 2%) at 6 months and 97% (SE 2%) at 12 months. Only 2 participants had a compliance < 85% (84% and 81%)
Other bias	Low risk	None noted

## SCIMO 1999

Methods	<p>Study on prevention of Coronary atherosclerosis with Marine Omega 3 fatty acids (SCIMO)</p> <p>RCT, parallel (omega 3 vs average European fats), 2 years</p> <p>Summary risk of bias: low</p>
Participants	<p>People with angiographically proven coronary artery disease</p> <p>N: 112 intervention, 111 control (analysed 82 intervention, 80 control)</p> <p>Level of risk for CVD: high</p> <p>Men: 82% intervention, 78.6% control</p> <p>Mean age in years (SD): 57.8 (9.7) intervention, 58.9 (8.1) control</p> <p>Age range: unclear (18-75 inclusion criteria)</p> <p>Smokers: 16.2% intervention, 22.3% control</p> <p>Hypertension: 53.1% intervention, 45.5% control (history of high blood pressure)</p> <p>Medications taken by at least 50% of those in the control group: platelet inhibitors, beta-blockers</p> <p>Medications taken by 20%-49% of those in the control group: long-term nitrate therapy, lipid-lowering agents, ACE inhibitors, diuretics, calcium antagonists, other antihypertensive agents and digitalis</p> <p>Medications taken by some, but less than 20% of the control group: nitrates only on demand</p> <p>Location: Germany</p> <p>Ethnicity: not reported</p>
Interventions	<p>Type: supplement (capsule)</p> <p>Comparison: EPA + DHA vs SFA + MUFA (average European fat composition)</p> <p>Intervention: concentrated fish oil capsules, 6x 1 g capsules/d for first 3 months, 3 x 1 g/d for rest of study (4 g/d EPA +DHA + DPA + ALA for first 3 months, then 2 g/d).</p> <p>Dose: ~2 g/d LCn3</p> <p>Control: capsules containing fat which replicated the fat composition of the average European diet, 6/d for first 3 months, 3/d for rest of study, opaque soft gelatin capsules identical to fish capsules in identical screw-top containers</p> <p>Compliance: capsule count, overall 2284 (SD 313) capsules taken of 2460 prescribed for each person, erythrocyte phospholipids rose from 4.6% to 11.8% at 24 months in intervention, and didn't alter from baseline in controls</p> <p>Length of intervention: 24 months</p>
Outcomes	<p>Main study outcome: changes in stenosis on angiography</p> <p>Dropouts: unclear</p> <p>Available outcomes: mortality, MI, CV events, revascularisation, angina, stroke, cancer diagnosis, weight, lipids, BP, side effects</p> <p>Response to contact: yes</p>
Notes	<p>Asked participants to guess treatment allocation, of those in intervention 63/90 were unsure, 5/90 guessed placebo and 22/90 guessed fish oil; of those in control 66/85 were unsure, 9/85 guessed placebo and 10/85 guessed fish oil</p> <p>Study funding: Pronova provided capsules and funds for study monitoring but it was stated that the funders played no part in analysis or publication</p>
<b><i>Risk of bias</i></b>	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Stratified, and for the resulting 9 strata "a random sequence of study group assignments was computer generated by the trial monitor"
Allocation concealment (selection bias)	Low risk	Sealed, sequential numbered envelopes used (opaque not stated, but provided only a random number which linked to a specific container of capsules)
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo and fish oil capsules "looked identical and were made of soft opaque gelatin and each contained 1 g of a fatty acid mixture". These were provided in identical containers with identical labels with a randomisation number. Patients were told that capsules differed in composition but not in taste
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding is described and is very strong for angiographic outcomes, but there is no description of how cardiovascular events were assessed or recorded. However outcomes assessors were probably the same assessors and so blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear for how many participants clinical events were assessed (though described in detail for angiographic outcomes), so trial flow unclear
Selective reporting (reporting bias)	Unclear risk	No study trials register entry or protocol was found
Attention	Low risk	As study personnel were unaware of assignments bias in attention was not possible
Compliance	Low risk	Capsule count, overall 2284 (SD 313) capsules taken of 2460 prescribed for each person, erythrocyte phospholipids rose from 4.6% to 11.8% at 24 months in intervention and didn't alter from baseline in controls
Other bias	Low risk	No further bias noted

Methods	RCT, parallel (fish oil capsule vs soybean oil capsule), 12 months Summary risk of bias: moderate to high
Participants	Patients aged 55 or more with probable Alzheimer dementia diagnosis N: 13 intervention, 13 control Level of risk for CVD: low Men: 61% intervention 46% control Mean age in years (SD): 75.9 (8.1) intervention, 75.2 (10.8) control Age range: 55+ (inclusion criteria) Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: anti-cholinesterases or memantine Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Lipid-lowering medications and many other drugs were not allowed Location: USA Ethnicity: 100% white
Interventions	Type: fish oil capsules Comparison: EPA + DHA vs n-6 Intervention: 3 × 1 g capsules/day of fish oils (975 mg EPA, 675 mg DHA per day). Dose: 1.65 g/d EPA + DHA Control: 3 × 1 g capsules/day soybean oil (which contains 5% fish oil) Both groups had a placebo lipoic acid tablet and lemon-flavoured capsules Compliance: assessed by pill counts and FA in red blood cell membranes. Results showed increased EPA + DHA levels in the intervention group Length of intervention: 12 months
Outcomes	Main study outcome: F2-isoprostane levels (oxidative stress measure) Dropouts: 2 intervention, 2 control Available outcomes: mortality, CVD events, adverse events, serum fatty acids, measures of cognition (ADAS Cog and MMSE), ADL, IADL (also F2 isoprostane) Response to contact: not attempted
Notes	Study funding: National Institutes of Health/National Institute of Aging (NIH/NIA) and NIH General Clinical Research

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomised by a computer-generated scheme that was stratified by smoking status
Allocation concealment (selection bias)	Unclear risk	No details

**Shinto 2014** (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	Capsules matched for taste and flavour. Blinding assessed at the end and majority of staff and participants were unaware of treatment
Blinding of outcome assessment (detection bias) All outcomes	Low risk	As above
Incomplete outcome data (attrition bias) All outcomes	Low risk	15% dropouts explained and included
Selective reporting (reporting bias)	Low risk	NCT00090402 first received: 25 August 2004, study start date April 2004. More secondary outcomes reported than included in the trial register entry
Attention	Low risk	Both arms seem to have had the same contact
Compliance	Low risk	Compliance measured and FAs levels reported. Results showed increased EPA + DHA levels in the intervention group
Other bias	Low risk	None noted

**SHOT 1996**

Methods	SHunt Occlusion Trial (SHOT) RCT, parallel (omega 3 vs nil), 4 arms, 1 year Summary risk of bias: moderate or high
Participants	People admitted for coronary bypass grafting N: 317 intervention, 293 control Level of risk for CVD: high Men: 86% intervention, 88% control Mean age in years (SD): 59.9 (8.7) intervention, 59.4 (8.8) control Age range: unclear Smokers: 19% intervention, 20% control Hypertension: 20% intervention, 25% control Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: antihypertensives Medications taken by some, but less than 20% of the control group: not reported Location: Norway Ethnicity: not reported
Interventions	Type: supplement (capsule) Comparison: EPA + DHA vs nil

	<p>Intervention: 4 fish-oil concentrate soft gelatin capsules/d (Omacor; Pronova AS, Oslo, Norway) containing 51% EPA and 32% DHA ethyl esters and 3.7 mg vitamin E as an antioxidant. Dose: 3.3 g/d EPA + DHA</p> <p>Control: no treatment</p> <p>Compliance: capsule count, 88% taken, serum EPA + DHA rose in the intervention group (176 to 257 mg/L at 9 months) and fell in the control group (170 to 169 mg/L at 9 months)</p> <p>Length of intervention: 12 months</p>
Outcomes	<p>Main study outcome: CABG graft patency</p> <p>Dropouts: 15 intervention, 14 control</p> <p>Available outcomes: deaths, CV deaths, MI, stroke, repeat CABG, combined CV events, lipids, side effects</p> <p>Response to contact: yes</p>
Notes	<p>The study had 4 arms; aspirin; warfarin; fish oil + aspirin; and warfarin + fish oil. The first 2 groups are combined as the control and the last two combined as intervention</p> <p>Dietary assessment suggested total diet plus supplement intakes as follows: 2.7 g/d EPA + DHA at baseline, 5.5 g/d at 9 months intervention, 2.5 g/d at baseline, 2.2 g/d at 9 months control group</p> <p>Study funding: in part by Pronova and Nycomed Pharma</p>

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random numbers were provided in consecutively sealed envelopes generated centrally
Allocation concealment (selection bias)	Unclear risk	Envelopes not reported as opaque
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open trial, no blinding apart from outcome assessors so participants and study personnel were aware of assignments. However, author suggested in personal communication that participants were not aware of their assignments
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome assessors (radiologists) reported as blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	Reasons for attrition and exclusions stated, numbers clear, dropouts < 20% per year
Selective reporting (reporting bias)	Unclear risk	No study protocol or trials register entry was found

**SHOT 1996** (Continued)

Attention	Low risk	Appeared equivalent between arms
Compliance	Low risk	Capsule count, 88% taken, serum EPA + DHA rose in the intervention group (176 to 257 mg/L at 9 months) and fell in the control group (170 to 169 mg/L at 9 months)
Other bias	Low risk	No further bias noted

**Sianni 2013**

Methods	RCT, parallel, (fish oil vs placebo), 12 months Summary risk of bias: moderate or high	
Participants	Patients with hypertension and paroxysmal or persistent atrial fibrillation (AF) N: 268 intervention, 60 control Level of risk for CVD: moderate Men: not reported Mean age (SD) years: 62 (6), not reported by arm Age range: not reported Smokers: not reported Hypertension: 100% Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: Greece Ethnicity: not reported	
Interventions	Type: supplement Comparison: fish oil vs unclear placebo Intervention: omega-3 fatty acids with no further details. Dose: 4 g/d omega Control: placebo, no further details Compliance: no details Duration of intervention: 12 months	
Outcomes	Main study outcome: AF recurrence and BP Dropouts: no details Available outcomes: new AF episodes, BP (not in a usable format) Response to contact: no	
Notes	Study funding: unclear The study's only publication was a conference abstract.	
Risk of bias		
Bias	Authors' judgement	Support for judgement

**Sianni 2013** (Continued)

Random sequence generation (selection bias)	Unclear risk	No details, probably randomised but unclear
Allocation concealment (selection bias)	Unclear risk	No details
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No details
Selective reporting (reporting bias)	Unclear risk	No protocol or trial register record found
Attention	Unclear risk	No details
Compliance	Unclear risk	No details
Other bias	Unclear risk	No details

**SMART 2013**

Methods	SMART trial (from the Smart Foods Centre) RCT, 3-arm parallel, (Fish + S: hypocaloric diet plus fish plus fish oil capsules vs Fish: hypocaloric diet plus fish plus olive oil capsules vs control: hypocaloric diet plus olive oil capsules), 12 months Summary risk of bias: moderate or high
Participants	Overweight adults N: fish + S intervention 41, fish 43, control 42. (analysed, fish + S intervention 21, fish 25, control 18) Level of risk for CVD: low Men: 27% fish + S intervention, 23% fish intervention, 28% control Mean age (SD) years: unclear by arm, overall 45.1 (8.4) Age range: not reported but 18-60 years eligible Smokers: not reported but 5.9% overall Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: Australia Ethnicity: not reported



Interventions	Type: supplement and food Comparison: EPA + DHA vs MUFA (Fish plus fish oil supplements vs Fish plus olive oil supplements vs olive oil supplements) Intervention, Fish + S: hypocaloric diet aiming at 30% E from fat, 25% E from protein, 45% E from CHO, plus 180 g fish/week plus capsules including 420 mg/d EPA + 210 mg/d DHA (Blackmores Promega Heart). Dose: 0.63 g/d EPA + DHA Intervention, fish: hypocaloric diet aiming at 30% E from fat, 25% E from protein, 45% E from CHO, plus 180 g fish/week plus capsules including 1 g olive oil/d Control: hypocaloric diet aiming at 30% E from fat, 25% E from protein, 45% E from CHO, plus capsules including 1 g olive oil/d Compliance: assessed through diet histories (fish) and erythrocyte fatty acid supplements (capsules), but results not reported Duration of intervention: 12 months	
Outcomes	Main study outcome: total % body fat Dropouts: fish + supplement intervention 20, fish intervention 18, control 24 Available outcomes: weight, BMI, lipids, BP, fasting glucose, fasting insulin, % body fat (leptin also reported), no deaths or cardiovascular events occurred (authors report) Response to contact: authors provided data on CVD events (none) and mean/SD data for TGs and fasting insulin	
Notes	To assess effects of omega 3 fats the best comparison in this study is fish + S vs fish, so numerical data reflect this comparison Study funding: Australian National Health and Medical Research Council, fish and olive oil capsules were provided free by Blackmores Australia	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "A researcher independent of the subject interface undertook the randomisation of participants into diet groups (stratified by sex and block randomised...)"
Allocation concealment (selection bias)	Low risk	Quote: "Randomisation was performed centrally, off-site and the holder of the allocation schedule provided the codes to a single researcher who was independent to the subject interface. The placebo and active ingredient capsules were coded off-site. The codes were kept from the researchers collecting dietary data and delivering treatment. Allocation concealment was maintained as the persons responsible for screening eligible participants for inclusion in the trial was unaware to which supplement group the subject would be allocated. Dif-

		ferent dietitians collected the dietary data and provided dietary advice”
Blinding of participants and personnel (performance bias) All outcomes	High risk	As above, but impossible to blind participants to the fish advice
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	As above
Incomplete outcome data (attrition bias) All outcomes	Low risk	Very high levels of attrition, though intention-to-treat analyses carried out
Selective reporting (reporting bias)	High risk	We were unable to find data on 24 hour energy expenditure, oxidation or heart rate which were stated as primary and secondary outcomes in the trials registry
Attention	Unclear risk	While dietary education was for 1 hour then 6 further half hour follow-ups plus written materials and monthly newsletters plus dietary interviews it is not clear whether this was in all arms or only some of them
Compliance	High risk	Quote: “Of the 12 months completers, 57% were judged to be compliant, 39% (n = 7) for the control group who reported < 180 g fish/week, 48% (n = 12) for the Fish group who reported ≥ 180 g fish/week, and 85% (n = 17) for the Fish + S group who reported ≥ 180 g fish/week or ≥ 90% supplements”. However, erythrocyte (EPA + DHA)/total fatty acids × 100 was significantly different for the fish oil supplemented group compared to the two others - but it was only measured in around half of the participants as the others dropped out, so presumably were non-compliant
Other bias	Low risk	None noted

## SOFA 2006

Methods	Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) 2 arm, parallel RCT (n-3 EPA + DHA vs MUFA), 12 months Summary risk of bias: low	
Participants	People with previous ventricular arrhythmias and implantable cardioverter defibrillators N: 273 intervention, 273 control (273 intervention, 273 control analysed) Level of risk for CVD: high Men: 84% intervention, 85 % control Mean age in years (SD): 60.5 (12.8) intervention, 62.4 (11.4) control Age range: unclear (18 years and older) Smokers: 16% intervention, 8% control Hypertension: 53% intervention, 49% control Medications taken by at least 50% of those in the control group: beta-blockers Medications taken by 20%-49% of those in the control group: lipid lowering, antiarrhythmic medications (combined) Medications taken by some, but less than 20% of the control group: amiodarone, sotalol Location: 8 countries in Europe Ethnicity: not reported	
Interventions	Type: supplement (capsule) Comparison: EPA + DHA vs MUFA + omega 6 Intervention: 2 g/d (4 capsules) purified fish oil. 961 mg n-3 PUFAS (464 mg EPA + 335 mg DHA and 162 mg other n-3 PUFAs) daily. 3000 ppm vitamin E (Loders Croklann, Wormerveer). Dose: 0.8 g/d EPA + DHA Control: 2 g/d high-oleic acid sunflower oil. 3000 ppm vitamin E (Loders Croklann, Wormerveer) Compliance: daily diary, checked by research nurses every 4 months. Judging by capsule count, 207 patients in the fish oil group and 218 in the placebo took more than 80% of their capsules. N-3 fatty acid composition in serum cholesterol levels was measured at baseline and the end of the trial. The EPA concentration in serum cholesterol esters increased in the expected range. No data provided Length of intervention: 12 months	
Outcomes	Main study outcome: spontaneous ventricular tachyarrhythmias and all-cause mortality Dropouts: 33 intervention (23 partial follow-up), 33 control (14 partial follow-up) Available outcomes: deaths, MI, new angina, new heart failure, no fatal arrhythmias, cancer, cardiovascular events, side effects Response to contact: yes but no data provided	
Notes	Study funding: Wageningen Centre for Food Sciences (alliance of major Dutch food industries and others)	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Patients using beta-blockers were separately randomised in blocks of 2. A computer randomisation programme randomly took the

		first treatment of a block. The second patient in a block of 2 always received the opposite treatment
Allocation concealment (selection bias)	Low risk	Treatments (blinded medication numbers) were centrally assigned by a telephone allocation service
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double blinding. Bottles containing capsules labelled with medication numbers that are unidentifiable for patients as well as investigators. Fish oil and placebo capsules have identical appearance. Difference can't be tasted if swallowed with water (as suggested)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "blinded endpoint adjudication committee"
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis. Did a partial follow-up on some patients who dropped out due to non-compliance
Selective reporting (reporting bias)	Low risk	NCT00110838, trial registered in May 2005, end of trial January 2005, trial results published in 2006. However, rationale and design paper (stating outcomes) published in 2003. Outcomes in the 2006 paper appear to be the same as in Rationale paper
Attention	Low risk	Unlikely as intervention blinded to investigators and only intervention was capsules
Compliance	Unclear risk	Daily diary, checked by research nurses every 4 months. Judging by capsule count, 207 patients in the fish oil group and 218 in the placebo took more than 80% of their capsules. N-3 fatty acid composition in serum cholesterol levels was measured at baseline and the end of the trial. The EPA concentration in serum cholesterol esters increased in the expected range. No data provided
Other bias	Low risk	No further bias noted

Methods	2-arm, parallel RCT (enriched olive oil vs olive oil), 12 months Summary risk of bias: moderate or high	
Participants	Non-alcoholic fatty liver disease patients N: 6 intervention, 5 control Level of risk for CVD: low Men: 66.7% intervention, 100% control Median age: 55 intervention, 54 control Age range: 30-41 intervention, 42-70 control Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: Italy Ethnicity: not reported	
Interventions	Type: supplement (oil) Comparison: EPA + DHA vs MUFA Intervention: 6.5 mL/d olive oil enriched with n-3 (t-Omega 3, tFarma srl, Italy) containing 0.47 g EPA, 0.24 g DHA plus dietary recommendations. Dose: 0.83 g/d EPA + DHA Control: 6.5 mL/d olive oil plus dietary recommendations Compliance: was verified by counting the empty boxes on return but no data reported Length of intervention: 12 months	
Outcomes	Main study outcome: fatty liver status Dropouts: unclear Available outcomes: lipids, glucose, insulin, HOMA, (BMI not in usable format, also LFTs, oxidative markers, adiponectin, fatty liver and steatosis outcomes) Response to contact: not yet attempted	
Notes	Study funding: oil supplied by tFarma and funding not stated	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "The patients were randomized into two groups"
Allocation concealment (selection bias)	Unclear risk	No details
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Numbers analysed for liver health are for those randomised. Numbers analysed for other outcomes not stated. No mention of dropouts
Selective reporting (reporting bias)	Unclear risk	No protocol or trial registration
Attention	Low risk	Both groups received same contact
Compliance	Unclear risk	Measured but no results reported
Other bias	Low risk	None noted

## SU.FOL.OM3 2010

Methods	Supplementation en Folates et Omega 3 (SU.FOL.OM3) RCT, 2 × 2 factorial (LCn3 omega 3 vs placebo, also B vitamin comparison), 4 years Summary risk of bias: low
Participants	People with a history of MI, unstable angina or ischemic stroke N: control: 1248, intervention: 1253 Level of risk for CVD: high Men: 80.85% intervention, 78.25% control Mean age in years (SD): 61.1 (8.8) intervention, 60.8 (8.7) control Age range: 53-68 years intervention, 54-68 years control Smokers: 11.1% intervention, 10.4% control Hypertension: not reported Medications taken by at least 50% of those in the control group: beta-blockers, aspirin or antiplatelets, lipid lowering, ACE inhibitors Medications taken by 20%-49%: not reported Medications taken by some, but < 20%: calcium channel blocker, angiotensin II receptor blockers Location: France Ethnicity: not reported
Interventions	Type: supplement (capsule) Comparison: EPA + DHA vs non fat placebo Intervention: 2 gelatin capsules Pierre Fabre omega 3 (400 mg/d EPA and 200 mg/d DHA) Control: 2 gelatin capsules/d placebo (liquid paraffin with fish flavour) Compliance: tested by questionnaire, response rate was on average 96%. Out of this, 86% complied Duration of intervention: 4 years

Outcomes	Main study outcome: composite of myocardial infarction, cerebral vascular ischemic accident or cardiovascular deaths Dropouts: control: 145 (66 withdrew, 11 lost to follow-up, 68 deaths), intervention: 134 (61 withdrew, 7 lost to follow-up, 66 deaths) Available outcomes: deaths, cardiovascular death, non fatal MI, stroke, CV events, coronary events, cancer events, Geriatric Depression Scale score, authors provided additional information on outcomes and methodology Response to contact: yes (data provided)	
Notes	The other factorial intervention was B-vitamins (560 µg methyl-terahydrofolate, 3 mg B-6, 20 µg B12) vs placebo Study funding: French Ministry of Research, Ministry of Health, Sodexo, Candia, Unilever, Danone, Roche, Merck	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Used computerized block randomisation with stratification by sex, age, prior CVD, and city of residence". "Per-mutated block randomisation (with a block size randomly selected as 8) was used"
Allocation concealment (selection bias)	Low risk	Allocation of participants was programmed by the statistical coordinating centre, who sent participants sufficient treatment capsules for 1 year in an appropriately labelled package
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "All subjects and investigators were blinded to treatment allocation", and placebo capsules looked and tasted "identical to the active supplementation". Fish oil flavour was used in placebos
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome investigators were blinded to allocation
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attritions and exclusions were well described. Only 10% loss over 4 years, well balanced
Selective reporting (reporting bias)	Low risk	ISRCTN41926726 registered 2005, 2003 publication on background and rationale, recruitment started April 2003, 2008 protocol, recruitment ended June 2009, 2010

		results published. Outcomes in registry entry appear to have been published
Attention	Low risk	Not likely as capsules used
Compliance	Low risk	Quote: "Allocation to omega 3 fatty acids increased plasma concentrations of omega 3 fatty acids by 37% compared with placebo" (appears statistically significantly different, though not explicitly stated) ... "The overall response rate for return of completed questionnaires was 99%, 96%, 94%, and 95% at 6, 12, and 24 months and at the end of the trial, respectively. About 86% of those who returned a questionnaire reported that they were compliant with the study treatment and compliance was similar in all four groups"
Other bias	Low risk	No further bias noted

## Tande 2016

Methods	2 arm, parallel RCT (calanus (marine) oil vs olive oil), 12 months Summary risk of bias: moderate to high
Participants	Healthy male and female volunteers with BMI 25-35 kg/m <sup>2</sup> N: 64 intervention, 63 control (50 intervention, 50 control analysed) Level of risk for CVD: low Men: 42% intervention, 43 % control Mean age in years (SD): 50.7 (7.7) intervention, 49 (9.4) control Age range: unclear (18 years and older) Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: Norway Ethnicity: not reported
Interventions	Type: supplement (capsule) Comparison: EPA + DHA vs MUFA Intervention: 2 × 500 mg Calanus oil capsules twice daily to provide a daily dose of 2 g. Supplements were provided by Ayanda AS (Norway) as blister packs of 60 capsules each. The Calanus oil contained approximately 85% wax ester with a sum of neutral lipids > 90%. Dose: 2 g/d EPA + DHA Control: identical capsules of olive oil. Compositional analysis indicated that the fatty acid content of the olive oil was primarily oleic acid (76.9%), palmitic acid (10.2%),



	and linoleic acid (7.7%) Compliance: assessed through the return of unused capsules. Compliance rate reported for both intervention and placebo groups was good (86-88%) Length of intervention: 12 months	
Outcomes	Main study outcome: safety of Calanus oil consumption Dropouts: 14 intervention, 13 control Available outcomes: BMI, waist-hip ratio, BP, pulse, HbA1c, ESR, CRP, lipids, glucose tolerance, insulin, clinical chemistry parameters, adverse events (no CVD events, deaths or other major health outcomes occurred according to author reply) Response to contact: author replied with methodological and event information	
Notes	Study funding: Calanus AS	
<i>Risk of bias</i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote: "Randomization of the study subjects into the intervention group or the placebo group was performed by the University Hospital of North Norway clinical research unit and was stratified by gender." Author reply stated that "[r]andomization was performed by competent people at the drugstore affiliated to the University Hospital, with no interconnection, formally or materially with the research department from where the study was managed. Randomization was performed prior to recruiting subjects."
Allocation concealment (selection bias)	Unclear risk	As above, unclear.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants in the placebo group received identical capsules at similar daily doses as the intervention group. However, no information provided as to their smell and taste. Also unclear if investigators were blinded. Author reply stated "Each study subject was given a randomization number, which carried the name of the person, date of birth and treatment information (intervention or control). The randomization number was the only information made available to the study personnel, and the code was managed by personnel outside the research department. This code was broken

**Tande 2016** (Continued)

		after the completion of all analysis with all primary data processed.” Blinding of participants only possible for fish plus supplementation vs fish plus placebo
Blinding of outcome assessment (detection bias) All outcomes	Low risk	As above
Incomplete outcome data (attrition bias) All outcomes	Low risk	All dropouts (~20%) are explained
Selective reporting (reporting bias)	Unclear risk	No trials registry entry or protocol found
Attention	Low risk	Appear to be similar in both groups
Compliance	Unclear risk	Quote: “levels of DHA and EPA in the blood were generally higher in the Calanus oil group over baseline values relative to the placebo controls” but no data provided
Other bias	Low risk	None noted

**THIS DIET 2008**

Methods	The Heart Institute of Spokane Diet Study (THIS-DIET) RCT- parallel, 24 months Summary risk of bias: moderate or high
Participants	Recent survivors of first myocardial infarction (within < 6 weeks) N: 51 intervention, 50 control Level of CVD risk: high Men: 80% intervention, 68% control Mean age in years (SD): 58 (10) intervention, 58 (9) control Age range: unclear Smokers: 25% intervention, 30% control Hypertension: 43% intervention, 50% control (uncontrolled or secondary hypertension excluded) Medications taken by at least 50% of those in the control group: aspirin, statins, beta-blockers, and ACE inhibitors or angiotensin receptor blockers Medications taken by 20%-49%: not reported Medications taken by some, but < 20%: not reported Location: USA Ethnicity: intervention 98% white; control 94% white
Interventions	Type: dietary advice (to follow a Mediterranean style diet high in n-3) Comparison: EPA + DHA vs MUFA (biggest dietary change) Intervention: Mediterranean style diet high in n-3. Dietary counselling group sessions; two in first month then at months 3, 6, 12 and 24. Sessions focused on behaviour

	<p>modification and practical aspects of assigned diet including recipes, shopping and dining out. Aim to increase omega 3 fat intake to &gt; 0.75% kcal. Dose: ~1.5 g/d omega 3 fat, or 0.31% E by intake assessment</p> <p>Control: dietary advice (to follow the American Heart Association Step II diet). Same number of group sessions as intervention</p> <p>The 2 diets were low in saturated fat (&lt; 7% kcal) and cholesterol (&lt; 200 mg/day); the Mediterranean-style diet was distinguished by greater omega-3 fat intake (&gt; 0.75% kcal)</p> <p>Compliance: participants were required to attend six sessions and only invited but not required to attend extra sessions. 3-day food diaries were reviewed with dietitians. Compliance results not stated</p> <p><b>Dietary achievements:</b></p> <p>Total fat intake, % E (at 24 months): control 29.7 (SD 9.3), intervention 29.1 (SD 8.6)</p> <p>Saturated fat intake, % E (at 24 months): control 8.0 (SD 2.9), intervention 7.9 (SD 3.2)</p> <p>PUFA intake, % E (at 24 months): control 5.7 (SD 3.1), intervention 5.7 (SD 2.4)</p> <p>PUFA n-3 intake, % E: control 0.46 (SD 0.38), intervention 0.67 (SD 0.35) g/week</p> <p>PUFA n-6 intake: not reported</p> <p>MUFA intake, % E (at 24 months): control 10.3 (SD 5.1), intervention 9.7 (SD 3.6)</p> <p>CHO intake, % E (at 24 months): control 54 (SD 11), intervention 54 (SD 10)</p> <p>Protein intake, % E (at 24 months): control 17 (SD 2), intervention 18 (SD 3)</p> <p>Trans fat intake: not reported</p> <p>Length of intervention: 24 months</p>	
Outcomes	<p>Main study outcome: a composite of endpoints including all-cause and cardiac death, MI, hospital admissions for heart failure, unstable angina, or stroke</p> <p>Dropouts: none for primary outcomes</p> <p>Available outcomes: total and CVD deaths (nil deaths), CV events, stroke, MI, diagnosis of diabetes mellitus, BMI and weight (different at baseline hence not used), waist circum, lipids, blood pressure, albuminuria, CRP, creatinine and dietary intake (authors supplied further data on newly diagnosed DM, glucose and insulin data, cancers, depression, atrial fibrillation)</p> <p>Response to contact: yes further data supplied as above</p>	
Notes	<p>The study compared the 2 intervention groups to a non-randomised usual care control group (not reported here)</p> <p>Study funding: no funding details is provided but some reported conflict of interests for an author</p>	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Sealed envelopes concealing the allocation sequence were prepared by a research co-ordinator. Assignment was stratified by diabetes mellitus status using 10-envelope blocks. Envelopes were selected in the prepared order from a locked drawer by a study dietitian to assign interventions

**THIS DIET 2008** (Continued)

Allocation concealment (selection bias)	Unclear risk	As above but opacity of envelopes is not stated.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Neither the intervention team nor participants could be blinded to dietary assignment
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The PI was blinded for the purpose of adjudicating clinical end points and adverse events by the removal of identifiers from records used for review
Incomplete outcome data (attrition bias) All outcomes	Low risk	Primary outcomes data provided for all randomised
Selective reporting (reporting bias)	High risk	NCT00269425. Trial was registered in 2005, data collection started in October 2000, January 2008 (final data collection date for primary outcome measure), publication 2008. A number of the outcomes from the registration were not reported e. g. cardiovascular revascularisation, peripheral revascularisation or amputation, doubling of serum creatinine, dialysis, or kidney transplant, new hypertension. Also numerous secondary measures were reported that were not in the original registration
Attention	Low risk	Both arms had the same contact and attention
Compliance	Unclear risk	No details
Other bias	Low risk	None noted

**WAHA 2016**

Methods	The Walnut and Healthy Aging Study (WAHA) 2-arm, parallel RCT (usual diet plus walnuts vs usual diet), 2 years Summary risk of bias: moderate to high
Participants	Middle-aged healthy adults N: 362 intervention, 346 control (only preliminary data on 312 participants from one of the two centres is available) Level of risk for CVD: low Men: 32.6% intervention, 31.5% control Mean age in years (SD): 69.4 (3.8) intervention, 68.9 (3.5) control Age range: 63-79 (inclusion criteria) Smokers: 4.4% intervention, 1.2% control

	Hypertension: 52.8% intervention, 52.9% control Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: Spain and USA Ethnicity: not reported	
Interventions	Type: supplement (food) Comparison: ALA vs unclear Intervention: 15% of daily energy intake as walnuts. The estimated amount of walnuts ranged from about 30-60 g/day (1-2 ounces). Sachets for daily consumption containing 30 g, 45 g, or 60 g of raw, pieced walnuts were provided as 8-week allotments to be eaten daily, preferably as the raw product, either as a snack or by incorporating them into shakes, yogurts, cereals, or salads. To improve participants' compliance, 1-kg extra walnut allowances were provided every 2 months to take into account family needs. Dose: ~5 g/d ALA Control: usual diet without walnut Compliance: assessed by dietitians through FFQs, recount of empty packages, and changes in FAs concentrations. 95% consumed at least 30 g/d. The proportion of $\alpha$ -linolenic acid in red blood cells increased in the walnut group by 0.16% (95% CI 0.14 to 0.18) and in the control group by 0.02% (95% CI -0.01 to 0.04; P < 0.001). No data on dietary intake provided. Length of intervention: 2 years (only 1 year results have partly been published)	
Outcomes	Main study outcome: change in cognitive decline (results not yet published) Dropouts: 36 intervention, 21 control (after 1 year) Available outcomes: lipids (for TG and HDL only data states "no between diet differences were observed"), weight (waist circumference was provided but without variance, abstract stated that "there were no significant changes in body fat and waist-to-hip ratio over time and between the two groups"). Authors provided data on mortality, CVD events, cancer deaths and diagnoses, IBD diagnosis (no CVD deaths). Cognitive, ophthalmological, inflammatory markers, glycaemic status and other outcomes are not yet available Response to contact: authors provided additional outcome and methodology data	
Notes	Study funding: California Walnut Commission The 2-year results as well the full 1-year results are yet to be published. Outcome data reported are for only for participants from one centre (USA)	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "randomized to either the control or walnut group using a computerized random number table with stratification by center, sex, and age range. Couples entering the study were treated as one number and were randomized into the same group"

Allocation concealment (selection bias)	Low risk	Author reply states, "Baseline subject data was collected before randomization. Randomization was done by the clinician, pressing the key on the computer. Since this was a dual center (Barcelona and Loma Linda) trial, a single computer software randomized participants for both the centers."
Blinding of participants and personnel (performance bias) All outcomes	High risk	Single blind. "An unavoidable limitation of the study is not being able to blind participants to the intervention since it consists of a whole food" Rajaram 2017
Blinding of outcome assessment (detection bias) All outcomes	High risk	Author reply states "Study personnel not in contact with the subjects were blind to the treatment assignment. So (lab technicians, ophthalmology technician, neuro cognitive testers) were not aware of the treatment assignment. Of course clinicians who were visited by subjects every two months, knew the treatment assignment". This suggests that allocation was known by physicians, so high risk for event data
Incomplete outcome data (attrition bias) All outcomes	Low risk	38/362 dropouts in intervention group = 10.5%. 34/346 dropouts in control group = 9.8%. Similar dropout in groups over 2 years
Selective reporting (reporting bias)	Unclear risk	Although prospectively registered, no full results paper published - results from conference abstracts only report some secondary outcomes
Attention	Unclear risk	Not enough details
Compliance	Low risk	ALA levels were significantly higher in the intervention group
Other bias	Low risk	None noted

Methods	RCT, parallel, (low fat diet (15% fat) with n-3 fish oils vs AHA Step I diet (fat $\leq$ 30%) with olive oil supplements), 12 months Summary risk of bias: moderate or high
Participants	Population: adults with multiple sclerosis N: 15 intervention, 16 control (analysed, intervention: 13, control: 14) Level of risk for CVD: low Men: 15.4% intervention, 14.3% control Mean age in years (SD): 39.9 (10.0) intervention, 45.1 (7.7) control Age range: not reported Smokers: not reported Hypertension: not reported Medications taken by at least 50% of those in the control group: all patients received 400 units of vitamin E, one multivitamin tablet (not containing any PUFA) and at least 500 mg calcium per day Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: USA Ethnicity: not reported
Interventions	Type: dietary advice plus supplement Comparison: EPA + DHA vs MUFA (low fat diet (15% fat) with n-3 fish oils vs AHA Step I diet (fat $\leq$ 30%) with olive oil supplements) Intervention: 1.98 g/d EPA, 1.32 g/d DHA supplements (EPAX 5500 EE, Tishcon Corp) + low fat diet (< 15% total calories). Dose: 3.3 g/d EPA + DHA Control: one 1 g olive oil placebo capsules 6 times daily, moderate fat diet (< 30% total calories) (American Heart Association Step 1 diet) Compliance: assessed by individual food records; intervention 69.2% control 66.7% compliance; also at 12 months there was a significant difference between the fatty acid status of the intervention and control groups in terms of EPA ( $P = 0.027$ ), as described in table 3 of the main paper Duration of intervention: 12 months
Outcomes	Main study outcome: physical component scale (PCS) Dropouts: 3 intervention, 7 control Available outcomes: Mental Health Inventory, Modified Fatigue Impact Scale, weight change, HDL and LDL cholesterol, adverse events (MS relapse, TNF-alpha, ICAM-1, VCAM-1 and other inflammatory markers, SF-36 not used) Response to contact: no
Notes	Study funding: National Multiple Sclerosis Society (PP0620T), Mellen Center Foundation and "The Jog for the Jake" grant

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	States "randomly assigned", no further details

# Weinstock-Guttman 2005 (Continued)

Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "Patients knew the percentage of dietary fat but did not know the assignment of capsules oil supplementation."
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	Discrepancy in numbers of participants discontinued and numbers analysed. Per protocol analysis
Selective reporting (reporting bias)	Unclear risk	No protocol or trials register entry found
Attention	Low risk	Treated equally
Compliance	Low risk	Assessed by individual food records; intervention 69.2% control 66.7% compliance. At 12 months there was a significant difference between the EPA status of the intervention and control groups (P = 0.027)
Other bias	Low risk	None noted

# WELCOME 2015

Methods	Wessex Evaluation of Fatty Liver and Cardiovascular Markers in NAFLD with Omacor Therapy (WELCOME) RCT, parallel, (Omacor or placebo), 15-18 months Summary risk of bias: low
Participants	Patients with NAFLD N: 51 intervention, 52 control (analysed, 47 intervention, 48 control) Level of risk for CVD: moderate Men: 49% intervention, 67% control Mean age in years (SD): 48.6 (11.1) intervention, 54 (9.6) control Age range: not reported (18-75 years inclusion criteria) Smokers: 14.3% intervention, 11.8% control Hypertension: not reported Medications taken by at least 50% of those in the control group: lipid lowering drugs Medications taken by 20%-49% of those in the control group: antihypertensives, metformin (data not provided by group) Medications taken by some, but less than 20% of the control group: none reported Location: UK Ethnicity: not reported



Interventions	<p>Type: supplement (Omacor capsules)</p> <p>Comparison: DHA + EPA vs MUFA</p> <p>Intervention: 4 g OMACOR per day (providing 1.84 g EPA, 1.52 g DHA as ethyl esters)</p> <p>]. Dose: 3.36 g/d EPA + DHA</p> <p>Control: 4 g olive oil capsules/ day (providing; ALA1%, oleic acid 67%, palmitic acid 15%, stearic acid 2%, n-6 fat: 15%)</p> <p>Compliance: was assessed by recording the returned unused capsules and quantification of erythrocyte EPA + DHA enrichment (a prespecified threshold of 2% for DHA &amp; threshold of 0.7% for EPA enrichment)</p> <p>Duration of intervention: 15-18 months</p>
Outcomes	<p>Main study outcome: changes in mean liver fat %, changes in 2 liver fibrosis scores, change in serum biomarkers</p> <p>Dropouts: 4 intervention, 4 control</p> <p>Available outcomes: weight, BMI, lipids, blood pressure, glucose, insulin sensitivity, body fat measures, liver enzymes, HbA1c, serum n-3 FAs, authors provided details of diabetes diagnoses, % body fat, BP and carotid intima media thickness</p> <p>Response to contact: yes</p>
Notes	<p>Study funding: National Institute for Health Research (NIHR) Southampton Biomedical Research Unit grant and by a Diabetes UK allied health research training fellowship awarded to KGM (Diabetes UK. BDA 09/ 0003937). CDB, PCC and ES are supported in part by the NIHR Southampton Biomedical Research Centre. Omacor and placebo were provided by Pronova Biopharma through Abbott Laboratories, Southampton, UK</p>

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	<p>Participants were block randomised by an independent clinical trials pharmacist to treatment with identical capsules by mouth of either n-3 fatty acid ethyl esters (4 g/d Omacor; Pronova, Sandefjord, Norway) or placebo (4 g/d olive oil) for a minimum of 15 months and a maximum of 18 months (McCormick-2015, p2)</p> <p>Patients were randomised according to standardised procedures (computerised block randomisation) by a research pharmacist at University Hospital Southampton NHS Foundation Trust. Simple randomisation in blocks of 4, either to trial medication or placebo was used. (Scorletti-2014, p 2)</p>
Allocation concealment (selection bias)	Low risk	<p>Participants were block randomised by an independent clinical trials pharmacist to</p>

		treatment with identical capsules by mouth of either n-3 fatty acid ethyl esters (4 g/d Omacor; Pronova, Sandefjord, Norway) or placebo (4 g/d olive oil) for a minimum of 15 months and a maximum of 18 months (McCormick-2015, p2). Only the clinical trials pharmacist was unblinded, and randomisation group allocation was concealed from all study members throughout the trial. (McCormick-2015, p 2)
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Paper states that only the clinical trials pharmacist was unblinded, and randomisation group allocation was concealed from all study members throughout the trial. However, the trial register record states "single blind (investigator)". Although the capsules were identical, no information provided as to their smell and taste
Blinding of outcome assessment (detection bias) All outcomes	Low risk	As above
Incomplete outcome data (attrition bias) All outcomes	Low risk	The ITT analysis included all patients randomised who had complete data (baseline and end-of-study measurements), regardless of whether they were later found to be ineligible, a protocol violator, given the wrong treatment allocation, or never treated) (Scorletti 2014, p 4)
Selective reporting (reporting bias)	Unclear risk	Prospectively registered September 2008, study start September 2009, end February 2017. Outcome data for cardiac function not yet published, though other cardiovascular measures reported - take as ongoing as recent end date
Attention	Low risk	Both groups had the same attention
Compliance	Low risk	Assessed by recording the returned unused capsules and quantification of erythrocyte EPA + DHA enrichment (a prespecified threshold of 2% for DHA and threshold of 0.7% for EPA enrichment). Quote: "Enrichment was highly variable in the DHA+EPA group and 5 and 6 participants in the DHA+EPA group did not reach the

		prespecified threshold for EPA and DHA enrichment, respectively. In the placebo group, we expected no enrichment between baseline and end of study in all participants in this group, but 3 and 4 participants reached the thresholds set for the DHA+EPA group, for EPA and DHA, respectively. One participant in the placebo group admitted to taking cod liver oil during the study and another markedly increased consumption of fish." 10 of 95 non-compliant
Other bias	Low risk	None noted

**Zhang 2017**

Methods	RCT, parallel, (n-3 DHA vs n-6 LA), 12 months Summary risk of bias: moderate to high
Participants	Otherwise healthy elderly people with mild cognitive impairment N: 120 intervention, 120 control (analysed, intervention: 110 control: 109) Level of risk for CVD: low Men: 35.8% intervention, 34.2% control Mean age in years (SD): 74.5 (2.65) intervention, 74.6 (3.31) control Age range: eligibility criteria were age 65-85 years at trial start Smokers: 59.17% intervention, 61.67% control Hypertension: 9.17% intervention, 7.50% control Medications taken by at least 50% of those in the control group: not reported Medications taken by 20%-49% of those in the control group: not reported Medications taken by some, but less than 20% of the control group: not reported Location: China Ethnicity: assumed Chinese
Interventions	Type: supplement (capsule) Comparison: DHA vs corn oil (n-6) Intervention: 1 capsule twice a day, with meals, including 2 g algal DHA (45-55% DHA by weight). Martek Biosciences, Columbia, MD. Dose: ~1 g/d DHA Control: corn oil, orange-flavoured and orange colour to protect the study blind Compliance: participants were asked to return any remaining tablets. Compliance was defined as a ratio (actually taken/should have taken). Achieved 97% for intervention, 95% for control. Serum levels of DHA also measured, DHA at 6 months barely higher in intervention than in controls Duration of intervention: 12 months
Outcomes	Main study outcome: cognitive function and hippocampal volume Dropouts: 10 intervention, 11 control Available outcomes: mortality, cognitive outcomes and cerebral volume measurements Response to contact: no reply to date

Notes	Study funding: Chinese Nutrition Society (CNS) Nutrition Research Foundation- DSM Research Fund	
<i>Risk of bias</i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Computer-generated, also statistics analyst ignorant to this study used random number table
Allocation concealment (selection bias)	Unclear risk	Insufficient information
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo capsules ... identical in appearance. All capsules were orange-flavoured and orange colour to protect the study blind . Packaged into identical pots, each containing 180 capsules, and labelled by staff who were not involved in the study. A blinding key linked each participant to his or her assigned treatment. This key was kept by an investigator not involved in any data collection or analyses, in a secure electronic file. The code was revealed at the completion of the trial following analyses of the main study aims
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All project staff were unaware of group assignments until the completion of the trial and after data analysis
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	They did not describe how they imputed missing data (lost contact with patients, but called this an ITT analysis). Overall well matched and not high attrition
Selective reporting (reporting bias)	Low risk	Registered trial prospectively. Outcomes match protocol
Attention	Low risk	“Adherence was encouraged and monitored throughout the trial by telephone assessment at 15 time points, and by blood assay at baseline” 6 months and 12 months. This and assessments were described as same for both arms

Compliance	Unclear risk	Quote: “participants were requested to return any remaining tablets in order to measure compliance, together with the replenishment of capsules for the following month.” Compliance ... defined “as a ratio = actually taken/should have taken”. “Adherence was encouraged and monitored throughout the trial by telephone assessment at 15 time points, and by blood assay at baseline” 6 months and 12 months On compliance tree, leads to “No, because no P values were supplied” therefore risk of compliance bias unclear
Other bias	Unclear risk	Although the register says single blind, the publication very clearly describes a double-blind RCT

## Özaydin 2011

Methods	RCT, parallel, (n-3 fish oil + amiodarone vs amiodarone), 12 months Summary risk of bias: moderate or high
Participants	Patients with persistent atrial fibrillation (AF) referred to cardioversion N: 23 intervention, 24 control Level of risk for CVD: high Men: 47.8% intervention, 37.5% control Mean age in years (SD): 62 (12) intervention, 61 (11) control Age range: 37-81 Smokers: not reported Hypertension: 56.5% intervention, 50% control Medications taken by at least 50% of those in the control group: all patients received amiodarone (an antiarrhythmic medication) Medications taken by 20%-49% of those in the control group: beta-blockers, statins, ACE inhibitors and ARBs Medications taken by some, but less than 20% of the control group: calcium antagonists Location: Turkey Ethnicity: not reported
Interventions	Type: supplement (capsule) Comparison: LCn3 vs nil Intervention: 2 g/d n-3 PUFA (Marincap, Kocak, Turkey). 4 × 500 mg capsules providing EPA 18% (360 mg/d); DHA 12% (240 mg/d). Dose: 0.6 g/d EPA + DHA Control: no placebo. Amiodarone was given to both groups. Compliance: no details Duration of intervention: 12 months or AF recurrence

Outcomes	Main study outcome: AF recurrence(endpoint) Dropouts: no details Available outcomes: all cause mortality (nil death), stroke, TIA, AF recurrence (hyper-thyroidism diagnosis, hospitalisation) Response to contact: not yet attempted	
Notes	Study funding: unclear	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	No details
Allocation concealment (selection bias)	Unclear risk	Quote: “randomised”; no further details
Blinding of participants and personnel (performance bias) All outcomes	High risk	No placebo
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details
Incomplete outcome data (attrition bias) All outcomes	Low risk	All were accounted for
Selective reporting (reporting bias)	Unclear risk	No trial registry entry or protocol found
Attention	Low risk	Both groups seem to have the same care
Compliance	Unclear risk	No information
Other bias	Low risk	None noted

**ACE:** angiotensin-converting enzyme; **ADAS:** Alzheimer's Disease Assessment Scale; **ADL:** activities of daily living; **AF:** atrial fibrillation; **AHA:** American Heart Association; **BMI:** body mass index; **ALT:** alanine transaminase; **ARB:** angiotensin-receptor blocker; **BMD:** bone mineral density; **BMI:** body mass index; **BP:** blood pressure; **CABG:** coronary artery bypass grafting; **CDAI:** Clinical Disease Activity Index; **CHD:** coronary heart disease; **CHO:** carbohydrate; **CV:** cardiovascular; **CRP:** C-reactive protein; **CVD:** cardiovascular disease; **DAS:** Disease Activity Score; **DBP:** diastolic blood pressure; **DHA:** docosahexaenoic acid; **DM:** diabetes mellitus; **DMARD:** disease-modifying antirheumatic drugs; **DPA:** docosapentaenoic acid; **E:** dietary energy; **ECG:** electrocardiogram; **EDSS:** Expanded Disability Status Scale; **EPA:** eicosapentaenoic acid; **ESR:** erythrocyte sedimentation rate; **FA:** fatty acid; **FFQ:** food frequency questionnaire; **FH:** family history; **FMD:** flow-mediated dilation; **GFR:** glomerular filtration rate; **GLA:** gamma linolenic acid; **HbA1c:** glycated haemoglobin; **HCQ:** hydroxychloroquine; **HDL:** high-density lipoprotein; **H/O:** personal history of; **HOMA-IR:** homeostatic model assessment of insulin resistance; **HRT:** hormone replacement therapy; **HT:** hypertension; **IBD:** inflammatory bowel disease; **IADL:** instrumental activities of daily living; **ICAM-1:** intercellular adhesion molecule 1; **IL:** inter-

leukin; **IMT**: immune-mediated thrombocytopenia; **IQR**: interquartile range; **LCn3**: long-chain omega-3 fatty acids; **LDL**: low-density lipoprotein; **MD**: mean difference; **MDA**: malondialdehyde; **MI**: myocardial infarction; **MMSE**: Mini-Mental State Examination; **MS**: multiple sclerosis; **MUFA**: mono-unsaturated fatty acids; **MXT**: methotrexate; **n-3**: omega-3; **NASH**: non-alcoholic steatohepatitis; **NSAID**: non-steroidal anti-inflammatory drug; **PAI1**: plasminogen activator inhibitor-1; **PI**: principal investigator; **PUFA**: poly-unsaturated fatty acids; **PTCA**: percutaneous transluminal coronary angioplasty; **P/S**: poly-unsaturated/saturated fat ratio; **QoL**: quality of life; **QUICKI**: quantitative insulin sensitivity check index; **RA**: rheumatoid arthritis; **RCT**: randomised controlled trial; **SBP**: systolic blood pressure; **SD**: standard deviation; **SE**: standard error; **RCT**: randomised controlled trial; **SFA**: saturated fatty acids; **SSZ**: sulfasalazine; **TAG**: triacylglycerol; **TG**: serum triglycerides; **TIA**: transient ischaemic attack; **TNF**: tumour necrosis factor; **VCAM-1**: vascular cell adhesion molecule 1; **WHO**: World Health Organization.

## Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
<a href="#">Alekseeva 2000</a>	Study not randomised
<a href="#">Baleztena 2015</a>	No relevant outcomes measured
<a href="#">Belch 1988</a>	No relevant outcomes measured
<a href="#">Belluzzi 1996</a>	Authors confirmed no relevant outcomes measured
<a href="#">Berthoux 1992</a>	Participants not adult humans, or participants unwell at baseline
<a href="#">Borchgrevink 1966</a>	Mean duration of intervention 10 months (range 3 to 16 months)
<a href="#">Busnach 1998</a>	Participants not adult humans, or participants unwell at baseline
<a href="#">CANN 2015</a>	Intervention is multifactorial (FA/flavanoid blend)
<a href="#">Cappelli 1997</a>	Participants not adult humans, or participants unwell at baseline
<a href="#">CARES 2015</a>	Multisupplement intervention
<a href="#">Cheng 1990a</a>	No appropriate control group
<a href="#">Cheng 1990b</a>	No appropriate control group
<a href="#">Clark 1993</a>	No relevant outcomes measured
<a href="#">Clark 1994</a>	Participants not adult humans, or participants unwell at baseline
<a href="#">Clark 2001</a>	Participants not adult humans, or participants unwell at baseline
<a href="#">Clausen 1989</a>	Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, behavioural or drug interventions)
<a href="#">Diskin 1990</a>	No omega-3 supplementation or dietary advice

(Continued)

Donadio 1994	Participants not adult humans, or participants unwell at baseline
Doyle 2001	Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, behavioural or drug interventions)
Dry 1991	No relevant outcomes measured
Ezaki 1999	Study not randomised
Feher 2005	Intervention is multifactorial (omega 3 given with coenzyme Q and other compounds vs placebo)
FISH 2012	No clinical outcomes collected (confirmed by corresponding author, 30 November 2016)
Fonolla 2009	Intervention was milk enriched with EPA and DHA but also other vitamins and minerals - multifactorial dietary intervention
Fonolla-Joya 2016	Intervention was milk enriched with EPA and DHA but also other vitamins and minerals - multifactorial dietary intervention
Franzen 1989	Study not randomised
Galarraga 2008	9-month intervention period
Gapparova 2000	Study not randomised
Gazso 1992	No omega-3 supplementation or dietary advice
Geusens 1994	No relevant outcomes measured
Gogos 1998	Participants not adult humans, or participants unwell at baseline
Greatrex 2000	Study not randomised
Griffin 1999	Study not randomised
Hamazaki 1984	Participants not adult humans, or participants unwell at baseline
Hansen 1996	Multi-factorial intervention (cannot separate effects of omega-3 fats from those of other dietary, behavioural or drug interventions)
Harris 1991	No appropriate control group
Hashimoto 2012	No relevant outcomes measured
Hashimoto 2016	No relevant outcomes measured
Hawthorne 1992	Authors confirmed no relevant outcomes measured



(Continued)

HEARTS 2015	Intervention included intensive behavioural changes including exercise and nutrition counselling geared towards weight loss
Hogg 1995	Participants not adult humans, or participants unwell at baseline
HOPE epilepsy 2012	Trial recruitment was suspended due to lack of funding
Huang 1996	No relevant outcomes measured
Huang 2008	Intervention was 9 months and no relevant outcomes
ISRCTN38354847	The proposed one-year study was never conducted
Junker 1990	Follow-up not at least a year
Kachorovskii 1977	No omega-3 supplementation or dietary advice
Kanorskii 2007	LCn3 compared to sotalol (group 1), sotalol & perindopril (group 2), sotalol, perindopril & rosuvastatin (group 3), so no useful control group
Karlsson 1998	Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, behavioural or drug interventions)
Kaul 1992	Intervention duration 6 months
Khan 2003	Intervention was 8 months
Konya 2000	Study not randomised
Kremer 1995	< 1 year duration
Kruger 1998	No relevant outcomes measured
Kurabayashi 2000	< 1 year duration
Lau 1993	Authors confirmed no relevant outcomes
Leaf 1995	Study not randomised
Lee 2010	Authors confirmed no relevant outcomes measured
Leng 1998	Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, behavioural or drug interventions)
LipiDiDiet 2016	Multifactorial dietary intervention that included omega 3 fats but many other nutrition components
Loeschke 1996	No relevant outcomes measured

(Continued)

<a href="#">LUTEGA 2013</a>	Multisupplement intervention
<a href="#">Lyon Diet Heart 1994</a>	Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary interventions)
<a href="#">Maachi 1995</a>	Participants not adult humans, or participants unwell at baseline
<a href="#">Macasai 2008</a>	No relevant outcomes measured
<a href="#">Mansel 1990</a>	Not an omega-3 intervention
<a href="#">Mantzaris 1996</a>	No relevant outcomes measured
<a href="#">Mate-Jimenez 1991</a>	Authors confirmed no relevant outcomes
<a href="#">Matsuyama 2005</a>	Publication retracted (fraudulent)
<a href="#">Middleton 2002</a>	Unbalanced intervention as the intervention arm contains additional GLA
<a href="#">MoodFOOD 2016</a>	Multisupplement intervention
<a href="#">NAYAB 2017</a>	No planned relevant outcomes. Follow-up < 12 months
<a href="#">NCT01235533</a>	48 weeks intervention planned in trials register entry
<a href="#">NU-AGE 2014</a>	Multifactorial dietary intervention
<a href="#">NutriMEMO 2014</a>	Mutlisupplement intervention
<a href="#">OFAMS 2012</a>	No relevant outcomes measured
<a href="#">Okuda 1996</a>	No appropriate control group
<a href="#">OLIVE 1998</a>	Study was not funded and did not achieve full recruitment (info provided by co-author)
<a href="#">Oslo DIET HEART 1970</a>	Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, behavioural or drug interventions)
<a href="#">Pogozheva 1997</a>	Study not randomised
<a href="#">Pogozheva 2000</a>	Study not randomised
<a href="#">Puri 2008</a>	Authors confirmed no relevant outcomes
<a href="#">Quazi 1994</a>	Study not randomised, < 1 year intervention
<a href="#">Sacks 1994</a>	< 1 year intervention

(Continued)

Saynor 1988	Study not randomised
Saynor 1992	No appropriate control group
Selvais 1995	Intervention was < 1 year
Shimizu 1995	Authors confirmed no relevant outcomes
Singh 1992	Expressions of concern issued by the <i>BMJ</i> and <i>The Lancet</i> regarding research by this first author (BMJ 2005; Horton 2005)
Singh 1997a	Expressions of concern issued by the <i>BMJ</i> and <i>The Lancet</i> regarding research by this first author (BMJ 2005; Horton 2005)
Singh 1997b	Expressions of concern issued by the <i>BMJ</i> and <i>The Lancet</i> regarding research by this first author (BMJ 2005; Horton 2005)
Singh 2002	Expressions of concern issued by the <i>BMJ</i> and <i>The Lancet</i> regarding research by this first author (BMJ 2005; Horton 2005)
Tariq 1989	Participants not adult humans, or participants unwell at baseline and intervention is < 1 year
Terano 1999	Authors confirmed no relevant outcomes during trial
Tomer 2001	No relevant outcomes. Measured lipids but unclear baseline and endpoint is probably 4 weeks
Torjesen 1997	Multifactorial intervention (cannot separate effects of omega-3 fats from those of other dietary, behavioural or drug interventions)
VSDR 2015	The supplement (Nutrof Omega) contained DHA, Vit C, E, B1, B2, B3, B6, B9, B12, Zn, Mn, Se, Cu, lutein and zeaxanthin (multifactorial dietary intervention)
Wheaton 2010	Participants were not a minimum of 18 years old
Yasui 2001	No appropriate control group
Zinger 1987	Study not randomised

**DHA:** docosahexaenoic acid; **EPA:** eicosapentaenoic acid; **FA:** fatty acid; **GLA:** gamma linolenic acid.

## Characteristics of ongoing studies *[ordered by study ID]*

### AC Omega3 2014

Trial name or title	Aboriginal Cardiovascular Omega-3 randomised controlled trial (AC Omega3)
Methods	RCT
Participants	Indigenous Australian adults with stable coronary artery disease
Interventions	Each for 12 months: Arm 1: omega-3 (1800 mg/d AlaskOmega: 3 capsules/d: 400 mg EPA and 200 mg DHA) Arm 2: placebo mixed oil capsules (1000 mg/d: 3 capsules/d containing palm oil, gelatin, glycerol, sunflower oil, rapeseed oil, mixed tocopherols, and a "small amount" of fish oil (for taste to aid blinding)
Outcomes	Primary: serum non-HDL-C Secondary: triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, lipid functionality by cholesterol efflux and CETP, heart rate variability, platelet function and thrombosis markers, inflammation markers, cumulative combined rate of major adverse cardiac events (including death, non-fatal MI, unstable angina, non-fatal stroke, revascularisation and cardiac related hospital admissions)
Starting date	Registered on trials registry: 10 July 2014 Study start date: 1 October 2014 Estimated study completion date: unclear
Contact information	Alex Brown (PI), Wardliparingga Aboriginal Unit, Adelaide, Australia, alex.brown@sahmri.com
Notes	ACTRN12614000732684 Alex Brown contacted in 2016: confirmed study is actively recruiting

### AFORRD 2010

Trial name or title	Atorvastatin in Factorial with Omega-3 fatty acid Risk Reduction in Diabetes (AFORRD)
Methods	RCT
Participants	Patients with type 2 diabetes with no known CVD and not taking lipid-lowering therapy, adults (> 18 years) N: intervention 397, control 403 (analysed intervention 371, control 361)
Interventions	Each for 12 months: Arm 1: atorvastatin (Lipitor 20 mg/d) and olive oil placebo (2 g/d) Arm 2: omega-3 (Omacor 2 g/d: 46% EPA, 38% DHA) and placebo tablets for atorvastatin Arm 3: atorvastatin (Lipitor 20 mg/d) and Omega-3 (Omacor 2 g/d: 46% EPA, 38% DHA) Arm 4: placebo tablets for atorvastatin and olive oil placebo (2 g/d)
Outcomes	Primary: lipid profiles Secondary: phytosterol changes, HbA1c, estimated CVD risk using the UK Prospective Diabetes Study risk engine

**AFORRD 2010** (Continued)

Starting date	Registered on trials registry: 4 April 2004 Study start date: 1 November 2004 Estimated study completion date: 31 July 2006
Contact information	Rury Holman, Oxford Centre for Diabetes
Notes	ISRCTN76737502 Rury Holman contacted in 2016: confirmed results are not yet published, but planned

**ASCEND 2012**

Trial name or title	A Study of Cardiovascular Events in Diabetes (ASCEND)
Methods	RCT
Participants	Patients with diabetes, without vascular disease
Interventions	Each for 7 years: Arm 1: omega-3 (1 g/d: 0.41 g EPA, 0.34 g DHA) and placebo tablets for aspirin Arm 2: aspirin (100 mg/d) and olive oil placebo capsule Arm 3: omega-3 (1 g/d) and aspirin (100 mg/d) Arm 4: olive oil placebo and placebo tablets for aspirin
Outcomes	Primary: cardiovascular events Secondary: mortality, hospitalisations, cancer
Starting date	Registered on trials registry: 24 August 2005 Study start date: March 2005 Estimated study completion date: September 2017
Contact information	Jane Armitage (PI), University of Oxford Clinical Trial Service Unit
Notes	NCT00135226 Trial website: <a href="http://ascend.medsci.ox.ac.uk">ascend.medsci.ox.ac.uk</a> ; <a href="http://rum.cts.ox.ac.uk/ascend">rum.cts.ox.ac.uk/ascend</a>

**Bartold 2010**

Trial name or title	Clinical efficacy of fish oil as adjunct therapy for patients with chronic periodontitis
Methods	RCT
Participants	Patients (25-80 years, non-smokers) with newly diagnosed severe but non-aggressive periodontitis
Interventions	Each for 13 months: Arm 1: fish oil rich in EPA (6 × 500 mg capsules/d: 277 mg EPA; 27 mg DHA) and standard periodontal treatment (scaling and debridement) Arm 2: fish oil rich in DHA (6 × 500 mg capsules/d: 66 mg EPA; 258 mg DHA) and standard periodontal

**Bartold 2010** (Continued)

	treatment Arm 3: soya oil placebo (6 × 500 mg capsules/d) and standard periodontal treatment
Outcomes	Primary: probing pocket depth, clinical attachment level (CAL) Secondary: inflammatory biomarkers in gingival crevicular fluid, erythrocyte omega-3, C-reactive protein
Starting date	Registered on trials registry: 23 July 2010 Study start date: July 2010 Estimated study completion date: unclear
Contact information	Mark Bartold, University of Adelaide, mark.bartold@adelaide.edu.au
Notes	ACTRN12610000594022 PhD, Boram Park, available giving 4 month outcome data for pilot study N = 33 participants Mark Bartold written to in 2016. Confirmed preparing full publications for submission

**Beyond Aging Project 2015**

Trial name or title	Beyond Ageing Project phase 2: a selective prevention trial using novel pharmacotherapies in an older age cohort at risk for depression
Methods	RCT
Participants	Older adults (60+ years) at risk of depression (K-10 score ranging from 16-29) who initially participated in the first Beyond Ageing Project
Interventions	Each for 12 months: Arm 1: omega-3 (4 capsules, total 2 g/d: 1200 mg EPA and 800 mg DHA) and placebo microcrystalline cellulose (1 capsule) Arm 2: paraffin oil placebo (4 capsules) and sertraline hydrochloride (1 capsule, 50 mg) Arm 3: paraffin oil placebo (4 capsules) and placebo microcrystalline cellulose (1 capsule)
Outcomes	Primary: depressive symptoms (PHQ-9, patient health questionnaire 9) Secondary: cognitive decline, MMSE, brain metabolism, hippocampal volume, anxiety (assessed using GAD-7), disability (WHODAS-II), sleeping problems (PSQI, Pittsburgh Sleep Quality Index), exercise (Active Australian Survey)
Starting date	Registered on trials registry: 12 January 2010 Study start date: June 2011 Estimated study completion date: main results expected in 2017
Contact information	Ian Hickie (PI), Brain and Mind Centre, University of Sydney, ian.hickie@sydney.edu.au
Notes	ACTRN12610000032055

### Chandrakala 2010

Trial name or title	Long-term effects of a reduced fat diet intervention in pre-diabetes
Methods	RCT
Participants	Participants with pre-diabetes, impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), 201 participants discussed in one abstract, 134 in a later abstract
Interventions	Each for 3 years: Arm 1: reduced fat diet (fat content at or below 20% total energy, ratio of PUFA/SFA 0.8 to 1.0) Arm 2: normal/control diet
Outcomes	Incidence of diabetes, BMI, lipids, insulin, plasma glucose, HbA1c, blood pressure, nutritional intake
Starting date	Registered on trials registry: no registration found Study start date: not stated Estimated study completion date: not stated
Contact information	Chandrakala Galla, chandrakala.galla@gmail.com; Arpana Gaddam, dr.arpanag@gmail.com
Notes	Authors written to in 2016: Dr Gaddam confirmed work submitted as a PhD but not published in full. Requested copy of PhD thesis, but no reply to date Funding: DiabetOmics India

### ChiCTR-TRC-12002014

Trial name or title	Influence of different sources of n-3 fatty acid on plasma lipid in moderately hypercholesterolaemic subjects
Methods	RCT
Participants	Adults (40-65 years) with mild to moderate hypercholesterolaemia
Interventions	Arm 1: EPA/DHA 1.8 g/d Arm 2: EPA/DHA 3.6 g/d Arm 3: ALA 4 g/d Arm 4: placebo
Outcomes	Fatty acids, lipids, cytokines (IL-6, IL-1a)
Starting date	Registered on trials registry: 13 March 2012 Study start date: unclear Estimated study completion date: unclear
Contact information	Su Yixiang, Sun-Yat Sen University, China, suyx@mail.sysu.edu.cn; Zhou Quan, Guangzhou Medical University, joan_zq@126.com
Notes	ChiCTR-TRC-12002014 Su Yixiang and Zhou Quan contacted in 2016: no response

## DO HEALTH

Trial name or title	Vitamin D3- omega3- home exercise- healthy ageing and longevity trial (DO-HEALTH)
Methods	RCT
Participants	Community dwelling adults 70 years and older, 50% of seniors enrolled based on a fall in the year before enrolment
Interventions	Each for 3 years: Arm 1: omega-3 (1 g/d, ratio EPA:DHA = 1:2) and vitamin D3 (2000 IU/d) capsules and strength home exercise (3 × 30 min/week) Arm 2: omega-3 (1 g/d, ratio EPA:DHA = 1:2) and vitamin D3 (2000 IU/d) capsules and flexibility home exercise (3 × 30 min/week) Arm 3: omega-3 (1 g/d, ratio EPA:DHA = 1:2) and placebo capsules and strength home exercise (3 × 30 min/week) Arm 4: omega-3 (1 g/d, ratio EPA:DHA = 1:2) and placebo capsules and flexibility home exercise (3 × 30 min/week) Arm 5: placebo and vitamin D3 (2000 IU/d) capsules and strength home exercise (3 × 30 min/week) Arm 6: placebo and vitamin D3 (2000 IU/d) capsules and flexibility home exercise (3 × 30 min/week) Arm 7: placebo and placebo capsules and strength home exercise (3 × 30 min/week) Arm 8: placebo and placebo capsules and flexibility home exercise (3 × 30 min/week)
Outcomes	Primary: non-vertebral fractures, functional decline, blood pressure, cognitive decline, rate of any infection Secondary: other fractures, falls, pain in knee osteoarthritis, musculoskeletal changes, gastro-intestinal symptoms, mental and oral health, quality of life, life-expectancy, cardiovascular events, cancer, glucose measures, cost-benefit. All endpoints supported by a DO-HEALTH biomarker study
Starting date	Registered on trials registry: 6 December 2012 Study start date: December 2012 Estimated study completion date: November 2017
Contact information	Heike Bischoff-Ferrari (PI), Centre on Aging and Mobility, University of Zurich
Notes	NCT01745263 EudraCT: 2012–001249-41 <a href="http://www.do-health.eu">www.do-health.eu</a>

## DREAM 2014

Trial name or title	DRy Eye Assessment and Management study (DREAM)
Methods	RCT
Participants	Adults with dry eye
Interventions	Each for 2 years Arm 1: omega-3 supplements (2000 mg EPA + 1000 mgDHA/d as 5 gel caps) Arm 2: olive oil supplements (5 gel caps)



**DREAM 2014** (Continued)

Outcomes	Primary: OSDI score (ocular surface disease index) Secondary: other eye health measures, SF-36, healthcare utilisation costs, cost-effectiveness
Starting date	Registered on Trials Registry 28 April 2014 Study start date: November 2014 Estimated study completion date: July 2017
Contact information	Penny Asbell, Mount Sinai Icahn School of Medicine (Study Chair), Maureen Maguire, University of Pennsylvania (PI)
Notes	NCT02128763

**ENRGISE 2016**

Trial name or title	ENabling Reduction of low-Grade Inflammation in SENiors (ENRGISE)
Methods	RCT
Participants	People aged 70+ years with self-reported walking or stair-climbing difficulty
Interventions	Each for 1 year Arm 1: omega-3 fish oil (1.4 g/d for 6 months, possibly increasing to 2.8 g/d) Arm 2: losartan 25 mg/d Arm 3: placebo corn oil (for omega-3) plus placebo cellulose (for losartan) Arm 4: omega-3 plus losartan Arm 5: placebo corn oil (for omega-3) Arm 6: placebo cellulose (for losartan)
Outcomes	Primary: IL-6, 400 meter walk test Secondary: short physical performance battery, frailty, hand grip strength, knee dynamometry, SF-36
Starting date	Registered on Trials Registry 3 February 2016 Study start date: February 2016 Estimated study completion date: March 2018
Contact information	Jane Lu janelu@ufl.edu Michael Stancil mstancil@ufl.edu
Notes	NCT02676466

**InTrePad 2013**

Trial name or title	Intervention of testosterone and fish oil for the prevention of Alzheimer's Disease: InTrePad
Methods	RCT
Participants	PiB-PET (Pittsburgh compound B) positive men aged 60 years and over with subjective memory complaints

Interventions	Each for 56 weeks: Arm 1: DHA capsules (1720 mg/d) and testosterone undecanoate (intramuscular injection 1000 mg/4 mL every 8 weeks) Arm 2: placebo DHA and testosterone undecanoate (intramuscular injection 1000 mg/4 mL every 8 weeks) Arm 3: placebo DHA and placebo testosterone
Outcomes	Primary: PiB score Secondary: neuropsychological, mood and daily functioning questionnaires, beta amyloid levels, fluoro-deoxyglucose to assess brain glucose metabolism, inflammatory and oxidative biomarkers, hippocampal volume, quality of life, safety and tolerability of treatment
Starting date	Registered on trials registry: 14 January 2013 Study start date: 28 February 2013 Estimated study completion date: not stated
Contact information	Ralph Martins (PI), Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Medical Centre, Nedlands, Australia, r.martins@ecu.edu.au
Notes	ACTRN12613000034730 Ralph Martins written to in 2016- no response

**MAPT PLUS**

Trial name or title	Long-term effects of interventional strategies to prevent cognitive decline in elderly (MAPT PLUS)
Methods	RCT - extension of MAPT trial
Participants	Participants of MAPT trial
Interventions	Follow-up 2 year extension of patients in MAPT, after completion of MAPT interventions
Outcomes	Primary: cognitive and functional status (Grober and Buschke test) Secondary: markers of cerebral atrophy, cost-effectiveness
Starting date	Registered on trials registry: 30 December 2011 Study start date: December 2011 Estimated study completion date: November 2016
Contact information	Bruno Vellas (PI), University Hospital, Toulouse, vellas.b@chu-toulouse.fr
Notes	NCT01513252 Bruno Vellas written to in 2016- no response

**NCT00010868**

Trial name or title	Omega 3 fatty acids in bipolar disorder prophylaxis
Methods	RCT
Participants	People aged 18 to 65 with bipolar disorder
Interventions	Each for 12 months: Arm 1: omega-3 Arm 2: placebo
Outcomes	Prophylactic efficacy
Starting date	Trial Registration entry: 2 February 2001 Trial start date: July 2000 Estimated study completion: July 2004
Contact information	Andrew Stoll, Mclean Hospital
Notes	NCT00010868 The PI, Andrew Stoll, appears to have been struck off the medical register in Massachusetts in 2011 (Commonwealth of Massachusetts Board of Registration in Medicine, Adjudicatory Case number 2011–026) so it has not been possible to contact him and no publication of results has been found

**NCT00309439**

Trial name or title	Studies of serum PSA (prostate specific antigen) to help resolve the current implication of alpha-linolenic acid and prostate cancer
Methods	RCT
Participants	Adults 18-77 years
Interventions	Arm 1: ALA rich diet Arm 2: control (not detailed)
Outcomes	Prostate specific antigen, atrial fibrillation
Starting date	Registered on trials registry: 29 March 2006 Study start date: unclear Estimated study completion date: unclear
Contact information	David Jenkins, University of Toronto, nutritionproject@smh.toronto.on.ca
Notes	NCT00309439 David Jenkins written to in 2016: confirmed not published in full and data incomplete

**NCT00410020**

Trial name or title	Arrhythmia prevention with an alpha-linolenic enriched diet
Methods	RCT, parallel, 2 arm, 12 months
Participants	98 people with successful atrial fibrillation electrical cardioversion
Interventions	Canola margarine and oil, rich in ALA, versus a conventional diet (control), for 1 year
Outcomes	Length of time to first recurrence of AF
Starting date	June 1999, expected finish date June 2003, registered December 2006 so appears to have been carried out
Contact information	Principal Investigator: Jean-Paul Broustet, MD, PhD, Universitary Hospital Haut-Lévêque Bordeaux France
Notes	NCT00410020, registered December 2006, no publication found

**NCT01784042**

Trial name or title	Dietary energy restriction and omega-3 fatty acids on mammary tissue
Methods	RCT
Participants	Overweight women (30-55 years) with increased breast cancer risk
Interventions	For 1 year: Arm 1: lovaza (omega-3-acid ethyl esters) Arm 2: lovaza and dietary energy restriction Arm 3: placebo Arm 4: placebo and dietary energy restriction
Outcomes	Ki67 expression at 1 year
Starting date	Registered on trials registry: 31 January 2013 Study start date: March 2013 Estimated study completion date: March 2018
Contact information	Andrea Manni, Hershey Medical Centre, amanni@hmc.psu.edu (PI) or Cynthia DuBrock, cdubrock@hmc.psu.edu
Notes	NCT01784042. Trials register states "Withdrawn (no funding)"

**NCT02211560**

Trial name or title	Investigating a phosphatidylserine based dietary approach for the management of mild cognitive impairment
Methods	RCT
Participants	People with mild cognitive impairment (MCI) aged 65-85 years
Interventions	Each for 24 months: Arm 1: phosphatidylserine omega-3 (DHA enriched) Arm 2: placebo cellulose capsules
Outcomes	Primary: selective reminding test (SRT) Secondary: mini mental state examination (MMSE), neurological battery test (NBT), dementia (DSM-4 criteria), mini sleep questionnaire (MSQ), Hamilton Anxiety rating scale (HAM-A), safety and adverse events
Starting date	Registered on trials registry: 6 August 2014 Study start date: September 2014 Estimated study completion date: September 2019
Contact information	Nadia Niemerzyanski, nadiaN@enzymotec.com; Yael Richter, yaelr@enzymotec.com
Notes	NCT02211560

**NCT02295059**

Trial name or title	Omega 3 fatty acids and ERPR(-)HER2(±) breast cancer prevention
Methods	RCT
Participants	Women at risk for recurrent breast cancer- with prior diagnosis of stage 0 to III breast cancer and completion of surgery, chemotherapy or trastuzumab or radiation therapy
Interventions	Each for 12 months: Arm 1: omega-3 high dose capsules (5 g/d EPA + DHA) Arm 2: omega-3 low dose capsules (0.9 g/d EPA + DHA)
Outcomes	Primary: breast adipose tissue metabolites Secondary: cytomorphology or cell proliferation of mammary epithelial cells, DNA promoter methylation and pro-inflammatory gene expression in mammary epithelial and adipose tissue
Starting date	Registered on trials registry: 14 October 2014 Study start date: August 2014 Estimated study completion date: January 2019
Contact information	Anitra Sumbry, anitra.sumbry@osumc.edu; Lisa Yee (PI), Ohio State University
Notes	NCT02295059

**NCT02719327**

Trial name or title	Impact of icosapent ethyl on Alzheimer's disease (AD) biomarkers in preclinical adults
Methods	RCT
Participants	Cognitively healthy adults aged 50 to 70 years whose parents had AD
Interventions	Each for 18 months: Arm 1: Icosapent ethyl EPA (Vascepa) 4 g/d gel cap Arm 2: matching gel cap placebo
Outcomes	Primary: cerebral blood flow by MRI (magnetic resonance imaging) Secondary: CSF biomarkers of AD, cognitive performance (preclinical Alzheimer's cognitive composite, PACC)
Starting date	Registered on trials registry: 21 March 2016 Study start date: December 2016 Estimated study completion date: November 2021
Contact information	Cynthia Carlsson, cynthia.carlsson@va.gov; Elena Beckman, elena.beckman@va.gov
Notes	NCT02719327

**OMEMI 2014**

Trial name or title	OMega-3 fatty acids in Elderly patients with Myocardial Infarction study (OMEMI)
Methods	RCT
Participants	Elderly patients (70-82 years) with acute MI
Interventions	Each for 24 months: Arm 1: omega-3 capsules, 3/d (Pikazol, total of 1.8 g/d EPA + DHA) and standard therapy Arm 2: corn oil placebo, 3/d and standard therapy
Outcomes	Primary: composite of total mortality, first non-fatal recurring AMI, stroke and revascularisation Secondary: new onset atrial fibrillation, adipose tissue, serum fatty acids, makers of endothelial function, inflammation, coagulation and fibrinolytic activity, genes associated with atherothrombosis
Starting date	Registered on trials registry: 16 April 2013 Study start date: November 2012 Estimated study completion date: November 2019
Contact information	Svein Solheim, Center for Clinical Heart Research, Oslo University Hospital, arnljot.tveit@vestreviken.no
Notes	NCT01841944

### REDUCE-IT 2011

Trial name or title	Reduction of cardiovascular events with EPA-intervention trial (REDUCE-IT)
Methods	RCT
Participants	Patients (45 years or over) with hypertriglyceridaemia, with cardiovascular disease or at high risk for cardiovascular disease, and on statin
Interventions	Each for 4-6 years: Arm 1: EPA ethyl ester (AMR101 4 g/d) Arm 2: placebo
Outcomes	Primary: composite of cardiovascular death, MI, stroke, coronary revascularisation and hospitalisation for unstable angina Secondary: incidence of additional cardiovascular events, lipid and lipoprotein levels
Starting date	Registered on trials registry: 13 December 2011 Study start date: November 2011 Estimated study completion date: December 2017
Contact information	Deepak Bhatt (PI), Brigham and Women's Hospital
Notes	NCT01492361

### seAFOOD 2013

Trial name or title	The seAFOod (systematic evaluation of Aspirin and Fish Oil) Polyp Prevention Trial
Methods	RCT
Participants	NHS Bowel Cancer Screening Programme patients (55-73 years) identified as "high risk" (5 or more small adenomas; or 3 or more adenomas with at least one being 10 mm or more in diameter) after their 1st screening colonoscopy
Interventions	Each for 12 months: Arm 1: EPA (ALFA capsules: 2 × 500 mg twice daily = 2 g/d) and aspirin placebo (1/d) Arm 2: EPA placebo (capric and caprylic acid triglycerides: 2/d) and aspirin (1/d = 300 mg/d) Arm 3: EPA (ALFA capsules: 2 × 500 mg twice daily = 2 g/d) and aspirin (1/d = 300 mg/d) Arm 4: EPA placebo (capric and caprylic acid triglycerides: 2/d) and aspirin placebo (1/d)
Outcomes	Primary: number of patients with one or more adenomas at 12 months Secondary: adverse events, number of "advanced" adenomas per patients, number of "high risk" patients reclassified as "intermediate risk", number patients with one or more advanced adenomas, adenoma region in the colorectum, total number of adenomas per patient, number of patients with colorectal cancer, levels of bioactive lipid mediators e.g. omega-3
Starting date	Trial Registration entry: 6 May 2011 Trial start date: 30 May 2011 Estimated study completion: 31 July 2017

Contact information	Mark Hull, Leeds Institute of Molecular Medicine, m.a.hull@leeds.ac.uk
Notes	ISRCTN05926847 EudraCT 2010—020943—10 <a href="http://www.seafood-trial.co.uk">www.seafood-trial.co.uk</a>

**Shinto 2015**

Trial name or title	N-3 PUFA for vascular cognitive aging
Methods	RCT
Participants	Older adults (80 years and older) at high risk for cognitive decline and dementia of Alzheimer's type
Interventions	Each for 3 years: Arm 1: omega-3 fish oil (1.65 g/d EPA + DHA) Arm 2: soybean oil placebo (1.65 g/d)
Outcomes	Primary: total cerebral white matter volume Secondary: biomarkers of endothelial health, total brain atrophy, medial temporal lobe atrophy, ventricular expansion, trail making test part B, digit symbol WAIS-R, cerebral blood flow, fractional anisotropy within frontal gyri
Starting date	Registered on trials registry: 24 September 2013 Study start date: May 2014 Estimated study completion date: March 2019
Contact information	Alena Borgatti, borgatti@ohsu.edu; James Dursch, dursch@ohsu.edu; Gene Bowman and Lynne Shinto (PIs), Oregon Health and Science University
Notes	NCT01953705

**STRENGTH 2015**

Trial name or title	A long-term outcomes study to assess statin residual risk reduction with EpaNova in high cardiovascular risk patients with hypertriglyceridemia (STRENGTH)
Methods	RCT
Participants	Adult patients with hypertriglyceridaemia and low HDL and high risk for CVD
Interventions	Each for 3-5 years: Arm 1: omega-3 carboxylic acid capsule (Epanova, not less than 800 mg/g) and statin (once daily) Arm 2: corn oil placebo capsule and statin (once daily)



**STRENGTH 2015** (Continued)

Outcomes	Primary: time to first occurrence of any component of the composite MACE (cardiovascular death, nonfatal MI, nonfatal stroke, emergent/elective coronary revascularisation, hospitalisation for unstable angina) Secondary: composite measure of cardiovascular events that include the first occurrence of cardiovascular death, nonfatal MI and non-fatal stroke; composite measure of coronary events that include the first occurrence of cardiac death; first occurrence of individual components of MACE; time to cardiovascular death. Other measures include: all cause mortality, new atrial fibrillation, thrombotic events, heart failure events
Starting date	Trial Registration entry: 2 April 2014 Trial start date: October 2014 Estimated study completion: November 2019
Contact information	AstraZeneca Clinical Study Information Centre, information.center@astrazeneca.com. PIs Steven Nissen (Cleveland Clinic), Michael Lincoff (Cleveland Clinic) Stephen Nicholls (Adelaide Clinical Research)
Notes	NCT02104817 EudraCT: 2014-001069-28

**SUPERIORSVG 2010**

Trial name or title	Improving the results of heart bypass surgery using new approaches to surgery and medication (SUPERIORSVG)
Methods	RCT
Participants	Adults having coronary artery bypass graft (CABG) using saphenous vein graft (SVG)
Interventions	Each for 12 months: Arm 1: fish oil supplements (2 × 1 g/d Ocean Nutrition capsules: 55% fish oils EPA:DHA 33%:22%) and SVG conventionally harvested Arm 2: placebo and SVG conventionally harvested Arm 3: fish oil supplements (2 × 1 g/d Ocean Nutrition capsules: 55% fish oils EPA:DHA 33%:22%) and SVG no-touch harvest Arm 4: placebo and SVG no-touch harvest
Outcomes	Primary: proportion of grafts occluded Secondary: significant stenosis, adverse SVG harvesting events, composite outcome of all-cause mortality, non-fatal MI and repeat revascularisation
Starting date	Registered on trials registry: 12 January 2010 Study start date: July 2011 Estimated study completion date: December 2016
Contact information	Stephen Fremes, Sunnybrook Health Sciences Centre (PI)
Notes	NCT01047449

**UMIN000012825**

Trial name or title	Effect of PUFA on vascular healing process in hypercholesterolemic patients with ACS
Methods	RCT
Participants	Hypercholesterolemic patients (20-80 years) with acute coronary syndrome who have received successful OCT-guided PCI (optical coherence tomography-guided percutaneous coronary intervention)
Interventions	Each for 12 months: Arm 1: intensive lipid lowering therapy with both statin and EPA + DHA Arm 2: intensive lipid lowering therapy with both statin and EPA Arm 3: standard lipid lowering therapy with statins
Outcomes	Primary: changes in OCT parameter Secondary: lipids, serum plasma profile, inflammatory parameters, adverse cardiovascular events
Starting date	Registered on trials registry: 1 February 2014 Study start date: 1 February 2014 Estimated study completion date: 30 June 2019
Contact information	Shiro Uemura (PI), Nara Medical University, Japan, suemura@naramed-u.ac.jp
Notes	UMIN000012825

**VITAL 2018**

Trial name or title	VITamin D and omegA-3 trial (VITAL)
Methods	RCT
Participants	Multi-ethnic population of > 25,000 apparently healthy adults (men 50 years plus, women 55 years plus) without cancer or CVD at baseline
Interventions	Each for mean 5 years: Arm 1: omega-3 (Omacor fish oil, EPA + DHA 1 g/d: 465 mg EPA; 375 mg DHA) and placebo Arm 2: placebo and vitamin D3 (1/d, 2,000IU) Arm 3: omega-3 (Omacor fish oil, EPA + DHA 1 g/d: 465 mg EPA; 375 mg DHA) and vitamin D3 (1/d, 2000 IU) Arm 4: placebo and placebo
Outcomes	Primary: reduction in risk for total cancer and CVD events (a composite of MI, stroke, and cardiovascular mortality) Secondary: lowered risk for expanded composite cardiovascular endpoint (MI, stroke, cardiovascular mortality, coronary revascularisation), the individual components of the primary endpoint, site specific cancers, mortality, diabetes, hypertension, cognitive decline, autoimmune conditions, infections, chronic respiratory disease, depression, bone health, fractures, chronic knee pain, body composition, physical disability, falls, plasma biomarker measures

Starting date	Registered on trials registry: 13 January 2010 Study start date: July 2010 Estimated study completion date: December 2017
Contact information	JoAnn Manson or Julie Buring (PIs), Brigham and Women's Hospital, Boston and Harvard School of Public Health, Boston, vitalstudy@rics.bwh.harvard.edu
Notes	NCT01169259 <a href="http://www.vitalstudy.org">www.vitalstudy.org</a>

**ACS:** acute coronary syndrome; **AD:** Alzheimer's disease; **AF:** atrial fibrillation; **BMI:** body mass index; **BMI:** body mass index; **CABG:** coronary artery bypass graft; **CETP:** cholesteryl ester transfer protein; **CHD:** coronary heart disease; **CVD:** cardiovascular disease; **DHA:** docosahexaenoic acid; **EPA:** eicosapentaenoic acid; **GAD-7:** generalised anxiety disorder 7; **HbA1c:** glycated haemoglobin; **HDL:** high-density lipoprotein; **IFG:** impaired fasting glucose; **IGT:** impaired glucose tolerance; **IL:** interleukin; **LDL:** low-density lipoprotein; **MACE:** major adverse coronary event; **MI:** myocardial infarction; **MRI:** magnetic resonance imaging; **OCT:** optical coherence tomography; **OSDI:** ocular surface disease index; **PCI:** percutaneous coronary intervention; **PHQ-9:** patient health questionnaire 9; **PI:** principal investigator; **PSA:** prostate specific antigen; **PSQI:** Pittsburgh Sleep Quality Index; **PUFA:** polyunsaturated fatty acids; **RCT:** randomised controlled trial; **RCT:** randomised controlled trial; **SFA:** saturated fatty acids; **SVG:** saphenous vein graft.

## DATA AND ANALYSES

### Comparison 1. High vs low LCn3 omega-3 fats (primary outcomes)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All-cause mortality (overall) - LCn3	39	92653	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.93, 1.03]
2 All-cause mortality - LCn3 - sensitivity analysis (SA) fixed-effect	39	90244	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.93, 1.01]
3 All-cause mortality - LCn3 - SA by summary risk of bias	39	92653	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.93, 1.03]
3.1 Low risk of bias	15	33146	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.94, 1.08]
3.2 Moderate/high risk of bias	24	59507	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.86, 1.03]
4 All-cause mortality - LCn3 - SA by compliance and study size	38		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
4.1 SA - low risk of compliance bias	18	15654	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.86, 1.14]
4.2 SA - 100+ randomised	35	92397	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.93, 1.03]
5 All-cause mortality - LCn3 - subgroup by dose	39	92653	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.93, 1.03]
5.1 LCn3 ≤150 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
5.2 LCn3 > 150 ≤ 250 mg/d	1	407	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.27, 2.18]
5.3 LCn3 > 250 ≤400 mg/d	1	2033	Risk Ratio (M-H, Random, 95% CI)	0.72 [0.56, 0.92]
5.4 LCn3 > 400 ≤ 2400 mg/d	28	87445	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.93, 1.05]
5.5 LCn3 > 2.4 ≤ 4.4 g/d	7	2486	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.67, 1.70]
5.6 LCn3 > 4.4 g/d	2	282	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.03, 3.08]
6 All-cause mortality - LCn3 - subgroup by replacement	39		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
6.1 LCn3 replacing SFA	5	3279	Risk Ratio (M-H, Random, 95% CI)	0.72 [0.56, 0.92]
6.2 LCn3 replacing MUFA	15	46176	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.90, 1.02]
6.3 LCn3 replacing N-6	9	2806	Risk Ratio (M-H, Random, 95% CI)	0.74 [0.51, 1.09]
6.4 LCn3 replacing CHO	1	281	Risk Ratio (M-H, Random, 95% CI)	0.52 [0.05, 5.65]
6.5 LCn3 replacing nil/low n-3 placebo	10	39601	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.86, 1.14]
6.6 LCn3 replacement unclear	3	3593	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.46, 1.79]
7 All-cause mortality - LCn3 - subgroup by intervention type	39	92653	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.93, 1.03]
7.1 Dietary advice	3	5554	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.60, 1.35]
7.2 Supplemental foods	2	5039	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.84, 1.24]
7.3 Supplements (capsule)	33	81855	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.92, 1.01]
7.4 Any combination	1	205	Risk Ratio (M-H, Random, 95% CI)	0.65 [0.11, 3.79]
8 All-cause mortality - LCn3 - subgroup by duration	39	92653	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.93, 1.03]
8.1 Medium duration 1 to < 2 years in study	18	9737	Risk Ratio (M-H, Random, 95% CI)	1.03 [0.82, 1.30]
8.2 Medium-long duration: 2 to < 4 years in study	14	29234	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.86, 0.96]

8.3 Long duration: $\geq 4$ years in study	7	53682	Risk Ratio (M-H, Random, 95% CI)	1.03 [0.98, 1.09]
9 All-cause mortality - LCn3 - subgroup by primary or secondary prevention	39	92653	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.93, 1.03]
9.1 Primary CVD prevention	17	41202	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.94, 1.08]
9.2 Secondary CVD prevention	22	51451	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.88, 1.04]
10 All-cause mortality - LCn3 - subgroup by statin use	39	90244	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.92, 1.03]
10.1 LCn3 - $\geq 50\%$ of control group on statins	8	40500	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.93, 1.11]
10.2 LCn3 - $< 50\%$ of control group on statins	26	46604	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.88, 1.03]
10.3 LCn3 - use of statins unclear	5	3140	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.58, 1.63]
11 Cardiovascular mortality (overall) - LCn3	25	67772	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.87, 1.03]
12 CVD mortality - LCn3 - SA fixed-effect	25	67772	Risk Ratio (M-H, Fixed, 95% CI)	0.94 [0.89, 1.00]
13 CVD mortality - LCn3 - SA by summary risk of bias	25	67772	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.87, 1.03]
13.1 Low risk of bias	9	29133	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.90, 1.09]
13.2 Moderate/high risk of bias	16	38639	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.80, 1.05]
14 CVD mortality - LCn3 - SA by compliance and study size	24		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
14.1 SA - low risk of compliance bias	12	13244	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.23]
14.2 SA - 100+ randomised	21	67516	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.87, 1.04]
15 CVD mortality - LCn3 - subgroup by dose	26	67873	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.87, 1.03]
15.1 LCn3 $\leq 150$ mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
15.2 LCn3 $> 150 \leq 250$ mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
15.3 LCn3 $> 250 \leq 400$ mg/d	1	2033	Risk Ratio (M-H, Random, 95% CI)	0.70 [0.53, 0.91]
15.4 LCn3 $> 400 \leq 2400$ mg/d	19	64126	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.89, 1.06]
15.5 LCn3 $> 2.4 \leq 4.4$ g/d	4	1432	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.58, 1.77]
15.6 LCn3 $> 4.4$ g/d	2	282	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.03, 3.08]
16 CVD mortality - LCn3 - subgroup by replacement	26		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
16.1 N-3 replacing SFA	3	2537	Risk Ratio (M-H, Random, 95% CI)	0.69 [0.53, 0.90]
16.2 N-3 replacing MUFA	12	44242	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.86, 1.04]
16.3 N-3 replacing N-6	4	1435	Risk Ratio (M-H, Random, 95% CI)	0.69 [0.41, 1.19]
16.4 N-3 replacing carbohydrates/sugars	1	281	Risk Ratio (M-H, Random, 95% CI)	0.69 [0.12, 4.07]
16.5 N-3 replacing nil/low n-3 placebo	8	19275	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.73, 0.96]
16.6 Replacement unclear	2	3186	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.05, 5.77]
17 CVD mortality - LCn3 - subgroup by intervention type	25	67772	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.87, 1.03]

17.1 Dietary advice	2	5147	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.52, 1.71]
17.2 Supplemental foods	2	5039	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.72, 1.32]
17.3 Supplements (capsule)	21	57586	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.88, 0.99]
17.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
18 CVD mortality - LCn3 - subgroup by duration	25	67772	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.87, 1.03]
18.1 Medium duration 1 to < 2 years in study	10	6177	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.57, 1.36]
18.2 Medium-long duration: 2 to < 4 years in study	10	26736	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.82, 0.95]
18.3 Long duration: $\geq 4$ years in study	5	34859	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.93, 1.18]
19 CVD mortality - LCn3 - subgroup by primary or secondary prevention	25	67772	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.87, 1.03]
19.1 Primary prevention	7	17931	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.88, 1.09]
19.2 Secondary prevention	18	49841	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.83, 1.06]
20 CVD mortality - LCn3 - subgroup by statin uses	25	67772	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.87, 1.03]
20.1 LCn3 - $\geq 50\%$ of control group on statins	6	23994	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.90, 1.10]
20.2 LCn3 - < 50% of control group on statins	17	43425	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.82, 1.04]
20.3 LCn3- Use of statins unclear	2	353	Risk Ratio (M-H, Random, 95% CI)	0.36 [0.06, 2.30]
21 Cardiovascular events (overall) - LCn3	38	90378	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.94, 1.04]
22 CVD events - LCn3 - SA fixed-effect	38	90378	Risk Ratio (M-H, Fixed, 95% CI)	0.98 [0.95, 1.00]
23 CVD events - LCn3 - SA by summary risk of bias	38	90378	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.94, 1.04]
23.1 Low risk of bias	14	31649	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.96, 1.05]
23.2 Moderate/high risk of bias	24	58729	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.87, 1.03]
24 CVD events - LCn3 - SA by compliance and study size	37		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
24.1 SA - low risk of compliance bias	16	13649	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.84, 1.14]
24.2 SA - 100+ randomised	33	90058	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.94, 1.04]
25 CVD events - LCn3 - subgroup by dose	38	90453	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.94, 1.04]
25.1 LCn3 $\leq 150$ mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
25.2 LCn3 $> 150 \leq 250$ mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
25.3 LCn3 $> 250 \leq 400$ mg/d	1	2033	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.88, 1.05]
25.4 LCn3 $> 400 \leq 2400$ mg/d	28	85818	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.93, 1.05]
25.5 LCn3 $> 2.4 \leq 4.4$ g/d	7	2180	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.75, 1.28]
25.6 LCn3 $> 4.4$ g/d	3	422	Risk Ratio (M-H, Random, 95% CI)	1.09 [0.65, 1.81]
26 CVD events - LCn3 - subgroup by replacement	38		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
26.1 N-3 replacing SFA	4	2888	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.87, 1.04]

26.2 N-3 replacing MUFA	16	45065	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.94, 1.02]
26.3 N-3 replacing n-6	6	1891	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.90, 1.35]
26.4 N-3 replacing carbohydrates/sugars	1	258	Risk Ratio (M-H, Random, 95% CI)	0.68 [0.12, 3.98]
26.5 N-3 replacing nil/low n-3 placebo	12	39907	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.85, 1.07]
26.6 Replacement unclear	3	3429	Risk Ratio (M-H, Random, 95% CI)	0.58 [0.16, 2.07]
27 CVD events - LCn3 - subgroup by intervention type	38	90378	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.94, 1.04]
27.1 Dietary advice	3	5248	Risk Ratio (M-H, Random, 95% CI)	1.13 [0.86, 1.49]
27.2 Supplemental foods	2	5039	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.89, 1.17]
27.3 Supplements (capsule)	33	80091	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.91, 1.02]
27.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
28 CVD events - LCn3 - subgroup by duration	38	90378	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.94, 1.04]
28.1 Medium duration 1 to < 2 years in study	18	8107	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.68, 1.16]
28.2 Medium-long duration: 2 to < 4 years in study	14	28767	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.93, 1.01]
28.3 Long duration: ≥ 4 years in study	6	53504	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.91, 1.08]
29 CVD events - LCn3 - subgroup by primary or secondary prevention	38	90378	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.94, 1.04]
29.1 Primary prevention of CVD	16	39751	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.89, 1.05]
29.2 Secondary prevention	22	50627	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.93, 1.07]
30 CVD events - LCn3 - subgroup by statin use	38	90378	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.94, 1.04]
30.1 LCn3 - ≥ 50% of control group on statins	8	42389	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.89, 1.08]
30.2 LCn3 - < 50% of control group on statins	24	45160	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.91, 1.04]
30.3 LCn3 - use of statins unclear	6	2829	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.53, 1.63]
31 Coronary heart disease mortality (overall) - LCn3	21	73491	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.79, 1.09]
32 CHD mortality - LCn3 - SA fixed-effect	21	73491	Risk Ratio (M-H, Fixed, 95% CI)	0.94 [0.85, 1.03]
33 CHD mortality - LCn3 - SA by summary risk of bias	21	73491	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.79, 1.09]
33.1 Low risk of bias	7	16372	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.72, 1.37]
33.2 Moderate/high risk of bias	14	57119	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.75, 1.10]
34 CHD mortality - LCn3 - SA by compliance and study size	21		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
34.1 SA - low risk of compliance bias	9	12938	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.83, 1.32]
34.2 SA - 100+ randomised	20	73411	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.79, 1.09]
35 CHD mortality - LCn3 - SA omitting cardiac death	16	65325	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.74, 0.94]

35.1 Low risk of bias	5	12022	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.69, 1.30]
35.2 Moderate/high risk of bias	11	53303	Risk Ratio (M-H, Random, 95% CI)	0.82 [0.72, 0.94]
<b>36 CHD mortality - LCn3 - subgroup by dose</b>	21	73491	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.79, 1.09]
36.1 LCn3 ≤ 150 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
36.2 LCn3 > 150 ≤ 250 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
36.3 LCn3 > 250 ≤ 400 mg/d	2	5147	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.50, 1.74]
36.4 LCn3 > 400 ≤ 2400 mg/d	15	67442	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.80, 1.07]
36.5 LCn3 > 2.4 ≤ 4.4 g/d	3	822	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.49, 1.78]
36.6 LCn3 > 4.4 g/d	1	80	Risk Ratio (M-H, Random, 95% CI)	0.32 [0.01, 7.57]
<b>37 CHD mortality - LCn3 - subgroup by replacement</b>	21		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
37.1 N-3 replacing SFA	3	2514	Risk Ratio (M-H, Random, 95% CI)	0.67 [0.51, 0.88]
37.2 N-3 replacing MUFA	10	31605	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.72, 1.10]
37.3 N-3 replacing n-6	3	1409	Risk Ratio (M-H, Random, 95% CI)	0.64 [0.33, 1.24]
37.4 N-3 replacing carbohydrates/sugars	1	258	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.01, 8.23]
37.5 N-3 replacing nil/low n-3 placebo	7	37651	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.70, 0.97]
37.6 Replacement unclear	1	3114	Risk Ratio (M-H, Random, 95% CI)	1.27 [1.03, 1.57]
<b>38 CHD mortality - LCn3 - subgroup by intervention type</b>	21	73491	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.79, 1.09]
38.1 Dietary advice	2	5147	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.50, 1.74]
38.2 Supplemental foods	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.69, 1.33]
38.3 Supplements (capsule)	18	63507	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.79, 1.02]
38.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
<b>39 CHD mortality - LCn3 - subgroup by duration</b>	21	73491	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.79, 1.09]
39.1 Medium duration 1 to < 2 years in study	7	5978	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.62, 1.50]
39.2 Medium-long duration: 2 to < 4 years in study	9	26545	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.69, 0.90]
39.3 Long duration: ≥ 4 years in study	5	40968	Risk Ratio (M-H, Random, 95% CI)	1.18 [1.00, 1.39]
<b>40 CHD mortality - LCn3 - subgroup by primary or secondary prevention</b>	21	73491	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.79, 1.09]
40.1 Primary prevention of CVD	5	23789	Risk Ratio (M-H, Random, 95% CI)	0.86 [0.46, 1.61]
40.2 Secondary prevention of CVD	16	49702	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.79, 1.11]
<b>41 CHD mortality - LCn3 - subgroup by statin use</b>	21	73491	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.79, 1.09]
41.1 LCn3 - ≥ 50% of control group on statins	5	30025	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.84, 1.30]
41.2 LCn3 - < 50% of control group on statins	15	43208	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.72, 1.10]
41.3 LCn3 - use of statins unclear	1	258	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.01, 8.23]



42 CHD mortality - LCn3 - subgroup by CAD history	21	73491	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.80, 1.09]
42.1 Previous CAD	11	29074	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.77, 1.20]
42.2 No previous CAD	10	44417	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.74, 1.16]
43 Coronary heart disease events (overall) - LCn3	28	84301	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.88, 0.97]
44 CHD events - LCn3 - SA fixed-effect	28	84301	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.88, 0.97]
45 CHD events - LCn3 - SA by summary risk of bias	28	84301	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.88, 0.97]
45.1 Low risk of bias	12	30227	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.90, 1.05]
45.2 Moderate/high risk of bias	16	54074	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.84, 0.95]
46 CHD events - LCn3 - SA by compliance and study size	27		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
46.1 SA - low risk of compliance bias	12	13447	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.86, 1.02]
46.2 SA - 100+ randomised	25	84084	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.88, 0.98]
47 CHD events - LCn3 - subgroup by dose	28	84376	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.89, 0.98]
47.1 LCn3 $\leq$ 150 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
47.2 LCn3 $>$ 150 $\leq$ 250 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
47.3 LCn3 $>$ 250 $\leq$ 400 mg/d	1	2033	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.82, 1.04]
47.4 LCn3 $>$ 400 $\leq$ 2400 mg/d	21	80730	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.88, 0.98]
47.5 LCn3 $>$ 2.4 $\leq$ 4.4 g/d	4	1191	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.53, 1.53]
47.6 LCn3 $>$ 4.4 g/d	3	422	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.54, 1.85]
48 CHD events - LCn3 - subgroup by replacement	28		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
48.1 N-3 replacing SFA	3	2514	Risk Ratio (M-H, Random, 95% CI)	0.53 [0.16, 1.75]
48.2 N-3 replacing MUFA	15	44954	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.90, 1.01]
48.3 N-3 replacing n-6	4	1549	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.88, 1.39]
48.4 N-3 replacing carbohydrates/sugars	1	258	Risk Ratio (M-H, Random, 95% CI)	0.11 [0.01, 2.07]
48.5 N-3 replacing nil/low n-3 placebo	8	37843	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.78, 0.94]
48.6 Replacement unclear	1	243	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.08, 9.70]
49 CHD events - LCn3 - subgroup by intervention type	28	84301	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.89, 0.98]
49.1 Dietary advice	2	2134	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.67, 1.52]
49.2 Supplemental foods	2	5039	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.75, 1.18]
49.3 Supplements (capsule)	24	77128	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.88, 0.98]
49.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
50 CHD events - LCn3 - subgroup by duration	28	84301	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.89, 0.98]
50.1 Medium duration 1 to $<$ 2 years in study	11	7009	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.86, 1.03]
50.2 Medium-long duration: 2 to $<$ 4 years in study	12	26902	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.84, 0.98]
50.3 Long duration: $\geq$ 4 years in study	5	50390	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.83, 1.07]

51 CHD events - LCn3 - subgroup by primary or secondary prevention	28	84301	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.89, 0.98]
51.1 Primary prevention of CVD	11	37365	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.81, 1.10]
51.2 Secondary prevention of CVD	17	46936	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.88, 0.98]
52 CHD events - LCn3 - subgroup by statin use	28	84301	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.89, 0.98]
52.1 LCn3 - $\geq$ 50% of control group on statins	8	42735	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.85, 1.05]
52.2 LCn3 - < 50% of control group on statins	17	40674	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.86, 0.98]
52.3 LCn3 - use of statins unclear	3	892	Risk Ratio (M-H, Random, 95% CI)	0.65 [0.11, 3.83]
53 CHD events - LCn3 subgroup by CAD history	28	84301	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.88, 0.97]
53.1 Previous CAD	12	26124	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.87, 0.98]
53.2 No previous CAD	16	58177	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.86, 1.01]
54 Stroke (overall) - LCn3	28	89358	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.96, 1.16]
55 Stroke - LCn3 - SA fixed-effect	28	89358	Risk Ratio (M-H, Fixed, 95% CI)	1.06 [0.97, 1.16]
56 Stroke - LCn3 - SA by summary risk of bias	28	89358	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.96, 1.16]
56.1 Low risk of bias	12	32039	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.86, 1.12]
56.2 Moderate/high risk of bias	16	57319	Risk Ratio (M-H, Random, 95% CI)	1.13 [1.00, 1.29]
57 Stroke - LCn3 - SA by compliance and study size	27		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
57.1 SA - low risk of compliance bias	12	14451	Risk Ratio (M-H, Random, 95% CI)	1.19 [0.86, 1.65]
57.2 SA - 100+ randomised	26	89231	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.97, 1.18]
58 Stroke - LCn3 - subgroup by stroke type	13		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
58.1 Ischaemic stroke - LCn3	8	35040	Risk Ratio (M-H, Random, 95% CI)	1.09 [0.89, 1.33]
58.2 Haemorrhagic stroke - LCn3	8	36645	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.85, 1.69]
58.3 Transient ischaemic attack (TIA)	5	5032	Risk Ratio (M-H, Random, 95% CI)	0.74 [0.39, 1.39]
59 Stroke - LCn3 - subgroup by dose	28		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
59.1 LCn3 $\leq$ 150 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
59.2 LCn3 $>$ 150 $\leq$ 250 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
59.3 LCn3 $>$ 250 $\leq$ 400 mg/d	1	2033	Risk Ratio (M-H, Random, 95% CI)	0.45 [0.14, 1.44]
59.4 LCn3 $>$ 400 $\leq$ 2400 mg/d	24	86335	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.97, 1.16]
59.5 LCn3 $>$ 2.4 $\leq$ 4.4 g/d	1	610	Risk Ratio (M-H, Random, 95% CI)	0.69 [0.16, 3.07]
59.6 LCn3 $>$ 4.4 g/d	2	380	Risk Ratio (M-H, Random, 95% CI)	6.58 [0.78, 55.16]
60 Stroke - LCn3 - subgroup by replacement	28		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
60.1 N-3 replacing SFA	3	2514	Risk Ratio (M-H, Random, 95% CI)	0.53 [0.19, 1.50]
60.2 N-3 replacing MUFA	14	45252	Risk Ratio (M-H, Random, 95% CI)	1.11 [0.94, 1.31]

60.3 N-3 replacing n-6	3	1179	Risk Ratio (M-H, Random, 95% CI)	2.08 [0.18, 24.31]
60.4 N-3 replacing carbohydrates/sugars	1	258	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.01, 8.23]
60.5 N-3 replacing nil/low n-3 placebo	9	39555	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.92, 1.24]
60.6 Replacement unclear	1	3114	Risk Ratio (M-H, Random, 95% CI)	1.12 [0.55, 2.29]
61 Stroke - LCn3 - subgroup by intervention type	28	89358	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.96, 1.16]
61.1 Dietary advice	3	5248	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.42, 2.05]
61.2 Supplemental foods	1	4837	Risk Ratio (M-H, Random, 95% CI)	1.11 [0.47, 2.62]
61.3 Supplements (capsule)	24	79273	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.97, 1.18]
61.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
62 Stroke - LCn3 - subgroup by duration	28	89358	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.96, 1.16]
62.1 Medium duration 1 to < 2 years in study	11	7467	Risk Ratio (M-H, Random, 95% CI)	1.35 [0.86, 2.12]
62.2 Medium-long duration: 2 to < 4 years in study	11	28387	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.93, 1.41]
62.3 Long duration: ≥ 4 years in study	6	53504	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.91, 1.13]
63 Stroke - LCn3 - subgroup by primary or secondary prevention	28	89358	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.96, 1.16]
63.1 Primary prevention of CVD	9	39332	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.86, 1.09]
63.2 Secondary prevention of CVD	19	50026	Risk Ratio (M-H, Random, 95% CI)	1.21 [1.05, 1.40]
64 Stroke - LCn3 - subgroup by statin use	28	89358	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.96, 1.16]
64.1 LCn3 - ≥ 50% of control group on statins	8	42962	Risk Ratio (M-H, Random, 95% CI)	1.03 [0.86, 1.23]
64.2 LCn3 - < 50% of control group on statins	17	44999	Risk Ratio (M-H, Random, 95% CI)	1.18 [1.02, 1.37]
64.3 LCn3 - use of statins unclear	3	1397	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.38, 2.34]
65 Arrhythmia (overall) - LCn3	27	53796	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.90, 1.05]
66 Arrhythmia- LCn3 - SA fixed-effect	27	53796	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.96, 1.07]
67 Arrhythmia- LCn3 - SA by summary risk of bias	27	53796	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.90, 1.05]
67.1 Low risk of bias	10	25801	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.98, 1.23]
67.2 Moderate/high risk of bias	17	27995	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.84, 1.02]
68 Arrhythmia- LCn3 - SA by compliance and study size	26		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
68.1 SA - low risk of compliance bias	10	12914	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.86, 1.09]
68.2 SA - 100+ randomised	26	53749	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.89, 1.05]
69 Arrhythmia - LCn3 - subgroup by new or recurrent	27		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
69.1 New arrhythmia	16	50175	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.99, 1.16]

69.2 Recurrent arrhythmia	12	4425	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.84, 1.03]
<b>70 Arrhythmia - LCn3 - subgroup by fatality</b>	17		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
70.1 Fatal arrhythmias - LCn3	2	12938	Risk Ratio (M-H, Random, 95% CI)	1.11 [0.95, 1.31]
70.2 Non-fatal arrhythmias - LCn3	8	2079	Risk Ratio (M-H, Random, 95% CI)	0.74 [0.57, 0.96]
70.3 Fatal and non-fatal arrhythmias combined - LCn3	10	36007	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.97, 1.17]
<b>71 Arrhythmia - LCn3 - subgroup by dose</b>	27	53796	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.89, 1.04]
71.1 LCn3 ≤ 150 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
71.2 LCn3 > 150 ≤ 250 mg/d	1	407	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.90, 1.12]
71.3 LCn3 > 250 ≤ 400 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
71.4 LCn3 > 400 ≤ 2400 mg/d	19	51535	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.88, 1.08]
71.5 LCn3 > 2.4 ≤ 4.4 g/d	3	1076	Risk Ratio (M-H, Random, 95% CI)	0.72 [0.55, 0.94]
71.6 LCn3 > 4.4 g/d	2	342	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.32, 3.83]
71.7 Unclear LCn3 dose	2	436	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.76, 1.28]
<b>72 Arrhythmia - LCn3 - subgroup by replacement</b>	27		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
72.1 N-3 replacing SFA	2	632	Risk Ratio (M-H, Random, 95% CI)	0.74 [0.10, 5.67]
72.2 N-3 replacing MUFA	12	42246	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.88, 1.11]
72.3 N-3 replacing n-6	4	1302	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.86, 1.16]
72.4 N-3 replacing carbohydrates/sugars	1	258	Risk Ratio (M-H, Random, 95% CI)	0.34 [0.04, 3.21]
72.5 N-3 replacing nil/low n-3 placebo	6	8983	Risk Ratio (M-H, Random, 95% CI)	0.80 [0.69, 0.91]
72.6 Replacement unclear	4	1179	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.91, 1.08]
<b>73 Arrhythmia - LCn3 - subgroup by intervention type</b>	27	53796	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.90, 1.05]
73.1 Dietary advice	2	508	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.44, 1.72]
73.2 Supplemental foods	2	5039	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.67, 1.26]
73.3 Supplements (capsule)	23	48249	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.88, 1.06]
73.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
<b>74 Arrhythmia - LCn3 - subgroup by duration</b>	27	53796	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.89, 1.04]
74.1 Medium duration 1 to < 2 years in study	17	8553	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.84, 1.04]
74.2 Medium-long duration: 2 to < 4 years in study	7	17701	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.84, 1.10]
74.3 Long duration: ≥ 4 years in study	3	27542	Risk Ratio (M-H, Random, 95% CI)	1.13 [0.99, 1.29]
<b>75 Arrhythmia - LCn3 - subgroup by primary or secondary prevention</b>	27		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
75.1 Primary prevention	8	14565	Risk Ratio (M-H, Random, 95% CI)	1.11 [0.97, 1.28]
75.2 Secondary prevention	19	39231	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.86, 1.03]
<b>76 Arrhythmia - LCn3 - subgroup by statin use</b>	27		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
76.1 LCn3 - ≥ 50% of control group on statins	5	23779	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.95, 1.22]

76.2 LCn3 - < 50% of control group on statins	18	28932	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.85, 1.04]
76.3 LCn3 - use of statins unclear	4	1085	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.80, 1.18]

## Comparison 2. High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 MACCEs - LCn3	5	34730	Risk Ratio (M-H, Random, 95% CI)	1.03 [0.97, 1.09]
2 Myocardial infarction (overall) - LCn3	23	72159	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.88, 1.03]
3 Total MI - sensitivity analysis (SA) by summary risk of bias	23	72159	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.88, 1.03]
3.1 Low summary risk of bias	11	30025	Risk Ratio (M-H, Random, 95% CI)	1.03 [0.92, 1.15]
3.2 Moderate to high risk of bias	12	42134	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.79, 0.99]
4 Total MI - LCn3 - SA by compliance and study size	23		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
4.1 SA - low risk of compliance bias	10	13002	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.79, 1.13]
4.2 SA - 100+ randomised	21	72015	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.88, 1.03]
5 Total MI - LCn3 - subgroup by fatality	23		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
5.1 Fatal MI	15	60471	Risk Ratio (M-H, Random, 95% CI)	0.76 [0.53, 1.10]
5.2 Non-fatal MI	21	70407	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.87, 1.06]
6 Sudden cardiac death (overall) - LCn3	14	65004	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.80, 1.18]
7 Angina - LCn3	11	39907	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.91, 1.06]
8 Heart failure - LCn3	15	49644	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.85, 1.03]
8.1 Low summary risk of bias	6	24176	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.89, 1.06]
8.2 Moderate to high risk of bias	9	25468	Risk Ratio (M-H, Random, 95% CI)	0.78 [0.57, 1.08]
9 Revascularisation - LCn3	15		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
9.1 CABG - LCn3	5	1535	Risk Ratio (M-H, Random, 95% CI)	0.56 [0.15, 2.14]
9.2 Angioplasty - LCn3	4	3195	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.24]
9.3 Any revascularisation - LCn3	12	66095	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.94, 1.03]
10 Peripheral arterial disease - LCn3	6	49035	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.74, 1.18]
11 PAD - LCn3 - SA by summary risk of bias	6		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
11.1 Low summary risk of bias	2	12738	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.75, 1.62]
11.2 Moderate to high summary risk of bias	4	36297	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.64, 1.14]
12 PAD - LCn3 - SA compliance and study size	6		Risk Ratio (M-H, Random, 95% CI)	Subtotals only

12.1 SA compliance	1	202	Risk Ratio (M-H, Random, 95% CI)	1.0 [0.06, 15.77]
12.2 SA study size 100+	6	49035	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.74, 1.18]
13 Acute coronary syndrome - LCn3	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
13.1 LCn3	2	2703	Risk Ratio (M-H, Random, 95% CI)	1.19 [0.71, 2.00]
14 Body weight, kg - LCn3	12	15812	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.84, 0.82]
15 Weight, kg - LCn3 - SA by summary risk of bias	12	15812	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.84, 0.82]
15.1 Low risk of bias	7	15458	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.91, 0.90]
15.2 Moderate/high risk of bias	5	354	Mean Difference (IV, Random, 95% CI)	-0.28 [-3.12, 2.55]
16 Weight, kg - LCn3 - SA by compliance and study size	10		Mean Difference (IV, Random, 95% CI)	Subtotals only
16.1 SA - low risk of compliance bias	7	828	Mean Difference (IV, Random, 95% CI)	0.58 [-0.52, 1.69]
16.2 SA - 100+ randomised	7	15545	Mean Difference (IV, Random, 95% CI)	0.07 [-0.84, 0.97]
17 Weight, kg - LCn3 - subgroup by dose	12		Mean Difference (IV, Random, 95% CI)	Subtotals only
17.1 LCn3 ≤ 150 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
17.2 LCn3 > 150 ≤ 250 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
17.3 LCn3 > 250 ≤ 400 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
17.4 LCn3 > 400 ≤ 2400 mg/d	8	15420	Mean Difference (IV, Random, 95% CI)	-0.29 [-1.16, 0.58]
17.5 LCn3 > 2.4 ≤ 4.4 g/d	3	241	Mean Difference (IV, Random, 95% CI)	0.07 [-6.38, 6.51]
17.6 LCn3 > 4.4 g/d	2	261	Mean Difference (IV, Random, 95% CI)	1.51 [0.28, 2.75]
18 Weight, kg - LCn3 - subgroup by replacement	12		Mean Difference (IV, Random, 95% CI)	Subtotals only
18.1 N-3 replacing SFA	2	433	Mean Difference (IV, Random, 95% CI)	-2.51 [-4.30, -0.72]
18.2 N-3 replacing MUFA	7	15088	Mean Difference (IV, Random, 95% CI)	0.23 [-0.28, 0.75]
18.3 N-3 replacing n-6	1	41	Mean Difference (IV, Random, 95% CI)	-1.3 [-3.83, 1.23]
18.4 N-3 replacing carbs/sugars	1	258	Mean Difference (IV, Random, 95% CI)	-2.70 [-4.75, -0.65]
18.5 N-3 replacing nil/low n-3 placebo	1	202	Mean Difference (IV, Random, 95% CI)	1.5 [0.25, 2.75]
18.6 Replacement unclear	2	223	Mean Difference (IV, Random, 95% CI)	0.60 [-4.93, 6.13]
19 Weight, kg - LCn3 - subgroup by intervention type	12	15812	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.84, 0.82]
19.1 Dietary advice	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
19.2 Supplemental foods	1	202	Mean Difference (IV, Random, 95% CI)	1.5 [0.25, 2.75]
19.3 Supplement (capsule)	9	15538	Mean Difference (IV, Random, 95% CI)	-0.23 [-1.08, 0.63]
19.4 Any combination	2	72	Mean Difference (IV, Random, 95% CI)	-0.43 [-6.47, 5.61]
20 Weight, kg - LCn3 - subgroup by duration	12		Mean Difference (IV, Random, 95% CI)	Subtotals only
20.1 Medium duration 1 to < 2 years in study	8	840	Mean Difference (IV, Random, 95% CI)	-0.54 [-2.21, 1.12]
20.2 Medium-long duration: 2 to < 4 years in study	3	436	Mean Difference (IV, Random, 95% CI)	0.67 [-1.58, 2.91]
20.3 Long duration ≥ 4 years in study	1	14536	Mean Difference (IV, Random, 95% CI)	0.10 [-0.48, 0.68]

21 Weight, kg - LCn3 - subgroup by primary or secondary prevention	12		Mean Difference (IV, Random, 95% CI)	Subtotals only
21.1 Primary CVD prevention	10	15578	Mean Difference (IV, Random, 95% CI)	0.05 [-0.83, 0.92]
21.2 Secondary CVD prevention	2	234	Mean Difference (IV, Random, 95% CI)	-1.13 [-4.43, 2.16]
22 Weight, kg - LCn3 - subgroup by statin use	12		Mean Difference (IV, Random, 95% CI)	Subtotals only
22.1 LCn3 - $\geq$ 50% of control group on statins	2	14631	Mean Difference (IV, Random, 95% CI)	0.64 [-1.88, 3.17]
22.2 LCn3 - < 50% of control group on statins	5	614	Mean Difference (IV, Random, 95% CI)	0.47 [-0.66, 1.60]
22.3 LCn3 - use of statins unclear	5	567	Mean Difference (IV, Random, 95% CI)	-1.51 [-3.30, 0.27]
23 Body mass index, kg/m <sup>2</sup> - LCn3	14	15234	Mean Difference (IV, Random, 95% CI)	0.04 [-0.16, 0.24]
24 BMI, kg/m <sup>2</sup> - LCn3 - SA by summary risk of bias	14	15234	Mean Difference (IV, Random, 95% CI)	0.04 [-0.16, 0.24]
24.1 Low risk of bias	5	14190	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.36, 0.33]
24.2 Moderate/high risk of bias	9	1044	Mean Difference (IV, Random, 95% CI)	0.04 [-0.13, 0.20]
25 BMI, kg/m <sup>2</sup> - LCn3 - SA by compliance and study size	10		Mean Difference (IV, Random, 95% CI)	Subtotals only
25.1 SA - low risk of compliance bias	5	1848	Mean Difference (IV, Random, 95% CI)	0.09 [-0.21, 0.38]
25.2 SA - 100+ randomised	9	14982	Mean Difference (IV, Random, 95% CI)	0.01 [-0.12, 0.14]
26 BMI, kg/m <sup>2</sup> - LCn3 - subgroup by dose	14		Mean Difference (IV, Random, 95% CI)	Subtotals only
26.1 LCn3 > 150 $\leq$ 250 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
26.2 LCn3 $\leq$ 150 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
26.3 LCn3 > 250 $\leq$ 400 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
26.4 LCn3 > 400 $\leq$ 2400 mg/d	11	14789	Mean Difference (IV, Random, 95% CI)	0.01 [-0.11, 0.13]
26.5 LCn3 > 2.4 $\leq$ 4.4 g/d	3	445	Mean Difference (IV, Random, 95% CI)	1.42 [-0.51, 3.35]
26.6 LCn3 > 4.4 g/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
27 BMI, kg/m <sup>2</sup> - LCn3 - subgroup by replacement	14		Mean Difference (IV, Random, 95% CI)	Subtotals only
27.1 N-3 replacing SFA	1	258	Mean Difference (IV, Random, 95% CI)	-0.60 [-1.14, -0.06]
27.2 N-3 replacing MUFA	7	14180	Mean Difference (IV, Random, 95% CI)	0.08 [-0.12, 0.28]
27.3 N-3 replacing n-6	3	513	Mean Difference (IV, Random, 95% CI)	0.18 [-0.46, 0.81]
27.4 N-3 replacing carbs/sugars	1	258	Mean Difference (IV, Random, 95% CI)	-0.60 [-1.14, -0.06]
27.5 N-3 replacing nil/low n-3 placebo	1	60	Mean Difference (IV, Random, 95% CI)	1.0 [-1.18, 3.18]
27.6 Replacement unclear	2	223	Mean Difference (IV, Random, 95% CI)	0.58 [-1.17, 2.33]
28 BMI, kg/m <sup>2</sup> - LCn3 - subgroup by intervention type	14	15234	Mean Difference (IV, Random, 95% CI)	0.04 [-0.16, 0.24]
28.1 Dietary advice	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
28.2 Supplemental foods	1	1260	Mean Difference (IV, Random, 95% CI)	0.1 [-0.10, 0.30]
28.3 Supplement (capsule)	12	13929	Mean Difference (IV, Random, 95% CI)	0.01 [-0.25, 0.27]
28.4 Any combination	1	45	Mean Difference (IV, Random, 95% CI)	1.60 [-0.43, 3.63]



29 BMI, kg/m <sup>2</sup> - LCn3 - subgroup by duration	14		Mean Difference (IV, Random, 95% CI)	Subtotals only
29.1 Medium duration 1 to < 2 years in study	9	906	Mean Difference (IV, Random, 95% CI)	0.24 [-0.40, 0.88]
29.2 Medium-long duration: 2 to < 4 years in study	4	1792	Mean Difference (IV, Random, 95% CI)	0.12 [-0.07, 0.31]
29.3 Long duration ≥ 4 years in study	1	12536	Mean Difference (IV, Random, 95% CI)	0.0 [-0.20, 0.20]
30 BMI, kg/m <sup>2</sup> - LCn3 - subgroup by primary or secondary prevention	14		Mean Difference (IV, Random, 95% CI)	Subtotals only
30.1 Primary CVD prevention	11	13610	Mean Difference (IV, Random, 95% CI)	0.15 [-0.36, 0.66]
30.2 Secondary CVD prevention	3	1624	Mean Difference (IV, Random, 95% CI)	0.05 [-0.08, 0.18]
31 BMI, kg/m <sup>2</sup> - LCn3 - subgroup by statin use	14		Mean Difference (IV, Random, 95% CI)	Subtotals only
31.1 LCn3 - ≥ 50% of control group on statins	3	13891	Mean Difference (IV, Random, 95% CI)	0.13 [-0.22, 0.48]
31.2 LCn3 - < 50% of control group on statins	4	665	Mean Difference (IV, Random, 95% CI)	0.02 [-0.15, 0.19]
31.3 LCn3 - use of statins unclear	7	678	Mean Difference (IV, Random, 95% CI)	0.06 [-0.86, 0.97]
32 Other measures of adiposity - LCn3	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
32.1 Percentage body fat	2	127	Mean Difference (IV, Random, 95% CI)	0.85 [-6.87, 8.57]
32.2 Percentage visceral fat	1	95	Mean Difference (IV, Random, 95% CI)	-1.80 [-15.03, 11.43]
32.3 Waist circumference, cm	3	676	Mean Difference (IV, Random, 95% CI)	0.66 [-0.09, 1.42]
32.4 Waist-hip ratio	1	100	Mean Difference (IV, Random, 95% CI)	0.0 [-0.01, 0.01]
32.5 Abdominal circumference, cm	1	256	Mean Difference (IV, Random, 95% CI)	-0.70 [-8.78, 7.38]
32.6 Hip circumference, cm	1	258	Mean Difference (IV, Random, 95% CI)	-2.40 [-9.80, 5.00]
33 Total cholesterol, serum, mmol/L - LCn3	28	37281	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.05, 0.04]
34 TC, mmol/L - LCn3 - SA by summary risk of bias	28	37281	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.05, 0.03]
34.1 Low risk of bias	9	14930	Mean Difference (IV, Random, 95% CI)	0.01 [-0.05, 0.06]
34.2 Moderate/high risk of bias	19	22351	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.09, 0.03]
35 TC, mmol/L - LCn3 - SA by compliance and study size	20		Mean Difference (IV, Random, 95% CI)	Subtotals only
35.1 SA - low risk of compliance bias	14	3341	Mean Difference (IV, Random, 95% CI)	0.02 [-0.05, 0.09]
35.2 SA - 100+ randomised	15	36622	Mean Difference (IV, Random, 95% CI)	0.00 [-0.05, 0.06]
36 TC, mmol/L - LCn3 - subgroup by dose	28		Mean Difference (IV, Random, 95% CI)	Subtotals only
36.1 LCn3 ≤ 150 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
36.2 LCn3 > 150 ≤ 250 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
36.3 LCn3 > 250 ≤ 400 mg/d	1	1715	Mean Difference (IV, Random, 95% CI)	0.10 [-0.01, 0.21]
36.4 LCn3 > 400 ≤ 2400 mg/d	18	34262	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.06, 0.00]



36.5 LCn3 > 2.4 ≤ 4.4 g/d	7	1216	Mean Difference (IV, Random, 95% CI)	-0.14 [-0.28, -0.01]
36.6 LCn3 > 4.4 g/d	2	88	Mean Difference (IV, Random, 95% CI)	0.08 [-0.28, 0.45]
37 TC, mmol/L - LCn3 - subgroup by replacement	28		Mean Difference (IV, Random, 95% CI)	Subtotals only
37.1 N-3 replacing SFA	3	2148	Mean Difference (IV, Random, 95% CI)	0.10 [-0.01, 0.20]
37.2 N-3 replacing MUFA	15	16504	Mean Difference (IV, Random, 95% CI)	0.01 [-0.04, 0.06]
37.3 N-3 replacing n-6	5	895	Mean Difference (IV, Random, 95% CI)	0.02 [-0.22, 0.26]
37.4 N-3 replacing carbs/sugars	1	258	Mean Difference (IV, Random, 95% CI)	-0.20 [-1.03, 0.63]
37.5 N-3 replacing nil/low n-3 placebo	5	19431	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.07, -0.03]
37.6 Replacement unclear	2	193	Mean Difference (IV, Random, 95% CI)	-0.15 [-0.47, 0.17]
38 TC, mmol/L - LCn3 - subgroup by intervention type	28		Mean Difference (IV, Random, 95% CI)	Subtotals only
38.1 Dietary advice	1	1715	Mean Difference (IV, Random, 95% CI)	0.10 [-0.01, 0.21]
38.2 Supplemental foods	1	1210	Mean Difference (IV, Random, 95% CI)	0.02 [-0.09, 0.13]
38.3 Supplement (capsule)	24	34145	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.07, -0.03]
38.4 Any combination	2	211	Mean Difference (IV, Random, 95% CI)	0.13 [-0.10, 0.37]
39 TC, mmol/L - LCn3 - subgroup by duration	28		Mean Difference (IV, Random, 95% CI)	Subtotals only
39.1 Medium duration 1 to < 2 years in study	15	1661	Mean Difference (IV, Random, 95% CI)	-0.06 [-0.16, 0.04]
39.2 Medium-long duration: 2 to < 4 years in study	10	4231	Mean Difference (IV, Random, 95% CI)	0.02 [-0.05, 0.10]
39.3 Long duration ≥ 4 years in study	3	31389	Mean Difference (IV, Random, 95% CI)	0.00 [-0.09, 0.09]
40 TC, mmol/L - LCn3 - subgroup by primary or secondary prevention	28		Mean Difference (IV, Random, 95% CI)	Subtotals only
40.1 Primary prevention	17	32796	Mean Difference (IV, Random, 95% CI)	-0.04 [-0.07, -0.02]
40.2 Secondary prevention	11	4485	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.09, 0.08]
41 TC, mmol/L - LCn3 - subgroup by statin use	28		Mean Difference (IV, Random, 95% CI)	Subtotals only
41.1 LCn3 - ≥ 50% of control group on statins	6	32823	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.07, -0.02]
41.2 LCn3 - < 50% of control group on statins	15	3871	Mean Difference (IV, Random, 95% CI)	0.01 [-0.08, 0.10]
41.3 LCn3 - use of statins unclear	7	587	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.27, 0.22]
42 Triglycerides, fasting, serum, mmol/L - LCn3	25	35579	Mean Difference (IV, Random, 95% CI)	-0.24 [-0.31, -0.16]
43 TG, fasting, mmol/L - LCn3 - SA by summary risk of bias	25	35579	Mean Difference (IV, Random, 95% CI)	-0.23 [-0.30, -0.16]
43.1 Low risk of bias	8	14654	Mean Difference (IV, Random, 95% CI)	-0.17 [-0.25, -0.09]
43.2 Moderate/high risk of bias	17	20925	Mean Difference (IV, Random, 95% CI)	-0.25 [-0.35, -0.15]
44 TG, fasting, mmol/L - LCn3 - SA by compliance and study size	19		Mean Difference (IV, Random, 95% CI)	Subtotals only
44.1 SA - low risk of compliance bias	12	3306	Mean Difference (IV, Random, 95% CI)	-0.26 [-0.36, -0.16]

44.2 SA - 100+ randomised	18	35197	Mean Difference (IV, Random, 95% CI)	-0.24 [-0.32, -0.16]
45 TG, fasting, mmol/L - LCn3 - subgroup by dose	25		Mean Difference (IV, Random, 95% CI)	Subtotals only
45.1 LCn3 ≤ 150 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
45.2 LCn3 > 150 ≤ 250 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
45.3 LCn3 > 250 ≤ 400 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
45.4 LCn3 > 400 ≤ 2400 mg/d	18	34388	Mean Difference (IV, Random, 95% CI)	-0.18 [-0.25, -0.11]
45.5 LCn3 > 2.4 ≤ 4.4 g/d	5	1107	Mean Difference (IV, Random, 95% CI)	-0.36 [-0.53, -0.20]
45.6 LCn3 > 4.4 g/d	2	84	Mean Difference (IV, Random, 95% CI)	-0.41 [-0.68, -0.14]
46 TG, fasting, mmol/L - LCn3 - subgroup by replacement	25		Mean Difference (IV, Random, 95% CI)	Subtotals only
46.1 N-3 replacing SFA	2	429	Mean Difference (IV, Random, 95% CI)	-0.27 [-0.59, 0.04]
46.2 N-3 replacing MUFA	13	14634	Mean Difference (IV, Random, 95% CI)	-0.18 [-0.25, -0.10]
46.3 N-3 replacing n-6	5	876	Mean Difference (IV, Random, 95% CI)	-0.27 [-0.45, -0.08]
46.4 N-3 replacing carbs/sugars	1	258	Mean Difference (IV, Random, 95% CI)	-0.5 [-1.49, 0.49]
46.5 N-3 replacing nil/low n-3 placebo	4	19357	Mean Difference (IV, Random, 95% CI)	-0.18 [-0.51, 0.14]
46.6 Replacement unclear	2	454	Mean Difference (IV, Random, 95% CI)	-0.38 [-0.57, -0.19]
47 TG, fasting, mmol/L - LCn3 - subgroup by intervention type	25		Mean Difference (IV, Random, 95% CI)	Subtotals only
47.1 Dietary advice	1	71	Mean Difference (IV, Random, 95% CI)	0.02 [-0.36, 0.40]
47.2 Supplemental foods	1	1210	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.15, 0.09]
47.3 Supplement (capsule)	22	34137	Mean Difference (IV, Random, 95% CI)	-0.19 [-0.38, -0.00]
47.4 Any combination	1	161	Mean Difference (IV, Random, 95% CI)	0.01 [-0.28, 0.30]
48 TG, fasting, mmol/L - LCn3 - subgroup by duration	25		Mean Difference (IV, Random, 95% CI)	Subtotals only
48.1 Medium duration 1 to < 2 years in study	13	1880	Mean Difference (IV, Random, 95% CI)	-0.27 [-0.36, -0.19]
48.2 Medium-long duration: 2 to < 4 years in study	9	2310	Mean Difference (IV, Random, 95% CI)	-0.16 [-0.31, -0.02]
48.3 Long duration ≥ 4 years in study	3	31389	Mean Difference (IV, Random, 95% CI)	-0.20 [-0.32, -0.07]
49 TG, fasting, mmol/L - LCn3 - subgroup by primary or secondary prevention	25		Mean Difference (IV, Random, 95% CI)	Subtotals only
49.1 Primary prevention	17	33114	Mean Difference (IV, Random, 95% CI)	-0.20 [-0.26, -0.14]
49.2 Secondary prevention	8	2465	Mean Difference (IV, Random, 95% CI)	-0.27 [-0.44, -0.10]
50 TG, fasting, mmol/L - LCn3 - subgroup by statin use	25		Mean Difference (IV, Random, 95% CI)	Subtotals only
50.1 LCn3 - ≥ 50% of control group on statins	5	32557	Mean Difference (IV, Random, 95% CI)	-0.11 [-0.21, -0.01]
50.2 LCn3 - < 50% of control group on statins	14	2414	Mean Difference (IV, Random, 95% CI)	-0.27 [-0.36, -0.18]
50.3 LCn3 - use of statins unclear	6	608	Mean Difference (IV, Random, 95% CI)	-0.23 [-0.38, -0.08]
51 High-density lipoprotein, serum, mmol/L - LCn3	27	37237	Mean Difference (IV, Random, 95% CI)	0.02 [0.00, 0.04]
52 HDL, mmol/L - LCn3 - SA by summary risk of bias	27	37237	Mean Difference (IV, Random, 95% CI)	0.03 [0.01, 0.05]

52.1 Low risk of bias	8	14892	Mean Difference (IV, Random, 95% CI)	0.03 [-0.01, 0.07]
52.2 Moderate/high risk of bias	19	22345	Mean Difference (IV, Random, 95% CI)	0.03 [0.00, 0.06]
53 HDL, mmol/L - LCn3 - SA by compliance and study size	20		Mean Difference (IV, Random, 95% CI)	Subtotals only
53.1 SA - low risk of compliance bias	13	3202	Mean Difference (IV, Random, 95% CI)	0.05 [0.01, 0.10]
53.2 SA - 100+ randomised	15	36573	Mean Difference (IV, Random, 95% CI)	0.03 [0.00, 0.05]
54 HDL, mmol/L - LCn3 - subgroup by dose	27		Mean Difference (IV, Random, 95% CI)	Subtotals only
54.1 LCn3 ≤ 150 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
54.2 LCn3 > 150 ≤ 250 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
54.3 LCn3 > 250 ≤ 400 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
54.4 LCn3 > 400 ≤ 2400 mg/d	19	35972	Mean Difference (IV, Random, 95% CI)	0.02 [-0.00, 0.04]
54.5 LCn3 > 2.4 ≤ 4.4 g/d	7	1206	Mean Difference (IV, Random, 95% CI)	0.06 [0.00, 0.12]
54.6 LCn3 > 4.4 g/d	1	59	Mean Difference (IV, Random, 95% CI)	0.0 [-0.16, 0.16]
55 HDL, mmol/L - LCn3 - subgroup by replacement	27		Mean Difference (IV, Random, 95% CI)	Subtotals only
55.1 N-3 replacing SFA	3	2143	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.10, 0.07]
55.2 N-3 replacing MUFA	15	16505	Mean Difference (IV, Random, 95% CI)	0.02 [-0.01, 0.06]
55.3 N-3 replacing n-6	4	850	Mean Difference (IV, Random, 95% CI)	0.04 [-0.01, 0.09]
55.4 N-3 replacing carbs/sugars	1	258	Mean Difference (IV, Random, 95% CI)	0.10 [-0.17, 0.37]
55.5 N-3 replacing nil/low n-3 placebo	5	19431	Mean Difference (IV, Random, 95% CI)	0.04 [-0.03, 0.11]
55.6 Replacement unclear	2	193	Mean Difference (IV, Random, 95% CI)	0.05 [-0.10, 0.20]
56 HDL, mmol/L - LCn3 - subgroup by intervention type	27		Mean Difference (IV, Random, 95% CI)	Subtotals only
56.1 Dietary advice	2	1785	Mean Difference (IV, Random, 95% CI)	0.01 [-0.02, 0.04]
56.2 Supplemental foods	1	1210	Mean Difference (IV, Random, 95% CI)	0.03 [0.00, 0.06]
56.3 Supplement (capsule)	21	34008	Mean Difference (IV, Random, 95% CI)	0.03 [0.00, 0.06]
56.4 Any combination	3	234	Mean Difference (IV, Random, 95% CI)	0.10 [-0.10, 0.31]
57 HDL, mmol/L - LCn3 - subgroup by duration	27		Mean Difference (IV, Random, 95% CI)	Subtotals only
57.1 Medium duration 1 to < 2 years in study	13	1562	Mean Difference (IV, Random, 95% CI)	0.08 [0.01, 0.14]
57.2 Medium-long duration: 2 to < 4 years in study	11	4286	Mean Difference (IV, Random, 95% CI)	0.02 [-0.01, 0.04]
57.3 Long duration ≥ 4 years in study	3	31389	Mean Difference (IV, Random, 95% CI)	0.00 [-0.01, 0.01]
58 HDL, mmol/L - LCn3 - subgroup by primary or secondary prevention	26		Mean Difference (IV, Random, 95% CI)	Subtotals only
58.1 Primary prevention	17	32856	Mean Difference (IV, Random, 95% CI)	0.03 [-0.00, 0.05]
58.2 Secondary prevention	9	4307	Mean Difference (IV, Random, 95% CI)	0.03 [-0.01, 0.07]
59 HDL, mmol/L - LCn3 - subgroup by statin use	27		Mean Difference (IV, Random, 95% CI)	Subtotals only
59.1 LCn3 - ≥ 50% of control group on statins	7	32894	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.03]

59.2 LCn3 - < 50% of control group on statins	13	3690	Mean Difference (IV, Random, 95% CI)	0.04 [-0.00, 0.08]
59.3 LCn3 - use of statins unclear	7	653	Mean Difference (IV, Random, 95% CI)	0.07 [-0.07, 0.21]
60 Low-density lipoprotein, serum, mmol/L - LCn3	23	35035	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.03]
61 LDL, mmol/L - LCn3 - SA by summary risk of bias	23	35035	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.03]
61.1 Low risk of bias	9	14840	Mean Difference (IV, Random, 95% CI)	0.02 [-0.03, 0.07]
61.2 Moderate/high risk of bias	14	20195	Mean Difference (IV, Random, 95% CI)	0.00 [-0.02, 0.03]
62 LDL, mmol/L - LCn3 - SA by compliance and study size	17	37718	Mean Difference (IV, Random, 95% CI)	0.02 [-0.01, 0.05]
62.1 SA - low risk of compliance bias	13	3165	Mean Difference (IV, Random, 95% CI)	0.05 [-0.02, 0.11]
62.2 SA - 100+ randomised	14	34553	Mean Difference (IV, Random, 95% CI)	0.01 [-0.02, 0.04]
63 LDL, mmol/L - LCn3 - subgroup by dose	23		Mean Difference (IV, Random, 95% CI)	Subtotals only
63.1 LCn3 ≤ 150 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
63.2 LCn3 > 150 ≤ 250 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
63.3 LCn3 > 250 ≤ 400 mg/d	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
63.4 LCn3 > 400 ≤ 2400 mg/d	16	34054	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.02]
63.5 LCn3 > 2.4 ≤ 4.4 g/d	5	893	Mean Difference (IV, Random, 95% CI)	0.01 [-0.14, 0.15]
63.6 LCn3 > 4.4 g/d	2	88	Mean Difference (IV, Random, 95% CI)	0.22 [-0.09, 0.54]
64 LDL, mmol/L - LCn3 - subgroup by replacement	23		Mean Difference (IV, Random, 95% CI)	Subtotals only
64.1 N-3 replacing SFA	2	429	Mean Difference (IV, Random, 95% CI)	0.17 [-0.14, 0.47]
64.2 N-3 replacing MUFA	14	14710	Mean Difference (IV, Random, 95% CI)	0.01 [-0.03, 0.05]
64.3 N-3 replacing n-6	2	242	Mean Difference (IV, Random, 95% CI)	0.14 [-0.26, 0.55]
64.4 N-3 replacing carbs/sugars	1	258	Mean Difference (IV, Random, 95% CI)	0.20 [-0.51, 0.91]
64.5 N-3 replacing nil/low n-3 placebo	3	19297	Mean Difference (IV, Random, 95% CI)	0.00 [-0.02, 0.02]
64.6 Replacement unclear	3	528	Mean Difference (IV, Random, 95% CI)	0.10 [-0.03, 0.23]
65 LDL, mmol/L - LCn3 - subgroup by intervention type	23		Mean Difference (IV, Random, 95% CI)	Subtotals only
65.1 Dietary advice	1	71	Mean Difference (IV, Random, 95% CI)	0.08 [-0.22, 0.38]
65.2 Supplemental foods	1	1124	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.10, 0.06]
65.3 Supplement (capsule)	19	33768	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.03]
65.4 Any combination	2	72	Mean Difference (IV, Random, 95% CI)	0.08 [-0.44, 0.61]
66 LDL, mmol/L - LCn3 - subgroup by duration	23		Mean Difference (IV, Random, 95% CI)	Subtotals only
66.1 Medium duration 1 to < 2 years in study	14	1862	Mean Difference (IV, Random, 95% CI)	0.06 [-0.03, 0.14]
66.2 Medium-long duration: 2 to < 4 years in study	6	1784	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.08, 0.06]
66.3 Long duration ≥ 4 years in study	3	31389	Mean Difference (IV, Random, 95% CI)	0.03 [-0.04, 0.10]

67 LDL, mmol/L - LCn3 - subgroup by primary or secondary prevention	23		Mean Difference (IV, Random, 95% CI)	Subtotals only
67.1 Primary prevention	16	32717	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.03]
67.2 Secondary prevention	7	2318	Mean Difference (IV, Random, 95% CI)	0.01 [-0.05, 0.08]
68 LDL, mmol/L - LCn3 - subgroup by statin use	23		Mean Difference (IV, Random, 95% CI)	Subtotals only
68.1 LCn3 - $\geq$ 50% of control group on statins	7	32808	Mean Difference (IV, Random, 95% CI)	0.00 [-0.02, 0.02]
68.2 LCn3 - < 50% of control group on statins	9	1564	Mean Difference (IV, Random, 95% CI)	0.12 [0.03, 0.21]
68.3 LCn3 - use of statins unclear	7	663	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.17, 0.14]

### Comparison 3. High vs low LCn3 omega-3 fats (tertiary outcomes)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Blood pressure, mmHg - LCn3	15		Mean Difference (IV, Random, 95% CI)	Subtotals only
1.1 Systolic BP - LCn3	15	34413	Mean Difference (IV, Random, 95% CI)	0.02 [-0.32, 0.35]
1.2 Diastolic BP - LCn3	14	35386	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.22, 0.17]
2 Serious adverse events - LCn3	14		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Any serious adverse events	1	402	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.78, 1.41]
2.2 Bleeding	8	45562	Risk Ratio (M-H, Random, 95% CI)	1.06 [0.73, 1.52]
2.3 GI hospitalisation	1	200	Risk Ratio (M-H, Random, 95% CI)	1.75 [0.53, 5.79]
2.4 Pulmonary embolus or DVT - LCn3	4	3011	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.41, 3.78]
2.5 Progression to advanced AMD (age-related macular degeneration)	1	4203	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.90, 1.02]
3 Side effects - LCn3	33		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
3.1 Dropouts due to side effects	23	16755	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.99, 1.36]
3.2 Abdominal pain or discomfort	7	14650	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.84, 1.45]
3.3 Diarrhoea	10	2428	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.92, 1.43]
3.4 Nausea	5	1234	Risk Ratio (M-H, Random, 95% CI)	1.73 [1.23, 2.44]
3.5 Any gastrointestinal side effect - LCn3 fats	29	65185	Risk Ratio (M-H, Random, 95% CI)	1.12 [0.94, 1.34]
3.6 Skin problems (itching, rashes)	8	36186	Risk Ratio (M-H, Random, 95% CI)	1.04 [0.47, 2.30]
3.7 Headache or worsening migraine	3	991	Risk Ratio (M-H, Random, 95% CI)	0.80 [0.48, 1.35]
3.8 Reflux	1	202	Risk Ratio (M-H, Random, 95% CI)	1.42 [0.71, 2.81]
3.9 Pain (joint, lumbar, muscle pain)	1	18645	Risk Ratio (M-H, Random, 95% CI)	0.80 [0.64, 0.99]
3.10 All side effects combined	13	38904	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.95, 1.08]
4 Dropouts - LCn3	30	31321	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.95, 1.09]

#### Comparison 4. High vs low ALA omega-3 fat (primary outcomes)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All-cause mortality (overall) - ALA	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.84, 1.20]
2 All-cause mortality - ALA - sensitivity analysis (SA) fixed-effect	5	16923	Risk Ratio (M-H, Fixed, 95% CI)	1.06 [0.84, 1.34]
3 All-cause mortality - ALA - SA by summary risk of bias	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.84, 1.20]
3.1 Low risk of bias	3	5213	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.72, 1.45]
3.2 Moderate/high risk of bias	2	14114	Risk Ratio (M-H, Random, 95% CI)	1.09 [0.71, 1.67]
4 All-cause mortality - ALA - SA by compliance and study size	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
4.1 SA - low risk of compliance bias	3	5811	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.68, 1.63]
4.2 SA - 100+ randomised	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.84, 1.20]
5 All-cause mortality - ALA - subgroup by dose	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.84, 1.20]
5.1 ALA low < 5 g/d	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.80, 1.19]
5.2 ALA high ≥ 5 g/d	4	14490	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.77, 1.75]
6 All-cause mortality - ALA - subgroup by replacement	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
6.1 ALA replacing SFA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6.2 ALA replacing MUFA	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.80, 1.19]
6.3 ALA replacing n-6	2	13672	Risk Ratio (M-H, Random, 95% CI)	1.37 [0.48, 3.86]
6.4 ALA replacing CHO	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6.5 ALA replacing nil/low n-3 placebo	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6.6 ALA replacement unclear	2	818	Risk Ratio (M-H, Random, 95% CI)	2.78 [0.29, 26.49]
7 All cause mortality - ALA - subgroup by intervention type	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.84, 1.20]
7.1 Dietary advice	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
7.2 Supplemental foods	4	5921	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.82, 1.21]
7.3 Supplements (capsule)	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.70, 1.64]
7.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
8 All-cause mortality - ALA - subgroup by duration	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.84, 1.20]
8.1 Medium duration 1 to < 2 years in study	2	13516	Risk Ratio (M-H, Random, 95% CI)	1.09 [0.71, 1.67]
8.2 Medium-long duration: 2 to < 4 years in study	3	5811	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.68, 1.63]
8.3 Long duration: ≥ 4 years in study	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
9 All-cause mortality - ALA - subgroup by primary or secondary prevention	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.84, 1.20]
9.1 Primary CVD prevention	3	14380	Risk Ratio (M-H, Random, 95% CI)	1.14 [0.75, 1.74]

9.2 Secondary CVD prevention	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.81, 1.19]
10 All-cause mortality - ALA - subgroup by statin use	5	16923	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.84, 1.33]
10.1 ALA - $\geq$ 50% of control group on statins	2	2543	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.77, 1.34]
10.2 ALA - < 50% of control group on statins	3	14380	Risk Ratio (M-H, Random, 95% CI)	1.14 [0.75, 1.74]
11 Cardiovascular mortality (overall) - ALA	4	18619	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.25]
12 CVD mortality - ALA - SA fixed-effect	4	18619	Risk Ratio (M-H, Fixed, 95% CI)	0.96 [0.74, 1.25]
13 CVD mortality - ALA - SA by summary risk of bias	4	18619	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.25]
13.1 Low risk of bias	3	5213	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.70, 1.28]
13.2 Moderate/high risk of bias	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.58, 1.70]
14 CVD mortality - ALA - SA by compliance and study size	4	23722	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.78, 1.16]
14.1 SA - low risk of compliance bias	2	5103	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.70, 1.27]
14.2 SA - 100+ randomised	4	18619	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.25]
15 CVD mortality - ALA - subgroup by dose	4	18619	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.25]
15.1 ALA low < 5 g/d	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.69, 1.27]
15.2 ALA high $\geq$ 5 g/d	3	13782	Risk Ratio (M-H, Random, 95% CI)	1.04 [0.62, 1.73]
16 CVD mortality - ALA - subgroup by replacement	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
16.1 N-3 replacing SFA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
16.2 N-3 replacing MUFA	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.69, 1.27]
16.3 N-3 replacing n-6	2	13672	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.60, 1.70]
16.4 N-3 replacing carbohydrates/sugars	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
16.5 N-3 replacing nil/low n-3 placebo	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
16.6 Replacement unclear	1	110	Risk Ratio (M-H, Random, 95% CI)	2.69 [0.11, 64.74]
17 CVD mortality - ALA - subgroup by intervention type	4	18619	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.25]
17.1 Dietary advice	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
17.2 Supplemental foods	3	5213	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.70, 1.28]
17.3 Supplements (capsule)	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.58, 1.70]
17.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
18 CVD mortality - ALA - subgroup by duration	4	18619	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.25]
18.1 Medium duration 1 to < 2 years in study	2	13516	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.61, 1.73]
18.2 Medium-long duration: 2 to < 4 years in study	2	5103	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.70, 1.27]
18.3 Long duration: $\geq$ 4 years in study	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]



19 CVD mortality - ALA - subgroup by primary or secondary prevention	4	18619	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.25]
19.1 Primary prevention	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.58, 1.70]
19.2 Secondary prevention	3	5213	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.70, 1.28]
20 CVD mortality - ALA - subgroup by statin uses	4	18619	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.74, 1.25]
20.1 ALA - $\geq$ 50% of control group on statins	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.70, 1.28]
20.2 ALA - < 50% of control group on statins	2	13672	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.60, 1.70]
21 Cardiovascular events (overall) - ALA	5	19327	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.83, 1.07]
22 CVD events - ALA - SA fixed-effect	5	19327	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.84, 1.07]
23 CVD events - ALA - SA by summary risk of bias	5	19327	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.83, 1.07]
23.1 Low risk of bias	3	5213	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.79, 1.04]
23.2 Moderate/high risk of bias	2	14114	Risk Ratio (M-H, Random, 95% CI)	1.12 [0.84, 1.48]
24 CVD events - ALA - SA by compliance and study size	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
24.1 SA - low risk of compliance bias	3	5811	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.79, 1.04]
24.2 SA - 100+ randomised	5	19327	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.83, 1.07]
25 CVD events - ALA - subgroup by dose	5	19327	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.83, 1.07]
25.1 ALA low < 5 g/d	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.79, 1.05]
25.2 ALA high $\geq$ 5 g/d	4	14490	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.82, 1.40]
26 CVD events - ALA - subgroup by replacement	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
26.1 N-3 replacing SFA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
26.2 N-3 replacing MUFA	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.79, 1.05]
26.3 N-3 replacing n-6	2	13672	Risk Ratio (M-H, Random, 95% CI)	0.76 [0.24, 2.41]
26.4 N-3 replacing carbohydrates/sugars	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
26.5 N-3 replacing nil/low n-3 placebo	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
26.6 Replacement unclear	2	818	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.36, 2.43]
27 CVD events - ALA - subgroup by intervention type	6	19526	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.83, 1.07]
27.1 Dietary advice	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
27.2 Supplemental foods	5	6120	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.79, 1.04]
27.3 Supplements (capsule)	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.13 [0.85, 1.51]
27.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
28 CVD events - ALA - subgroup by duration	5	19327	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.83, 1.07]
28.1 Medium duration 1 to < 2 years in study	2	13516	Risk Ratio (M-H, Random, 95% CI)	1.13 [0.86, 1.50]
28.2 Medium-long duration: 2 to < 4 years in study	3	5811	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.79, 1.04]



28.3 Long duration: $\geq 4$ years in study	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
29 CVD events - ALA - subgroup by primary or secondary prevention	5	19327	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.83, 1.07]
29.1 Primary prevention	3	14380	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.46, 1.67]
29.2 Secondary prevention	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.80, 1.05]
30 CVD events - ALA - subgroup by statin use	5	19327	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.83, 1.07]
30.1 ALA - $\geq 50\%$ of control group on statins	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.80, 1.05]
30.2 ALA - $< 50\%$ of control group on statins	3	14380	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.46, 1.67]
31 Coronary heart disease mortality (overall) - ALA	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]
32 CHD mortality - ALA - SA fixed-effect	3	18353	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.72, 1.26]
33 CHD mortality - ALA - SA by summary risk of bias	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]
33.1 Low risk of bias	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.67, 1.30]
33.2 Moderate/high risk of bias	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.58, 1.70]
34 CHD mortality - ALA - SA by compliance and study size	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
34.1 SA - low risk of compliance bias	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.66, 1.28]
34.2 SA - 100+ randomised	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]
35 CHD mortality - ALA - subgroup by dose	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]
35.1 ALA low $< 5$ g/d	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.66, 1.28]
35.2 ALA high $\geq 5$ g/d	2	13516	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.61, 1.73]
36 CHD mortality - ALA - subgroup by replacement	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
36.1 N-3 replacing SFA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
36.2 Coronary heart mortality- ALA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
36.3 N-3 replacing MUFA	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.66, 1.28]
36.4 N-3 replacing n-6	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.58, 1.70]
36.5 N-3 replacing carbohydrates/sugars	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
36.6 N-3 replacing nil/low n-3 placebo	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
36.7 Replacement unclear	1	110	Risk Ratio (M-H, Random, 95% CI)	2.69 [0.11, 64.74]
37 CHD mortality - ALA - subgroup by intervention type	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]
37.1 Dietary advice	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
37.2 Supplemental foods	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.67, 1.30]
37.3 Supplements (capsule)	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.58, 1.70]
37.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
38 CHD mortality - ALA - subgroup by duration	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]

38.1 Medium duration 1 to < 2 years in study	2	13516	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.61, 1.73]
38.2 Medium-long duration: 2 to < 4 years in study	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.66, 1.28]
38.3 Long duration: $\geq 4$ years in study	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
39 CHD mortality - ALA - subgroup by primary or secondary prevention	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]
39.1 Primary prevention of CVD	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.58, 1.70]
39.2 Secondary prevention of CVD	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.67, 1.30]
40 CHD mortality - ALA - subgroup by statin use	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]
40.1 ALA - $\geq 50\%$ of control group on statins	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.67, 1.30]
40.2 ALA - < 50% of control group on statins	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.58, 1.70]
41 CHD mortality - ALA - subgroup by CAD history	3	18353	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.72, 1.26]
41.1 Previous CAD	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.66, 1.28]
41.2 No previous CAD	2	13516	Risk Ratio (M-H, Random, 95% CI)	1.02 [0.61, 1.73]
42 Coronary heart disease events (overall) - ALA	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
43 CHD events - ALA - SA fixed-effect	4	19061	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.82, 1.21]
44 CHD events - ALA - SA by summary risk of bias	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
44.1 Low risk of bias	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.71, 1.15]
44.2 Moderate/high risk of bias	2	14114	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.86, 1.67]
45 CHD events - ALA - SA by compliance and study size	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
45.1 SA - low risk of compliance bias	2	5545	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.73, 1.17]
45.2 SA - 100+ randomised	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
46 CHD events - ALA - subgroup by dose	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
46.1 ALA low < 5 g/d	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.72, 1.17]
46.2 ALA high $\geq 5$ g/d	3	14224	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.84, 1.61]
47 CHD events - ALA - subgroup by replacement	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
47.1 N-3 replacing SFA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
47.2 N-3 replacing MUFA	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.72, 1.17]
47.3 N-3 replacing n-6	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.19 [0.85, 1.65]
47.4 N-3 replacing carbohydrates/sugars	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
47.5 N-3 replacing nil/low n-3 placebo	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
47.6 Replacement unclear	2	818	Risk Ratio (M-H, Random, 95% CI)	0.69 [0.08, 5.81]

48 CHD events - ALA - subgroup by intervention type	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
48.1 Dietary advice	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
48.2 Supplemental foods	3	5655	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.72, 1.16]
48.3 Supplements (capsule)	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.19 [0.85, 1.65]
48.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
49 CHD events - ALA - subgroup by duration	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
49.1 Medium duration 1 to < 2 years in study	2	13516	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.34, 2.58]
49.2 Medium-long duration: 2 to < 4 years in study	2	5545	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.73, 1.17]
49.3 Long duration: $\geq$ 4 years in study	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
50 CHD events - ALA - subgroup by primary or secondary prevention	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
50.1 Primary prevention	2	14114	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.86, 1.67]
50.2 Secondary prevention	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.71, 1.15]
51 CHD events - ALA - subgroup by statin use	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
51.1 ALA - $\geq$ 50% of control group on statins	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.71, 1.15]
51.2 ALA - < 50% of control group on statins	2	14114	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.86, 1.67]
52 CHD events - ALA - subgroup by CAD history	4	19061	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.82, 1.22]
52.1 Previous CAD	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.72, 1.17]
52.2 No previous CAD	3	14224	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.84, 1.61]
53 Stroke (overall) - ALA	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.66, 2.01]
54 Stroke - ALA - SA fixed-effect	5	19327	Risk Ratio (M-H, Fixed, 95% CI)	1.23 [0.71, 2.13]
55 Stroke - ALA - SA by summary risk of bias	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.66, 2.01]
55.1 Low risk of bias	3	5213	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.45, 2.09]
55.2 Moderate/high risk of bias	2	14114	Risk Ratio (M-H, Random, 95% CI)	1.39 [0.62, 3.13]
56 Stroke - ALA - SA by compliance and study size	5	25138	Risk Ratio (M-H, Random, 95% CI)	1.04 [0.66, 1.64]
56.1 SA - low risk of compliance bias	3	5811	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.39, 1.87]
56.2 SA - 100+ randomised	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.66, 2.01]
57 Stroke - ALA - subgroup by dose	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
57.1 ALA low < 5 g/d	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.39, 2.15]
57.2 ALA high $\geq$ 5 g/d	4	14490	Risk Ratio (M-H, Random, 95% CI)	1.36 [0.65, 2.85]
58 Stroke - ALA - subgroup by replacement	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
58.1 N-3 replacing SFA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
58.2 N-3 replacing MUFA	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.39, 2.15]
58.3 N-3 replacing n-6	2	13672	Risk Ratio (M-H, Random, 95% CI)	1.26 [0.53, 3.01]

58.4 N-3 replacing carbohydrates/sugars	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
58.5 N-3 replacing nil/low n-3 placebo	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
58.6 Replacement unclear	2	818	Risk Ratio (M-H, Random, 95% CI)	1.79 [0.31, 10.17]
59 Stroke - ALA - subgroup by intervention type	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.66, 2.01]
59.1 Dietary advice	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
59.2 Supplemental foods	4	5921	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.46, 2.03]
59.3 Supplements (capsule)	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.44 [0.62, 3.36]
59.4 Any combination	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
60 Stroke - ALA - subgroup by duration	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.66, 2.01]
60.1 Medium duration 1 to < 2 years in study	2	13516	Risk Ratio (M-H, Random, 95% CI)	1.56 [0.70, 3.44]
60.2 Medium-long duration: 2 to < 4 years in study	3	5811	Risk Ratio (M-H, Random, 95% CI)	0.85 [0.39, 1.87]
60.3 Long duration: ≥ 4 years in study	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
61 Stroke - ALA - subgroup by primary or secondary prevention	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.15 [0.66, 2.01]
61.1 Primary prevention	3	14380	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.57, 2.74]
61.2 Secondary prevention	2	4947	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.47, 2.34]
62 Stroke - ALA - subgroup by statin use	5	19327	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.71, 2.18]
62.1 ALA - ≥ 50% of control group on statins	2	4947	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.56, 2.77]
62.2 ALA - < 50% of control group on statins	3	14380	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.57, 2.74]
63 Stroke - ALA - subgroup by stroke type	3	13782	Risk Ratio (M-H, Random, 95% CI)	1.40 [0.65, 3.01]
63.1 Ischaemic stroke - ALA	3	13782	Risk Ratio (M-H, Random, 95% CI)	1.40 [0.65, 3.01]
63.2 Haemorrhagic stroke - ALA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
64 Arrhythmia (overall) - ALA	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.57, 1.10]
64.1 ALA - new arrhythmias	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.57, 1.10]
64.2 ALA - recurrent arrhythmias	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
65 Arrhythmia - ALA - SA by summary risk of bias	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.57, 1.10]
65.1 Low risk of bias	1	4837	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.57, 1.10]
65.2 Moderate/high risk of bias	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]

### Comparison 5. High vs low ALA omega-3 fat (secondary outcomes)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 MACCEs - ALA	1	110	Risk Ratio (M-H, Random, 95% CI)	1.12 [0.32, 3.95]
2 Myocardial infarction (overall) - ALA	3	18353	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.76, 1.32]
3 Total MI - ALA - subgroup by fatality	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
3.1 Fatal MI	2	4947	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.62, 1.46]
3.2 Non-fatal MI	3	5213	Risk Ratio (M-H, Random, 95% CI)	0.52 [0.15, 1.77]
4 Angina - ALA	2	13516	Risk Ratio (M-H, Random, 95% CI)	1.41 [0.75, 2.64]
5 Revascularisation - ALA	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
5.1 CABG - ALA	1	266	Risk Ratio (M-H, Random, 95% CI)	0.29 [0.01, 5.93]
5.2 Angioplasty - ALA	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
5.3 Any revascularisation - ALA	1	266	Risk Ratio (M-H, Random, 95% CI)	0.72 [0.07, 7.84]
6 Peripheral arterial disease - ALA	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
7 Body weight, kg - ALA	4	664	Mean Difference (IV, Random, 95% CI)	-1.49 [-4.17, 1.18]
8 Weight, kg - ALA - sensitivity analysis (SA) fixed-effect	4	664	Mean Difference (IV, Fixed, 95% CI)	0.17 [-0.61, 0.96]
9 Weight, kg - ALA - SA by summary risk of bias	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
9.1 Low risk of bias	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
9.2 Moderate/high risk of bias	4	664	Mean Difference (IV, Random, 95% CI)	-1.49 [-4.17, 1.18]
10 Weight, kg - ALA - SA by compliance and study size	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
10.1 SA - low risk of compliance bias	3	629	Mean Difference (IV, Random, 95% CI)	-1.59 [-4.47, 1.30]
10.2 SA - 100+ randomised	3	629	Mean Difference (IV, Random, 95% CI)	-1.59 [-4.47, 1.30]
11 Weight, kg - ALA - subgroup by dose	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
11.1 ALA low < 5 g/d	3	485	Mean Difference (IV, Random, 95% CI)	-0.71 [-3.31, 1.90]
11.2 ALA high > 5 g/d	1	179	Mean Difference (IV, Random, 95% CI)	-4.20 [-7.61, -0.79]
12 Weight, kg - ALA - subgroup by intervention type	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
12.1 Dietary advice	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
12.2 Supplemental foods	3	526	Mean Difference (IV, Random, 95% CI)	-1.23 [-5.27, 2.80]
12.3 Supplement (capsule)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
12.4 Any combination	1	138	Mean Difference (IV, Random, 95% CI)	-1.98 [-5.89, 1.92]
13 Weight, kg - ALA - subgroup by replacement	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
13.1 ALA replacing SFA	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
13.2 ALA replacing MUFA	1	138	Mean Difference (IV, Random, 95% CI)	-1.98 [-5.89, 1.92]
13.3 ALA replacing n-6	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
13.4 ALA replacing carbs/sugars	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
13.5 ALA replacing nil/low n-3 placebo	1	35	Mean Difference (IV, Random, 95% CI)	-0.30 [-10.57, 9.97]
13.6 Replacement unclear	2	491	Mean Difference (IV, Random, 95% CI)	-1.43 [-6.26, 3.39]

14 Weight, kg - ALA - subgroup by duration	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
14.1 Medium duration 1 to < 2 years in study	4	664	Mean Difference (IV, Random, 95% CI)	-1.49 [-4.17, 1.18]
14.2 Medium-long duration: 2 to < 4 years in study	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
14.3 Long duration ≥ 4 years in study	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
15 Weight, kg - ALA - subgroup by statin use	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
15.1 ALA - ≥ 50% of control group on statins	1	35	Mean Difference (IV, Random, 95% CI)	-0.30 [-10.57, 9.97]
15.2 ALA - < 50% of control group on statins	1	138	Mean Difference (IV, Random, 95% CI)	-1.98 [-5.89, 1.92]
15.3 ALA - use of statins unclear	2	491	Mean Difference (IV, Random, 95% CI)	-1.43 [-6.26, 3.39]
16 Weight, kg - ALA - subgroup by primary or secondary prevention	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
16.1 Low CVD risk	3	629	Mean Difference (IV, Random, 95% CI)	-1.59 [-4.47, 1.30]
16.2 Moderate CVD risk	1	35	Mean Difference (IV, Random, 95% CI)	-0.30 [-10.57, 9.97]
16.3 High CVD risk	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
17 Body mass index, kg/m <sup>2</sup> - ALA	3	1581	Mean Difference (IV, Random, 95% CI)	-0.42 [-1.53, 0.69]
18 BMI, kg/m <sup>2</sup> - ALA - SA fixed-effect	3	1581	Mean Difference (IV, Fixed, 95% CI)	0.12 [-0.06, 0.30]
19 BMI, kg/m <sup>2</sup> - ALA - SA by summary risk of bias	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
19.1 Low risk of bias	2	1402	Mean Difference (IV, Random, 95% CI)	0.15 [-0.04, 0.33]
19.2 Moderate/high risk of bias	1	179	Mean Difference (IV, Random, 95% CI)	-1.5 [-2.86, -0.14]
20 BMI, kg/m <sup>2</sup> - ALA - SA by compliance and study size	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
20.1 SA - low risk of compliance bias	3	1581	Mean Difference (IV, Random, 95% CI)	-0.42 [-1.53, 0.69]
20.2 SA - 100+ randomised	3	1581	Mean Difference (IV, Random, 95% CI)	-0.42 [-1.53, 0.69]
21 BMI, kg/m <sup>2</sup> - ALA - subgroup by dose	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
21.1 ALA low < 5 g/d	1	1260	Mean Difference (IV, Random, 95% CI)	0.15 [-0.03, 0.33]
21.2 ALA high > 5 g/d	2	321	Mean Difference (IV, Random, 95% CI)	-1.12 [-2.24, 0.01]
22 BMI, kg/m <sup>2</sup> - ALA - subgroup by intervention type	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
22.1 Dietary advice	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
22.2 Supplemental foods	3	1581	Mean Difference (IV, Random, 95% CI)	-0.42 [-1.53, 0.69]
22.3 Supplement (capsule)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
22.4 Any combination	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
23 BMI, kg/m <sup>2</sup> - ALA - subgroup by replacement	3	1581	Mean Difference (IV, Random, 95% CI)	-0.42 [-1.53, 0.69]
23.1 ALA replacing SFA	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
23.2 ALA replacing MUFA	1	1260	Mean Difference (IV, Random, 95% CI)	0.15 [-0.03, 0.33]
23.3 ALA replacing n-6	1	142	Mean Difference (IV, Random, 95% CI)	-0.3 [-2.29, 1.69]

23.4 ALA replacing carbs/ sugars	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
23.5 ALA replacing nil/low n- 3 placebo	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
23.6 Replacement unclear	1	179	Mean Difference (IV, Random, 95% CI)	-1.5 [-2.86, -0.14]
24 BMI, kg/m <sup>2</sup> - ALA - subgroup by duration	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
24.1 Medium duration 1 to < 2 years in study	1	179	Mean Difference (IV, Random, 95% CI)	-1.5 [-2.86, -0.14]
24.2 Medium-long duration: 2 to < 4 years in study	2	1402	Mean Difference (IV, Random, 95% CI)	0.15 [-0.04, 0.33]
24.3 Long duration ≥ 4 years in study	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
25 BMI, kg/m <sup>2</sup> - ALA - subgroup by statin use	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
25.1 ALA - ≥ 50% of control group on statins	1	1260	Mean Difference (IV, Random, 95% CI)	0.15 [-0.03, 0.33]
25.2 ALA - < 50% of control group on statins	1	142	Mean Difference (IV, Random, 95% CI)	-0.3 [-2.29, 1.69]
25.3 ALA - use of statins unclear	1	179	Mean Difference (IV, Random, 95% CI)	-1.5 [-2.86, -0.14]
26 BMI, kg/m <sup>2</sup> - ALA - subgroup by primary or secondary preventionA	3		Mean Difference (IV, Random, 95% CI)	Subtotals only
26.1 Primary prevention of CVD	2	321	Mean Difference (IV, Random, 95% CI)	-1.12 [-2.24, 0.01]
26.2 Secondary prevention of CVD	1	1260	Mean Difference (IV, Random, 95% CI)	0.15 [-0.03, 0.33]
27 Other measures of adiposity - ALA	4		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
27.1 Visceral adipose tissue, cm <sup>2</sup>	1	35	Mean Difference (IV, Fixed, 95% CI)	27.0 [-21.28, 75.28]
27.2 Subcutaneous adipose tissue, cm <sup>2</sup>	1	35	Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
27.3 Waist circumference, cm	3	629	Mean Difference (IV, Fixed, 95% CI)	-1.59 [-3.10, -0.07]
28 Total cholesterol, serum, mmol/L - ALA	6	2164	Mean Difference (IV, Random, 95% CI)	-0.09 [-0.23, 0.05]
29 TC, mmol/L - ALA - SA fixed-effect	6	2164	Mean Difference (IV, Fixed, 95% CI)	-0.10 [-0.17, -0.03]
30 TC, mmol/L - ALA - SA by summary risk of bias	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
30.1 Low risk of bias	3	1436	Mean Difference (IV, Random, 95% CI)	0.00 [-0.13, 0.14]
30.2 Moderate/high risk of bias	3	728	Mean Difference (IV, Random, 95% CI)	-0.19 [-0.36, -0.01]
31 TC, mmol/L - ALA - SA by compliance and study size	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
31.1 SA - low risk of compliance bias	4	2045	Mean Difference (IV, Random, 95% CI)	-0.10 [-0.25, 0.05]
31.2 SA - 100+ randomised	4	2045	Mean Difference (IV, Random, 95% CI)	-0.10 [-0.25, 0.05]
32 TC, mmol/L - ALA - subgroup by dose	6		Mean Difference (IV, Random, 95% CI)	Subtotals only



32.1 ALA low < 5 g/d	3	1759	Mean Difference (IV, Random, 95% CI)	-0.07 [-0.24, 0.09]
32.2 ALA high > 5 g/d	3	405	Mean Difference (IV, Random, 95% CI)	-0.13 [-0.47, 0.21]
33 TC, mmol/L - ALA - subgroup by intervention type	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
33.1 Dietary advice	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
33.2 Supplemental foods	6	2164	Mean Difference (IV, Random, 95% CI)	-0.09 [-0.23, 0.05]
33.3 Supplement (capsule)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
33.4 Any combination	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
34 TC, mmol/L - ALA - subgroup by replacement	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
34.1 ALA replacing SFA	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
34.2 ALA replacing MUFA	1	1210	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.13, 0.09]
34.3 ALA replacing n-6	1	142	Mean Difference (IV, Random, 95% CI)	0.14 [-0.10, 0.38]
34.4 ALA replacing carbs/sugars	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
34.5 ALA replacing nil/low n-3 placebo	1	35	Mean Difference (IV, Random, 95% CI)	0.30 [-0.30, 0.90]
34.6 Replacement unclear	3	777	Mean Difference (IV, Random, 95% CI)	-0.21 [-0.31, -0.11]
35 TC, mmol/L - ALA - subgroup by duration	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
35.1 Medium duration 1 to < 2 years in study	4	812	Mean Difference (IV, Random, 95% CI)	-0.20 [-0.33, -0.07]
35.2 Medium-long duration: 2 to < 4 years in study	2	1352	Mean Difference (IV, Random, 95% CI)	0.02 [-0.12, 0.16]
35.3 Long duration ≥ 4 years in study	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
36 TC, mmol/L - ALA - subgroup by statin use	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
36.1 ALA - ≥ 50% of control group on statins	3	1329	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.15, 0.11]
36.2 ALA - < 50% of control group on statins	1	142	Mean Difference (IV, Random, 95% CI)	0.14 [-0.10, 0.38]
36.3 ALA - use of statins unclear	2	693	Mean Difference (IV, Random, 95% CI)	-0.21 [-0.30, -0.11]
37 TC, mmol/L - ALA - subgroup by primary or secondary preventionA	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
37.1 Primary prevention of CVD	4	870	Mean Difference (IV, Random, 95% CI)	-0.09 [-0.30, 0.12]
37.2 Secondary prevention of CVD	2	1294	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.14, 0.08]
38 Triglycerides, fasting, serum, mmol/L - ALA	6	1776	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.11, 0.05]
39 TG, fasting, mmol/L - ALA - SA fixed-effect	6	1776	Mean Difference (IV, Fixed, 95% CI)	-0.03 [-0.11, 0.05]
40 TG, fasting, mmol/L - ALA - SA by summary risk of bias	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
40.1 Low risk of bias	3	1436	Mean Difference (IV, Random, 95% CI)	0.03 [-0.13, 0.19]
40.2 Moderate/high risk of bias	3	340	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.18, 0.09]



41 TG, fasting, mmol/L- ALA - SA by compliance and study size	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
41.1 SA - low risk of compliance bias	4	1657	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.13, 0.04]
41.2 SA - 100+ randomised	4	1657	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.13, 0.04]
42 TG, fasting, mmol/L - ALA - subgroup by dose	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
42.1 ALA low < 5 g/d	3	1371	Mean Difference (IV, Random, 95% CI)	-0.07 [-0.16, 0.03]
42.2 ALA high > 5 g/d	3	405	Mean Difference (IV, Random, 95% CI)	0.05 [-0.09, 0.19]
43 TG, fasting, mmol/L- ALA - subgroup by intervention type	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
43.1 Dietary advice	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
43.2 Supplemental foods	5	1650	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.10, 0.07]
43.3 Supplement (capsule)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
43.4 Any combination	1	126	Mean Difference (IV, Random, 95% CI)	-0.12 [-0.33, 0.09]
44 TG, fasting, mmol/L-AL - subgroup by replacementA	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
44.1 ALA replacing SFA	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
44.2 ALA replacing MUFA	2	1336	Mean Difference (IV, Random, 95% CI)	-0.07 [-0.17, 0.02]
44.3 ALA replacing n-6	1	142	Mean Difference (IV, Random, 95% CI)	0.13 [-0.16, 0.42]
44.4 ALA replacing carbs/sugars	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
44.5 ALA replacing nil/low n-3 placebo	1	35	Mean Difference (IV, Random, 95% CI)	0.30 [-0.39, 0.99]
44.6 Replacement unclear	2	263	Mean Difference (IV, Random, 95% CI)	0.04 [-0.15, 0.23]
45 TG, fasting, mmol/L- ALA - subgroup by duration	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
45.1 Medium duration 1 to < 2 years in study	4	424	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.15, 0.12]
45.2 Medium-long duration: 2 to < 4 years in study	2	1352	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.17, 0.15]
45.3 Long duration ≥ 4 years in study	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
46 TG, fasting, mmol/L - ALA - subgroup by statin use	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
46.1 ALA - ≥ 50% of control group on statins	3	1329	Mean Difference (IV, Random, 95% CI)	0.03 [-0.17, 0.23]
46.2 ALA - < 50% of control group on statins	2	268	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.26, 0.23]
46.3 ALA - use of statins unclear	1	179	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.20, 0.16]
47 TG, fasting, mmol/L- ALA - subgroup by primary or secondary prevention	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
47.1 Primary prevention	4	482	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.14, 0.11]
47.2 Secondary prevention	2	1294	Mean Difference (IV, Random, 95% CI)	0.02 [-0.22, 0.25]
48 High-density lipoprotein, serum, mmol/L - ALA	6	1776	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.08, 0.03]
49 HDL, mmol/L - ALA - SA fixed-effect	6	1776	Mean Difference (IV, Fixed, 95% CI)	-0.02 [-0.05, 0.00]

50 HDL, mmol/L - ALA - SA by summary risk of bias	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
50.1 Low risk of bias	3	1436	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.06, 0.00]
50.2 Moderate/high risk of bias	3	340	Mean Difference (IV, Random, 95% CI)	0.04 [-0.14, 0.22]
51 HDL, mmol/L - ALA - SA by compliance and study size	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
51.1 SA - low risk of compliance bias	4	1657	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.08, 0.04]
51.2 SA - 100+ randomised	4	1657	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.08, 0.04]
52 HDL, mmol/L - ALA - subgroup by dose	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
52.1 ALA low < 5 g/d	3	1371	Mean Difference (IV, Random, 95% CI)	0.06 [-0.08, 0.19]
52.2 ALA high > 5 g/d	3	405	Mean Difference (IV, Random, 95% CI)	-0.07 [-0.12, -0.01]
53 HDL, mmol/L - ALA - subgroup by intervention type	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
53.1 Dietary advice	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
53.2 Supplemental foods	5	1650	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.06, -0.00]
53.3 Supplement (capsule)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
53.4 Any combination	1	126	Mean Difference (IV, Random, 95% CI)	0.15 [0.01, 0.29]
54 HDL, mmol/L - ALA - subgroup by replacement	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
54.1 ALA replacing SFA	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
54.2 ALA replacing MUFA	2	1336	Mean Difference (IV, Random, 95% CI)	0.05 [-0.11, 0.22]
54.3 ALA replacing n-6	1	142	Mean Difference (IV, Random, 95% CI)	-0.04 [-0.11, 0.03]
54.4 ALA replacing carbs/sugars	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
54.5 ALA replacing nil/low n-3 placebo	1	35	Mean Difference (IV, Random, 95% CI)	0.10 [-0.17, 0.37]
54.6 Replacement unclear	2	263	Mean Difference (IV, Random, 95% CI)	-0.09 [-0.17, -0.02]
55 HDL, mmol/L - ALA - subgroup by duration	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
55.1 Medium duration 1 to < 2 years in study	4	424	Mean Difference (IV, Random, 95% CI)	-0.00 [-0.13, 0.13]
55.2 Medium-long duration: 2 to < 4 years in study	2	1352	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.05, 0.00]
55.3 Long duration ≥ 4 years in study	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
56 HDL, mmol/L - ALA - subgroup by statin use	6		Mean Difference (IV, Random, 95% CI)	Subtotals only
56.1 ALA - ≥ 50% of control group on statins	3	1329	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.09, 0.03]
56.2 ALA - < 50% of control group on statins	2	268	Mean Difference (IV, Random, 95% CI)	0.05 [-0.14, 0.23]
56.3 ALA - use of statins unclear	1	179	Mean Difference (IV, Random, 95% CI)	-0.09 [-0.20, 0.02]
57 HDL, mmol/L - ALA - subgroup by primary or secondary prevention	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
57.1 Low CVD risk	2	305	Mean Difference (IV, Random, 95% CI)	0.03 [-0.21, 0.26]
57.2 Moderate CVD risk	2	177	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.10, 0.04]

57.3 High CVD risk	3	1368	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.08, 0.03]
58 Low-density lipoprotein, serum, mmol/L - ALA	7	2201	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.15, 0.04]
59 LDL, mmol/L - ALA - SA fixed-effect	7	2201	Mean Difference (IV, Fixed, 95% CI)	-0.05 [-0.11, 0.00]
60 LDL, mmol/L - ALA - SA by summary risk of bias	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
60.1 Low risk of bias	3	1350	Mean Difference (IV, Random, 95% CI)	0.02 [-0.05, 0.10]
60.2 Moderate/high risk of bias	4	851	Mean Difference (IV, Random, 95% CI)	-0.14 [-0.22, -0.06]
61 LDL, mmol/L - ALA - SA by compliance and study size	5		Mean Difference (IV, Random, 95% CI)	Subtotals only
61.1 SA - low risk of compliance bias	5	2085	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.16, 0.06]
61.2 SA - 100+ randomised	5	2085	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.16, 0.06]
62 LDL, mmol/L - ALA - subgroup by dose	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
62.1 ALA low < 5 g/d	4	1796	Mean Difference (IV, Random, 95% CI)	-0.06 [-0.17, 0.05]
62.2 ALA high > 5 g/d	3	405	Mean Difference (IV, Random, 95% CI)	-0.04 [-0.28, 0.19]
63 LDL, mmol/L - ALA - subgroup by intervention type	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
63.1 Dietary advice	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
63.2 Supplemental foods	6	2075	Mean Difference (IV, Random, 95% CI)	-0.06 [-0.17, 0.05]
63.3 Supplement (capsule)	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
63.4 Any combination	1	126	Mean Difference (IV, Random, 95% CI)	0.0 [-0.25, 0.25]
64 LDL, mmol/L - ALA - subgroup by replacement	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
64.1 ALA replacing SFA	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
64.2 ALA replacing MUFA	2	1250	Mean Difference (IV, Random, 95% CI)	0.01 [-0.07, 0.09]
64.3 ALA replacing n-6	1	142	Mean Difference (IV, Random, 95% CI)	0.14 [-0.08, 0.36]
64.4 ALA replacing carbs/sugars	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
64.5 ALA replacing nil/low n-3 placebo	1	32	Mean Difference (IV, Random, 95% CI)	-0.10 [-0.59, 0.39]
64.6 Replacement unclear	3	777	Mean Difference (IV, Random, 95% CI)	-0.16 [-0.24, -0.07]
65 LDL, mmol/L - ALA - subgroup by duration	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
65.1 Medium duration 1 to < 2 years in study	5	935	Mean Difference (IV, Random, 95% CI)	-0.14 [-0.22, -0.06]
65.2 Medium-long duration: 2 to < 4 years in study	2	1266	Mean Difference (IV, Random, 95% CI)	0.03 [-0.06, 0.13]
65.3 Long duration ≥ 4 years in study	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
66 LDL, mmol/L - ALA - subgroup by statin use	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
66.1 ALA - ≥ 50% of control group on statins	3	1240	Mean Difference (IV, Random, 95% CI)	0.00 [-0.08, 0.08]
66.2 ALA - < 50% of control group on statins	2	268	Mean Difference (IV, Random, 95% CI)	0.08 [-0.09, 0.24]
66.3 ALA - use of statins unclear	2	693	Mean Difference (IV, Random, 95% CI)	-0.16 [-0.25, -0.07]

67 LDL, mmol/L - ALA - subgroup by primary or secondary prevention	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
67.1 Primary prevention of CVD	5	993	Mean Difference (IV, Random, 95% CI)	-0.08 [-0.20, 0.05]
67.2 Secondary prevention of CVD	2	1208	Mean Difference (IV, Random, 95% CI)	0.01 [-0.08, 0.09]

### Comparison 6. High vs low ALA omega-3 fats (tertiary outcomes)


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Blood pressure, mmHg - ALA	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
1.1 Systolic BP - ALA	4	1671	Mean Difference (IV, Random, 95% CI)	-0.87 [-4.48, 2.75]
1.2 Diastolic BP - ALA	4	1671	Mean Difference (IV, Random, 95% CI)	-1.42 [-4.40, 1.57]
2 Serious adverse events - ALA	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Any serious adverse events	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2.2 Bleeding	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2.3 GI hospitalisation	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2.4 Pulmonary embolus or DVT	1	708	Risk Ratio (M-H, Random, 95% CI)	0.32 [0.01, 7.80]
2.5 Thrombophlebitis	1	13406	Risk Ratio (M-H, Random, 95% CI)	1.59 [0.72, 3.51]
2.6 Urolithiasis	1	13406	Risk Ratio (M-H, Random, 95% CI)	0.80 [0.47, 1.36]
3 Side effects - ALA	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
3.1 Dropouts due to side effects	5	3480	Risk Ratio (M-H, Random, 95% CI)	2.10 [0.66, 6.71]
3.2 Abdominal pain or discomfort	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
3.3 Diarrhoea	1	708	Risk Ratio (M-H, Random, 95% CI)	3.82 [0.82, 17.88]
3.4 Nausea	1	110	Risk Ratio (M-H, Random, 95% CI)	6.29 [0.33, 118.93]
3.5 Any gastrointestinal side effect - ALA	4	3450	Risk Ratio (M-H, Random, 95% CI)	2.06 [0.62, 6.80]
3.6 Pain (joint, lumbar, muscle pain)	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
3.7 All side effects combined	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
4 Dropouts - ALA	6	3663	Risk Ratio (M-H, Random, 95% CI)	1.08 [0.92, 1.25]

# **Analysis 1.1. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 1 All-cause mortality (overall) - LCn3.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 1 All-cause mortality (overall) - LCn3



(Continued ...)

(... Continued)




(1) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA

## Analysis 1.2. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 2 All-cause mortality - LCn3 - sensitivity analysis (SA) fixed-effect.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 2 All-cause mortality - LCn3 - sensitivity analysis (SA) fixed-effect



(Continued ...)



(1) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA




### Analysis 1.3. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 3 All-cause mortality - LCn3 - SA by summary risk of bias.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 3 All-cause mortality - LCn3 - SA by summary risk of bias



(Continued ...)




(1) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA

# **Analysis 1.4. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 4 All-cause mortality - LCn3 - SA by compliance and study size.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)


Outcome: 4 All-cause mortality - LCn3 - SA by compliance and study size



(Continued ...)



(Continued . . .)




- (1) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA
- (2) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA

# **Analysis 1.5. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 5 All-cause mortality - LCn3 - subgroup by dose.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 5 All-cause mortality - LCn3 - subgroup by dose



(Continued . . .)





(I) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA




## Analysis 1.6. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 6 All-cause mortality - LCn3 - subgroup by replacement.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 6 All-cause mortality - LCn3 - subgroup by replacement



(Continued ...)






(I) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA

# **Analysis 1.7. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 7 All-cause mortality - LCn3 - subgroup by intervention type.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 7 All-cause mortality - LCn3 - subgroup by intervention type



(Continued ...)






(1) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA

### Analysis 1.8. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 8 All-cause mortality - LCn3 - subgroup by duration.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 8 All-cause mortality - LCn3 - subgroup by duration



(Continued . . .)





(1) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA




# **Analysis 1.9. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 9 All-cause mortality - LCn3 - subgroup by primary or secondary prevention.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 9 All-cause mortality - LCn3 - subgroup by primary or secondary prevention



(Continued ...)




(1) AlphaOmega - comparing EPA+DHA    ALA with no EPA+DHA    ALA

# **Analysis 1.10. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 10 All-cause mortality - LCn3 - subgroup by statin use.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 10 All-cause mortality - LCn3 - subgroup by statin use



(Continued ...)

(... Continued)




(1) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA

### Analysis 1.11. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 11 Cardiovascular mortality (overall) - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 11 Cardiovascular mortality (overall) - LCn3



(Continued ...)

(... Continued)




- (1) Cardiac death
- (2) Cardiac death
- (3) Cardiac death
- (4) Cardiac death
- (5) Cardiac death

# **Analysis 1.12. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 12 CVD mortality - LCn3 - SA fixed-effect.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 12 CVD mortality - LCn3 - SA fixed-effect



(Continued ...)




### Analysis 1.13. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 13 CVD mortality - LCn3 - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 13 CVD mortality - LCn3 - SA by summary risk of bias



(Continued . . .)






### Analysis 1.14. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 14 CVD mortality - LCn3 - SA by compliance and study size.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 14 CVD mortality - LCn3 - SA by compliance and study size



(Continued ...)




### Analysis 1.15. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 15 CVD mortality - LCn3 - subgroup by dose.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 15 CVD mortality - LCn3 - subgroup by dose



(Continued . . .)




# **Analysis 1.16. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 16 CVD mortality - LCn3 - subgroup by replacement.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 16 CVD mortality - LCn3 - subgroup by replacement



(Continued ...)




### Analysis 1.17. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 17 CVD mortality - LCn3 - subgroup by intervention type.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 17 CVD mortality - LCn3 - subgroup by intervention type



(Continued ...)






# **Analysis 1.18. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 18 CVD mortality - LCn3 - subgroup by duration.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 18 CVD mortality - LCn3 - subgroup by duration



(Continued ...)




# **Analysis 1.19. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 19 CVD mortality - LCn3 - subgroup by primary or secondary prevention.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 19 CVD mortality - LCn3 - subgroup by primary or secondary prevention



(Continued ...)




## Analysis 1.20. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 20 CVD mortality - LCn3 - subgroup by statin uses.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 20 CVD mortality - LCn3 - subgroup by statin uses



(Continued ...)




### Analysis 1.21. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 21 Cardiovascular events (overall) - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)


Outcome: 21 Cardiovascular events (overall) - LCn3



(Continued ...)



(... Continued)



(1) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA

(2) Higher EPA vs lower EPA

(3) CHD events

(4) CVD death data used

(5) CV death used

(6) Cardiac death data

(7) CV mortality data


(8) Cardiac adverse event

## Analysis 1.22. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 22 CVD events - LCn3 - SA fixed-effect.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 22 CVD events - LCn3 - SA fixed-effect



(Continued ...)



(1) AlphaOmega - comparing EPA+DHA   ALA with no EPA+DHA   ALA

(2) CHD events

(3) CVD death data used

(4) CV death used

(5) Cardiac death data

(6) CV mortality data


(7) Cardiac adverse event

### Analysis 1.23. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 23 CVD events - LCn3 - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 23 CVD events - LCn3 - SA by summary risk of bias



(Continued ...)

(... Continued)




- (1) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA
- (2) Cardiac adverse event
- (3) CHD events
- (4) CVD death data used
- (5) CV death used
- (6) Cardiac death data
- (7) CV mortality data

#### Analysis 1.24. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 24 CVD events - LCn3 - SA by compliance and study size.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)


Outcome: 24 CVD events - LCn3 - SA by compliance and study size



(Continued ...)



(Continued . . .)



- (1) AlphaOmega - comparing EPA+DHA   ALA with no EPA+DHA   ALA
- (2) CVD death data used
- (3) Cardiac death data
- (4) CV mortality data
- (5) AlphaOmega - comparing EPA+DHA   ALA with no EPA+DHA   ALA
- (6) CHD events
- (7) Cardiac death data
- (8) Cardiac adverse event




## Analysis 1.25. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 25 CVD events - LCn3 - subgroup by dose.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 25 CVD events - LCn3 - subgroup by dose



(Continued . . .)





(1) AlphaOmega - comparing EPA+DHA   ALA with no EPA+DHA   ALA

(2) CHD events

(3) CVD death data used

(4) CV death used

(5) Cardiac death data

(6) CV mortality data


(7) Cardiac adverse event

## Analysis 1.26. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 26 CVD events - LCn3 - subgroup by replacement.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 26 CVD events - LCn3 - subgroup by replacement



(Continued ...)





(1) AlphaOmega - comparing EPA+DHA   ALA with no EPA+DHA   ALA

(2) Cardiac death data

(3) Cardiac adverse event

(4) CV mortality data

(5) Cardiac adverse event

(6) CHD events

(7) CVD death data used


(8) CV death used

## Analysis 1.27. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 27 CVD events - LCn3 - subgroup by intervention type.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)


Outcome: 27 CVD events - LCn3 - subgroup by intervention type



(Continued ...)








## Analysis 1.28. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 28 CVD events - LCn3 - subgroup by duration.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 28 CVD events - LCn3 - subgroup by duration



(Continued ...)

(... Continued)




- (1) CVD death data used
- (2) CV death used
- (3) CV mortality data
- (4) Cardiac adverse event
- (5) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA
- (6) Cardiac death data
- (7) CHD events

### Analysis 1.29. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 29 CVD events - LCn3 - subgroup by primary or secondary prevention.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 29 CVD events - LCn3 - subgroup by primary or secondary prevention



(Continued ...)





(1) High EPA vs low EPA

(2) CHD events

(3) CV mortality data

(4) AlphaOmega - comparing EPA+DHA   ALA with no EPA+DHA   ALA

(5) CVD death data used

(6) CV death used

(7) Cardiac death data


(8) Cardiac adverse event

### Analysis 1.30. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 30 CVD events - LCn3 - subgroup by statin use.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 30 CVD events - LCn3 - subgroup by statin use



(Continued ...)

(... Continued)






- (1) AlphaOmega - comparing EPA+DHA ALA with no EPA+DHA ALA
- (2) CHD events
- (3) CVD death data used
- (4) Cardiac death data
- (5) CV mortality data
- (6) Cardiac adverse event
- (7) CV death used

### Analysis 1.31. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 31 Coronary heart disease mortality (overall) - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 31 Coronary heart disease mortality (overall) - LCn3



(Continued ...)

(... Continued)




- (1) Fatal MI
- (2) Fatal MI
- (3) Cardiac deaths
- (4) Fatal MI
- (5) Fatal MI
- (6) Fatal MI/ sudden death
- (7) Cardiac deaths
- (8) Fatal MI
- (9) Cardiac deaths
- (10) Cardiac death
- (11) Fatal MI
- (12) Fatal MI
- (13) Cardiac death
- (14) Fatal MI

### Analysis 1.32. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 32 CHD mortality - LCn3 - SA fixed-effect.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 32 CHD mortality - LCn3 - SA fixed-effect




- (1) Fatal MI
- (2) Fatal MI
- (3) Cardiac deaths
- (4) Fatal MI
- (5) Fatal MI
- (6) Fatal MI/ sudden death
- (7) Cardiac deaths
- (8) Fatal MI
- (9) Cardiac deaths
- (10) Cardiac death
- (11) Fatal MI
- (12) Fatal MI
- (13) Cardiac death
- (14) Fatal MI

### Analysis 1.33. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 33 CHD mortality - LCn3 - SA by summary risk of bias.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 33 CHD mortality - LCn3 - SA by summary risk of bias



(Continued ...)




- (1) Fatal MI
- (2) Fatal MI
- (3) Cardiac death
- (4) Fatal MI
- (5) Cardiac death
- (6) Fatal MI
- (7) Fatal MI
- (8) Cardiac deaths
- (9) Fatal MI
- (10) Fatal MI/ sudden death
- (11) Cardiac deaths
- (12) Fatal MI
- (13) Cardiac deaths
- (14) Fatal MI

### Analysis 1.34. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 34 CHD mortality - LCn3 - SA by compliance and study size.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 34 CHD mortality - LCn3 - SA by compliance and study size



(Continued ...)

(... Continued)






- (1) Fatal MI
- (2) Fatal MI
- (3) Cardiac death
- (4) Fatal MI
- (5) Fatal MI
- (6) Fatal MI
- (7) Fatal MI
- (8) Fatal MI
- (9) Cardiac deaths
- (10) Fatal MI
- (11) Fatal MI
- (12) Fatal MI/ sudden death
- (13) Cardiac deaths
- (14) Fatal MI
- (15) Cardiac deaths
- (16) Cardiac death
- (17) Fatal MI
- (18) Fatal MI
- (19) Cardiac death
- (20) Fatal MI

### Analysis 1.35. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 35 CHD mortality - LCn3 - SA omitting cardiac death.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 35 CHD mortality - LCn3 - SA omitting cardiac death



(Continued ...)




### Analysis 1.36. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 36 CHD mortality - LCn3 - subgroup by dose.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 36 CHD mortality - LCn3 - subgroup by dose



(Continued . . .)

(... Continued)




- (1) Cardiac deaths
- (2) Fatal MI
- (3) Fatal MI
- (4) Fatal MI
- (5) Fatal MI/ sudden death
- (6) Fatal MI
- (7) Cardiac death
- (8) Fatal MI
- (9) Fatal MI
- (10) Cardiac death
- (11) Fatal MI
- (12) Fatal MI
- (13) Cardiac deaths
- (14) Cardiac deaths

### Analysis 1.37. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 37 CHD mortality - LCn3 - subgroup by replacement.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 37 CHD mortality - LCn3 - subgroup by replacement



(Continued ...)

(... Continued)






- (1) Fatal MI
- (2) Fatal MI
- (3) Cardiac deaths
- (4) Fatal MI
- (5) Cardiac death
- (6) Fatal MI
- (7) Cardiac death
- (8) Fatal MI
- (9) Cardiac deaths
- (10) Cardiac death
- (11) Fatal MI
- (12) Fatal MI
- (13) Fatal MI
- (14) Fatal MI/ sudden death
- (15) Fatal MI
- (16) Fatal MI
- (17) Cardiac deaths

### Analysis 1.38. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 38 CHD mortality - LCn3 - subgroup by intervention type.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 38 CHD mortality - LCn3 - subgroup by intervention type



(Continued ...)




### Analysis 1.39. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 39 CHD mortality - LCn3 - subgroup by duration.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 39 CHD mortality - LCn3 - subgroup by duration



(Continued ...)




- (1) Fatal MI
- (2) Fatal MI
- (3) Fatal MI/ sudden death
- (4) Cardiac deaths
- (5) Cardiac death
- (6) Fatal MI
- (7) Cardiac death
- (8) Fatal MI
- (9) Fatal MI
- (10) Cardiac deaths
- (11) Fatal MI
- (12) Fatal MI
- (13) Cardiac deaths
- (14) Fatal MI

# **Analysis 1.40. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 40 CHD mortality - LCn3 - subgroup by primary or secondary prevention.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 40 CHD mortality - LCn3 - subgroup by primary or secondary prevention



(Continued ...)




- (1) Fatal MI
- (2) Fatal MI
- (3) Fatal MI
- (4) Fatal MI
- (5) Cardiac deaths
- (6) Fatal MI/ sudden death
- (7) Cardiac deaths
- (8) Fatal MI
- (9) Cardiac deaths
- (10) Cardiac death
- (11) Fatal MI
- (12) Fatal MI
- (13) Cardiac death
- (14) Fatal MI

### Analysis 1.41. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 41 CHD mortality - LCn3 - subgroup by statin use.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 41 CHD mortality - LCn3 - subgroup by statin use



(Continued ...)






- (1) Fatal MI/ sudden death
- (2) Cardiac death
- (3) Fatal MI
- (4) Fatal MI
- (5) Fatal MI
- (6) Cardiac deaths
- (7) Fatal MI
- (8) Cardiac deaths
- (9) Fatal MI
- (10) Cardiac deaths
- (11) Fatal MI
- (12) Fatal MI
- (13) Cardiac death
- (14) Fatal MI

# **Analysis 1.42. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 42 CHD mortality - LCn3 - subgroup by CAD history.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 42 CHD mortality - LCn3 - subgroup by CAD history



(Continued ...)



(1) Cardiac deaths

(2) Fatal MI

(3) Cardiac deaths

(4) Cardiac death

(5) Fatal MI

(6) Fatal MI

(7) Fatal MI

(8) Fatal MI

(9) Fatal MI

(10) Fatal MI

(11) Fatal MI

(12) Cardiac deaths

(13) Fatal MI


(14) Cardiac death

### Analysis 1.43. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 43 Coronary heart disease events (overall) - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 43 Coronary heart disease events (overall) - LCn3



(Continued ...)

(... Continued)




- (1) Total MI
- (2) Total MI
- (3) Total MI
- (4) Total MI
- (5) Total MI
- (6) Angina
- (7) Total MI
- (8) Total MI
- (9) Acute coronary syndrome
- (10) Total MI
- (11) Angina
- (12) Fatal or non fatal cardiac event
- (13) Total MI
- (14) Total MI
- (15) Total MI
- (16) Total MI
- (17) Total MI
- (18) Total MI

#### Analysis 1.44. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 44 CHD events - LCn3 - SA fixed-effect.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 44 CHD events - LCn3 - SA fixed-effect



(Continued ...)




- (1) Total MI
- (2) Total MI
- (3) Total MI
- (4) Total MI
- (5) Total MI
- (6) Angina
- (7) Total MI
- (8) Total MI
- (9) Acute coronary syndrome
- (10) Total MI
- (11) Angina
- (12) Fatal or non fatal cardiac event
- (13) Total MI
- (14) Total MI
- (15) Total MI
- (16) Total MI
- (17) Total MI

# **Analysis 1.45. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 45 CHD events - LCn3 - SA by summary risk of bias.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)


Outcome: 45 CHD events - LCn3 - SA by summary risk of bias



(Continued ...)



(... Continued)




- (1) Total MI
- (2) Total MI
- (3) Total MI
- (4) Acute coronary syndrome
- (5) Total MI
- (6) Total MI
- (7) Total MI
- (8) Total MI
- (9) Total MI
- (10) Total MI
- (11) Total MI
- (12) Total MI
- (13) Angina
- (14) Total MI
- (15) Angina
- (16) Fatal or non fatal cardiac event
- (17) Total MI
- (18) Total MI

# **Analysis 1.46. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 46 CHD events - LCn3 - SA by compliance and study size.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 46 CHD events - LCn3 - SA by compliance and study size



(Continued ...)

(... Continued)




- (1) Total MI
- (2) Total MI
- (3) Total MI
- (4) Angina
- (5) Acute coronary syndrome
- (6) Total MI
- (7) Total MI
- (8) Total MI
- (9) Total MI
- (10) Total MI
- (11) Total MI
- (12) Total MI
- (13) Angina
- (14) Total MI
- (15) Total MI
- (16) Acute coronary syndrome
- (17) Total MI
- (18) Fatal or non fatal cardiac event
- (19) Total MI
- (20) Total MI
- (21) Total MI
- (22) Total MI
- (23) Total MI
- (24) Total MI

# **Analysis 1.47. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 47 CHD events - LCn3 - subgroup by dose.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 47 CHD events - LCn3 - subgroup by dose



(Continued . . .)

(... Continued)



- (1) Total MI
- (2) Total MI
- (3) Total MI
- (4) Total MI
- (5) Angina (EPE-A low)
- (6) Total MI
- (7) Total MI
- (8) Total MI
- (9) Angina
- (10) Total MI
- (11) Total MI
- (12) Total MI
- (13) Total MI
- (14) Angina (EPE-A high)
- (15) Fatal or non fatal cardiac event
- (16) Total MI
- (17) Acute coronary syndrome
- (18) Total MI




# **Analysis 1.48. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 48 CHD events - LCn3 - subgroup by replacement.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 48 CHD events - LCn3 - subgroup by replacement



(Continued ...)

(... Continued)




- (1) Total MI
- (2) Total MI
- (3) Total MI
- (4) Total MI
- (5) Total MI
- (6) Angina
- (7) Total MI
- (8) Total MI
- (9) Total MI
- (10) Total MI
- (11) Fatal or non fatal cardiac event
- (12) Total MI
- (13) Total MI
- (14) Total MI
- (15) Total MI
- (16) Acute coronary syndrome
- (17) Total MI
- (18) Angina

# **Analysis 1.49. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 49 CHD events - LCn3 - subgroup by intervention type.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 49 CHD events - LCn3 - subgroup by intervention type



(Continued ...)

(... Continued)




- (1) Acute coronary syndrome
- (2) Total MI
- (3) Total MI
- (4) Total MI
- (5) Total MI
- (6) Total MI
- (7) Angina
- (8) Total MI
- (9) Total MI
- (10) Total MI
- (11) Angina
- (12) Fatal or non fatal cardiac event
- (13) Total MI
- (14) Total MI
- (15) Total MI
- (16) Total MI
- (17) Total MI

# **Analysis 1.50. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 50 CHD events - LCn3 - subgroup by duration.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 50 CHD events - LCn3 - subgroup by duration



(Continued ...)

(... Continued)






- (1) Total MI
- (2) Total MI
- (3) Angina
- (4) Total MI
- (5) Total MI
- (6) Angina
- (7) Total MI
- (8) Total MI
- (9) Total MI
- (10) Total MI
- (11) Acute coronary syndrome
- (12) Total MI
- (13) Fatal or non fatal cardiac event
- (14) Total MI
- (15) Total MI
- (16) Total MI
- (17) Total MI

# **Analysis 1.51. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 51 CHD events - LCn3 - subgroup by primary or secondary prevention.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 51 CHD events - LCn3 - subgroup by primary or secondary prevention



(Continued ...)

(... Continued)




- (1) Total MI
- (2) Total MI
- (3) Total MI
- (4) Total MI
- (5) Angina
- (6) Total MI
- (7) Acute coronary syndrome
- (8) Total MI
- (9) Total MI
- (10) Total MI
- (11) Total MI
- (12) Total MI
- (13) Angina
- (14) Fatal or non fatal cardiac event
- (15) Total MI
- (16) Total MI
- (17) Total MI

## Analysis 1.52. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 52 CHD events - LCn3 - subgroup by statin use.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 52 CHD events - LCn3 - subgroup by statin use



(Continued ...)

(... Continued)




- (1) Total MI
- (2) Angina
- (3) Total MI
- (4) Total MI
- (5) Total MI
- (6) Total MI
- (7) Total MI
- (8) Total MI
- (9) Acute coronary syndrome
- (10) Total MI
- (11) Fatal or non fatal cardiac event
- (12) Total MI
- (13) Total MI
- (14) Total MI
- (15) Total MI
- (16) Angina
- (17) Total MI

### Analysis 1.53. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 53 CHD events - LCn3 subgroup by CAD history.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)


Outcome: 53 CHD events - LCn3 subgroup by CAD history



(Continued ...)



(... Continued)




- (1) Total MI
- (2) Angina
- (3) Fatal or non fatal cardiac event
- (4) Total MI
- (5) Total MI
- (6) Total MI
- (7) Total MI
- (8) Total MI
- (9) Total MI
- (10) Angina
- (11) Total MI
- (12) Total MI
- (13) Acute coronary syndrome
- (14) Total MI
- (15) Total MI
- (16) Total MI
- (17) Total MI
- (18) Total MI

# **Analysis 1.54. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 54 Stroke (overall) - LCn3.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 54 Stroke (overall) - LCn3



(Continued ...)

(... Continued)




### Analysis 1.55. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 55 Stroke - LCn3 - SA fixed-effect.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 55 Stroke - LCn3 - SA fixed-effect



(Continued ...)




### Analysis 1.56. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 56 Stroke - LCn3 - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 56 Stroke - LCn3 - SA by summary risk of bias



(Continued . . .)

(... Continued)




### Analysis 1.57. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 57 Stroke - LCn3 - SA by compliance and study size.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 57 Stroke - LCn3 - SA by compliance and study size



(Continued ...)






### Analysis 1.58. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 58 Stroke - LCn3 - subgroup by stroke type.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 58 Stroke - LCn3 - subgroup by stroke type



(Continued ...)




### Analysis 1.59. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 59 Stroke - LCn3 - subgroup by dose.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 59 Stroke - LCn3 - subgroup by dose



(Continued ...)





# **Analysis 1.60. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 60 Stroke - LCn3 - subgroup by replacement.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 60 Stroke - LCn3 - subgroup by replacement






# **Analysis 1.61. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 61 Stroke - LCn3 - subgroup by intervention type.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 61 Stroke - LCn3 - subgroup by intervention type



(Continued ...)






## Analysis 1.62. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 62 Stroke - LCn3 - subgroup by duration.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 62 Stroke - LCn3 - subgroup by duration



(Continued ...)




### Analysis 1.63. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 63 Stroke - LCn3 - subgroup by primary or secondary prevention.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 63 Stroke - LCn3 - subgroup by primary or secondary prevention



(Continued ...)




# **Analysis 1.64. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 64 Stroke - LCn3 - subgroup by statin use.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 64 Stroke - LCn3 - subgroup by statin use



(Continued ...)




### Analysis 1.65. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 65 Arrhythmia (overall) - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)


Outcome: 65 Arrhythmia (overall) - LCn3



(Continued ...)



(... Continued)




(I) ICD therapy for VT/VF

# **Analysis 1.66. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 66 Arrhythmia-LCn3 - SA fixed-effect.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 66 Arrhythmia- LCn3 - SA fixed-effect



(Continued ...)




(I) ICD therapy for VT/VF

### Analysis 1.67. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 67 Arrhythmia-LCn3 - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 67 Arrhythmia- LCn3 - SA by summary risk of bias



(Continued . . .)

(... Continued)




(1) ICD therapy for VT/VF

# **Analysis 1.68. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 68 Arrhythmia-LCn3 - SA by compliance and study size.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 68 Arrhythmia- LCn3 - SA by compliance and study size



(Continued ...)



(1) ICD therapy for VT/VF


(2) ICD therapy for VT/VF

# **Analysis 1.69. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 69 Arrhythmia - LCn3 - subgroup by new or recurrent.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 69 Arrhythmia - LCn3 - subgroup by new or recurrent



(Continued ...)



(1) ICD therapy for VT/VF




# **Analysis 1.70. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 70 Arrhythmia - LCn3 - subgroup by fatality.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 70 Arrhythmia - LCn3 - subgroup by fatality



(Continued ...)




# **Analysis 1.71. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 71 Arrhythmia - LCn3 - subgroup by dose.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)


Outcome: 71 Arrhythmia - LCn3 - subgroup by dose



(Continued . . .)



(Continued . . .)




(I) ICD therapy for VT/VF

## Analysis 1.72. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 72 Arrhythmia - LCn3 - subgroup by replacement.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)


Outcome: 72 Arrhythmia - LCn3 - subgroup by replacement



(Continued ...)



(Continued . . .)



(1) new arrhythmia


(2) ICD therapy for VT/VF

# **Analysis 1.73. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 73 Arrhythmia - LCn3 - subgroup by intervention type.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 73 Arrhythmia - LCn3 - subgroup by intervention type



(Continued ...)






(1) ICD therapy for VT/VF

# **Analysis 1.74. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 74 Arrhythmia - LCn3 - subgroup by duration.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 74 Arrhythmia - LCn3 - subgroup by duration



(Continued ...)




(1) ICD therapy for VT/VF

# **Analysis 1.75. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 75 Arrhythmia - LCn3 - subgroup by primary or secondary prevention3.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 75 Arrhythmia - LCn3 - subgroup by primary or secondary prevention3



(Continued ...)




(1) ICD therapy for VT/VF

# **Analysis 1.76. Comparison 1 High vs low LCn3 omega-3 fats (primary outcomes), Outcome 76 Arrhythmia - LCn3 - subgroup by statin use.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 1 High vs low LCn3 omega-3 fats (primary outcomes)

Outcome: 76 Arrhythmia - LCn3 - subgroup by statin use



(Continued ...)




(1) ICD therapy for VT/VF

## Analysis 2.1. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 1 MACCEs - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 1 MACCEs - LCn3






## Analysis 2.2. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 2 Myocardial infarction (overall) - LCn3.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 2 Myocardial infarction (overall) - LCn3



(Continued ...)




### Analysis 2.3. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 3 Total MI - sensitivity analysis (SA) by summary risk of bias.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 3 Total MI - sensitivity analysis (SA) by summary risk of bias



(Continued . . .)




## Analysis 2.4. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 4 Total MI - LCn3 - SA by compliance and study size.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 4 Total MI - LCn3 - SA by compliance and study size



(Continued ...)




## Analysis 2.5. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 5 Total MI - LCn3 - subgroup by fatality.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 5 Total MI - LCn3 - subgroup by fatality



(Continued ...)




## Analysis 2.6. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 6 Sudden cardiac death (overall) - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 6 Sudden cardiac death (overall) - LCn3






## Analysis 2.7. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 7 Angina - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 7 Angina - LCn3




(1) Worsening angina

## Analysis 2.8. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 8 Heart failure - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 8 Heart failure - LCn3




## Analysis 2.9. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 9 Revascularisation - LCn3.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 9 Revascularisation - LCn3



(Continued ...)




## Analysis 2.10. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 10 Peripheral arterial disease - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 10 Peripheral arterial disease - LCn3




## Analysis 2.11. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 11 PAD - LCn3 - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 11 PAD - LCn3 - SA by summary risk of bias




## Analysis 2.12. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 12 PAD - LCn3 - SA compliance and study size.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 12 PAD - LCn3 - SA compliance and study size




### Analysis 2.13. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 13 Acute coronary syndrome - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 13 Acute coronary syndrome - LCn3






## Analysis 2.14. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 14 Body weight, kg - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 14 Body weight, kg - LCn3



(1) Unbalanced at baseline, change data used

(2) median change from baseline, highest EPA vs placebo


(3) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)

## Analysis 2.15. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 15 Weight, kg - LCn3 - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 15 Weight, kg - LCn3 - SA by summary risk of bias



(1) Unbalanced at baseline, change data used

(2) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)


(3) median change from baseline, highest EPA vs placebo

## Analysis 2.16. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 16 Weight, kg - LCn3 - SA by compliance and study size.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 16 Weight, kg - LCn3 - SA by compliance and study size



(1) median change from baseline, highest EPA vs placebo

(2) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)

(3) median change from baseline, highest EPA vs placebo


(4) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)

## Analysis 2.17. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 17 Weight, kg - LCn3 - subgroup by dose.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 17 Weight, kg - LCn3 - subgroup by dose



(Continued ...)

(... Continued)



(1) Unbalanced at baseline, change data used

(2) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)


(3) median change from baseline, highest EPA vs placebo

## Analysis 2.18. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 18 Weight, kg - LCn3 - subgroup by replacement.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 18 Weight, kg - LCn3 - subgroup by replacement



(Continued ...)

(... Continued)



(1) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)

(2) Unbalanced at baseline, change data used


(3) median change from baseline, highest EPA vs placebo

## Analysis 2.19. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 19 Weight, kg - LCn3 - subgroup by intervention type.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)


Outcome: 19 Weight, kg - LCn3 - subgroup by intervention type



(Continued ...)



(... Continued)



(1) Unbalanced at baseline, change data used

(2) median change from baseline, highest EPA vs placebo


(3) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)

## Analysis 2.20. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 20 Weight, kg - LCn3 - subgroup by duration.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 20 Weight, kg - LCn3 - subgroup by duration



(Continued ...)

(... Continued)



(1) Unbalanced at baseline, change data used

(2) median change from baseline, highest EPA vs placebo


(3) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)

## Analysis 2.21. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 21 Weight, kg - LCn3 - subgroup by primary or secondary prevention.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 21 Weight, kg - LCn3 - subgroup by primary or secondary prevention



(1) Unbalanced at baseline, change data used

(2) median change from baseline, highest EPA vs placebo


(3) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)

## Analysis 2.22. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 22 Weight, kg - LCn3 - subgroup by statin use.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 22 Weight, kg - LCn3 - subgroup by statin use



(1) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)

(2) Unbalanced at baseline, change data used


(3) median change from baseline, highest EPA vs placebo

## Analysis 2.23. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 23 Body mass index, kg/m<sup>2</sup> - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 23 Body mass index, kg/m<sup>2</sup> - LCn3



(1) Number of participants equally divided between groups

(2) Unbalanced at baseline, change data used

(3) median change from baseline, highest EPA vs placebo


(4) median change at 1 year

## Analysis 2.24. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 24 BMI, kg/m<sup>2</sup>- LCn3 - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 24 BMI, kg/m<sup>2</sup>- LCn3 - SA by summary risk of bias



(1) Unbalanced at baseline, change data used

(2) median change from baseline, highest EPA vs placebo


(3) median change at 1 year

## Analysis 2.25. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 25 BMI, kg/m<sup>2</sup>- LCn3 - SA by compliance and study size.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 25 BMI, kg/m<sup>2</sup>- LCn3 - SA by compliance and study size



(1) median change from baseline, highest EPA vs placebo


(2) median change from baseline, highest EPA vs placebo

## Analysis 2.26. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 26 BMI, kg/m<sup>2</sup> - LCn3 - subgroup by dose.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 26 BMI, kg/m<sup>2</sup> - LCn3 - subgroup by dose



(Continued . . .)





(1) Unbalanced at baseline, change data used

(2) median change at 1 year


(3) median change from baseline, highest EPA vs placebo

## Analysis 2.27. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 27 BMI, kg/m<sup>2</sup> - LCn3 - subgroup by replacement.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 27 BMI, kg/m<sup>2</sup> - LCn3 - subgroup by replacement



(Continued ...)

(... Continued)



(1) median change at 1 year

(2) Unbalanced at baseline, change data used


(3) median change from baseline, highest EPA vs placebo

## Analysis 2.28. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 28 BMI, kg/m<sup>2</sup> - LCn3 - subgroup by intervention type.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 28 BMI, kg/m<sup>2</sup> - LCn3 - subgroup by intervention type



(Continued . . .)

(... Continued)



(1) Unbalanced at baseline, change data used

(2) median change from baseline, highest EPA vs placebo


(3) median change at 1 year

## Analysis 2.29. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 29 BMI, kg/m<sup>2</sup> - LCn3 - subgroup by duration.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 29 BMI, kg/m<sup>2</sup> - LCn3 - subgroup by duration



(Continued ...)

(... Continued)



(1) Unbalanced at baseline, change data used

(2) median change from baseline, highest EPA vs placebo


(3) median change at 1 year

### Analysis 2.30. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 30 BMI, kg/m<sup>2</sup> - LCn3 - subgroup by primary or secondary prevention.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 30 BMI, kg/m<sup>2</sup> - LCn3 - subgroup by primary or secondary prevention



(1) Unbalanced at baseline, change data used

(2) median change from baseline, highest EPA vs placebo


(3) median change at 1 year

## Analysis 2.31. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 31 BMI, kg/m<sup>2</sup> - LCn3 - subgroup by statin use.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 31 BMI, kg/m<sup>2</sup> - LCn3 - subgroup by statin use



(1) Unbalanced at baseline, change data used

(2) median change from baseline, highest EPA vs placebo

(3) median change at 1 year




## Analysis 2.32. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 32 Other measures of adiposity - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 32 Other measures of adiposity - LCn3



(Continued ...)

(... Continued)




(I) SE assumed

### Analysis 2.33. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 33 Total cholesterol, serum, mmol/L - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 33 Total cholesterol, serum, mmol/L - LCn3



(Continued ...)

(... Continued)



(1) 14 month data, cod liver oil vs control

(2) SDs unlikely so converted assuming they were SEs

(3) 2 year data


(4) median change from baseline, highest EPA vs placebo

### Analysis 2.34. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 34 TC, mmol/L - LCn3 - SA by summary risk of bias.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 34 TC, mmol/L - LCn3 - SA by summary risk of bias



(Continued ...)



(1) SDs unlikely, so converted assuming SEs

(2) 14 month data, cod liver oil gp int

(3) 2 year data


(4) median change from baseline, highest EPA vs placebo

### Analysis 2.35. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 35 TC, mmol/L - LCn3 - SA by compliance and study size.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 35 TC, mmol/L - LCn3 - SA by compliance and study size



(Continued ...)



(1) 14 month data, cod liver oil gp int

(2) median change from baseline, highest EPA vs placebo

(3) SDs unlikely, so converted assuming SEs

(4) 2 year data


(5) median change from baseline, highest EPA vs placebo

### Analysis 2.36. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 36 TC, mmol/L - LCn3 - subgroup by dose.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)


Outcome: 36 TC, mmol/L - LCn3 - subgroup by dose



(Continued ...)



(... Continued)



(1) SDs unlikely so converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

### Analysis 2.37. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 37 TC, mmol/L - LCn3 - subgroup by replacement.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 37 TC, mmol/L - LCn3 - subgroup by replacement



(Continued ...)

(... Continued)



(1) SDs unlikely, so converted assuming SEs

(2) SDs unlikely, so converted assuming SEs


(3) median change from baseline, highest EPA vs placebo

### Analysis 2.38. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 38 TC, mmol/L - LCn3 - subgroup by intervention type.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 38 TC, mmol/L - LCn3 - subgroup by intervention type



(Continued ...)

(... Continued)



(1) SDs unlikely so converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

### Analysis 2.39. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 39 TC, mmol/L - LCn3 - subgroup by duration.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 39 TC, mmol/L - LCn3 - subgroup by duration



(Continued ...)



(1) SDs unlikely so converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

# **Analysis 2.40. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 40 TC, mmol/L - LCn3 - subgroup by primary or secondary prevention.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)


Outcome: 40 TC, mmol/L - LCn3 - subgroup by primary or secondary prevention



(Continued ...)



(... Continued)



(1) SDs unlikely so converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

## Analysis 2.41. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 41 TC, mmol/L - LCn3 - subgroup by statin use.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 41 TC, mmol/L - LCn3 - subgroup by statin use



(Continued ...)

(... Continued)



(1) SDs unlikely to be converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

## Analysis 2.42. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 42 Triglycerides, fasting, serum, mmol/L - LCn3.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 42 Triglycerides, fasting, serum, mmol/L - LCn3



(... Continued)




- (1) SDs unlikely so converted assuming SEs
- (2) median change from baseline, highest EPA vs placebo
- (3) Medians, in participants with impaired glucose metabolism
- (4) medians in normoglycaemic participants

### Analysis 2.43. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 43 TG, fasting, mmol/L - LCn3 - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 43 TG, fasting, mmol/L - LCn3 - SA by summary risk of bias



(Continued ...)

(... Continued)



(1) SDs unlikely, converted assuming SEs

(2) median change from baseline, highest EPA vs placebo

(3) medians in normoglycaemic participants


(4) Medians, in participants with impaired glucose metabolism

## Analysis 2.44. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 44 TG, fasting, mmol/L - LCn3 - SA by compliance and study size.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)


Outcome: 44 TG, fasting, mmol/L - LCn3 - SA by compliance and study size



(Continued ...)



(... Continued)



(1) median change from baseline, highest EPA vs placebo

(2) SDs unlikely, converted assuming SEs

(3) median change from baseline, highest EPA vs placebo

(4) Medians, in participants with impaired glucose metabolism


(5) medians in normoglycaemic participants

## Analysis 2.45. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 45 TG, fasting, mmol/L - LCn3 - subgroup by dose.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 45 TG, fasting, mmol/L - LCn3 - subgroup by dose



(Continued ...)

(... Continued)



(1) SDs unlikely, converted assuming SEs

(2) Medians, in participants with impaired glucose metabolism

(3) medians in normoglycaemic participants


(4) median change from baseline, highest EPA vs placebo

## Analysis 2.46. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 46 TG, fasting, mmol/L - LCn3 - subgroup by replacement.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 46 TG, fasting, mmol/L - LCn3 - subgroup by replacement



(... Continued)



(1) SDs unlikely, converted assuming SEs

(2) SDs unlikely, converted assuming SEs

(3) Medians, in participants with impaired glucose metabolism

(4) medians in normoglycaemic participants


(5) median change from baseline, highest EPA vs placebo

## Analysis 2.47. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 47 TG, fasting, mmol/L - LCn3 - subgroup by intervention type.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 47 TG, fasting, mmol/L - LCn3 - subgroup by intervention type



(Continued ...)

(... Continued)



(1) SDs unlikely, converted assuming SEs

(2) median change from baseline, highest EPA vs placebo

(3) Medians, in participants with impaired glucose metabolism


(4) medians in normoglycaemic participants

## Analysis 2.48. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 48 TG, fasting, mmol/L - LCn3 - subgroup by duration.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)


Outcome: 48 TG, fasting, mmol/L - LCn3 - subgroup by duration



(Continued ...)



(... Continued)




- (1) SDs unlikely, converted assuming SEs
- (2) median change from baseline, highest EPA vs placebo
- (3) data provided as % change from baseline only (no baseline)
- (4) Medians, in participants with impaired glucose metabolism
- (5) medians in normoglycaemic participants

## Analysis 2.49. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 49 TG, fasting, mmol/L - LCn3 - subgroup by primary or secondary prevention.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 49 TG, fasting, mmol/L - LCn3 - subgroup by primary or secondary prevention



(Continued ...)

(... Continued)




- (1) SDs unlikely, converted assuming SEs
- (2) median change from baseline, highest EPA vs placebo
- (3) medians in normoglycaemic participants
- (4) Medians, in participants with impaired glucose metabolism

## Analysis 2.50. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 50 TG, fasting, mmol/L - LCn3 - subgroup by statin use.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 50 TG, fasting, mmol/L - LCn3 - subgroup by statin use



(Continued ...)

(... Continued)



(1) Medians, in participants with impaired glucose metabolism

(2) medians in normoglycaemic participants

(3) SDs unlikely, converted assuming SEs


(4) median change from baseline, highest EPA vs placebo

## Analysis 2.51. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 51 High-density lipoprotein, serum, mmol/L - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 51 High-density lipoprotein, serum, mmol/L - LCn3



(Continued ...)

(... Continued)



(1) 14 month data for cod liver oil vs control

(2) SDs unlikely, converted assuming SEs


(3) median change from baseline, highest EPA vs placebo

## Analysis 2.52. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 52 HDL, mmol/L - LCn3 - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)


Outcome: 52 HDL, mmol/L - LCn3 - SA by summary risk of bias



(Continued ...)



(... Continued)



(1) SDs unlikely, converted assuming SEs

(2) 14 month data, cod liver oil arm vs control


(3) median change from baseline, highest EPA vs placebo

### Analysis 2.53. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 53 HDL, mmol/L - LCn3 - SA by compliance and study size.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 53 HDL, mmol/L - LCn3 - SA by compliance and study size



(Continued ...)

(... Continued)




- (1) 14 month data, cod liver oil arm vs control
- (2) median change from baseline, highest EPA vs placebo
- (3) SDs unlikely, converted assuming SEs
- (4) median change from baseline, highest EPA vs placebo

## Analysis 2.54. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 54 HDL, mmol/L - LCn3 - subgroup by dose.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 54 HDL, mmol/L - LCn3 - subgroup by dose



(Continued . . .)

(... Continued)



(1) SDs unlikely, converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

## Analysis 2.55. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 55 HDL, mmol/L - LCn3 - subgroup by replacement.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 55 HDL, mmol/L - LCn3 - subgroup by replacement



(Continued ...)

(... Continued)



(1) SDs unlikely, converted assuming SEs

(2) SDs unlikely, converted assuming SEs


(3) median change from baseline, highest EPA vs placebo

## Analysis 2.56. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 56 HDL, mmol/L - LCn3 - subgroup by intervention type.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)


Outcome: 56 HDL, mmol/L - LCn3 - subgroup by intervention type



(Continued ...)



(... Continued)



(1) SDs unlikely, converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

## Analysis 2.57. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 57 HDL, mmol/L - LCn3 - subgroup by duration.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 57 HDL, mmol/L - LCn3 - subgroup by duration



(Continued ...)

(... Continued)



(1) SDs unlikely, converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

## Analysis 2.58. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 58 HDL, mmol/L - LCn3 - subgroup by primary or secondary prevention.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 58 HDL, mmol/L - LCn3 - subgroup by primary or secondary prevention



(Continued ...)



(1) SDs unlikely, converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

## Analysis 2.59. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 59 HDL, mmol/L - LCn3 - subgroup by statin use.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 59 HDL, mmol/L - LCn3 - subgroup by statin use



(Continued . . .)

(... Continued)



(1) SDs unlikely, converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

## Analysis 2.60. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 60 Low-density lipoprotein, serum, mmol/L - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 60 Low-density lipoprotein, serum, mmol/L - LCn3





(1) SDs unlikely, converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

## Analysis 2.61. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 61 LDL, mmol/L - LCn3 - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 61 LDL, mmol/L - LCn3 - SA by summary risk of bias



(Continued ...)

(... Continued)



(1) SDs unlikely, converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

## Analysis 2.62. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 62 LDL, mmol/L - LCn3 - SA by compliance and study size.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 62 LDL, mmol/L - LCn3 - SA by compliance and study size



(Continued ...)



(1) median change from baseline, highest EPA vs placebo

(2) SDs unlikely, converted assuming SEs


(3) median change from baseline, highest EPA vs placebo

### Analysis 2.63. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 63 LDL, mmol/L - LCn3 - subgroup by dose.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 63 LDL, mmol/L - LCn3 - subgroup by dose



(Continued . . .)

(... Continued)



(1) SDs unlikely, converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

## Analysis 2.64. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 64 LDL, mmol/L - LCn3 - subgroup by replacement.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 64 LDL, mmol/L - LCn3 - subgroup by replacement



(Continued ...)

(... Continued)



(1) SDs unlikely, converted assuming SEs

(2) SDs unlikely, converted assuming SEs

(3) median change from baseline, highest EPA vs placebo




## Analysis 2.65. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 65 LDL, mmol/L - LCn3 - subgroup by intervention type.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 65 LDL, mmol/L - LCn3 - subgroup by intervention type



(Continued ...)

(... Continued)



(1) SDs unlikely, converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

## Analysis 2.66. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 66 LDL, mmol/L - LCn3 - subgroup by duration.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 66 LDL, mmol/L - LCn3 - subgroup by duration



(Continued ...)

(... Continued)



(1) SDs unlikely, converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

**Analysis 2.67. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 67 LDL, mmol/L - LCn3 - subgroup by primary or secondary prevention.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 67 LDL, mmol/L - LCn3 - subgroup by primary or secondary prevention



(Continued ...)



(1) SDs unlikely, converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

## Analysis 2.68. Comparison 2 High vs low LCn3 omega-3 fats (secondary outcomes), Outcome 68 LDL, mmol/L - LCn3 - subgroup by statin use.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 2 High vs low LCn3 omega-3 fats (secondary outcomes)

Outcome: 68 LDL, mmol/L - LCn3 - subgroup by statin use



(... Continued)



(1) SDs unlikely, converted assuming SEs


(2) median change from baseline, highest EPA vs placebo

### Analysis 3.1. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 1 Blood pressure, mmHg - LCn3.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 3 High vs low LCn3 omega-3 fats (tertiary outcomes)


Outcome: 1 Blood pressure, mmHg - LCn3



(Continued ...)



(... Continued)




### Analysis 3.2. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 2 Serious adverse events - LCn3.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 3 High vs low LCn3 omega-3 fats (tertiary outcomes)

Outcome: 2 Serious adverse events - LCn3



(Continued ...)




### Analysis 3.3. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 3 Side effects - LCn3.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 3 High vs low LCn3 omega-3 fats (tertiary outcomes)

Outcome: 3 Side effects - LCn3




(Continued ...)






(Continued . . .)



(Continued . . .)



- (1) Diarrhoea data used
- (2) Abdominal pain data used here
- (3) Abdominal pain data used
- (4) Eructation data used
- (5) Diarrhoea data used
- (6) Nausea data used
- (7) GI discomfort causing withdrawal
- (8) Diarrhoea data used




### Analysis 3.4. Comparison 3 High vs low LCn3 omega-3 fats (tertiary outcomes), Outcome 4 Dropouts - LCn3.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 3 High vs low LCn3 omega-3 fats (tertiary outcomes)

Outcome: 4 Dropouts - LCn3



(Continued ...)




#### Analysis 4.1. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 1 All-cause mortality (overall) - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 1 All-cause mortality (overall) - ALA




(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA

## Analysis 4.2. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 2 All-cause mortality - ALA - sensitivity analysis (SA) fixed-effect.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 2 All-cause mortality - ALA - sensitivity analysis (SA) fixed-effect




(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA

### Analysis 4.3. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 3 All-cause mortality - ALA - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 3 All-cause mortality - ALA - SA by summary risk of bias




(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA

#### Analysis 4.4. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 4 All-cause mortality - ALA - SA by compliance and study size.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 4 All-cause mortality - ALA - SA by compliance and study size



(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA


(2) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA

#### Analysis 4.5. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 5 All-cause mortality - ALA - subgroup by dose.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 5 All-cause mortality - ALA - subgroup by dose




(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA

#### Analysis 4.6. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 6 All-cause mortality - ALA - subgroup by replacement.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 6 All-cause mortality - ALA - subgroup by replacement



(Continued . . .)






#### Analysis 4.7. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 7 All cause mortality - ALA - subgroup by intervention type.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 7 All cause mortality - ALA - subgroup by intervention type



(Continued . . .)




(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA

#### Analysis 4.8. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 8 All-cause mortality - ALA - subgroup by duration.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 8 All-cause mortality - ALA - subgroup by duration




(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA

#### Analysis 4.9. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 9 All-cause mortality - ALA - subgroup by primary or secondary prevention.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 9 All-cause mortality - ALA - subgroup by primary or secondary prevention




(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA

# **Analysis 4.10. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 10 All-cause mortality - ALA - subgroup by statin use.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 10 All-cause mortality - ALA - subgroup by statin use




(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA

# **Analysis 4.11. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 11 Cardiovascular mortality (overall) - ALA.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 11 Cardiovascular mortality (overall) - ALA




#### Analysis 4.12. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 12 CVD mortality - ALA - SA fixed-effect.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 12 CVD mortality - ALA - SA fixed-effect




### Analysis 4.13. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 13 CVD mortality - ALA - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 13 CVD mortality - ALA - SA by summary risk of bias






#### Analysis 4.14. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 14 CVD mortality - ALA - SA by compliance and study size.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 14 CVD mortality - ALA - SA by compliance and study size




# **Analysis 4.15. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 15 CVD mortality - ALA - subgroup by dose.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 15 CVD mortality - ALA - subgroup by dose




# **Analysis 4.16. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 16 CVD mortality - ALA - subgroup by replacement.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 16 CVD mortality - ALA - subgroup by replacement




# **Analysis 4.17. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 17 CVD mortality - ALA - subgroup by intervention type.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 17 CVD mortality - ALA - subgroup by intervention type




# **Analysis 4.18. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 18 CVD mortality - ALA - subgroup by duration.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 18 CVD mortality - ALA - subgroup by duration




# **Analysis 4.19. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 19 CVD mortality - ALA - subgroup by primary or secondary prevention.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 19 CVD mortality - ALA - subgroup by primary or secondary prevention




# **Analysis 4.20. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 20 CVD mortality - ALA - subgroup by statin uses.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 20 CVD mortality - ALA - subgroup by statin uses




# **Analysis 4.21. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 21 Cardiovascular events (overall) - ALA.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 21 Cardiovascular events (overall) - ALA



(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA




# **Analysis 4.22. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 22 CVD events - ALA - SA fixed-effect.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 22 CVD events - ALA - SA fixed-effect




(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA

### Analysis 4.23. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 23 CVD events - ALA - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 23 CVD events - ALA - SA by summary risk of bias




(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA

#### Analysis 4.24. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 24 CVD events - ALA - SA by compliance and study size.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 24 CVD events - ALA - SA by compliance and study size



(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA


(2) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA

# **Analysis 4.25. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 25 CVD events - ALA - subgroup by dose.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 25 CVD events - ALA - subgroup by dose




(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA

# **Analysis 4.26. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 26 CVD events - ALA - subgroup by replacement.**


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 26 CVD events - ALA - subgroup by replacement



(Continued . . .)




#### Analysis 4.27. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 27 CVD events - ALA - subgroup by intervention type.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 27 CVD events - ALA - subgroup by intervention type



(Continued . . .)




(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA

# **Analysis 4.28. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 28 CVD events - ALA - subgroup by duration.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 28 CVD events - ALA - subgroup by duration



(I) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA




# **Analysis 4.29. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 29 CVD events - ALA - subgroup by primary or secondary prevention.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 29 CVD events - ALA - subgroup by primary or secondary prevention




(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA

### Analysis 4.30. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 30 CVD events - ALA - subgroup by statin use.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 30 CVD events - ALA - subgroup by statin use




(1) MARGARIN study - comparing ALA EPA+DHA with no ALA EPA+DHA

### Analysis 4.31. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 31 Coronary heart disease mortality (overall) - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 31 Coronary heart disease mortality (overall) - ALA



(1) Fatal MI


(2) Coronary heart plus sudden death

### Analysis 4.32. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 32 CHD mortality - ALA - SA fixed-effect.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 32 CHD mortality - ALA - SA fixed-effect



(1) Fatal MI


(2) Coronary heart plus sudden death

### Analysis 4.33. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 33 CHD mortality - ALA - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 33 CHD mortality - ALA - SA by summary risk of bias



(1) Fatal MI


(2) Coronary heart plus sudden death

### Analysis 4.34. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 34 CHD mortality - ALA - SA by compliance and study size.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 34 CHD mortality - ALA - SA by compliance and study size



(1) Fatal MI


(2) Coronary heart plus sudden death

### Analysis 4.35. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 35 CHD mortality - ALA - subgroup by dose.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 35 CHD mortality - ALA - subgroup by dose



(1) Fatal MI


(2) Coronary heart plus sudden death

### Analysis 4.36. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 36 CHD mortality - ALA - subgroup by replacement.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 36 CHD mortality - ALA - subgroup by replacement



(Continued ...)





(1) Coronary heart plus sudden death


(2) Fatal MI

#### Analysis 4.37. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 37 CHD mortality - ALA - subgroup by intervention type.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 37 CHD mortality - ALA - subgroup by intervention type



(Continued . . .)



(1) Fatal MI


(2) Coronary heart plus sudden death

### Analysis 4.38. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 38 CHD mortality - ALA - subgroup by duration.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 38 CHD mortality - ALA - subgroup by duration



(1) Fatal MI


(2) Coronary heart plus sudden death

### Analysis 4.39. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 39 CHD mortality - ALA - subgroup by primary or secondary prevention.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 39 CHD mortality - ALA - subgroup by primary or secondary prevention



(1) Coronary heart plus sudden death


(2) Fatal MI

#### Analysis 4.40. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 40 CHD mortality - ALA - subgroup by statin use.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 40 CHD mortality - ALA - subgroup by statin use



(1) Fatal MI


(2) Coronary heart plus sudden death

#### Analysis 4.41. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 41 CHD mortality - ALA - subgroup by CAD history.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 41 CHD mortality - ALA - subgroup by CAD history



(1) Fatal MI


(2) Coronary heart plus sudden death

#### Analysis 4.42. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 42 Coronary heart disease events (overall) - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 42 Coronary heart disease events (overall) - ALA



(1) Total MI


(2) Total MI

#### Analysis 4.43. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 43 CHD events - ALA - SA fixed-effect.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 43 CHD events - ALA - SA fixed-effect



(1) Total MI

(2) Total MI




#### Analysis 4.44. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 44 CHD events - ALA - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 44 CHD events - ALA - SA by summary risk of bias



(1) Total MI


(2) Total MI

#### Analysis 4.45. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 45 CHD events - ALA - SA by compliance and study size.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 45 CHD events - ALA - SA by compliance and study size



(1) Total MI


(2) Total MI

#### Analysis 4.46. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 46 CHD events - ALA - subgroup by dose.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 46 CHD events - ALA - subgroup by dose



(1) Total MI


(2) Total MI

# **Analysis 4.47. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 47 CHD events - ALA - subgroup by replacement.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 47 CHD events - ALA - subgroup by replacement



(1) Total MI


(2) Total MI

#### Analysis 4.48. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 48 CHD events - ALA - subgroup by intervention type.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 48 CHD events - ALA - subgroup by intervention type



(Continued ...)



(1) Total MI


(2) Total MI

#### Analysis 4.49. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 49 CHD events - ALA - subgroup by duration.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 49 CHD events - ALA - subgroup by duration



(Continued . . .)



(1) Total MI


(2) Total MI

# **Analysis 4.50. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 50 CHD events - ALA - subgroup by primary or secondary prevention.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 50 CHD events - ALA - subgroup by primary or secondary prevention



(1) Total MI

(2) Total MI




# **Analysis 4.51. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 51 CHD events - ALA - subgroup by statin use.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 51 CHD events - ALA - subgroup by statin use



(1) Total MI


(2) Total MI

# **Analysis 4.52. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 52 CHD events - ALA - subgroup by CAD history.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 52 CHD events - ALA - subgroup by CAD history



(1) Total MI


(2) Total MI

### Analysis 4.53. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 53 Stroke (overall) - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 53 Stroke (overall) - ALA




#### Analysis 4.54. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 54 Stroke - ALA - SA fixed-effect.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 54 Stroke - ALA - SA fixed-effect




# **Analysis 4.55. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 55 Stroke - ALA - SA by summary risk of bias.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 55 Stroke - ALA - SA by summary risk of bias




# **Analysis 4.56. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 56 Stroke - ALA - SA by compliance and study size.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 56 Stroke - ALA - SA by compliance and study size




#### Analysis 4.57. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 57 Stroke - ALA - subgroup by dose.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 57 Stroke - ALA - subgroup by dose




# **Analysis 4.58. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 58 Stroke - ALA - subgroup by replacement.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease


Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 58 Stroke - ALA - subgroup by replacement



(Continued . . .)






#### Analysis 4.59. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 59 Stroke - ALA - subgroup by intervention type.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 59 Stroke - ALA - subgroup by intervention type



(Continued . . .)




# **Analysis 4.60. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 60 Stroke - ALA - subgroup by duration.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 60 Stroke - ALA - subgroup by duration




# **Analysis 4.61. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 61 Stroke - ALA - subgroup by primary or secondary prevention.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 61 Stroke - ALA - subgroup by primary or secondary prevention




# **Analysis 4.62. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 62 Stroke - ALA - subgroup by statin use.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 62 Stroke - ALA - subgroup by statin use




### Analysis 4.63. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 63 Stroke - ALA - subgroup by stroke type.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 63 Stroke - ALA - subgroup by stroke type




#### Analysis 4.64. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 64 Arrhythmia (overall) - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 64 Arrhythmia (overall) - ALA




# **Analysis 4.65. Comparison 4 High vs low ALA omega-3 fat (primary outcomes), Outcome 65 Arrhythmia - ALA - SA by summary risk of bias.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 4 High vs low ALA omega-3 fat (primary outcomes)

Outcome: 65 Arrhythmia - ALA - SA by summary risk of bias






### Analysis 5.1. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 1 MACCEs - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 1 MACCEs - ALA




### Analysis 5.2. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 2 Myocardial infarction (overall) - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 2 Myocardial infarction (overall) - ALA




### Analysis 5.3. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 3 Total MI - ALA - subgroup by fatality.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 3 Total MI - ALA - subgroup by fatality




#### Analysis 5.4. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 4 Angina - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 4 Angina - ALA




### Analysis 5.5. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 5 Revascularisation - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 5 Revascularisation - ALA




### Analysis 5.6. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 6 Peripheral arterial disease - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 6 Peripheral arterial disease - ALA




### Analysis 5.7. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 7 Body weight, kg - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 7 Body weight, kg - ALA



(1) Insulin sensitive participants


(2) Insulin resistant participants

### Analysis 5.8. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 8 Weight, kg - ALA - sensitivity analysis (SA) fixed-effect.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 8 Weight, kg - ALA - sensitivity analysis (SA) fixed-effect



(1) Insulin resistant participants


(2) Insulin sensitive participants

### Analysis 5.9. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 9 Weight, kg - ALA - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 9 Weight, kg - ALA - SA by summary risk of bias



(1) Insulin sensitive participants


(2) Insulin resistant participants

### Analysis 5.10. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 10 Weight, kg - ALA - SA by compliance and study size.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 10 Weight, kg - ALA - SA by compliance and study size



(1) Insulin resistant participants

(2) Insulin sensitive participants

(3) Insulin sensitive participants

(4) Insulin resistant participants




## Analysis 5.11. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 11 Weight, kg - ALA - subgroup by dose.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 11 Weight, kg - ALA - subgroup by dose



(1) Insulin sensitive participants


(2) Insulin resistant participants

## Analysis 5.12. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 12 Weight, kg - ALA - subgroup by intervention type.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 12 Weight, kg - ALA - subgroup by intervention type



(1) Insulin sensitive participants


(2) Insulin resistant participants

### Analysis 5.13. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 13 Weight, kg - ALA - subgroup by replacement.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 13 Weight, kg - ALA - subgroup by replacement



(1) Insulin sensitive participants


(2) Insulin resistant participants

### Analysis 5.14. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 14 Weight, kg - ALA - subgroup by duration.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 14 Weight, kg - ALA - subgroup by duration



(1) Insulin resistant participants


(2) Insulin sensitive participants

### Analysis 5.15. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 15 Weight, kg - ALA - subgroup by statin use.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 15 Weight, kg - ALA - subgroup by statin use



(1) Insulin resistant participants


(2) Insulin sensitive participants

# **Analysis 5.16. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 16 Weight, kg - ALA - subgroup by primary or secondary prevention.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 16 Weight, kg - ALA - subgroup by primary or secondary prevention



(1) Insulin resistant participants


(2) Insulin sensitive participants

### Analysis 5.17. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 17 Body mass index, kg/m<sup>2</sup> - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 17 Body mass index, kg/m<sup>2</sup> - ALA




(1) Numer of participants equally divided between groups

# **Analysis 5.18. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 18 BMI, kg/m<sup>2</sup> - ALA - SA fixed-effect.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 18 BMI, kg/m<sup>2</sup> - ALA - SA fixed-effect






# **Analysis 5.19. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 19 BMI, kg/m<sup>2</sup> - ALA - SA by summary risk of bias.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 19 BMI, kg/m<sup>2</sup> - ALA - SA by summary risk of bias




**Analysis 5.20. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 20 BMI, kg/m<sup>2</sup> - ALA - SA by compliance and study size.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 20 BMI, kg/m<sup>2</sup> - ALA - SA by compliance and study size




## Analysis 5.21. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 21 BMI, kg/m<sup>2</sup> - ALA - subgroup by dose.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 21 BMI, kg/m<sup>2</sup> - ALA - subgroup by dose




**Analysis 5.22. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 22 BMI, kg/m<sup>2</sup> - ALA - subgroup by intervention type.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 22 BMI, kg/m<sup>2</sup> - ALA - subgroup by intervention type




### Analysis 5.23. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 23 BMI, kg/m<sup>2</sup> - ALA - subgroup by replacement.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 23 BMI, kg/m<sup>2</sup> - ALA - subgroup by replacement




## Analysis 5.24. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 24 BMI, kg/m<sup>2</sup> - ALA - subgroup by duration.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 24 BMI, kg/m<sup>2</sup> - ALA - subgroup by duration




### Analysis 5.25. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 25 BMI, kg/m<sup>2</sup> - ALA - subgroup by statin use.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 25 BMI, kg/m<sup>2</sup> - ALA - subgroup by statin use




## Analysis 5.26. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 26 BMI, kg/m<sup>2</sup> - ALA - subgroup by primary or secondary preventionA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 26 BMI, kg/m<sup>2</sup> - ALA - subgroup by primary or secondary preventionA






## Analysis 5.27. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 27 Other measures of adiposity - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 27 Other measures of adiposity - ALA



(1) change data (no SDs found)

(2) Insulin sensitive participants


(3) Insulin resistant participants

### Analysis 5.28. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 28 Total cholesterol, serum, mmol/L - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 28 Total cholesterol, serum, mmol/L - ALA




### Analysis 5.29. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 29 TC, mmol/L - ALA - SA fixed-effect.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 29 TC, mmol/L - ALA - SA fixed-effect




### Analysis 5.30. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 30 TC, mmol/L - ALA - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 30 TC, mmol/L - ALA - SA by summary risk of bias




### Analysis 5.31. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 31 TC, mmol/L - ALA - SA by compliance and study size.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 31 TC, mmol/L - ALA - SA by compliance and study size




### Analysis 5.32. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 32 TC, mmol/L - ALA - subgroup by dose.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 32 TC, mmol/L - ALA - subgroup by dose




### Analysis 5.33. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 33 TC, mmol/L - ALA - subgroup by intervention type.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 33 TC, mmol/L - ALA - subgroup by intervention type




### Analysis 5.34. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 34 TC, mmol/L - ALA - subgroup by replacement.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 34 TC, mmol/L - ALA - subgroup by replacement






### Analysis 5.35. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 35 TC, mmol/L - ALA - subgroup by duration.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 35 TC, mmol/L - ALA - subgroup by duration




### Analysis 5.36. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 36 TC, mmol/L - ALA - subgroup by statin use.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 36 TC, mmol/L - ALA - subgroup by statin use




### Analysis 5.37. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 37 TC, mmol/L - ALA - subgroup by primary or secondary preventionA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 37 TC, mmol/L - ALA - subgroup by primary or secondary preventionA




### Analysis 5.38. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 38 Triglycerides, fasting, serum, mmol/L - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 38 Triglycerides, fasting, serum, mmol/L - ALA




### Analysis 5.39. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 39 TG, fasting, mmol/L - ALA - SA fixed-effect.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 39 TG, fasting, mmol/L - ALA - SA fixed-effect




# **Analysis 5.40. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 40 TG, fasting, mmol/L- ALA - SA by summary risk of bias.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 40 TG, fasting, mmol/L- ALA - SA by summary risk of bias




# **Analysis 5.41. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 41 TG, fasting, mmol/L- ALA - SA by compliance and study size.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 41 TG, fasting, mmol/L- ALA - SA by compliance and study size




**Analysis 5.42. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 42 TG, fasting, mmol/L - ALA - subgroup by dose.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 42 TG, fasting, mmol/L - ALA - subgroup by dose






### Analysis 5.43. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 43 TG, fasting, mmol/L- ALA - subgroup by intervention type.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 43 TG, fasting, mmol/L- ALA - subgroup by intervention type




# **Analysis 5.44. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 44 TG, fasting, mmol/L-AL - subgroup by replacementA.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 44 TG, fasting, mmol/L-AL - subgroup by replacementA




# **Analysis 5.45. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 45 TG, fasting, mmol/L- ALA - subgroup by duration.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 45 TG, fasting, mmol/L- ALA - subgroup by duration




# **Analysis 5.46. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 46 TG, fasting, mmol/L - ALA - subgroup by statin use.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 46 TG, fasting, mmol/L - ALA - subgroup by statin use




# **Analysis 5.47. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 47 TG, fasting, mmol/L- ALA - subgroup by primary or secondary prevention.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 47 TG, fasting, mmol/L- ALA - subgroup by primary or secondary prevention




# **Analysis 5.48. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 48 High-density lipoprotein, serum, mmol/L - ALA.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 48 High-density lipoprotein, serum, mmol/L - ALA




### Analysis 5.49. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 49 HDL, mmol/L - ALA - SA fixed-effect.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 49 HDL, mmol/L - ALA - SA fixed-effect




### Analysis 5.50. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 50 HDL, mmol/L - ALA - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 50 HDL, mmol/L - ALA - SA by summary risk of bias






### Analysis 5.51. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 51 HDL, mmol/L - ALA - SA by compliance and study size.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 51 HDL, mmol/L - ALA - SA by compliance and study size




## Analysis 5.52. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 52 HDL, mmol/L - ALA - subgroup by dose.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 52 HDL, mmol/L - ALA - subgroup by dose




### Analysis 5.53. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 53 HDL, mmol/L - ALA - subgroup by intervention type.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 53 HDL, mmol/L - ALA - subgroup by intervention type




### Analysis 5.54. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 54 HDL, mmol/L - ALA - subgroup by replacement.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 54 HDL, mmol/L - ALA - subgroup by replacement




### Analysis 5.55. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 55 HDL, mmol/L - ALA - subgroup by duration.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 55 HDL, mmol/L - ALA - subgroup by duration




### Analysis 5.56. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 56 HDL, mmol/L - ALA - subgroup by statin use.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 56 HDL, mmol/L - ALA - subgroup by statin use




### Analysis 5.57. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 57 HDL, mmol/L - ALA - subgroup by primary or secondary prevention.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 57 HDL, mmol/L - ALA - subgroup by primary or secondary prevention




# **Analysis 5.58. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 58 Low-density lipoprotein, serum, mmol/L - ALA.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 58 Low-density lipoprotein, serum, mmol/L - ALA



(I) change from baseline




### Analysis 5.59. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 59 LDL, mmol/L - ALA - SA fixed-effect.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 59 LDL, mmol/L - ALA - SA fixed-effect




(1) change from baseline

### Analysis 5.60. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 60 LDL, mmol/L - ALA - SA by summary risk of bias.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 60 LDL, mmol/L - ALA - SA by summary risk of bias




(I) change from baseline

### Analysis 5.61. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 61 LDL, mmol/L - ALA - SA by compliance and study size.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 61 LDL, mmol/L - ALA - SA by compliance and study size



(1) change from baseline


(2) change from baseline

## Analysis 5.62. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 62 LDL, mmol/L - ALA - subgroup by dose.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 62 LDL, mmol/L - ALA - subgroup by dose




(1) change from baseline

### Analysis 5.63. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 63 LDL, mmol/L - ALA - subgroup by intervention type.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 63 LDL, mmol/L - ALA - subgroup by intervention type




(1) change from baseline

### Analysis 5.64. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 64 LDL, mmol/L - ALA - subgroup by replacement.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 64 LDL, mmol/L - ALA - subgroup by replacement




(I) change from baseline

### Analysis 5.65. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 65 LDL, mmol/L - ALA - subgroup by duration.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 65 LDL, mmol/L - ALA - subgroup by duration




(I) change from baseline

# **Analysis 5.66. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 66 LDL, mmol/L - ALA - subgroup by statin use.**

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 66 LDL, mmol/L - ALA - subgroup by statin use



(1) change from baseline




### Analysis 5.67. Comparison 5 High vs low ALA omega-3 fat (secondary outcomes), Outcome 67 LDL, mmol/L - ALA - subgroup by primary or secondary prevention.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 5 High vs low ALA omega-3 fat (secondary outcomes)

Outcome: 67 LDL, mmol/L - ALA - subgroup by primary or secondary prevention




(I) change from baseline

## Analysis 6.1. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 1 Blood pressure, mmHg - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 6 High vs low ALA omega-3 fats (tertiary outcomes)

Outcome: 1 Blood pressure, mmHg - ALA




## Analysis 6.2. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 2 Serious adverse events - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 6 High vs low ALA omega-3 fats (tertiary outcomes)

Outcome: 2 Serious adverse events - ALA




### Analysis 6.3. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 3 Side effects - ALA.


Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 6 High vs low ALA omega-3 fats (tertiary outcomes)

Outcome: 3 Side effects - ALA



(Continued ...)




(1) Nausea data used

#### Analysis 6.4. Comparison 6 High vs low ALA omega-3 fats (tertiary outcomes), Outcome 4 Dropouts - ALA.

Review: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Comparison: 6 High vs low ALA omega-3 fats (tertiary outcomes)

Outcome: 4 Dropouts - ALA



## ADDITIONAL TABLES

Table 1. Risk of bias assessment methods in greater detail

Risk of bias element	Criteria for low risk of bias	Criteria for unclear	Criteria for high risk of bias
<b>Selection bias: random sequence generation</b>	The study authors needed to have described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. For example “the randomisation sequence was computer generated”. We allowed that a good method of randomisation was strongly implied if the authors discussed stratification and/or blocking. There-	The study authors have not described their method in sufficient detail for the assessment of whether it would produce comparable groups. For example, the authors state “the trial was randomised” and provide no further information	The randomisation method was assessed as not truly random, and may not produce comparable groups

**Table 1. Risk of bias assessment methods in greater detail** (Continued)

	fore, if the authors were not explicit about their randomisation method but did describe stratification or blocking we assessed this as corresponding to low risk		
<b>Selection bias: allocation concealment</b>	The study authors needed to have described the method used to conceal allocation sequence in sufficient detail to determine whether the allocations could have been foreseen in advance of, or during, enrolment. Good methods included putting allocation codes in opaque sealed envelopes (ideally prepared by someone outside the treatment or assessment teams and sequentially numbered), using a telephone allocation system after the participants had consented to participate or providing a random number that links to a specific set of capsules prepared and distributed centrally or by an arms-length pharmacist	The authors gave insufficient detail as to method.	The allocation was known in advance of participants consenting to take part in the study
<b>Performance bias: blinding of participants and personnel</b>	The study authors needed to have described all measures used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. Ideally, they should also have provided information relating to whether the intended blinding was effective. For example, the authors could say “both the intervention and placebo capsules looked and tasted the same.” However, if the study authors did not provide information on whether the blinding was effective, but sufficient detail was given on a good method of blinding, then it was assumed that the blinding was effective and the risk of bias was low	Insufficient methodological details were provided e.g. “the study was blinded.”	The study was unblinded or where blinding was broken, e.g. “the capsules were visually identical but the participants reported a strong fishy flavour in the intervention group only.”

**Table 1. Risk of bias assessment methods in greater detail** (Continued)

<b>Detection bias: blinding of outcome assessment</b>	<p>Study authors needed to have described measures used, if any, to blind outcome assessors from knowledge of which intervention a participant received. Ideally, they should also have provided information relating to whether the intended blinding was effective. For example, the authors could say “the outcome assessors had no knowledge of the group allocation, and both the intervention and placebo capsules looked and tasted the same so the self-assessment scales were also blinded.” However if the study authors did not provide information on whether the blinding was effective, but sufficient detail was given on a good method of blinding of the assessors, then it was assumed that the blinding was effective and the risk of bias is low. All biochemical assessment (lipids, glucose, CRP, insulin, PSA, etc.) were considered at low risk of detection bias if outcome assessor blinding or double blinding was stated</p>	<p>Insufficient methodological details were provided e.g. “the study was blinded.”</p>	<p>The study was unblinded or blinding was broken, e.g. for a self-assessment measure “the capsules were visually identical but the participants reported a strong fishy flavour in the intervention group only.”</p> <p>Because the level of blinding could vary by outcome assessment of risk of bias was based on blinding of the review’s primary outcome(s). Where primary outcomes had different assessments we opted for the higher risk of bias but noted that that risk of bias was lower for other outcomes</p>
<b>Attrition bias: incomplete outcome data</b>	<p>The study authors needed to describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. They needed to report the number of attrition/exclusions, the numbers in each group at each time point, reasons for attrition/exclusion and any re-inclusions in analyses. Ideally, they would report how they imputed any missing data e.g. last observation carried forward. There needed to be a reasonable balance of attrition/exclusions between study arms and <math>\leq 20\%</math> of the sample should be lost over a</p>	<p>The authors didn’t state reasons for attrition/exclusion, or were unclear about the numbers lost to attrition/exclusion in each study arm</p>	<p>The authors demonstrated a substantial difference in the rates of attrition/exclusions between the study arms and/or <math>&gt; 20\%</math> of the baseline sample was lost over a year (<math>&gt; 10\%</math> over 6 months)</p>



**Table 1. Risk of bias assessment methods in greater detail** (Continued)

	year		
<b>Reporting bias: selective outcome reporting</b>	The study authors needed to have published their trial protocol or trials registry entry before the end of the study's recruitment period i.e. prospectively. They needed to have reported on all of the primary and secondary outcomes listed in the protocol/registry entry. Reporting additional secondary outcomes in the results paper(s), although not ideal, was deemed to still be low risk	No trial protocol or trials registry entry was found, it was registered retrospectively, or the dates of registration and participant recruitment were unclear	The study authors did not report at least one primary or secondary outcome listed in the protocol/registry entry <i>or</i> the results paper(s) reported a primary outcome that was not listed at all in the protocol or not listed as a primary outcome in the protocol
<b>Other sources of bias: attention bias</b>	The study authors needed to have reported that participants in all study arms received the same amount of attention and time from researchers and clinical teams. For example, "All participants attended the clinic for a baseline assessment which took 2 hours. They were then followed with monthly telephone calls, and finally attended for a 6 month assessment at the clinic which took 1 hour." If the study only differed by the content of the capsules, and the assessment schedule was not stated to differ between the two arms, it was assumed to be at low risk	The authors did not state the attention each arm received.	Participants in different arms received different amounts of attention. For example "the intervention group only attended for additional assessments at months 2, 4, and 6" or "the rates of relapse differed substantially between the groups which led to differing amounts of treatment time and attention," or "the intervention group received a 40 minute dietary education session."
<b>Other sources of bias: limited compliance</b>	The study authors needed to have reported on the level of compliance in all arms in sufficient detail to determine whether the study results were robust. We followed a flow chart to make this determination. A statistically significant difference between the intervention and control groups in a body measure of at least 50% of the text fatty acids. Where no body measures were	Compliance not reported or not in a way that could be interpreted	Measures of compliance were reported but fell below the appropriate thresholds

**Table 1. Risk of bias assessment methods in greater detail** (Continued)

	reported then estimated compliance needed to be greater than 64% (proportion complying multiplied by compliance threshold)		
<b>Other sources of bias: other</b>	In the absence of any additional issues this item was coded “low risk of bias”	-	If fraud concerns had been raised and the paper had been withdrawn, or the author had been found guilty of fraud by a legal or medical entity the paper was excluded from the review. However if fraud concerns were raised, but the journal had not withdrawn the paper, and the author had not been formally sanctioned; then the study was included in the review, but concerns were raised here, and the risk of bias for this item was high

**CRP:** C-reactive protein; **PSA:** prostate specific antigen.

**Table 2. Meta-regression results for cardiovascular mortality<sup>a</sup>**

Variable assessed	P value
LCn3 dose	0.61
ALA dose	0.91
Omega-6 dose	0.81
Total PUFA dose	0.82
Duration, months	0.68
Primary or secondary CVD prevention	0.88
Food or capsule	0.54
Risk of bias	0.94
Food or capsule	0.70
+ LCn3 dose	0.96
+ duration	0.69

**ALA:** alpha-linolenic acid; **CVD:** cardiovascular disease; **LCn3:** long-chain omega-3 fatty acids; **PUFA:** poly-unsaturated fatty acids.

<sup>a</sup>Random-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on cardiovascular mortality. We ran the meta-regression using all included trials that reported this outcome in this review, and its sister reviews (update of [Hooper 2018](#), and [Abdelhamid 2018](#)). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when  $P < 0.10$ ). Meta-regression was of each variable singly, plus a multivariate meta-regression of the 3 single variables with lowest P values. See methods for further information.

**Table 3. Meta-regression results for cardiovascular events<sup>a</sup>**

Variable assessed	P value
LCn3 dose	0.91
ALA dose	0.70
omega-6 dose	0.34
Total PUFA dose	0.34
Duration, months	0.62
Primary or secondary CVD prevention	0.78
Food or capsule	0.83
Risk of bias	0.24
Risk of bias + PUFA dose	0.25 0.87
+ Omega-6 dose	0.83

**ALA:** alpha-linolenic acid; **CVD:** cardiovascular disease; **LCn3:** long-chain omega-3 fatty acids; **PUFA:** poly-unsaturated fatty acids.

<sup>a</sup>Random-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on cardiovascular events. We ran the meta-regression using all included trials that reported this outcome in this review, and its sister reviews (update of [Hooper 2018](#), and [Abdelhamid 2018](#)). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when  $P < 0.10$ ). Meta-regression was of each variable singly, plus a multivariate meta-regression of the 3 single variables with lowest P values. See methods for further information.

**Table 4. Meta-regression results for CHD deaths<sup>a</sup>**

Variable assessed	P value
LCn3 dose	0.94
ALA dose	0.93
Omega-6 dose	0.66

**Table 4. Meta-regression results for CHD deaths<sup>a</sup>** (Continued)

Total PUFA dose	0.64
Duration, months	0.41
Primary or secondary CVD prevention	0.63
Food or capsule	0.78
Risk of bias	0.89
Duration	0.73
+ Primary or secondary prevention	0.90
+ PUFA dose	0.76

**ALA:** alpha-linolenic acid; **CVD:** cardiovascular disease; **LCn3:** long-chain omega-3 fatty acids; **PUFA:** poly-unsaturated fatty acids.  
<sup>a</sup>Random-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on CHD mortality. We ran the meta-regression using all included trials that reported this outcome in this review, and its sister reviews (update of [Hooper 2018](#), and [Abdelhamid 2018](#)). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when  $P < 0.10$ ). Meta-regression was of each variable singly, plus a multivariate meta-regression of the 3 single variables with lowest P values. See methods for further information.

**Table 5. Metaregression results for CHD events<sup>a</sup>**

Variable assessed	P value
LCn3 dose	0.68
ALA dose	0.23
Omega-6 dose	0.84
Total PUFA dose	0.79
Duration, months	0.87
Primary or secondary CVD prevention	0.42
Food or capsule	0.91
Risk of bias	0.98
ALA dose	0.32
+ Prim or sec prev	0.46
+ LCn3 dose	0.86

**ALA:** alpha-linolenic acid; **CVD:** cardiovascular disease; **LCn3:** long-chain omega-3 fatty acids; **PUFA:** poly-unsaturated fatty acids.

<sup>a</sup>Random-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on CHD events. We ran the meta-regression using all included trials that reported this outcome in this review, and its sister reviews (update of [Hooper 2018](#), and [Abdelhamid 2018](#)). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when  $P < 0.10$ ). Meta-regression was of each variable singly, plus a multivariate meta-regression of the 3 single variables with lowest P values. See methods for further information.

**Table 6. Metaregression results for stroke<sup>a</sup>**

Variable assessed	P value	Coefficient sign where $P < 0.10$
LCn3 dose	0.42	-
ALA dose	0.81	-
Omega-6 dose	0.19	-
Total PUFA dose	0.21	-
Duration, months	0.012	Negative (greater effect with shorter duration)
Primary or secondary CVD prevention	0.04	Positive (greater effect with secondary prevention)
Food or capsule	0.21	-
Risk of bias	0.25	-
Duration	0.21	-
+ primary or secondary prevention	0.67	
+ omega-6	0.38	

**ALA:** alpha-linolenic acid; **CVD:** cardiovascular disease; **LCn3:** long-chain omega-3 fatty acids; **PUFA:** poly-unsaturated fatty acids.

<sup>a</sup>Random-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on stroke. We ran the meta-regression using all included trials that reported this outcome in this review, and its sister reviews (update of [Hooper 2018](#), and [Abdelhamid 2018](#)). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when  $P < 0.10$ ). Meta-regression was of each variable singly, plus a multivariate meta-regression of the 3 single variables with lowest P values. See methods for further information.

**Table 7. Meta-regression results for arrhythmias<sup>a</sup>**

Variable assessed	P value	Coefficient sign where $P < 0.10$
LCn3 dose	0.06	Negative (greater effect at lower dose)
ALA dose	0.67	-
Omega-6 dose	0.59	-

**Table 7. Meta-regression results for arrhythmias<sup>a</sup>** (Continued)

Total PUFA dose	0.54	-
Duration, months	0.16	-
Primary or secondary CVD prevention	0.07	Negative (greater effect with primary prevention)
Food or capsule	0.82	-
Risk of bias	0.51	-
LCn3 dose	0.09	-
+ Primary secondary prevention	0.12	
+ duration	0.46	

**ALA:** alpha-linolenic acid; **CVD:** cardiovascular disease; **LCn3:** long-chain omega-3 fatty acids; **PUFA:** poly-unsaturated fatty acids.  
<sup>a</sup>Random-effects meta-regression exploring effects of LCn3 dose, ALA dose, omega-6 dose, total PUFA dose, study duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on arrhythmia. We ran the meta-regression using all included trials that reported this outcome in this review, and its sister reviews (update of [Hooper 2018](#), and [Abdelhamid 2018](#)). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when  $P < 0.10$ ). Meta-regression was of each variable singly, plus a multivariate meta-regression of the 3 single variables with lowest P values. See methods for further information.

**Table 8. Comparison of the results of this review with Balk 2016 and Aung 2018<sup>a</sup>**

	<a href="#">Balk 2016</a>		<a href="#">Aung 2018</a>		This review	
	Number of people experiencing events	RR (95% CI)	Number of people experiencing events	RR (95% CI)	No of people experiencing events	RR (95% CI)
All-cause mortality	8480	0.97 (0.92 to 1.03)	-	Not assessed	8647	0.98 (0.93 to 1.03)
Cardiovascular deaths	3799	0.92 (0.82 to 1.02)	-	Not assessed	4763	0.95 (0.87 to 1.03)
CVD events (MACCEs in <a href="#">Balk 2016</a> )	8085	0.96 (0.91 to 1.02)	12001	0.97 (0.93 to 1.01)	15614	0.99 (0.94 to 1.04)
CHD deaths	-	Not pooled	2695	0.93, (0.83 to 1.03)	1791	0.93 (0.79 to 1.09)
CHD events	-	Not assessed	6273	0.96, (0.90 to 1.01)	5865	0.93 (0.88 to 0.97)

**Table 8. Comparison of the results of this review with Balk 2016 and Aung 2018<sup>a</sup>** (Continued)

Stroke	1467	0.98 (0.88 to 1.09)	1713	1.03 (0.93 to 1.13)	1871	1.06 (0.96, 1.16)
Arrhythmia	-	Not pooled	-	Not assessed	3788	0.97 (0.90 to 1.05)

**CHD:** coronary heart disease; **CI:** confidence interval; **CVD:** cardiovascular disease; **MACCE:** major adverse cerebrovascular or cardiovascular event; **RR:** risk ratio.

<sup>a</sup>Meta-analysis of effects of LCn3 in [Balk 2016](#) and [Aung 2018](#) systematic reviews, comparing their findings with our findings for our primary outcomes.

## APPENDICES

### Appendix I. Medline (Ovid) search strategy run in 2002 for the previous version of this review.

1 exp Fish Oils/  
2 exp Linseed Oil/  
3 linolenic acids/ or exp alpha-linolenic acid/  
4 exp Fatty Acids, Omega-3/  
5 (fish adj5 (diet\$ or nutrit\$ or oil\$ or supplement\$)).tw.  
6 (oil\$ adj3 (cod\$ or marin\$ or rapeseed\$ or canola\$)).tw.  
7 (omega-3 or omega3).tw.  
8 (eicosapentaen\$ or icosapentaen\$).tw.  
9 docosahexaen\$.tw.  
10 (Linolen\$ or alpha-linolen\$ or alphaslinolen\$).tw.  
11 (maxepa\$ or omacor\$).tw.  
12 (trout or kipper\$ or salmon or mackerel\$ or tuna or tunafish or sardine\$ or pilchard\$ or herring\$).tw.  
13 flax\$.tw.  
14 rapeseed\$.tw.  
15 canola\$.tw.  
16 alphaslinolen\$.tw.  
17 perilla\$.tw.  
18 linolen\$.tw.  
19 linseed\$.tw.  
20 maxepa\$.tw.  
21 (oil\$ adj3 colza).tw.  
22 (marin\$ adj3 (lipid\$ or oil\$)).tw.  
23 naudicelle\$.tw.  
24 sild.tw.  
25 (clupe\$ adj3 hareng\$).tw.  
26 whitebait\$.tw.  
27 sprat\$.tw.  
28 brisling\$.tw.  
29 (salmo adj3 trut\$).tw.

30 bloater.tw.  
 31 scomb\$.tw.  
 32 conger\$.tw.  
 33 tunny.tw.  
 34 tuna-fish.tw.  
 35 thunnus\$.tw.  
 36 swordfish\$.tw.  
 37 xiphias\$.tw.  
 38 dogfish.tw.  
 39 scyliorhinus\$.tw.  
 40 (crab or crabs).tw.  
 41 (cancer adj3 pagurus).tw.  
 42 (laks or lax).tw.  
 43 exp Flax/  
 44 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43  
 45 randomized controlled trial.pt.  
 46 controlled clinical trial.pt.  
 47 randomized.ab.  
 48 placebo.ab.  
 49 clinical trials as topic.sh.  
 50 randomly.ab.  
 51 trial.ti.  
 52 50 or 47 or 51 or 46 or 45 or 48 or 49  
 53 (animals not (human and animals)).sh.  
 54 52 not 53  
 55 44 and 54  
 56 (20\$ not (2000\$ or 2001\$)).ed.  
 57 55 and 56

## Appendix 2. Searches run in July 2016 to update the omega-3 review

### CENTRAL

#1 MeSH descriptor: [Fish Oils] explode all trees  
 #2 MeSH descriptor: [Linseed Oil] this term only  
 #3 MeSH descriptor: [Linolenic Acids] this term only  
 #4 MeSH descriptor: [Fatty Acids, Omega-3] explode all trees  
 #5 (fish near/3 oil\*)  
 #6 (oil\* near/3 (cod\* or marin\*))  
 #7 (omega-3 or omega3 or (omega\* near/5 fat\*))  
 #8 eicosapentaen\*  
 #9 docosahexaen\*  
 #10 (oil\* near/3 (flax\* or rapeseed\* or canola\*))  
 #11 (Linolen\* or alpha-linolen\* or alphaslinolen\*)  
 #12 (perilla\* or linseed\* or maxepa\*)  
 #13 (oil\* near/3 (rape or colza))  
 #14 (marin\* near/3 lipid\*)  
 #15 (naudicelle\* or herring\* or sild)  
 #16 (clupe\* near/3 hareng\*)  
 #17 (whitebait or sardine\* or sardina\* or pilchard\* or sprat\* or brisling\*)  
 #18 (salmo\* near/3 trut\*)  
 #19 (trout or bloater or kipper\* or salmon or mackerel\* or scomb\* or conger\* or tuna or tunny or tunafish or tuna-fish)



#20 (thunnus\* or swordfish\* or xiphias\* or dogfish or scyliorhinus\*)  
 #21 (crab or crabs or (cancer pagarus))  
 #22 (DHA or EPA)  
 #23 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 Publication Year from 2002 to 2016  
 #24 MeSH descriptor: [Salmoniformes] explode all trees  
 #25 MeSH descriptor: [Tuna] this term only  
 #26 MeSH descriptor: [alpha-Linolenic Acid] this term only  
 #27 MeSH descriptor: [Flax] this term only  
 #28 (fish near/3 (diet\* or capsul\* or nutrit\* or supplement\*))  
 #29 (icosapentaen\* or docosapentaen\*)  
 #30 (oil\* near/3 (purslane or mustard\* or candlenut\* or stillingia or walnut\*))  
 #31 (laks or lax)  
 #32 (ALA or DPA)  
 #33 (algal near oil\*)  
 #34 #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33  
 #35 #23 or #34

# MEDLINE Ovid

1. exp Fish Oils/
2. Linseed Oil/
3. linolenic acids/ or alpha-linolenic acid/
4. Flax/
5. exp Fatty Acids, Omega-3/
6. (fish adj3 (diet\* or nutrit\* or oil\* or supplement\*)).ti,ab.
7. (oil\* adj3 (cod\* or marin\*)).ti,ab.
8. (omega-3 or omega3 or (omega\* adj5 fat\*)).ti,ab.
9. eicosapentaen\*.ti,ab.
10. docosahexaen\*.ti,ab.
11. (oil\* adj3 (flax\* or rapeseed\* or canola\*)).ti,ab.
12. (Linolen\* or alpha-linolen\* or alphalinolen\*).ti,ab.
13. (perilla\* or linseed\* or maxepa\*).ti,ab.
14. (oil\* adj3 (rape or colza)).ti,ab.
15. (marin\* adj3 lipid\*).ti,ab.
16. (naudicelle\* or herring\* or sild).ti,ab.
17. (clupe\* adj3 hareng\*).ti,ab.
18. (whitebait or sardine\* or sardina\* or pilchard\* or sprat\* or brisling\*).ti,ab.
19. (salmo\* adj3 trut\*).ti,ab.
20. (trout or bloater or kipper\* or salmon or mackerel\* or scomb\* or conger\* or tuna or tunny or tunafish or tuna-fish).ti,ab.
21. (thunnus\* or swordfish\* or xiphias\* or dogfish or scyliorhinus\* or laks or lax).ti,ab.
22. (crab or crabs or cancer pagarus).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. randomized controlled trial.pt.
25. controlled clinical trial.pt.
26. randomized.ab.
27. placebo.ab.
28. clinical trials as topic.sh.
29. randomly.ab.
30. trial.ti.
31. 24 or 25 or 26 or 27 or 28 or 29 or 30
32. exp animals/ not humans.sh.
33. 31 not 32
34. 23 and 33
35. limit 34 to ed=20020201-20160721

36. exp salmoniformes/ or tuna/
37. (fish adj3 capsul\*).ti,ab.
38. icosapentaen\*.ti,ab.
39. docosapentaen\*.ti,ab.
40. (oil\* adj3 (purslane or mustard\* or candlenut\* or stillingia or walnut\*)).ti,ab.
41. 36 or 37 or 38 or 39 or 40
42. 33 and 41
43. 35 or 42

#### **Embase Ovid**

1. exp salmoniformes/ or tuna/
2. fish oil/
3. linseed oil/
4. linolenic acid/
5. Flax/
6. omega 3 fatty acid/
7. (fish adj3 (diet\* or nutrit\* or oil\* or supplement\*)).ti,ab.
8. (oil\* adj3 (cod\* or marin\*)).ti,ab.
9. (omega-3 or omega3 or (omega\* adj5 fat\*)).ti,ab.
10. (eicosapentaen\* or icosapentaen\*).ti,ab.
11. docosahexaen\*.ti,ab.
12. (oil\* adj3 (flax\* or rapeseed\* or canola\*)).ti,ab.
13. (Linolen\* or alpha-linolen\* or alphaslinolen\*).ti,ab.
14. (perilla\* or linseed\* or maxepa\*).ti,ab.
15. (marin\* adj3 lipid\*).ti,ab.
16. (naudicelle\* or herring\* or sild).ti,ab.
17. (clupe\* adj3 hareng\*).ti,ab.
18. (whitebait or sardine\* or sardina\* or pilchard\* or sprat\* or brisling\*).ti,ab.
19. (salmo\* adj3 trut\*).ti,ab.
20. (trout or bloater or kipper\* or salmon or mackerel\* or scomb\* or conger\* or tuna or tunny or tunafish or tuna-fish).ti,ab.
21. (thunnus\* or swordfish\* or xiphias\* or dogfish or scyliorhinus\* or laks or lax).ti,ab.
22. (crab or crabs or (cancer adj3 pagarus)).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. random\$.tw.
25. placebo\$.tw.
26. (doubl\$ adj blind\$).tw.
27. (singl\$ adj blind\$).tw.
28. double blind procedure/
29. randomized controlled trial/
30. single blind procedure/
31. 24 or 25 or 26 or 27 or 28 or 29 or 30
32. (animal/ or nonhuman/) not human/
33. 31 not 32
34. 23 and 33
35. (2002\* or 2003\* or 2004\* or 2005\* or 2006\* or 2007\* or 2008\* or 2009\* or 2010\* or 2011\* or 2012\* or 2013\* or 2014\* or 2015\* or 2016\*).dd,em.
36. 34 and 35
37. exp salmonine/
38. (fish adj3 capsul\*).ti,ab.
39. docosapentaen\*.ti,ab.
40. (ALA or DHA or DPA or EPA).ti,ab.
41. (algal adj oil\*).ti,ab.
42. 37 or 38 or 39 or 40 or 41
43. 33 and 42

### Appendix 3. Searches run in April 2017 for allied reviews

These searches were developed and run to collect relevant trials for the systematic reviews on omega-6 fats (the update of [Hooper 2018](#)) and on total PUFA fats ([Abdelhamid 2018](#)) on health. They are shown here as these searches were run with the searches for this review, the identified titles and abstracts de-duplicated and combined, so that we assessed titles and abstracts for all three reviews together. These searches were each run from database inception, due to the widening of the inclusion criteria, then de-duplicated with each other. The RCT filter for MEDLINE is the Cochrane sensitivity and precision-maximising RCT filter, and for Embase, terms as recommended in the Cochrane Handbook have been applied ([Lefebvre 2011](#)).

#### CENTRAL

- #1 MeSH descriptor: [Fatty Acids, Essential] explode all trees
- #2 MeSH descriptor: [Fatty Acids, Unsaturated] this term only
- #3 ((polyunsaturat\* or poly-unsaturat\*) near/3 fat\*)
- #4 (poly\* adj4 unsat\* near/4 fatty acid\*)
- #5 PUFA
- #6 MeSH descriptor: [Fatty Acids, Omega-6] explode all trees
- #7 omega-6
- #8 (n-6 near/4 acid\*) or ("n 6" near/4 acid\*)
- #9 linoleic acid\*
- #10 MeSH descriptor: [Corn Oil] this term only
- #11 MeSH descriptor: [Cottonseed Oil] this term only
- #12 MeSH descriptor: [Olive Oil] this term only
- #13 MeSH descriptor: [Safflower Oil] this term only
- #14 MeSH descriptor: [Sesame Oil] this term only
- #15 MeSH descriptor: [Soybean Oil] this term only
- #16 ((corn or maize or mazola) near/4 oil\*)
- #17 (cottonseed\* or (cotton next seed\*))
- #18 (olive near/4 oil\*)
- #19 (safflower near/4 oil\*)
- #20 (sesame near/4 oil\*)
- #21 ((soy bean or soybean) near/4 (oil\* or fat\*))
- #22 (so?a near/4 oil\*)
- #23 so?aoil\*
- #24 (soy near/4 oil\*)
- #25 (sunflower near/4 oil\*)
- #26 helianth\*
- #27 (grapeseed near/4 oil\*)
- #28 (canola near/4 oil\*)
- #29 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28

#### MEDLINE Ovid

- 1. exp fatty acids, essential/
- 2. fatty acids, unsaturated/
- 3. ((polyunsaturat\* or poly-unsaturat\*) adj3 fat\*).ti,ab.
- 4. (poly\* adj4 unsat\* adj4 fatty acid\*).ti,ab.
- 5. PUFA.ti,ab.
- 6. exp fatty acids, omega-6/
- 7. omega-6.ti,ab.
- 8. (n-6 adj4 acid\*).ti,ab.
- 9. linoleic acid\*.ti,ab.
- 10. corn oil/ or cottonseed oil/ or olive oil/ or safflower oil/ or sesame oil/ or soybean oil/

11. ((corn or maize or mazola) adj4 oil\*).ti,ab.
12. (cottonseed\* or (cotton adj seed\*)).ti,ab.
13. (olive adj4 oil\*).ti,ab.
14. (safflower adj4 oil\*).ti,ab.
15. (sesame adj4 oil\*).ti,ab.
16. ((soy bean or soybean) adj4 (oil\* or fat\*)).ti,ab.
17. (so?a adj4 oil\*).ti,ab.
18. so?aoil\*.ti,ab.
19. (soy adj4 oil\*).ti,ab.
20. (sunflower adj4 oil\*).ti,ab.
21. helianth\*.ti,ab.
22. (grapeseed adj4 oil\*).ti,ab.
23. (canola adj4 oil\*).ti,ab.
24. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. randomized controlled trial.pt.
26. controlled clinical trial.pt.
27. randomized.ab.
28. placebo.ab.
29. clinical trials as topic.sh.
30. randomly.ab.
31. trial.ti.
32. 25 or 26 or 27 or 28 or 29 or 30 or 31
33. exp animals/ not humans.sh.
34. 32 not 33
35. 24 and 34

#### **Embase Ovid**

1. exp essential fatty acid/
2. unsaturated fatty acid/ or docosapentaenoic acid/ or omega 6 fatty acid/ or polyunsaturated fatty acid/
3. ((polyunsaturat\* or poly-unsaturat\*) adj3 fat\*).ti,ab.
4. (poly\* adj4 unsat\* adj4 fatty acid\*).ti,ab.
5. PUFA.ti,ab.
6. omega-6.ti,ab.
7. (n-6 adj4 acid\*).ti,ab.
8. linoleic acid\*.ti,ab.
9. edible oil/ or canola oil/ or corn oil/ or cotton seed oil/ or olive oil/ or safflower oil/ or safflower oil plus soybean oil/ or sesame seed oil/ or soybean oil/ or sunflower oil/
10. ((corn or maize or mazola) adj4 oil\*).ti,ab.
11. (cottonseed\* or (cotton adj seed\*)).ti,ab.
12. (olive adj4 oil\*).ti,ab.
13. (safflower adj4 oil\*).ti,ab.
14. (sesame adj4 oil\*).ti,ab.
15. ((soy bean or soybean) adj4 (oil\* or fat\*)).ti,ab.
16. (so?a adj4 oil\*).ti,ab.
17. so?aoil\*.ti,ab.
18. (soy adj4 oil\*).ti,ab.
19. (sunflower adj4 oil\*).ti,ab.
20. helianth\*.ti,ab.
21. (grapeseed adj4 oil\*).ti,ab.
22. (canola adj4 oil\*).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. double blind procedure/
25. single blind procedure/
26. randomized controlled trial/

27. ((double\* or single\*) adj blind\*).ti,ab.  
 28. (random\* or placebo\*).ti,ab.  
 29. 24 or 25 or 26 or 27 or 28  
 30. (animal/ or nonhuman/) not human/  
 31. 29 not 30  
 32. 23 and 31

## WHAT'S NEW

Last assessed as up-to-date: 27 April 2017.

Date	Event	Description
13 March 2018	New citation required and conclusions have changed	<p>This update now reports arrhythmia (atrial fibrillation) and cardiovascular mortality data. Data now included from 79 RCTs (112,059 participants) lasting at least one year, of which 25 were at low summary risk of bias</p> <p>We added the following outcomes to the list of primary outcomes upon the request of World Health Organization (WHO) Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health</p> <ol style="list-style-type: none"> <li>1. Cardiovascular mortality.</li> <li>2. Arrhythmia (new and recurrent).</li> </ol> <p>We altered inclusion criteria to include only RCTs of at least 12 months' duration (rather than 6 months as previously), and we excluded cohort studies</p> <p>We are assessing effects of long-chain omega-3 fats separately from effects of alpha-linolenic acid (as planned in the previously published version)</p>
27 April 2017	New search has been performed	Electronic searches updated to 27 April 2017

## HISTORY

Protocol first published: Issue 2, 1999

Review first published: Issue 4, 2004

Date	Event	Description
14 March 2012	Amended	Additional tables re-numbered
16 October 2011	New search has been performed	<p>Searches updated to July 2011.</p> <p>Cohort studies not included in this update, and previously included cohort studies and related text have been removed</p>

(Continued)

		Previously included trials where we know that no deaths or primary or secondary health events occurred were removed New secondary outcomes added (fatal and non-fatal arrhythmias, and diabetes) Cardiovascular mortality added as a primary outcome.
9 September 2008	Amended	Converted to new review format.
1 August 2004	New citation required and conclusions have changed	Substantive amendment

## CONTRIBUTIONS OF AUTHORS

LH and CDS conceived and led the original version of this review; LH, CDS, HM and HVW were authors of the original version of this review. LH designed the searches, and CB developed, refined, ran and de-duplicated them. ASA, TJB, JSB, PB, GCT, KHOD, HVW, FS and LH screened titles and abstracts; ASA, JSB, PB, GCT and LH assessed full-text papers for inclusion; LH, PB and JSB searched trials registers and assessed entries for inclusion; LH and ASA located full texts, managed assessment and collection of titles, abstracts and full texts, data extraction and risk of bias assessment. All authors carried out data extraction and assessed risk of bias. LH, KHOD and JSB designed risk of bias assessment; JSB, KHOD, TJB, ASA and LH wrote to study authors; LH, KHOD, JSB, TJB and ASA carried out data checks; JSB, TJB, LH and ASA tabulated intake and status data. FS, KHOD, JSB, HVW, CDS and LH provided methodological support. ASA, FKA and LH entered data into RevMan and ran meta-analyses, ASA and LH carried out sensitivity and subgroup analyses, and LH the meta-regression. ASA wrote the first draft of the review and LH the WHO NUGAG Subgroup on Diet and Health report; both carried out GRADE assessment and interpretation. All authors critically read and commented on the final draft and agreed on it for submission.

## DECLARATIONS OF INTEREST

ASA: none known.

TJB: none known.

JSB: none known.

PB: none known.

GCT: none known.

HJM: none known.

KHOD: none known.

FKA: none known.

CDS: none known.

HVW: none known.

FS: none known.

LH: none known.

## SOURCES OF SUPPORT

### Internal sources

- University of East Anglia, UK.
- Cochrane Heart Group, UK.

This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Heart Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health, UK

### External sources

- World Health Organization nutrition guidance expert advisory group (NUGAG), Not specified.
- WHO NUGAG Subgroup on Diet and Health requested and funded the update and extension of this review.

## DIFFERENCES BETWEEN PROTOCOL AND REVIEW

Differences between the previous version of this review (2004) and this update (2018):

- **Authors** altered. The Acknowledgments recognise authors of the previous version who chose not to participate in this update.
- **Background** updated.
- **Objectives: primary objective** altered from 'Do dietary or supplemental omega-3 fatty acids alter total mortality, cardiovascular events, cancers or other adverse events?' to 'Do long-chain omega-3 (LCn3, fish-based omega-3 fats) or ALA (plant-based omega-3 fats) fats alter risk of all-cause mortality, cardiovascular deaths, cardiovascular events, coronary heart disease deaths, coronary heart disease events, stroke, arrhythmia, adiposity and lipids?' This change in emphasis, which we anticipated in the original review, focuses on long-chain omega-3 fats (EPA, DHA, DPA) and ALA separately. We discuss changes in outcomes assessed below.
- **Secondary questions:** we added assessment of effects of omega-3 fats (including both LCn3 and ALA) as a secondary question.
- **Types of studies included:** included RCTs had to be at least one year in duration in the update (the limit was six months in the original review). We excluded cohort studies from the update.
- **Types of outcomes: primary outcomes** assessed were updated, removing cancers and adverse events as primary outcomes and adding cardiovascular deaths, coronary heart disease deaths and events, stroke and arrhythmia (atrial fibrillation) as primary outcomes. Adiposity and lipids were added as key secondary outcomes. Cancer outcomes and other non-cardiovascular outcomes, including diabetes, were assessed in separate reviews ([Abdelhamid 2018](#); [Abdelhamid 2017](#); [Brown 2017](#); [Hanson 2017a](#); [Hanson 2017b](#); [Jimoh 2017](#); [Thorpe 2017](#)).
- **Secondary outcomes:** we added new secondary outcomes (major adverse cardiac or cerebrovascular events (MACCEs), myocardial infarction, sudden cardiac death, angina, heart failure, peripheral arterial disease, re-vascularisation and acute coronary syndrome). Blood pressure (a secondary outcome in the original review) became a tertiary outcome in the update. We dropped urinary thromboxane and participant fatty acid data as secondary outcomes but collected fatty acid data to help assess compliance.
- **Risk of bias:** we updated this review to incorporate the Cochrane 'Risk of bias' tool (for all included studies). We slightly updated our assessment of summary risk of bias from low summary risk when "allocation concealment was adequate, and participant, provider and outcome assessor blinding were all coded 'yes'" to low summary risk for a supplement or capsule type trial where "we judged randomisation, allocation concealment, blinding of participants and personnel, and blinding of outcome assessors to be adequate" and for a dietary advice or all-food provided type trial where "we judged randomisation, allocation concealment, and blinding of outcome assessors to be adequate".
- **Subgroup analyses:** in the update we carried out separate subgroup analyses for LCn3 and ALA studies. Subgrouping in the update was as in the original review (by dose, dietary or supplemental source and trial duration), with the addition of some new subgroups. We added new subgroup analyses at the request of the WHO NUGAG Subgroup on Diet and Health.

- Replacement of SFA, MUFA, omega-6 fats, fat mixture, carbohydrates or sugars, non-fat or no placebo (or unclear) by LCn3 or ALA.

- Primary prevention versus secondary prevention of CVD.

- Statin use (< 50% of control group on statins, ≥ 50% of control group on statins, use of statins unclear).

- Baseline LCn3 or ALA intake.

- **Sensitivity analyses:** updated for this review. Limiting analyses to studies at low summary risk of bias was continued in the update from the original review, and we added sensitivity analyses by study size (retaining only trials that randomised at least 100 participants across all study arms), fixed-effect meta-analysis and compliance (retaining only studies at low risk of compliance bias, this latter at the request of WHO NUGAG Subgroup on Diet and Health).

- **Heterogeneity:** the original review used Cochran's test while the update used  $I^2$ . This reflects current best methodology.

## INDEX TERMS

### Medical Subject Headings (MeSH)

\*Dietary Supplements; Cardiovascular Diseases [\*diet therapy; mortality; prevention & control]; Fatty Acids, Omega-3 [\*therapeutic use]; Randomized Controlled Trials as Topic

### MeSH check words

Humans